Idiopathic Pulmonary Fibrosis - Market Insight, Epidemiology and Market Forecast - 2027

Idiopathic Pulmonary Fibrosis - Market Insight, Epidemiology and Market Forecast - 2027

  • Pages: 178
  • Geography: Global
  • Delivery Timeline: 24 Hours
  • Publication: Aug, 2018
  • SKU: DIMI0111
  • Single User License
    (20% Off)
    $6,250.00
    $5000
  • Site License
    (30% Off)
    $12,500.00
    $8750
  • Global License
    (40% Off)
    $18,750.00
    $11250
Request Sample

Name*  
Email ID*  
Mobile*  
Company*  
Country*  
Zip Code*  
Address*  
Message*  
X

Request Sample Pages

Request Before Buy
Name*  
Email ID*  
Mobile*  
Company*  
Message*  
X

Inquire Before Buy

Send Friend
Name*  
Email ID*  
Mobile*  
Company*  
Message*  
X

Send to Friend

DelveInsight’s ‘Idiopathic Pulmonary Fibrosis (IPF) - Market Insights, Epidemiology and Market Forecast-2027’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of IPF in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan. 
The Report provides the current treatment practices, emerging drugs having the potential to get launched in the forecast period, market share of the individual therapies, current and forecasted market size of Idiopathic Pulmonary Fibrosis (IPF) from 2016 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered

• The United States

• EU5 (Germany, France, Italy, Spain and the United Kingdom)

• Japan

Study Period: 2016-2027

Idiopathic Pulmonary Fibrosis (IPF) - Disease Understanding and Treatment Algorithm
The DelveInsight Idiopathic Pulmonary Fibrosis (IPF) market report gives the thorough understanding of the Idiopathic Pulmonary Fibrosis by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Idiopathic Pulmonary Fibrosis in the US, Europe, and Japan.

Idiopathic Pulmonary Fibrosis Epidemiology
The Idiopathic Pulmonary Fibrosis (IPF) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken. 
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total prevalent cases, diagnosed prevalent cases, age-specific, gender-specific cases and severity specific prevalent cases) scenario of Idiopathic Pulmonary Fibrosis (IPF) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2016-2027.
According to DelveInsight, the total number of diagnosed prevalent population of Idiopathic Pulmonary Fibrosis (IPF) was found to be 261,482, in the year 2016.

Idiopathic Pulmonary Fibrosis Drug Chapters 
This segment of the Idiopathic Pulmonary Fibrosis report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
At present, the companies are using recombinant protein and monoclonal antibody type therapeutic classes of drugs which are contributing towards the market size of IPF. Detailed chapter for upcoming therapies like Thrombomodulin Alfa (Asahi Kasei Pharma Corporation), CC-90001 (Celgene Corporation), Gefapixant (Merck & Co., Inc.), GLPG1690 (Galapagos NV), LT-1001(LTT Bio-Pharma), BG-00011(Biogen ), BMS-986020(Bristol-Myers Squibb), LT-1002(Chong Kun Dang Pharmaceutical), Pamrevlumab (FibroGen, Inc.), PBI4050 (ProMetic Life Sciences), PRM 151 (Promedior Inc), TAS-115 (Taiho Pharmaceutical), VAY-736(MorphoSys; Novartis), Tipelukast (MediciNova)and TD139 (Bristol-Myers Squibb) have been covered in the report.

Idiopathic Pulmonary Fibrosis Market Outlook
The Idiopathic Pulmonary Fibrosis market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology. 
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight. 
According to DelveInsight, the market of Idiopathic Pulmonary Fibrosis in 7MM was found to be USD 1,386.6 million in 2016.

Idiopathic Pulmonary Fibrosis Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Idiopathic Pulmonary Fibrosis Report Insights

• Patient Population

• Therapeutic Approaches

• Pipeline Analysis

• Market Size and Trends

• Market Opportunities

• Impact of upcoming Therapies

Idiopathic Pulmonary Fibrosis Report Key Strengths

• 10 Year Forecast

• 7MM Coverage

• Epidemiology Segmentation

• Drugs Uptake

• Highly Analyzed Market

• Key Cross Competition

Idiopathic Pulmonary Fibrosis Report Assessment

• Current Treatment Practices

• Unmet Needs

• Detailed Pipeline Product Profiles

• Market Attractiveness

• Market Drivers and Barriers

Key Benefits

• This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Idiopathic Pulmonary Fibrosis market

• Organize sales and marketing efforts by identifying the best opportunities for Idiopathic Pulmonary Fibrosis market

• To understand the future market competition in the Idiopathic Pulmonary Fibrosis market.

1. Key Insights
2. IPF Market Overview at a Glance
2.1. Market Share (%) Distribution of IPF in 2017
2.2. Market Share (%) Distribution of IPF in 2027
3. Disease Background and Overview: Idiopathic Pulmonary Fibrosis (IPF)
3.1. Introduction
3.2. Staging of IPF
3.3. Risk Factors & Disease Causes
3.4. Symptoms
3.5. Pathogenesis
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7 MM Prevalent Population of IPF
4.3. Country Wise-Epidemiology of IPF
4.3.1. United States
4.3.2. Prevalent cases of IPF in the United States
4.3.3. Prevalent Population of IPF by severity
4.3.4. Gender-Specific IPF Prevalence
4.3.5. Age-Specific IPF Prevalence
4.3.6. EU5
4.3.7. Prevalent Population of IPF in EU5
4.3.8. France
4.3.9. Prevalent Population of IPF
4.3.10. Prevalent Population of IPF by severity
4.3.11. Gender-Specific IPF Prevalence
4.3.12. Age-Specific IPF Prevalence
4.3.13. Germany
4.3.14. Prevalent Population of IPF
4.3.15. Prevalent Population of IPF by severity
4.3.16. Gender-Specific IPF Prevalence
4.3.17. Age-Specific IPF Prevalence
4.3.18. Italy
4.3.19. Prevalent Population of IPF
4.3.20. Prevalent Population of IPF by severity
4.3.21. Gender-Specific IPF Prevalence
4.3.22. Age-Specific IPF Prevalence
4.3.23. Spain
4.3.24. Prevalent Population of IPF
4.3.25. Prevalent Population of IPF by severity
4.3.26. Gender-Specific IPF Prevalence
4.3.27. Age-Specific IPF Prevalence
4.3.28. United Kingdom
4.3.29. Prevalent Population of IPF
4.3.30. Prevalent Population of IPF by severity
4.3.31. Gender-Specific IPF Prevalence
4.3.32. Age-Specific IPF Prevalence
4.3.33. Japan
4.3.34. Prevalent Population of IPF
4.3.35. Prevalent Population of IPF by severity
4.3.36. Gender-SPECIFIC IPF Prevalence
4.3.37. Age-Specific IPF Prevalence
5. Current Treatment Practices
5.1. ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of IPF (An Update of 2011 Clinical Practice Guideline)
6. Unmet needs
7. Marketed Products
7.1. Esbriet (Pirfenidone): InterMune Inc.
7.1.1. Product Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Safety and Efficacy of Esbriet
7.1.5. Side effects of Esbriet
7.1.6. Product Profile
7.2. Ofev (Nintedanib): Boehringer Ingelheim Pharma GmbH & Co. KG
7.2.1. Product Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Safety and Efficacy of Ofev
7.2.5. Side effects of Ofev
7.2.6. Product Profile
8. Emerging Therapies
9. Key Cross Competition
10. Phase III Drugs
10.1. Thrombomodulin Alfa: Asahi Kasei Pharma Corporation
10.1.1. Drug Description
10.1.2. Product Profile
10.1.3. Clinical Development
10.1.4. Clinical Trials Information
10.1.5. Safety and Efficacy
11. Phase II Drugs
11.1. CC-90001: Celgene Corporation
11.1.1. Drug Description
11.1.2. Product Profile
11.1.3. Clinical Development
11.1.4. Clinical Trials Information
11.1.5. Safety and Efficacy
11.1.6. Drug Description
11.1.7. Product Profile
11.1.8. Other Development Activities
11.1.9. Clinical Development
11.1.10. Clinical Trials Information
11.1.11. Safety and Efficacy
11.2. Gefapixant: Merck & Co., Inc.
11.2.1. Drug Description
11.2.2. Product Profile
11.2.3. Other Development Activities
11.2.4. Clinical Development
11.2.5. Clinical Trials Information
11.2.6. Safety and Efficacy
11.3. GLPG1690: Galapagos NV
11.3.1. Drug Description
11.3.2. Product Profile
11.3.3. Regulatory Milestones
11.3.4. Other Development Activities
11.3.5. Clinical Development
11.3.6. Clinical Trials Information
11.3.7. Safety and Efficacy
11.4. LT-1001: LTT Bio-Pharma
11.4.1. Drug Description
11.4.2. Product Profile
11.4.3. Other Development Activities
11.4.4. Clinical Development
11.4.5. Clinical Trials Information
11.4.6. Safety and Efficacy
11.5. BG00011: Biogen Inc.
11.5.1. Drug Description
11.5.2. Product Profile
11.5.3. Regulatory Milestones
11.5.4. Other Development Activities
11.5.5. Clinical Development
11.5.6. Clinical Trials Information
11.5.7. Safety and Efficacy
11.6. BMS-986020: Bristol-Myers Squibb
11.6.1. Drug Description
11.6.2. Product Profile
11.6.3. Regulatory Milestones
11.6.4. Other Development Activities
11.6.5. Clinical Development
11.6.6. Clinical Trials Information
11.6.7. Safety and Efficacy
11.7. LT-1002: Chong Kun Dang Pharmaceutical
11.7.1. Drug Description
11.7.2. Product Profile
11.7.3. Other Development Activities
11.8. Pamrevlumab: FibroGen
11.8.1. Drug Description
11.8.2. Product Profile
11.8.3. Regulatory Milestones
11.8.4. Other Development Activities
11.8.5. Clinical Development
11.8.6. Clinical Trials Information
11.8.7. Safety and Efficacy
11.9. PBI4050: ProMetic Life Sciences
11.9.1. Drug Description
11.9.2. Product Profile
11.9.3. Regulatory Milestones
11.9.4. Other Development Activities
11.9.5. Clinical Development
11.9.6. Clinical Trials Information
11.9.7. Safety and Efficacy
11.10. PRM 151: Promedior, Inc.
11.10.1. Drug Description
11.10.2. Product Profile
11.10.3. Regulatory Milestones
11.10.4. Other Development Activities
11.10.5. Clinical Development
11.10.6. Clinical Trials Information
11.10.7. Safety and Efficacy
11.11. Tipelukast: MediciNova
11.11.1. Drug Description
11.11.2. Product Profile
11.11.3. Regulatory Milestones
11.11.4. Other Development Activities
11.11.5. Clinical Development
11.11.6. Clinical Trials Information
11.11.7. Safety and Efficacy
11.12. TD139: Bristol-Myers Squibb
11.12.1. Drug Description
11.12.2. Product Profile
11.12.3. Other Development Activities
11.12.4. Clinical Development
11.12.5. Clinical Trials Information
11.12.6. Safety and Efficacy
11.13. VAY736: Novartis
11.13.1. Drug Description
11.13.2. Product Profile
11.13.3. Other Development Activities
11.13.4. Clinical Development
11.13.5. Clinical Trials Information
11.14. TAS-115: Taiho Pharmaceutical
11.14.1. Drug Description
11.14.2. Product Profile
11.14.3. Clinical Development
11.14.4. Clinical Trials Information
12. IPF: Market Analysis
12.1. Key Findings
12.2. Total Market Size of IPF in 7 MM
12.3. Therapy Based Market Size of IPF in 7 MM
13. Market Size of IPF by Country
13.1. United States Market Analysis
13.1.1. Market Size of IPF in the US
13.1.2. Therapy Based Market Size of IPF in the US
13.2. EU5 Market Outlook
13.3. Germany
13.3.1. Market Size of IPF in Germany
13.3.2. Therapy Based Market Size of IPF in Germany
13.4. France
13.4.1. Market Size of IPF in France
13.4.2. Therapy Based Market Size of IPF in France
13.5. Italy
13.5.1. Market Size of IPF in Italy
13.5.2. Therapy Based Market Size of IPF in Italy
13.6. United Kingdom
13.6.1. Market Size of IPF in the UK
13.6.2. Therapy Based Market Size of IPF in the UK
13.7. Spain
13.7.1. Market Size of IPF in Spain
13.7.2. Therapy Based Market Size of IPF in Spain
13.8. Japan: Market Analysis
13.8.1. Market Size of IPF in Japan
13.8.2. Therapy Based Market Size of IPF in Japan
14. Market Drivers of IPF
15. Market Barriers of IPF
16. Appendix
16.1. Report Methodology
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

 

1. Key Insights
2. IPF Market Overview at a Glance
2.1. Market Share (%) Distribution of IPF in 2017
2.2. Market Share (%) Distribution of IPF in 2027
3. Disease Background and Overview: Idiopathic Pulmonary Fibrosis (IPF)
3.1. Introduction
3.2. Staging of IPF
3.3. Risk Factors & Disease Causes
3.4. Symptoms
3.5. Pathogenesis
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7 MM Prevalent Population of IPF
4.3. Country Wise-Epidemiology of IPF
4.3.1. United States
4.3.2. Prevalent cases of IPF in the United States
4.3.3. Prevalent Population of IPF by severity
4.3.4. Gender-Specific IPF Prevalence
4.3.5. Age-Specific IPF Prevalence
4.3.6. EU5
4.3.7. Prevalent Population of IPF in EU5
4.3.8. France
4.3.9. Prevalent Population of IPF
4.3.10. Prevalent Population of IPF by severity
4.3.11. Gender-Specific IPF Prevalence
4.3.12. Age-Specific IPF Prevalence
4.3.13. Germany
4.3.14. Prevalent Population of IPF
4.3.15. Prevalent Population of IPF by severity
4.3.16. Gender-Specific IPF Prevalence
4.3.17. Age-Specific IPF Prevalence
4.3.18. Italy
4.3.19. Prevalent Population of IPF
4.3.20. Prevalent Population of IPF by severity
4.3.21. Gender-Specific IPF Prevalence
4.3.22. Age-Specific IPF Prevalence
4.3.23. Spain
4.3.24. Prevalent Population of IPF
4.3.25. Prevalent Population of IPF by severity
4.3.26. Gender-Specific IPF Prevalence
4.3.27. Age-Specific IPF Prevalence
4.3.28. United Kingdom
4.3.29. Prevalent Population of IPF
4.3.30. Prevalent Population of IPF by severity
4.3.31. Gender-Specific IPF Prevalence
4.3.32. Age-Specific IPF Prevalence
4.3.33. Japan
4.3.34. Prevalent Population of IPF
4.3.35. Prevalent Population of IPF by severity
4.3.36. Gender-SPECIFIC IPF Prevalence
4.3.37. Age-Specific IPF Prevalence
5. Current Treatment Practices
5.1. ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of IPF (An Update of 2011 Clinical Practice Guideline)
6. Unmet needs
7. Marketed Products
7.1. Esbriet (Pirfenidone): InterMune Inc.
7.1.1. Product Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Safety and Efficacy of Esbriet
7.1.5. Side effects of Esbriet
7.1.6. Product Profile
7.2. Ofev (Nintedanib): Boehringer Ingelheim Pharma GmbH & Co. KG
7.2.1. Product Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Safety and Efficacy of Ofev
7.2.5. Side effects of Ofev
7.2.6. Product Profile
8. Emerging Therapies
9. Key Cross Competition
10. Phase III Drugs
10.1. Thrombomodulin Alfa: Asahi Kasei Pharma Corporation
10.1.1. Drug Description
10.1.2. Product Profile
10.1.3. Clinical Development
10.1.4. Clinical Trials Information
10.1.5. Safety and Efficacy
11. Phase II Drugs
11.1. CC-90001: Celgene Corporation
11.1.1. Drug Description
11.1.2. Product Profile
11.1.3. Clinical Development
11.1.4. Clinical Trials Information
11.1.5. Safety and Efficacy
11.1.6. Drug Description
11.1.7. Product Profile
11.1.8. Other Development Activities
11.1.9. Clinical Development
11.1.10. Clinical Trials Information
11.1.11. Safety and Efficacy
11.2. Gefapixant: Merck & Co., Inc.
11.2.1. Drug Description
11.2.2. Product Profile
11.2.3. Other Development Activities
11.2.4. Clinical Development
11.2.5. Clinical Trials Information
11.2.6. Safety and Efficacy
11.3. GLPG1690: Galapagos NV
11.3.1. Drug Description
11.3.2. Product Profile
11.3.3. Regulatory Milestones
11.3.4. Other Development Activities
11.3.5. Clinical Development
11.3.6. Clinical Trials Information
11.3.7. Safety and Efficacy
11.4. LT-1001: LTT Bio-Pharma
11.4.1. Drug Description
11.4.2. Product Profile
11.4.3. Other Development Activities
11.4.4. Clinical Development
11.4.5. Clinical Trials Information
11.4.6. Safety and Efficacy
11.5. BG00011: Biogen Inc.
11.5.1. Drug Description
11.5.2. Product Profile
11.5.3. Regulatory Milestones
11.5.4. Other Development Activities
11.5.5. Clinical Development
11.5.6. Clinical Trials Information
11.5.7. Safety and Efficacy
11.6. BMS-986020: Bristol-Myers Squibb
11.6.1. Drug Description
11.6.2. Product Profile
11.6.3. Regulatory Milestones
11.6.4. Other Development Activities
11.6.5. Clinical Development
11.6.6. Clinical Trials Information
11.6.7. Safety and Efficacy
11.7. LT-1002: Chong Kun Dang Pharmaceutical
11.7.1. Drug Description
11.7.2. Product Profile
11.7.3. Other Development Activities
11.8. Pamrevlumab: FibroGen
11.8.1. Drug Description
11.8.2. Product Profile
11.8.3. Regulatory Milestones
11.8.4. Other Development Activities
11.8.5. Clinical Development
11.8.6. Clinical Trials Information
11.8.7. Safety and Efficacy
11.9. PBI4050: ProMetic Life Sciences
11.9.1. Drug Description
11.9.2. Product Profile
11.9.3. Regulatory Milestones
11.9.4. Other Development Activities
11.9.5. Clinical Development
11.9.6. Clinical Trials Information
11.9.7. Safety and Efficacy
11.10. PRM 151: Promedior, Inc.
11.10.1. Drug Description
11.10.2. Product Profile
11.10.3. Regulatory Milestones
11.10.4. Other Development Activities
11.10.5. Clinical Development
11.10.6. Clinical Trials Information
11.10.7. Safety and Efficacy
11.11. Tipelukast: MediciNova
11.11.1. Drug Description
11.11.2. Product Profile
11.11.3. Regulatory Milestones
11.11.4. Other Development Activities
11.11.5. Clinical Development
11.11.6. Clinical Trials Information
11.11.7. Safety and Efficacy
11.12. TD139: Bristol-Myers Squibb
11.12.1. Drug Description
11.12.2. Product Profile
11.12.3. Other Development Activities
11.12.4. Clinical Development
11.12.5. Clinical Trials Information
11.12.6. Safety and Efficacy
11.13. VAY736: Novartis
11.13.1. Drug Description
11.13.2. Product Profile
11.13.3. Other Development Activities
11.13.4. Clinical Development
11.13.5. Clinical Trials Information
11.14. TAS-115: Taiho Pharmaceutical
11.14.1. Drug Description
11.14.2. Product Profile
11.14.3. Clinical Development
11.14.4. Clinical Trials Information
12. IPF: Market Analysis
12.1. Key Findings
12.2. Total Market Size of IPF in 7 MM
12.3. Therapy Based Market Size of IPF in 7 MM
13. Market Size of IPF by Country
13.1. United States Market Analysis
13.1.1. Market Size of IPF in the US
13.1.2. Therapy Based Market Size of IPF in the US
13.2. EU5 Market Outlook
13.3. Germany
13.3.1. Market Size of IPF in Germany
13.3.2. Therapy Based Market Size of IPF in Germany
13.4. France
13.4.1. Market Size of IPF in France
13.4.2. Therapy Based Market Size of IPF in France
13.5. Italy
13.5.1. Market Size of IPF in Italy
13.5.2. Therapy Based Market Size of IPF in Italy
13.6. United Kingdom
13.6.1. Market Size of IPF in the UK
13.6.2. Therapy Based Market Size of IPF in the UK
13.7. Spain
13.7.1. Market Size of IPF in Spain
13.7.2. Therapy Based Market Size of IPF in Spain
13.8. Japan: Market Analysis
13.8.1. Market Size of IPF in Japan
13.8.2. Therapy Based Market Size of IPF in Japan
14. Market Drivers of IPF
15. Market Barriers of IPF
16. Appendix
16.1. Report Methodology
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

 

1. Key Insights
2. IPF Market Overview at a Glance
2.1. Market Share (%) Distribution of IPF in 2017
2.2. Market Share (%) Distribution of IPF in 2027
3. Disease Background and Overview: Idiopathic Pulmonary Fibrosis (IPF)
3.1. Introduction
3.2. Staging of IPF
3.3. Risk Factors & Disease Causes
3.4. Symptoms
3.5. Pathogenesis
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7 MM Prevalent Population of IPF
4.3. Country Wise-Epidemiology of IPF
4.3.1. United States
4.3.2. Prevalent cases of IPF in the United States
4.3.3. Prevalent Population of IPF by severity
4.3.4. Gender-Specific IPF Prevalence
4.3.5. Age-Specific IPF Prevalence
4.3.6. EU5
4.3.7. Prevalent Population of IPF in EU5
4.3.8. France
4.3.9. Prevalent Population of IPF
4.3.10. Prevalent Population of IPF by severity
4.3.11. Gender-Specific IPF Prevalence
4.3.12. Age-Specific IPF Prevalence
4.3.13. Germany
4.3.14. Prevalent Population of IPF
4.3.15. Prevalent Population of IPF by severity
4.3.16. Gender-Specific IPF Prevalence
4.3.17. Age-Specific IPF Prevalence
4.3.18. Italy
4.3.19. Prevalent Population of IPF
4.3.20. Prevalent Population of IPF by severity
4.3.21. Gender-Specific IPF Prevalence
4.3.22. Age-Specific IPF Prevalence
4.3.23. Spain
4.3.24. Prevalent Population of IPF
4.3.25. Prevalent Population of IPF by severity
4.3.26. Gender-Specific IPF Prevalence
4.3.27. Age-Specific IPF Prevalence
4.3.28. United Kingdom
4.3.29. Prevalent Population of IPF
4.3.30. Prevalent Population of IPF by severity
4.3.31. Gender-Specific IPF Prevalence
4.3.32. Age-Specific IPF Prevalence
4.3.33. Japan
4.3.34. Prevalent Population of IPF
4.3.35. Prevalent Population of IPF by severity
4.3.36. Gender-SPECIFIC IPF Prevalence
4.3.37. Age-Specific IPF Prevalence
5. Current Treatment Practices
5.1. ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of IPF (An Update of 2011 Clinical Practice Guideline)
6. Unmet needs
7. Marketed Products
7.1. Esbriet (Pirfenidone): InterMune Inc.
7.1.1. Product Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Safety and Efficacy of Esbriet
7.1.5. Side effects of Esbriet
7.1.6. Product Profile
7.2. Ofev (Nintedanib): Boehringer Ingelheim Pharma GmbH & Co. KG
7.2.1. Product Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Safety and Efficacy of Ofev
7.2.5. Side effects of Ofev
7.2.6. Product Profile
8. Emerging Therapies
9. Key Cross Competition
10. Phase III Drugs
10.1. Thrombomodulin Alfa: Asahi Kasei Pharma Corporation
10.1.1. Drug Description
10.1.2. Product Profile
10.1.3. Clinical Development
10.1.4. Clinical Trials Information
10.1.5. Safety and Efficacy
11. Phase II Drugs
11.1. CC-90001: Celgene Corporation
11.1.1. Drug Description
11.1.2. Product Profile
11.1.3. Clinical Development
11.1.4. Clinical Trials Information
11.1.5. Safety and Efficacy
11.1.6. Drug Description
11.1.7. Product Profile
11.1.8. Other Development Activities
11.1.9. Clinical Development
11.1.10. Clinical Trials Information
11.1.11. Safety and Efficacy
11.2. Gefapixant: Merck & Co., Inc.
11.2.1. Drug Description
11.2.2. Product Profile
11.2.3. Other Development Activities
11.2.4. Clinical Development
11.2.5. Clinical Trials Information
11.2.6. Safety and Efficacy
11.3. GLPG1690: Galapagos NV
11.3.1. Drug Description
11.3.2. Product Profile
11.3.3. Regulatory Milestones
11.3.4. Other Development Activities
11.3.5. Clinical Development
11.3.6. Clinical Trials Information
11.3.7. Safety and Efficacy
11.4. LT-1001: LTT Bio-Pharma
11.4.1. Drug Description
11.4.2. Product Profile
11.4.3. Other Development Activities
11.4.4. Clinical Development
11.4.5. Clinical Trials Information
11.4.6. Safety and Efficacy
11.5. BG00011: Biogen Inc.
11.5.1. Drug Description
11.5.2. Product Profile
11.5.3. Regulatory Milestones
11.5.4. Other Development Activities
11.5.5. Clinical Development
11.5.6. Clinical Trials Information
11.5.7. Safety and Efficacy
11.6. BMS-986020: Bristol-Myers Squibb
11.6.1. Drug Description
11.6.2. Product Profile
11.6.3. Regulatory Milestones
11.6.4. Other Development Activities
11.6.5. Clinical Development
11.6.6. Clinical Trials Information
11.6.7. Safety and Efficacy
11.7. LT-1002: Chong Kun Dang Pharmaceutical
11.7.1. Drug Description
11.7.2. Product Profile
11.7.3. Other Development Activities
11.8. Pamrevlumab: FibroGen
11.8.1. Drug Description
11.8.2. Product Profile
11.8.3. Regulatory Milestones
11.8.4. Other Development Activities
11.8.5. Clinical Development
11.8.6. Clinical Trials Information
11.8.7. Safety and Efficacy
11.9. PBI4050: ProMetic Life Sciences
11.9.1. Drug Description
11.9.2. Product Profile
11.9.3. Regulatory Milestones
11.9.4. Other Development Activities
11.9.5. Clinical Development
11.9.6. Clinical Trials Information
11.9.7. Safety and Efficacy
11.10. PRM 151: Promedior, Inc.
11.10.1. Drug Description
11.10.2. Product Profile
11.10.3. Regulatory Milestones
11.10.4. Other Development Activities
11.10.5. Clinical Development
11.10.6. Clinical Trials Information
11.10.7. Safety and Efficacy
11.11. Tipelukast: MediciNova
11.11.1. Drug Description
11.11.2. Product Profile
11.11.3. Regulatory Milestones
11.11.4. Other Development Activities
11.11.5. Clinical Development
11.11.6. Clinical Trials Information
11.11.7. Safety and Efficacy
11.12. TD139: Bristol-Myers Squibb
11.12.1. Drug Description
11.12.2. Product Profile
11.12.3. Other Development Activities
11.12.4. Clinical Development
11.12.5. Clinical Trials Information
11.12.6. Safety and Efficacy
11.13. VAY736: Novartis
11.13.1. Drug Description
11.13.2. Product Profile
11.13.3. Other Development Activities
11.13.4. Clinical Development
11.13.5. Clinical Trials Information
11.14. TAS-115: Taiho Pharmaceutical
11.14.1. Drug Description
11.14.2. Product Profile
11.14.3. Clinical Development
11.14.4. Clinical Trials Information
12. IPF: Market Analysis
12.1. Key Findings
12.2. Total Market Size of IPF in 7 MM
12.3. Therapy Based Market Size of IPF in 7 MM
13. Market Size of IPF by Country
13.1. United States Market Analysis
13.1.1. Market Size of IPF in the US
13.1.2. Therapy Based Market Size of IPF in the US
13.2. EU5 Market Outlook
13.3. Germany
13.3.1. Market Size of IPF in Germany
13.3.2. Therapy Based Market Size of IPF in Germany
13.4. France
13.4.1. Market Size of IPF in France
13.4.2. Therapy Based Market Size of IPF in France
13.5. Italy
13.5.1. Market Size of IPF in Italy
13.5.2. Therapy Based Market Size of IPF in Italy
13.6. United Kingdom
13.6.1. Market Size of IPF in the UK
13.6.2. Therapy Based Market Size of IPF in the UK
13.7. Spain
13.7.1. Market Size of IPF in Spain
13.7.2. Therapy Based Market Size of IPF in Spain
13.8. Japan: Market Analysis
13.8.1. Market Size of IPF in Japan
13.8.2. Therapy Based Market Size of IPF in Japan
14. Market Drivers of IPF
15. Market Barriers of IPF
16. Appendix
16.1. Report Methodology
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

 

1. Key Insights
2. IPF Market Overview at a Glance
2.1. Market Share (%) Distribution of IPF in 2017
2.2. Market Share (%) Distribution of IPF in 2027
3. Disease Background and Overview: Idiopathic Pulmonary Fibrosis (IPF)
3.1. Introduction
3.2. Staging of IPF
3.3. Risk Factors & Disease Causes
3.4. Symptoms
3.5. Pathogenesis
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7 MM Prevalent Population of IPF
4.3. Country Wise-Epidemiology of IPF
4.3.1. United States
4.3.2. Prevalent cases of IPF in the United States
4.3.3. Prevalent Population of IPF by severity
4.3.4. Gender-Specific IPF Prevalence
4.3.5. Age-Specific IPF Prevalence
4.3.6. EU5
4.3.7. Prevalent Population of IPF in EU5
4.3.8. France
4.3.9. Prevalent Population of IPF
4.3.10. Prevalent Population of IPF by severity
4.3.11. Gender-Specific IPF Prevalence
4.3.12. Age-Specific IPF Prevalence
4.3.13. Germany
4.3.14. Prevalent Population of IPF
4.3.15. Prevalent Population of IPF by severity
4.3.16. Gender-Specific IPF Prevalence
4.3.17. Age-Specific IPF Prevalence
4.3.18. Italy
4.3.19. Prevalent Population of IPF
4.3.20. Prevalent Population of IPF by severity
4.3.21. Gender-Specific IPF Prevalence
4.3.22. Age-Specific IPF Prevalence
4.3.23. Spain
4.3.24. Prevalent Population of IPF
4.3.25. Prevalent Population of IPF by severity
4.3.26. Gender-Specific IPF Prevalence
4.3.27. Age-Specific IPF Prevalence
4.3.28. United Kingdom
4.3.29. Prevalent Population of IPF
4.3.30. Prevalent Population of IPF by severity
4.3.31. Gender-Specific IPF Prevalence
4.3.32. Age-Specific IPF Prevalence
4.3.33. Japan
4.3.34. Prevalent Population of IPF
4.3.35. Prevalent Population of IPF by severity
4.3.36. Gender-SPECIFIC IPF Prevalence
4.3.37. Age-Specific IPF Prevalence
5. Current Treatment Practices
5.1. ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of IPF (An Update of 2011 Clinical Practice Guideline)
6. Unmet needs
7. Marketed Products
7.1. Esbriet (Pirfenidone): InterMune Inc.
7.1.1. Product Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Safety and Efficacy of Esbriet
7.1.5. Side effects of Esbriet
7.1.6. Product Profile
7.2. Ofev (Nintedanib): Boehringer Ingelheim Pharma GmbH & Co. KG
7.2.1. Product Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Safety and Efficacy of Ofev
7.2.5. Side effects of Ofev
7.2.6. Product Profile
8. Emerging Therapies
9. Key Cross Competition
10. Phase III Drugs
10.1. Thrombomodulin Alfa: Asahi Kasei Pharma Corporation
10.1.1. Drug Description
10.1.2. Product Profile
10.1.3. Clinical Development
10.1.4. Clinical Trials Information
10.1.5. Safety and Efficacy
11. Phase II Drugs
11.1. CC-90001: Celgene Corporation
11.1.1. Drug Description
11.1.2. Product Profile
11.1.3. Clinical Development
11.1.4. Clinical Trials Information
11.1.5. Safety and Efficacy
11.1.6. Drug Description
11.1.7. Product Profile
11.1.8. Other Development Activities
11.1.9. Clinical Development
11.1.10. Clinical Trials Information
11.1.11. Safety and Efficacy
11.2. Gefapixant: Merck & Co., Inc.
11.2.1. Drug Description
11.2.2. Product Profile
11.2.3. Other Development Activities
11.2.4. Clinical Development
11.2.5. Clinical Trials Information
11.2.6. Safety and Efficacy
11.3. GLPG1690: Galapagos NV
11.3.1. Drug Description
11.3.2. Product Profile
11.3.3. Regulatory Milestones
11.3.4. Other Development Activities
11.3.5. Clinical Development
11.3.6. Clinical Trials Information
11.3.7. Safety and Efficacy
11.4. LT-1001: LTT Bio-Pharma
11.4.1. Drug Description
11.4.2. Product Profile
11.4.3. Other Development Activities
11.4.4. Clinical Development
11.4.5. Clinical Trials Information
11.4.6. Safety and Efficacy
11.5. BG00011: Biogen Inc.
11.5.1. Drug Description
11.5.2. Product Profile
11.5.3. Regulatory Milestones
11.5.4. Other Development Activities
11.5.5. Clinical Development
11.5.6. Clinical Trials Information
11.5.7. Safety and Efficacy
11.6. BMS-986020: Bristol-Myers Squibb
11.6.1. Drug Description
11.6.2. Product Profile
11.6.3. Regulatory Milestones
11.6.4. Other Development Activities
11.6.5. Clinical Development
11.6.6. Clinical Trials Information
11.6.7. Safety and Efficacy
11.7. LT-1002: Chong Kun Dang Pharmaceutical
11.7.1. Drug Description
11.7.2. Product Profile
11.7.3. Other Development Activities
11.8. Pamrevlumab: FibroGen
11.8.1. Drug Description
11.8.2. Product Profile
11.8.3. Regulatory Milestones
11.8.4. Other Development Activities
11.8.5. Clinical Development
11.8.6. Clinical Trials Information
11.8.7. Safety and Efficacy
11.9. PBI4050: ProMetic Life Sciences
11.9.1. Drug Description
11.9.2. Product Profile
11.9.3. Regulatory Milestones
11.9.4. Other Development Activities
11.9.5. Clinical Development
11.9.6. Clinical Trials Information
11.9.7. Safety and Efficacy
11.10. PRM 151: Promedior, Inc.
11.10.1. Drug Description
11.10.2. Product Profile
11.10.3. Regulatory Milestones
11.10.4. Other Development Activities
11.10.5. Clinical Development
11.10.6. Clinical Trials Information
11.10.7. Safety and Efficacy
11.11. Tipelukast: MediciNova
11.11.1. Drug Description
11.11.2. Product Profile
11.11.3. Regulatory Milestones
11.11.4. Other Development Activities
11.11.5. Clinical Development
11.11.6. Clinical Trials Information
11.11.7. Safety and Efficacy
11.12. TD139: Bristol-Myers Squibb
11.12.1. Drug Description
11.12.2. Product Profile
11.12.3. Other Development Activities
11.12.4. Clinical Development
11.12.5. Clinical Trials Information
11.12.6. Safety and Efficacy
11.13. VAY736: Novartis
11.13.1. Drug Description
11.13.2. Product Profile
11.13.3. Other Development Activities
11.13.4. Clinical Development
11.13.5. Clinical Trials Information
11.14. TAS-115: Taiho Pharmaceutical
11.14.1. Drug Description
11.14.2. Product Profile
11.14.3. Clinical Development
11.14.4. Clinical Trials Information
12. IPF: Market Analysis
12.1. Key Findings
12.2. Total Market Size of IPF in 7 MM
12.3. Therapy Based Market Size of IPF in 7 MM
13. Market Size of IPF by Country
13.1. United States Market Analysis
13.1.1. Market Size of IPF in the US
13.1.2. Therapy Based Market Size of IPF in the US
13.2. EU5 Market Outlook
13.3. Germany
13.3.1. Market Size of IPF in Germany
13.3.2. Therapy Based Market Size of IPF in Germany
13.4. France
13.4.1. Market Size of IPF in France
13.4.2. Therapy Based Market Size of IPF in France
13.5. Italy
13.5.1. Market Size of IPF in Italy
13.5.2. Therapy Based Market Size of IPF in Italy
13.6. United Kingdom
13.6.1. Market Size of IPF in the UK
13.6.2. Therapy Based Market Size of IPF in the UK
13.7. Spain
13.7.1. Market Size of IPF in Spain
13.7.2. Therapy Based Market Size of IPF in Spain
13.8. Japan: Market Analysis
13.8.1. Market Size of IPF in Japan
13.8.2. Therapy Based Market Size of IPF in Japan
14. Market Drivers of IPF
15. Market Barriers of IPF
16. Appendix
16.1. Report Methodology
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

 

1. Key Insights
2. IPF Market Overview at a Glance
2.1. Market Share (%) Distribution of IPF in 2017
2.2. Market Share (%) Distribution of IPF in 2027
3. Disease Background and Overview: Idiopathic Pulmonary Fibrosis (IPF)
3.1. Introduction
3.2. Staging of IPF
3.3. Risk Factors & Disease Causes
3.4. Symptoms
3.5. Pathogenesis
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7 MM Prevalent Population of IPF
4.3. Country Wise-Epidemiology of IPF
4.3.1. United States
4.3.2. Prevalent cases of IPF in the United States
4.3.3. Prevalent Population of IPF by severity
4.3.4. Gender-Specific IPF Prevalence
4.3.5. Age-Specific IPF Prevalence
4.3.6. EU5
4.3.7. Prevalent Population of IPF in EU5
4.3.8. France
4.3.9. Prevalent Population of IPF
4.3.10. Prevalent Population of IPF by severity
4.3.11. Gender-Specific IPF Prevalence
4.3.12. Age-Specific IPF Prevalence
4.3.13. Germany
4.3.14. Prevalent Population of IPF
4.3.15. Prevalent Population of IPF by severity
4.3.16. Gender-Specific IPF Prevalence
4.3.17. Age-Specific IPF Prevalence
4.3.18. Italy
4.3.19. Prevalent Population of IPF
4.3.20. Prevalent Population of IPF by severity
4.3.21. Gender-Specific IPF Prevalence
4.3.22. Age-Specific IPF Prevalence
4.3.23. Spain
4.3.24. Prevalent Population of IPF
4.3.25. Prevalent Population of IPF by severity
4.3.26. Gender-Specific IPF Prevalence
4.3.27. Age-Specific IPF Prevalence
4.3.28. United Kingdom
4.3.29. Prevalent Population of IPF
4.3.30. Prevalent Population of IPF by severity
4.3.31. Gender-Specific IPF Prevalence
4.3.32. Age-Specific IPF Prevalence
4.3.33. Japan
4.3.34. Prevalent Population of IPF
4.3.35. Prevalent Population of IPF by severity
4.3.36. Gender-SPECIFIC IPF Prevalence
4.3.37. Age-Specific IPF Prevalence
5. Current Treatment Practices
5.1. ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of IPF (An Update of 2011 Clinical Practice Guideline)
6. Unmet needs
7. Marketed Products
7.1. Esbriet (Pirfenidone): InterMune Inc.
7.1.1. Product Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Safety and Efficacy of Esbriet
7.1.5. Side effects of Esbriet
7.1.6. Product Profile
7.2. Ofev (Nintedanib): Boehringer Ingelheim Pharma GmbH & Co. KG
7.2.1. Product Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Safety and Efficacy of Ofev
7.2.5. Side effects of Ofev
7.2.6. Product Profile
8. Emerging Therapies
9. Key Cross Competition
10. Phase III Drugs
10.1. Thrombomodulin Alfa: Asahi Kasei Pharma Corporation
10.1.1. Drug Description
10.1.2. Product Profile
10.1.3. Clinical Development
10.1.4. Clinical Trials Information
10.1.5. Safety and Efficacy
11. Phase II Drugs
11.1. CC-90001: Celgene Corporation
11.1.1. Drug Description
11.1.2. Product Profile
11.1.3. Clinical Development
11.1.4. Clinical Trials Information
11.1.5. Safety and Efficacy
11.1.6. Drug Description
11.1.7. Product Profile
11.1.8. Other Development Activities
11.1.9. Clinical Development
11.1.10. Clinical Trials Information
11.1.11. Safety and Efficacy
11.2. Gefapixant: Merck & Co., Inc.
11.2.1. Drug Description
11.2.2. Product Profile
11.2.3. Other Development Activities
11.2.4. Clinical Development
11.2.5. Clinical Trials Information
11.2.6. Safety and Efficacy
11.3. GLPG1690: Galapagos NV
11.3.1. Drug Description
11.3.2. Product Profile
11.3.3. Regulatory Milestones
11.3.4. Other Development Activities
11.3.5. Clinical Development
11.3.6. Clinical Trials Information
11.3.7. Safety and Efficacy
11.4. LT-1001: LTT Bio-Pharma
11.4.1. Drug Description
11.4.2. Product Profile
11.4.3. Other Development Activities
11.4.4. Clinical Development
11.4.5. Clinical Trials Information
11.4.6. Safety and Efficacy
11.5. BG00011: Biogen Inc.
11.5.1. Drug Description
11.5.2. Product Profile
11.5.3. Regulatory Milestones
11.5.4. Other Development Activities
11.5.5. Clinical Development
11.5.6. Clinical Trials Information
11.5.7. Safety and Efficacy
11.6. BMS-986020: Bristol-Myers Squibb
11.6.1. Drug Description
11.6.2. Product Profile
11.6.3. Regulatory Milestones
11.6.4. Other Development Activities
11.6.5. Clinical Development
11.6.6. Clinical Trials Information
11.6.7. Safety and Efficacy
11.7. LT-1002: Chong Kun Dang Pharmaceutical
11.7.1. Drug Description
11.7.2. Product Profile
11.7.3. Other Development Activities
11.8. Pamrevlumab: FibroGen
11.8.1. Drug Description
11.8.2. Product Profile
11.8.3. Regulatory Milestones
11.8.4. Other Development Activities
11.8.5. Clinical Development
11.8.6. Clinical Trials Information
11.8.7. Safety and Efficacy
11.9. PBI4050: ProMetic Life Sciences
11.9.1. Drug Description
11.9.2. Product Profile
11.9.3. Regulatory Milestones
11.9.4. Other Development Activities
11.9.5. Clinical Development
11.9.6. Clinical Trials Information
11.9.7. Safety and Efficacy
11.10. PRM 151: Promedior, Inc.
11.10.1. Drug Description
11.10.2. Product Profile
11.10.3. Regulatory Milestones
11.10.4. Other Development Activities
11.10.5. Clinical Development
11.10.6. Clinical Trials Information
11.10.7. Safety and Efficacy
11.11. Tipelukast: MediciNova
11.11.1. Drug Description
11.11.2. Product Profile
11.11.3. Regulatory Milestones
11.11.4. Other Development Activities
11.11.5. Clinical Development
11.11.6. Clinical Trials Information
11.11.7. Safety and Efficacy
11.12. TD139: Bristol-Myers Squibb
11.12.1. Drug Description
11.12.2. Product Profile
11.12.3. Other Development Activities
11.12.4. Clinical Development
11.12.5. Clinical Trials Information
11.12.6. Safety and Efficacy
11.13. VAY736: Novartis
11.13.1. Drug Description
11.13.2. Product Profile
11.13.3. Other Development Activities
11.13.4. Clinical Development
11.13.5. Clinical Trials Information
11.14. TAS-115: Taiho Pharmaceutical
11.14.1. Drug Description
11.14.2. Product Profile
11.14.3. Clinical Development
11.14.4. Clinical Trials Information
12. IPF: Market Analysis
12.1. Key Findings
12.2. Total Market Size of IPF in 7 MM
12.3. Therapy Based Market Size of IPF in 7 MM
13. Market Size of IPF by Country
13.1. United States Market Analysis
13.1.1. Market Size of IPF in the US
13.1.2. Therapy Based Market Size of IPF in the US
13.2. EU5 Market Outlook
13.3. Germany
13.3.1. Market Size of IPF in Germany
13.3.2. Therapy Based Market Size of IPF in Germany
13.4. France
13.4.1. Market Size of IPF in France
13.4.2. Therapy Based Market Size of IPF in France
13.5. Italy
13.5.1. Market Size of IPF in Italy
13.5.2. Therapy Based Market Size of IPF in Italy
13.6. United Kingdom
13.6.1. Market Size of IPF in the UK
13.6.2. Therapy Based Market Size of IPF in the UK
13.7. Spain
13.7.1. Market Size of IPF in Spain
13.7.2. Therapy Based Market Size of IPF in Spain
13.8. Japan: Market Analysis
13.8.1. Market Size of IPF in Japan
13.8.2. Therapy Based Market Size of IPF in Japan
14. Market Drivers of IPF
15. Market Barriers of IPF
16. Appendix
16.1. Report Methodology
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

 

1. Key Insights
2. IPF Market Overview at a Glance
2.1. Market Share (%) Distribution of IPF in 2017
2.2. Market Share (%) Distribution of IPF in 2027
3. Disease Background and Overview: Idiopathic Pulmonary Fibrosis (IPF)
3.1. Introduction
3.2. Staging of IPF
3.3. Risk Factors & Disease Causes
3.4. Symptoms
3.5. Pathogenesis
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7 MM Prevalent Population of IPF
4.3. Country Wise-Epidemiology of IPF
4.3.1. United States
4.3.2. Prevalent cases of IPF in the United States
4.3.3. Prevalent Population of IPF by severity
4.3.4. Gender-Specific IPF Prevalence
4.3.5. Age-Specific IPF Prevalence
4.3.6. EU5
4.3.7. Prevalent Population of IPF in EU5
4.3.8. France
4.3.9. Prevalent Population of IPF
4.3.10. Prevalent Population of IPF by severity
4.3.11. Gender-Specific IPF Prevalence
4.3.12. Age-Specific IPF Prevalence
4.3.13. Germany
4.3.14. Prevalent Population of IPF
4.3.15. Prevalent Population of IPF by severity
4.3.16. Gender-Specific IPF Prevalence
4.3.17. Age-Specific IPF Prevalence
4.3.18. Italy
4.3.19. Prevalent Population of IPF
4.3.20. Prevalent Population of IPF by severity
4.3.21. Gender-Specific IPF Prevalence
4.3.22. Age-Specific IPF Prevalence
4.3.23. Spain
4.3.24. Prevalent Population of IPF
4.3.25. Prevalent Population of IPF by severity
4.3.26. Gender-Specific IPF Prevalence
4.3.27. Age-Specific IPF Prevalence
4.3.28. United Kingdom
4.3.29. Prevalent Population of IPF
4.3.30. Prevalent Population of IPF by severity
4.3.31. Gender-Specific IPF Prevalence
4.3.32. Age-Specific IPF Prevalence
4.3.33. Japan
4.3.34. Prevalent Population of IPF
4.3.35. Prevalent Population of IPF by severity
4.3.36. Gender-SPECIFIC IPF Prevalence
4.3.37. Age-Specific IPF Prevalence
5. Current Treatment Practices
5.1. ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of IPF (An Update of 2011 Clinical Practice Guideline)
6. Unmet needs
7. Marketed Products
7.1. Esbriet (Pirfenidone): InterMune Inc.
7.1.1. Product Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Safety and Efficacy of Esbriet
7.1.5. Side effects of Esbriet
7.1.6. Product Profile
7.2. Ofev (Nintedanib): Boehringer Ingelheim Pharma GmbH & Co. KG
7.2.1. Product Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Safety and Efficacy of Ofev
7.2.5. Side effects of Ofev
7.2.6. Product Profile
8. Emerging Therapies
9. Key Cross Competition
10. Phase III Drugs
10.1. Thrombomodulin Alfa: Asahi Kasei Pharma Corporation
10.1.1. Drug Description
10.1.2. Product Profile
10.1.3. Clinical Development
10.1.4. Clinical Trials Information
10.1.5. Safety and Efficacy
11. Phase II Drugs
11.1. CC-90001: Celgene Corporation
11.1.1. Drug Description
11.1.2. Product Profile
11.1.3. Clinical Development
11.1.4. Clinical Trials Information
11.1.5. Safety and Efficacy
11.1.6. Drug Description
11.1.7. Product Profile
11.1.8. Other Development Activities
11.1.9. Clinical Development
11.1.10. Clinical Trials Information
11.1.11. Safety and Efficacy
11.2. Gefapixant: Merck & Co., Inc.
11.2.1. Drug Description
11.2.2. Product Profile
11.2.3. Other Development Activities
11.2.4. Clinical Development
11.2.5. Clinical Trials Information
11.2.6. Safety and Efficacy
11.3. GLPG1690: Galapagos NV
11.3.1. Drug Description
11.3.2. Product Profile
11.3.3. Regulatory Milestones
11.3.4. Other Development Activities
11.3.5. Clinical Development
11.3.6. Clinical Trials Information
11.3.7. Safety and Efficacy
11.4. LT-1001: LTT Bio-Pharma
11.4.1. Drug Description
11.4.2. Product Profile
11.4.3. Other Development Activities
11.4.4. Clinical Development
11.4.5. Clinical Trials Information
11.4.6. Safety and Efficacy
11.5. BG00011: Biogen Inc.
11.5.1. Drug Description
11.5.2. Product Profile
11.5.3. Regulatory Milestones
11.5.4. Other Development Activities
11.5.5. Clinical Development
11.5.6. Clinical Trials Information
11.5.7. Safety and Efficacy
11.6. BMS-986020: Bristol-Myers Squibb
11.6.1. Drug Description
11.6.2. Product Profile
11.6.3. Regulatory Milestones
11.6.4. Other Development Activities
11.6.5. Clinical Development
11.6.6. Clinical Trials Information
11.6.7. Safety and Efficacy
11.7. LT-1002: Chong Kun Dang Pharmaceutical
11.7.1. Drug Description
11.7.2. Product Profile
11.7.3. Other Development Activities
11.8. Pamrevlumab: FibroGen
11.8.1. Drug Description
11.8.2. Product Profile
11.8.3. Regulatory Milestones
11.8.4. Other Development Activities
11.8.5. Clinical Development
11.8.6. Clinical Trials Information
11.8.7. Safety and Efficacy
11.9. PBI4050: ProMetic Life Sciences
11.9.1. Drug Description
11.9.2. Product Profile
11.9.3. Regulatory Milestones
11.9.4. Other Development Activities
11.9.5. Clinical Development
11.9.6. Clinical Trials Information
11.9.7. Safety and Efficacy
11.10. PRM 151: Promedior, Inc.
11.10.1. Drug Description
11.10.2. Product Profile
11.10.3. Regulatory Milestones
11.10.4. Other Development Activities
11.10.5. Clinical Development
11.10.6. Clinical Trials Information
11.10.7. Safety and Efficacy
11.11. Tipelukast: MediciNova
11.11.1. Drug Description
11.11.2. Product Profile
11.11.3. Regulatory Milestones
11.11.4. Other Development Activities
11.11.5. Clinical Development
11.11.6. Clinical Trials Information
11.11.7. Safety and Efficacy
11.12. TD139: Bristol-Myers Squibb
11.12.1. Drug Description
11.12.2. Product Profile
11.12.3. Other Development Activities
11.12.4. Clinical Development
11.12.5. Clinical Trials Information
11.12.6. Safety and Efficacy
11.13. VAY736: Novartis
11.13.1. Drug Description
11.13.2. Product Profile
11.13.3. Other Development Activities
11.13.4. Clinical Development
11.13.5. Clinical Trials Information
11.14. TAS-115: Taiho Pharmaceutical
11.14.1. Drug Description
11.14.2. Product Profile
11.14.3. Clinical Development
11.14.4. Clinical Trials Information
12. IPF: Market Analysis
12.1. Key Findings
12.2. Total Market Size of IPF in 7 MM
12.3. Therapy Based Market Size of IPF in 7 MM
13. Market Size of IPF by Country
13.1. United States Market Analysis
13.1.1. Market Size of IPF in the US
13.1.2. Therapy Based Market Size of IPF in the US
13.2. EU5 Market Outlook
13.3. Germany
13.3.1. Market Size of IPF in Germany
13.3.2. Therapy Based Market Size of IPF in Germany
13.4. France
13.4.1. Market Size of IPF in France
13.4.2. Therapy Based Market Size of IPF in France
13.5. Italy
13.5.1. Market Size of IPF in Italy
13.5.2. Therapy Based Market Size of IPF in Italy
13.6. United Kingdom
13.6.1. Market Size of IPF in the UK
13.6.2. Therapy Based Market Size of IPF in the UK
13.7. Spain
13.7.1. Market Size of IPF in Spain
13.7.2. Therapy Based Market Size of IPF in Spain
13.8. Japan: Market Analysis
13.8.1. Market Size of IPF in Japan
13.8.2. Therapy Based Market Size of IPF in Japan
14. Market Drivers of IPF
15. Market Barriers of IPF
16. Appendix
16.1. Report Methodology
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

 

1. Key Insights
2. IPF Market Overview at a Glance
2.1. Market Share (%) Distribution of IPF in 2017
2.2. Market Share (%) Distribution of IPF in 2027
3. Disease Background and Overview: Idiopathic Pulmonary Fibrosis (IPF)
3.1. Introduction
3.2. Staging of IPF
3.3. Risk Factors & Disease Causes
3.4. Symptoms
3.5. Pathogenesis
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7 MM Prevalent Population of IPF
4.3. Country Wise-Epidemiology of IPF
4.3.1. United States
4.3.2. Prevalent cases of IPF in the United States
4.3.3. Prevalent Population of IPF by severity
4.3.4. Gender-Specific IPF Prevalence
4.3.5. Age-Specific IPF Prevalence
4.3.6. EU5
4.3.7. Prevalent Population of IPF in EU5
4.3.8. France
4.3.9. Prevalent Population of IPF
4.3.10. Prevalent Population of IPF by severity
4.3.11. Gender-Specific IPF Prevalence
4.3.12. Age-Specific IPF Prevalence
4.3.13. Germany
4.3.14. Prevalent Population of IPF
4.3.15. Prevalent Population of IPF by severity
4.3.16. Gender-Specific IPF Prevalence
4.3.17. Age-Specific IPF Prevalence
4.3.18. Italy
4.3.19. Prevalent Population of IPF
4.3.20. Prevalent Population of IPF by severity
4.3.21. Gender-Specific IPF Prevalence
4.3.22. Age-Specific IPF Prevalence
4.3.23. Spain
4.3.24. Prevalent Population of IPF
4.3.25. Prevalent Population of IPF by severity
4.3.26. Gender-Specific IPF Prevalence
4.3.27. Age-Specific IPF Prevalence
4.3.28. United Kingdom
4.3.29. Prevalent Population of IPF
4.3.30. Prevalent Population of IPF by severity
4.3.31. Gender-Specific IPF Prevalence
4.3.32. Age-Specific IPF Prevalence
4.3.33. Japan
4.3.34. Prevalent Population of IPF
4.3.35. Prevalent Population of IPF by severity
4.3.36. Gender-SPECIFIC IPF Prevalence
4.3.37. Age-Specific IPF Prevalence
5. Current Treatment Practices
5.1. ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of IPF (An Update of 2011 Clinical Practice Guideline)
6. Unmet needs
7. Marketed Products
7.1. Esbriet (Pirfenidone): InterMune Inc.
7.1.1. Product Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Safety and Efficacy of Esbriet
7.1.5. Side effects of Esbriet
7.1.6. Product Profile
7.2. Ofev (Nintedanib): Boehringer Ingelheim Pharma GmbH & Co. KG
7.2.1. Product Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Safety and Efficacy of Ofev
7.2.5. Side effects of Ofev
7.2.6. Product Profile
8. Emerging Therapies
9. Key Cross Competition
10. Phase III Drugs
10.1. Thrombomodulin Alfa: Asahi Kasei Pharma Corporation
10.1.1. Drug Description
10.1.2. Product Profile
10.1.3. Clinical Development
10.1.4. Clinical Trials Information
10.1.5. Safety and Efficacy
11. Phase II Drugs
11.1. CC-90001: Celgene Corporation
11.1.1. Drug Description
11.1.2. Product Profile
11.1.3. Clinical Development
11.1.4. Clinical Trials Information
11.1.5. Safety and Efficacy
11.1.6. Drug Description
11.1.7. Product Profile
11.1.8. Other Development Activities
11.1.9. Clinical Development
11.1.10. Clinical Trials Information
11.1.11. Safety and Efficacy
11.2. Gefapixant: Merck & Co., Inc.
11.2.1. Drug Description
11.2.2. Product Profile
11.2.3. Other Development Activities
11.2.4. Clinical Development
11.2.5. Clinical Trials Information
11.2.6. Safety and Efficacy
11.3. GLPG1690: Galapagos NV
11.3.1. Drug Description
11.3.2. Product Profile
11.3.3. Regulatory Milestones
11.3.4. Other Development Activities
11.3.5. Clinical Development
11.3.6. Clinical Trials Information
11.3.7. Safety and Efficacy
11.4. LT-1001: LTT Bio-Pharma
11.4.1. Drug Description
11.4.2. Product Profile
11.4.3. Other Development Activities
11.4.4. Clinical Development
11.4.5. Clinical Trials Information
11.4.6. Safety and Efficacy
11.5. BG00011: Biogen Inc.
11.5.1. Drug Description
11.5.2. Product Profile
11.5.3. Regulatory Milestones
11.5.4. Other Development Activities
11.5.5. Clinical Development
11.5.6. Clinical Trials Information
11.5.7. Safety and Efficacy
11.6. BMS-986020: Bristol-Myers Squibb
11.6.1. Drug Description
11.6.2. Product Profile
11.6.3. Regulatory Milestones
11.6.4. Other Development Activities
11.6.5. Clinical Development
11.6.6. Clinical Trials Information
11.6.7. Safety and Efficacy
11.7. LT-1002: Chong Kun Dang Pharmaceutical
11.7.1. Drug Description
11.7.2. Product Profile
11.7.3. Other Development Activities
11.8. Pamrevlumab: FibroGen
11.8.1. Drug Description
11.8.2. Product Profile
11.8.3. Regulatory Milestones
11.8.4. Other Development Activities
11.8.5. Clinical Development
11.8.6. Clinical Trials Information
11.8.7. Safety and Efficacy
11.9. PBI4050: ProMetic Life Sciences
11.9.1. Drug Description
11.9.2. Product Profile
11.9.3. Regulatory Milestones
11.9.4. Other Development Activities
11.9.5. Clinical Development
11.9.6. Clinical Trials Information
11.9.7. Safety and Efficacy
11.10. PRM 151: Promedior, Inc.
11.10.1. Drug Description
11.10.2. Product Profile
11.10.3. Regulatory Milestones
11.10.4. Other Development Activities
11.10.5. Clinical Development
11.10.6. Clinical Trials Information
11.10.7. Safety and Efficacy
11.11. Tipelukast: MediciNova
11.11.1. Drug Description
11.11.2. Product Profile
11.11.3. Regulatory Milestones
11.11.4. Other Development Activities
11.11.5. Clinical Development
11.11.6. Clinical Trials Information
11.11.7. Safety and Efficacy
11.12. TD139: Bristol-Myers Squibb
11.12.1. Drug Description
11.12.2. Product Profile
11.12.3. Other Development Activities
11.12.4. Clinical Development
11.12.5. Clinical Trials Information
11.12.6. Safety and Efficacy
11.13. VAY736: Novartis
11.13.1. Drug Description
11.13.2. Product Profile
11.13.3. Other Development Activities
11.13.4. Clinical Development
11.13.5. Clinical Trials Information
11.14. TAS-115: Taiho Pharmaceutical
11.14.1. Drug Description
11.14.2. Product Profile
11.14.3. Clinical Development
11.14.4. Clinical Trials Information
12. IPF: Market Analysis
12.1. Key Findings
12.2. Total Market Size of IPF in 7 MM
12.3. Therapy Based Market Size of IPF in 7 MM
13. Market Size of IPF by Country
13.1. United States Market Analysis
13.1.1. Market Size of IPF in the US
13.1.2. Therapy Based Market Size of IPF in the US
13.2. EU5 Market Outlook
13.3. Germany
13.3.1. Market Size of IPF in Germany
13.3.2. Therapy Based Market Size of IPF in Germany
13.4. France
13.4.1. Market Size of IPF in France
13.4.2. Therapy Based Market Size of IPF in France
13.5. Italy
13.5.1. Market Size of IPF in Italy
13.5.2. Therapy Based Market Size of IPF in Italy
13.6. United Kingdom
13.6.1. Market Size of IPF in the UK
13.6.2. Therapy Based Market Size of IPF in the UK
13.7. Spain
13.7.1. Market Size of IPF in Spain
13.7.2. Therapy Based Market Size of IPF in Spain
13.8. Japan: Market Analysis
13.8.1. Market Size of IPF in Japan
13.8.2. Therapy Based Market Size of IPF in Japan
14. Market Drivers of IPF
15. Market Barriers of IPF
16. Appendix
16.1. Report Methodology
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

 

1. Key Insights
2. IPF Market Overview at a Glance
2.1. Market Share (%) Distribution of IPF in 2017
2.2. Market Share (%) Distribution of IPF in 2027
3. Disease Background and Overview: Idiopathic Pulmonary Fibrosis (IPF)
3.1. Introduction
3.2. Staging of IPF
3.3. Risk Factors & Disease Causes
3.4. Symptoms
3.5. Pathogenesis
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7 MM Prevalent Population of IPF
4.3. Country Wise-Epidemiology of IPF
4.3.1. United States
4.3.2. Prevalent cases of IPF in the United States
4.3.3. Prevalent Population of IPF by severity
4.3.4. Gender-Specific IPF Prevalence
4.3.5. Age-Specific IPF Prevalence
4.3.6. EU5
4.3.7. Prevalent Population of IPF in EU5
4.3.8. France
4.3.9. Prevalent Population of IPF
4.3.10. Prevalent Population of IPF by severity
4.3.11. Gender-Specific IPF Prevalence
4.3.12. Age-Specific IPF Prevalence
4.3.13. Germany
4.3.14. Prevalent Population of IPF
4.3.15. Prevalent Population of IPF by severity
4.3.16. Gender-Specific IPF Prevalence
4.3.17. Age-Specific IPF Prevalence
4.3.18. Italy
4.3.19. Prevalent Population of IPF
4.3.20. Prevalent Population of IPF by severity
4.3.21. Gender-Specific IPF Prevalence
4.3.22. Age-Specific IPF Prevalence
4.3.23. Spain
4.3.24. Prevalent Population of IPF
4.3.25. Prevalent Population of IPF by severity
4.3.26. Gender-Specific IPF Prevalence
4.3.27. Age-Specific IPF Prevalence
4.3.28. United Kingdom
4.3.29. Prevalent Population of IPF
4.3.30. Prevalent Population of IPF by severity
4.3.31. Gender-Specific IPF Prevalence
4.3.32. Age-Specific IPF Prevalence
4.3.33. Japan
4.3.34. Prevalent Population of IPF
4.3.35. Prevalent Population of IPF by severity
4.3.36. Gender-SPECIFIC IPF Prevalence
4.3.37. Age-Specific IPF Prevalence
5. Current Treatment Practices
5.1. ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of IPF (An Update of 2011 Clinical Practice Guideline)
6. Unmet needs
7. Marketed Products
7.1. Esbriet (Pirfenidone): InterMune Inc.
7.1.1. Product Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Safety and Efficacy of Esbriet
7.1.5. Side effects of Esbriet
7.1.6. Product Profile
7.2. Ofev (Nintedanib): Boehringer Ingelheim Pharma GmbH & Co. KG
7.2.1. Product Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Safety and Efficacy of Ofev
7.2.5. Side effects of Ofev
7.2.6. Product Profile
8. Emerging Therapies
9. Key Cross Competition
10. Phase III Drugs
10.1. Thrombomodulin Alfa: Asahi Kasei Pharma Corporation
10.1.1. Drug Description
10.1.2. Product Profile
10.1.3. Clinical Development
10.1.4. Clinical Trials Information
10.1.5. Safety and Efficacy
11. Phase II Drugs
11.1. CC-90001: Celgene Corporation
11.1.1. Drug Description
11.1.2. Product Profile
11.1.3. Clinical Development
11.1.4. Clinical Trials Information
11.1.5. Safety and Efficacy
11.1.6. Drug Description
11.1.7. Product Profile
11.1.8. Other Development Activities
11.1.9. Clinical Development
11.1.10. Clinical Trials Information
11.1.11. Safety and Efficacy
11.2. Gefapixant: Merck & Co., Inc.
11.2.1. Drug Description
11.2.2. Product Profile
11.2.3. Other Development Activities
11.2.4. Clinical Development
11.2.5. Clinical Trials Information
11.2.6. Safety and Efficacy
11.3. GLPG1690: Galapagos NV
11.3.1. Drug Description
11.3.2. Product Profile
11.3.3. Regulatory Milestones
11.3.4. Other Development Activities
11.3.5. Clinical Development
11.3.6. Clinical Trials Information
11.3.7. Safety and Efficacy
11.4. LT-1001: LTT Bio-Pharma
11.4.1. Drug Description
11.4.2. Product Profile
11.4.3. Other Development Activities
11.4.4. Clinical Development
11.4.5. Clinical Trials Information
11.4.6. Safety and Efficacy
11.5. BG00011: Biogen Inc.
11.5.1. Drug Description
11.5.2. Product Profile
11.5.3. Regulatory Milestones
11.5.4. Other Development Activities
11.5.5. Clinical Development
11.5.6. Clinical Trials Information
11.5.7. Safety and Efficacy
11.6. BMS-986020: Bristol-Myers Squibb
11.6.1. Drug Description
11.6.2. Product Profile
11.6.3. Regulatory Milestones
11.6.4. Other Development Activities
11.6.5. Clinical Development
11.6.6. Clinical Trials Information
11.6.7. Safety and Efficacy
11.7. LT-1002: Chong Kun Dang Pharmaceutical
11.7.1. Drug Description
11.7.2. Product Profile
11.7.3. Other Development Activities
11.8. Pamrevlumab: FibroGen
11.8.1. Drug Description
11.8.2. Product Profile
11.8.3. Regulatory Milestones
11.8.4. Other Development Activities
11.8.5. Clinical Development
11.8.6. Clinical Trials Information
11.8.7. Safety and Efficacy
11.9. PBI4050: ProMetic Life Sciences
11.9.1. Drug Description
11.9.2. Product Profile
11.9.3. Regulatory Milestones
11.9.4. Other Development Activities
11.9.5. Clinical Development
11.9.6. Clinical Trials Information
11.9.7. Safety and Efficacy
11.10. PRM 151: Promedior, Inc.
11.10.1. Drug Description
11.10.2. Product Profile
11.10.3. Regulatory Milestones
11.10.4. Other Development Activities
11.10.5. Clinical Development
11.10.6. Clinical Trials Information
11.10.7. Safety and Efficacy
11.11. Tipelukast: MediciNova
11.11.1. Drug Description
11.11.2. Product Profile
11.11.3. Regulatory Milestones
11.11.4. Other Development Activities
11.11.5. Clinical Development
11.11.6. Clinical Trials Information
11.11.7. Safety and Efficacy
11.12. TD139: Bristol-Myers Squibb
11.12.1. Drug Description
11.12.2. Product Profile
11.12.3. Other Development Activities
11.12.4. Clinical Development
11.12.5. Clinical Trials Information
11.12.6. Safety and Efficacy
11.13. VAY736: Novartis
11.13.1. Drug Description
11.13.2. Product Profile
11.13.3. Other Development Activities
11.13.4. Clinical Development
11.13.5. Clinical Trials Information
11.14. TAS-115: Taiho Pharmaceutical
11.14.1. Drug Description
11.14.2. Product Profile
11.14.3. Clinical Development
11.14.4. Clinical Trials Information
12. IPF: Market Analysis
12.1. Key Findings
12.2. Total Market Size of IPF in 7 MM
12.3. Therapy Based Market Size of IPF in 7 MM
13. Market Size of IPF by Country
13.1. United States Market Analysis
13.1.1. Market Size of IPF in the US
13.1.2. Therapy Based Market Size of IPF in the US
13.2. EU5 Market Outlook
13.3. Germany
13.3.1. Market Size of IPF in Germany
13.3.2. Therapy Based Market Size of IPF in Germany
13.4. France
13.4.1. Market Size of IPF in France
13.4.2. Therapy Based Market Size of IPF in France
13.5. Italy
13.5.1. Market Size of IPF in Italy
13.5.2. Therapy Based Market Size of IPF in Italy
13.6. United Kingdom
13.6.1. Market Size of IPF in the UK
13.6.2. Therapy Based Market Size of IPF in the UK
13.7. Spain
13.7.1. Market Size of IPF in Spain
13.7.2. Therapy Based Market Size of IPF in Spain
13.8. Japan: Market Analysis
13.8.1. Market Size of IPF in Japan
13.8.2. Therapy Based Market Size of IPF in Japan
14. Market Drivers of IPF
15. Market Barriers of IPF
16. Appendix
16.1. Report Methodology
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

 

1. Key Insights
2. IPF Market Overview at a Glance
2.1. Market Share (%) Distribution of IPF in 2017
2.2. Market Share (%) Distribution of IPF in 2027
3. Disease Background and Overview: Idiopathic Pulmonary Fibrosis (IPF)
3.1. Introduction
3.2. Staging of IPF
3.3. Risk Factors & Disease Causes
3.4. Symptoms
3.5. Pathogenesis
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7 MM Prevalent Population of IPF
4.3. Country Wise-Epidemiology of IPF
4.3.1. United States
4.3.2. Prevalent cases of IPF in the United States
4.3.3. Prevalent Population of IPF by severity
4.3.4. Gender-Specific IPF Prevalence
4.3.5. Age-Specific IPF Prevalence
4.3.6. EU5
4.3.7. Prevalent Population of IPF in EU5
4.3.8. France
4.3.9. Prevalent Population of IPF
4.3.10. Prevalent Population of IPF by severity
4.3.11. Gender-Specific IPF Prevalence
4.3.12. Age-Specific IPF Prevalence
4.3.13. Germany
4.3.14. Prevalent Population of IPF
4.3.15. Prevalent Population of IPF by severity
4.3.16. Gender-Specific IPF Prevalence
4.3.17. Age-Specific IPF Prevalence
4.3.18. Italy
4.3.19. Prevalent Population of IPF
4.3.20. Prevalent Population of IPF by severity
4.3.21. Gender-Specific IPF Prevalence
4.3.22. Age-Specific IPF Prevalence
4.3.23. Spain
4.3.24. Prevalent Population of IPF
4.3.25. Prevalent Population of IPF by severity
4.3.26. Gender-Specific IPF Prevalence
4.3.27. Age-Specific IPF Prevalence
4.3.28. United Kingdom
4.3.29. Prevalent Population of IPF
4.3.30. Prevalent Population of IPF by severity
4.3.31. Gender-Specific IPF Prevalence
4.3.32. Age-Specific IPF Prevalence
4.3.33. Japan
4.3.34. Prevalent Population of IPF
4.3.35. Prevalent Population of IPF by severity
4.3.36. Gender-SPECIFIC IPF Prevalence
4.3.37. Age-Specific IPF Prevalence
5. Current Treatment Practices
5.1. ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of IPF (An Update of 2011 Clinical Practice Guideline)
6. Unmet needs
7. Marketed Products
7.1. Esbriet (Pirfenidone): InterMune Inc.
7.1.1. Product Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Safety and Efficacy of Esbriet
7.1.5. Side effects of Esbriet
7.1.6. Product Profile
7.2. Ofev (Nintedanib): Boehringer Ingelheim Pharma GmbH & Co. KG
7.2.1. Product Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Safety and Efficacy of Ofev
7.2.5. Side effects of Ofev
7.2.6. Product Profile
8. Emerging Therapies
9. Key Cross Competition
10. Phase III Drugs
10.1. Thrombomodulin Alfa: Asahi Kasei Pharma Corporation
10.1.1. Drug Description
10.1.2. Product Profile
10.1.3. Clinical Development
10.1.4. Clinical Trials Information
10.1.5. Safety and Efficacy
11. Phase II Drugs
11.1. CC-90001: Celgene Corporation
11.1.1. Drug Description
11.1.2. Product Profile
11.1.3. Clinical Development
11.1.4. Clinical Trials Information
11.1.5. Safety and Efficacy
11.1.6. Drug Description
11.1.7. Product Profile
11.1.8. Other Development Activities
11.1.9. Clinical Development
11.1.10. Clinical Trials Information
11.1.11. Safety and Efficacy
11.2. Gefapixant: Merck & Co., Inc.
11.2.1. Drug Description
11.2.2. Product Profile
11.2.3. Other Development Activities
11.2.4. Clinical Development
11.2.5. Clinical Trials Information
11.2.6. Safety and Efficacy
11.3. GLPG1690: Galapagos NV
11.3.1. Drug Description
11.3.2. Product Profile
11.3.3. Regulatory Milestones
11.3.4. Other Development Activities
11.3.5. Clinical Development
11.3.6. Clinical Trials Information
11.3.7. Safety and Efficacy
11.4. LT-1001: LTT Bio-Pharma
11.4.1. Drug Description
11.4.2. Product Profile
11.4.3. Other Development Activities
11.4.4. Clinical Development
11.4.5. Clinical Trials Information
11.4.6. Safety and Efficacy
11.5. BG00011: Biogen Inc.
11.5.1. Drug Description
11.5.2. Product Profile
11.5.3. Regulatory Milestones
11.5.4. Other Development Activities
11.5.5. Clinical Development
11.5.6. Clinical Trials Information
11.5.7. Safety and Efficacy
11.6. BMS-986020: Bristol-Myers Squibb
11.6.1. Drug Description
11.6.2. Product Profile
11.6.3. Regulatory Milestones
11.6.4. Other Development Activities
11.6.5. Clinical Development
11.6.6. Clinical Trials Information
11.6.7. Safety and Efficacy
11.7. LT-1002: Chong Kun Dang Pharmaceutical
11.7.1. Drug Description
11.7.2. Product Profile
11.7.3. Other Development Activities
11.8. Pamrevlumab: FibroGen
11.8.1. Drug Description
11.8.2. Product Profile
11.8.3. Regulatory Milestones
11.8.4. Other Development Activities
11.8.5. Clinical Development
11.8.6. Clinical Trials Information
11.8.7. Safety and Efficacy
11.9. PBI4050: ProMetic Life Sciences
11.9.1. Drug Description
11.9.2. Product Profile
11.9.3. Regulatory Milestones
11.9.4. Other Development Activities
11.9.5. Clinical Development
11.9.6. Clinical Trials Information
11.9.7. Safety and Efficacy
11.10. PRM 151: Promedior, Inc.
11.10.1. Drug Description
11.10.2. Product Profile
11.10.3. Regulatory Milestones
11.10.4. Other Development Activities
11.10.5. Clinical Development
11.10.6. Clinical Trials Information
11.10.7. Safety and Efficacy
11.11. Tipelukast: MediciNova
11.11.1. Drug Description
11.11.2. Product Profile
11.11.3. Regulatory Milestones
11.11.4. Other Development Activities
11.11.5. Clinical Development
11.11.6. Clinical Trials Information
11.11.7. Safety and Efficacy
11.12. TD139: Bristol-Myers Squibb
11.12.1. Drug Description
11.12.2. Product Profile
11.12.3. Other Development Activities
11.12.4. Clinical Development
11.12.5. Clinical Trials Information
11.12.6. Safety and Efficacy
11.13. VAY736: Novartis
11.13.1. Drug Description
11.13.2. Product Profile
11.13.3. Other Development Activities
11.13.4. Clinical Development
11.13.5. Clinical Trials Information
11.14. TAS-115: Taiho Pharmaceutical
11.14.1. Drug Description
11.14.2. Product Profile
11.14.3. Clinical Development
11.14.4. Clinical Trials Information
12. IPF: Market Analysis
12.1. Key Findings
12.2. Total Market Size of IPF in 7 MM
12.3. Therapy Based Market Size of IPF in 7 MM
13. Market Size of IPF by Country
13.1. United States Market Analysis
13.1.1. Market Size of IPF in the US
13.1.2. Therapy Based Market Size of IPF in the US
13.2. EU5 Market Outlook
13.3. Germany
13.3.1. Market Size of IPF in Germany
13.3.2. Therapy Based Market Size of IPF in Germany
13.4. France
13.4.1. Market Size of IPF in France
13.4.2. Therapy Based Market Size of IPF in France
13.5. Italy
13.5.1. Market Size of IPF in Italy
13.5.2. Therapy Based Market Size of IPF in Italy
13.6. United Kingdom
13.6.1. Market Size of IPF in the UK
13.6.2. Therapy Based Market Size of IPF in the UK
13.7. Spain
13.7.1. Market Size of IPF in Spain
13.7.2. Therapy Based Market Size of IPF in Spain
13.8. Japan: Market Analysis
13.8.1. Market Size of IPF in Japan
13.8.2. Therapy Based Market Size of IPF in Japan
14. Market Drivers of IPF
15. Market Barriers of IPF
16. Appendix
16.1. Report Methodology
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

 

1. Key Insights
2. IPF Market Overview at a Glance
2.1. Market Share (%) Distribution of IPF in 2017
2.2. Market Share (%) Distribution of IPF in 2027
3. Disease Background and Overview: Idiopathic Pulmonary Fibrosis (IPF)
3.1. Introduction
3.2. Staging of IPF
3.3. Risk Factors & Disease Causes
3.4. Symptoms
3.5. Pathogenesis
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7 MM Prevalent Population of IPF
4.3. Country Wise-Epidemiology of IPF
4.3.1. United States
4.3.2. Prevalent cases of IPF in the United States
4.3.3. Prevalent Population of IPF by severity
4.3.4. Gender-Specific IPF Prevalence
4.3.5. Age-Specific IPF Prevalence
4.3.6. EU5
4.3.7. Prevalent Population of IPF in EU5
4.3.8. France
4.3.9. Prevalent Population of IPF
4.3.10. Prevalent Population of IPF by severity
4.3.11. Gender-Specific IPF Prevalence
4.3.12. Age-Specific IPF Prevalence
4.3.13. Germany
4.3.14. Prevalent Population of IPF
4.3.15. Prevalent Population of IPF by severity
4.3.16. Gender-Specific IPF Prevalence
4.3.17. Age-Specific IPF Prevalence
4.3.18. Italy
4.3.19. Prevalent Population of IPF
4.3.20. Prevalent Population of IPF by severity
4.3.21. Gender-Specific IPF Prevalence
4.3.22. Age-Specific IPF Prevalence
4.3.23. Spain
4.3.24. Prevalent Population of IPF
4.3.25. Prevalent Population of IPF by severity
4.3.26. Gender-Specific IPF Prevalence
4.3.27. Age-Specific IPF Prevalence
4.3.28. United Kingdom
4.3.29. Prevalent Population of IPF
4.3.30. Prevalent Population of IPF by severity
4.3.31. Gender-Specific IPF Prevalence
4.3.32. Age-Specific IPF Prevalence
4.3.33. Japan
4.3.34. Prevalent Population of IPF
4.3.35. Prevalent Population of IPF by severity
4.3.36. Gender-SPECIFIC IPF Prevalence
4.3.37. Age-Specific IPF Prevalence
5. Current Treatment Practices
5.1. ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of IPF (An Update of 2011 Clinical Practice Guideline)
6. Unmet needs
7. Marketed Products
7.1. Esbriet (Pirfenidone): InterMune Inc.
7.1.1. Product Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Safety and Efficacy of Esbriet
7.1.5. Side effects of Esbriet
7.1.6. Product Profile
7.2. Ofev (Nintedanib): Boehringer Ingelheim Pharma GmbH & Co. KG
7.2.1. Product Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Safety and Efficacy of Ofev
7.2.5. Side effects of Ofev
7.2.6. Product Profile
8. Emerging Therapies
9. Key Cross Competition
10. Phase III Drugs
10.1. Thrombomodulin Alfa: Asahi Kasei Pharma Corporation
10.1.1. Drug Description
10.1.2. Product Profile
10.1.3. Clinical Development
10.1.4. Clinical Trials Information
10.1.5. Safety and Efficacy
11. Phase II Drugs
11.1. CC-90001: Celgene Corporation
11.1.1. Drug Description
11.1.2. Product Profile
11.1.3. Clinical Development
11.1.4. Clinical Trials Information
11.1.5. Safety and Efficacy
11.1.6. Drug Description
11.1.7. Product Profile
11.1.8. Other Development Activities
11.1.9. Clinical Development
11.1.10. Clinical Trials Information
11.1.11. Safety and Efficacy
11.2. Gefapixant: Merck & Co., Inc.
11.2.1. Drug Description
11.2.2. Product Profile
11.2.3. Other Development Activities
11.2.4. Clinical Development
11.2.5. Clinical Trials Information
11.2.6. Safety and Efficacy
11.3. GLPG1690: Galapagos NV
11.3.1. Drug Description
11.3.2. Product Profile
11.3.3. Regulatory Milestones
11.3.4. Other Development Activities
11.3.5. Clinical Development
11.3.6. Clinical Trials Information
11.3.7. Safety and Efficacy
11.4. LT-1001: LTT Bio-Pharma
11.4.1. Drug Description
11.4.2. Product Profile
11.4.3. Other Development Activities
11.4.4. Clinical Development
11.4.5. Clinical Trials Information
11.4.6. Safety and Efficacy
11.5. BG00011: Biogen Inc.
11.5.1. Drug Description
11.5.2. Product Profile
11.5.3. Regulatory Milestones
11.5.4. Other Development Activities
11.5.5. Clinical Development
11.5.6. Clinical Trials Information
11.5.7. Safety and Efficacy
11.6. BMS-986020: Bristol-Myers Squibb
11.6.1. Drug Description
11.6.2. Product Profile
11.6.3. Regulatory Milestones
11.6.4. Other Development Activities
11.6.5. Clinical Development
11.6.6. Clinical Trials Information
11.6.7. Safety and Efficacy
11.7. LT-1002: Chong Kun Dang Pharmaceutical
11.7.1. Drug Description
11.7.2. Product Profile
11.7.3. Other Development Activities
11.8. Pamrevlumab: FibroGen
11.8.1. Drug Description
11.8.2. Product Profile
11.8.3. Regulatory Milestones
11.8.4. Other Development Activities
11.8.5. Clinical Development
11.8.6. Clinical Trials Information
11.8.7. Safety and Efficacy
11.9. PBI4050: ProMetic Life Sciences
11.9.1. Drug Description
11.9.2. Product Profile
11.9.3. Regulatory Milestones
11.9.4. Other Development Activities
11.9.5. Clinical Development
11.9.6. Clinical Trials Information
11.9.7. Safety and Efficacy
11.10. PRM 151: Promedior, Inc.
11.10.1. Drug Description
11.10.2. Product Profile
11.10.3. Regulatory Milestones
11.10.4. Other Development Activities
11.10.5. Clinical Development
11.10.6. Clinical Trials Information
11.10.7. Safety and Efficacy
11.11. Tipelukast: MediciNova
11.11.1. Drug Description
11.11.2. Product Profile
11.11.3. Regulatory Milestones
11.11.4. Other Development Activities
11.11.5. Clinical Development
11.11.6. Clinical Trials Information
11.11.7. Safety and Efficacy
11.12. TD139: Bristol-Myers Squibb
11.12.1. Drug Description
11.12.2. Product Profile
11.12.3. Other Development Activities
11.12.4. Clinical Development
11.12.5. Clinical Trials Information
11.12.6. Safety and Efficacy
11.13. VAY736: Novartis
11.13.1. Drug Description
11.13.2. Product Profile
11.13.3. Other Development Activities
11.13.4. Clinical Development
11.13.5. Clinical Trials Information
11.14. TAS-115: Taiho Pharmaceutical
11.14.1. Drug Description
11.14.2. Product Profile
11.14.3. Clinical Development
11.14.4. Clinical Trials Information
12. IPF: Market Analysis
12.1. Key Findings
12.2. Total Market Size of IPF in 7 MM
12.3. Therapy Based Market Size of IPF in 7 MM
13. Market Size of IPF by Country
13.1. United States Market Analysis
13.1.1. Market Size of IPF in the US
13.1.2. Therapy Based Market Size of IPF in the US
13.2. EU5 Market Outlook
13.3. Germany
13.3.1. Market Size of IPF in Germany
13.3.2. Therapy Based Market Size of IPF in Germany
13.4. France
13.4.1. Market Size of IPF in France
13.4.2. Therapy Based Market Size of IPF in France
13.5. Italy
13.5.1. Market Size of IPF in Italy
13.5.2. Therapy Based Market Size of IPF in Italy
13.6. United Kingdom
13.6.1. Market Size of IPF in the UK
13.6.2. Therapy Based Market Size of IPF in the UK
13.7. Spain
13.7.1. Market Size of IPF in Spain
13.7.2. Therapy Based Market Size of IPF in Spain
13.8. Japan: Market Analysis
13.8.1. Market Size of IPF in Japan
13.8.2. Therapy Based Market Size of IPF in Japan
14. Market Drivers of IPF
15. Market Barriers of IPF
16. Appendix
16.1. Report Methodology
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

 

1. Key Insights
2. IPF Market Overview at a Glance
2.1. Market Share (%) Distribution of IPF in 2017
2.2. Market Share (%) Distribution of IPF in 2027
3. Disease Background and Overview: Idiopathic Pulmonary Fibrosis (IPF)
3.1. Introduction
3.2. Staging of IPF
3.3. Risk Factors & Disease Causes
3.4. Symptoms
3.5. Pathogenesis
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7 MM Prevalent Population of IPF
4.3. Country Wise-Epidemiology of IPF
4.3.1. United States
4.3.2. Prevalent cases of IPF in the United States
4.3.3. Prevalent Population of IPF by severity
4.3.4. Gender-Specific IPF Prevalence
4.3.5. Age-Specific IPF Prevalence
4.3.6. EU5
4.3.7. Prevalent Population of IPF in EU5
4.3.8. France
4.3.9. Prevalent Population of IPF
4.3.10. Prevalent Population of IPF by severity
4.3.11. Gender-Specific IPF Prevalence
4.3.12. Age-Specific IPF Prevalence
4.3.13. Germany
4.3.14. Prevalent Population of IPF
4.3.15. Prevalent Population of IPF by severity
4.3.16. Gender-Specific IPF Prevalence
4.3.17. Age-Specific IPF Prevalence
4.3.18. Italy
4.3.19. Prevalent Population of IPF
4.3.20. Prevalent Population of IPF by severity
4.3.21. Gender-Specific IPF Prevalence
4.3.22. Age-Specific IPF Prevalence
4.3.23. Spain
4.3.24. Prevalent Population of IPF
4.3.25. Prevalent Population of IPF by severity
4.3.26. Gender-Specific IPF Prevalence
4.3.27. Age-Specific IPF Prevalence
4.3.28. United Kingdom
4.3.29. Prevalent Population of IPF
4.3.30. Prevalent Population of IPF by severity
4.3.31. Gender-Specific IPF Prevalence
4.3.32. Age-Specific IPF Prevalence
4.3.33. Japan
4.3.34. Prevalent Population of IPF
4.3.35. Prevalent Population of IPF by severity
4.3.36. Gender-SPECIFIC IPF Prevalence
4.3.37. Age-Specific IPF Prevalence
5. Current Treatment Practices
5.1. ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of IPF (An Update of 2011 Clinical Practice Guideline)
6. Unmet needs
7. Marketed Products
7.1. Esbriet (Pirfenidone): InterMune Inc.
7.1.1. Product Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Safety and Efficacy of Esbriet
7.1.5. Side effects of Esbriet
7.1.6. Product Profile
7.2. Ofev (Nintedanib): Boehringer Ingelheim Pharma GmbH & Co. KG
7.2.1. Product Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Safety and Efficacy of Ofev
7.2.5. Side effects of Ofev
7.2.6. Product Profile
8. Emerging Therapies
9. Key Cross Competition
10. Phase III Drugs
10.1. Thrombomodulin Alfa: Asahi Kasei Pharma Corporation
10.1.1. Drug Description
10.1.2. Product Profile
10.1.3. Clinical Development
10.1.4. Clinical Trials Information
10.1.5. Safety and Efficacy
11. Phase II Drugs
11.1. CC-90001: Celgene Corporation
11.1.1. Drug Description
11.1.2. Product Profile
11.1.3. Clinical Development
11.1.4. Clinical Trials Information
11.1.5. Safety and Efficacy
11.1.6. Drug Description
11.1.7. Product Profile
11.1.8. Other Development Activities
11.1.9. Clinical Development
11.1.10. Clinical Trials Information
11.1.11. Safety and Efficacy
11.2. Gefapixant: Merck & Co., Inc.
11.2.1. Drug Description
11.2.2. Product Profile
11.2.3. Other Development Activities
11.2.4. Clinical Development
11.2.5. Clinical Trials Information
11.2.6. Safety and Efficacy
11.3. GLPG1690: Galapagos NV
11.3.1. Drug Description
11.3.2. Product Profile
11.3.3. Regulatory Milestones
11.3.4. Other Development Activities
11.3.5. Clinical Development
11.3.6. Clinical Trials Information
11.3.7. Safety and Efficacy
11.4. LT-1001: LTT Bio-Pharma
11.4.1. Drug Description
11.4.2. Product Profile
11.4.3. Other Development Activities
11.4.4. Clinical Development
11.4.5. Clinical Trials Information
11.4.6. Safety and Efficacy
11.5. BG00011: Biogen Inc.
11.5.1. Drug Description
11.5.2. Product Profile
11.5.3. Regulatory Milestones
11.5.4. Other Development Activities
11.5.5. Clinical Development
11.5.6. Clinical Trials Information
11.5.7. Safety and Efficacy
11.6. BMS-986020: Bristol-Myers Squibb
11.6.1. Drug Description
11.6.2. Product Profile
11.6.3. Regulatory Milestones
11.6.4. Other Development Activities
11.6.5. Clinical Development
11.6.6. Clinical Trials Information
11.6.7. Safety and Efficacy
11.7. LT-1002: Chong Kun Dang Pharmaceutical
11.7.1. Drug Description
11.7.2. Product Profile
11.7.3. Other Development Activities
11.8. Pamrevlumab: FibroGen
11.8.1. Drug Description
11.8.2. Product Profile
11.8.3. Regulatory Milestones
11.8.4. Other Development Activities
11.8.5. Clinical Development
11.8.6. Clinical Trials Information
11.8.7. Safety and Efficacy
11.9. PBI4050: ProMetic Life Sciences
11.9.1. Drug Description
11.9.2. Product Profile
11.9.3. Regulatory Milestones
11.9.4. Other Development Activities
11.9.5. Clinical Development
11.9.6. Clinical Trials Information
11.9.7. Safety and Efficacy
11.10. PRM 151: Promedior, Inc.
11.10.1. Drug Description
11.10.2. Product Profile
11.10.3. Regulatory Milestones
11.10.4. Other Development Activities
11.10.5. Clinical Development
11.10.6. Clinical Trials Information
11.10.7. Safety and Efficacy
11.11. Tipelukast: MediciNova
11.11.1. Drug Description
11.11.2. Product Profile
11.11.3. Regulatory Milestones
11.11.4. Other Development Activities
11.11.5. Clinical Development
11.11.6. Clinical Trials Information
11.11.7. Safety and Efficacy
11.12. TD139: Bristol-Myers Squibb
11.12.1. Drug Description
11.12.2. Product Profile
11.12.3. Other Development Activities
11.12.4. Clinical Development
11.12.5. Clinical Trials Information
11.12.6. Safety and Efficacy
11.13. VAY736: Novartis
11.13.1. Drug Description
11.13.2. Product Profile
11.13.3. Other Development Activities
11.13.4. Clinical Development
11.13.5. Clinical Trials Information
11.14. TAS-115: Taiho Pharmaceutical
11.14.1. Drug Description
11.14.2. Product Profile
11.14.3. Clinical Development
11.14.4. Clinical Trials Information
12. IPF: Market Analysis
12.1. Key Findings
12.2. Total Market Size of IPF in 7 MM
12.3. Therapy Based Market Size of IPF in 7 MM
13. Market Size of IPF by Country
13.1. United States Market Analysis
13.1.1. Market Size of IPF in the US
13.1.2. Therapy Based Market Size of IPF in the US
13.2. EU5 Market Outlook
13.3. Germany
13.3.1. Market Size of IPF in Germany
13.3.2. Therapy Based Market Size of IPF in Germany
13.4. France
13.4.1. Market Size of IPF in France
13.4.2. Therapy Based Market Size of IPF in France
13.5. Italy
13.5.1. Market Size of IPF in Italy
13.5.2. Therapy Based Market Size of IPF in Italy
13.6. United Kingdom
13.6.1. Market Size of IPF in the UK
13.6.2. Therapy Based Market Size of IPF in the UK
13.7. Spain
13.7.1. Market Size of IPF in Spain
13.7.2. Therapy Based Market Size of IPF in Spain
13.8. Japan: Market Analysis
13.8.1. Market Size of IPF in Japan
13.8.2. Therapy Based Market Size of IPF in Japan
14. Market Drivers of IPF
15. Market Barriers of IPF
16. Appendix
16.1. Report Methodology
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

 

1. Key Insights
2. IPF Market Overview at a Glance
2.1. Market Share (%) Distribution of IPF in 2017
2.2. Market Share (%) Distribution of IPF in 2027
3. Disease Background and Overview: Idiopathic Pulmonary Fibrosis (IPF)
3.1. Introduction
3.2. Staging of IPF
3.3. Risk Factors & Disease Causes
3.4. Symptoms
3.5. Pathogenesis
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7 MM Prevalent Population of IPF
4.3. Country Wise-Epidemiology of IPF
4.3.1. United States
4.3.2. Prevalent cases of IPF in the United States
4.3.3. Prevalent Population of IPF by severity
4.3.4. Gender-Specific IPF Prevalence
4.3.5. Age-Specific IPF Prevalence
4.3.6. EU5
4.3.7. Prevalent Population of IPF in EU5
4.3.8. France
4.3.9. Prevalent Population of IPF
4.3.10. Prevalent Population of IPF by severity
4.3.11. Gender-Specific IPF Prevalence
4.3.12. Age-Specific IPF Prevalence
4.3.13. Germany
4.3.14. Prevalent Population of IPF
4.3.15. Prevalent Population of IPF by severity
4.3.16. Gender-Specific IPF Prevalence
4.3.17. Age-Specific IPF Prevalence
4.3.18. Italy
4.3.19. Prevalent Population of IPF
4.3.20. Prevalent Population of IPF by severity
4.3.21. Gender-Specific IPF Prevalence
4.3.22. Age-Specific IPF Prevalence
4.3.23. Spain
4.3.24. Prevalent Population of IPF
4.3.25. Prevalent Population of IPF by severity
4.3.26. Gender-Specific IPF Prevalence
4.3.27. Age-Specific IPF Prevalence
4.3.28. United Kingdom
4.3.29. Prevalent Population of IPF
4.3.30. Prevalent Population of IPF by severity
4.3.31. Gender-Specific IPF Prevalence
4.3.32. Age-Specific IPF Prevalence
4.3.33. Japan
4.3.34. Prevalent Population of IPF
4.3.35. Prevalent Population of IPF by severity
4.3.36. Gender-SPECIFIC IPF Prevalence
4.3.37. Age-Specific IPF Prevalence
5. Current Treatment Practices
5.1. ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of IPF (An Update of 2011 Clinical Practice Guideline)
6. Unmet needs
7. Marketed Products
7.1. Esbriet (Pirfenidone): InterMune Inc.
7.1.1. Product Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Safety and Efficacy of Esbriet
7.1.5. Side effects of Esbriet
7.1.6. Product Profile
7.2. Ofev (Nintedanib): Boehringer Ingelheim Pharma GmbH & Co. KG
7.2.1. Product Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Safety and Efficacy of Ofev
7.2.5. Side effects of Ofev
7.2.6. Product Profile
8. Emerging Therapies
9. Key Cross Competition
10. Phase III Drugs
10.1. Thrombomodulin Alfa: Asahi Kasei Pharma Corporation
10.1.1. Drug Description
10.1.2. Product Profile
10.1.3. Clinical Development
10.1.4. Clinical Trials Information
10.1.5. Safety and Efficacy
11. Phase II Drugs
11.1. CC-90001: Celgene Corporation
11.1.1. Drug Description
11.1.2. Product Profile
11.1.3. Clinical Development
11.1.4. Clinical Trials Information
11.1.5. Safety and Efficacy
11.1.6. Drug Description
11.1.7. Product Profile
11.1.8. Other Development Activities
11.1.9. Clinical Development
11.1.10. Clinical Trials Information
11.1.11. Safety and Efficacy
11.2. Gefapixant: Merck & Co., Inc.
11.2.1. Drug Description
11.2.2. Product Profile
11.2.3. Other Development Activities
11.2.4. Clinical Development
11.2.5. Clinical Trials Information
11.2.6. Safety and Efficacy
11.3. GLPG1690: Galapagos NV
11.3.1. Drug Description
11.3.2. Product Profile
11.3.3. Regulatory Milestones
11.3.4. Other Development Activities
11.3.5. Clinical Development
11.3.6. Clinical Trials Information
11.3.7. Safety and Efficacy
11.4. LT-1001: LTT Bio-Pharma
11.4.1. Drug Description
11.4.2. Product Profile
11.4.3. Other Development Activities
11.4.4. Clinical Development
11.4.5. Clinical Trials Information
11.4.6. Safety and Efficacy
11.5. BG00011: Biogen Inc.
11.5.1. Drug Description
11.5.2. Product Profile
11.5.3. Regulatory Milestones
11.5.4. Other Development Activities
11.5.5. Clinical Development
11.5.6. Clinical Trials Information
11.5.7. Safety and Efficacy
11.6. BMS-986020: Bristol-Myers Squibb
11.6.1. Drug Description
11.6.2. Product Profile
11.6.3. Regulatory Milestones
11.6.4. Other Development Activities
11.6.5. Clinical Development
11.6.6. Clinical Trials Information
11.6.7. Safety and Efficacy
11.7. LT-1002: Chong Kun Dang Pharmaceutical
11.7.1. Drug Description
11.7.2. Product Profile
11.7.3. Other Development Activities
11.8. Pamrevlumab: FibroGen
11.8.1. Drug Description
11.8.2. Product Profile
11.8.3. Regulatory Milestones
11.8.4. Other Development Activities
11.8.5. Clinical Development
11.8.6. Clinical Trials Information
11.8.7. Safety and Efficacy
11.9. PBI4050: ProMetic Life Sciences
11.9.1. Drug Description
11.9.2. Product Profile
11.9.3. Regulatory Milestones
11.9.4. Other Development Activities
11.9.5. Clinical Development
11.9.6. Clinical Trials Information
11.9.7. Safety and Efficacy
11.10. PRM 151: Promedior, Inc.
11.10.1. Drug Description
11.10.2. Product Profile
11.10.3. Regulatory Milestones
11.10.4. Other Development Activities
11.10.5. Clinical Development
11.10.6. Clinical Trials Information
11.10.7. Safety and Efficacy
11.11. Tipelukast: MediciNova
11.11.1. Drug Description
11.11.2. Product Profile
11.11.3. Regulatory Milestones
11.11.4. Other Development Activities
11.11.5. Clinical Development
11.11.6. Clinical Trials Information
11.11.7. Safety and Efficacy
11.12. TD139: Bristol-Myers Squibb
11.12.1. Drug Description
11.12.2. Product Profile
11.12.3. Other Development Activities
11.12.4. Clinical Development
11.12.5. Clinical Trials Information
11.12.6. Safety and Efficacy
11.13. VAY736: Novartis
11.13.1. Drug Description
11.13.2. Product Profile
11.13.3. Other Development Activities
11.13.4. Clinical Development
11.13.5. Clinical Trials Information
11.14. TAS-115: Taiho Pharmaceutical
11.14.1. Drug Description
11.14.2. Product Profile
11.14.3. Clinical Development
11.14.4. Clinical Trials Information
12. IPF: Market Analysis
12.1. Key Findings
12.2. Total Market Size of IPF in 7 MM
12.3. Therapy Based Market Size of IPF in 7 MM
13. Market Size of IPF by Country
13.1. United States Market Analysis
13.1.1. Market Size of IPF in the US
13.1.2. Therapy Based Market Size of IPF in the US
13.2. EU5 Market Outlook
13.3. Germany
13.3.1. Market Size of IPF in Germany
13.3.2. Therapy Based Market Size of IPF in Germany
13.4. France
13.4.1. Market Size of IPF in France
13.4.2. Therapy Based Market Size of IPF in France
13.5. Italy
13.5.1. Market Size of IPF in Italy
13.5.2. Therapy Based Market Size of IPF in Italy
13.6. United Kingdom
13.6.1. Market Size of IPF in the UK
13.6.2. Therapy Based Market Size of IPF in the UK
13.7. Spain
13.7.1. Market Size of IPF in Spain
13.7.2. Therapy Based Market Size of IPF in Spain
13.8. Japan: Market Analysis
13.8.1. Market Size of IPF in Japan
13.8.2. Therapy Based Market Size of IPF in Japan
14. Market Drivers of IPF
15. Market Barriers of IPF
16. Appendix
16.1. Report Methodology
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

 

1. Key Insights
2. IPF Market Overview at a Glance
2.1. Market Share (%) Distribution of IPF in 2017
2.2. Market Share (%) Distribution of IPF in 2027
3. Disease Background and Overview: Idiopathic Pulmonary Fibrosis (IPF)
3.1. Introduction
3.2. Staging of IPF
3.3. Risk Factors & Disease Causes
3.4. Symptoms
3.5. Pathogenesis
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7 MM Prevalent Population of IPF
4.3. Country Wise-Epidemiology of IPF
4.3.1. United States
4.3.2. Prevalent cases of IPF in the United States
4.3.3. Prevalent Population of IPF by severity
4.3.4. Gender-Specific IPF Prevalence
4.3.5. Age-Specific IPF Prevalence
4.3.6. EU5
4.3.7. Prevalent Population of IPF in EU5
4.3.8. France
4.3.9. Prevalent Population of IPF
4.3.10. Prevalent Population of IPF by severity
4.3.11. Gender-Specific IPF Prevalence
4.3.12. Age-Specific IPF Prevalence
4.3.13. Germany
4.3.14. Prevalent Population of IPF
4.3.15. Prevalent Population of IPF by severity
4.3.16. Gender-Specific IPF Prevalence
4.3.17. Age-Specific IPF Prevalence
4.3.18. Italy
4.3.19. Prevalent Population of IPF
4.3.20. Prevalent Population of IPF by severity
4.3.21. Gender-Specific IPF Prevalence
4.3.22. Age-Specific IPF Prevalence
4.3.23. Spain
4.3.24. Prevalent Population of IPF
4.3.25. Prevalent Population of IPF by severity
4.3.26. Gender-Specific IPF Prevalence
4.3.27. Age-Specific IPF Prevalence
4.3.28. United Kingdom
4.3.29. Prevalent Population of IPF
4.3.30. Prevalent Population of IPF by severity
4.3.31. Gender-Specific IPF Prevalence
4.3.32. Age-Specific IPF Prevalence
4.3.33. Japan
4.3.34. Prevalent Population of IPF
4.3.35. Prevalent Population of IPF by severity
4.3.36. Gender-SPECIFIC IPF Prevalence
4.3.37. Age-Specific IPF Prevalence
5. Current Treatment Practices
5.1. ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of IPF (An Update of 2011 Clinical Practice Guideline)
6. Unmet needs
7. Marketed Products
7.1. Esbriet (Pirfenidone): InterMune Inc.
7.1.1. Product Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Safety and Efficacy of Esbriet
7.1.5. Side effects of Esbriet
7.1.6. Product Profile
7.2. Ofev (Nintedanib): Boehringer Ingelheim Pharma GmbH & Co. KG
7.2.1. Product Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Safety and Efficacy of Ofev
7.2.5. Side effects of Ofev
7.2.6. Product Profile
8. Emerging Therapies
9. Key Cross Competition
10. Phase III Drugs
10.1. Thrombomodulin Alfa: Asahi Kasei Pharma Corporation
10.1.1. Drug Description
10.1.2. Product Profile
10.1.3. Clinical Development
10.1.4. Clinical Trials Information
10.1.5. Safety and Efficacy
11. Phase II Drugs
11.1. CC-90001: Celgene Corporation
11.1.1. Drug Description
11.1.2. Product Profile
11.1.3. Clinical Development
11.1.4. Clinical Trials Information
11.1.5. Safety and Efficacy
11.1.6. Drug Description
11.1.7. Product Profile
11.1.8. Other Development Activities
11.1.9. Clinical Development
11.1.10. Clinical Trials Information
11.1.11. Safety and Efficacy
11.2. Gefapixant: Merck & Co., Inc.
11.2.1. Drug Description
11.2.2. Product Profile
11.2.3. Other Development Activities
11.2.4. Clinical Development
11.2.5. Clinical Trials Information
11.2.6. Safety and Efficacy
11.3. GLPG1690: Galapagos NV
11.3.1. Drug Description
11.3.2. Product Profile
11.3.3. Regulatory Milestones
11.3.4. Other Development Activities
11.3.5. Clinical Development
11.3.6. Clinical Trials Information
11.3.7. Safety and Efficacy
11.4. LT-1001: LTT Bio-Pharma
11.4.1. Drug Description
11.4.2. Product Profile
11.4.3. Other Development Activities
11.4.4. Clinical Development
11.4.5. Clinical Trials Information
11.4.6. Safety and Efficacy
11.5. BG00011: Biogen Inc.
11.5.1. Drug Description
11.5.2. Product Profile
11.5.3. Regulatory Milestones
11.5.4. Other Development Activities
11.5.5. Clinical Development
11.5.6. Clinical Trials Information
11.5.7. Safety and Efficacy
11.6. BMS-986020: Bristol-Myers Squibb
11.6.1. Drug Description
11.6.2. Product Profile
11.6.3. Regulatory Milestones
11.6.4. Other Development Activities
11.6.5. Clinical Development
11.6.6. Clinical Trials Information
11.6.7. Safety and Efficacy
11.7. LT-1002: Chong Kun Dang Pharmaceutical
11.7.1. Drug Description
11.7.2. Product Profile
11.7.3. Other Development Activities
11.8. Pamrevlumab: FibroGen
11.8.1. Drug Description
11.8.2. Product Profile
11.8.3. Regulatory Milestones
11.8.4. Other Development Activities
11.8.5. Clinical Development
11.8.6. Clinical Trials Information
11.8.7. Safety and Efficacy
11.9. PBI4050: ProMetic Life Sciences
11.9.1. Drug Description
11.9.2. Product Profile
11.9.3. Regulatory Milestones
11.9.4. Other Development Activities
11.9.5. Clinical Development
11.9.6. Clinical Trials Information
11.9.7. Safety and Efficacy
11.10. PRM 151: Promedior, Inc.
11.10.1. Drug Description
11.10.2. Product Profile
11.10.3. Regulatory Milestones
11.10.4. Other Development Activities
11.10.5. Clinical Development
11.10.6. Clinical Trials Information
11.10.7. Safety and Efficacy
11.11. Tipelukast: MediciNova
11.11.1. Drug Description
11.11.2. Product Profile
11.11.3. Regulatory Milestones
11.11.4. Other Development Activities
11.11.5. Clinical Development
11.11.6. Clinical Trials Information
11.11.7. Safety and Efficacy
11.12. TD139: Bristol-Myers Squibb
11.12.1. Drug Description
11.12.2. Product Profile
11.12.3. Other Development Activities
11.12.4. Clinical Development
11.12.5. Clinical Trials Information
11.12.6. Safety and Efficacy
11.13. VAY736: Novartis
11.13.1. Drug Description
11.13.2. Product Profile
11.13.3. Other Development Activities
11.13.4. Clinical Development
11.13.5. Clinical Trials Information
11.14. TAS-115: Taiho Pharmaceutical
11.14.1. Drug Description
11.14.2. Product Profile
11.14.3. Clinical Development
11.14.4. Clinical Trials Information
12. IPF: Market Analysis
12.1. Key Findings
12.2. Total Market Size of IPF in 7 MM
12.3. Therapy Based Market Size of IPF in 7 MM
13. Market Size of IPF by Country
13.1. United States Market Analysis
13.1.1. Market Size of IPF in the US
13.1.2. Therapy Based Market Size of IPF in the US
13.2. EU5 Market Outlook
13.3. Germany
13.3.1. Market Size of IPF in Germany
13.3.2. Therapy Based Market Size of IPF in Germany
13.4. France
13.4.1. Market Size of IPF in France
13.4.2. Therapy Based Market Size of IPF in France
13.5. Italy
13.5.1. Market Size of IPF in Italy
13.5.2. Therapy Based Market Size of IPF in Italy
13.6. United Kingdom
13.6.1. Market Size of IPF in the UK
13.6.2. Therapy Based Market Size of IPF in the UK
13.7. Spain
13.7.1. Market Size of IPF in Spain
13.7.2. Therapy Based Market Size of IPF in Spain
13.8. Japan: Market Analysis
13.8.1. Market Size of IPF in Japan
13.8.2. Therapy Based Market Size of IPF in Japan
14. Market Drivers of IPF
15. Market Barriers of IPF
16. Appendix
16.1. Report Methodology
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

 

1. Key Insights
2. IPF Market Overview at a Glance
2.1. Market Share (%) Distribution of IPF in 2017
2.2. Market Share (%) Distribution of IPF in 2027
3. Disease Background and Overview: Idiopathic Pulmonary Fibrosis (IPF)
3.1. Introduction
3.2. Staging of IPF
3.3. Risk Factors & Disease Causes
3.4. Symptoms
3.5. Pathogenesis
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7 MM Prevalent Population of IPF
4.3. Country Wise-Epidemiology of IPF
4.3.1. United States
4.3.2. Prevalent cases of IPF in the United States
4.3.3. Prevalent Population of IPF by severity
4.3.4. Gender-Specific IPF Prevalence
4.3.5. Age-Specific IPF Prevalence
4.3.6. EU5
4.3.7. Prevalent Population of IPF in EU5
4.3.8. France
4.3.9. Prevalent Population of IPF
4.3.10. Prevalent Population of IPF by severity
4.3.11. Gender-Specific IPF Prevalence
4.3.12. Age-Specific IPF Prevalence
4.3.13. Germany
4.3.14. Prevalent Population of IPF
4.3.15. Prevalent Population of IPF by severity
4.3.16. Gender-Specific IPF Prevalence
4.3.17. Age-Specific IPF Prevalence
4.3.18. Italy
4.3.19. Prevalent Population of IPF
4.3.20. Prevalent Population of IPF by severity
4.3.21. Gender-Specific IPF Prevalence
4.3.22. Age-Specific IPF Prevalence
4.3.23. Spain
4.3.24. Prevalent Population of IPF
4.3.25. Prevalent Population of IPF by severity
4.3.26. Gender-Specific IPF Prevalence
4.3.27. Age-Specific IPF Prevalence
4.3.28. United Kingdom
4.3.29. Prevalent Population of IPF
4.3.30. Prevalent Population of IPF by severity
4.3.31. Gender-Specific IPF Prevalence
4.3.32. Age-Specific IPF Prevalence
4.3.33. Japan
4.3.34. Prevalent Population of IPF
4.3.35. Prevalent Population of IPF by severity
4.3.36. Gender-SPECIFIC IPF Prevalence
4.3.37. Age-Specific IPF Prevalence
5. Current Treatment Practices
5.1. ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of IPF (An Update of 2011 Clinical Practice Guideline)
6. Unmet needs
7. Marketed Products
7.1. Esbriet (Pirfenidone): InterMune Inc.
7.1.1. Product Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Safety and Efficacy of Esbriet
7.1.5. Side effects of Esbriet
7.1.6. Product Profile
7.2. Ofev (Nintedanib): Boehringer Ingelheim Pharma GmbH & Co. KG
7.2.1. Product Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Safety and Efficacy of Ofev
7.2.5. Side effects of Ofev
7.2.6. Product Profile
8. Emerging Therapies
9. Key Cross Competition
10. Phase III Drugs
10.1. Thrombomodulin Alfa: Asahi Kasei Pharma Corporation
10.1.1. Drug Description
10.1.2. Product Profile
10.1.3. Clinical Development
10.1.4. Clinical Trials Information
10.1.5. Safety and Efficacy
11. Phase II Drugs
11.1. CC-90001: Celgene Corporation
11.1.1. Drug Description
11.1.2. Product Profile
11.1.3. Clinical Development
11.1.4. Clinical Trials Information
11.1.5. Safety and Efficacy
11.1.6. Drug Description
11.1.7. Product Profile
11.1.8. Other Development Activities
11.1.9. Clinical Development
11.1.10. Clinical Trials Information
11.1.11. Safety and Efficacy
11.2. Gefapixant: Merck & Co., Inc.
11.2.1. Drug Description
11.2.2. Product Profile
11.2.3. Other Development Activities
11.2.4. Clinical Development
11.2.5. Clinical Trials Information
11.2.6. Safety and Efficacy
11.3. GLPG1690: Galapagos NV
11.3.1. Drug Description
11.3.2. Product Profile
11.3.3. Regulatory Milestones
11.3.4. Other Development Activities
11.3.5. Clinical Development
11.3.6. Clinical Trials Information
11.3.7. Safety and Efficacy
11.4. LT-1001: LTT Bio-Pharma
11.4.1. Drug Description
11.4.2. Product Profile
11.4.3. Other Development Activities
11.4.4. Clinical Development
11.4.5. Clinical Trials Information
11.4.6. Safety and Efficacy
11.5. BG00011: Biogen Inc.
11.5.1. Drug Description
11.5.2. Product Profile
11.5.3. Regulatory Milestones
11.5.4. Other Development Activities
11.5.5. Clinical Development
11.5.6. Clinical Trials Information
11.5.7. Safety and Efficacy
11.6. BMS-986020: Bristol-Myers Squibb
11.6.1. Drug Description
11.6.2. Product Profile
11.6.3. Regulatory Milestones
11.6.4. Other Development Activities
11.6.5. Clinical Development
11.6.6. Clinical Trials Information
11.6.7. Safety and Efficacy
11.7. LT-1002: Chong Kun Dang Pharmaceutical
11.7.1. Drug Description
11.7.2. Product Profile
11.7.3. Other Development Activities
11.8. Pamrevlumab: FibroGen
11.8.1. Drug Description
11.8.2. Product Profile
11.8.3. Regulatory Milestones
11.8.4. Other Development Activities
11.8.5. Clinical Development
11.8.6. Clinical Trials Information
11.8.7. Safety and Efficacy
11.9. PBI4050: ProMetic Life Sciences
11.9.1. Drug Description
11.9.2. Product Profile
11.9.3. Regulatory Milestones
11.9.4. Other Development Activities
11.9.5. Clinical Development
11.9.6. Clinical Trials Information
11.9.7. Safety and Efficacy
11.10. PRM 151: Promedior, Inc.
11.10.1. Drug Description
11.10.2. Product Profile
11.10.3. Regulatory Milestones
11.10.4. Other Development Activities
11.10.5. Clinical Development
11.10.6. Clinical Trials Information
11.10.7. Safety and Efficacy
11.11. Tipelukast: MediciNova
11.11.1. Drug Description
11.11.2. Product Profile
11.11.3. Regulatory Milestones
11.11.4. Other Development Activities
11.11.5. Clinical Development
11.11.6. Clinical Trials Information
11.11.7. Safety and Efficacy
11.12. TD139: Bristol-Myers Squibb
11.12.1. Drug Description
11.12.2. Product Profile
11.12.3. Other Development Activities
11.12.4. Clinical Development
11.12.5. Clinical Trials Information
11.12.6. Safety and Efficacy
11.13. VAY736: Novartis
11.13.1. Drug Description
11.13.2. Product Profile
11.13.3. Other Development Activities
11.13.4. Clinical Development
11.13.5. Clinical Trials Information
11.14. TAS-115: Taiho Pharmaceutical
11.14.1. Drug Description
11.14.2. Product Profile
11.14.3. Clinical Development
11.14.4. Clinical Trials Information
12. IPF: Market Analysis
12.1. Key Findings
12.2. Total Market Size of IPF in 7 MM
12.3. Therapy Based Market Size of IPF in 7 MM
13. Market Size of IPF by Country
13.1. United States Market Analysis
13.1.1. Market Size of IPF in the US
13.1.2. Therapy Based Market Size of IPF in the US
13.2. EU5 Market Outlook
13.3. Germany
13.3.1. Market Size of IPF in Germany
13.3.2. Therapy Based Market Size of IPF in Germany
13.4. France
13.4.1. Market Size of IPF in France
13.4.2. Therapy Based Market Size of IPF in France
13.5. Italy
13.5.1. Market Size of IPF in Italy
13.5.2. Therapy Based Market Size of IPF in Italy
13.6. United Kingdom
13.6.1. Market Size of IPF in the UK
13.6.2. Therapy Based Market Size of IPF in the UK
13.7. Spain
13.7.1. Market Size of IPF in Spain
13.7.2. Therapy Based Market Size of IPF in Spain
13.8. Japan: Market Analysis
13.8.1. Market Size of IPF in Japan
13.8.2. Therapy Based Market Size of IPF in Japan
14. Market Drivers of IPF
15. Market Barriers of IPF
16. Appendix
16.1. Report Methodology
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

 

1. Key Insights
2. IPF Market Overview at a Glance
2.1. Market Share (%) Distribution of IPF in 2017
2.2. Market Share (%) Distribution of IPF in 2027
3. Disease Background and Overview: Idiopathic Pulmonary Fibrosis (IPF)
3.1. Introduction
3.2. Staging of IPF
3.3. Risk Factors & Disease Causes
3.4. Symptoms
3.5. Pathogenesis
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7 MM Prevalent Population of IPF
4.3. Country Wise-Epidemiology of IPF
4.3.1. United States
4.3.2. Prevalent cases of IPF in the United States
4.3.3. Prevalent Population of IPF by severity
4.3.4. Gender-Specific IPF Prevalence
4.3.5. Age-Specific IPF Prevalence
4.3.6. EU5
4.3.7. Prevalent Population of IPF in EU5
4.3.8. France
4.3.9. Prevalent Population of IPF
4.3.10. Prevalent Population of IPF by severity
4.3.11. Gender-Specific IPF Prevalence
4.3.12. Age-Specific IPF Prevalence
4.3.13. Germany
4.3.14. Prevalent Population of IPF
4.3.15. Prevalent Population of IPF by severity
4.3.16. Gender-Specific IPF Prevalence
4.3.17. Age-Specific IPF Prevalence
4.3.18. Italy
4.3.19. Prevalent Population of IPF
4.3.20. Prevalent Population of IPF by severity
4.3.21. Gender-Specific IPF Prevalence
4.3.22. Age-Specific IPF Prevalence
4.3.23. Spain
4.3.24. Prevalent Population of IPF
4.3.25. Prevalent Population of IPF by severity
4.3.26. Gender-Specific IPF Prevalence
4.3.27. Age-Specific IPF Prevalence
4.3.28. United Kingdom
4.3.29. Prevalent Population of IPF
4.3.30. Prevalent Population of IPF by severity
4.3.31. Gender-Specific IPF Prevalence
4.3.32. Age-Specific IPF Prevalence
4.3.33. Japan
4.3.34. Prevalent Population of IPF
4.3.35. Prevalent Population of IPF by severity
4.3.36. Gender-SPECIFIC IPF Prevalence
4.3.37. Age-Specific IPF Prevalence
5. Current Treatment Practices
5.1. ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of IPF (An Update of 2011 Clinical Practice Guideline)
6. Unmet needs
7. Marketed Products
7.1. Esbriet (Pirfenidone): InterMune Inc.
7.1.1. Product Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Safety and Efficacy of Esbriet
7.1.5. Side effects of Esbriet
7.1.6. Product Profile
7.2. Ofev (Nintedanib): Boehringer Ingelheim Pharma GmbH & Co. KG
7.2.1. Product Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Safety and Efficacy of Ofev
7.2.5. Side effects of Ofev
7.2.6. Product Profile
8. Emerging Therapies
9. Key Cross Competition
10. Phase III Drugs
10.1. Thrombomodulin Alfa: Asahi Kasei Pharma Corporation
10.1.1. Drug Description
10.1.2. Product Profile
10.1.3. Clinical Development
10.1.4. Clinical Trials Information
10.1.5. Safety and Efficacy
11. Phase II Drugs
11.1. CC-90001: Celgene Corporation
11.1.1. Drug Description
11.1.2. Product Profile
11.1.3. Clinical Development
11.1.4. Clinical Trials Information
11.1.5. Safety and Efficacy
11.1.6. Drug Description
11.1.7. Product Profile
11.1.8. Other Development Activities
11.1.9. Clinical Development
11.1.10. Clinical Trials Information
11.1.11. Safety and Efficacy
11.2. Gefapixant: Merck & Co., Inc.
11.2.1. Drug Description
11.2.2. Product Profile
11.2.3. Other Development Activities
11.2.4. Clinical Development
11.2.5. Clinical Trials Information
11.2.6. Safety and Efficacy
11.3. GLPG1690: Galapagos NV
11.3.1. Drug Description
11.3.2. Product Profile
11.3.3. Regulatory Milestones
11.3.4. Other Development Activities
11.3.5. Clinical Development
11.3.6. Clinical Trials Information
11.3.7. Safety and Efficacy
11.4. LT-1001: LTT Bio-Pharma
11.4.1. Drug Description
11.4.2. Product Profile
11.4.3. Other Development Activities
11.4.4. Clinical Development
11.4.5. Clinical Trials Information
11.4.6. Safety and Efficacy
11.5. BG00011: Biogen Inc.
11.5.1. Drug Description
11.5.2. Product Profile
11.5.3. Regulatory Milestones
11.5.4. Other Development Activities
11.5.5. Clinical Development
11.5.6. Clinical Trials Information
11.5.7. Safety and Efficacy
11.6. BMS-986020: Bristol-Myers Squibb
11.6.1. Drug Description
11.6.2. Product Profile
11.6.3. Regulatory Milestones
11.6.4. Other Development Activities
11.6.5. Clinical Development
11.6.6. Clinical Trials Information
11.6.7. Safety and Efficacy
11.7. LT-1002: Chong Kun Dang Pharmaceutical
11.7.1. Drug Description
11.7.2. Product Profile
11.7.3. Other Development Activities
11.8. Pamrevlumab: FibroGen
11.8.1. Drug Description
11.8.2. Product Profile
11.8.3. Regulatory Milestones
11.8.4. Other Development Activities
11.8.5. Clinical Development
11.8.6. Clinical Trials Information
11.8.7. Safety and Efficacy
11.9. PBI4050: ProMetic Life Sciences
11.9.1. Drug Description
11.9.2. Product Profile
11.9.3. Regulatory Milestones
11.9.4. Other Development Activities
11.9.5. Clinical Development
11.9.6. Clinical Trials Information
11.9.7. Safety and Efficacy
11.10. PRM 151: Promedior, Inc.
11.10.1. Drug Description
11.10.2. Product Profile
11.10.3. Regulatory Milestones
11.10.4. Other Development Activities
11.10.5. Clinical Development
11.10.6. Clinical Trials Information
11.10.7. Safety and Efficacy
11.11. Tipelukast: MediciNova
11.11.1. Drug Description
11.11.2. Product Profile
11.11.3. Regulatory Milestones
11.11.4. Other Development Activities
11.11.5. Clinical Development
11.11.6. Clinical Trials Information
11.11.7. Safety and Efficacy
11.12. TD139: Bristol-Myers Squibb
11.12.1. Drug Description
11.12.2. Product Profile
11.12.3. Other Development Activities
11.12.4. Clinical Development
11.12.5. Clinical Trials Information
11.12.6. Safety and Efficacy
11.13. VAY736: Novartis
11.13.1. Drug Description
11.13.2. Product Profile
11.13.3. Other Development Activities
11.13.4. Clinical Development
11.13.5. Clinical Trials Information
11.14. TAS-115: Taiho Pharmaceutical
11.14.1. Drug Description
11.14.2. Product Profile
11.14.3. Clinical Development
11.14.4. Clinical Trials Information
12. IPF: Market Analysis
12.1. Key Findings
12.2. Total Market Size of IPF in 7 MM
12.3. Therapy Based Market Size of IPF in 7 MM
13. Market Size of IPF by Country
13.1. United States Market Analysis
13.1.1. Market Size of IPF in the US
13.1.2. Therapy Based Market Size of IPF in the US
13.2. EU5 Market Outlook
13.3. Germany
13.3.1. Market Size of IPF in Germany
13.3.2. Therapy Based Market Size of IPF in Germany
13.4. France
13.4.1. Market Size of IPF in France
13.4.2. Therapy Based Market Size of IPF in France
13.5. Italy
13.5.1. Market Size of IPF in Italy
13.5.2. Therapy Based Market Size of IPF in Italy
13.6. United Kingdom
13.6.1. Market Size of IPF in the UK
13.6.2. Therapy Based Market Size of IPF in the UK
13.7. Spain
13.7.1. Market Size of IPF in Spain
13.7.2. Therapy Based Market Size of IPF in Spain
13.8. Japan: Market Analysis
13.8.1. Market Size of IPF in Japan
13.8.2. Therapy Based Market Size of IPF in Japan
14. Market Drivers of IPF
15. Market Barriers of IPF
16. Appendix
16.1. Report Methodology
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

 

1. Key Insights
2. IPF Market Overview at a Glance
2.1. Market Share (%) Distribution of IPF in 2017
2.2. Market Share (%) Distribution of IPF in 2027
3. Disease Background and Overview: Idiopathic Pulmonary Fibrosis (IPF)
3.1. Introduction
3.2. Staging of IPF
3.3. Risk Factors & Disease Causes
3.4. Symptoms
3.5. Pathogenesis
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7 MM Prevalent Population of IPF
4.3. Country Wise-Epidemiology of IPF
4.3.1. United States
4.3.2. Prevalent cases of IPF in the United States
4.3.3. Prevalent Population of IPF by severity
4.3.4. Gender-Specific IPF Prevalence
4.3.5. Age-Specific IPF Prevalence
4.3.6. EU5
4.3.7. Prevalent Population of IPF in EU5
4.3.8. France
4.3.9. Prevalent Population of IPF
4.3.10. Prevalent Population of IPF by severity
4.3.11. Gender-Specific IPF Prevalence
4.3.12. Age-Specific IPF Prevalence
4.3.13. Germany
4.3.14. Prevalent Population of IPF
4.3.15. Prevalent Population of IPF by severity
4.3.16. Gender-Specific IPF Prevalence
4.3.17. Age-Specific IPF Prevalence
4.3.18. Italy
4.3.19. Prevalent Population of IPF
4.3.20. Prevalent Population of IPF by severity
4.3.21. Gender-Specific IPF Prevalence
4.3.22. Age-Specific IPF Prevalence
4.3.23. Spain
4.3.24. Prevalent Population of IPF
4.3.25. Prevalent Population of IPF by severity
4.3.26. Gender-Specific IPF Prevalence
4.3.27. Age-Specific IPF Prevalence
4.3.28. United Kingdom
4.3.29. Prevalent Population of IPF
4.3.30. Prevalent Population of IPF by severity
4.3.31. Gender-Specific IPF Prevalence
4.3.32. Age-Specific IPF Prevalence
4.3.33. Japan
4.3.34. Prevalent Population of IPF
4.3.35. Prevalent Population of IPF by severity
4.3.36. Gender-SPECIFIC IPF Prevalence
4.3.37. Age-Specific IPF Prevalence
5. Current Treatment Practices
5.1. ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of IPF (An Update of 2011 Clinical Practice Guideline)
6. Unmet needs
7. Marketed Products
7.1. Esbriet (Pirfenidone): InterMune Inc.
7.1.1. Product Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Safety and Efficacy of Esbriet
7.1.5. Side effects of Esbriet
7.1.6. Product Profile
7.2. Ofev (Nintedanib): Boehringer Ingelheim Pharma GmbH & Co. KG
7.2.1. Product Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Safety and Efficacy of Ofev
7.2.5. Side effects of Ofev
7.2.6. Product Profile
8. Emerging Therapies
9. Key Cross Competition
10. Phase III Drugs
10.1. Thrombomodulin Alfa: Asahi Kasei Pharma Corporation
10.1.1. Drug Description
10.1.2. Product Profile
10.1.3. Clinical Development
10.1.4. Clinical Trials Information
10.1.5. Safety and Efficacy
11. Phase II Drugs
11.1. CC-90001: Celgene Corporation
11.1.1. Drug Description
11.1.2. Product Profile
11.1.3. Clinical Development
11.1.4. Clinical Trials Information
11.1.5. Safety and Efficacy
11.1.6. Drug Description
11.1.7. Product Profile
11.1.8. Other Development Activities
11.1.9. Clinical Development
11.1.10. Clinical Trials Information
11.1.11. Safety and Efficacy
11.2. Gefapixant: Merck & Co., Inc.
11.2.1. Drug Description
11.2.2. Product Profile
11.2.3. Other Development Activities
11.2.4. Clinical Development
11.2.5. Clinical Trials Information
11.2.6. Safety and Efficacy
11.3. GLPG1690: Galapagos NV
11.3.1. Drug Description
11.3.2. Product Profile
11.3.3. Regulatory Milestones
11.3.4. Other Development Activities
11.3.5. Clinical Development
11.3.6. Clinical Trials Information
11.3.7. Safety and Efficacy
11.4. LT-1001: LTT Bio-Pharma
11.4.1. Drug Description
11.4.2. Product Profile
11.4.3. Other Development Activities
11.4.4. Clinical Development
11.4.5. Clinical Trials Information
11.4.6. Safety and Efficacy
11.5. BG00011: Biogen Inc.
11.5.1. Drug Description
11.5.2. Product Profile
11.5.3. Regulatory Milestones
11.5.4. Other Development Activities
11.5.5. Clinical Development
11.5.6. Clinical Trials Information
11.5.7. Safety and Efficacy
11.6. BMS-986020: Bristol-Myers Squibb
11.6.1. Drug Description
11.6.2. Product Profile
11.6.3. Regulatory Milestones
11.6.4. Other Development Activities
11.6.5. Clinical Development
11.6.6. Clinical Trials Information
11.6.7. Safety and Efficacy
11.7. LT-1002: Chong Kun Dang Pharmaceutical
11.7.1. Drug Description
11.7.2. Product Profile
11.7.3. Other Development Activities
11.8. Pamrevlumab: FibroGen
11.8.1. Drug Description
11.8.2. Product Profile
11.8.3. Regulatory Milestones
11.8.4. Other Development Activities
11.8.5. Clinical Development
11.8.6. Clinical Trials Information
11.8.7. Safety and Efficacy
11.9. PBI4050: ProMetic Life Sciences
11.9.1. Drug Description
11.9.2. Product Profile
11.9.3. Regulatory Milestones
11.9.4. Other Development Activities
11.9.5. Clinical Development
11.9.6. Clinical Trials Information
11.9.7. Safety and Efficacy
11.10. PRM 151: Promedior, Inc.
11.10.1. Drug Description
11.10.2. Product Profile
11.10.3. Regulatory Milestones
11.10.4. Other Development Activities
11.10.5. Clinical Development
11.10.6. Clinical Trials Information
11.10.7. Safety and Efficacy
11.11. Tipelukast: MediciNova
11.11.1. Drug Description
11.11.2. Product Profile
11.11.3. Regulatory Milestones
11.11.4. Other Development Activities
11.11.5. Clinical Development
11.11.6. Clinical Trials Information
11.11.7. Safety and Efficacy
11.12. TD139: Bristol-Myers Squibb
11.12.1. Drug Description
11.12.2. Product Profile
11.12.3. Other Development Activities
11.12.4. Clinical Development
11.12.5. Clinical Trials Information
11.12.6. Safety and Efficacy
11.13. VAY736: Novartis
11.13.1. Drug Description
11.13.2. Product Profile
11.13.3. Other Development Activities
11.13.4. Clinical Development
11.13.5. Clinical Trials Information
11.14. TAS-115: Taiho Pharmaceutical
11.14.1. Drug Description
11.14.2. Product Profile
11.14.3. Clinical Development
11.14.4. Clinical Trials Information
12. IPF: Market Analysis
12.1. Key Findings
12.2. Total Market Size of IPF in 7 MM
12.3. Therapy Based Market Size of IPF in 7 MM
13. Market Size of IPF by Country
13.1. United States Market Analysis
13.1.1. Market Size of IPF in the US
13.1.2. Therapy Based Market Size of IPF in the US
13.2. EU5 Market Outlook
13.3. Germany
13.3.1. Market Size of IPF in Germany
13.3.2. Therapy Based Market Size of IPF in Germany
13.4. France
13.4.1. Market Size of IPF in France
13.4.2. Therapy Based Market Size of IPF in France
13.5. Italy
13.5.1. Market Size of IPF in Italy
13.5.2. Therapy Based Market Size of IPF in Italy
13.6. United Kingdom
13.6.1. Market Size of IPF in the UK
13.6.2. Therapy Based Market Size of IPF in the UK
13.7. Spain
13.7.1. Market Size of IPF in Spain
13.7.2. Therapy Based Market Size of IPF in Spain
13.8. Japan: Market Analysis
13.8.1. Market Size of IPF in Japan
13.8.2. Therapy Based Market Size of IPF in Japan
14. Market Drivers of IPF
15. Market Barriers of IPF
16. Appendix
16.1. Report Methodology
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

 

1. Key Insights
2. IPF Market Overview at a Glance
2.1. Market Share (%) Distribution of IPF in 2017
2.2. Market Share (%) Distribution of IPF in 2027
3. Disease Background and Overview: Idiopathic Pulmonary Fibrosis (IPF)
3.1. Introduction
3.2. Staging of IPF
3.3. Risk Factors & Disease Causes
3.4. Symptoms
3.5. Pathogenesis
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7 MM Prevalent Population of IPF
4.3. Country Wise-Epidemiology of IPF
4.3.1. United States
4.3.2. Prevalent cases of IPF in the United States
4.3.3. Prevalent Population of IPF by severity
4.3.4. Gender-Specific IPF Prevalence
4.3.5. Age-Specific IPF Prevalence
4.3.6. EU5
4.3.7. Prevalent Population of IPF in EU5
4.3.8. France
4.3.9. Prevalent Population of IPF
4.3.10. Prevalent Population of IPF by severity
4.3.11. Gender-Specific IPF Prevalence
4.3.12. Age-Specific IPF Prevalence
4.3.13. Germany
4.3.14. Prevalent Population of IPF
4.3.15. Prevalent Population of IPF by severity
4.3.16. Gender-Specific IPF Prevalence
4.3.17. Age-Specific IPF Prevalence
4.3.18. Italy
4.3.19. Prevalent Population of IPF
4.3.20. Prevalent Population of IPF by severity
4.3.21. Gender-Specific IPF Prevalence
4.3.22. Age-Specific IPF Prevalence
4.3.23. Spain
4.3.24. Prevalent Population of IPF
4.3.25. Prevalent Population of IPF by severity
4.3.26. Gender-Specific IPF Prevalence
4.3.27. Age-Specific IPF Prevalence
4.3.28. United Kingdom
4.3.29. Prevalent Population of IPF
4.3.30. Prevalent Population of IPF by severity
4.3.31. Gender-Specific IPF Prevalence
4.3.32. Age-Specific IPF Prevalence
4.3.33. Japan
4.3.34. Prevalent Population of IPF
4.3.35. Prevalent Population of IPF by severity
4.3.36. Gender-SPECIFIC IPF Prevalence
4.3.37. Age-Specific IPF Prevalence
5. Current Treatment Practices
5.1. ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of IPF (An Update of 2011 Clinical Practice Guideline)
6. Unmet needs
7. Marketed Products
7.1. Esbriet (Pirfenidone): InterMune Inc.
7.1.1. Product Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Safety and Efficacy of Esbriet
7.1.5. Side effects of Esbriet
7.1.6. Product Profile
7.2. Ofev (Nintedanib): Boehringer Ingelheim Pharma GmbH & Co. KG
7.2.1. Product Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Safety and Efficacy of Ofev
7.2.5. Side effects of Ofev
7.2.6. Product Profile
8. Emerging Therapies
9. Key Cross Competition
10. Phase III Drugs
10.1. Thrombomodulin Alfa: Asahi Kasei Pharma Corporation
10.1.1. Drug Description
10.1.2. Product Profile
10.1.3. Clinical Development
10.1.4. Clinical Trials Information
10.1.5. Safety and Efficacy
11. Phase II Drugs
11.1. CC-90001: Celgene Corporation
11.1.1. Drug Description
11.1.2. Product Profile
11.1.3. Clinical Development
11.1.4. Clinical Trials Information
11.1.5. Safety and Efficacy
11.1.6. Drug Description
11.1.7. Product Profile
11.1.8. Other Development Activities
11.1.9. Clinical Development
11.1.10. Clinical Trials Information
11.1.11. Safety and Efficacy
11.2. Gefapixant: Merck & Co., Inc.
11.2.1. Drug Description
11.2.2. Product Profile
11.2.3. Other Development Activities
11.2.4. Clinical Development
11.2.5. Clinical Trials Information
11.2.6. Safety and Efficacy
11.3. GLPG1690: Galapagos NV
11.3.1. Drug Description
11.3.2. Product Profile
11.3.3. Regulatory Milestones
11.3.4. Other Development Activities
11.3.5. Clinical Development
11.3.6. Clinical Trials Information
11.3.7. Safety and Efficacy
11.4. LT-1001: LTT Bio-Pharma
11.4.1. Drug Description
11.4.2. Product Profile
11.4.3. Other Development Activities
11.4.4. Clinical Development
11.4.5. Clinical Trials Information
11.4.6. Safety and Efficacy
11.5. BG00011: Biogen Inc.
11.5.1. Drug Description
11.5.2. Product Profile
11.5.3. Regulatory Milestones
11.5.4. Other Development Activities
11.5.5. Clinical Development
11.5.6. Clinical Trials Information
11.5.7. Safety and Efficacy
11.6. BMS-986020: Bristol-Myers Squibb
11.6.1. Drug Description
11.6.2. Product Profile
11.6.3. Regulatory Milestones
11.6.4. Other Development Activities
11.6.5. Clinical Development
11.6.6. Clinical Trials Information
11.6.7. Safety and Efficacy
11.7. LT-1002: Chong Kun Dang Pharmaceutical
11.7.1. Drug Description
11.7.2. Product Profile
11.7.3. Other Development Activities
11.8. Pamrevlumab: FibroGen
11.8.1. Drug Description
11.8.2. Product Profile
11.8.3. Regulatory Milestones
11.8.4. Other Development Activities
11.8.5. Clinical Development
11.8.6. Clinical Trials Information
11.8.7. Safety and Efficacy
11.9. PBI4050: ProMetic Life Sciences
11.9.1. Drug Description
11.9.2. Product Profile
11.9.3. Regulatory Milestones
11.9.4. Other Development Activities
11.9.5. Clinical Development
11.9.6. Clinical Trials Information
11.9.7. Safety and Efficacy
11.10. PRM 151: Promedior, Inc.
11.10.1. Drug Description
11.10.2. Product Profile
11.10.3. Regulatory Milestones
11.10.4. Other Development Activities
11.10.5. Clinical Development
11.10.6. Clinical Trials Information
11.10.7. Safety and Efficacy
11.11. Tipelukast: MediciNova
11.11.1. Drug Description
11.11.2. Product Profile
11.11.3. Regulatory Milestones
11.11.4. Other Development Activities
11.11.5. Clinical Development
11.11.6. Clinical Trials Information
11.11.7. Safety and Efficacy
11.12. TD139: Bristol-Myers Squibb
11.12.1. Drug Description
11.12.2. Product Profile
11.12.3. Other Development Activities
11.12.4. Clinical Development
11.12.5. Clinical Trials Information
11.12.6. Safety and Efficacy
11.13. VAY736: Novartis
11.13.1. Drug Description
11.13.2. Product Profile
11.13.3. Other Development Activities
11.13.4. Clinical Development
11.13.5. Clinical Trials Information
11.14. TAS-115: Taiho Pharmaceutical
11.14.1. Drug Description
11.14.2. Product Profile
11.14.3. Clinical Development
11.14.4. Clinical Trials Information
12. IPF: Market Analysis
12.1. Key Findings
12.2. Total Market Size of IPF in 7 MM
12.3. Therapy Based Market Size of IPF in 7 MM
13. Market Size of IPF by Country
13.1. United States Market Analysis
13.1.1. Market Size of IPF in the US
13.1.2. Therapy Based Market Size of IPF in the US
13.2. EU5 Market Outlook
13.3. Germany
13.3.1. Market Size of IPF in Germany
13.3.2. Therapy Based Market Size of IPF in Germany
13.4. France
13.4.1. Market Size of IPF in France
13.4.2. Therapy Based Market Size of IPF in France
13.5. Italy
13.5.1. Market Size of IPF in Italy
13.5.2. Therapy Based Market Size of IPF in Italy
13.6. United Kingdom
13.6.1. Market Size of IPF in the UK
13.6.2. Therapy Based Market Size of IPF in the UK
13.7. Spain
13.7.1. Market Size of IPF in Spain
13.7.2. Therapy Based Market Size of IPF in Spain
13.8. Japan: Market Analysis
13.8.1. Market Size of IPF in Japan
13.8.2. Therapy Based Market Size of IPF in Japan
14. Market Drivers of IPF
15. Market Barriers of IPF
16. Appendix
16.1. Report Methodology
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

 

1. Key Insights
2. IPF Market Overview at a Glance
2.1. Market Share (%) Distribution of IPF in 2017
2.2. Market Share (%) Distribution of IPF in 2027
3. Disease Background and Overview: Idiopathic Pulmonary Fibrosis (IPF)
3.1. Introduction
3.2. Staging of IPF
3.3. Risk Factors & Disease Causes
3.4. Symptoms
3.5. Pathogenesis
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7 MM Prevalent Population of IPF
4.3. Country Wise-Epidemiology of IPF
4.3.1. United States
4.3.2. Prevalent cases of IPF in the United States
4.3.3. Prevalent Population of IPF by severity
4.3.4. Gender-Specific IPF Prevalence
4.3.5. Age-Specific IPF Prevalence
4.3.6. EU5
4.3.7. Prevalent Population of IPF in EU5
4.3.8. France
4.3.9. Prevalent Population of IPF
4.3.10. Prevalent Population of IPF by severity
4.3.11. Gender-Specific IPF Prevalence
4.3.12. Age-Specific IPF Prevalence
4.3.13. Germany
4.3.14. Prevalent Population of IPF
4.3.15. Prevalent Population of IPF by severity
4.3.16. Gender-Specific IPF Prevalence
4.3.17. Age-Specific IPF Prevalence
4.3.18. Italy
4.3.19. Prevalent Population of IPF
4.3.20. Prevalent Population of IPF by severity
4.3.21. Gender-Specific IPF Prevalence
4.3.22. Age-Specific IPF Prevalence
4.3.23. Spain
4.3.24. Prevalent Population of IPF
4.3.25. Prevalent Population of IPF by severity
4.3.26. Gender-Specific IPF Prevalence
4.3.27. Age-Specific IPF Prevalence
4.3.28. United Kingdom
4.3.29. Prevalent Population of IPF
4.3.30. Prevalent Population of IPF by severity
4.3.31. Gender-Specific IPF Prevalence
4.3.32. Age-Specific IPF Prevalence
4.3.33. Japan
4.3.34. Prevalent Population of IPF
4.3.35. Prevalent Population of IPF by severity
4.3.36. Gender-SPECIFIC IPF Prevalence
4.3.37. Age-Specific IPF Prevalence
5. Current Treatment Practices
5.1. ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of IPF (An Update of 2011 Clinical Practice Guideline)
6. Unmet needs
7. Marketed Products
7.1. Esbriet (Pirfenidone): InterMune Inc.
7.1.1. Product Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Safety and Efficacy of Esbriet
7.1.5. Side effects of Esbriet
7.1.6. Product Profile
7.2. Ofev (Nintedanib): Boehringer Ingelheim Pharma GmbH & Co. KG
7.2.1. Product Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Safety and Efficacy of Ofev
7.2.5. Side effects of Ofev
7.2.6. Product Profile
8. Emerging Therapies
9. Key Cross Competition
10. Phase III Drugs
10.1. Thrombomodulin Alfa: Asahi Kasei Pharma Corporation
10.1.1. Drug Description
10.1.2. Product Profile
10.1.3. Clinical Development
10.1.4. Clinical Trials Information
10.1.5. Safety and Efficacy
11. Phase II Drugs
11.1. CC-90001: Celgene Corporation
11.1.1. Drug Description
11.1.2. Product Profile
11.1.3. Clinical Development
11.1.4. Clinical Trials Information
11.1.5. Safety and Efficacy
11.1.6. Drug Description
11.1.7. Product Profile
11.1.8. Other Development Activities
11.1.9. Clinical Development
11.1.10. Clinical Trials Information
11.1.11. Safety and Efficacy
11.2. Gefapixant: Merck & Co., Inc.
11.2.1. Drug Description
11.2.2. Product Profile
11.2.3. Other Development Activities
11.2.4. Clinical Development
11.2.5. Clinical Trials Information
11.2.6. Safety and Efficacy
11.3. GLPG1690: Galapagos NV
11.3.1. Drug Description
11.3.2. Product Profile
11.3.3. Regulatory Milestones
11.3.4. Other Development Activities
11.3.5. Clinical Development
11.3.6. Clinical Trials Information
11.3.7. Safety and Efficacy
11.4. LT-1001: LTT Bio-Pharma
11.4.1. Drug Description
11.4.2. Product Profile
11.4.3. Other Development Activities
11.4.4. Clinical Development
11.4.5. Clinical Trials Information
11.4.6. Safety and Efficacy
11.5. BG00011: Biogen Inc.
11.5.1. Drug Description
11.5.2. Product Profile
11.5.3. Regulatory Milestones
11.5.4. Other Development Activities
11.5.5. Clinical Development
11.5.6. Clinical Trials Information
11.5.7. Safety and Efficacy
11.6. BMS-986020: Bristol-Myers Squibb
11.6.1. Drug Description
11.6.2. Product Profile
11.6.3. Regulatory Milestones
11.6.4. Other Development Activities
11.6.5. Clinical Development
11.6.6. Clinical Trials Information
11.6.7. Safety and Efficacy
11.7. LT-1002: Chong Kun Dang Pharmaceutical
11.7.1. Drug Description
11.7.2. Product Profile
11.7.3. Other Development Activities
11.8. Pamrevlumab: FibroGen
11.8.1. Drug Description
11.8.2. Product Profile
11.8.3. Regulatory Milestones
11.8.4. Other Development Activities
11.8.5. Clinical Development
11.8.6. Clinical Trials Information
11.8.7. Safety and Efficacy
11.9. PBI4050: ProMetic Life Sciences
11.9.1. Drug Description
11.9.2. Product Profile
11.9.3. Regulatory Milestones
11.9.4. Other Development Activities
11.9.5. Clinical Development
11.9.6. Clinical Trials Information
11.9.7. Safety and Efficacy
11.10. PRM 151: Promedior, Inc.
11.10.1. Drug Description
11.10.2. Product Profile
11.10.3. Regulatory Milestones
11.10.4. Other Development Activities
11.10.5. Clinical Development
11.10.6. Clinical Trials Information
11.10.7. Safety and Efficacy
11.11. Tipelukast: MediciNova
11.11.1. Drug Description
11.11.2. Product Profile
11.11.3. Regulatory Milestones
11.11.4. Other Development Activities
11.11.5. Clinical Development
11.11.6. Clinical Trials Information
11.11.7. Safety and Efficacy
11.12. TD139: Bristol-Myers Squibb
11.12.1. Drug Description
11.12.2. Product Profile
11.12.3. Other Development Activities
11.12.4. Clinical Development
11.12.5. Clinical Trials Information
11.12.6. Safety and Efficacy
11.13. VAY736: Novartis
11.13.1. Drug Description
11.13.2. Product Profile
11.13.3. Other Development Activities
11.13.4. Clinical Development
11.13.5. Clinical Trials Information
11.14. TAS-115: Taiho Pharmaceutical
11.14.1. Drug Description
11.14.2. Product Profile
11.14.3. Clinical Development
11.14.4. Clinical Trials Information
12. IPF: Market Analysis
12.1. Key Findings
12.2. Total Market Size of IPF in 7 MM
12.3. Therapy Based Market Size of IPF in 7 MM
13. Market Size of IPF by Country
13.1. United States Market Analysis
13.1.1. Market Size of IPF in the US
13.1.2. Therapy Based Market Size of IPF in the US
13.2. EU5 Market Outlook
13.3. Germany
13.3.1. Market Size of IPF in Germany
13.3.2. Therapy Based Market Size of IPF in Germany
13.4. France
13.4.1. Market Size of IPF in France
13.4.2. Therapy Based Market Size of IPF in France
13.5. Italy
13.5.1. Market Size of IPF in Italy
13.5.2. Therapy Based Market Size of IPF in Italy
13.6. United Kingdom
13.6.1. Market Size of IPF in the UK
13.6.2. Therapy Based Market Size of IPF in the UK
13.7. Spain
13.7.1. Market Size of IPF in Spain
13.7.2. Therapy Based Market Size of IPF in Spain
13.8. Japan: Market Analysis
13.8.1. Market Size of IPF in Japan
13.8.2. Therapy Based Market Size of IPF in Japan
14. Market Drivers of IPF
15. Market Barriers of IPF
16. Appendix
16.1. Report Methodology
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

 

1. Key Insights
2. IPF Market Overview at a Glance
2.1. Market Share (%) Distribution of IPF in 2017
2.2. Market Share (%) Distribution of IPF in 2027
3. Disease Background and Overview: Idiopathic Pulmonary Fibrosis (IPF)
3.1. Introduction
3.2. Staging of IPF
3.3. Risk Factors & Disease Causes
3.4. Symptoms
3.5. Pathogenesis
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7 MM Prevalent Population of IPF
4.3. Country Wise-Epidemiology of IPF
4.3.1. United States
4.3.2. Prevalent cases of IPF in the United States
4.3.3. Prevalent Population of IPF by severity
4.3.4. Gender-Specific IPF Prevalence
4.3.5. Age-Specific IPF Prevalence
4.3.6. EU5
4.3.7. Prevalent Population of IPF in EU5
4.3.8. France
4.3.9. Prevalent Population of IPF
4.3.10. Prevalent Population of IPF by severity
4.3.11. Gender-Specific IPF Prevalence
4.3.12. Age-Specific IPF Prevalence
4.3.13. Germany
4.3.14. Prevalent Population of IPF
4.3.15. Prevalent Population of IPF by severity
4.3.16. Gender-Specific IPF Prevalence
4.3.17. Age-Specific IPF Prevalence
4.3.18. Italy
4.3.19. Prevalent Population of IPF
4.3.20. Prevalent Population of IPF by severity
4.3.21. Gender-Specific IPF Prevalence
4.3.22. Age-Specific IPF Prevalence
4.3.23. Spain
4.3.24. Prevalent Population of IPF
4.3.25. Prevalent Population of IPF by severity
4.3.26. Gender-Specific IPF Prevalence
4.3.27. Age-Specific IPF Prevalence
4.3.28. United Kingdom
4.3.29. Prevalent Population of IPF
4.3.30. Prevalent Population of IPF by severity
4.3.31. Gender-Specific IPF Prevalence
4.3.32. Age-Specific IPF Prevalence
4.3.33. Japan
4.3.34. Prevalent Population of IPF
4.3.35. Prevalent Population of IPF by severity
4.3.36. Gender-SPECIFIC IPF Prevalence
4.3.37. Age-Specific IPF Prevalence
5. Current Treatment Practices
5.1. ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of IPF (An Update of 2011 Clinical Practice Guideline)
6. Unmet needs
7. Marketed Products
7.1. Esbriet (Pirfenidone): InterMune Inc.
7.1.1. Product Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Safety and Efficacy of Esbriet
7.1.5. Side effects of Esbriet
7.1.6. Product Profile
7.2. Ofev (Nintedanib): Boehringer Ingelheim Pharma GmbH & Co. KG
7.2.1. Product Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Safety and Efficacy of Ofev
7.2.5. Side effects of Ofev
7.2.6. Product Profile
8. Emerging Therapies
9. Key Cross Competition
10. Phase III Drugs
10.1. Thrombomodulin Alfa: Asahi Kasei Pharma Corporation
10.1.1. Drug Description
10.1.2. Product Profile
10.1.3. Clinical Development
10.1.4. Clinical Trials Information
10.1.5. Safety and Efficacy
11. Phase II Drugs
11.1. CC-90001: Celgene Corporation
11.1.1. Drug Description
11.1.2. Product Profile
11.1.3. Clinical Development
11.1.4. Clinical Trials Information
11.1.5. Safety and Efficacy
11.1.6. Drug Description
11.1.7. Product Profile
11.1.8. Other Development Activities
11.1.9. Clinical Development
11.1.10. Clinical Trials Information
11.1.11. Safety and Efficacy
11.2. Gefapixant: Merck & Co., Inc.
11.2.1. Drug Description
11.2.2. Product Profile
11.2.3. Other Development Activities
11.2.4. Clinical Development
11.2.5. Clinical Trials Information
11.2.6. Safety and Efficacy
11.3. GLPG1690: Galapagos NV
11.3.1. Drug Description
11.3.2. Product Profile
11.3.3. Regulatory Milestones
11.3.4. Other Development Activities
11.3.5. Clinical Development
11.3.6. Clinical Trials Information
11.3.7. Safety and Efficacy
11.4. LT-1001: LTT Bio-Pharma
11.4.1. Drug Description
11.4.2. Product Profile
11.4.3. Other Development Activities
11.4.4. Clinical Development
11.4.5. Clinical Trials Information
11.4.6. Safety and Efficacy
11.5. BG00011: Biogen Inc.
11.5.1. Drug Description
11.5.2. Product Profile
11.5.3. Regulatory Milestones
11.5.4. Other Development Activities
11.5.5. Clinical Development
11.5.6. Clinical Trials Information
11.5.7. Safety and Efficacy
11.6. BMS-986020: Bristol-Myers Squibb
11.6.1. Drug Description
11.6.2. Product Profile
11.6.3. Regulatory Milestones
11.6.4. Other Development Activities
11.6.5. Clinical Development
11.6.6. Clinical Trials Information
11.6.7. Safety and Efficacy
11.7. LT-1002: Chong Kun Dang Pharmaceutical
11.7.1. Drug Description
11.7.2. Product Profile
11.7.3. Other Development Activities
11.8. Pamrevlumab: FibroGen
11.8.1. Drug Description
11.8.2. Product Profile
11.8.3. Regulatory Milestones
11.8.4. Other Development Activities
11.8.5. Clinical Development
11.8.6. Clinical Trials Information
11.8.7. Safety and Efficacy
11.9. PBI4050: ProMetic Life Sciences
11.9.1. Drug Description
11.9.2. Product Profile
11.9.3. Regulatory Milestones
11.9.4. Other Development Activities
11.9.5. Clinical Development
11.9.6. Clinical Trials Information
11.9.7. Safety and Efficacy
11.10. PRM 151: Promedior, Inc.
11.10.1. Drug Description
11.10.2. Product Profile
11.10.3. Regulatory Milestones
11.10.4. Other Development Activities
11.10.5. Clinical Development
11.10.6. Clinical Trials Information
11.10.7. Safety and Efficacy
11.11. Tipelukast: MediciNova
11.11.1. Drug Description
11.11.2. Product Profile
11.11.3. Regulatory Milestones
11.11.4. Other Development Activities
11.11.5. Clinical Development
11.11.6. Clinical Trials Information
11.11.7. Safety and Efficacy
11.12. TD139: Bristol-Myers Squibb
11.12.1. Drug Description
11.12.2. Product Profile
11.12.3. Other Development Activities
11.12.4. Clinical Development
11.12.5. Clinical Trials Information
11.12.6. Safety and Efficacy
11.13. VAY736: Novartis
11.13.1. Drug Description
11.13.2. Product Profile
11.13.3. Other Development Activities
11.13.4. Clinical Development
11.13.5. Clinical Trials Information
11.14. TAS-115: Taiho Pharmaceutical
11.14.1. Drug Description
11.14.2. Product Profile
11.14.3. Clinical Development
11.14.4. Clinical Trials Information
12. IPF: Market Analysis
12.1. Key Findings
12.2. Total Market Size of IPF in 7 MM
12.3. Therapy Based Market Size of IPF in 7 MM
13. Market Size of IPF by Country
13.1. United States Market Analysis
13.1.1. Market Size of IPF in the US
13.1.2. Therapy Based Market Size of IPF in the US
13.2. EU5 Market Outlook
13.3. Germany
13.3.1. Market Size of IPF in Germany
13.3.2. Therapy Based Market Size of IPF in Germany
13.4. France
13.4.1. Market Size of IPF in France
13.4.2. Therapy Based Market Size of IPF in France
13.5. Italy
13.5.1. Market Size of IPF in Italy
13.5.2. Therapy Based Market Size of IPF in Italy
13.6. United Kingdom
13.6.1. Market Size of IPF in the UK
13.6.2. Therapy Based Market Size of IPF in the UK
13.7. Spain
13.7.1. Market Size of IPF in Spain
13.7.2. Therapy Based Market Size of IPF in Spain
13.8. Japan: Market Analysis
13.8.1. Market Size of IPF in Japan
13.8.2. Therapy Based Market Size of IPF in Japan
14. Market Drivers of IPF
15. Market Barriers of IPF
16. Appendix
16.1. Report Methodology
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

 

1. Key Insights
2. IPF Market Overview at a Glance
2.1. Market Share (%) Distribution of IPF in 2017
2.2. Market Share (%) Distribution of IPF in 2027
3. Disease Background and Overview: Idiopathic Pulmonary Fibrosis (IPF)
3.1. Introduction
3.2. Staging of IPF
3.3. Risk Factors & Disease Causes
3.4. Symptoms
3.5. Pathogenesis
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7 MM Prevalent Population of IPF
4.3. Country Wise-Epidemiology of IPF
4.3.1. United States
4.3.2. Prevalent cases of IPF in the United States
4.3.3. Prevalent Population of IPF by severity
4.3.4. Gender-Specific IPF Prevalence
4.3.5. Age-Specific IPF Prevalence
4.3.6. EU5
4.3.7. Prevalent Population of IPF in EU5
4.3.8. France
4.3.9. Prevalent Population of IPF
4.3.10. Prevalent Population of IPF by severity
4.3.11. Gender-Specific IPF Prevalence
4.3.12. Age-Specific IPF Prevalence
4.3.13. Germany
4.3.14. Prevalent Population of IPF
4.3.15. Prevalent Population of IPF by severity
4.3.16. Gender-Specific IPF Prevalence
4.3.17. Age-Specific IPF Prevalence
4.3.18. Italy
4.3.19. Prevalent Population of IPF
4.3.20. Prevalent Population of IPF by severity
4.3.21. Gender-Specific IPF Prevalence
4.3.22. Age-Specific IPF Prevalence
4.3.23. Spain
4.3.24. Prevalent Population of IPF
4.3.25. Prevalent Population of IPF by severity
4.3.26. Gender-Specific IPF Prevalence
4.3.27. Age-Specific IPF Prevalence
4.3.28. United Kingdom
4.3.29. Prevalent Population of IPF
4.3.30. Prevalent Population of IPF by severity
4.3.31. Gender-Specific IPF Prevalence
4.3.32. Age-Specific IPF Prevalence
4.3.33. Japan
4.3.34. Prevalent Population of IPF
4.3.35. Prevalent Population of IPF by severity
4.3.36. Gender-SPECIFIC IPF Prevalence
4.3.37. Age-Specific IPF Prevalence
5. Current Treatment Practices
5.1. ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of IPF (An Update of 2011 Clinical Practice Guideline)
6. Unmet needs
7. Marketed Products
7.1. Esbriet (Pirfenidone): InterMune Inc.
7.1.1. Product Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Safety and Efficacy of Esbriet
7.1.5. Side effects of Esbriet
7.1.6. Product Profile
7.2. Ofev (Nintedanib): Boehringer Ingelheim Pharma GmbH & Co. KG
7.2.1. Product Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Safety and Efficacy of Ofev
7.2.5. Side effects of Ofev
7.2.6. Product Profile
8. Emerging Therapies
9. Key Cross Competition
10. Phase III Drugs
10.1. Thrombomodulin Alfa: Asahi Kasei Pharma Corporation
10.1.1. Drug Description
10.1.2. Product Profile
10.1.3. Clinical Development
10.1.4. Clinical Trials Information
10.1.5. Safety and Efficacy
11. Phase II Drugs
11.1. CC-90001: Celgene Corporation
11.1.1. Drug Description
11.1.2. Product Profile
11.1.3. Clinical Development
11.1.4. Clinical Trials Information
11.1.5. Safety and Efficacy
11.1.6. Drug Description
11.1.7. Product Profile
11.1.8. Other Development Activities
11.1.9. Clinical Development
11.1.10. Clinical Trials Information
11.1.11. Safety and Efficacy
11.2. Gefapixant: Merck & Co., Inc.
11.2.1. Drug Description
11.2.2. Product Profile
11.2.3. Other Development Activities
11.2.4. Clinical Development
11.2.5. Clinical Trials Information
11.2.6. Safety and Efficacy
11.3. GLPG1690: Galapagos NV
11.3.1. Drug Description
11.3.2. Product Profile
11.3.3. Regulatory Milestones
11.3.4. Other Development Activities
11.3.5. Clinical Development
11.3.6. Clinical Trials Information
11.3.7. Safety and Efficacy
11.4. LT-1001: LTT Bio-Pharma
11.4.1. Drug Description
11.4.2. Product Profile
11.4.3. Other Development Activities
11.4.4. Clinical Development
11.4.5. Clinical Trials Information
11.4.6. Safety and Efficacy
11.5. BG00011: Biogen Inc.
11.5.1. Drug Description
11.5.2. Product Profile
11.5.3. Regulatory Milestones
11.5.4. Other Development Activities
11.5.5. Clinical Development
11.5.6. Clinical Trials Information
11.5.7. Safety and Efficacy
11.6. BMS-986020: Bristol-Myers Squibb
11.6.1. Drug Description
11.6.2. Product Profile
11.6.3. Regulatory Milestones
11.6.4. Other Development Activities
11.6.5. Clinical Development
11.6.6. Clinical Trials Information
11.6.7. Safety and Efficacy
11.7. LT-1002: Chong Kun Dang Pharmaceutical
11.7.1. Drug Description
11.7.2. Product Profile
11.7.3. Other Development Activities
11.8. Pamrevlumab: FibroGen
11.8.1. Drug Description
11.8.2. Product Profile
11.8.3. Regulatory Milestones
11.8.4. Other Development Activities
11.8.5. Clinical Development
11.8.6. Clinical Trials Information
11.8.7. Safety and Efficacy
11.9. PBI4050: ProMetic Life Sciences
11.9.1. Drug Description
11.9.2. Product Profile
11.9.3. Regulatory Milestones
11.9.4. Other Development Activities
11.9.5. Clinical Development
11.9.6. Clinical Trials Information
11.9.7. Safety and Efficacy
11.10. PRM 151: Promedior, Inc.
11.10.1. Drug Description
11.10.2. Product Profile
11.10.3. Regulatory Milestones
11.10.4. Other Development Activities
11.10.5. Clinical Development
11.10.6. Clinical Trials Information
11.10.7. Safety and Efficacy
11.11. Tipelukast: MediciNova
11.11.1. Drug Description
11.11.2. Product Profile
11.11.3. Regulatory Milestones
11.11.4. Other Development Activities
11.11.5. Clinical Development
11.11.6. Clinical Trials Information
11.11.7. Safety and Efficacy
11.12. TD139: Bristol-Myers Squibb
11.12.1. Drug Description
11.12.2. Product Profile
11.12.3. Other Development Activities
11.12.4. Clinical Development
11.12.5. Clinical Trials Information
11.12.6. Safety and Efficacy
11.13. VAY736: Novartis
11.13.1. Drug Description
11.13.2. Product Profile
11.13.3. Other Development Activities
11.13.4. Clinical Development
11.13.5. Clinical Trials Information
11.14. TAS-115: Taiho Pharmaceutical
11.14.1. Drug Description
11.14.2. Product Profile
11.14.3. Clinical Development
11.14.4. Clinical Trials Information
12. IPF: Market Analysis
12.1. Key Findings
12.2. Total Market Size of IPF in 7 MM
12.3. Therapy Based Market Size of IPF in 7 MM
13. Market Size of IPF by Country
13.1. United States Market Analysis
13.1.1. Market Size of IPF in the US
13.1.2. Therapy Based Market Size of IPF in the US
13.2. EU5 Market Outlook
13.3. Germany
13.3.1. Market Size of IPF in Germany
13.3.2. Therapy Based Market Size of IPF in Germany
13.4. France
13.4.1. Market Size of IPF in France
13.4.2. Therapy Based Market Size of IPF in France
13.5. Italy
13.5.1. Market Size of IPF in Italy
13.5.2. Therapy Based Market Size of IPF in Italy
13.6. United Kingdom
13.6.1. Market Size of IPF in the UK
13.6.2. Therapy Based Market Size of IPF in the UK
13.7. Spain
13.7.1. Market Size of IPF in Spain
13.7.2. Therapy Based Market Size of IPF in Spain
13.8. Japan: Market Analysis
13.8.1. Market Size of IPF in Japan
13.8.2. Therapy Based Market Size of IPF in Japan
14. Market Drivers of IPF
15. Market Barriers of IPF
16. Appendix
16.1. Report Methodology
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

 

1. Key Insights
2. IPF Market Overview at a Glance
2.1. Market Share (%) Distribution of IPF in 2017
2.2. Market Share (%) Distribution of IPF in 2027
3. Disease Background and Overview: Idiopathic Pulmonary Fibrosis (IPF)
3.1. Introduction
3.2. Staging of IPF
3.3. Risk Factors & Disease Causes
3.4. Symptoms
3.5. Pathogenesis
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7 MM Prevalent Population of IPF
4.3. Country Wise-Epidemiology of IPF
4.3.1. United States
4.3.2. Prevalent cases of IPF in the United States
4.3.3. Prevalent Population of IPF by severity
4.3.4. Gender-Specific IPF Prevalence
4.3.5. Age-Specific IPF Prevalence
4.3.6. EU5
4.3.7. Prevalent Population of IPF in EU5
4.3.8. France
4.3.9. Prevalent Population of IPF
4.3.10. Prevalent Population of IPF by severity
4.3.11. Gender-Specific IPF Prevalence
4.3.12. Age-Specific IPF Prevalence
4.3.13. Germany
4.3.14. Prevalent Population of IPF
4.3.15. Prevalent Population of IPF by severity
4.3.16. Gender-Specific IPF Prevalence
4.3.17. Age-Specific IPF Prevalence
4.3.18. Italy
4.3.19. Prevalent Population of IPF
4.3.20. Prevalent Population of IPF by severity
4.3.21. Gender-Specific IPF Prevalence
4.3.22. Age-Specific IPF Prevalence
4.3.23. Spain
4.3.24. Prevalent Population of IPF
4.3.25. Prevalent Population of IPF by severity
4.3.26. Gender-Specific IPF Prevalence
4.3.27. Age-Specific IPF Prevalence
4.3.28. United Kingdom
4.3.29. Prevalent Population of IPF
4.3.30. Prevalent Population of IPF by severity
4.3.31. Gender-Specific IPF Prevalence
4.3.32. Age-Specific IPF Prevalence
4.3.33. Japan
4.3.34. Prevalent Population of IPF
4.3.35. Prevalent Population of IPF by severity
4.3.36. Gender-SPECIFIC IPF Prevalence
4.3.37. Age-Specific IPF Prevalence
5. Current Treatment Practices
5.1. ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of IPF (An Update of 2011 Clinical Practice Guideline)
6. Unmet needs
7. Marketed Products
7.1. Esbriet (Pirfenidone): InterMune Inc.
7.1.1. Product Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Safety and Efficacy of Esbriet
7.1.5. Side effects of Esbriet
7.1.6. Product Profile
7.2. Ofev (Nintedanib): Boehringer Ingelheim Pharma GmbH & Co. KG
7.2.1. Product Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Safety and Efficacy of Ofev
7.2.5. Side effects of Ofev
7.2.6. Product Profile
8. Emerging Therapies
9. Key Cross Competition
10. Phase III Drugs
10.1. Thrombomodulin Alfa: Asahi Kasei Pharma Corporation
10.1.1. Drug Description
10.1.2. Product Profile
10.1.3. Clinical Development
10.1.4. Clinical Trials Information
10.1.5. Safety and Efficacy
11. Phase II Drugs
11.1. CC-90001: Celgene Corporation
11.1.1. Drug Description
11.1.2. Product Profile
11.1.3. Clinical Development
11.1.4. Clinical Trials Information
11.1.5. Safety and Efficacy
11.1.6. Drug Description
11.1.7. Product Profile
11.1.8. Other Development Activities
11.1.9. Clinical Development
11.1.10. Clinical Trials Information
11.1.11. Safety and Efficacy
11.2. Gefapixant: Merck & Co., Inc.
11.2.1. Drug Description
11.2.2. Product Profile
11.2.3. Other Development Activities
11.2.4. Clinical Development
11.2.5. Clinical Trials Information
11.2.6. Safety and Efficacy
11.3. GLPG1690: Galapagos NV
11.3.1. Drug Description
11.3.2. Product Profile
11.3.3. Regulatory Milestones
11.3.4. Other Development Activities
11.3.5. Clinical Development
11.3.6. Clinical Trials Information
11.3.7. Safety and Efficacy
11.4. LT-1001: LTT Bio-Pharma
11.4.1. Drug Description
11.4.2. Product Profile
11.4.3. Other Development Activities
11.4.4. Clinical Development
11.4.5. Clinical Trials Information
11.4.6. Safety and Efficacy
11.5. BG00011: Biogen Inc.
11.5.1. Drug Description
11.5.2. Product Profile
11.5.3. Regulatory Milestones
11.5.4. Other Development Activities
11.5.5. Clinical Development
11.5.6. Clinical Trials Information
11.5.7. Safety and Efficacy
11.6. BMS-986020: Bristol-Myers Squibb
11.6.1. Drug Description
11.6.2. Product Profile
11.6.3. Regulatory Milestones
11.6.4. Other Development Activities
11.6.5. Clinical Development
11.6.6. Clinical Trials Information
11.6.7. Safety and Efficacy
11.7. LT-1002: Chong Kun Dang Pharmaceutical
11.7.1. Drug Description
11.7.2. Product Profile
11.7.3. Other Development Activities
11.8. Pamrevlumab: FibroGen
11.8.1. Drug Description
11.8.2. Product Profile
11.8.3. Regulatory Milestones
11.8.4. Other Development Activities
11.8.5. Clinical Development
11.8.6. Clinical Trials Information
11.8.7. Safety and Efficacy
11.9. PBI4050: ProMetic Life Sciences
11.9.1. Drug Description
11.9.2. Product Profile
11.9.3. Regulatory Milestones
11.9.4. Other Development Activities
11.9.5. Clinical Development
11.9.6. Clinical Trials Information
11.9.7. Safety and Efficacy
11.10. PRM 151: Promedior, Inc.
11.10.1. Drug Description
11.10.2. Product Profile
11.10.3. Regulatory Milestones
11.10.4. Other Development Activities
11.10.5. Clinical Development
11.10.6. Clinical Trials Information
11.10.7. Safety and Efficacy
11.11. Tipelukast: MediciNova
11.11.1. Drug Description
11.11.2. Product Profile
11.11.3. Regulatory Milestones
11.11.4. Other Development Activities
11.11.5. Clinical Development
11.11.6. Clinical Trials Information
11.11.7. Safety and Efficacy
11.12. TD139: Bristol-Myers Squibb
11.12.1. Drug Description
11.12.2. Product Profile
11.12.3. Other Development Activities
11.12.4. Clinical Development
11.12.5. Clinical Trials Information
11.12.6. Safety and Efficacy
11.13. VAY736: Novartis
11.13.1. Drug Description
11.13.2. Product Profile
11.13.3. Other Development Activities
11.13.4. Clinical Development
11.13.5. Clinical Trials Information
11.14. TAS-115: Taiho Pharmaceutical
11.14.1. Drug Description
11.14.2. Product Profile
11.14.3. Clinical Development
11.14.4. Clinical Trials Information
12. IPF: Market Analysis
12.1. Key Findings
12.2. Total Market Size of IPF in 7 MM
12.3. Therapy Based Market Size of IPF in 7 MM
13. Market Size of IPF by Country
13.1. United States Market Analysis
13.1.1. Market Size of IPF in the US
13.1.2. Therapy Based Market Size of IPF in the US
13.2. EU5 Market Outlook
13.3. Germany
13.3.1. Market Size of IPF in Germany
13.3.2. Therapy Based Market Size of IPF in Germany
13.4. France
13.4.1. Market Size of IPF in France
13.4.2. Therapy Based Market Size of IPF in France
13.5. Italy
13.5.1. Market Size of IPF in Italy
13.5.2. Therapy Based Market Size of IPF in Italy
13.6. United Kingdom
13.6.1. Market Size of IPF in the UK
13.6.2. Therapy Based Market Size of IPF in the UK
13.7. Spain
13.7.1. Market Size of IPF in Spain
13.7.2. Therapy Based Market Size of IPF in Spain
13.8. Japan: Market Analysis
13.8.1. Market Size of IPF in Japan
13.8.2. Therapy Based Market Size of IPF in Japan
14. Market Drivers of IPF
15. Market Barriers of IPF
16. Appendix
16.1. Report Methodology
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

 

1. Key Insights
2. IPF Market Overview at a Glance
2.1. Market Share (%) Distribution of IPF in 2017
2.2. Market Share (%) Distribution of IPF in 2027
3. Disease Background and Overview: Idiopathic Pulmonary Fibrosis (IPF)
3.1. Introduction
3.2. Staging of IPF
3.3. Risk Factors & Disease Causes
3.4. Symptoms
3.5. Pathogenesis
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7 MM Prevalent Population of IPF
4.3. Country Wise-Epidemiology of IPF
4.3.1. United States
4.3.2. Prevalent cases of IPF in the United States
4.3.3. Prevalent Population of IPF by severity
4.3.4. Gender-Specific IPF Prevalence
4.3.5. Age-Specific IPF Prevalence
4.3.6. EU5
4.3.7. Prevalent Population of IPF in EU5
4.3.8. France
4.3.9. Prevalent Population of IPF
4.3.10. Prevalent Population of IPF by severity
4.3.11. Gender-Specific IPF Prevalence
4.3.12. Age-Specific IPF Prevalence
4.3.13. Germany
4.3.14. Prevalent Population of IPF
4.3.15. Prevalent Population of IPF by severity
4.3.16. Gender-Specific IPF Prevalence
4.3.17. Age-Specific IPF Prevalence
4.3.18. Italy
4.3.19. Prevalent Population of IPF
4.3.20. Prevalent Population of IPF by severity
4.3.21. Gender-Specific IPF Prevalence
4.3.22. Age-Specific IPF Prevalence
4.3.23. Spain
4.3.24. Prevalent Population of IPF
4.3.25. Prevalent Population of IPF by severity
4.3.26. Gender-Specific IPF Prevalence
4.3.27. Age-Specific IPF Prevalence
4.3.28. United Kingdom
4.3.29. Prevalent Population of IPF
4.3.30. Prevalent Population of IPF by severity
4.3.31. Gender-Specific IPF Prevalence
4.3.32. Age-Specific IPF Prevalence
4.3.33. Japan
4.3.34. Prevalent Population of IPF
4.3.35. Prevalent Population of IPF by severity
4.3.36. Gender-SPECIFIC IPF Prevalence
4.3.37. Age-Specific IPF Prevalence
5. Current Treatment Practices
5.1. ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of IPF (An Update of 2011 Clinical Practice Guideline)
6. Unmet needs
7. Marketed Products
7.1. Esbriet (Pirfenidone): InterMune Inc.
7.1.1. Product Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Safety and Efficacy of Esbriet
7.1.5. Side effects of Esbriet
7.1.6. Product Profile
7.2. Ofev (Nintedanib): Boehringer Ingelheim Pharma GmbH & Co. KG
7.2.1. Product Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Safety and Efficacy of Ofev
7.2.5. Side effects of Ofev
7.2.6. Product Profile
8. Emerging Therapies
9. Key Cross Competition
10. Phase III Drugs
10.1. Thrombomodulin Alfa: Asahi Kasei Pharma Corporation
10.1.1. Drug Description
10.1.2. Product Profile
10.1.3. Clinical Development
10.1.4. Clinical Trials Information
10.1.5. Safety and Efficacy
11. Phase II Drugs
11.1. CC-90001: Celgene Corporation
11.1.1. Drug Description
11.1.2. Product Profile
11.1.3. Clinical Development
11.1.4. Clinical Trials Information
11.1.5. Safety and Efficacy
11.1.6. Drug Description
11.1.7. Product Profile
11.1.8. Other Development Activities
11.1.9. Clinical Development
11.1.10. Clinical Trials Information
11.1.11. Safety and Efficacy
11.2. Gefapixant: Merck & Co., Inc.
11.2.1. Drug Description
11.2.2. Product Profile
11.2.3. Other Development Activities
11.2.4. Clinical Development
11.2.5. Clinical Trials Information
11.2.6. Safety and Efficacy
11.3. GLPG1690: Galapagos NV
11.3.1. Drug Description
11.3.2. Product Profile
11.3.3. Regulatory Milestones
11.3.4. Other Development Activities
11.3.5. Clinical Development
11.3.6. Clinical Trials Information
11.3.7. Safety and Efficacy
11.4. LT-1001: LTT Bio-Pharma
11.4.1. Drug Description
11.4.2. Product Profile
11.4.3. Other Development Activities
11.4.4. Clinical Development
11.4.5. Clinical Trials Information
11.4.6. Safety and Efficacy
11.5. BG00011: Biogen Inc.
11.5.1. Drug Description
11.5.2. Product Profile
11.5.3. Regulatory Milestones
11.5.4. Other Development Activities
11.5.5. Clinical Development
11.5.6. Clinical Trials Information
11.5.7. Safety and Efficacy
11.6. BMS-986020: Bristol-Myers Squibb
11.6.1. Drug Description
11.6.2. Product Profile
11.6.3. Regulatory Milestones
11.6.4. Other Development Activities
11.6.5. Clinical Development
11.6.6. Clinical Trials Information
11.6.7. Safety and Efficacy
11.7. LT-1002: Chong Kun Dang Pharmaceutical
11.7.1. Drug Description
11.7.2. Product Profile
11.7.3. Other Development Activities
11.8. Pamrevlumab: FibroGen
11.8.1. Drug Description
11.8.2. Product Profile
11.8.3. Regulatory Milestones
11.8.4. Other Development Activities
11.8.5. Clinical Development
11.8.6. Clinical Trials Information
11.8.7. Safety and Efficacy
11.9. PBI4050: ProMetic Life Sciences
11.9.1. Drug Description
11.9.2. Product Profile
11.9.3. Regulatory Milestones
11.9.4. Other Development Activities
11.9.5. Clinical Development
11.9.6. Clinical Trials Information
11.9.7. Safety and Efficacy
11.10. PRM 151: Promedior, Inc.
11.10.1. Drug Description
11.10.2. Product Profile
11.10.3. Regulatory Milestones
11.10.4. Other Development Activities
11.10.5. Clinical Development
11.10.6. Clinical Trials Information
11.10.7. Safety and Efficacy
11.11. Tipelukast: MediciNova
11.11.1. Drug Description
11.11.2. Product Profile
11.11.3. Regulatory Milestones
11.11.4. Other Development Activities
11.11.5. Clinical Development
11.11.6. Clinical Trials Information
11.11.7. Safety and Efficacy
11.12. TD139: Bristol-Myers Squibb
11.12.1. Drug Description
11.12.2. Product Profile
11.12.3. Other Development Activities
11.12.4. Clinical Development
11.12.5. Clinical Trials Information
11.12.6. Safety and Efficacy
11.13. VAY736: Novartis
11.13.1. Drug Description
11.13.2. Product Profile
11.13.3. Other Development Activities
11.13.4. Clinical Development
11.13.5. Clinical Trials Information
11.14. TAS-115: Taiho Pharmaceutical
11.14.1. Drug Description
11.14.2. Product Profile
11.14.3. Clinical Development
11.14.4. Clinical Trials Information
12. IPF: Market Analysis
12.1. Key Findings
12.2. Total Market Size of IPF in 7 MM
12.3. Therapy Based Market Size of IPF in 7 MM
13. Market Size of IPF by Country
13.1. United States Market Analysis
13.1.1. Market Size of IPF in the US
13.1.2. Therapy Based Market Size of IPF in the US
13.2. EU5 Market Outlook
13.3. Germany
13.3.1. Market Size of IPF in Germany
13.3.2. Therapy Based Market Size of IPF in Germany
13.4. France
13.4.1. Market Size of IPF in France
13.4.2. Therapy Based Market Size of IPF in France
13.5. Italy
13.5.1. Market Size of IPF in Italy
13.5.2. Therapy Based Market Size of IPF in Italy
13.6. United Kingdom
13.6.1. Market Size of IPF in the UK
13.6.2. Therapy Based Market Size of IPF in the UK
13.7. Spain
13.7.1. Market Size of IPF in Spain
13.7.2. Therapy Based Market Size of IPF in Spain
13.8. Japan: Market Analysis
13.8.1. Market Size of IPF in Japan
13.8.2. Therapy Based Market Size of IPF in Japan
14. Market Drivers of IPF
15. Market Barriers of IPF
16. Appendix
16.1. Report Methodology
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

 

1. Key Insights
2. IPF Market Overview at a Glance
2.1. Market Share (%) Distribution of IPF in 2017
2.2. Market Share (%) Distribution of IPF in 2027
3. Disease Background and Overview: Idiopathic Pulmonary Fibrosis (IPF)
3.1. Introduction
3.2. Staging of IPF
3.3. Risk Factors & Disease Causes
3.4. Symptoms
3.5. Pathogenesis
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7 MM Prevalent Population of IPF
4.3. Country Wise-Epidemiology of IPF
4.3.1. United States
4.3.2. Prevalent cases of IPF in the United States
4.3.3. Prevalent Population of IPF by severity
4.3.4. Gender-Specific IPF Prevalence
4.3.5. Age-Specific IPF Prevalence
4.3.6. EU5
4.3.7. Prevalent Population of IPF in EU5
4.3.8. France
4.3.9. Prevalent Population of IPF
4.3.10. Prevalent Population of IPF by severity
4.3.11. Gender-Specific IPF Prevalence
4.3.12. Age-Specific IPF Prevalence
4.3.13. Germany
4.3.14. Prevalent Population of IPF
4.3.15. Prevalent Population of IPF by severity
4.3.16. Gender-Specific IPF Prevalence
4.3.17. Age-Specific IPF Prevalence
4.3.18. Italy
4.3.19. Prevalent Population of IPF
4.3.20. Prevalent Population of IPF by severity
4.3.21. Gender-Specific IPF Prevalence
4.3.22. Age-Specific IPF Prevalence
4.3.23. Spain
4.3.24. Prevalent Population of IPF
4.3.25. Prevalent Population of IPF by severity
4.3.26. Gender-Specific IPF Prevalence
4.3.27. Age-Specific IPF Prevalence
4.3.28. United Kingdom
4.3.29. Prevalent Population of IPF
4.3.30. Prevalent Population of IPF by severity
4.3.31. Gender-Specific IPF Prevalence
4.3.32. Age-Specific IPF Prevalence
4.3.33. Japan
4.3.34. Prevalent Population of IPF
4.3.35. Prevalent Population of IPF by severity
4.3.36. Gender-SPECIFIC IPF Prevalence
4.3.37. Age-Specific IPF Prevalence
5. Current Treatment Practices
5.1. ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of IPF (An Update of 2011 Clinical Practice Guideline)
6. Unmet needs
7. Marketed Products
7.1. Esbriet (Pirfenidone): InterMune Inc.
7.1.1. Product Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Safety and Efficacy of Esbriet
7.1.5. Side effects of Esbriet
7.1.6. Product Profile
7.2. Ofev (Nintedanib): Boehringer Ingelheim Pharma GmbH & Co. KG
7.2.1. Product Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Safety and Efficacy of Ofev
7.2.5. Side effects of Ofev
7.2.6. Product Profile
8. Emerging Therapies
9. Key Cross Competition
10. Phase III Drugs
10.1. Thrombomodulin Alfa: Asahi Kasei Pharma Corporation
10.1.1. Drug Description
10.1.2. Product Profile
10.1.3. Clinical Development
10.1.4. Clinical Trials Information
10.1.5. Safety and Efficacy
11. Phase II Drugs
11.1. CC-90001: Celgene Corporation
11.1.1. Drug Description
11.1.2. Product Profile
11.1.3. Clinical Development
11.1.4. Clinical Trials Information
11.1.5. Safety and Efficacy
11.1.6. Drug Description
11.1.7. Product Profile
11.1.8. Other Development Activities
11.1.9. Clinical Development
11.1.10. Clinical Trials Information
11.1.11. Safety and Efficacy
11.2. Gefapixant: Merck & Co., Inc.
11.2.1. Drug Description
11.2.2. Product Profile
11.2.3. Other Development Activities
11.2.4. Clinical Development
11.2.5. Clinical Trials Information
11.2.6. Safety and Efficacy
11.3. GLPG1690: Galapagos NV
11.3.1. Drug Description
11.3.2. Product Profile
11.3.3. Regulatory Milestones
11.3.4. Other Development Activities
11.3.5. Clinical Development
11.3.6. Clinical Trials Information
11.3.7. Safety and Efficacy
11.4. LT-1001: LTT Bio-Pharma
11.4.1. Drug Description
11.4.2. Product Profile
11.4.3. Other Development Activities
11.4.4. Clinical Development
11.4.5. Clinical Trials Information
11.4.6. Safety and Efficacy
11.5. BG00011: Biogen Inc.
11.5.1. Drug Description
11.5.2. Product Profile
11.5.3. Regulatory Milestones
11.5.4. Other Development Activities
11.5.5. Clinical Development
11.5.6. Clinical Trials Information
11.5.7. Safety and Efficacy
11.6. BMS-986020: Bristol-Myers Squibb
11.6.1. Drug Description
11.6.2. Product Profile
11.6.3. Regulatory Milestones
11.6.4. Other Development Activities
11.6.5. Clinical Development
11.6.6. Clinical Trials Information
11.6.7. Safety and Efficacy
11.7. LT-1002: Chong Kun Dang Pharmaceutical
11.7.1. Drug Description
11.7.2. Product Profile
11.7.3. Other Development Activities
11.8. Pamrevlumab: FibroGen
11.8.1. Drug Description
11.8.2. Product Profile
11.8.3. Regulatory Milestones
11.8.4. Other Development Activities
11.8.5. Clinical Development
11.8.6. Clinical Trials Information
11.8.7. Safety and Efficacy
11.9. PBI4050: ProMetic Life Sciences
11.9.1. Drug Description
11.9.2. Product Profile
11.9.3. Regulatory Milestones
11.9.4. Other Development Activities
11.9.5. Clinical Development
11.9.6. Clinical Trials Information
11.9.7. Safety and Efficacy
11.10. PRM 151: Promedior, Inc.
11.10.1. Drug Description
11.10.2. Product Profile
11.10.3. Regulatory Milestones
11.10.4. Other Development Activities
11.10.5. Clinical Development
11.10.6. Clinical Trials Information
11.10.7. Safety and Efficacy
11.11. Tipelukast: MediciNova
11.11.1. Drug Description
11.11.2. Product Profile
11.11.3. Regulatory Milestones
11.11.4. Other Development Activities
11.11.5. Clinical Development
11.11.6. Clinical Trials Information
11.11.7. Safety and Efficacy
11.12. TD139: Bristol-Myers Squibb
11.12.1. Drug Description
11.12.2. Product Profile
11.12.3. Other Development Activities
11.12.4. Clinical Development
11.12.5. Clinical Trials Information
11.12.6. Safety and Efficacy
11.13. VAY736: Novartis
11.13.1. Drug Description
11.13.2. Product Profile
11.13.3. Other Development Activities
11.13.4. Clinical Development
11.13.5. Clinical Trials Information
11.14. TAS-115: Taiho Pharmaceutical
11.14.1. Drug Description
11.14.2. Product Profile
11.14.3. Clinical Development
11.14.4. Clinical Trials Information
12. IPF: Market Analysis
12.1. Key Findings
12.2. Total Market Size of IPF in 7 MM
12.3. Therapy Based Market Size of IPF in 7 MM
13. Market Size of IPF by Country
13.1. United States Market Analysis
13.1.1. Market Size of IPF in the US
13.1.2. Therapy Based Market Size of IPF in the US
13.2. EU5 Market Outlook
13.3. Germany
13.3.1. Market Size of IPF in Germany
13.3.2. Therapy Based Market Size of IPF in Germany
13.4. France
13.4.1. Market Size of IPF in France
13.4.2. Therapy Based Market Size of IPF in France
13.5. Italy
13.5.1. Market Size of IPF in Italy
13.5.2. Therapy Based Market Size of IPF in Italy
13.6. United Kingdom
13.6.1. Market Size of IPF in the UK
13.6.2. Therapy Based Market Size of IPF in the UK
13.7. Spain
13.7.1. Market Size of IPF in Spain
13.7.2. Therapy Based Market Size of IPF in Spain
13.8. Japan: Market Analysis
13.8.1. Market Size of IPF in Japan
13.8.2. Therapy Based Market Size of IPF in Japan
14. Market Drivers of IPF
15. Market Barriers of IPF
16. Appendix
16.1. Report Methodology
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

 

1. Key Insights
2. IPF Market Overview at a Glance
2.1. Market Share (%) Distribution of IPF in 2017
2.2. Market Share (%) Distribution of IPF in 2027
3. Disease Background and Overview: Idiopathic Pulmonary Fibrosis (IPF)
3.1. Introduction
3.2. Staging of IPF
3.3. Risk Factors & Disease Causes
3.4. Symptoms
3.5. Pathogenesis
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7 MM Prevalent Population of IPF
4.3. Country Wise-Epidemiology of IPF
4.3.1. United States
4.3.2. Prevalent cases of IPF in the United States
4.3.3. Prevalent Population of IPF by severity
4.3.4. Gender-Specific IPF Prevalence
4.3.5. Age-Specific IPF Prevalence
4.3.6. EU5
4.3.7. Prevalent Population of IPF in EU5
4.3.8. France
4.3.9. Prevalent Population of IPF
4.3.10. Prevalent Population of IPF by severity
4.3.11. Gender-Specific IPF Prevalence
4.3.12. Age-Specific IPF Prevalence
4.3.13. Germany
4.3.14. Prevalent Population of IPF
4.3.15. Prevalent Population of IPF by severity
4.3.16. Gender-Specific IPF Prevalence
4.3.17. Age-Specific IPF Prevalence
4.3.18. Italy
4.3.19. Prevalent Population of IPF
4.3.20. Prevalent Population of IPF by severity
4.3.21. Gender-Specific IPF Prevalence
4.3.22. Age-Specific IPF Prevalence
4.3.23. Spain
4.3.24. Prevalent Population of IPF
4.3.25. Prevalent Population of IPF by severity
4.3.26. Gender-Specific IPF Prevalence
4.3.27. Age-Specific IPF Prevalence
4.3.28. United Kingdom
4.3.29. Prevalent Population of IPF
4.3.30. Prevalent Population of IPF by severity
4.3.31. Gender-Specific IPF Prevalence
4.3.32. Age-Specific IPF Prevalence
4.3.33. Japan
4.3.34. Prevalent Population of IPF
4.3.35. Prevalent Population of IPF by severity
4.3.36. Gender-SPECIFIC IPF Prevalence
4.3.37. Age-Specific IPF Prevalence
5. Current Treatment Practices
5.1. ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of IPF (An Update of 2011 Clinical Practice Guideline)
6. Unmet needs
7. Marketed Products
7.1. Esbriet (Pirfenidone): InterMune Inc.
7.1.1. Product Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Safety and Efficacy of Esbriet
7.1.5. Side effects of Esbriet
7.1.6. Product Profile
7.2. Ofev (Nintedanib): Boehringer Ingelheim Pharma GmbH & Co. KG
7.2.1. Product Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Safety and Efficacy of Ofev
7.2.5. Side effects of Ofev
7.2.6. Product Profile
8. Emerging Therapies
9. Key Cross Competition
10. Phase III Drugs
10.1. Thrombomodulin Alfa: Asahi Kasei Pharma Corporation
10.1.1. Drug Description
10.1.2. Product Profile
10.1.3. Clinical Development
10.1.4. Clinical Trials Information
10.1.5. Safety and Efficacy
11. Phase II Drugs
11.1. CC-90001: Celgene Corporation
11.1.1. Drug Description
11.1.2. Product Profile
11.1.3. Clinical Development
11.1.4. Clinical Trials Information
11.1.5. Safety and Efficacy
11.1.6. Drug Description
11.1.7. Product Profile
11.1.8. Other Development Activities
11.1.9. Clinical Development
11.1.10. Clinical Trials Information
11.1.11. Safety and Efficacy
11.2. Gefapixant: Merck & Co., Inc.
11.2.1. Drug Description
11.2.2. Product Profile
11.2.3. Other Development Activities
11.2.4. Clinical Development
11.2.5. Clinical Trials Information
11.2.6. Safety and Efficacy
11.3. GLPG1690: Galapagos NV
11.3.1. Drug Description
11.3.2. Product Profile
11.3.3. Regulatory Milestones
11.3.4. Other Development Activities
11.3.5. Clinical Development
11.3.6. Clinical Trials Information
11.3.7. Safety and Efficacy
11.4. LT-1001: LTT Bio-Pharma
11.4.1. Drug Description
11.4.2. Product Profile
11.4.3. Other Development Activities
11.4.4. Clinical Development
11.4.5. Clinical Trials Information
11.4.6. Safety and Efficacy
11.5. BG00011: Biogen Inc.
11.5.1. Drug Description
11.5.2. Product Profile
11.5.3. Regulatory Milestones
11.5.4. Other Development Activities
11.5.5. Clinical Development
11.5.6. Clinical Trials Information
11.5.7. Safety and Efficacy
11.6. BMS-986020: Bristol-Myers Squibb
11.6.1. Drug Description
11.6.2. Product Profile
11.6.3. Regulatory Milestones
11.6.4. Other Development Activities
11.6.5. Clinical Development
11.6.6. Clinical Trials Information
11.6.7. Safety and Efficacy
11.7. LT-1002: Chong Kun Dang Pharmaceutical
11.7.1. Drug Description
11.7.2. Product Profile
11.7.3. Other Development Activities
11.8. Pamrevlumab: FibroGen
11.8.1. Drug Description
11.8.2. Product Profile
11.8.3. Regulatory Milestones
11.8.4. Other Development Activities
11.8.5. Clinical Development
11.8.6. Clinical Trials Information
11.8.7. Safety and Efficacy
11.9. PBI4050: ProMetic Life Sciences
11.9.1. Drug Description
11.9.2. Product Profile
11.9.3. Regulatory Milestones
11.9.4. Other Development Activities
11.9.5. Clinical Development
11.9.6. Clinical Trials Information
11.9.7. Safety and Efficacy
11.10. PRM 151: Promedior, Inc.
11.10.1. Drug Description
11.10.2. Product Profile
11.10.3. Regulatory Milestones
11.10.4. Other Development Activities
11.10.5. Clinical Development
11.10.6. Clinical Trials Information
11.10.7. Safety and Efficacy
11.11. Tipelukast: MediciNova
11.11.1. Drug Description
11.11.2. Product Profile
11.11.3. Regulatory Milestones
11.11.4. Other Development Activities
11.11.5. Clinical Development
11.11.6. Clinical Trials Information
11.11.7. Safety and Efficacy
11.12. TD139: Bristol-Myers Squibb
11.12.1. Drug Description
11.12.2. Product Profile
11.12.3. Other Development Activities
11.12.4. Clinical Development
11.12.5. Clinical Trials Information
11.12.6. Safety and Efficacy
11.13. VAY736: Novartis
11.13.1. Drug Description
11.13.2. Product Profile
11.13.3. Other Development Activities
11.13.4. Clinical Development
11.13.5. Clinical Trials Information
11.14. TAS-115: Taiho Pharmaceutical
11.14.1. Drug Description
11.14.2. Product Profile
11.14.3. Clinical Development
11.14.4. Clinical Trials Information
12. IPF: Market Analysis
12.1. Key Findings
12.2. Total Market Size of IPF in 7 MM
12.3. Therapy Based Market Size of IPF in 7 MM
13. Market Size of IPF by Country
13.1. United States Market Analysis
13.1.1. Market Size of IPF in the US
13.1.2. Therapy Based Market Size of IPF in the US
13.2. EU5 Market Outlook
13.3. Germany
13.3.1. Market Size of IPF in Germany
13.3.2. Therapy Based Market Size of IPF in Germany
13.4. France
13.4.1. Market Size of IPF in France
13.4.2. Therapy Based Market Size of IPF in France
13.5. Italy
13.5.1. Market Size of IPF in Italy
13.5.2. Therapy Based Market Size of IPF in Italy
13.6. United Kingdom
13.6.1. Market Size of IPF in the UK
13.6.2. Therapy Based Market Size of IPF in the UK
13.7. Spain
13.7.1. Market Size of IPF in Spain
13.7.2. Therapy Based Market Size of IPF in Spain
13.8. Japan: Market Analysis
13.8.1. Market Size of IPF in Japan
13.8.2. Therapy Based Market Size of IPF in Japan
14. Market Drivers of IPF
15. Market Barriers of IPF
16. Appendix
16.1. Report Methodology
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

 

1. Key Insights
2. IPF Market Overview at a Glance
2.1. Market Share (%) Distribution of IPF in 2017
2.2. Market Share (%) Distribution of IPF in 2027
3. Disease Background and Overview: Idiopathic Pulmonary Fibrosis (IPF)
3.1. Introduction
3.2. Staging of IPF
3.3. Risk Factors & Disease Causes
3.4. Symptoms
3.5. Pathogenesis
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7 MM Prevalent Population of IPF
4.3. Country Wise-Epidemiology of IPF
4.3.1. United States
4.3.2. Prevalent cases of IPF in the United States
4.3.3. Prevalent Population of IPF by severity
4.3.4. Gender-Specific IPF Prevalence
4.3.5. Age-Specific IPF Prevalence
4.3.6. EU5
4.3.7. Prevalent Population of IPF in EU5
4.3.8. France
4.3.9. Prevalent Population of IPF
4.3.10. Prevalent Population of IPF by severity
4.3.11. Gender-Specific IPF Prevalence
4.3.12. Age-Specific IPF Prevalence
4.3.13. Germany
4.3.14. Prevalent Population of IPF
4.3.15. Prevalent Population of IPF by severity
4.3.16. Gender-Specific IPF Prevalence
4.3.17. Age-Specific IPF Prevalence
4.3.18. Italy
4.3.19. Prevalent Population of IPF
4.3.20. Prevalent Population of IPF by severity
4.3.21. Gender-Specific IPF Prevalence
4.3.22. Age-Specific IPF Prevalence
4.3.23. Spain
4.3.24. Prevalent Population of IPF
4.3.25. Prevalent Population of IPF by severity
4.3.26. Gender-Specific IPF Prevalence
4.3.27. Age-Specific IPF Prevalence
4.3.28. United Kingdom
4.3.29. Prevalent Population of IPF
4.3.30. Prevalent Population of IPF by severity
4.3.31. Gender-Specific IPF Prevalence
4.3.32. Age-Specific IPF Prevalence
4.3.33. Japan
4.3.34. Prevalent Population of IPF
4.3.35. Prevalent Population of IPF by severity
4.3.36. Gender-SPECIFIC IPF Prevalence
4.3.37. Age-Specific IPF Prevalence
5. Current Treatment Practices
5.1. ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of IPF (An Update of 2011 Clinical Practice Guideline)
6. Unmet needs
7. Marketed Products
7.1. Esbriet (Pirfenidone): InterMune Inc.
7.1.1. Product Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Safety and Efficacy of Esbriet
7.1.5. Side effects of Esbriet
7.1.6. Product Profile
7.2. Ofev (Nintedanib): Boehringer Ingelheim Pharma GmbH & Co. KG
7.2.1. Product Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Safety and Efficacy of Ofev
7.2.5. Side effects of Ofev
7.2.6. Product Profile
8. Emerging Therapies
9. Key Cross Competition
10. Phase III Drugs
10.1. Thrombomodulin Alfa: Asahi Kasei Pharma Corporation
10.1.1. Drug Description
10.1.2. Product Profile
10.1.3. Clinical Development
10.1.4. Clinical Trials Information
10.1.5. Safety and Efficacy
11. Phase II Drugs
11.1. CC-90001: Celgene Corporation
11.1.1. Drug Description
11.1.2. Product Profile
11.1.3. Clinical Development
11.1.4. Clinical Trials Information
11.1.5. Safety and Efficacy
11.1.6. Drug Description
11.1.7. Product Profile
11.1.8. Other Development Activities
11.1.9. Clinical Development
11.1.10. Clinical Trials Information
11.1.11. Safety and Efficacy
11.2. Gefapixant: Merck & Co., Inc.
11.2.1. Drug Description
11.2.2. Product Profile
11.2.3. Other Development Activities
11.2.4. Clinical Development
11.2.5. Clinical Trials Information
11.2.6. Safety and Efficacy
11.3. GLPG1690: Galapagos NV
11.3.1. Drug Description
11.3.2. Product Profile
11.3.3. Regulatory Milestones
11.3.4. Other Development Activities
11.3.5. Clinical Development
11.3.6. Clinical Trials Information
11.3.7. Safety and Efficacy
11.4. LT-1001: LTT Bio-Pharma
11.4.1. Drug Description
11.4.2. Product Profile
11.4.3. Other Development Activities
11.4.4. Clinical Development
11.4.5. Clinical Trials Information
11.4.6. Safety and Efficacy
11.5. BG00011: Biogen Inc.
11.5.1. Drug Description
11.5.2. Product Profile
11.5.3. Regulatory Milestones
11.5.4. Other Development Activities
11.5.5. Clinical Development
11.5.6. Clinical Trials Information
11.5.7. Safety and Efficacy
11.6. BMS-986020: Bristol-Myers Squibb
11.6.1. Drug Description
11.6.2. Product Profile
11.6.3. Regulatory Milestones
11.6.4. Other Development Activities
11.6.5. Clinical Development
11.6.6. Clinical Trials Information
11.6.7. Safety and Efficacy
11.7. LT-1002: Chong Kun Dang Pharmaceutical
11.7.1. Drug Description
11.7.2. Product Profile
11.7.3. Other Development Activities
11.8. Pamrevlumab: FibroGen
11.8.1. Drug Description
11.8.2. Product Profile
11.8.3. Regulatory Milestones
11.8.4. Other Development Activities
11.8.5. Clinical Development
11.8.6. Clinical Trials Information
11.8.7. Safety and Efficacy
11.9. PBI4050: ProMetic Life Sciences
11.9.1. Drug Description
11.9.2. Product Profile
11.9.3. Regulatory Milestones
11.9.4. Other Development Activities
11.9.5. Clinical Development
11.9.6. Clinical Trials Information
11.9.7. Safety and Efficacy
11.10. PRM 151: Promedior, Inc.
11.10.1. Drug Description
11.10.2. Product Profile
11.10.3. Regulatory Milestones
11.10.4. Other Development Activities
11.10.5. Clinical Development
11.10.6. Clinical Trials Information
11.10.7. Safety and Efficacy
11.11. Tipelukast: MediciNova
11.11.1. Drug Description
11.11.2. Product Profile
11.11.3. Regulatory Milestones
11.11.4. Other Development Activities
11.11.5. Clinical Development
11.11.6. Clinical Trials Information
11.11.7. Safety and Efficacy
11.12. TD139: Bristol-Myers Squibb
11.12.1. Drug Description
11.12.2. Product Profile
11.12.3. Other Development Activities
11.12.4. Clinical Development
11.12.5. Clinical Trials Information
11.12.6. Safety and Efficacy
11.13. VAY736: Novartis
11.13.1. Drug Description
11.13.2. Product Profile
11.13.3. Other Development Activities
11.13.4. Clinical Development
11.13.5. Clinical Trials Information
11.14. TAS-115: Taiho Pharmaceutical
11.14.1. Drug Description
11.14.2. Product Profile
11.14.3. Clinical Development
11.14.4. Clinical Trials Information
12. IPF: Market Analysis
12.1. Key Findings
12.2. Total Market Size of IPF in 7 MM
12.3. Therapy Based Market Size of IPF in 7 MM
13. Market Size of IPF by Country
13.1. United States Market Analysis
13.1.1. Market Size of IPF in the US
13.1.2. Therapy Based Market Size of IPF in the US
13.2. EU5 Market Outlook
13.3. Germany
13.3.1. Market Size of IPF in Germany
13.3.2. Therapy Based Market Size of IPF in Germany
13.4. France
13.4.1. Market Size of IPF in France
13.4.2. Therapy Based Market Size of IPF in France
13.5. Italy
13.5.1. Market Size of IPF in Italy
13.5.2. Therapy Based Market Size of IPF in Italy
13.6. United Kingdom
13.6.1. Market Size of IPF in the UK
13.6.2. Therapy Based Market Size of IPF in the UK
13.7. Spain
13.7.1. Market Size of IPF in Spain
13.7.2. Therapy Based Market Size of IPF in Spain
13.8. Japan: Market Analysis
13.8.1. Market Size of IPF in Japan
13.8.2. Therapy Based Market Size of IPF in Japan
14. Market Drivers of IPF
15. Market Barriers of IPF
16. Appendix
16.1. Report Methodology
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

 

1. Key Insights
2. IPF Market Overview at a Glance
2.1. Market Share (%) Distribution of IPF in 2017
2.2. Market Share (%) Distribution of IPF in 2027
3. Disease Background and Overview: Idiopathic Pulmonary Fibrosis (IPF)
3.1. Introduction
3.2. Staging of IPF
3.3. Risk Factors & Disease Causes
3.4. Symptoms
3.5. Pathogenesis
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7 MM Prevalent Population of IPF
4.3. Country Wise-Epidemiology of IPF
4.3.1. United States
4.3.2. Prevalent cases of IPF in the United States
4.3.3. Prevalent Population of IPF by severity
4.3.4. Gender-Specific IPF Prevalence
4.3.5. Age-Specific IPF Prevalence
4.3.6. EU5
4.3.7. Prevalent Population of IPF in EU5
4.3.8. France
4.3.9. Prevalent Population of IPF
4.3.10. Prevalent Population of IPF by severity
4.3.11. Gender-Specific IPF Prevalence
4.3.12. Age-Specific IPF Prevalence
4.3.13. Germany
4.3.14. Prevalent Population of IPF
4.3.15. Prevalent Population of IPF by severity
4.3.16. Gender-Specific IPF Prevalence
4.3.17. Age-Specific IPF Prevalence
4.3.18. Italy
4.3.19. Prevalent Population of IPF
4.3.20. Prevalent Population of IPF by severity
4.3.21. Gender-Specific IPF Prevalence
4.3.22. Age-Specific IPF Prevalence
4.3.23. Spain
4.3.24. Prevalent Population of IPF
4.3.25. Prevalent Population of IPF by severity
4.3.26. Gender-Specific IPF Prevalence
4.3.27. Age-Specific IPF Prevalence
4.3.28. United Kingdom
4.3.29. Prevalent Population of IPF
4.3.30. Prevalent Population of IPF by severity
4.3.31. Gender-Specific IPF Prevalence
4.3.32. Age-Specific IPF Prevalence
4.3.33. Japan
4.3.34. Prevalent Population of IPF
4.3.35. Prevalent Population of IPF by severity
4.3.36. Gender-SPECIFIC IPF Prevalence
4.3.37. Age-Specific IPF Prevalence
5. Current Treatment Practices
5.1. ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of IPF (An Update of 2011 Clinical Practice Guideline)
6. Unmet needs
7. Marketed Products
7.1. Esbriet (Pirfenidone): InterMune Inc.
7.1.1. Product Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Safety and Efficacy of Esbriet
7.1.5. Side effects of Esbriet
7.1.6. Product Profile
7.2. Ofev (Nintedanib): Boehringer Ingelheim Pharma GmbH & Co. KG
7.2.1. Product Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Safety and Efficacy of Ofev
7.2.5. Side effects of Ofev
7.2.6. Product Profile
8. Emerging Therapies
9. Key Cross Competition
10. Phase III Drugs
10.1. Thrombomodulin Alfa: Asahi Kasei Pharma Corporation
10.1.1. Drug Description
10.1.2. Product Profile
10.1.3. Clinical Development
10.1.4. Clinical Trials Information
10.1.5. Safety and Efficacy
11. Phase II Drugs
11.1. CC-90001: Celgene Corporation
11.1.1. Drug Description
11.1.2. Product Profile
11.1.3. Clinical Development
11.1.4. Clinical Trials Information
11.1.5. Safety and Efficacy
11.1.6. Drug Description
11.1.7. Product Profile
11.1.8. Other Development Activities
11.1.9. Clinical Development
11.1.10. Clinical Trials Information
11.1.11. Safety and Efficacy
11.2. Gefapixant: Merck & Co., Inc.
11.2.1. Drug Description
11.2.2. Product Profile
11.2.3. Other Development Activities
11.2.4. Clinical Development
11.2.5. Clinical Trials Information
11.2.6. Safety and Efficacy
11.3. GLPG1690: Galapagos NV
11.3.1. Drug Description
11.3.2. Product Profile
11.3.3. Regulatory Milestones
11.3.4. Other Development Activities
11.3.5. Clinical Development
11.3.6. Clinical Trials Information
11.3.7. Safety and Efficacy
11.4. LT-1001: LTT Bio-Pharma
11.4.1. Drug Description
11.4.2. Product Profile
11.4.3. Other Development Activities
11.4.4. Clinical Development
11.4.5. Clinical Trials Information
11.4.6. Safety and Efficacy
11.5. BG00011: Biogen Inc.
11.5.1. Drug Description
11.5.2. Product Profile
11.5.3. Regulatory Milestones
11.5.4. Other Development Activities
11.5.5. Clinical Development
11.5.6. Clinical Trials Information
11.5.7. Safety and Efficacy
11.6. BMS-986020: Bristol-Myers Squibb
11.6.1. Drug Description
11.6.2. Product Profile
11.6.3. Regulatory Milestones
11.6.4. Other Development Activities
11.6.5. Clinical Development
11.6.6. Clinical Trials Information
11.6.7. Safety and Efficacy
11.7. LT-1002: Chong Kun Dang Pharmaceutical
11.7.1. Drug Description
11.7.2. Product Profile
11.7.3. Other Development Activities
11.8. Pamrevlumab: FibroGen
11.8.1. Drug Description
11.8.2. Product Profile
11.8.3. Regulatory Milestones
11.8.4. Other Development Activities
11.8.5. Clinical Development
11.8.6. Clinical Trials Information
11.8.7. Safety and Efficacy
11.9. PBI4050: ProMetic Life Sciences
11.9.1. Drug Description
11.9.2. Product Profile
11.9.3. Regulatory Milestones
11.9.4. Other Development Activities
11.9.5. Clinical Development
11.9.6. Clinical Trials Information
11.9.7. Safety and Efficacy
11.10. PRM 151: Promedior, Inc.
11.10.1. Drug Description
11.10.2. Product Profile
11.10.3. Regulatory Milestones
11.10.4. Other Development Activities
11.10.5. Clinical Development
11.10.6. Clinical Trials Information
11.10.7. Safety and Efficacy
11.11. Tipelukast: MediciNova
11.11.1. Drug Description
11.11.2. Product Profile
11.11.3. Regulatory Milestones
11.11.4. Other Development Activities
11.11.5. Clinical Development
11.11.6. Clinical Trials Information
11.11.7. Safety and Efficacy
11.12. TD139: Bristol-Myers Squibb
11.12.1. Drug Description
11.12.2. Product Profile
11.12.3. Other Development Activities
11.12.4. Clinical Development
11.12.5. Clinical Trials Information
11.12.6. Safety and Efficacy
11.13. VAY736: Novartis
11.13.1. Drug Description
11.13.2. Product Profile
11.13.3. Other Development Activities
11.13.4. Clinical Development
11.13.5. Clinical Trials Information
11.14. TAS-115: Taiho Pharmaceutical
11.14.1. Drug Description
11.14.2. Product Profile
11.14.3. Clinical Development
11.14.4. Clinical Trials Information
12. IPF: Market Analysis
12.1. Key Findings
12.2. Total Market Size of IPF in 7 MM
12.3. Therapy Based Market Size of IPF in 7 MM
13. Market Size of IPF by Country
13.1. United States Market Analysis
13.1.1. Market Size of IPF in the US
13.1.2. Therapy Based Market Size of IPF in the US
13.2. EU5 Market Outlook
13.3. Germany
13.3.1. Market Size of IPF in Germany
13.3.2. Therapy Based Market Size of IPF in Germany
13.4. France
13.4.1. Market Size of IPF in France
13.4.2. Therapy Based Market Size of IPF in France
13.5. Italy
13.5.1. Market Size of IPF in Italy
13.5.2. Therapy Based Market Size of IPF in Italy
13.6. United Kingdom
13.6.1. Market Size of IPF in the UK
13.6.2. Therapy Based Market Size of IPF in the UK
13.7. Spain
13.7.1. Market Size of IPF in Spain
13.7.2. Therapy Based Market Size of IPF in Spain
13.8. Japan: Market Analysis
13.8.1. Market Size of IPF in Japan
13.8.2. Therapy Based Market Size of IPF in Japan
14. Market Drivers of IPF
15. Market Barriers of IPF
16. Appendix
16.1. Report Methodology
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

 

1. Key Insights
2. IPF Market Overview at a Glance
2.1. Market Share (%) Distribution of IPF in 2017
2.2. Market Share (%) Distribution of IPF in 2027
3. Disease Background and Overview: Idiopathic Pulmonary Fibrosis (IPF)
3.1. Introduction
3.2. Staging of IPF
3.3. Risk Factors & Disease Causes
3.4. Symptoms
3.5. Pathogenesis
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7 MM Prevalent Population of IPF
4.3. Country Wise-Epidemiology of IPF
4.3.1. United States
4.3.2. Prevalent cases of IPF in the United States
4.3.3. Prevalent Population of IPF by severity
4.3.4. Gender-Specific IPF Prevalence
4.3.5. Age-Specific IPF Prevalence
4.3.6. EU5
4.3.7. Prevalent Population of IPF in EU5
4.3.8. France
4.3.9. Prevalent Population of IPF
4.3.10. Prevalent Population of IPF by severity
4.3.11. Gender-Specific IPF Prevalence
4.3.12. Age-Specific IPF Prevalence
4.3.13. Germany
4.3.14. Prevalent Population of IPF
4.3.15. Prevalent Population of IPF by severity
4.3.16. Gender-Specific IPF Prevalence
4.3.17. Age-Specific IPF Prevalence
4.3.18. Italy
4.3.19. Prevalent Population of IPF
4.3.20. Prevalent Population of IPF by severity
4.3.21. Gender-Specific IPF Prevalence
4.3.22. Age-Specific IPF Prevalence
4.3.23. Spain
4.3.24. Prevalent Population of IPF
4.3.25. Prevalent Population of IPF by severity
4.3.26. Gender-Specific IPF Prevalence
4.3.27. Age-Specific IPF Prevalence
4.3.28. United Kingdom
4.3.29. Prevalent Population of IPF
4.3.30. Prevalent Population of IPF by severity
4.3.31. Gender-Specific IPF Prevalence
4.3.32. Age-Specific IPF Prevalence
4.3.33. Japan
4.3.34. Prevalent Population of IPF
4.3.35. Prevalent Population of IPF by severity
4.3.36. Gender-SPECIFIC IPF Prevalence
4.3.37. Age-Specific IPF Prevalence
5. Current Treatment Practices
5.1. ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of IPF (An Update of 2011 Clinical Practice Guideline)
6. Unmet needs
7. Marketed Products
7.1. Esbriet (Pirfenidone): InterMune Inc.
7.1.1. Product Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Safety and Efficacy of Esbriet
7.1.5. Side effects of Esbriet
7.1.6. Product Profile
7.2. Ofev (Nintedanib): Boehringer Ingelheim Pharma GmbH & Co. KG
7.2.1. Product Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Safety and Efficacy of Ofev
7.2.5. Side effects of Ofev
7.2.6. Product Profile
8. Emerging Therapies
9. Key Cross Competition
10. Phase III Drugs
10.1. Thrombomodulin Alfa: Asahi Kasei Pharma Corporation
10.1.1. Drug Description
10.1.2. Product Profile
10.1.3. Clinical Development
10.1.4. Clinical Trials Information
10.1.5. Safety and Efficacy
11. Phase II Drugs
11.1. CC-90001: Celgene Corporation
11.1.1. Drug Description
11.1.2. Product Profile
11.1.3. Clinical Development
11.1.4. Clinical Trials Information
11.1.5. Safety and Efficacy
11.1.6. Drug Description
11.1.7. Product Profile
11.1.8. Other Development Activities
11.1.9. Clinical Development
11.1.10. Clinical Trials Information
11.1.11. Safety and Efficacy
11.2. Gefapixant: Merck & Co., Inc.
11.2.1. Drug Description
11.2.2. Product Profile
11.2.3. Other Development Activities
11.2.4. Clinical Development
11.2.5. Clinical Trials Information
11.2.6. Safety and Efficacy
11.3. GLPG1690: Galapagos NV
11.3.1. Drug Description
11.3.2. Product Profile
11.3.3. Regulatory Milestones
11.3.4. Other Development Activities
11.3.5. Clinical Development
11.3.6. Clinical Trials Information
11.3.7. Safety and Efficacy
11.4. LT-1001: LTT Bio-Pharma
11.4.1. Drug Description
11.4.2. Product Profile
11.4.3. Other Development Activities
11.4.4. Clinical Development
11.4.5. Clinical Trials Information
11.4.6. Safety and Efficacy
11.5. BG00011: Biogen Inc.
11.5.1. Drug Description
11.5.2. Product Profile
11.5.3. Regulatory Milestones
11.5.4. Other Development Activities
11.5.5. Clinical Development
11.5.6. Clinical Trials Information
11.5.7. Safety and Efficacy
11.6. BMS-986020: Bristol-Myers Squibb
11.6.1. Drug Description
11.6.2. Product Profile
11.6.3. Regulatory Milestones
11.6.4. Other Development Activities
11.6.5. Clinical Development
11.6.6. Clinical Trials Information
11.6.7. Safety and Efficacy
11.7. LT-1002: Chong Kun Dang Pharmaceutical
11.7.1. Drug Description
11.7.2. Product Profile
11.7.3. Other Development Activities
11.8. Pamrevlumab: FibroGen
11.8.1. Drug Description
11.8.2. Product Profile
11.8.3. Regulatory Milestones
11.8.4. Other Development Activities
11.8.5. Clinical Development
11.8.6. Clinical Trials Information
11.8.7. Safety and Efficacy
11.9. PBI4050: ProMetic Life Sciences
11.9.1. Drug Description
11.9.2. Product Profile
11.9.3. Regulatory Milestones
11.9.4. Other Development Activities
11.9.5. Clinical Development
11.9.6. Clinical Trials Information
11.9.7. Safety and Efficacy
11.10. PRM 151: Promedior, Inc.
11.10.1. Drug Description
11.10.2. Product Profile
11.10.3. Regulatory Milestones
11.10.4. Other Development Activities
11.10.5. Clinical Development
11.10.6. Clinical Trials Information
11.10.7. Safety and Efficacy
11.11. Tipelukast: MediciNova
11.11.1. Drug Description
11.11.2. Product Profile
11.11.3. Regulatory Milestones
11.11.4. Other Development Activities
11.11.5. Clinical Development
11.11.6. Clinical Trials Information
11.11.7. Safety and Efficacy
11.12. TD139: Bristol-Myers Squibb
11.12.1. Drug Description
11.12.2. Product Profile
11.12.3. Other Development Activities
11.12.4. Clinical Development
11.12.5. Clinical Trials Information
11.12.6. Safety and Efficacy
11.13. VAY736: Novartis
11.13.1. Drug Description
11.13.2. Product Profile
11.13.3. Other Development Activities
11.13.4. Clinical Development
11.13.5. Clinical Trials Information
11.14. TAS-115: Taiho Pharmaceutical
11.14.1. Drug Description
11.14.2. Product Profile
11.14.3. Clinical Development
11.14.4. Clinical Trials Information
12. IPF: Market Analysis
12.1. Key Findings
12.2. Total Market Size of IPF in 7 MM
12.3. Therapy Based Market Size of IPF in 7 MM
13. Market Size of IPF by Country
13.1. United States Market Analysis
13.1.1. Market Size of IPF in the US
13.1.2. Therapy Based Market Size of IPF in the US
13.2. EU5 Market Outlook
13.3. Germany
13.3.1. Market Size of IPF in Germany
13.3.2. Therapy Based Market Size of IPF in Germany
13.4. France
13.4.1. Market Size of IPF in France
13.4.2. Therapy Based Market Size of IPF in France
13.5. Italy
13.5.1. Market Size of IPF in Italy
13.5.2. Therapy Based Market Size of IPF in Italy
13.6. United Kingdom
13.6.1. Market Size of IPF in the UK
13.6.2. Therapy Based Market Size of IPF in the UK
13.7. Spain
13.7.1. Market Size of IPF in Spain
13.7.2. Therapy Based Market Size of IPF in Spain
13.8. Japan: Market Analysis
13.8.1. Market Size of IPF in Japan
13.8.2. Therapy Based Market Size of IPF in Japan
14. Market Drivers of IPF
15. Market Barriers of IPF
16. Appendix
16.1. Report Methodology
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

 

1. Key Insights
2. IPF Market Overview at a Glance
2.1. Market Share (%) Distribution of IPF in 2017
2.2. Market Share (%) Distribution of IPF in 2027
3. Disease Background and Overview: Idiopathic Pulmonary Fibrosis (IPF)
3.1. Introduction
3.2. Staging of IPF
3.3. Risk Factors & Disease Causes
3.4. Symptoms
3.5. Pathogenesis
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7 MM Prevalent Population of IPF
4.3. Country Wise-Epidemiology of IPF
4.3.1. United States
4.3.2. Prevalent cases of IPF in the United States
4.3.3. Prevalent Population of IPF by severity
4.3.4. Gender-Specific IPF Prevalence
4.3.5. Age-Specific IPF Prevalence
4.3.6. EU5
4.3.7. Prevalent Population of IPF in EU5
4.3.8. France
4.3.9. Prevalent Population of IPF
4.3.10. Prevalent Population of IPF by severity
4.3.11. Gender-Specific IPF Prevalence
4.3.12. Age-Specific IPF Prevalence
4.3.13. Germany
4.3.14. Prevalent Population of IPF
4.3.15. Prevalent Population of IPF by severity
4.3.16. Gender-Specific IPF Prevalence
4.3.17. Age-Specific IPF Prevalence
4.3.18. Italy
4.3.19. Prevalent Population of IPF
4.3.20. Prevalent Population of IPF by severity
4.3.21. Gender-Specific IPF Prevalence
4.3.22. Age-Specific IPF Prevalence
4.3.23. Spain
4.3.24. Prevalent Population of IPF
4.3.25. Prevalent Population of IPF by severity
4.3.26. Gender-Specific IPF Prevalence
4.3.27. Age-Specific IPF Prevalence
4.3.28. United Kingdom
4.3.29. Prevalent Population of IPF
4.3.30. Prevalent Population of IPF by severity
4.3.31. Gender-Specific IPF Prevalence
4.3.32. Age-Specific IPF Prevalence
4.3.33. Japan
4.3.34. Prevalent Population of IPF
4.3.35. Prevalent Population of IPF by severity
4.3.36. Gender-SPECIFIC IPF Prevalence
4.3.37. Age-Specific IPF Prevalence
5. Current Treatment Practices
5.1. ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of IPF (An Update of 2011 Clinical Practice Guideline)
6. Unmet needs
7. Marketed Products
7.1. Esbriet (Pirfenidone): InterMune Inc.
7.1.1. Product Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Safety and Efficacy of Esbriet
7.1.5. Side effects of Esbriet
7.1.6. Product Profile
7.2. Ofev (Nintedanib): Boehringer Ingelheim Pharma GmbH & Co. KG
7.2.1. Product Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Safety and Efficacy of Ofev
7.2.5. Side effects of Ofev
7.2.6. Product Profile
8. Emerging Therapies
9. Key Cross Competition
10. Phase III Drugs
10.1. Thrombomodulin Alfa: Asahi Kasei Pharma Corporation
10.1.1. Drug Description
10.1.2. Product Profile
10.1.3. Clinical Development
10.1.4. Clinical Trials Information
10.1.5. Safety and Efficacy
11. Phase II Drugs
11.1. CC-90001: Celgene Corporation
11.1.1. Drug Description
11.1.2. Product Profile
11.1.3. Clinical Development
11.1.4. Clinical Trials Information
11.1.5. Safety and Efficacy
11.1.6. Drug Description
11.1.7. Product Profile
11.1.8. Other Development Activities
11.1.9. Clinical Development
11.1.10. Clinical Trials Information
11.1.11. Safety and Efficacy
11.2. Gefapixant: Merck & Co., Inc.
11.2.1. Drug Description
11.2.2. Product Profile
11.2.3. Other Development Activities
11.2.4. Clinical Development
11.2.5. Clinical Trials Information
11.2.6. Safety and Efficacy
11.3. GLPG1690: Galapagos NV
11.3.1. Drug Description
11.3.2. Product Profile
11.3.3. Regulatory Milestones
11.3.4. Other Development Activities
11.3.5. Clinical Development
11.3.6. Clinical Trials Information
11.3.7. Safety and Efficacy
11.4. LT-1001: LTT Bio-Pharma
11.4.1. Drug Description
11.4.2. Product Profile
11.4.3. Other Development Activities
11.4.4. Clinical Development
11.4.5. Clinical Trials Information
11.4.6. Safety and Efficacy
11.5. BG00011: Biogen Inc.
11.5.1. Drug Description
11.5.2. Product Profile
11.5.3. Regulatory Milestones
11.5.4. Other Development Activities
11.5.5. Clinical Development
11.5.6. Clinical Trials Information
11.5.7. Safety and Efficacy
11.6. BMS-986020: Bristol-Myers Squibb
11.6.1. Drug Description
11.6.2. Product Profile
11.6.3. Regulatory Milestones
11.6.4. Other Development Activities
11.6.5. Clinical Development
11.6.6. Clinical Trials Information
11.6.7. Safety and Efficacy
11.7. LT-1002: Chong Kun Dang Pharmaceutical
11.7.1. Drug Description
11.7.2. Product Profile
11.7.3. Other Development Activities
11.8. Pamrevlumab: FibroGen
11.8.1. Drug Description
11.8.2. Product Profile
11.8.3. Regulatory Milestones
11.8.4. Other Development Activities
11.8.5. Clinical Development
11.8.6. Clinical Trials Information
11.8.7. Safety and Efficacy
11.9. PBI4050: ProMetic Life Sciences
11.9.1. Drug Description
11.9.2. Product Profile
11.9.3. Regulatory Milestones
11.9.4. Other Development Activities
11.9.5. Clinical Development
11.9.6. Clinical Trials Information
11.9.7. Safety and Efficacy
11.10. PRM 151: Promedior, Inc.
11.10.1. Drug Description
11.10.2. Product Profile
11.10.3. Regulatory Milestones
11.10.4. Other Development Activities
11.10.5. Clinical Development
11.10.6. Clinical Trials Information
11.10.7. Safety and Efficacy
11.11. Tipelukast: MediciNova
11.11.1. Drug Description
11.11.2. Product Profile
11.11.3. Regulatory Milestones
11.11.4. Other Development Activities
11.11.5. Clinical Development
11.11.6. Clinical Trials Information
11.11.7. Safety and Efficacy
11.12. TD139: Bristol-Myers Squibb
11.12.1. Drug Description
11.12.2. Product Profile
11.12.3. Other Development Activities
11.12.4. Clinical Development
11.12.5. Clinical Trials Information
11.12.6. Safety and Efficacy
11.13. VAY736: Novartis
11.13.1. Drug Description
11.13.2. Product Profile
11.13.3. Other Development Activities
11.13.4. Clinical Development
11.13.5. Clinical Trials Information
11.14. TAS-115: Taiho Pharmaceutical
11.14.1. Drug Description
11.14.2. Product Profile
11.14.3. Clinical Development
11.14.4. Clinical Trials Information
12. IPF: Market Analysis
12.1. Key Findings
12.2. Total Market Size of IPF in 7 MM
12.3. Therapy Based Market Size of IPF in 7 MM
13. Market Size of IPF by Country
13.1. United States Market Analysis
13.1.1. Market Size of IPF in the US
13.1.2. Therapy Based Market Size of IPF in the US
13.2. EU5 Market Outlook
13.3. Germany
13.3.1. Market Size of IPF in Germany
13.3.2. Therapy Based Market Size of IPF in Germany
13.4. France
13.4.1. Market Size of IPF in France
13.4.2. Therapy Based Market Size of IPF in France
13.5. Italy
13.5.1. Market Size of IPF in Italy
13.5.2. Therapy Based Market Size of IPF in Italy
13.6. United Kingdom
13.6.1. Market Size of IPF in the UK
13.6.2. Therapy Based Market Size of IPF in the UK
13.7. Spain
13.7.1. Market Size of IPF in Spain
13.7.2. Therapy Based Market Size of IPF in Spain
13.8. Japan: Market Analysis
13.8.1. Market Size of IPF in Japan
13.8.2. Therapy Based Market Size of IPF in Japan
14. Market Drivers of IPF
15. Market Barriers of IPF
16. Appendix
16.1. Report Methodology
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

 

1. Key Insights
2. IPF Market Overview at a Glance
2.1. Market Share (%) Distribution of IPF in 2017
2.2. Market Share (%) Distribution of IPF in 2027
3. Disease Background and Overview: Idiopathic Pulmonary Fibrosis (IPF)
3.1. Introduction
3.2. Staging of IPF
3.3. Risk Factors & Disease Causes
3.4. Symptoms
3.5. Pathogenesis
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7 MM Prevalent Population of IPF
4.3. Country Wise-Epidemiology of IPF
4.3.1. United States
4.3.2. Prevalent cases of IPF in the United States
4.3.3. Prevalent Population of IPF by severity
4.3.4. Gender-Specific IPF Prevalence
4.3.5. Age-Specific IPF Prevalence
4.3.6. EU5
4.3.7. Prevalent Population of IPF in EU5
4.3.8. France
4.3.9. Prevalent Population of IPF
4.3.10. Prevalent Population of IPF by severity
4.3.11. Gender-Specific IPF Prevalence
4.3.12. Age-Specific IPF Prevalence
4.3.13. Germany
4.3.14. Prevalent Population of IPF
4.3.15. Prevalent Population of IPF by severity
4.3.16. Gender-Specific IPF Prevalence
4.3.17. Age-Specific IPF Prevalence
4.3.18. Italy
4.3.19. Prevalent Population of IPF
4.3.20. Prevalent Population of IPF by severity
4.3.21. Gender-Specific IPF Prevalence
4.3.22. Age-Specific IPF Prevalence
4.3.23. Spain
4.3.24. Prevalent Population of IPF
4.3.25. Prevalent Population of IPF by severity
4.3.26. Gender-Specific IPF Prevalence
4.3.27. Age-Specific IPF Prevalence
4.3.28. United Kingdom
4.3.29. Prevalent Population of IPF
4.3.30. Prevalent Population of IPF by severity
4.3.31. Gender-Specific IPF Prevalence
4.3.32. Age-Specific IPF Prevalence
4.3.33. Japan
4.3.34. Prevalent Population of IPF
4.3.35. Prevalent Population of IPF by severity
4.3.36. Gender-SPECIFIC IPF Prevalence
4.3.37. Age-Specific IPF Prevalence
5. Current Treatment Practices
5.1. ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of IPF (An Update of 2011 Clinical Practice Guideline)
6. Unmet needs
7. Marketed Products
7.1. Esbriet (Pirfenidone): InterMune Inc.
7.1.1. Product Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Safety and Efficacy of Esbriet
7.1.5. Side effects of Esbriet
7.1.6. Product Profile
7.2. Ofev (Nintedanib): Boehringer Ingelheim Pharma GmbH & Co. KG
7.2.1. Product Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Safety and Efficacy of Ofev
7.2.5. Side effects of Ofev
7.2.6. Product Profile
8. Emerging Therapies
9. Key Cross Competition
10. Phase III Drugs
10.1. Thrombomodulin Alfa: Asahi Kasei Pharma Corporation
10.1.1. Drug Description
10.1.2. Product Profile
10.1.3. Clinical Development
10.1.4. Clinical Trials Information
10.1.5. Safety and Efficacy
11. Phase II Drugs
11.1. CC-90001: Celgene Corporation
11.1.1. Drug Description
11.1.2. Product Profile
11.1.3. Clinical Development
11.1.4. Clinical Trials Information
11.1.5. Safety and Efficacy
11.1.6. Drug Description
11.1.7. Product Profile
11.1.8. Other Development Activities
11.1.9. Clinical Development
11.1.10. Clinical Trials Information
11.1.11. Safety and Efficacy
11.2. Gefapixant: Merck & Co., Inc.
11.2.1. Drug Description
11.2.2. Product Profile
11.2.3. Other Development Activities
11.2.4. Clinical Development
11.2.5. Clinical Trials Information
11.2.6. Safety and Efficacy
11.3. GLPG1690: Galapagos NV
11.3.1. Drug Description
11.3.2. Product Profile
11.3.3. Regulatory Milestones
11.3.4. Other Development Activities
11.3.5. Clinical Development
11.3.6. Clinical Trials Information
11.3.7. Safety and Efficacy
11.4. LT-1001: LTT Bio-Pharma
11.4.1. Drug Description
11.4.2. Product Profile
11.4.3. Other Development Activities
11.4.4. Clinical Development
11.4.5. Clinical Trials Information
11.4.6. Safety and Efficacy
11.5. BG00011: Biogen Inc.
11.5.1. Drug Description
11.5.2. Product Profile
11.5.3. Regulatory Milestones
11.5.4. Other Development Activities
11.5.5. Clinical Development
11.5.6. Clinical Trials Information
11.5.7. Safety and Efficacy
11.6. BMS-986020: Bristol-Myers Squibb
11.6.1. Drug Description
11.6.2. Product Profile
11.6.3. Regulatory Milestones
11.6.4. Other Development Activities
11.6.5. Clinical Development
11.6.6. Clinical Trials Information
11.6.7. Safety and Efficacy
11.7. LT-1002: Chong Kun Dang Pharmaceutical
11.7.1. Drug Description
11.7.2. Product Profile
11.7.3. Other Development Activities
11.8. Pamrevlumab: FibroGen
11.8.1. Drug Description
11.8.2. Product Profile
11.8.3. Regulatory Milestones
11.8.4. Other Development Activities
11.8.5. Clinical Development
11.8.6. Clinical Trials Information
11.8.7. Safety and Efficacy
11.9. PBI4050: ProMetic Life Sciences
11.9.1. Drug Description
11.9.2. Product Profile
11.9.3. Regulatory Milestones
11.9.4. Other Development Activities
11.9.5. Clinical Development
11.9.6. Clinical Trials Information
11.9.7. Safety and Efficacy
11.10. PRM 151: Promedior, Inc.
11.10.1. Drug Description
11.10.2. Product Profile
11.10.3. Regulatory Milestones
11.10.4. Other Development Activities
11.10.5. Clinical Development
11.10.6. Clinical Trials Information
11.10.7. Safety and Efficacy
11.11. Tipelukast: MediciNova
11.11.1. Drug Description
11.11.2. Product Profile
11.11.3. Regulatory Milestones
11.11.4. Other Development Activities
11.11.5. Clinical Development
11.11.6. Clinical Trials Information
11.11.7. Safety and Efficacy
11.12. TD139: Bristol-Myers Squibb
11.12.1. Drug Description
11.12.2. Product Profile
11.12.3. Other Development Activities
11.12.4. Clinical Development
11.12.5. Clinical Trials Information
11.12.6. Safety and Efficacy
11.13. VAY736: Novartis
11.13.1. Drug Description
11.13.2. Product Profile
11.13.3. Other Development Activities
11.13.4. Clinical Development
11.13.5. Clinical Trials Information
11.14. TAS-115: Taiho Pharmaceutical
11.14.1. Drug Description
11.14.2. Product Profile
11.14.3. Clinical Development
11.14.4. Clinical Trials Information
12. IPF: Market Analysis
12.1. Key Findings
12.2. Total Market Size of IPF in 7 MM
12.3. Therapy Based Market Size of IPF in 7 MM
13. Market Size of IPF by Country
13.1. United States Market Analysis
13.1.1. Market Size of IPF in the US
13.1.2. Therapy Based Market Size of IPF in the US
13.2. EU5 Market Outlook
13.3. Germany
13.3.1. Market Size of IPF in Germany
13.3.2. Therapy Based Market Size of IPF in Germany
13.4. France
13.4.1. Market Size of IPF in France
13.4.2. Therapy Based Market Size of IPF in France
13.5. Italy
13.5.1. Market Size of IPF in Italy
13.5.2. Therapy Based Market Size of IPF in Italy
13.6. United Kingdom
13.6.1. Market Size of IPF in the UK
13.6.2. Therapy Based Market Size of IPF in the UK
13.7. Spain
13.7.1. Market Size of IPF in Spain
13.7.2. Therapy Based Market Size of IPF in Spain
13.8. Japan: Market Analysis
13.8.1. Market Size of IPF in Japan
13.8.2. Therapy Based Market Size of IPF in Japan
14. Market Drivers of IPF
15. Market Barriers of IPF
16. Appendix
16.1. Report Methodology
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

 

1. Key Insights
2. IPF Market Overview at a Glance
2.1. Market Share (%) Distribution of IPF in 2017
2.2. Market Share (%) Distribution of IPF in 2027
3. Disease Background and Overview: Idiopathic Pulmonary Fibrosis (IPF)
3.1. Introduction
3.2. Staging of IPF
3.3. Risk Factors & Disease Causes
3.4. Symptoms
3.5. Pathogenesis
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7 MM Prevalent Population of IPF
4.3. Country Wise-Epidemiology of IPF
4.3.1. United States
4.3.2. Prevalent cases of IPF in the United States
4.3.3. Prevalent Population of IPF by severity
4.3.4. Gender-Specific IPF Prevalence
4.3.5. Age-Specific IPF Prevalence
4.3.6. EU5
4.3.7. Prevalent Population of IPF in EU5
4.3.8. France
4.3.9. Prevalent Population of IPF
4.3.10. Prevalent Population of IPF by severity
4.3.11. Gender-Specific IPF Prevalence
4.3.12. Age-Specific IPF Prevalence
4.3.13. Germany
4.3.14. Prevalent Population of IPF
4.3.15. Prevalent Population of IPF by severity
4.3.16. Gender-Specific IPF Prevalence
4.3.17. Age-Specific IPF Prevalence
4.3.18. Italy
4.3.19. Prevalent Population of IPF
4.3.20. Prevalent Population of IPF by severity
4.3.21. Gender-Specific IPF Prevalence
4.3.22. Age-Specific IPF Prevalence
4.3.23. Spain
4.3.24. Prevalent Population of IPF
4.3.25. Prevalent Population of IPF by severity
4.3.26. Gender-Specific IPF Prevalence
4.3.27. Age-Specific IPF Prevalence
4.3.28. United Kingdom
4.3.29. Prevalent Population of IPF
4.3.30. Prevalent Population of IPF by severity
4.3.31. Gender-Specific IPF Prevalence
4.3.32. Age-Specific IPF Prevalence
4.3.33. Japan
4.3.34. Prevalent Population of IPF
4.3.35. Prevalent Population of IPF by severity
4.3.36. Gender-SPECIFIC IPF Prevalence
4.3.37. Age-Specific IPF Prevalence
5. Current Treatment Practices
5.1. ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of IPF (An Update of 2011 Clinical Practice Guideline)
6. Unmet needs
7. Marketed Products
7.1. Esbriet (Pirfenidone): InterMune Inc.
7.1.1. Product Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Safety and Efficacy of Esbriet
7.1.5. Side effects of Esbriet
7.1.6. Product Profile
7.2. Ofev (Nintedanib): Boehringer Ingelheim Pharma GmbH & Co. KG
7.2.1. Product Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Safety and Efficacy of Ofev
7.2.5. Side effects of Ofev
7.2.6. Product Profile
8. Emerging Therapies
9. Key Cross Competition
10. Phase III Drugs
10.1. Thrombomodulin Alfa: Asahi Kasei Pharma Corporation
10.1.1. Drug Description
10.1.2. Product Profile
10.1.3. Clinical Development
10.1.4. Clinical Trials Information
10.1.5. Safety and Efficacy
11. Phase II Drugs
11.1. CC-90001: Celgene Corporation
11.1.1. Drug Description
11.1.2. Product Profile
11.1.3. Clinical Development
11.1.4. Clinical Trials Information
11.1.5. Safety and Efficacy
11.1.6. Drug Description
11.1.7. Product Profile
11.1.8. Other Development Activities
11.1.9. Clinical Development
11.1.10. Clinical Trials Information
11.1.11. Safety and Efficacy
11.2. Gefapixant: Merck & Co., Inc.
11.2.1. Drug Description
11.2.2. Product Profile
11.2.3. Other Development Activities
11.2.4. Clinical Development
11.2.5. Clinical Trials Information
11.2.6. Safety and Efficacy
11.3. GLPG1690: Galapagos NV
11.3.1. Drug Description
11.3.2. Product Profile
11.3.3. Regulatory Milestones
11.3.4. Other Development Activities
11.3.5. Clinical Development
11.3.6. Clinical Trials Information
11.3.7. Safety and Efficacy
11.4. LT-1001: LTT Bio-Pharma
11.4.1. Drug Description
11.4.2. Product Profile
11.4.3. Other Development Activities
11.4.4. Clinical Development
11.4.5. Clinical Trials Information
11.4.6. Safety and Efficacy
11.5. BG00011: Biogen Inc.
11.5.1. Drug Description
11.5.2. Product Profile
11.5.3. Regulatory Milestones
11.5.4. Other Development Activities
11.5.5. Clinical Development
11.5.6. Clinical Trials Information
11.5.7. Safety and Efficacy
11.6. BMS-986020: Bristol-Myers Squibb
11.6.1. Drug Description
11.6.2. Product Profile
11.6.3. Regulatory Milestones
11.6.4. Other Development Activities
11.6.5. Clinical Development
11.6.6. Clinical Trials Information
11.6.7. Safety and Efficacy
11.7. LT-1002: Chong Kun Dang Pharmaceutical
11.7.1. Drug Description
11.7.2. Product Profile
11.7.3. Other Development Activities
11.8. Pamrevlumab: FibroGen
11.8.1. Drug Description
11.8.2. Product Profile
11.8.3. Regulatory Milestones
11.8.4. Other Development Activities
11.8.5. Clinical Development
11.8.6. Clinical Trials Information
11.8.7. Safety and Efficacy
11.9. PBI4050: ProMetic Life Sciences
11.9.1. Drug Description
11.9.2. Product Profile
11.9.3. Regulatory Milestones
11.9.4. Other Development Activities
11.9.5. Clinical Development
11.9.6. Clinical Trials Information
11.9.7. Safety and Efficacy
11.10. PRM 151: Promedior, Inc.
11.10.1. Drug Description
11.10.2. Product Profile
11.10.3. Regulatory Milestones
11.10.4. Other Development Activities
11.10.5. Clinical Development
11.10.6. Clinical Trials Information
11.10.7. Safety and Efficacy
11.11. Tipelukast: MediciNova
11.11.1. Drug Description
11.11.2. Product Profile
11.11.3. Regulatory Milestones
11.11.4. Other Development Activities
11.11.5. Clinical Development
11.11.6. Clinical Trials Information
11.11.7. Safety and Efficacy
11.12. TD139: Bristol-Myers Squibb
11.12.1. Drug Description
11.12.2. Product Profile
11.12.3. Other Development Activities
11.12.4. Clinical Development
11.12.5. Clinical Trials Information
11.12.6. Safety and Efficacy
11.13. VAY736: Novartis
11.13.1. Drug Description
11.13.2. Product Profile
11.13.3. Other Development Activities
11.13.4. Clinical Development
11.13.5. Clinical Trials Information
11.14. TAS-115: Taiho Pharmaceutical
11.14.1. Drug Description
11.14.2. Product Profile
11.14.3. Clinical Development
11.14.4. Clinical Trials Information
12. IPF: Market Analysis
12.1. Key Findings
12.2. Total Market Size of IPF in 7 MM
12.3. Therapy Based Market Size of IPF in 7 MM
13. Market Size of IPF by Country
13.1. United States Market Analysis
13.1.1. Market Size of IPF in the US
13.1.2. Therapy Based Market Size of IPF in the US
13.2. EU5 Market Outlook
13.3. Germany
13.3.1. Market Size of IPF in Germany
13.3.2. Therapy Based Market Size of IPF in Germany
13.4. France
13.4.1. Market Size of IPF in France
13.4.2. Therapy Based Market Size of IPF in France
13.5. Italy
13.5.1. Market Size of IPF in Italy
13.5.2. Therapy Based Market Size of IPF in Italy
13.6. United Kingdom
13.6.1. Market Size of IPF in the UK
13.6.2. Therapy Based Market Size of IPF in the UK
13.7. Spain
13.7.1. Market Size of IPF in Spain
13.7.2. Therapy Based Market Size of IPF in Spain
13.8. Japan: Market Analysis
13.8.1. Market Size of IPF in Japan
13.8.2. Therapy Based Market Size of IPF in Japan
14. Market Drivers of IPF
15. Market Barriers of IPF
16. Appendix
16.1. Report Methodology
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

 

1. Key Insights
2. IPF Market Overview at a Glance
2.1. Market Share (%) Distribution of IPF in 2017
2.2. Market Share (%) Distribution of IPF in 2027
3. Disease Background and Overview: Idiopathic Pulmonary Fibrosis (IPF)
3.1. Introduction
3.2. Staging of IPF
3.3. Risk Factors & Disease Causes
3.4. Symptoms
3.5. Pathogenesis
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7 MM Prevalent Population of IPF
4.3. Country Wise-Epidemiology of IPF
4.3.1. United States
4.3.2. Prevalent cases of IPF in the United States
4.3.3. Prevalent Population of IPF by severity
4.3.4. Gender-Specific IPF Prevalence
4.3.5. Age-Specific IPF Prevalence
4.3.6. EU5
4.3.7. Prevalent Population of IPF in EU5
4.3.8. France
4.3.9. Prevalent Population of IPF
4.3.10. Prevalent Population of IPF by severity
4.3.11. Gender-Specific IPF Prevalence
4.3.12. Age-Specific IPF Prevalence
4.3.13. Germany
4.3.14. Prevalent Population of IPF
4.3.15. Prevalent Population of IPF by severity
4.3.16. Gender-Specific IPF Prevalence
4.3.17. Age-Specific IPF Prevalence
4.3.18. Italy
4.3.19. Prevalent Population of IPF
4.3.20. Prevalent Population of IPF by severity
4.3.21. Gender-Specific IPF Prevalence
4.3.22. Age-Specific IPF Prevalence
4.3.23. Spain
4.3.24. Prevalent Population of IPF
4.3.25. Prevalent Population of IPF by severity
4.3.26. Gender-Specific IPF Prevalence
4.3.27. Age-Specific IPF Prevalence
4.3.28. United Kingdom
4.3.29. Prevalent Population of IPF
4.3.30. Prevalent Population of IPF by severity
4.3.31. Gender-Specific IPF Prevalence
4.3.32. Age-Specific IPF Prevalence
4.3.33. Japan
4.3.34. Prevalent Population of IPF
4.3.35. Prevalent Population of IPF by severity
4.3.36. Gender-SPECIFIC IPF Prevalence
4.3.37. Age-Specific IPF Prevalence
5. Current Treatment Practices
5.1. ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of IPF (An Update of 2011 Clinical Practice Guideline)
6. Unmet needs
7. Marketed Products
7.1. Esbriet (Pirfenidone): InterMune Inc.
7.1.1. Product Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Safety and Efficacy of Esbriet
7.1.5. Side effects of Esbriet
7.1.6. Product Profile
7.2. Ofev (Nintedanib): Boehringer Ingelheim Pharma GmbH & Co. KG
7.2.1. Product Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Safety and Efficacy of Ofev
7.2.5. Side effects of Ofev
7.2.6. Product Profile
8. Emerging Therapies
9. Key Cross Competition
10. Phase III Drugs
10.1. Thrombomodulin Alfa: Asahi Kasei Pharma Corporation
10.1.1. Drug Description
10.1.2. Product Profile
10.1.3. Clinical Development
10.1.4. Clinical Trials Information
10.1.5. Safety and Efficacy
11. Phase II Drugs
11.1. CC-90001: Celgene Corporation
11.1.1. Drug Description
11.1.2. Product Profile
11.1.3. Clinical Development
11.1.4. Clinical Trials Information
11.1.5. Safety and Efficacy
11.1.6. Drug Description
11.1.7. Product Profile
11.1.8. Other Development Activities
11.1.9. Clinical Development
11.1.10. Clinical Trials Information
11.1.11. Safety and Efficacy
11.2. Gefapixant: Merck & Co., Inc.
11.2.1. Drug Description
11.2.2. Product Profile
11.2.3. Other Development Activities
11.2.4. Clinical Development
11.2.5. Clinical Trials Information
11.2.6. Safety and Efficacy
11.3. GLPG1690: Galapagos NV
11.3.1. Drug Description
11.3.2. Product Profile
11.3.3. Regulatory Milestones
11.3.4. Other Development Activities
11.3.5. Clinical Development
11.3.6. Clinical Trials Information
11.3.7. Safety and Efficacy
11.4. LT-1001: LTT Bio-Pharma
11.4.1. Drug Description
11.4.2. Product Profile
11.4.3. Other Development Activities
11.4.4. Clinical Development
11.4.5. Clinical Trials Information
11.4.6. Safety and Efficacy
11.5. BG00011: Biogen Inc.
11.5.1. Drug Description
11.5.2. Product Profile
11.5.3. Regulatory Milestones
11.5.4. Other Development Activities
11.5.5. Clinical Development
11.5.6. Clinical Trials Information
11.5.7. Safety and Efficacy
11.6. BMS-986020: Bristol-Myers Squibb
11.6.1. Drug Description
11.6.2. Product Profile
11.6.3. Regulatory Milestones
11.6.4. Other Development Activities
11.6.5. Clinical Development
11.6.6. Clinical Trials Information
11.6.7. Safety and Efficacy
11.7. LT-1002: Chong Kun Dang Pharmaceutical
11.7.1. Drug Description
11.7.2. Product Profile
11.7.3. Other Development Activities
11.8. Pamrevlumab: FibroGen
11.8.1. Drug Description
11.8.2. Product Profile
11.8.3. Regulatory Milestones
11.8.4. Other Development Activities
11.8.5. Clinical Development
11.8.6. Clinical Trials Information
11.8.7. Safety and Efficacy
11.9. PBI4050: ProMetic Life Sciences
11.9.1. Drug Description
11.9.2. Product Profile
11.9.3. Regulatory Milestones
11.9.4. Other Development Activities
11.9.5. Clinical Development
11.9.6. Clinical Trials Information
11.9.7. Safety and Efficacy
11.10. PRM 151: Promedior, Inc.
11.10.1. Drug Description
11.10.2. Product Profile
11.10.3. Regulatory Milestones
11.10.4. Other Development Activities
11.10.5. Clinical Development
11.10.6. Clinical Trials Information
11.10.7. Safety and Efficacy
11.11. Tipelukast: MediciNova
11.11.1. Drug Description
11.11.2. Product Profile
11.11.3. Regulatory Milestones
11.11.4. Other Development Activities
11.11.5. Clinical Development
11.11.6. Clinical Trials Information
11.11.7. Safety and Efficacy
11.12. TD139: Bristol-Myers Squibb
11.12.1. Drug Description
11.12.2. Product Profile
11.12.3. Other Development Activities
11.12.4. Clinical Development
11.12.5. Clinical Trials Information
11.12.6. Safety and Efficacy
11.13. VAY736: Novartis
11.13.1. Drug Description
11.13.2. Product Profile
11.13.3. Other Development Activities
11.13.4. Clinical Development
11.13.5. Clinical Trials Information
11.14. TAS-115: Taiho Pharmaceutical
11.14.1. Drug Description
11.14.2. Product Profile
11.14.3. Clinical Development
11.14.4. Clinical Trials Information
12. IPF: Market Analysis
12.1. Key Findings
12.2. Total Market Size of IPF in 7 MM
12.3. Therapy Based Market Size of IPF in 7 MM
13. Market Size of IPF by Country
13.1. United States Market Analysis
13.1.1. Market Size of IPF in the US
13.1.2. Therapy Based Market Size of IPF in the US
13.2. EU5 Market Outlook
13.3. Germany
13.3.1. Market Size of IPF in Germany
13.3.2. Therapy Based Market Size of IPF in Germany
13.4. France
13.4.1. Market Size of IPF in France
13.4.2. Therapy Based Market Size of IPF in France
13.5. Italy
13.5.1. Market Size of IPF in Italy
13.5.2. Therapy Based Market Size of IPF in Italy
13.6. United Kingdom
13.6.1. Market Size of IPF in the UK
13.6.2. Therapy Based Market Size of IPF in the UK
13.7. Spain
13.7.1. Market Size of IPF in Spain
13.7.2. Therapy Based Market Size of IPF in Spain
13.8. Japan: Market Analysis
13.8.1. Market Size of IPF in Japan
13.8.2. Therapy Based Market Size of IPF in Japan
14. Market Drivers of IPF
15. Market Barriers of IPF
16. Appendix
16.1. Report Methodology
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

 

1. Key Insights
2. IPF Market Overview at a Glance
2.1. Market Share (%) Distribution of IPF in 2017
2.2. Market Share (%) Distribution of IPF in 2027
3. Disease Background and Overview: Idiopathic Pulmonary Fibrosis (IPF)
3.1. Introduction
3.2. Staging of IPF
3.3. Risk Factors & Disease Causes
3.4. Symptoms
3.5. Pathogenesis
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7 MM Prevalent Population of IPF
4.3. Country Wise-Epidemiology of IPF
4.3.1. United States
4.3.2. Prevalent cases of IPF in the United States
4.3.3. Prevalent Population of IPF by severity
4.3.4. Gender-Specific IPF Prevalence
4.3.5. Age-Specific IPF Prevalence
4.3.6. EU5
4.3.7. Prevalent Population of IPF in EU5
4.3.8. France
4.3.9. Prevalent Population of IPF
4.3.10. Prevalent Population of IPF by severity
4.3.11. Gender-Specific IPF Prevalence
4.3.12. Age-Specific IPF Prevalence
4.3.13. Germany
4.3.14. Prevalent Population of IPF
4.3.15. Prevalent Population of IPF by severity
4.3.16. Gender-Specific IPF Prevalence
4.3.17. Age-Specific IPF Prevalence
4.3.18. Italy
4.3.19. Prevalent Population of IPF
4.3.20. Prevalent Population of IPF by severity
4.3.21. Gender-Specific IPF Prevalence
4.3.22. Age-Specific IPF Prevalence
4.3.23. Spain
4.3.24. Prevalent Population of IPF
4.3.25. Prevalent Population of IPF by severity
4.3.26. Gender-Specific IPF Prevalence
4.3.27. Age-Specific IPF Prevalence
4.3.28. United Kingdom
4.3.29. Prevalent Population of IPF
4.3.30. Prevalent Population of IPF by severity
4.3.31. Gender-Specific IPF Prevalence
4.3.32. Age-Specific IPF Prevalence
4.3.33. Japan
4.3.34. Prevalent Population of IPF
4.3.35. Prevalent Population of IPF by severity
4.3.36. Gender-SPECIFIC IPF Prevalence
4.3.37. Age-Specific IPF Prevalence
5. Current Treatment Practices
5.1. ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of IPF (An Update of 2011 Clinical Practice Guideline)
6. Unmet needs
7. Marketed Products
7.1. Esbriet (Pirfenidone): InterMune Inc.
7.1.1. Product Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Safety and Efficacy of Esbriet
7.1.5. Side effects of Esbriet
7.1.6. Product Profile
7.2. Ofev (Nintedanib): Boehringer Ingelheim Pharma GmbH & Co. KG
7.2.1. Product Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Safety and Efficacy of Ofev
7.2.5. Side effects of Ofev
7.2.6. Product Profile
8. Emerging Therapies
9. Key Cross Competition
10. Phase III Drugs
10.1. Thrombomodulin Alfa: Asahi Kasei Pharma Corporation
10.1.1. Drug Description
10.1.2. Product Profile
10.1.3. Clinical Development
10.1.4. Clinical Trials Information
10.1.5. Safety and Efficacy
11. Phase II Drugs
11.1. CC-90001: Celgene Corporation
11.1.1. Drug Description
11.1.2. Product Profile
11.1.3. Clinical Development
11.1.4. Clinical Trials Information
11.1.5. Safety and Efficacy
11.1.6. Drug Description
11.1.7. Product Profile
11.1.8. Other Development Activities
11.1.9. Clinical Development
11.1.10. Clinical Trials Information
11.1.11. Safety and Efficacy
11.2. Gefapixant: Merck & Co., Inc.
11.2.1. Drug Description
11.2.2. Product Profile
11.2.3. Other Development Activities
11.2.4. Clinical Development
11.2.5. Clinical Trials Information
11.2.6. Safety and Efficacy
11.3. GLPG1690: Galapagos NV
11.3.1. Drug Description
11.3.2. Product Profile
11.3.3. Regulatory Milestones
11.3.4. Other Development Activities
11.3.5. Clinical Development
11.3.6. Clinical Trials Information
11.3.7. Safety and Efficacy
11.4. LT-1001: LTT Bio-Pharma
11.4.1. Drug Description
11.4.2. Product Profile
11.4.3. Other Development Activities
11.4.4. Clinical Development
11.4.5. Clinical Trials Information
11.4.6. Safety and Efficacy
11.5. BG00011: Biogen Inc.
11.5.1. Drug Description
11.5.2. Product Profile
11.5.3. Regulatory Milestones
11.5.4. Other Development Activities
11.5.5. Clinical Development
11.5.6. Clinical Trials Information
11.5.7. Safety and Efficacy
11.6. BMS-986020: Bristol-Myers Squibb
11.6.1. Drug Description
11.6.2. Product Profile
11.6.3. Regulatory Milestones
11.6.4. Other Development Activities
11.6.5. Clinical Development
11.6.6. Clinical Trials Information
11.6.7. Safety and Efficacy
11.7. LT-1002: Chong Kun Dang Pharmaceutical
11.7.1. Drug Description
11.7.2. Product Profile
11.7.3. Other Development Activities
11.8. Pamrevlumab: FibroGen
11.8.1. Drug Description
11.8.2. Product Profile
11.8.3. Regulatory Milestones
11.8.4. Other Development Activities
11.8.5. Clinical Development
11.8.6. Clinical Trials Information
11.8.7. Safety and Efficacy
11.9. PBI4050: ProMetic Life Sciences
11.9.1. Drug Description
11.9.2. Product Profile
11.9.3. Regulatory Milestones
11.9.4. Other Development Activities
11.9.5. Clinical Development
11.9.6. Clinical Trials Information
11.9.7. Safety and Efficacy
11.10. PRM 151: Promedior, Inc.
11.10.1. Drug Description
11.10.2. Product Profile
11.10.3. Regulatory Milestones
11.10.4. Other Development Activities
11.10.5. Clinical Development
11.10.6. Clinical Trials Information
11.10.7. Safety and Efficacy
11.11. Tipelukast: MediciNova
11.11.1. Drug Description
11.11.2. Product Profile
11.11.3. Regulatory Milestones
11.11.4. Other Development Activities
11.11.5. Clinical Development
11.11.6. Clinical Trials Information
11.11.7. Safety and Efficacy
11.12. TD139: Bristol-Myers Squibb
11.12.1. Drug Description
11.12.2. Product Profile
11.12.3. Other Development Activities
11.12.4. Clinical Development
11.12.5. Clinical Trials Information
11.12.6. Safety and Efficacy
11.13. VAY736: Novartis
11.13.1. Drug Description
11.13.2. Product Profile
11.13.3. Other Development Activities
11.13.4. Clinical Development
11.13.5. Clinical Trials Information
11.14. TAS-115: Taiho Pharmaceutical
11.14.1. Drug Description
11.14.2. Product Profile
11.14.3. Clinical Development
11.14.4. Clinical Trials Information
12. IPF: Market Analysis
12.1. Key Findings
12.2. Total Market Size of IPF in 7 MM
12.3. Therapy Based Market Size of IPF in 7 MM
13. Market Size of IPF by Country
13.1. United States Market Analysis
13.1.1. Market Size of IPF in the US
13.1.2. Therapy Based Market Size of IPF in the US
13.2. EU5 Market Outlook
13.3. Germany
13.3.1. Market Size of IPF in Germany
13.3.2. Therapy Based Market Size of IPF in Germany
13.4. France
13.4.1. Market Size of IPF in France
13.4.2. Therapy Based Market Size of IPF in France
13.5. Italy
13.5.1. Market Size of IPF in Italy
13.5.2. Therapy Based Market Size of IPF in Italy
13.6. United Kingdom
13.6.1. Market Size of IPF in the UK
13.6.2. Therapy Based Market Size of IPF in the UK
13.7. Spain
13.7.1. Market Size of IPF in Spain
13.7.2. Therapy Based Market Size of IPF in Spain
13.8. Japan: Market Analysis
13.8.1. Market Size of IPF in Japan
13.8.2. Therapy Based Market Size of IPF in Japan
14. Market Drivers of IPF
15. Market Barriers of IPF
16. Appendix
16.1. Report Methodology
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

 

1. Key Insights
2. IPF Market Overview at a Glance
2.1. Market Share (%) Distribution of IPF in 2017
2.2. Market Share (%) Distribution of IPF in 2027
3. Disease Background and Overview: Idiopathic Pulmonary Fibrosis (IPF)
3.1. Introduction
3.2. Staging of IPF
3.3. Risk Factors & Disease Causes
3.4. Symptoms
3.5. Pathogenesis
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7 MM Prevalent Population of IPF
4.3. Country Wise-Epidemiology of IPF
4.3.1. United States
4.3.2. Prevalent cases of IPF in the United States
4.3.3. Prevalent Population of IPF by severity
4.3.4. Gender-Specific IPF Prevalence
4.3.5. Age-Specific IPF Prevalence
4.3.6. EU5
4.3.7. Prevalent Population of IPF in EU5
4.3.8. France
4.3.9. Prevalent Population of IPF
4.3.10. Prevalent Population of IPF by severity
4.3.11. Gender-Specific IPF Prevalence
4.3.12. Age-Specific IPF Prevalence
4.3.13. Germany
4.3.14. Prevalent Population of IPF
4.3.15. Prevalent Population of IPF by severity
4.3.16. Gender-Specific IPF Prevalence
4.3.17. Age-Specific IPF Prevalence
4.3.18. Italy
4.3.19. Prevalent Population of IPF
4.3.20. Prevalent Population of IPF by severity
4.3.21. Gender-Specific IPF Prevalence
4.3.22. Age-Specific IPF Prevalence
4.3.23. Spain
4.3.24. Prevalent Population of IPF
4.3.25. Prevalent Population of IPF by severity
4.3.26. Gender-Specific IPF Prevalence
4.3.27. Age-Specific IPF Prevalence
4.3.28. United Kingdom
4.3.29. Prevalent Population of IPF
4.3.30. Prevalent Population of IPF by severity
4.3.31. Gender-Specific IPF Prevalence
4.3.32. Age-Specific IPF Prevalence
4.3.33. Japan
4.3.34. Prevalent Population of IPF
4.3.35. Prevalent Population of IPF by severity
4.3.36. Gender-SPECIFIC IPF Prevalence
4.3.37. Age-Specific IPF Prevalence
5. Current Treatment Practices
5.1. ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of IPF (An Update of 2011 Clinical Practice Guideline)
6. Unmet needs
7. Marketed Products
7.1. Esbriet (Pirfenidone): InterMune Inc.
7.1.1. Product Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Safety and Efficacy of Esbriet
7.1.5. Side effects of Esbriet
7.1.6. Product Profile
7.2. Ofev (Nintedanib): Boehringer Ingelheim Pharma GmbH & Co. KG
7.2.1. Product Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Safety and Efficacy of Ofev
7.2.5. Side effects of Ofev
7.2.6. Product Profile
8. Emerging Therapies
9. Key Cross Competition
10. Phase III Drugs
10.1. Thrombomodulin Alfa: Asahi Kasei Pharma Corporation
10.1.1. Drug Description
10.1.2. Product Profile
10.1.3. Clinical Development
10.1.4. Clinical Trials Information
10.1.5. Safety and Efficacy
11. Phase II Drugs
11.1. CC-90001: Celgene Corporation
11.1.1. Drug Description
11.1.2. Product Profile
11.1.3. Clinical Development
11.1.4. Clinical Trials Information
11.1.5. Safety and Efficacy
11.1.6. Drug Description
11.1.7. Product Profile
11.1.8. Other Development Activities
11.1.9. Clinical Development
11.1.10. Clinical Trials Information
11.1.11. Safety and Efficacy
11.2. Gefapixant: Merck & Co., Inc.
11.2.1. Drug Description
11.2.2. Product Profile
11.2.3. Other Development Activities
11.2.4. Clinical Development
11.2.5. Clinical Trials Information
11.2.6. Safety and Efficacy
11.3. GLPG1690: Galapagos NV
11.3.1. Drug Description
11.3.2. Product Profile
11.3.3. Regulatory Milestones
11.3.4. Other Development Activities
11.3.5. Clinical Development
11.3.6. Clinical Trials Information
11.3.7. Safety and Efficacy
11.4. LT-1001: LTT Bio-Pharma
11.4.1. Drug Description
11.4.2. Product Profile
11.4.3. Other Development Activities
11.4.4. Clinical Development
11.4.5. Clinical Trials Information
11.4.6. Safety and Efficacy
11.5. BG00011: Biogen Inc.
11.5.1. Drug Description
11.5.2. Product Profile
11.5.3. Regulatory Milestones
11.5.4. Other Development Activities
11.5.5. Clinical Development
11.5.6. Clinical Trials Information
11.5.7. Safety and Efficacy
11.6. BMS-986020: Bristol-Myers Squibb
11.6.1. Drug Description
11.6.2. Product Profile
11.6.3. Regulatory Milestones
11.6.4. Other Development Activities
11.6.5. Clinical Development
11.6.6. Clinical Trials Information
11.6.7. Safety and Efficacy
11.7. LT-1002: Chong Kun Dang Pharmaceutical
11.7.1. Drug Description
11.7.2. Product Profile
11.7.3. Other Development Activities
11.8. Pamrevlumab: FibroGen
11.8.1. Drug Description
11.8.2. Product Profile
11.8.3. Regulatory Milestones
11.8.4. Other Development Activities
11.8.5. Clinical Development
11.8.6. Clinical Trials Information
11.8.7. Safety and Efficacy
11.9. PBI4050: ProMetic Life Sciences
11.9.1. Drug Description
11.9.2. Product Profile
11.9.3. Regulatory Milestones
11.9.4. Other Development Activities
11.9.5. Clinical Development
11.9.6. Clinical Trials Information
11.9.7. Safety and Efficacy
11.10. PRM 151: Promedior, Inc.
11.10.1. Drug Description
11.10.2. Product Profile
11.10.3. Regulatory Milestones
11.10.4. Other Development Activities
11.10.5. Clinical Development
11.10.6. Clinical Trials Information
11.10.7. Safety and Efficacy
11.11. Tipelukast: MediciNova
11.11.1. Drug Description
11.11.2. Product Profile
11.11.3. Regulatory Milestones
11.11.4. Other Development Activities
11.11.5. Clinical Development
11.11.6. Clinical Trials Information
11.11.7. Safety and Efficacy
11.12. TD139: Bristol-Myers Squibb
11.12.1. Drug Description
11.12.2. Product Profile
11.12.3. Other Development Activities
11.12.4. Clinical Development
11.12.5. Clinical Trials Information
11.12.6. Safety and Efficacy
11.13. VAY736: Novartis
11.13.1. Drug Description
11.13.2. Product Profile
11.13.3. Other Development Activities
11.13.4. Clinical Development
11.13.5. Clinical Trials Information
11.14. TAS-115: Taiho Pharmaceutical
11.14.1. Drug Description
11.14.2. Product Profile
11.14.3. Clinical Development
11.14.4. Clinical Trials Information
12. IPF: Market Analysis
12.1. Key Findings
12.2. Total Market Size of IPF in 7 MM
12.3. Therapy Based Market Size of IPF in 7 MM
13. Market Size of IPF by Country
13.1. United States Market Analysis
13.1.1. Market Size of IPF in the US
13.1.2. Therapy Based Market Size of IPF in the US
13.2. EU5 Market Outlook
13.3. Germany
13.3.1. Market Size of IPF in Germany
13.3.2. Therapy Based Market Size of IPF in Germany
13.4. France
13.4.1. Market Size of IPF in France
13.4.2. Therapy Based Market Size of IPF in France
13.5. Italy
13.5.1. Market Size of IPF in Italy
13.5.2. Therapy Based Market Size of IPF in Italy
13.6. United Kingdom
13.6.1. Market Size of IPF in the UK
13.6.2. Therapy Based Market Size of IPF in the UK
13.7. Spain
13.7.1. Market Size of IPF in Spain
13.7.2. Therapy Based Market Size of IPF in Spain
13.8. Japan: Market Analysis
13.8.1. Market Size of IPF in Japan
13.8.2. Therapy Based Market Size of IPF in Japan
14. Market Drivers of IPF
15. Market Barriers of IPF
16. Appendix
16.1. Report Methodology
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

 

1. Key Insights
2. IPF Market Overview at a Glance
2.1. Market Share (%) Distribution of IPF in 2017
2.2. Market Share (%) Distribution of IPF in 2027
3. Disease Background and Overview: Idiopathic Pulmonary Fibrosis (IPF)
3.1. Introduction
3.2. Staging of IPF
3.3. Risk Factors & Disease Causes
3.4. Symptoms
3.5. Pathogenesis
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7 MM Prevalent Population of IPF
4.3. Country Wise-Epidemiology of IPF
4.3.1. United States
4.3.2. Prevalent cases of IPF in the United States
4.3.3. Prevalent Population of IPF by severity
4.3.4. Gender-Specific IPF Prevalence
4.3.5. Age-Specific IPF Prevalence
4.3.6. EU5
4.3.7. Prevalent Population of IPF in EU5
4.3.8. France
4.3.9. Prevalent Population of IPF
4.3.10. Prevalent Population of IPF by severity
4.3.11. Gender-Specific IPF Prevalence
4.3.12. Age-Specific IPF Prevalence
4.3.13. Germany
4.3.14. Prevalent Population of IPF
4.3.15. Prevalent Population of IPF by severity
4.3.16. Gender-Specific IPF Prevalence
4.3.17. Age-Specific IPF Prevalence
4.3.18. Italy
4.3.19. Prevalent Population of IPF
4.3.20. Prevalent Population of IPF by severity
4.3.21. Gender-Specific IPF Prevalence
4.3.22. Age-Specific IPF Prevalence
4.3.23. Spain
4.3.24. Prevalent Population of IPF
4.3.25. Prevalent Population of IPF by severity
4.3.26. Gender-Specific IPF Prevalence
4.3.27. Age-Specific IPF Prevalence
4.3.28. United Kingdom
4.3.29. Prevalent Population of IPF
4.3.30. Prevalent Population of IPF by severity
4.3.31. Gender-Specific IPF Prevalence
4.3.32. Age-Specific IPF Prevalence
4.3.33. Japan
4.3.34. Prevalent Population of IPF
4.3.35. Prevalent Population of IPF by severity
4.3.36. Gender-SPECIFIC IPF Prevalence
4.3.37. Age-Specific IPF Prevalence
5. Current Treatment Practices
5.1. ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of IPF (An Update of 2011 Clinical Practice Guideline)
6. Unmet needs
7. Marketed Products
7.1. Esbriet (Pirfenidone): InterMune Inc.
7.1.1. Product Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Safety and Efficacy of Esbriet
7.1.5. Side effects of Esbriet
7.1.6. Product Profile
7.2. Ofev (Nintedanib): Boehringer Ingelheim Pharma GmbH & Co. KG
7.2.1. Product Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Safety and Efficacy of Ofev
7.2.5. Side effects of Ofev
7.2.6. Product Profile
8. Emerging Therapies
9. Key Cross Competition
10. Phase III Drugs
10.1. Thrombomodulin Alfa: Asahi Kasei Pharma Corporation
10.1.1. Drug Description
10.1.2. Product Profile
10.1.3. Clinical Development
10.1.4. Clinical Trials Information
10.1.5. Safety and Efficacy
11. Phase II Drugs
11.1. CC-90001: Celgene Corporation
11.1.1. Drug Description
11.1.2. Product Profile
11.1.3. Clinical Development
11.1.4. Clinical Trials Information
11.1.5. Safety and Efficacy
11.1.6. Drug Description
11.1.7. Product Profile
11.1.8. Other Development Activities
11.1.9. Clinical Development
11.1.10. Clinical Trials Information
11.1.11. Safety and Efficacy
11.2. Gefapixant: Merck & Co., Inc.
11.2.1. Drug Description
11.2.2. Product Profile
11.2.3. Other Development Activities
11.2.4. Clinical Development
11.2.5. Clinical Trials Information
11.2.6. Safety and Efficacy
11.3. GLPG1690: Galapagos NV
11.3.1. Drug Description
11.3.2. Product Profile
11.3.3. Regulatory Milestones
11.3.4. Other Development Activities
11.3.5. Clinical Development
11.3.6. Clinical Trials Information
11.3.7. Safety and Efficacy
11.4. LT-1001: LTT Bio-Pharma
11.4.1. Drug Description
11.4.2. Product Profile
11.4.3. Other Development Activities
11.4.4. Clinical Development
11.4.5. Clinical Trials Information
11.4.6. Safety and Efficacy
11.5. BG00011: Biogen Inc.
11.5.1. Drug Description
11.5.2. Product Profile
11.5.3. Regulatory Milestones
11.5.4. Other Development Activities
11.5.5. Clinical Development
11.5.6. Clinical Trials Information
11.5.7. Safety and Efficacy
11.6. BMS-986020: Bristol-Myers Squibb
11.6.1. Drug Description
11.6.2. Product Profile
11.6.3. Regulatory Milestones
11.6.4. Other Development Activities
11.6.5. Clinical Development
11.6.6. Clinical Trials Information
11.6.7. Safety and Efficacy
11.7. LT-1002: Chong Kun Dang Pharmaceutical
11.7.1. Drug Description
11.7.2. Product Profile
11.7.3. Other Development Activities
11.8. Pamrevlumab: FibroGen
11.8.1. Drug Description
11.8.2. Product Profile
11.8.3. Regulatory Milestones
11.8.4. Other Development Activities
11.8.5. Clinical Development
11.8.6. Clinical Trials Information
11.8.7. Safety and Efficacy
11.9. PBI4050: ProMetic Life Sciences
11.9.1. Drug Description
11.9.2. Product Profile
11.9.3. Regulatory Milestones
11.9.4. Other Development Activities
11.9.5. Clinical Development
11.9.6. Clinical Trials Information
11.9.7. Safety and Efficacy
11.10. PRM 151: Promedior, Inc.
11.10.1. Drug Description
11.10.2. Product Profile
11.10.3. Regulatory Milestones
11.10.4. Other Development Activities
11.10.5. Clinical Development
11.10.6. Clinical Trials Information
11.10.7. Safety and Efficacy
11.11. Tipelukast: MediciNova
11.11.1. Drug Description
11.11.2. Product Profile
11.11.3. Regulatory Milestones
11.11.4. Other Development Activities
11.11.5. Clinical Development
11.11.6. Clinical Trials Information
11.11.7. Safety and Efficacy
11.12. TD139: Bristol-Myers Squibb
11.12.1. Drug Description
11.12.2. Product Profile
11.12.3. Other Development Activities
11.12.4. Clinical Development
11.12.5. Clinical Trials Information
11.12.6. Safety and Efficacy
11.13. VAY736: Novartis
11.13.1. Drug Description
11.13.2. Product Profile
11.13.3. Other Development Activities
11.13.4. Clinical Development
11.13.5. Clinical Trials Information
11.14. TAS-115: Taiho Pharmaceutical
11.14.1. Drug Description
11.14.2. Product Profile
11.14.3. Clinical Development
11.14.4. Clinical Trials Information
12. IPF: Market Analysis
12.1. Key Findings
12.2. Total Market Size of IPF in 7 MM
12.3. Therapy Based Market Size of IPF in 7 MM
13. Market Size of IPF by Country
13.1. United States Market Analysis
13.1.1. Market Size of IPF in the US
13.1.2. Therapy Based Market Size of IPF in the US
13.2. EU5 Market Outlook
13.3. Germany
13.3.1. Market Size of IPF in Germany
13.3.2. Therapy Based Market Size of IPF in Germany
13.4. France
13.4.1. Market Size of IPF in France
13.4.2. Therapy Based Market Size of IPF in France
13.5. Italy
13.5.1. Market Size of IPF in Italy
13.5.2. Therapy Based Market Size of IPF in Italy
13.6. United Kingdom
13.6.1. Market Size of IPF in the UK
13.6.2. Therapy Based Market Size of IPF in the UK
13.7. Spain
13.7.1. Market Size of IPF in Spain
13.7.2. Therapy Based Market Size of IPF in Spain
13.8. Japan: Market Analysis
13.8.1. Market Size of IPF in Japan
13.8.2. Therapy Based Market Size of IPF in Japan
14. Market Drivers of IPF
15. Market Barriers of IPF
16. Appendix
16.1. Report Methodology
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

 

1. Key Insights
2. IPF Market Overview at a Glance
2.1. Market Share (%) Distribution of IPF in 2017
2.2. Market Share (%) Distribution of IPF in 2027
3. Disease Background and Overview: Idiopathic Pulmonary Fibrosis (IPF)
3.1. Introduction
3.2. Staging of IPF
3.3. Risk Factors & Disease Causes
3.4. Symptoms
3.5. Pathogenesis
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7 MM Prevalent Population of IPF
4.3. Country Wise-Epidemiology of IPF
4.3.1. United States
4.3.2. Prevalent cases of IPF in the United States
4.3.3. Prevalent Population of IPF by severity
4.3.4. Gender-Specific IPF Prevalence
4.3.5. Age-Specific IPF Prevalence
4.3.6. EU5
4.3.7. Prevalent Population of IPF in EU5
4.3.8. France
4.3.9. Prevalent Population of IPF
4.3.10. Prevalent Population of IPF by severity
4.3.11. Gender-Specific IPF Prevalence
4.3.12. Age-Specific IPF Prevalence
4.3.13. Germany
4.3.14. Prevalent Population of IPF
4.3.15. Prevalent Population of IPF by severity
4.3.16. Gender-Specific IPF Prevalence
4.3.17. Age-Specific IPF Prevalence
4.3.18. Italy
4.3.19. Prevalent Population of IPF
4.3.20. Prevalent Population of IPF by severity
4.3.21. Gender-Specific IPF Prevalence
4.3.22. Age-Specific IPF Prevalence
4.3.23. Spain
4.3.24. Prevalent Population of IPF
4.3.25. Prevalent Population of IPF by severity
4.3.26. Gender-Specific IPF Prevalence
4.3.27. Age-Specific IPF Prevalence
4.3.28. United Kingdom
4.3.29. Prevalent Population of IPF
4.3.30. Prevalent Population of IPF by severity
4.3.31. Gender-Specific IPF Prevalence
4.3.32. Age-Specific IPF Prevalence
4.3.33. Japan
4.3.34. Prevalent Population of IPF
4.3.35. Prevalent Population of IPF by severity
4.3.36. Gender-SPECIFIC IPF Prevalence
4.3.37. Age-Specific IPF Prevalence
5. Current Treatment Practices
5.1. ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of IPF (An Update of 2011 Clinical Practice Guideline)
6. Unmet needs
7. Marketed Products
7.1. Esbriet (Pirfenidone): InterMune Inc.
7.1.1. Product Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Safety and Efficacy of Esbriet
7.1.5. Side effects of Esbriet
7.1.6. Product Profile
7.2. Ofev (Nintedanib): Boehringer Ingelheim Pharma GmbH & Co. KG
7.2.1. Product Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Safety and Efficacy of Ofev
7.2.5. Side effects of Ofev
7.2.6. Product Profile
8. Emerging Therapies
9. Key Cross Competition
10. Phase III Drugs
10.1. Thrombomodulin Alfa: Asahi Kasei Pharma Corporation
10.1.1. Drug Description
10.1.2. Product Profile
10.1.3. Clinical Development
10.1.4. Clinical Trials Information
10.1.5. Safety and Efficacy
11. Phase II Drugs
11.1. CC-90001: Celgene Corporation
11.1.1. Drug Description
11.1.2. Product Profile
11.1.3. Clinical Development
11.1.4. Clinical Trials Information
11.1.5. Safety and Efficacy
11.1.6. Drug Description
11.1.7. Product Profile
11.1.8. Other Development Activities
11.1.9. Clinical Development
11.1.10. Clinical Trials Information
11.1.11. Safety and Efficacy
11.2. Gefapixant: Merck & Co., Inc.
11.2.1. Drug Description
11.2.2. Product Profile
11.2.3. Other Development Activities
11.2.4. Clinical Development
11.2.5. Clinical Trials Information
11.2.6. Safety and Efficacy
11.3. GLPG1690: Galapagos NV
11.3.1. Drug Description
11.3.2. Product Profile
11.3.3. Regulatory Milestones
11.3.4. Other Development Activities
11.3.5. Clinical Development
11.3.6. Clinical Trials Information
11.3.7. Safety and Efficacy
11.4. LT-1001: LTT Bio-Pharma
11.4.1. Drug Description
11.4.2. Product Profile
11.4.3. Other Development Activities
11.4.4. Clinical Development
11.4.5. Clinical Trials Information
11.4.6. Safety and Efficacy
11.5. BG00011: Biogen Inc.
11.5.1. Drug Description
11.5.2. Product Profile
11.5.3. Regulatory Milestones
11.5.4. Other Development Activities
11.5.5. Clinical Development
11.5.6. Clinical Trials Information
11.5.7. Safety and Efficacy
11.6. BMS-986020: Bristol-Myers Squibb
11.6.1. Drug Description
11.6.2. Product Profile
11.6.3. Regulatory Milestones
11.6.4. Other Development Activities
11.6.5. Clinical Development
11.6.6. Clinical Trials Information
11.6.7. Safety and Efficacy
11.7. LT-1002: Chong Kun Dang Pharmaceutical
11.7.1. Drug Description
11.7.2. Product Profile
11.7.3. Other Development Activities
11.8. Pamrevlumab: FibroGen
11.8.1. Drug Description
11.8.2. Product Profile
11.8.3. Regulatory Milestones
11.8.4. Other Development Activities
11.8.5. Clinical Development
11.8.6. Clinical Trials Information
11.8.7. Safety and Efficacy
11.9. PBI4050: ProMetic Life Sciences
11.9.1. Drug Description
11.9.2. Product Profile
11.9.3. Regulatory Milestones
11.9.4. Other Development Activities
11.9.5. Clinical Development
11.9.6. Clinical Trials Information
11.9.7. Safety and Efficacy
11.10. PRM 151: Promedior, Inc.
11.10.1. Drug Description
11.10.2. Product Profile
11.10.3. Regulatory Milestones
11.10.4. Other Development Activities
11.10.5. Clinical Development
11.10.6. Clinical Trials Information
11.10.7. Safety and Efficacy
11.11. Tipelukast: MediciNova
11.11.1. Drug Description
11.11.2. Product Profile
11.11.3. Regulatory Milestones
11.11.4. Other Development Activities
11.11.5. Clinical Development
11.11.6. Clinical Trials Information
11.11.7. Safety and Efficacy
11.12. TD139: Bristol-Myers Squibb
11.12.1. Drug Description
11.12.2. Product Profile
11.12.3. Other Development Activities
11.12.4. Clinical Development
11.12.5. Clinical Trials Information
11.12.6. Safety and Efficacy
11.13. VAY736: Novartis
11.13.1. Drug Description
11.13.2. Product Profile
11.13.3. Other Development Activities
11.13.4. Clinical Development
11.13.5. Clinical Trials Information
11.14. TAS-115: Taiho Pharmaceutical
11.14.1. Drug Description
11.14.2. Product Profile
11.14.3. Clinical Development
11.14.4. Clinical Trials Information
12. IPF: Market Analysis
12.1. Key Findings
12.2. Total Market Size of IPF in 7 MM
12.3. Therapy Based Market Size of IPF in 7 MM
13. Market Size of IPF by Country
13.1. United States Market Analysis
13.1.1. Market Size of IPF in the US
13.1.2. Therapy Based Market Size of IPF in the US
13.2. EU5 Market Outlook
13.3. Germany
13.3.1. Market Size of IPF in Germany
13.3.2. Therapy Based Market Size of IPF in Germany
13.4. France
13.4.1. Market Size of IPF in France
13.4.2. Therapy Based Market Size of IPF in France
13.5. Italy
13.5.1. Market Size of IPF in Italy
13.5.2. Therapy Based Market Size of IPF in Italy
13.6. United Kingdom
13.6.1. Market Size of IPF in the UK
13.6.2. Therapy Based Market Size of IPF in the UK
13.7. Spain
13.7.1. Market Size of IPF in Spain
13.7.2. Therapy Based Market Size of IPF in Spain
13.8. Japan: Market Analysis
13.8.1. Market Size of IPF in Japan
13.8.2. Therapy Based Market Size of IPF in Japan
14. Market Drivers of IPF
15. Market Barriers of IPF
16. Appendix
16.1. Report Methodology
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

 

1. Key Insights
2. IPF Market Overview at a Glance
2.1. Market Share (%) Distribution of IPF in 2017
2.2. Market Share (%) Distribution of IPF in 2027
3. Disease Background and Overview: Idiopathic Pulmonary Fibrosis (IPF)
3.1. Introduction
3.2. Staging of IPF
3.3. Risk Factors & Disease Causes
3.4. Symptoms
3.5. Pathogenesis
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7 MM Prevalent Population of IPF
4.3. Country Wise-Epidemiology of IPF
4.3.1. United States
4.3.2. Prevalent cases of IPF in the United States
4.3.3. Prevalent Population of IPF by severity
4.3.4. Gender-Specific IPF Prevalence
4.3.5. Age-Specific IPF Prevalence
4.3.6. EU5
4.3.7. Prevalent Population of IPF in EU5
4.3.8. France
4.3.9. Prevalent Population of IPF
4.3.10. Prevalent Population of IPF by severity
4.3.11. Gender-Specific IPF Prevalence
4.3.12. Age-Specific IPF Prevalence
4.3.13. Germany
4.3.14. Prevalent Population of IPF
4.3.15. Prevalent Population of IPF by severity
4.3.16. Gender-Specific IPF Prevalence
4.3.17. Age-Specific IPF Prevalence
4.3.18. Italy
4.3.19. Prevalent Population of IPF
4.3.20. Prevalent Population of IPF by severity
4.3.21. Gender-Specific IPF Prevalence
4.3.22. Age-Specific IPF Prevalence
4.3.23. Spain
4.3.24. Prevalent Population of IPF
4.3.25. Prevalent Population of IPF by severity
4.3.26. Gender-Specific IPF Prevalence
4.3.27. Age-Specific IPF Prevalence
4.3.28. United Kingdom
4.3.29. Prevalent Population of IPF
4.3.30. Prevalent Population of IPF by severity
4.3.31. Gender-Specific IPF Prevalence
4.3.32. Age-Specific IPF Prevalence
4.3.33. Japan
4.3.34. Prevalent Population of IPF
4.3.35. Prevalent Population of IPF by severity
4.3.36. Gender-SPECIFIC IPF Prevalence
4.3.37. Age-Specific IPF Prevalence
5. Current Treatment Practices
5.1. ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of IPF (An Update of 2011 Clinical Practice Guideline)
6. Unmet needs
7. Marketed Products
7.1. Esbriet (Pirfenidone): InterMune Inc.
7.1.1. Product Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Safety and Efficacy of Esbriet
7.1.5. Side effects of Esbriet
7.1.6. Product Profile
7.2. Ofev (Nintedanib): Boehringer Ingelheim Pharma GmbH & Co. KG
7.2.1. Product Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Safety and Efficacy of Ofev
7.2.5. Side effects of Ofev
7.2.6. Product Profile
8. Emerging Therapies
9. Key Cross Competition
10. Phase III Drugs
10.1. Thrombomodulin Alfa: Asahi Kasei Pharma Corporation
10.1.1. Drug Description
10.1.2. Product Profile
10.1.3. Clinical Development
10.1.4. Clinical Trials Information
10.1.5. Safety and Efficacy
11. Phase II Drugs
11.1. CC-90001: Celgene Corporation
11.1.1. Drug Description
11.1.2. Product Profile
11.1.3. Clinical Development
11.1.4. Clinical Trials Information
11.1.5. Safety and Efficacy
11.1.6. Drug Description
11.1.7. Product Profile
11.1.8. Other Development Activities
11.1.9. Clinical Development
11.1.10. Clinical Trials Information
11.1.11. Safety and Efficacy
11.2. Gefapixant: Merck & Co., Inc.
11.2.1. Drug Description
11.2.2. Product Profile
11.2.3. Other Development Activities
11.2.4. Clinical Development
11.2.5. Clinical Trials Information
11.2.6. Safety and Efficacy
11.3. GLPG1690: Galapagos NV
11.3.1. Drug Description
11.3.2. Product Profile
11.3.3. Regulatory Milestones
11.3.4. Other Development Activities
11.3.5. Clinical Development
11.3.6. Clinical Trials Information
11.3.7. Safety and Efficacy
11.4. LT-1001: LTT Bio-Pharma
11.4.1. Drug Description
11.4.2. Product Profile
11.4.3. Other Development Activities
11.4.4. Clinical Development
11.4.5. Clinical Trials Information
11.4.6. Safety and Efficacy
11.5. BG00011: Biogen Inc.
11.5.1. Drug Description
11.5.2. Product Profile
11.5.3. Regulatory Milestones
11.5.4. Other Development Activities
11.5.5. Clinical Development
11.5.6. Clinical Trials Information
11.5.7. Safety and Efficacy
11.6. BMS-986020: Bristol-Myers Squibb
11.6.1. Drug Description
11.6.2. Product Profile
11.6.3. Regulatory Milestones
11.6.4. Other Development Activities
11.6.5. Clinical Development
11.6.6. Clinical Trials Information
11.6.7. Safety and Efficacy
11.7. LT-1002: Chong Kun Dang Pharmaceutical
11.7.1. Drug Description
11.7.2. Product Profile
11.7.3. Other Development Activities
11.8. Pamrevlumab: FibroGen
11.8.1. Drug Description
11.8.2. Product Profile
11.8.3. Regulatory Milestones
11.8.4. Other Development Activities
11.8.5. Clinical Development
11.8.6. Clinical Trials Information
11.8.7. Safety and Efficacy
11.9. PBI4050: ProMetic Life Sciences
11.9.1. Drug Description
11.9.2. Product Profile
11.9.3. Regulatory Milestones
11.9.4. Other Development Activities
11.9.5. Clinical Development
11.9.6. Clinical Trials Information
11.9.7. Safety and Efficacy
11.10. PRM 151: Promedior, Inc.
11.10.1. Drug Description
11.10.2. Product Profile
11.10.3. Regulatory Milestones
11.10.4. Other Development Activities
11.10.5. Clinical Development
11.10.6. Clinical Trials Information
11.10.7. Safety and Efficacy
11.11. Tipelukast: MediciNova
11.11.1. Drug Description
11.11.2. Product Profile
11.11.3. Regulatory Milestones
11.11.4. Other Development Activities
11.11.5. Clinical Development
11.11.6. Clinical Trials Information
11.11.7. Safety and Efficacy
11.12. TD139: Bristol-Myers Squibb
11.12.1. Drug Description
11.12.2. Product Profile
11.12.3. Other Development Activities
11.12.4. Clinical Development
11.12.5. Clinical Trials Information
11.12.6. Safety and Efficacy
11.13. VAY736: Novartis
11.13.1. Drug Description
11.13.2. Product Profile
11.13.3. Other Development Activities
11.13.4. Clinical Development
11.13.5. Clinical Trials Information
11.14. TAS-115: Taiho Pharmaceutical
11.14.1. Drug Description
11.14.2. Product Profile
11.14.3. Clinical Development
11.14.4. Clinical Trials Information
12. IPF: Market Analysis
12.1. Key Findings
12.2. Total Market Size of IPF in 7 MM
12.3. Therapy Based Market Size of IPF in 7 MM
13. Market Size of IPF by Country
13.1. United States Market Analysis
13.1.1. Market Size of IPF in the US
13.1.2. Therapy Based Market Size of IPF in the US
13.2. EU5 Market Outlook
13.3. Germany
13.3.1. Market Size of IPF in Germany
13.3.2. Therapy Based Market Size of IPF in Germany
13.4. France
13.4.1. Market Size of IPF in France
13.4.2. Therapy Based Market Size of IPF in France
13.5. Italy
13.5.1. Market Size of IPF in Italy
13.5.2. Therapy Based Market Size of IPF in Italy
13.6. United Kingdom
13.6.1. Market Size of IPF in the UK
13.6.2. Therapy Based Market Size of IPF in the UK
13.7. Spain
13.7.1. Market Size of IPF in Spain
13.7.2. Therapy Based Market Size of IPF in Spain
13.8. Japan: Market Analysis
13.8.1. Market Size of IPF in Japan
13.8.2. Therapy Based Market Size of IPF in Japan
14. Market Drivers of IPF
15. Market Barriers of IPF
16. Appendix
16.1. Report Methodology
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

 

1. Key Insights
2. IPF Market Overview at a Glance
2.1. Market Share (%) Distribution of IPF in 2017
2.2. Market Share (%) Distribution of IPF in 2027
3. Disease Background and Overview: Idiopathic Pulmonary Fibrosis (IPF)
3.1. Introduction
3.2. Staging of IPF
3.3. Risk Factors & Disease Causes
3.4. Symptoms
3.5. Pathogenesis
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7 MM Prevalent Population of IPF
4.3. Country Wise-Epidemiology of IPF
4.3.1. United States
4.3.2. Prevalent cases of IPF in the United States
4.3.3. Prevalent Population of IPF by severity
4.3.4. Gender-Specific IPF Prevalence
4.3.5. Age-Specific IPF Prevalence
4.3.6. EU5
4.3.7. Prevalent Population of IPF in EU5
4.3.8. France
4.3.9. Prevalent Population of IPF
4.3.10. Prevalent Population of IPF by severity
4.3.11. Gender-Specific IPF Prevalence
4.3.12. Age-Specific IPF Prevalence
4.3.13. Germany
4.3.14. Prevalent Population of IPF
4.3.15. Prevalent Population of IPF by severity
4.3.16. Gender-Specific IPF Prevalence
4.3.17. Age-Specific IPF Prevalence
4.3.18. Italy
4.3.19. Prevalent Population of IPF
4.3.20. Prevalent Population of IPF by severity
4.3.21. Gender-Specific IPF Prevalence
4.3.22. Age-Specific IPF Prevalence
4.3.23. Spain
4.3.24. Prevalent Population of IPF
4.3.25. Prevalent Population of IPF by severity
4.3.26. Gender-Specific IPF Prevalence
4.3.27. Age-Specific IPF Prevalence
4.3.28. United Kingdom
4.3.29. Prevalent Population of IPF
4.3.30. Prevalent Population of IPF by severity
4.3.31. Gender-Specific IPF Prevalence
4.3.32. Age-Specific IPF Prevalence
4.3.33. Japan
4.3.34. Prevalent Population of IPF
4.3.35. Prevalent Population of IPF by severity
4.3.36. Gender-SPECIFIC IPF Prevalence
4.3.37. Age-Specific IPF Prevalence
5. Current Treatment Practices
5.1. ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of IPF (An Update of 2011 Clinical Practice Guideline)
6. Unmet needs
7. Marketed Products
7.1. Esbriet (Pirfenidone): InterMune Inc.
7.1.1. Product Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Safety and Efficacy of Esbriet
7.1.5. Side effects of Esbriet
7.1.6. Product Profile
7.2. Ofev (Nintedanib): Boehringer Ingelheim Pharma GmbH & Co. KG
7.2.1. Product Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Safety and Efficacy of Ofev
7.2.5. Side effects of Ofev
7.2.6. Product Profile
8. Emerging Therapies
9. Key Cross Competition
10. Phase III Drugs
10.1. Thrombomodulin Alfa: Asahi Kasei Pharma Corporation
10.1.1. Drug Description
10.1.2. Product Profile
10.1.3. Clinical Development
10.1.4. Clinical Trials Information
10.1.5. Safety and Efficacy
11. Phase II Drugs
11.1. CC-90001: Celgene Corporation
11.1.1. Drug Description
11.1.2. Product Profile
11.1.3. Clinical Development
11.1.4. Clinical Trials Information
11.1.5. Safety and Efficacy
11.1.6. Drug Description
11.1.7. Product Profile
11.1.8. Other Development Activities
11.1.9. Clinical Development
11.1.10. Clinical Trials Information
11.1.11. Safety and Efficacy
11.2. Gefapixant: Merck & Co., Inc.
11.2.1. Drug Description
11.2.2. Product Profile
11.2.3. Other Development Activities
11.2.4. Clinical Development
11.2.5. Clinical Trials Information
11.2.6. Safety and Efficacy
11.3. GLPG1690: Galapagos NV
11.3.1. Drug Description
11.3.2. Product Profile
11.3.3. Regulatory Milestones
11.3.4. Other Development Activities
11.3.5. Clinical Development
11.3.6. Clinical Trials Information
11.3.7. Safety and Efficacy
11.4. LT-1001: LTT Bio-Pharma
11.4.1. Drug Description
11.4.2. Product Profile
11.4.3. Other Development Activities
11.4.4. Clinical Development
11.4.5. Clinical Trials Information
11.4.6. Safety and Efficacy
11.5. BG00011: Biogen Inc.
11.5.1. Drug Description
11.5.2. Product Profile
11.5.3. Regulatory Milestones
11.5.4. Other Development Activities
11.5.5. Clinical Development
11.5.6. Clinical Trials Information
11.5.7. Safety and Efficacy
11.6. BMS-986020: Bristol-Myers Squibb
11.6.1. Drug Description
11.6.2. Product Profile
11.6.3. Regulatory Milestones
11.6.4. Other Development Activities
11.6.5. Clinical Development
11.6.6. Clinical Trials Information
11.6.7. Safety and Efficacy
11.7. LT-1002: Chong Kun Dang Pharmaceutical
11.7.1. Drug Description
11.7.2. Product Profile
11.7.3. Other Development Activities
11.8. Pamrevlumab: FibroGen
11.8.1. Drug Description
11.8.2. Product Profile
11.8.3. Regulatory Milestones
11.8.4. Other Development Activities
11.8.5. Clinical Development
11.8.6. Clinical Trials Information
11.8.7. Safety and Efficacy
11.9. PBI4050: ProMetic Life Sciences
11.9.1. Drug Description
11.9.2. Product Profile
11.9.3. Regulatory Milestones
11.9.4. Other Development Activities
11.9.5. Clinical Development
11.9.6. Clinical Trials Information
11.9.7. Safety and Efficacy
11.10. PRM 151: Promedior, Inc.
11.10.1. Drug Description
11.10.2. Product Profile
11.10.3. Regulatory Milestones
11.10.4. Other Development Activities
11.10.5. Clinical Development
11.10.6. Clinical Trials Information
11.10.7. Safety and Efficacy
11.11. Tipelukast: MediciNova
11.11.1. Drug Description
11.11.2. Product Profile
11.11.3. Regulatory Milestones
11.11.4. Other Development Activities
11.11.5. Clinical Development
11.11.6. Clinical Trials Information
11.11.7. Safety and Efficacy
11.12. TD139: Bristol-Myers Squibb
11.12.1. Drug Description
11.12.2. Product Profile
11.12.3. Other Development Activities
11.12.4. Clinical Development
11.12.5. Clinical Trials Information
11.12.6. Safety and Efficacy
11.13. VAY736: Novartis
11.13.1. Drug Description
11.13.2. Product Profile
11.13.3. Other Development Activities
11.13.4. Clinical Development
11.13.5. Clinical Trials Information
11.14. TAS-115: Taiho Pharmaceutical
11.14.1. Drug Description
11.14.2. Product Profile
11.14.3. Clinical Development
11.14.4. Clinical Trials Information
12. IPF: Market Analysis
12.1. Key Findings
12.2. Total Market Size of IPF in 7 MM
12.3. Therapy Based Market Size of IPF in 7 MM
13. Market Size of IPF by Country
13.1. United States Market Analysis
13.1.1. Market Size of IPF in the US
13.1.2. Therapy Based Market Size of IPF in the US
13.2. EU5 Market Outlook
13.3. Germany
13.3.1. Market Size of IPF in Germany
13.3.2. Therapy Based Market Size of IPF in Germany
13.4. France
13.4.1. Market Size of IPF in France
13.4.2. Therapy Based Market Size of IPF in France
13.5. Italy
13.5.1. Market Size of IPF in Italy
13.5.2. Therapy Based Market Size of IPF in Italy
13.6. United Kingdom
13.6.1. Market Size of IPF in the UK
13.6.2. Therapy Based Market Size of IPF in the UK
13.7. Spain
13.7.1. Market Size of IPF in Spain
13.7.2. Therapy Based Market Size of IPF in Spain
13.8. Japan: Market Analysis
13.8.1. Market Size of IPF in Japan
13.8.2. Therapy Based Market Size of IPF in Japan
14. Market Drivers of IPF
15. Market Barriers of IPF
16. Appendix
16.1. Report Methodology
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

 

1. Key Insights
2. IPF Market Overview at a Glance
2.1. Market Share (%) Distribution of IPF in 2017
2.2. Market Share (%) Distribution of IPF in 2027
3. Disease Background and Overview: Idiopathic Pulmonary Fibrosis (IPF)
3.1. Introduction
3.2. Staging of IPF
3.3. Risk Factors & Disease Causes
3.4. Symptoms
3.5. Pathogenesis
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7 MM Prevalent Population of IPF
4.3. Country Wise-Epidemiology of IPF
4.3.1. United States
4.3.2. Prevalent cases of IPF in the United States
4.3.3. Prevalent Population of IPF by severity
4.3.4. Gender-Specific IPF Prevalence
4.3.5. Age-Specific IPF Prevalence
4.3.6. EU5
4.3.7. Prevalent Population of IPF in EU5
4.3.8. France
4.3.9. Prevalent Population of IPF
4.3.10. Prevalent Population of IPF by severity
4.3.11. Gender-Specific IPF Prevalence
4.3.12. Age-Specific IPF Prevalence
4.3.13. Germany
4.3.14. Prevalent Population of IPF
4.3.15. Prevalent Population of IPF by severity
4.3.16. Gender-Specific IPF Prevalence
4.3.17. Age-Specific IPF Prevalence
4.3.18. Italy
4.3.19. Prevalent Population of IPF
4.3.20. Prevalent Population of IPF by severity
4.3.21. Gender-Specific IPF Prevalence
4.3.22. Age-Specific IPF Prevalence
4.3.23. Spain
4.3.24. Prevalent Population of IPF
4.3.25. Prevalent Population of IPF by severity
4.3.26. Gender-Specific IPF Prevalence
4.3.27. Age-Specific IPF Prevalence
4.3.28. United Kingdom
4.3.29. Prevalent Population of IPF
4.3.30. Prevalent Population of IPF by severity
4.3.31. Gender-Specific IPF Prevalence
4.3.32. Age-Specific IPF Prevalence
4.3.33. Japan
4.3.34. Prevalent Population of IPF
4.3.35. Prevalent Population of IPF by severity
4.3.36. Gender-SPECIFIC IPF Prevalence
4.3.37. Age-Specific IPF Prevalence
5. Current Treatment Practices
5.1. ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of IPF (An Update of 2011 Clinical Practice Guideline)
6. Unmet needs
7. Marketed Products
7.1. Esbriet (Pirfenidone): InterMune Inc.
7.1.1. Product Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Safety and Efficacy of Esbriet
7.1.5. Side effects of Esbriet
7.1.6. Product Profile
7.2. Ofev (Nintedanib): Boehringer Ingelheim Pharma GmbH & Co. KG
7.2.1. Product Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Safety and Efficacy of Ofev
7.2.5. Side effects of Ofev
7.2.6. Product Profile
8. Emerging Therapies
9. Key Cross Competition
10. Phase III Drugs
10.1. Thrombomodulin Alfa: Asahi Kasei Pharma Corporation
10.1.1. Drug Description
10.1.2. Product Profile
10.1.3. Clinical Development
10.1.4. Clinical Trials Information
10.1.5. Safety and Efficacy
11. Phase II Drugs
11.1. CC-90001: Celgene Corporation
11.1.1. Drug Description
11.1.2. Product Profile
11.1.3. Clinical Development
11.1.4. Clinical Trials Information
11.1.5. Safety and Efficacy
11.1.6. Drug Description
11.1.7. Product Profile
11.1.8. Other Development Activities
11.1.9. Clinical Development
11.1.10. Clinical Trials Information
11.1.11. Safety and Efficacy
11.2. Gefapixant: Merck & Co., Inc.
11.2.1. Drug Description
11.2.2. Product Profile
11.2.3. Other Development Activities
11.2.4. Clinical Development
11.2.5. Clinical Trials Information
11.2.6. Safety and Efficacy
11.3. GLPG1690: Galapagos NV
11.3.1. Drug Description
11.3.2. Product Profile
11.3.3. Regulatory Milestones
11.3.4. Other Development Activities
11.3.5. Clinical Development
11.3.6. Clinical Trials Information
11.3.7. Safety and Efficacy
11.4. LT-1001: LTT Bio-Pharma
11.4.1. Drug Description
11.4.2. Product Profile
11.4.3. Other Development Activities
11.4.4. Clinical Development
11.4.5. Clinical Trials Information
11.4.6. Safety and Efficacy
11.5. BG00011: Biogen Inc.
11.5.1. Drug Description
11.5.2. Product Profile
11.5.3. Regulatory Milestones
11.5.4. Other Development Activities
11.5.5. Clinical Development
11.5.6. Clinical Trials Information
11.5.7. Safety and Efficacy
11.6. BMS-986020: Bristol-Myers Squibb
11.6.1. Drug Description
11.6.2. Product Profile
11.6.3. Regulatory Milestones
11.6.4. Other Development Activities
11.6.5. Clinical Development
11.6.6. Clinical Trials Information
11.6.7. Safety and Efficacy
11.7. LT-1002: Chong Kun Dang Pharmaceutical
11.7.1. Drug Description
11.7.2. Product Profile
11.7.3. Other Development Activities
11.8. Pamrevlumab: FibroGen
11.8.1. Drug Description
11.8.2. Product Profile
11.8.3. Regulatory Milestones
11.8.4. Other Development Activities
11.8.5. Clinical Development
11.8.6. Clinical Trials Information
11.8.7. Safety and Efficacy
11.9. PBI4050: ProMetic Life Sciences
11.9.1. Drug Description
11.9.2. Product Profile
11.9.3. Regulatory Milestones
11.9.4. Other Development Activities
11.9.5. Clinical Development
11.9.6. Clinical Trials Information
11.9.7. Safety and Efficacy
11.10. PRM 151: Promedior, Inc.
11.10.1. Drug Description
11.10.2. Product Profile
11.10.3. Regulatory Milestones
11.10.4. Other Development Activities
11.10.5. Clinical Development
11.10.6. Clinical Trials Information
11.10.7. Safety and Efficacy
11.11. Tipelukast: MediciNova
11.11.1. Drug Description
11.11.2. Product Profile
11.11.3. Regulatory Milestones
11.11.4. Other Development Activities
11.11.5. Clinical Development
11.11.6. Clinical Trials Information
11.11.7. Safety and Efficacy
11.12. TD139: Bristol-Myers Squibb
11.12.1. Drug Description
11.12.2. Product Profile
11.12.3. Other Development Activities
11.12.4. Clinical Development
11.12.5. Clinical Trials Information
11.12.6. Safety and Efficacy
11.13. VAY736: Novartis
11.13.1. Drug Description
11.13.2. Product Profile
11.13.3. Other Development Activities
11.13.4. Clinical Development
11.13.5. Clinical Trials Information
11.14. TAS-115: Taiho Pharmaceutical
11.14.1. Drug Description
11.14.2. Product Profile
11.14.3. Clinical Development
11.14.4. Clinical Trials Information
12. IPF: Market Analysis
12.1. Key Findings
12.2. Total Market Size of IPF in 7 MM
12.3. Therapy Based Market Size of IPF in 7 MM
13. Market Size of IPF by Country
13.1. United States Market Analysis
13.1.1. Market Size of IPF in the US
13.1.2. Therapy Based Market Size of IPF in the US
13.2. EU5 Market Outlook
13.3. Germany
13.3.1. Market Size of IPF in Germany
13.3.2. Therapy Based Market Size of IPF in Germany
13.4. France
13.4.1. Market Size of IPF in France
13.4.2. Therapy Based Market Size of IPF in France
13.5. Italy
13.5.1. Market Size of IPF in Italy
13.5.2. Therapy Based Market Size of IPF in Italy
13.6. United Kingdom
13.6.1. Market Size of IPF in the UK
13.6.2. Therapy Based Market Size of IPF in the UK
13.7. Spain
13.7.1. Market Size of IPF in Spain
13.7.2. Therapy Based Market Size of IPF in Spain
13.8. Japan: Market Analysis
13.8.1. Market Size of IPF in Japan
13.8.2. Therapy Based Market Size of IPF in Japan
14. Market Drivers of IPF
15. Market Barriers of IPF
16. Appendix
16.1. Report Methodology
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

 

1. Key Insights
2. IPF Market Overview at a Glance
2.1. Market Share (%) Distribution of IPF in 2017
2.2. Market Share (%) Distribution of IPF in 2027
3. Disease Background and Overview: Idiopathic Pulmonary Fibrosis (IPF)
3.1. Introduction
3.2. Staging of IPF
3.3. Risk Factors & Disease Causes
3.4. Symptoms
3.5. Pathogenesis
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7 MM Prevalent Population of IPF
4.3. Country Wise-Epidemiology of IPF
4.3.1. United States
4.3.2. Prevalent cases of IPF in the United States
4.3.3. Prevalent Population of IPF by severity
4.3.4. Gender-Specific IPF Prevalence
4.3.5. Age-Specific IPF Prevalence
4.3.6. EU5
4.3.7. Prevalent Population of IPF in EU5
4.3.8. France
4.3.9. Prevalent Population of IPF
4.3.10. Prevalent Population of IPF by severity
4.3.11. Gender-Specific IPF Prevalence
4.3.12. Age-Specific IPF Prevalence
4.3.13. Germany
4.3.14. Prevalent Population of IPF
4.3.15. Prevalent Population of IPF by severity
4.3.16. Gender-Specific IPF Prevalence
4.3.17. Age-Specific IPF Prevalence
4.3.18. Italy
4.3.19. Prevalent Population of IPF
4.3.20. Prevalent Population of IPF by severity
4.3.21. Gender-Specific IPF Prevalence
4.3.22. Age-Specific IPF Prevalence
4.3.23. Spain
4.3.24. Prevalent Population of IPF
4.3.25. Prevalent Population of IPF by severity
4.3.26. Gender-Specific IPF Prevalence
4.3.27. Age-Specific IPF Prevalence
4.3.28. United Kingdom
4.3.29. Prevalent Population of IPF
4.3.30. Prevalent Population of IPF by severity
4.3.31. Gender-Specific IPF Prevalence
4.3.32. Age-Specific IPF Prevalence
4.3.33. Japan
4.3.34. Prevalent Population of IPF
4.3.35. Prevalent Population of IPF by severity
4.3.36. Gender-SPECIFIC IPF Prevalence
4.3.37. Age-Specific IPF Prevalence
5. Current Treatment Practices
5.1. ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of IPF (An Update of 2011 Clinical Practice Guideline)
6. Unmet needs
7. Marketed Products
7.1. Esbriet (Pirfenidone): InterMune Inc.
7.1.1. Product Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Safety and Efficacy of Esbriet
7.1.5. Side effects of Esbriet
7.1.6. Product Profile
7.2. Ofev (Nintedanib): Boehringer Ingelheim Pharma GmbH & Co. KG
7.2.1. Product Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Safety and Efficacy of Ofev
7.2.5. Side effects of Ofev
7.2.6. Product Profile
8. Emerging Therapies
9. Key Cross Competition
10. Phase III Drugs
10.1. Thrombomodulin Alfa: Asahi Kasei Pharma Corporation
10.1.1. Drug Description
10.1.2. Product Profile
10.1.3. Clinical Development
10.1.4. Clinical Trials Information
10.1.5. Safety and Efficacy
11. Phase II Drugs
11.1. CC-90001: Celgene Corporation
11.1.1. Drug Description
11.1.2. Product Profile
11.1.3. Clinical Development
11.1.4. Clinical Trials Information
11.1.5. Safety and Efficacy
11.1.6. Drug Description
11.1.7. Product Profile
11.1.8. Other Development Activities
11.1.9. Clinical Development
11.1.10. Clinical Trials Information
11.1.11. Safety and Efficacy
11.2. Gefapixant: Merck & Co., Inc.
11.2.1. Drug Description
11.2.2. Product Profile
11.2.3. Other Development Activities
11.2.4. Clinical Development
11.2.5. Clinical Trials Information
11.2.6. Safety and Efficacy
11.3. GLPG1690: Galapagos NV
11.3.1. Drug Description
11.3.2. Product Profile
11.3.3. Regulatory Milestones
11.3.4. Other Development Activities
11.3.5. Clinical Development
11.3.6. Clinical Trials Information
11.3.7. Safety and Efficacy
11.4. LT-1001: LTT Bio-Pharma
11.4.1. Drug Description
11.4.2. Product Profile
11.4.3. Other Development Activities
11.4.4. Clinical Development
11.4.5. Clinical Trials Information
11.4.6. Safety and Efficacy
11.5. BG00011: Biogen Inc.
11.5.1. Drug Description
11.5.2. Product Profile
11.5.3. Regulatory Milestones
11.5.4. Other Development Activities
11.5.5. Clinical Development
11.5.6. Clinical Trials Information
11.5.7. Safety and Efficacy
11.6. BMS-986020: Bristol-Myers Squibb
11.6.1. Drug Description
11.6.2. Product Profile
11.6.3. Regulatory Milestones
11.6.4. Other Development Activities
11.6.5. Clinical Development
11.6.6. Clinical Trials Information
11.6.7. Safety and Efficacy
11.7. LT-1002: Chong Kun Dang Pharmaceutical
11.7.1. Drug Description
11.7.2. Product Profile
11.7.3. Other Development Activities
11.8. Pamrevlumab: FibroGen
11.8.1. Drug Description
11.8.2. Product Profile
11.8.3. Regulatory Milestones
11.8.4. Other Development Activities
11.8.5. Clinical Development
11.8.6. Clinical Trials Information
11.8.7. Safety and Efficacy
11.9. PBI4050: ProMetic Life Sciences
11.9.1. Drug Description
11.9.2. Product Profile
11.9.3. Regulatory Milestones
11.9.4. Other Development Activities
11.9.5. Clinical Development
11.9.6. Clinical Trials Information
11.9.7. Safety and Efficacy
11.10. PRM 151: Promedior, Inc.
11.10.1. Drug Description
11.10.2. Product Profile
11.10.3. Regulatory Milestones
11.10.4. Other Development Activities
11.10.5. Clinical Development
11.10.6. Clinical Trials Information
11.10.7. Safety and Efficacy
11.11. Tipelukast: MediciNova
11.11.1. Drug Description
11.11.2. Product Profile
11.11.3. Regulatory Milestones
11.11.4. Other Development Activities
11.11.5. Clinical Development
11.11.6. Clinical Trials Information
11.11.7. Safety and Efficacy
11.12. TD139: Bristol-Myers Squibb
11.12.1. Drug Description
11.12.2. Product Profile
11.12.3. Other Development Activities
11.12.4. Clinical Development
11.12.5. Clinical Trials Information
11.12.6. Safety and Efficacy
11.13. VAY736: Novartis
11.13.1. Drug Description
11.13.2. Product Profile
11.13.3. Other Development Activities
11.13.4. Clinical Development
11.13.5. Clinical Trials Information
11.14. TAS-115: Taiho Pharmaceutical
11.14.1. Drug Description
11.14.2. Product Profile
11.14.3. Clinical Development
11.14.4. Clinical Trials Information
12. IPF: Market Analysis
12.1. Key Findings
12.2. Total Market Size of IPF in 7 MM
12.3. Therapy Based Market Size of IPF in 7 MM
13. Market Size of IPF by Country
13.1. United States Market Analysis
13.1.1. Market Size of IPF in the US
13.1.2. Therapy Based Market Size of IPF in the US
13.2. EU5 Market Outlook
13.3. Germany
13.3.1. Market Size of IPF in Germany
13.3.2. Therapy Based Market Size of IPF in Germany
13.4. France
13.4.1. Market Size of IPF in France
13.4.2. Therapy Based Market Size of IPF in France
13.5. Italy
13.5.1. Market Size of IPF in Italy
13.5.2. Therapy Based Market Size of IPF in Italy
13.6. United Kingdom
13.6.1. Market Size of IPF in the UK
13.6.2. Therapy Based Market Size of IPF in the UK
13.7. Spain
13.7.1. Market Size of IPF in Spain
13.7.2. Therapy Based Market Size of IPF in Spain
13.8. Japan: Market Analysis
13.8.1. Market Size of IPF in Japan
13.8.2. Therapy Based Market Size of IPF in Japan
14. Market Drivers of IPF
15. Market Barriers of IPF
16. Appendix
16.1. Report Methodology
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

 

1. Key Insights
2. IPF Market Overview at a Glance
2.1. Market Share (%) Distribution of IPF in 2017
2.2. Market Share (%) Distribution of IPF in 2027
3. Disease Background and Overview: Idiopathic Pulmonary Fibrosis (IPF)
3.1. Introduction
3.2. Staging of IPF
3.3. Risk Factors & Disease Causes
3.4. Symptoms
3.5. Pathogenesis
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7 MM Prevalent Population of IPF
4.3. Country Wise-Epidemiology of IPF
4.3.1. United States
4.3.2. Prevalent cases of IPF in the United States
4.3.3. Prevalent Population of IPF by severity
4.3.4. Gender-Specific IPF Prevalence
4.3.5. Age-Specific IPF Prevalence
4.3.6. EU5
4.3.7. Prevalent Population of IPF in EU5
4.3.8. France
4.3.9. Prevalent Population of IPF
4.3.10. Prevalent Population of IPF by severity
4.3.11. Gender-Specific IPF Prevalence
4.3.12. Age-Specific IPF Prevalence
4.3.13. Germany
4.3.14. Prevalent Population of IPF
4.3.15. Prevalent Population of IPF by severity
4.3.16. Gender-Specific IPF Prevalence
4.3.17. Age-Specific IPF Prevalence
4.3.18. Italy
4.3.19. Prevalent Population of IPF
4.3.20. Prevalent Population of IPF by severity
4.3.21. Gender-Specific IPF Prevalence
4.3.22. Age-Specific IPF Prevalence
4.3.23. Spain
4.3.24. Prevalent Population of IPF
4.3.25. Prevalent Population of IPF by severity
4.3.26. Gender-Specific IPF Prevalence
4.3.27. Age-Specific IPF Prevalence
4.3.28. United Kingdom
4.3.29. Prevalent Population of IPF
4.3.30. Prevalent Population of IPF by severity
4.3.31. Gender-Specific IPF Prevalence
4.3.32. Age-Specific IPF Prevalence
4.3.33. Japan
4.3.34. Prevalent Population of IPF
4.3.35. Prevalent Population of IPF by severity
4.3.36. Gender-SPECIFIC IPF Prevalence
4.3.37. Age-Specific IPF Prevalence
5. Current Treatment Practices
5.1. ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of IPF (An Update of 2011 Clinical Practice Guideline)
6. Unmet needs
7. Marketed Products
7.1. Esbriet (Pirfenidone): InterMune Inc.
7.1.1. Product Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Safety and Efficacy of Esbriet
7.1.5. Side effects of Esbriet
7.1.6. Product Profile
7.2. Ofev (Nintedanib): Boehringer Ingelheim Pharma GmbH & Co. KG
7.2.1. Product Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Safety and Efficacy of Ofev
7.2.5. Side effects of Ofev
7.2.6. Product Profile
8. Emerging Therapies
9. Key Cross Competition
10. Phase III Drugs
10.1. Thrombomodulin Alfa: Asahi Kasei Pharma Corporation
10.1.1. Drug Description
10.1.2. Product Profile
10.1.3. Clinical Development
10.1.4. Clinical Trials Information
10.1.5. Safety and Efficacy
11. Phase II Drugs
11.1. CC-90001: Celgene Corporation
11.1.1. Drug Description
11.1.2. Product Profile
11.1.3. Clinical Development
11.1.4. Clinical Trials Information
11.1.5. Safety and Efficacy
11.1.6. Drug Description
11.1.7. Product Profile
11.1.8. Other Development Activities
11.1.9. Clinical Development
11.1.10. Clinical Trials Information
11.1.11. Safety and Efficacy
11.2. Gefapixant: Merck & Co., Inc.
11.2.1. Drug Description
11.2.2. Product Profile
11.2.3. Other Development Activities
11.2.4. Clinical Development
11.2.5. Clinical Trials Information
11.2.6. Safety and Efficacy
11.3. GLPG1690: Galapagos NV
11.3.1. Drug Description
11.3.2. Product Profile
11.3.3. Regulatory Milestones
11.3.4. Other Development Activities
11.3.5. Clinical Development
11.3.6. Clinical Trials Information
11.3.7. Safety and Efficacy
11.4. LT-1001: LTT Bio-Pharma
11.4.1. Drug Description
11.4.2. Product Profile
11.4.3. Other Development Activities
11.4.4. Clinical Development
11.4.5. Clinical Trials Information
11.4.6. Safety and Efficacy
11.5. BG00011: Biogen Inc.
11.5.1. Drug Description
11.5.2. Product Profile
11.5.3. Regulatory Milestones
11.5.4. Other Development Activities
11.5.5. Clinical Development
11.5.6. Clinical Trials Information
11.5.7. Safety and Efficacy
11.6. BMS-986020: Bristol-Myers Squibb
11.6.1. Drug Description
11.6.2. Product Profile
11.6.3. Regulatory Milestones
11.6.4. Other Development Activities
11.6.5. Clinical Development
11.6.6. Clinical Trials Information
11.6.7. Safety and Efficacy
11.7. LT-1002: Chong Kun Dang Pharmaceutical
11.7.1. Drug Description
11.7.2. Product Profile
11.7.3. Other Development Activities
11.8. Pamrevlumab: FibroGen
11.8.1. Drug Description
11.8.2. Product Profile
11.8.3. Regulatory Milestones
11.8.4. Other Development Activities
11.8.5. Clinical Development
11.8.6. Clinical Trials Information
11.8.7. Safety and Efficacy
11.9. PBI4050: ProMetic Life Sciences
11.9.1. Drug Description
11.9.2. Product Profile
11.9.3. Regulatory Milestones
11.9.4. Other Development Activities
11.9.5. Clinical Development
11.9.6. Clinical Trials Information
11.9.7. Safety and Efficacy
11.10. PRM 151: Promedior, Inc.
11.10.1. Drug Description
11.10.2. Product Profile
11.10.3. Regulatory Milestones
11.10.4. Other Development Activities
11.10.5. Clinical Development
11.10.6. Clinical Trials Information
11.10.7. Safety and Efficacy
11.11. Tipelukast: MediciNova
11.11.1. Drug Description
11.11.2. Product Profile
11.11.3. Regulatory Milestones
11.11.4. Other Development Activities
11.11.5. Clinical Development
11.11.6. Clinical Trials Information
11.11.7. Safety and Efficacy
11.12. TD139: Bristol-Myers Squibb
11.12.1. Drug Description
11.12.2. Product Profile
11.12.3. Other Development Activities
11.12.4. Clinical Development
11.12.5. Clinical Trials Information
11.12.6. Safety and Efficacy
11.13. VAY736: Novartis
11.13.1. Drug Description
11.13.2. Product Profile
11.13.3. Other Development Activities
11.13.4. Clinical Development
11.13.5. Clinical Trials Information
11.14. TAS-115: Taiho Pharmaceutical
11.14.1. Drug Description
11.14.2. Product Profile
11.14.3. Clinical Development
11.14.4. Clinical Trials Information
12. IPF: Market Analysis
12.1. Key Findings
12.2. Total Market Size of IPF in 7 MM
12.3. Therapy Based Market Size of IPF in 7 MM
13. Market Size of IPF by Country
13.1. United States Market Analysis
13.1.1. Market Size of IPF in the US
13.1.2. Therapy Based Market Size of IPF in the US
13.2. EU5 Market Outlook
13.3. Germany
13.3.1. Market Size of IPF in Germany
13.3.2. Therapy Based Market Size of IPF in Germany
13.4. France
13.4.1. Market Size of IPF in France
13.4.2. Therapy Based Market Size of IPF in France
13.5. Italy
13.5.1. Market Size of IPF in Italy
13.5.2. Therapy Based Market Size of IPF in Italy
13.6. United Kingdom
13.6.1. Market Size of IPF in the UK
13.6.2. Therapy Based Market Size of IPF in the UK
13.7. Spain
13.7.1. Market Size of IPF in Spain
13.7.2. Therapy Based Market Size of IPF in Spain
13.8. Japan: Market Analysis
13.8.1. Market Size of IPF in Japan
13.8.2. Therapy Based Market Size of IPF in Japan
14. Market Drivers of IPF
15. Market Barriers of IPF
16. Appendix
16.1. Report Methodology
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

 

1. Key Insights
2. IPF Market Overview at a Glance
2.1. Market Share (%) Distribution of IPF in 2017
2.2. Market Share (%) Distribution of IPF in 2027
3. Disease Background and Overview: Idiopathic Pulmonary Fibrosis (IPF)
3.1. Introduction
3.2. Staging of IPF
3.3. Risk Factors & Disease Causes
3.4. Symptoms
3.5. Pathogenesis
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7 MM Prevalent Population of IPF
4.3. Country Wise-Epidemiology of IPF
4.3.1. United States
4.3.2. Prevalent cases of IPF in the United States
4.3.3. Prevalent Population of IPF by severity
4.3.4. Gender-Specific IPF Prevalence
4.3.5. Age-Specific IPF Prevalence
4.3.6. EU5
4.3.7. Prevalent Population of IPF in EU5
4.3.8. France
4.3.9. Prevalent Population of IPF
4.3.10. Prevalent Population of IPF by severity
4.3.11. Gender-Specific IPF Prevalence
4.3.12. Age-Specific IPF Prevalence
4.3.13. Germany
4.3.14. Prevalent Population of IPF
4.3.15. Prevalent Population of IPF by severity
4.3.16. Gender-Specific IPF Prevalence
4.3.17. Age-Specific IPF Prevalence
4.3.18. Italy
4.3.19. Prevalent Population of IPF
4.3.20. Prevalent Population of IPF by severity
4.3.21. Gender-Specific IPF Prevalence
4.3.22. Age-Specific IPF Prevalence
4.3.23. Spain
4.3.24. Prevalent Population of IPF
4.3.25. Prevalent Population of IPF by severity
4.3.26. Gender-Specific IPF Prevalence
4.3.27. Age-Specific IPF Prevalence
4.3.28. United Kingdom
4.3.29. Prevalent Population of IPF
4.3.30. Prevalent Population of IPF by severity
4.3.31. Gender-Specific IPF Prevalence
4.3.32. Age-Specific IPF Prevalence
4.3.33. Japan
4.3.34. Prevalent Population of IPF
4.3.35. Prevalent Population of IPF by severity
4.3.36. Gender-SPECIFIC IPF Prevalence
4.3.37. Age-Specific IPF Prevalence
5. Current Treatment Practices
5.1. ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of IPF (An Update of 2011 Clinical Practice Guideline)
6. Unmet needs
7. Marketed Products
7.1. Esbriet (Pirfenidone): InterMune Inc.
7.1.1. Product Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Safety and Efficacy of Esbriet
7.1.5. Side effects of Esbriet
7.1.6. Product Profile
7.2. Ofev (Nintedanib): Boehringer Ingelheim Pharma GmbH & Co. KG
7.2.1. Product Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Safety and Efficacy of Ofev
7.2.5. Side effects of Ofev
7.2.6. Product Profile
8. Emerging Therapies
9. Key Cross Competition
10. Phase III Drugs
10.1. Thrombomodulin Alfa: Asahi Kasei Pharma Corporation
10.1.1. Drug Description
10.1.2. Product Profile
10.1.3. Clinical Development
10.1.4. Clinical Trials Information
10.1.5. Safety and Efficacy
11. Phase II Drugs
11.1. CC-90001: Celgene Corporation
11.1.1. Drug Description
11.1.2. Product Profile
11.1.3. Clinical Development
11.1.4. Clinical Trials Information
11.1.5. Safety and Efficacy
11.1.6. Drug Description
11.1.7. Product Profile
11.1.8. Other Development Activities
11.1.9. Clinical Development
11.1.10. Clinical Trials Information
11.1.11. Safety and Efficacy
11.2. Gefapixant: Merck & Co., Inc.
11.2.1. Drug Description
11.2.2. Product Profile
11.2.3. Other Development Activities
11.2.4. Clinical Development
11.2.5. Clinical Trials Information
11.2.6. Safety and Efficacy
11.3. GLPG1690: Galapagos NV
11.3.1. Drug Description
11.3.2. Product Profile
11.3.3. Regulatory Milestones
11.3.4. Other Development Activities
11.3.5. Clinical Development
11.3.6. Clinical Trials Information
11.3.7. Safety and Efficacy
11.4. LT-1001: LTT Bio-Pharma
11.4.1. Drug Description
11.4.2. Product Profile
11.4.3. Other Development Activities
11.4.4. Clinical Development
11.4.5. Clinical Trials Information
11.4.6. Safety and Efficacy
11.5. BG00011: Biogen Inc.
11.5.1. Drug Description
11.5.2. Product Profile
11.5.3. Regulatory Milestones
11.5.4. Other Development Activities
11.5.5. Clinical Development
11.5.6. Clinical Trials Information
11.5.7. Safety and Efficacy
11.6. BMS-986020: Bristol-Myers Squibb
11.6.1. Drug Description
11.6.2. Product Profile
11.6.3. Regulatory Milestones
11.6.4. Other Development Activities
11.6.5. Clinical Development
11.6.6. Clinical Trials Information
11.6.7. Safety and Efficacy
11.7. LT-1002: Chong Kun Dang Pharmaceutical
11.7.1. Drug Description
11.7.2. Product Profile
11.7.3. Other Development Activities
11.8. Pamrevlumab: FibroGen
11.8.1. Drug Description
11.8.2. Product Profile
11.8.3. Regulatory Milestones
11.8.4. Other Development Activities
11.8.5. Clinical Development
11.8.6. Clinical Trials Information
11.8.7. Safety and Efficacy
11.9. PBI4050: ProMetic Life Sciences
11.9.1. Drug Description
11.9.2. Product Profile
11.9.3. Regulatory Milestones
11.9.4. Other Development Activities
11.9.5. Clinical Development
11.9.6. Clinical Trials Information
11.9.7. Safety and Efficacy
11.10. PRM 151: Promedior, Inc.
11.10.1. Drug Description
11.10.2. Product Profile
11.10.3. Regulatory Milestones
11.10.4. Other Development Activities
11.10.5. Clinical Development
11.10.6. Clinical Trials Information
11.10.7. Safety and Efficacy
11.11. Tipelukast: MediciNova
11.11.1. Drug Description
11.11.2. Product Profile
11.11.3. Regulatory Milestones
11.11.4. Other Development Activities
11.11.5. Clinical Development
11.11.6. Clinical Trials Information
11.11.7. Safety and Efficacy
11.12. TD139: Bristol-Myers Squibb
11.12.1. Drug Description
11.12.2. Product Profile
11.12.3. Other Development Activities
11.12.4. Clinical Development
11.12.5. Clinical Trials Information
11.12.6. Safety and Efficacy
11.13. VAY736: Novartis
11.13.1. Drug Description
11.13.2. Product Profile
11.13.3. Other Development Activities
11.13.4. Clinical Development
11.13.5. Clinical Trials Information
11.14. TAS-115: Taiho Pharmaceutical
11.14.1. Drug Description
11.14.2. Product Profile
11.14.3. Clinical Development
11.14.4. Clinical Trials Information
12. IPF: Market Analysis
12.1. Key Findings
12.2. Total Market Size of IPF in 7 MM
12.3. Therapy Based Market Size of IPF in 7 MM
13. Market Size of IPF by Country
13.1. United States Market Analysis
13.1.1. Market Size of IPF in the US
13.1.2. Therapy Based Market Size of IPF in the US
13.2. EU5 Market Outlook
13.3. Germany
13.3.1. Market Size of IPF in Germany
13.3.2. Therapy Based Market Size of IPF in Germany
13.4. France
13.4.1. Market Size of IPF in France
13.4.2. Therapy Based Market Size of IPF in France
13.5. Italy
13.5.1. Market Size of IPF in Italy
13.5.2. Therapy Based Market Size of IPF in Italy
13.6. United Kingdom
13.6.1. Market Size of IPF in the UK
13.6.2. Therapy Based Market Size of IPF in the UK
13.7. Spain
13.7.1. Market Size of IPF in Spain
13.7.2. Therapy Based Market Size of IPF in Spain
13.8. Japan: Market Analysis
13.8.1. Market Size of IPF in Japan
13.8.2. Therapy Based Market Size of IPF in Japan
14. Market Drivers of IPF
15. Market Barriers of IPF
16. Appendix
16.1. Report Methodology
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

 

1. Key Insights
2. IPF Market Overview at a Glance
2.1. Market Share (%) Distribution of IPF in 2017
2.2. Market Share (%) Distribution of IPF in 2027
3. Disease Background and Overview: Idiopathic Pulmonary Fibrosis (IPF)
3.1. Introduction
3.2. Staging of IPF
3.3. Risk Factors & Disease Causes
3.4. Symptoms
3.5. Pathogenesis
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7 MM Prevalent Population of IPF
4.3. Country Wise-Epidemiology of IPF
4.3.1. United States
4.3.2. Prevalent cases of IPF in the United States
4.3.3. Prevalent Population of IPF by severity
4.3.4. Gender-Specific IPF Prevalence
4.3.5. Age-Specific IPF Prevalence
4.3.6. EU5
4.3.7. Prevalent Population of IPF in EU5
4.3.8. France
4.3.9. Prevalent Population of IPF
4.3.10. Prevalent Population of IPF by severity
4.3.11. Gender-Specific IPF Prevalence
4.3.12. Age-Specific IPF Prevalence
4.3.13. Germany
4.3.14. Prevalent Population of IPF
4.3.15. Prevalent Population of IPF by severity
4.3.16. Gender-Specific IPF Prevalence
4.3.17. Age-Specific IPF Prevalence
4.3.18. Italy
4.3.19. Prevalent Population of IPF
4.3.20. Prevalent Population of IPF by severity
4.3.21. Gender-Specific IPF Prevalence
4.3.22. Age-Specific IPF Prevalence
4.3.23. Spain
4.3.24. Prevalent Population of IPF
4.3.25. Prevalent Population of IPF by severity
4.3.26. Gender-Specific IPF Prevalence
4.3.27. Age-Specific IPF Prevalence
4.3.28. United Kingdom
4.3.29. Prevalent Population of IPF
4.3.30. Prevalent Population of IPF by severity
4.3.31. Gender-Specific IPF Prevalence
4.3.32. Age-Specific IPF Prevalence
4.3.33. Japan
4.3.34. Prevalent Population of IPF
4.3.35. Prevalent Population of IPF by severity
4.3.36. Gender-SPECIFIC IPF Prevalence
4.3.37. Age-Specific IPF Prevalence
5. Current Treatment Practices
5.1. ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of IPF (An Update of 2011 Clinical Practice Guideline)
6. Unmet needs
7. Marketed Products
7.1. Esbriet (Pirfenidone): InterMune Inc.
7.1.1. Product Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Safety and Efficacy of Esbriet
7.1.5. Side effects of Esbriet
7.1.6. Product Profile
7.2. Ofev (Nintedanib): Boehringer Ingelheim Pharma GmbH & Co. KG
7.2.1. Product Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Safety and Efficacy of Ofev
7.2.5. Side effects of Ofev
7.2.6. Product Profile
8. Emerging Therapies
9. Key Cross Competition
10. Phase III Drugs
10.1. Thrombomodulin Alfa: Asahi Kasei Pharma Corporation
10.1.1. Drug Description
10.1.2. Product Profile
10.1.3. Clinical Development
10.1.4. Clinical Trials Information
10.1.5. Safety and Efficacy
11. Phase II Drugs
11.1. CC-90001: Celgene Corporation
11.1.1. Drug Description
11.1.2. Product Profile
11.1.3. Clinical Development
11.1.4. Clinical Trials Information
11.1.5. Safety and Efficacy
11.1.6. Drug Description
11.1.7. Product Profile
11.1.8. Other Development Activities
11.1.9. Clinical Development
11.1.10. Clinical Trials Information
11.1.11. Safety and Efficacy
11.2. Gefapixant: Merck & Co., Inc.
11.2.1. Drug Description
11.2.2. Product Profile
11.2.3. Other Development Activities
11.2.4. Clinical Development
11.2.5. Clinical Trials Information
11.2.6. Safety and Efficacy
11.3. GLPG1690: Galapagos NV
11.3.1. Drug Description
11.3.2. Product Profile
11.3.3. Regulatory Milestones
11.3.4. Other Development Activities
11.3.5. Clinical Development
11.3.6. Clinical Trials Information
11.3.7. Safety and Efficacy
11.4. LT-1001: LTT Bio-Pharma
11.4.1. Drug Description
11.4.2. Product Profile
11.4.3. Other Development Activities
11.4.4. Clinical Development
11.4.5. Clinical Trials Information
11.4.6. Safety and Efficacy
11.5. BG00011: Biogen Inc.
11.5.1. Drug Description
11.5.2. Product Profile
11.5.3. Regulatory Milestones
11.5.4. Other Development Activities
11.5.5. Clinical Development
11.5.6. Clinical Trials Information
11.5.7. Safety and Efficacy
11.6. BMS-986020: Bristol-Myers Squibb
11.6.1. Drug Description
11.6.2. Product Profile
11.6.3. Regulatory Milestones
11.6.4. Other Development Activities
11.6.5. Clinical Development
11.6.6. Clinical Trials Information
11.6.7. Safety and Efficacy
11.7. LT-1002: Chong Kun Dang Pharmaceutical
11.7.1. Drug Description
11.7.2. Product Profile
11.7.3. Other Development Activities
11.8. Pamrevlumab: FibroGen
11.8.1. Drug Description
11.8.2. Product Profile
11.8.3. Regulatory Milestones
11.8.4. Other Development Activities
11.8.5. Clinical Development
11.8.6. Clinical Trials Information
11.8.7. Safety and Efficacy
11.9. PBI4050: ProMetic Life Sciences
11.9.1. Drug Description
11.9.2. Product Profile
11.9.3. Regulatory Milestones
11.9.4. Other Development Activities
11.9.5. Clinical Development
11.9.6. Clinical Trials Information
11.9.7. Safety and Efficacy
11.10. PRM 151: Promedior, Inc.
11.10.1. Drug Description
11.10.2. Product Profile
11.10.3. Regulatory Milestones
11.10.4. Other Development Activities
11.10.5. Clinical Development
11.10.6. Clinical Trials Information
11.10.7. Safety and Efficacy
11.11. Tipelukast: MediciNova
11.11.1. Drug Description
11.11.2. Product Profile
11.11.3. Regulatory Milestones
11.11.4. Other Development Activities
11.11.5. Clinical Development
11.11.6. Clinical Trials Information
11.11.7. Safety and Efficacy
11.12. TD139: Bristol-Myers Squibb
11.12.1. Drug Description
11.12.2. Product Profile
11.12.3. Other Development Activities
11.12.4. Clinical Development
11.12.5. Clinical Trials Information
11.12.6. Safety and Efficacy
11.13. VAY736: Novartis
11.13.1. Drug Description
11.13.2. Product Profile
11.13.3. Other Development Activities
11.13.4. Clinical Development
11.13.5. Clinical Trials Information
11.14. TAS-115: Taiho Pharmaceutical
11.14.1. Drug Description
11.14.2. Product Profile
11.14.3. Clinical Development
11.14.4. Clinical Trials Information
12. IPF: Market Analysis
12.1. Key Findings
12.2. Total Market Size of IPF in 7 MM
12.3. Therapy Based Market Size of IPF in 7 MM
13. Market Size of IPF by Country
13.1. United States Market Analysis
13.1.1. Market Size of IPF in the US
13.1.2. Therapy Based Market Size of IPF in the US
13.2. EU5 Market Outlook
13.3. Germany
13.3.1. Market Size of IPF in Germany
13.3.2. Therapy Based Market Size of IPF in Germany
13.4. France
13.4.1. Market Size of IPF in France
13.4.2. Therapy Based Market Size of IPF in France
13.5. Italy
13.5.1. Market Size of IPF in Italy
13.5.2. Therapy Based Market Size of IPF in Italy
13.6. United Kingdom
13.6.1. Market Size of IPF in the UK
13.6.2. Therapy Based Market Size of IPF in the UK
13.7. Spain
13.7.1. Market Size of IPF in Spain
13.7.2. Therapy Based Market Size of IPF in Spain
13.8. Japan: Market Analysis
13.8.1. Market Size of IPF in Japan
13.8.2. Therapy Based Market Size of IPF in Japan
14. Market Drivers of IPF
15. Market Barriers of IPF
16. Appendix
16.1. Report Methodology
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

 

1. Key Insights
2. IPF Market Overview at a Glance
2.1. Market Share (%) Distribution of IPF in 2017
2.2. Market Share (%) Distribution of IPF in 2027
3. Disease Background and Overview: Idiopathic Pulmonary Fibrosis (IPF)
3.1. Introduction
3.2. Staging of IPF
3.3. Risk Factors & Disease Causes
3.4. Symptoms
3.5. Pathogenesis
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7 MM Prevalent Population of IPF
4.3. Country Wise-Epidemiology of IPF
4.3.1. United States
4.3.2. Prevalent cases of IPF in the United States
4.3.3. Prevalent Population of IPF by severity
4.3.4. Gender-Specific IPF Prevalence
4.3.5. Age-Specific IPF Prevalence
4.3.6. EU5
4.3.7. Prevalent Population of IPF in EU5
4.3.8. France
4.3.9. Prevalent Population of IPF
4.3.10. Prevalent Population of IPF by severity
4.3.11. Gender-Specific IPF Prevalence
4.3.12. Age-Specific IPF Prevalence
4.3.13. Germany
4.3.14. Prevalent Population of IPF
4.3.15. Prevalent Population of IPF by severity
4.3.16. Gender-Specific IPF Prevalence
4.3.17. Age-Specific IPF Prevalence
4.3.18. Italy
4.3.19. Prevalent Population of IPF
4.3.20. Prevalent Population of IPF by severity
4.3.21. Gender-Specific IPF Prevalence
4.3.22. Age-Specific IPF Prevalence
4.3.23. Spain
4.3.24. Prevalent Population of IPF
4.3.25. Prevalent Population of IPF by severity
4.3.26. Gender-Specific IPF Prevalence
4.3.27. Age-Specific IPF Prevalence
4.3.28. United Kingdom
4.3.29. Prevalent Population of IPF
4.3.30. Prevalent Population of IPF by severity
4.3.31. Gender-Specific IPF Prevalence
4.3.32. Age-Specific IPF Prevalence
4.3.33. Japan
4.3.34. Prevalent Population of IPF
4.3.35. Prevalent Population of IPF by severity
4.3.36. Gender-SPECIFIC IPF Prevalence
4.3.37. Age-Specific IPF Prevalence
5. Current Treatment Practices
5.1. ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of IPF (An Update of 2011 Clinical Practice Guideline)
6. Unmet needs
7. Marketed Products
7.1. Esbriet (Pirfenidone): InterMune Inc.
7.1.1. Product Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Safety and Efficacy of Esbriet
7.1.5. Side effects of Esbriet
7.1.6. Product Profile
7.2. Ofev (Nintedanib): Boehringer Ingelheim Pharma GmbH & Co. KG
7.2.1. Product Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Safety and Efficacy of Ofev
7.2.5. Side effects of Ofev
7.2.6. Product Profile
8. Emerging Therapies
9. Key Cross Competition
10. Phase III Drugs
10.1. Thrombomodulin Alfa: Asahi Kasei Pharma Corporation
10.1.1. Drug Description
10.1.2. Product Profile
10.1.3. Clinical Development
10.1.4. Clinical Trials Information
10.1.5. Safety and Efficacy
11. Phase II Drugs
11.1. CC-90001: Celgene Corporation
11.1.1. Drug Description
11.1.2. Product Profile
11.1.3. Clinical Development
11.1.4. Clinical Trials Information
11.1.5. Safety and Efficacy
11.1.6. Drug Description
11.1.7. Product Profile
11.1.8. Other Development Activities
11.1.9. Clinical Development
11.1.10. Clinical Trials Information
11.1.11. Safety and Efficacy
11.2. Gefapixant: Merck & Co., Inc.
11.2.1. Drug Description
11.2.2. Product Profile
11.2.3. Other Development Activities
11.2.4. Clinical Development
11.2.5. Clinical Trials Information
11.2.6. Safety and Efficacy
11.3. GLPG1690: Galapagos NV
11.3.1. Drug Description
11.3.2. Product Profile
11.3.3. Regulatory Milestones
11.3.4. Other Development Activities
11.3.5. Clinical Development
11.3.6. Clinical Trials Information
11.3.7. Safety and Efficacy
11.4. LT-1001: LTT Bio-Pharma
11.4.1. Drug Description
11.4.2. Product Profile
11.4.3. Other Development Activities
11.4.4. Clinical Development
11.4.5. Clinical Trials Information
11.4.6. Safety and Efficacy
11.5. BG00011: Biogen Inc.
11.5.1. Drug Description
11.5.2. Product Profile
11.5.3. Regulatory Milestones
11.5.4. Other Development Activities
11.5.5. Clinical Development
11.5.6. Clinical Trials Information
11.5.7. Safety and Efficacy
11.6. BMS-986020: Bristol-Myers Squibb
11.6.1. Drug Description
11.6.2. Product Profile
11.6.3. Regulatory Milestones
11.6.4. Other Development Activities
11.6.5. Clinical Development
11.6.6. Clinical Trials Information
11.6.7. Safety and Efficacy
11.7. LT-1002: Chong Kun Dang Pharmaceutical
11.7.1. Drug Description
11.7.2. Product Profile
11.7.3. Other Development Activities
11.8. Pamrevlumab: FibroGen
11.8.1. Drug Description
11.8.2. Product Profile
11.8.3. Regulatory Milestones
11.8.4. Other Development Activities
11.8.5. Clinical Development
11.8.6. Clinical Trials Information
11.8.7. Safety and Efficacy
11.9. PBI4050: ProMetic Life Sciences
11.9.1. Drug Description
11.9.2. Product Profile
11.9.3. Regulatory Milestones
11.9.4. Other Development Activities
11.9.5. Clinical Development
11.9.6. Clinical Trials Information
11.9.7. Safety and Efficacy
11.10. PRM 151: Promedior, Inc.
11.10.1. Drug Description
11.10.2. Product Profile
11.10.3. Regulatory Milestones
11.10.4. Other Development Activities
11.10.5. Clinical Development
11.10.6. Clinical Trials Information
11.10.7. Safety and Efficacy
11.11. Tipelukast: MediciNova
11.11.1. Drug Description
11.11.2. Product Profile
11.11.3. Regulatory Milestones
11.11.4. Other Development Activities
11.11.5. Clinical Development
11.11.6. Clinical Trials Information
11.11.7. Safety and Efficacy
11.12. TD139: Bristol-Myers Squibb
11.12.1. Drug Description
11.12.2. Product Profile
11.12.3. Other Development Activities
11.12.4. Clinical Development
11.12.5. Clinical Trials Information
11.12.6. Safety and Efficacy
11.13. VAY736: Novartis
11.13.1. Drug Description
11.13.2. Product Profile
11.13.3. Other Development Activities
11.13.4. Clinical Development
11.13.5. Clinical Trials Information
11.14. TAS-115: Taiho Pharmaceutical
11.14.1. Drug Description
11.14.2. Product Profile
11.14.3. Clinical Development
11.14.4. Clinical Trials Information
12. IPF: Market Analysis
12.1. Key Findings
12.2. Total Market Size of IPF in 7 MM
12.3. Therapy Based Market Size of IPF in 7 MM
13. Market Size of IPF by Country
13.1. United States Market Analysis
13.1.1. Market Size of IPF in the US
13.1.2. Therapy Based Market Size of IPF in the US
13.2. EU5 Market Outlook
13.3. Germany
13.3.1. Market Size of IPF in Germany
13.3.2. Therapy Based Market Size of IPF in Germany
13.4. France
13.4.1. Market Size of IPF in France
13.4.2. Therapy Based Market Size of IPF in France
13.5. Italy
13.5.1. Market Size of IPF in Italy
13.5.2. Therapy Based Market Size of IPF in Italy
13.6. United Kingdom
13.6.1. Market Size of IPF in the UK
13.6.2. Therapy Based Market Size of IPF in the UK
13.7. Spain
13.7.1. Market Size of IPF in Spain
13.7.2. Therapy Based Market Size of IPF in Spain
13.8. Japan: Market Analysis
13.8.1. Market Size of IPF in Japan
13.8.2. Therapy Based Market Size of IPF in Japan
14. Market Drivers of IPF
15. Market Barriers of IPF
16. Appendix
16.1. Report Methodology
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

 

1. Key Insights
2. IPF Market Overview at a Glance
2.1. Market Share (%) Distribution of IPF in 2017
2.2. Market Share (%) Distribution of IPF in 2027
3. Disease Background and Overview: Idiopathic Pulmonary Fibrosis (IPF)
3.1. Introduction
3.2. Staging of IPF
3.3. Risk Factors & Disease Causes
3.4. Symptoms
3.5. Pathogenesis
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7 MM Prevalent Population of IPF
4.3. Country Wise-Epidemiology of IPF
4.3.1. United States
4.3.2. Prevalent cases of IPF in the United States
4.3.3. Prevalent Population of IPF by severity
4.3.4. Gender-Specific IPF Prevalence
4.3.5. Age-Specific IPF Prevalence
4.3.6. EU5
4.3.7. Prevalent Population of IPF in EU5
4.3.8. France
4.3.9. Prevalent Population of IPF
4.3.10. Prevalent Population of IPF by severity
4.3.11. Gender-Specific IPF Prevalence
4.3.12. Age-Specific IPF Prevalence
4.3.13. Germany
4.3.14. Prevalent Population of IPF
4.3.15. Prevalent Population of IPF by severity
4.3.16. Gender-Specific IPF Prevalence
4.3.17. Age-Specific IPF Prevalence
4.3.18. Italy
4.3.19. Prevalent Population of IPF
4.3.20. Prevalent Population of IPF by severity
4.3.21. Gender-Specific IPF Prevalence
4.3.22. Age-Specific IPF Prevalence
4.3.23. Spain
4.3.24. Prevalent Population of IPF
4.3.25. Prevalent Population of IPF by severity
4.3.26. Gender-Specific IPF Prevalence
4.3.27. Age-Specific IPF Prevalence
4.3.28. United Kingdom
4.3.29. Prevalent Population of IPF
4.3.30. Prevalent Population of IPF by severity
4.3.31. Gender-Specific IPF Prevalence
4.3.32. Age-Specific IPF Prevalence
4.3.33. Japan
4.3.34. Prevalent Population of IPF
4.3.35. Prevalent Population of IPF by severity
4.3.36. Gender-SPECIFIC IPF Prevalence
4.3.37. Age-Specific IPF Prevalence
5. Current Treatment Practices
5.1. ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of IPF (An Update of 2011 Clinical Practice Guideline)
6. Unmet needs
7. Marketed Products
7.1. Esbriet (Pirfenidone): InterMune Inc.
7.1.1. Product Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Safety and Efficacy of Esbriet
7.1.5. Side effects of Esbriet
7.1.6. Product Profile
7.2. Ofev (Nintedanib): Boehringer Ingelheim Pharma GmbH & Co. KG
7.2.1. Product Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Safety and Efficacy of Ofev
7.2.5. Side effects of Ofev
7.2.6. Product Profile
8. Emerging Therapies
9. Key Cross Competition
10. Phase III Drugs
10.1. Thrombomodulin Alfa: Asahi Kasei Pharma Corporation
10.1.1. Drug Description
10.1.2. Product Profile
10.1.3. Clinical Development
10.1.4. Clinical Trials Information
10.1.5. Safety and Efficacy
11. Phase II Drugs
11.1. CC-90001: Celgene Corporation
11.1.1. Drug Description
11.1.2. Product Profile
11.1.3. Clinical Development
11.1.4. Clinical Trials Information
11.1.5. Safety and Efficacy
11.1.6. Drug Description
11.1.7. Product Profile
11.1.8. Other Development Activities
11.1.9. Clinical Development
11.1.10. Clinical Trials Information
11.1.11. Safety and Efficacy
11.2. Gefapixant: Merck & Co., Inc.
11.2.1. Drug Description
11.2.2. Product Profile
11.2.3. Other Development Activities
11.2.4. Clinical Development
11.2.5. Clinical Trials Information
11.2.6. Safety and Efficacy
11.3. GLPG1690: Galapagos NV
11.3.1. Drug Description
11.3.2. Product Profile
11.3.3. Regulatory Milestones
11.3.4. Other Development Activities
11.3.5. Clinical Development
11.3.6. Clinical Trials Information
11.3.7. Safety and Efficacy
11.4. LT-1001: LTT Bio-Pharma
11.4.1. Drug Description
11.4.2. Product Profile
11.4.3. Other Development Activities
11.4.4. Clinical Development
11.4.5. Clinical Trials Information
11.4.6. Safety and Efficacy
11.5. BG00011: Biogen Inc.
11.5.1. Drug Description
11.5.2. Product Profile
11.5.3. Regulatory Milestones
11.5.4. Other Development Activities
11.5.5. Clinical Development
11.5.6. Clinical Trials Information
11.5.7. Safety and Efficacy
11.6. BMS-986020: Bristol-Myers Squibb
11.6.1. Drug Description
11.6.2. Product Profile
11.6.3. Regulatory Milestones
11.6.4. Other Development Activities
11.6.5. Clinical Development
11.6.6. Clinical Trials Information
11.6.7. Safety and Efficacy
11.7. LT-1002: Chong Kun Dang Pharmaceutical
11.7.1. Drug Description
11.7.2. Product Profile
11.7.3. Other Development Activities
11.8. Pamrevlumab: FibroGen
11.8.1. Drug Description
11.8.2. Product Profile
11.8.3. Regulatory Milestones
11.8.4. Other Development Activities
11.8.5. Clinical Development
11.8.6. Clinical Trials Information
11.8.7. Safety and Efficacy
11.9. PBI4050: ProMetic Life Sciences
11.9.1. Drug Description
11.9.2. Product Profile
11.9.3. Regulatory Milestones
11.9.4. Other Development Activities
11.9.5. Clinical Development
11.9.6. Clinical Trials Information
11.9.7. Safety and Efficacy
11.10. PRM 151: Promedior, Inc.
11.10.1. Drug Description
11.10.2. Product Profile
11.10.3. Regulatory Milestones
11.10.4. Other Development Activities
11.10.5. Clinical Development
11.10.6. Clinical Trials Information
11.10.7. Safety and Efficacy
11.11. Tipelukast: MediciNova
11.11.1. Drug Description
11.11.2. Product Profile
11.11.3. Regulatory Milestones
11.11.4. Other Development Activities
11.11.5. Clinical Development
11.11.6. Clinical Trials Information
11.11.7. Safety and Efficacy
11.12. TD139: Bristol-Myers Squibb
11.12.1. Drug Description
11.12.2. Product Profile
11.12.3. Other Development Activities
11.12.4. Clinical Development
11.12.5. Clinical Trials Information
11.12.6. Safety and Efficacy
11.13. VAY736: Novartis
11.13.1. Drug Description
11.13.2. Product Profile
11.13.3. Other Development Activities
11.13.4. Clinical Development
11.13.5. Clinical Trials Information
11.14. TAS-115: Taiho Pharmaceutical
11.14.1. Drug Description
11.14.2. Product Profile
11.14.3. Clinical Development
11.14.4. Clinical Trials Information
12. IPF: Market Analysis
12.1. Key Findings
12.2. Total Market Size of IPF in 7 MM
12.3. Therapy Based Market Size of IPF in 7 MM
13. Market Size of IPF by Country
13.1. United States Market Analysis
13.1.1. Market Size of IPF in the US
13.1.2. Therapy Based Market Size of IPF in the US
13.2. EU5 Market Outlook
13.3. Germany
13.3.1. Market Size of IPF in Germany
13.3.2. Therapy Based Market Size of IPF in Germany
13.4. France
13.4.1. Market Size of IPF in France
13.4.2. Therapy Based Market Size of IPF in France
13.5. Italy
13.5.1. Market Size of IPF in Italy
13.5.2. Therapy Based Market Size of IPF in Italy
13.6. United Kingdom
13.6.1. Market Size of IPF in the UK
13.6.2. Therapy Based Market Size of IPF in the UK
13.7. Spain
13.7.1. Market Size of IPF in Spain
13.7.2. Therapy Based Market Size of IPF in Spain
13.8. Japan: Market Analysis
13.8.1. Market Size of IPF in Japan
13.8.2. Therapy Based Market Size of IPF in Japan
14. Market Drivers of IPF
15. Market Barriers of IPF
16. Appendix
16.1. Report Methodology
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

 

1. Key Insights
2. IPF Market Overview at a Glance
2.1. Market Share (%) Distribution of IPF in 2017
2.2. Market Share (%) Distribution of IPF in 2027
3. Disease Background and Overview: Idiopathic Pulmonary Fibrosis (IPF)
3.1. Introduction
3.2. Staging of IPF
3.3. Risk Factors & Disease Causes
3.4. Symptoms
3.5. Pathogenesis
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7 MM Prevalent Population of IPF
4.3. Country Wise-Epidemiology of IPF
4.3.1. United States
4.3.2. Prevalent cases of IPF in the United States
4.3.3. Prevalent Population of IPF by severity
4.3.4. Gender-Specific IPF Prevalence
4.3.5. Age-Specific IPF Prevalence
4.3.6. EU5
4.3.7. Prevalent Population of IPF in EU5
4.3.8. France
4.3.9. Prevalent Population of IPF
4.3.10. Prevalent Population of IPF by severity
4.3.11. Gender-Specific IPF Prevalence
4.3.12. Age-Specific IPF Prevalence
4.3.13. Germany
4.3.14. Prevalent Population of IPF
4.3.15. Prevalent Population of IPF by severity
4.3.16. Gender-Specific IPF Prevalence
4.3.17. Age-Specific IPF Prevalence
4.3.18. Italy
4.3.19. Prevalent Population of IPF
4.3.20. Prevalent Population of IPF by severity
4.3.21. Gender-Specific IPF Prevalence
4.3.22. Age-Specific IPF Prevalence
4.3.23. Spain
4.3.24. Prevalent Population of IPF
4.3.25. Prevalent Population of IPF by severity
4.3.26. Gender-Specific IPF Prevalence
4.3.27. Age-Specific IPF Prevalence
4.3.28. United Kingdom
4.3.29. Prevalent Population of IPF
4.3.30. Prevalent Population of IPF by severity
4.3.31. Gender-Specific IPF Prevalence
4.3.32. Age-Specific IPF Prevalence
4.3.33. Japan
4.3.34. Prevalent Population of IPF
4.3.35. Prevalent Population of IPF by severity
4.3.36. Gender-SPECIFIC IPF Prevalence
4.3.37. Age-Specific IPF Prevalence
5. Current Treatment Practices
5.1. ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of IPF (An Update of 2011 Clinical Practice Guideline)
6. Unmet needs
7. Marketed Products
7.1. Esbriet (Pirfenidone): InterMune Inc.
7.1.1. Product Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Safety and Efficacy of Esbriet
7.1.5. Side effects of Esbriet
7.1.6. Product Profile
7.2. Ofev (Nintedanib): Boehringer Ingelheim Pharma GmbH & Co. KG
7.2.1. Product Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Safety and Efficacy of Ofev
7.2.5. Side effects of Ofev
7.2.6. Product Profile
8. Emerging Therapies
9. Key Cross Competition
10. Phase III Drugs
10.1. Thrombomodulin Alfa: Asahi Kasei Pharma Corporation
10.1.1. Drug Description
10.1.2. Product Profile
10.1.3. Clinical Development
10.1.4. Clinical Trials Information
10.1.5. Safety and Efficacy
11. Phase II Drugs
11.1. CC-90001: Celgene Corporation
11.1.1. Drug Description
11.1.2. Product Profile
11.1.3. Clinical Development
11.1.4. Clinical Trials Information
11.1.5. Safety and Efficacy
11.1.6. Drug Description
11.1.7. Product Profile
11.1.8. Other Development Activities
11.1.9. Clinical Development
11.1.10. Clinical Trials Information
11.1.11. Safety and Efficacy
11.2. Gefapixant: Merck & Co., Inc.
11.2.1. Drug Description
11.2.2. Product Profile
11.2.3. Other Development Activities
11.2.4. Clinical Development
11.2.5. Clinical Trials Information
11.2.6. Safety and Efficacy
11.3. GLPG1690: Galapagos NV
11.3.1. Drug Description
11.3.2. Product Profile
11.3.3. Regulatory Milestones
11.3.4. Other Development Activities
11.3.5. Clinical Development
11.3.6. Clinical Trials Information
11.3.7. Safety and Efficacy
11.4. LT-1001: LTT Bio-Pharma
11.4.1. Drug Description
11.4.2. Product Profile
11.4.3. Other Development Activities
11.4.4. Clinical Development
11.4.5. Clinical Trials Information
11.4.6. Safety and Efficacy
11.5. BG00011: Biogen Inc.
11.5.1. Drug Description
11.5.2. Product Profile
11.5.3. Regulatory Milestones
11.5.4. Other Development Activities
11.5.5. Clinical Development
11.5.6. Clinical Trials Information
11.5.7. Safety and Efficacy
11.6. BMS-986020: Bristol-Myers Squibb
11.6.1. Drug Description
11.6.2. Product Profile
11.6.3. Regulatory Milestones
11.6.4. Other Development Activities
11.6.5. Clinical Development
11.6.6. Clinical Trials Information
11.6.7. Safety and Efficacy
11.7. LT-1002: Chong Kun Dang Pharmaceutical
11.7.1. Drug Description
11.7.2. Product Profile
11.7.3. Other Development Activities
11.8. Pamrevlumab: FibroGen
11.8.1. Drug Description
11.8.2. Product Profile
11.8.3. Regulatory Milestones
11.8.4. Other Development Activities
11.8.5. Clinical Development
11.8.6. Clinical Trials Information
11.8.7. Safety and Efficacy
11.9. PBI4050: ProMetic Life Sciences
11.9.1. Drug Description
11.9.2. Product Profile
11.9.3. Regulatory Milestones
11.9.4. Other Development Activities
11.9.5. Clinical Development
11.9.6. Clinical Trials Information
11.9.7. Safety and Efficacy
11.10. PRM 151: Promedior, Inc.
11.10.1. Drug Description
11.10.2. Product Profile
11.10.3. Regulatory Milestones
11.10.4. Other Development Activities
11.10.5. Clinical Development
11.10.6. Clinical Trials Information
11.10.7. Safety and Efficacy
11.11. Tipelukast: MediciNova
11.11.1. Drug Description
11.11.2. Product Profile
11.11.3. Regulatory Milestones
11.11.4. Other Development Activities
11.11.5. Clinical Development
11.11.6. Clinical Trials Information
11.11.7. Safety and Efficacy
11.12. TD139: Bristol-Myers Squibb
11.12.1. Drug Description
11.12.2. Product Profile
11.12.3. Other Development Activities
11.12.4. Clinical Development
11.12.5. Clinical Trials Information
11.12.6. Safety and Efficacy
11.13. VAY736: Novartis
11.13.1. Drug Description
11.13.2. Product Profile
11.13.3. Other Development Activities
11.13.4. Clinical Development
11.13.5. Clinical Trials Information
11.14. TAS-115: Taiho Pharmaceutical
11.14.1. Drug Description
11.14.2. Product Profile
11.14.3. Clinical Development
11.14.4. Clinical Trials Information
12. IPF: Market Analysis
12.1. Key Findings
12.2. Total Market Size of IPF in 7 MM
12.3. Therapy Based Market Size of IPF in 7 MM
13. Market Size of IPF by Country
13.1. United States Market Analysis
13.1.1. Market Size of IPF in the US
13.1.2. Therapy Based Market Size of IPF in the US
13.2. EU5 Market Outlook
13.3. Germany
13.3.1. Market Size of IPF in Germany
13.3.2. Therapy Based Market Size of IPF in Germany
13.4. France
13.4.1. Market Size of IPF in France
13.4.2. Therapy Based Market Size of IPF in France
13.5. Italy
13.5.1. Market Size of IPF in Italy
13.5.2. Therapy Based Market Size of IPF in Italy
13.6. United Kingdom
13.6.1. Market Size of IPF in the UK
13.6.2. Therapy Based Market Size of IPF in the UK
13.7. Spain
13.7.1. Market Size of IPF in Spain
13.7.2. Therapy Based Market Size of IPF in Spain
13.8. Japan: Market Analysis
13.8.1. Market Size of IPF in Japan
13.8.2. Therapy Based Market Size of IPF in Japan
14. Market Drivers of IPF
15. Market Barriers of IPF
16. Appendix
16.1. Report Methodology
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

 

1. Key Insights
2. IPF Market Overview at a Glance
2.1. Market Share (%) Distribution of IPF in 2017
2.2. Market Share (%) Distribution of IPF in 2027
3. Disease Background and Overview: Idiopathic Pulmonary Fibrosis (IPF)
3.1. Introduction
3.2. Staging of IPF
3.3. Risk Factors & Disease Causes
3.4. Symptoms
3.5. Pathogenesis
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7 MM Prevalent Population of IPF
4.3. Country Wise-Epidemiology of IPF
4.3.1. United States
4.3.2. Prevalent cases of IPF in the United States
4.3.3. Prevalent Population of IPF by severity
4.3.4. Gender-Specific IPF Prevalence
4.3.5. Age-Specific IPF Prevalence
4.3.6. EU5
4.3.7. Prevalent Population of IPF in EU5
4.3.8. France
4.3.9. Prevalent Population of IPF
4.3.10. Prevalent Population of IPF by severity
4.3.11. Gender-Specific IPF Prevalence
4.3.12. Age-Specific IPF Prevalence
4.3.13. Germany
4.3.14. Prevalent Population of IPF
4.3.15. Prevalent Population of IPF by severity
4.3.16. Gender-Specific IPF Prevalence
4.3.17. Age-Specific IPF Prevalence
4.3.18. Italy
4.3.19. Prevalent Population of IPF
4.3.20. Prevalent Population of IPF by severity
4.3.21. Gender-Specific IPF Prevalence
4.3.22. Age-Specific IPF Prevalence
4.3.23. Spain
4.3.24. Prevalent Population of IPF
4.3.25. Prevalent Population of IPF by severity
4.3.26. Gender-Specific IPF Prevalence
4.3.27. Age-Specific IPF Prevalence
4.3.28. United Kingdom
4.3.29. Prevalent Population of IPF
4.3.30. Prevalent Population of IPF by severity
4.3.31. Gender-Specific IPF Prevalence
4.3.32. Age-Specific IPF Prevalence
4.3.33. Japan
4.3.34. Prevalent Population of IPF
4.3.35. Prevalent Population of IPF by severity
4.3.36. Gender-SPECIFIC IPF Prevalence
4.3.37. Age-Specific IPF Prevalence
5. Current Treatment Practices
5.1. ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of IPF (An Update of 2011 Clinical Practice Guideline)
6. Unmet needs
7. Marketed Products
7.1. Esbriet (Pirfenidone): InterMune Inc.
7.1.1. Product Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Safety and Efficacy of Esbriet
7.1.5. Side effects of Esbriet
7.1.6. Product Profile
7.2. Ofev (Nintedanib): Boehringer Ingelheim Pharma GmbH & Co. KG
7.2.1. Product Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Safety and Efficacy of Ofev
7.2.5. Side effects of Ofev
7.2.6. Product Profile
8. Emerging Therapies
9. Key Cross Competition
10. Phase III Drugs
10.1. Thrombomodulin Alfa: Asahi Kasei Pharma Corporation
10.1.1. Drug Description
10.1.2. Product Profile
10.1.3. Clinical Development
10.1.4. Clinical Trials Information
10.1.5. Safety and Efficacy
11. Phase II Drugs
11.1. CC-90001: Celgene Corporation
11.1.1. Drug Description
11.1.2. Product Profile
11.1.3. Clinical Development
11.1.4. Clinical Trials Information
11.1.5. Safety and Efficacy
11.1.6. Drug Description
11.1.7. Product Profile
11.1.8. Other Development Activities
11.1.9. Clinical Development
11.1.10. Clinical Trials Information
11.1.11. Safety and Efficacy
11.2. Gefapixant: Merck & Co., Inc.
11.2.1. Drug Description
11.2.2. Product Profile
11.2.3. Other Development Activities
11.2.4. Clinical Development
11.2.5. Clinical Trials Information
11.2.6. Safety and Efficacy
11.3. GLPG1690: Galapagos NV
11.3.1. Drug Description
11.3.2. Product Profile
11.3.3. Regulatory Milestones
11.3.4. Other Development Activities
11.3.5. Clinical Development
11.3.6. Clinical Trials Information
11.3.7. Safety and Efficacy
11.4. LT-1001: LTT Bio-Pharma
11.4.1. Drug Description
11.4.2. Product Profile
11.4.3. Other Development Activities
11.4.4. Clinical Development
11.4.5. Clinical Trials Information
11.4.6. Safety and Efficacy
11.5. BG00011: Biogen Inc.
11.5.1. Drug Description
11.5.2. Product Profile
11.5.3. Regulatory Milestones
11.5.4. Other Development Activities
11.5.5. Clinical Development
11.5.6. Clinical Trials Information
11.5.7. Safety and Efficacy
11.6. BMS-986020: Bristol-Myers Squibb
11.6.1. Drug Description
11.6.2. Product Profile
11.6.3. Regulatory Milestones
11.6.4. Other Development Activities
11.6.5. Clinical Development
11.6.6. Clinical Trials Information
11.6.7. Safety and Efficacy
11.7. LT-1002: Chong Kun Dang Pharmaceutical
11.7.1. Drug Description
11.7.2. Product Profile
11.7.3. Other Development Activities
11.8. Pamrevlumab: FibroGen
11.8.1. Drug Description
11.8.2. Product Profile
11.8.3. Regulatory Milestones
11.8.4. Other Development Activities
11.8.5. Clinical Development
11.8.6. Clinical Trials Information
11.8.7. Safety and Efficacy
11.9. PBI4050: ProMetic Life Sciences
11.9.1. Drug Description
11.9.2. Product Profile
11.9.3. Regulatory Milestones
11.9.4. Other Development Activities
11.9.5. Clinical Development
11.9.6. Clinical Trials Information
11.9.7. Safety and Efficacy
11.10. PRM 151: Promedior, Inc.
11.10.1. Drug Description
11.10.2. Product Profile
11.10.3. Regulatory Milestones
11.10.4. Other Development Activities
11.10.5. Clinical Development
11.10.6. Clinical Trials Information
11.10.7. Safety and Efficacy
11.11. Tipelukast: MediciNova
11.11.1. Drug Description
11.11.2. Product Profile
11.11.3. Regulatory Milestones
11.11.4. Other Development Activities
11.11.5. Clinical Development
11.11.6. Clinical Trials Information
11.11.7. Safety and Efficacy
11.12. TD139: Bristol-Myers Squibb
11.12.1. Drug Description
11.12.2. Product Profile
11.12.3. Other Development Activities
11.12.4. Clinical Development
11.12.5. Clinical Trials Information
11.12.6. Safety and Efficacy
11.13. VAY736: Novartis
11.13.1. Drug Description
11.13.2. Product Profile
11.13.3. Other Development Activities
11.13.4. Clinical Development
11.13.5. Clinical Trials Information
11.14. TAS-115: Taiho Pharmaceutical
11.14.1. Drug Description
11.14.2. Product Profile
11.14.3. Clinical Development
11.14.4. Clinical Trials Information
12. IPF: Market Analysis
12.1. Key Findings
12.2. Total Market Size of IPF in 7 MM
12.3. Therapy Based Market Size of IPF in 7 MM
13. Market Size of IPF by Country
13.1. United States Market Analysis
13.1.1. Market Size of IPF in the US
13.1.2. Therapy Based Market Size of IPF in the US
13.2. EU5 Market Outlook
13.3. Germany
13.3.1. Market Size of IPF in Germany
13.3.2. Therapy Based Market Size of IPF in Germany
13.4. France
13.4.1. Market Size of IPF in France
13.4.2. Therapy Based Market Size of IPF in France
13.5. Italy
13.5.1. Market Size of IPF in Italy
13.5.2. Therapy Based Market Size of IPF in Italy
13.6. United Kingdom
13.6.1. Market Size of IPF in the UK
13.6.2. Therapy Based Market Size of IPF in the UK
13.7. Spain
13.7.1. Market Size of IPF in Spain
13.7.2. Therapy Based Market Size of IPF in Spain
13.8. Japan: Market Analysis
13.8.1. Market Size of IPF in Japan
13.8.2. Therapy Based Market Size of IPF in Japan
14. Market Drivers of IPF
15. Market Barriers of IPF
16. Appendix
16.1. Report Methodology
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

 

1. Key Insights
2. IPF Market Overview at a Glance
2.1. Market Share (%) Distribution of IPF in 2017
2.2. Market Share (%) Distribution of IPF in 2027
3. Disease Background and Overview: Idiopathic Pulmonary Fibrosis (IPF)
3.1. Introduction
3.2. Staging of IPF
3.3. Risk Factors & Disease Causes
3.4. Symptoms
3.5. Pathogenesis
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7 MM Prevalent Population of IPF
4.3. Country Wise-Epidemiology of IPF
4.3.1. United States
4.3.2. Prevalent cases of IPF in the United States
4.3.3. Prevalent Population of IPF by severity
4.3.4. Gender-Specific IPF Prevalence
4.3.5. Age-Specific IPF Prevalence
4.3.6. EU5
4.3.7. Prevalent Population of IPF in EU5
4.3.8. France
4.3.9. Prevalent Population of IPF
4.3.10. Prevalent Population of IPF by severity
4.3.11. Gender-Specific IPF Prevalence
4.3.12. Age-Specific IPF Prevalence
4.3.13. Germany
4.3.14. Prevalent Population of IPF
4.3.15. Prevalent Population of IPF by severity
4.3.16. Gender-Specific IPF Prevalence
4.3.17. Age-Specific IPF Prevalence
4.3.18. Italy
4.3.19. Prevalent Population of IPF
4.3.20. Prevalent Population of IPF by severity
4.3.21. Gender-Specific IPF Prevalence
4.3.22. Age-Specific IPF Prevalence
4.3.23. Spain
4.3.24. Prevalent Population of IPF
4.3.25. Prevalent Population of IPF by severity
4.3.26. Gender-Specific IPF Prevalence
4.3.27. Age-Specific IPF Prevalence
4.3.28. United Kingdom
4.3.29. Prevalent Population of IPF
4.3.30. Prevalent Population of IPF by severity
4.3.31. Gender-Specific IPF Prevalence
4.3.32. Age-Specific IPF Prevalence
4.3.33. Japan
4.3.34. Prevalent Population of IPF
4.3.35. Prevalent Population of IPF by severity
4.3.36. Gender-SPECIFIC IPF Prevalence
4.3.37. Age-Specific IPF Prevalence
5. Current Treatment Practices
5.1. ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of IPF (An Update of 2011 Clinical Practice Guideline)
6. Unmet needs
7. Marketed Products
7.1. Esbriet (Pirfenidone): InterMune Inc.
7.1.1. Product Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Safety and Efficacy of Esbriet
7.1.5. Side effects of Esbriet
7.1.6. Product Profile
7.2. Ofev (Nintedanib): Boehringer Ingelheim Pharma GmbH & Co. KG
7.2.1. Product Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Safety and Efficacy of Ofev
7.2.5. Side effects of Ofev
7.2.6. Product Profile
8. Emerging Therapies
9. Key Cross Competition
10. Phase III Drugs
10.1. Thrombomodulin Alfa: Asahi Kasei Pharma Corporation
10.1.1. Drug Description
10.1.2. Product Profile
10.1.3. Clinical Development
10.1.4. Clinical Trials Information
10.1.5. Safety and Efficacy
11. Phase II Drugs
11.1. CC-90001: Celgene Corporation
11.1.1. Drug Description
11.1.2. Product Profile
11.1.3. Clinical Development
11.1.4. Clinical Trials Information
11.1.5. Safety and Efficacy
11.1.6. Drug Description
11.1.7. Product Profile
11.1.8. Other Development Activities
11.1.9. Clinical Development
11.1.10. Clinical Trials Information
11.1.11. Safety and Efficacy
11.2. Gefapixant: Merck & Co., Inc.
11.2.1. Drug Description
11.2.2. Product Profile
11.2.3. Other Development Activities
11.2.4. Clinical Development
11.2.5. Clinical Trials Information
11.2.6. Safety and Efficacy
11.3. GLPG1690: Galapagos NV
11.3.1. Drug Description
11.3.2. Product Profile
11.3.3. Regulatory Milestones
11.3.4. Other Development Activities
11.3.5. Clinical Development
11.3.6. Clinical Trials Information
11.3.7. Safety and Efficacy
11.4. LT-1001: LTT Bio-Pharma
11.4.1. Drug Description
11.4.2. Product Profile
11.4.3. Other Development Activities
11.4.4. Clinical Development
11.4.5. Clinical Trials Information
11.4.6. Safety and Efficacy
11.5. BG00011: Biogen Inc.
11.5.1. Drug Description
11.5.2. Product Profile
11.5.3. Regulatory Milestones
11.5.4. Other Development Activities
11.5.5. Clinical Development
11.5.6. Clinical Trials Information
11.5.7. Safety and Efficacy
11.6. BMS-986020: Bristol-Myers Squibb
11.6.1. Drug Description
11.6.2. Product Profile
11.6.3. Regulatory Milestones
11.6.4. Other Development Activities
11.6.5. Clinical Development
11.6.6. Clinical Trials Information
11.6.7. Safety and Efficacy
11.7. LT-1002: Chong Kun Dang Pharmaceutical
11.7.1. Drug Description
11.7.2. Product Profile
11.7.3. Other Development Activities
11.8. Pamrevlumab: FibroGen
11.8.1. Drug Description
11.8.2. Product Profile
11.8.3. Regulatory Milestones
11.8.4. Other Development Activities
11.8.5. Clinical Development
11.8.6. Clinical Trials Information
11.8.7. Safety and Efficacy
11.9. PBI4050: ProMetic Life Sciences
11.9.1. Drug Description
11.9.2. Product Profile
11.9.3. Regulatory Milestones
11.9.4. Other Development Activities
11.9.5. Clinical Development
11.9.6. Clinical Trials Information
11.9.7. Safety and Efficacy
11.10. PRM 151: Promedior, Inc.
11.10.1. Drug Description
11.10.2. Product Profile
11.10.3. Regulatory Milestones
11.10.4. Other Development Activities
11.10.5. Clinical Development
11.10.6. Clinical Trials Information
11.10.7. Safety and Efficacy
11.11. Tipelukast: MediciNova
11.11.1. Drug Description
11.11.2. Product Profile
11.11.3. Regulatory Milestones
11.11.4. Other Development Activities
11.11.5. Clinical Development
11.11.6. Clinical Trials Information
11.11.7. Safety and Efficacy
11.12. TD139: Bristol-Myers Squibb
11.12.1. Drug Description
11.12.2. Product Profile
11.12.3. Other Development Activities
11.12.4. Clinical Development
11.12.5. Clinical Trials Information
11.12.6. Safety and Efficacy
11.13. VAY736: Novartis
11.13.1. Drug Description
11.13.2. Product Profile
11.13.3. Other Development Activities
11.13.4. Clinical Development
11.13.5. Clinical Trials Information
11.14. TAS-115: Taiho Pharmaceutical
11.14.1. Drug Description
11.14.2. Product Profile
11.14.3. Clinical Development
11.14.4. Clinical Trials Information
12. IPF: Market Analysis
12.1. Key Findings
12.2. Total Market Size of IPF in 7 MM
12.3. Therapy Based Market Size of IPF in 7 MM
13. Market Size of IPF by Country
13.1. United States Market Analysis
13.1.1. Market Size of IPF in the US
13.1.2. Therapy Based Market Size of IPF in the US
13.2. EU5 Market Outlook
13.3. Germany
13.3.1. Market Size of IPF in Germany
13.3.2. Therapy Based Market Size of IPF in Germany
13.4. France
13.4.1. Market Size of IPF in France
13.4.2. Therapy Based Market Size of IPF in France
13.5. Italy
13.5.1. Market Size of IPF in Italy
13.5.2. Therapy Based Market Size of IPF in Italy
13.6. United Kingdom
13.6.1. Market Size of IPF in the UK
13.6.2. Therapy Based Market Size of IPF in the UK
13.7. Spain
13.7.1. Market Size of IPF in Spain
13.7.2. Therapy Based Market Size of IPF in Spain
13.8. Japan: Market Analysis
13.8.1. Market Size of IPF in Japan
13.8.2. Therapy Based Market Size of IPF in Japan
14. Market Drivers of IPF
15. Market Barriers of IPF
16. Appendix
16.1. Report Methodology
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

 

1. Key Insights
2. IPF Market Overview at a Glance
2.1. Market Share (%) Distribution of IPF in 2017
2.2. Market Share (%) Distribution of IPF in 2027
3. Disease Background and Overview: Idiopathic Pulmonary Fibrosis (IPF)
3.1. Introduction
3.2. Staging of IPF
3.3. Risk Factors & Disease Causes
3.4. Symptoms
3.5. Pathogenesis
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7 MM Prevalent Population of IPF
4.3. Country Wise-Epidemiology of IPF
4.3.1. United States
4.3.2. Prevalent cases of IPF in the United States
4.3.3. Prevalent Population of IPF by severity
4.3.4. Gender-Specific IPF Prevalence
4.3.5. Age-Specific IPF Prevalence
4.3.6. EU5
4.3.7. Prevalent Population of IPF in EU5
4.3.8. France
4.3.9. Prevalent Population of IPF
4.3.10. Prevalent Population of IPF by severity
4.3.11. Gender-Specific IPF Prevalence
4.3.12. Age-Specific IPF Prevalence
4.3.13. Germany
4.3.14. Prevalent Population of IPF
4.3.15. Prevalent Population of IPF by severity
4.3.16. Gender-Specific IPF Prevalence
4.3.17. Age-Specific IPF Prevalence
4.3.18. Italy
4.3.19. Prevalent Population of IPF
4.3.20. Prevalent Population of IPF by severity
4.3.21. Gender-Specific IPF Prevalence
4.3.22. Age-Specific IPF Prevalence
4.3.23. Spain
4.3.24. Prevalent Population of IPF
4.3.25. Prevalent Population of IPF by severity
4.3.26. Gender-Specific IPF Prevalence
4.3.27. Age-Specific IPF Prevalence
4.3.28. United Kingdom
4.3.29. Prevalent Population of IPF
4.3.30. Prevalent Population of IPF by severity
4.3.31. Gender-Specific IPF Prevalence
4.3.32. Age-Specific IPF Prevalence
4.3.33. Japan
4.3.34. Prevalent Population of IPF
4.3.35. Prevalent Population of IPF by severity
4.3.36. Gender-SPECIFIC IPF Prevalence
4.3.37. Age-Specific IPF Prevalence
5. Current Treatment Practices
5.1. ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of IPF (An Update of 2011 Clinical Practice Guideline)
6. Unmet needs
7. Marketed Products
7.1. Esbriet (Pirfenidone): InterMune Inc.
7.1.1. Product Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Safety and Efficacy of Esbriet
7.1.5. Side effects of Esbriet
7.1.6. Product Profile
7.2. Ofev (Nintedanib): Boehringer Ingelheim Pharma GmbH & Co. KG
7.2.1. Product Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Safety and Efficacy of Ofev
7.2.5. Side effects of Ofev
7.2.6. Product Profile
8. Emerging Therapies
9. Key Cross Competition
10. Phase III Drugs
10.1. Thrombomodulin Alfa: Asahi Kasei Pharma Corporation
10.1.1. Drug Description
10.1.2. Product Profile
10.1.3. Clinical Development
10.1.4. Clinical Trials Information
10.1.5. Safety and Efficacy
11. Phase II Drugs
11.1. CC-90001: Celgene Corporation
11.1.1. Drug Description
11.1.2. Product Profile
11.1.3. Clinical Development
11.1.4. Clinical Trials Information
11.1.5. Safety and Efficacy
11.1.6. Drug Description
11.1.7. Product Profile
11.1.8. Other Development Activities
11.1.9. Clinical Development
11.1.10. Clinical Trials Information
11.1.11. Safety and Efficacy
11.2. Gefapixant: Merck & Co., Inc.
11.2.1. Drug Description
11.2.2. Product Profile
11.2.3. Other Development Activities
11.2.4. Clinical Development
11.2.5. Clinical Trials Information
11.2.6. Safety and Efficacy
11.3. GLPG1690: Galapagos NV
11.3.1. Drug Description
11.3.2. Product Profile
11.3.3. Regulatory Milestones
11.3.4. Other Development Activities
11.3.5. Clinical Development
11.3.6. Clinical Trials Information
11.3.7. Safety and Efficacy
11.4. LT-1001: LTT Bio-Pharma
11.4.1. Drug Description
11.4.2. Product Profile
11.4.3. Other Development Activities
11.4.4. Clinical Development
11.4.5. Clinical Trials Information
11.4.6. Safety and Efficacy
11.5. BG00011: Biogen Inc.
11.5.1. Drug Description
11.5.2. Product Profile
11.5.3. Regulatory Milestones
11.5.4. Other Development Activities
11.5.5. Clinical Development
11.5.6. Clinical Trials Information
11.5.7. Safety and Efficacy
11.6. BMS-986020: Bristol-Myers Squibb
11.6.1. Drug Description
11.6.2. Product Profile
11.6.3. Regulatory Milestones
11.6.4. Other Development Activities
11.6.5. Clinical Development
11.6.6. Clinical Trials Information
11.6.7. Safety and Efficacy
11.7. LT-1002: Chong Kun Dang Pharmaceutical
11.7.1. Drug Description
11.7.2. Product Profile
11.7.3. Other Development Activities
11.8. Pamrevlumab: FibroGen
11.8.1. Drug Description
11.8.2. Product Profile
11.8.3. Regulatory Milestones
11.8.4. Other Development Activities
11.8.5. Clinical Development
11.8.6. Clinical Trials Information
11.8.7. Safety and Efficacy
11.9. PBI4050: ProMetic Life Sciences
11.9.1. Drug Description
11.9.2. Product Profile
11.9.3. Regulatory Milestones
11.9.4. Other Development Activities
11.9.5. Clinical Development
11.9.6. Clinical Trials Information
11.9.7. Safety and Efficacy
11.10. PRM 151: Promedior, Inc.
11.10.1. Drug Description
11.10.2. Product Profile
11.10.3. Regulatory Milestones
11.10.4. Other Development Activities
11.10.5. Clinical Development
11.10.6. Clinical Trials Information
11.10.7. Safety and Efficacy
11.11. Tipelukast: MediciNova
11.11.1. Drug Description
11.11.2. Product Profile
11.11.3. Regulatory Milestones
11.11.4. Other Development Activities
11.11.5. Clinical Development
11.11.6. Clinical Trials Information
11.11.7. Safety and Efficacy
11.12. TD139: Bristol-Myers Squibb
11.12.1. Drug Description
11.12.2. Product Profile
11.12.3. Other Development Activities
11.12.4. Clinical Development
11.12.5. Clinical Trials Information
11.12.6. Safety and Efficacy
11.13. VAY736: Novartis
11.13.1. Drug Description
11.13.2. Product Profile
11.13.3. Other Development Activities
11.13.4. Clinical Development
11.13.5. Clinical Trials Information
11.14. TAS-115: Taiho Pharmaceutical
11.14.1. Drug Description
11.14.2. Product Profile
11.14.3. Clinical Development
11.14.4. Clinical Trials Information
12. IPF: Market Analysis
12.1. Key Findings
12.2. Total Market Size of IPF in 7 MM
12.3. Therapy Based Market Size of IPF in 7 MM
13. Market Size of IPF by Country
13.1. United States Market Analysis
13.1.1. Market Size of IPF in the US
13.1.2. Therapy Based Market Size of IPF in the US
13.2. EU5 Market Outlook
13.3. Germany
13.3.1. Market Size of IPF in Germany
13.3.2. Therapy Based Market Size of IPF in Germany
13.4. France
13.4.1. Market Size of IPF in France
13.4.2. Therapy Based Market Size of IPF in France
13.5. Italy
13.5.1. Market Size of IPF in Italy
13.5.2. Therapy Based Market Size of IPF in Italy
13.6. United Kingdom
13.6.1. Market Size of IPF in the UK
13.6.2. Therapy Based Market Size of IPF in the UK
13.7. Spain
13.7.1. Market Size of IPF in Spain
13.7.2. Therapy Based Market Size of IPF in Spain
13.8. Japan: Market Analysis
13.8.1. Market Size of IPF in Japan
13.8.2. Therapy Based Market Size of IPF in Japan
14. Market Drivers of IPF
15. Market Barriers of IPF
16. Appendix
16.1. Report Methodology
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

 

1. Key Insights
2. IPF Market Overview at a Glance
2.1. Market Share (%) Distribution of IPF in 2017
2.2. Market Share (%) Distribution of IPF in 2027
3. Disease Background and Overview: Idiopathic Pulmonary Fibrosis (IPF)
3.1. Introduction
3.2. Staging of IPF
3.3. Risk Factors & Disease Causes
3.4. Symptoms
3.5. Pathogenesis
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7 MM Prevalent Population of IPF
4.3. Country Wise-Epidemiology of IPF
4.3.1. United States
4.3.2. Prevalent cases of IPF in the United States
4.3.3. Prevalent Population of IPF by severity
4.3.4. Gender-Specific IPF Prevalence
4.3.5. Age-Specific IPF Prevalence
4.3.6. EU5
4.3.7. Prevalent Population of IPF in EU5
4.3.8. France
4.3.9. Prevalent Population of IPF
4.3.10. Prevalent Population of IPF by severity
4.3.11. Gender-Specific IPF Prevalence
4.3.12. Age-Specific IPF Prevalence
4.3.13. Germany
4.3.14. Prevalent Population of IPF
4.3.15. Prevalent Population of IPF by severity
4.3.16. Gender-Specific IPF Prevalence
4.3.17. Age-Specific IPF Prevalence
4.3.18. Italy
4.3.19. Prevalent Population of IPF
4.3.20. Prevalent Population of IPF by severity
4.3.21. Gender-Specific IPF Prevalence
4.3.22. Age-Specific IPF Prevalence
4.3.23. Spain
4.3.24. Prevalent Population of IPF
4.3.25. Prevalent Population of IPF by severity
4.3.26. Gender-Specific IPF Prevalence
4.3.27. Age-Specific IPF Prevalence
4.3.28. United Kingdom
4.3.29. Prevalent Population of IPF
4.3.30. Prevalent Population of IPF by severity
4.3.31. Gender-Specific IPF Prevalence
4.3.32. Age-Specific IPF Prevalence
4.3.33. Japan
4.3.34. Prevalent Population of IPF
4.3.35. Prevalent Population of IPF by severity
4.3.36. Gender-SPECIFIC IPF Prevalence
4.3.37. Age-Specific IPF Prevalence
5. Current Treatment Practices
5.1. ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of IPF (An Update of 2011 Clinical Practice Guideline)
6. Unmet needs
7. Marketed Products
7.1. Esbriet (Pirfenidone): InterMune Inc.
7.1.1. Product Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Safety and Efficacy of Esbriet
7.1.5. Side effects of Esbriet
7.1.6. Product Profile
7.2. Ofev (Nintedanib): Boehringer Ingelheim Pharma GmbH & Co. KG
7.2.1. Product Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Safety and Efficacy of Ofev
7.2.5. Side effects of Ofev
7.2.6. Product Profile
8. Emerging Therapies
9. Key Cross Competition
10. Phase III Drugs
10.1. Thrombomodulin Alfa: Asahi Kasei Pharma Corporation
10.1.1. Drug Description
10.1.2. Product Profile
10.1.3. Clinical Development
10.1.4. Clinical Trials Information
10.1.5. Safety and Efficacy
11. Phase II Drugs
11.1. CC-90001: Celgene Corporation
11.1.1. Drug Description
11.1.2. Product Profile
11.1.3. Clinical Development
11.1.4. Clinical Trials Information
11.1.5. Safety and Efficacy
11.1.6. Drug Description
11.1.7. Product Profile
11.1.8. Other Development Activities
11.1.9. Clinical Development
11.1.10. Clinical Trials Information
11.1.11. Safety and Efficacy
11.2. Gefapixant: Merck & Co., Inc.
11.2.1. Drug Description
11.2.2. Product Profile
11.2.3. Other Development Activities
11.2.4. Clinical Development
11.2.5. Clinical Trials Information
11.2.6. Safety and Efficacy
11.3. GLPG1690: Galapagos NV
11.3.1. Drug Description
11.3.2. Product Profile
11.3.3. Regulatory Milestones
11.3.4. Other Development Activities
11.3.5. Clinical Development
11.3.6. Clinical Trials Information
11.3.7. Safety and Efficacy
11.4. LT-1001: LTT Bio-Pharma
11.4.1. Drug Description
11.4.2. Product Profile
11.4.3. Other Development Activities
11.4.4. Clinical Development
11.4.5. Clinical Trials Information
11.4.6. Safety and Efficacy
11.5. BG00011: Biogen Inc.
11.5.1. Drug Description
11.5.2. Product Profile
11.5.3. Regulatory Milestones
11.5.4. Other Development Activities
11.5.5. Clinical Development
11.5.6. Clinical Trials Information
11.5.7. Safety and Efficacy
11.6. BMS-986020: Bristol-Myers Squibb
11.6.1. Drug Description
11.6.2. Product Profile
11.6.3. Regulatory Milestones
11.6.4. Other Development Activities
11.6.5. Clinical Development
11.6.6. Clinical Trials Information
11.6.7. Safety and Efficacy
11.7. LT-1002: Chong Kun Dang Pharmaceutical
11.7.1. Drug Description
11.7.2. Product Profile
11.7.3. Other Development Activities
11.8. Pamrevlumab: FibroGen
11.8.1. Drug Description
11.8.2. Product Profile
11.8.3. Regulatory Milestones
11.8.4. Other Development Activities
11.8.5. Clinical Development
11.8.6. Clinical Trials Information
11.8.7. Safety and Efficacy
11.9. PBI4050: ProMetic Life Sciences
11.9.1. Drug Description
11.9.2. Product Profile
11.9.3. Regulatory Milestones
11.9.4. Other Development Activities
11.9.5. Clinical Development
11.9.6. Clinical Trials Information
11.9.7. Safety and Efficacy
11.10. PRM 151: Promedior, Inc.
11.10.1. Drug Description
11.10.2. Product Profile
11.10.3. Regulatory Milestones
11.10.4. Other Development Activities
11.10.5. Clinical Development
11.10.6. Clinical Trials Information
11.10.7. Safety and Efficacy
11.11. Tipelukast: MediciNova
11.11.1. Drug Description
11.11.2. Product Profile
11.11.3. Regulatory Milestones
11.11.4. Other Development Activities
11.11.5. Clinical Development
11.11.6. Clinical Trials Information
11.11.7. Safety and Efficacy
11.12. TD139: Bristol-Myers Squibb
11.12.1. Drug Description
11.12.2. Product Profile
11.12.3. Other Development Activities
11.12.4. Clinical Development
11.12.5. Clinical Trials Information
11.12.6. Safety and Efficacy
11.13. VAY736: Novartis
11.13.1. Drug Description
11.13.2. Product Profile
11.13.3. Other Development Activities
11.13.4. Clinical Development
11.13.5. Clinical Trials Information
11.14. TAS-115: Taiho Pharmaceutical
11.14.1. Drug Description
11.14.2. Product Profile
11.14.3. Clinical Development
11.14.4. Clinical Trials Information
12. IPF: Market Analysis
12.1. Key Findings
12.2. Total Market Size of IPF in 7 MM
12.3. Therapy Based Market Size of IPF in 7 MM
13. Market Size of IPF by Country
13.1. United States Market Analysis
13.1.1. Market Size of IPF in the US
13.1.2. Therapy Based Market Size of IPF in the US
13.2. EU5 Market Outlook
13.3. Germany
13.3.1. Market Size of IPF in Germany
13.3.2. Therapy Based Market Size of IPF in Germany
13.4. France
13.4.1. Market Size of IPF in France
13.4.2. Therapy Based Market Size of IPF in France
13.5. Italy
13.5.1. Market Size of IPF in Italy
13.5.2. Therapy Based Market Size of IPF in Italy
13.6. United Kingdom
13.6.1. Market Size of IPF in the UK
13.6.2. Therapy Based Market Size of IPF in the UK
13.7. Spain
13.7.1. Market Size of IPF in Spain
13.7.2. Therapy Based Market Size of IPF in Spain
13.8. Japan: Market Analysis
13.8.1. Market Size of IPF in Japan
13.8.2. Therapy Based Market Size of IPF in Japan
14. Market Drivers of IPF
15. Market Barriers of IPF
16. Appendix
16.1. Report Methodology
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

 

1. Key Insights
2. IPF Market Overview at a Glance
2.1. Market Share (%) Distribution of IPF in 2017
2.2. Market Share (%) Distribution of IPF in 2027
3. Disease Background and Overview: Idiopathic Pulmonary Fibrosis (IPF)
3.1. Introduction
3.2. Staging of IPF
3.3. Risk Factors & Disease Causes
3.4. Symptoms
3.5. Pathogenesis
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7 MM Prevalent Population of IPF
4.3. Country Wise-Epidemiology of IPF
4.3.1. United States
4.3.2. Prevalent cases of IPF in the United States
4.3.3. Prevalent Population of IPF by severity
4.3.4. Gender-Specific IPF Prevalence
4.3.5. Age-Specific IPF Prevalence
4.3.6. EU5
4.3.7. Prevalent Population of IPF in EU5
4.3.8. France
4.3.9. Prevalent Population of IPF
4.3.10. Prevalent Population of IPF by severity
4.3.11. Gender-Specific IPF Prevalence
4.3.12. Age-Specific IPF Prevalence
4.3.13. Germany
4.3.14. Prevalent Population of IPF
4.3.15. Prevalent Population of IPF by severity
4.3.16. Gender-Specific IPF Prevalence
4.3.17. Age-Specific IPF Prevalence
4.3.18. Italy
4.3.19. Prevalent Population of IPF
4.3.20. Prevalent Population of IPF by severity
4.3.21. Gender-Specific IPF Prevalence
4.3.22. Age-Specific IPF Prevalence
4.3.23. Spain
4.3.24. Prevalent Population of IPF
4.3.25. Prevalent Population of IPF by severity
4.3.26. Gender-Specific IPF Prevalence
4.3.27. Age-Specific IPF Prevalence
4.3.28. United Kingdom
4.3.29. Prevalent Population of IPF
4.3.30. Prevalent Population of IPF by severity
4.3.31. Gender-Specific IPF Prevalence
4.3.32. Age-Specific IPF Prevalence
4.3.33. Japan
4.3.34. Prevalent Population of IPF
4.3.35. Prevalent Population of IPF by severity
4.3.36. Gender-SPECIFIC IPF Prevalence
4.3.37. Age-Specific IPF Prevalence
5. Current Treatment Practices
5.1. ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of IPF (An Update of 2011 Clinical Practice Guideline)
6. Unmet needs
7. Marketed Products
7.1. Esbriet (Pirfenidone): InterMune Inc.
7.1.1. Product Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Safety and Efficacy of Esbriet
7.1.5. Side effects of Esbriet
7.1.6. Product Profile
7.2. Ofev (Nintedanib): Boehringer Ingelheim Pharma GmbH & Co. KG
7.2.1. Product Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Safety and Efficacy of Ofev
7.2.5. Side effects of Ofev
7.2.6. Product Profile
8. Emerging Therapies
9. Key Cross Competition
10. Phase III Drugs
10.1. Thrombomodulin Alfa: Asahi Kasei Pharma Corporation
10.1.1. Drug Description
10.1.2. Product Profile
10.1.3. Clinical Development
10.1.4. Clinical Trials Information
10.1.5. Safety and Efficacy
11. Phase II Drugs
11.1. CC-90001: Celgene Corporation
11.1.1. Drug Description
11.1.2. Product Profile
11.1.3. Clinical Development
11.1.4. Clinical Trials Information
11.1.5. Safety and Efficacy
11.1.6. Drug Description
11.1.7. Product Profile
11.1.8. Other Development Activities
11.1.9. Clinical Development
11.1.10. Clinical Trials Information
11.1.11. Safety and Efficacy
11.2. Gefapixant: Merck & Co., Inc.
11.2.1. Drug Description
11.2.2. Product Profile
11.2.3. Other Development Activities
11.2.4. Clinical Development
11.2.5. Clinical Trials Information
11.2.6. Safety and Efficacy
11.3. GLPG1690: Galapagos NV
11.3.1. Drug Description
11.3.2. Product Profile
11.3.3. Regulatory Milestones
11.3.4. Other Development Activities
11.3.5. Clinical Development
11.3.6. Clinical Trials Information
11.3.7. Safety and Efficacy
11.4. LT-1001: LTT Bio-Pharma
11.4.1. Drug Description
11.4.2. Product Profile
11.4.3. Other Development Activities
11.4.4. Clinical Development
11.4.5. Clinical Trials Information
11.4.6. Safety and Efficacy
11.5. BG00011: Biogen Inc.
11.5.1. Drug Description
11.5.2. Product Profile
11.5.3. Regulatory Milestones
11.5.4. Other Development Activities
11.5.5. Clinical Development
11.5.6. Clinical Trials Information
11.5.7. Safety and Efficacy
11.6. BMS-986020: Bristol-Myers Squibb
11.6.1. Drug Description
11.6.2. Product Profile
11.6.3. Regulatory Milestones
11.6.4. Other Development Activities
11.6.5. Clinical Development
11.6.6. Clinical Trials Information
11.6.7. Safety and Efficacy
11.7. LT-1002: Chong Kun Dang Pharmaceutical
11.7.1. Drug Description
11.7.2. Product Profile
11.7.3. Other Development Activities
11.8. Pamrevlumab: FibroGen
11.8.1. Drug Description
11.8.2. Product Profile
11.8.3. Regulatory Milestones
11.8.4. Other Development Activities
11.8.5. Clinical Development
11.8.6. Clinical Trials Information
11.8.7. Safety and Efficacy
11.9. PBI4050: ProMetic Life Sciences
11.9.1. Drug Description
11.9.2. Product Profile
11.9.3. Regulatory Milestones
11.9.4. Other Development Activities
11.9.5. Clinical Development
11.9.6. Clinical Trials Information
11.9.7. Safety and Efficacy
11.10. PRM 151: Promedior, Inc.
11.10.1. Drug Description
11.10.2. Product Profile
11.10.3. Regulatory Milestones
11.10.4. Other Development Activities
11.10.5. Clinical Development
11.10.6. Clinical Trials Information
11.10.7. Safety and Efficacy
11.11. Tipelukast: MediciNova
11.11.1. Drug Description
11.11.2. Product Profile
11.11.3. Regulatory Milestones
11.11.4. Other Development Activities
11.11.5. Clinical Development
11.11.6. Clinical Trials Information
11.11.7. Safety and Efficacy
11.12. TD139: Bristol-Myers Squibb
11.12.1. Drug Description
11.12.2. Product Profile
11.12.3. Other Development Activities
11.12.4. Clinical Development
11.12.5. Clinical Trials Information
11.12.6. Safety and Efficacy
11.13. VAY736: Novartis
11.13.1. Drug Description
11.13.2. Product Profile
11.13.3. Other Development Activities
11.13.4. Clinical Development
11.13.5. Clinical Trials Information
11.14. TAS-115: Taiho Pharmaceutical
11.14.1. Drug Description
11.14.2. Product Profile
11.14.3. Clinical Development
11.14.4. Clinical Trials Information
12. IPF: Market Analysis
12.1. Key Findings
12.2. Total Market Size of IPF in 7 MM
12.3. Therapy Based Market Size of IPF in 7 MM
13. Market Size of IPF by Country
13.1. United States Market Analysis
13.1.1. Market Size of IPF in the US
13.1.2. Therapy Based Market Size of IPF in the US
13.2. EU5 Market Outlook
13.3. Germany
13.3.1. Market Size of IPF in Germany
13.3.2. Therapy Based Market Size of IPF in Germany
13.4. France
13.4.1. Market Size of IPF in France
13.4.2. Therapy Based Market Size of IPF in France
13.5. Italy
13.5.1. Market Size of IPF in Italy
13.5.2. Therapy Based Market Size of IPF in Italy
13.6. United Kingdom
13.6.1. Market Size of IPF in the UK
13.6.2. Therapy Based Market Size of IPF in the UK
13.7. Spain
13.7.1. Market Size of IPF in Spain
13.7.2. Therapy Based Market Size of IPF in Spain
13.8. Japan: Market Analysis
13.8.1. Market Size of IPF in Japan
13.8.2. Therapy Based Market Size of IPF in Japan
14. Market Drivers of IPF
15. Market Barriers of IPF
16. Appendix
16.1. Report Methodology
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

 

1. Key Insights
2. IPF Market Overview at a Glance
2.1. Market Share (%) Distribution of IPF in 2017
2.2. Market Share (%) Distribution of IPF in 2027
3. Disease Background and Overview: Idiopathic Pulmonary Fibrosis (IPF)
3.1. Introduction
3.2. Staging of IPF
3.3. Risk Factors & Disease Causes
3.4. Symptoms
3.5. Pathogenesis
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7 MM Prevalent Population of IPF
4.3. Country Wise-Epidemiology of IPF
4.3.1. United States
4.3.2. Prevalent cases of IPF in the United States
4.3.3. Prevalent Population of IPF by severity
4.3.4. Gender-Specific IPF Prevalence
4.3.5. Age-Specific IPF Prevalence
4.3.6. EU5
4.3.7. Prevalent Population of IPF in EU5
4.3.8. France
4.3.9. Prevalent Population of IPF
4.3.10. Prevalent Population of IPF by severity
4.3.11. Gender-Specific IPF Prevalence
4.3.12. Age-Specific IPF Prevalence
4.3.13. Germany
4.3.14. Prevalent Population of IPF
4.3.15. Prevalent Population of IPF by severity
4.3.16. Gender-Specific IPF Prevalence
4.3.17. Age-Specific IPF Prevalence
4.3.18. Italy
4.3.19. Prevalent Population of IPF
4.3.20. Prevalent Population of IPF by severity
4.3.21. Gender-Specific IPF Prevalence
4.3.22. Age-Specific IPF Prevalence
4.3.23. Spain
4.3.24. Prevalent Population of IPF
4.3.25. Prevalent Population of IPF by severity
4.3.26. Gender-Specific IPF Prevalence
4.3.27. Age-Specific IPF Prevalence
4.3.28. United Kingdom
4.3.29. Prevalent Population of IPF
4.3.30. Prevalent Population of IPF by severity
4.3.31. Gender-Specific IPF Prevalence
4.3.32. Age-Specific IPF Prevalence
4.3.33. Japan
4.3.34. Prevalent Population of IPF
4.3.35. Prevalent Population of IPF by severity
4.3.36. Gender-SPECIFIC IPF Prevalence
4.3.37. Age-Specific IPF Prevalence
5. Current Treatment Practices
5.1. ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of IPF (An Update of 2011 Clinical Practice Guideline)
6. Unmet needs
7. Marketed Products
7.1. Esbriet (Pirfenidone): InterMune Inc.
7.1.1. Product Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Safety and Efficacy of Esbriet
7.1.5. Side effects of Esbriet
7.1.6. Product Profile
7.2. Ofev (Nintedanib): Boehringer Ingelheim Pharma GmbH & Co. KG
7.2.1. Product Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Safety and Efficacy of Ofev
7.2.5. Side effects of Ofev
7.2.6. Product Profile
8. Emerging Therapies
9. Key Cross Competition
10. Phase III Drugs
10.1. Thrombomodulin Alfa: Asahi Kasei Pharma Corporation
10.1.1. Drug Description
10.1.2. Product Profile
10.1.3. Clinical Development
10.1.4. Clinical Trials Information
10.1.5. Safety and Efficacy
11. Phase II Drugs
11.1. CC-90001: Celgene Corporation
11.1.1. Drug Description
11.1.2. Product Profile
11.1.3. Clinical Development
11.1.4. Clinical Trials Information
11.1.5. Safety and Efficacy
11.1.6. Drug Description
11.1.7. Product Profile
11.1.8. Other Development Activities
11.1.9. Clinical Development
11.1.10. Clinical Trials Information
11.1.11. Safety and Efficacy
11.2. Gefapixant: Merck & Co., Inc.
11.2.1. Drug Description
11.2.2. Product Profile
11.2.3. Other Development Activities
11.2.4. Clinical Development
11.2.5. Clinical Trials Information
11.2.6. Safety and Efficacy
11.3. GLPG1690: Galapagos NV
11.3.1. Drug Description
11.3.2. Product Profile
11.3.3. Regulatory Milestones
11.3.4. Other Development Activities
11.3.5. Clinical Development
11.3.6. Clinical Trials Information
11.3.7. Safety and Efficacy
11.4. LT-1001: LTT Bio-Pharma
11.4.1. Drug Description
11.4.2. Product Profile
11.4.3. Other Development Activities
11.4.4. Clinical Development
11.4.5. Clinical Trials Information
11.4.6. Safety and Efficacy
11.5. BG00011: Biogen Inc.
11.5.1. Drug Description
11.5.2. Product Profile
11.5.3. Regulatory Milestones
11.5.4. Other Development Activities
11.5.5. Clinical Development
11.5.6. Clinical Trials Information
11.5.7. Safety and Efficacy
11.6. BMS-986020: Bristol-Myers Squibb
11.6.1. Drug Description
11.6.2. Product Profile
11.6.3. Regulatory Milestones
11.6.4. Other Development Activities
11.6.5. Clinical Development
11.6.6. Clinical Trials Information
11.6.7. Safety and Efficacy
11.7. LT-1002: Chong Kun Dang Pharmaceutical
11.7.1. Drug Description
11.7.2. Product Profile
11.7.3. Other Development Activities
11.8. Pamrevlumab: FibroGen
11.8.1. Drug Description
11.8.2. Product Profile
11.8.3. Regulatory Milestones
11.8.4. Other Development Activities
11.8.5. Clinical Development
11.8.6. Clinical Trials Information
11.8.7. Safety and Efficacy
11.9. PBI4050: ProMetic Life Sciences
11.9.1. Drug Description
11.9.2. Product Profile
11.9.3. Regulatory Milestones
11.9.4. Other Development Activities
11.9.5. Clinical Development
11.9.6. Clinical Trials Information
11.9.7. Safety and Efficacy
11.10. PRM 151: Promedior, Inc.
11.10.1. Drug Description
11.10.2. Product Profile
11.10.3. Regulatory Milestones
11.10.4. Other Development Activities
11.10.5. Clinical Development
11.10.6. Clinical Trials Information
11.10.7. Safety and Efficacy
11.11. Tipelukast: MediciNova
11.11.1. Drug Description
11.11.2. Product Profile
11.11.3. Regulatory Milestones
11.11.4. Other Development Activities
11.11.5. Clinical Development
11.11.6. Clinical Trials Information
11.11.7. Safety and Efficacy
11.12. TD139: Bristol-Myers Squibb
11.12.1. Drug Description
11.12.2. Product Profile
11.12.3. Other Development Activities
11.12.4. Clinical Development
11.12.5. Clinical Trials Information
11.12.6. Safety and Efficacy
11.13. VAY736: Novartis
11.13.1. Drug Description
11.13.2. Product Profile
11.13.3. Other Development Activities
11.13.4. Clinical Development
11.13.5. Clinical Trials Information
11.14. TAS-115: Taiho Pharmaceutical
11.14.1. Drug Description
11.14.2. Product Profile
11.14.3. Clinical Development
11.14.4. Clinical Trials Information
12. IPF: Market Analysis
12.1. Key Findings
12.2. Total Market Size of IPF in 7 MM
12.3. Therapy Based Market Size of IPF in 7 MM
13. Market Size of IPF by Country
13.1. United States Market Analysis
13.1.1. Market Size of IPF in the US
13.1.2. Therapy Based Market Size of IPF in the US
13.2. EU5 Market Outlook
13.3. Germany
13.3.1. Market Size of IPF in Germany
13.3.2. Therapy Based Market Size of IPF in Germany
13.4. France
13.4.1. Market Size of IPF in France
13.4.2. Therapy Based Market Size of IPF in France
13.5. Italy
13.5.1. Market Size of IPF in Italy
13.5.2. Therapy Based Market Size of IPF in Italy
13.6. United Kingdom
13.6.1. Market Size of IPF in the UK
13.6.2. Therapy Based Market Size of IPF in the UK
13.7. Spain
13.7.1. Market Size of IPF in Spain
13.7.2. Therapy Based Market Size of IPF in Spain
13.8. Japan: Market Analysis
13.8.1. Market Size of IPF in Japan
13.8.2. Therapy Based Market Size of IPF in Japan
14. Market Drivers of IPF
15. Market Barriers of IPF
16. Appendix
16.1. Report Methodology
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

 

1. Key Insights
2. IPF Market Overview at a Glance
2.1. Market Share (%) Distribution of IPF in 2017
2.2. Market Share (%) Distribution of IPF in 2027
3. Disease Background and Overview: Idiopathic Pulmonary Fibrosis (IPF)
3.1. Introduction
3.2. Staging of IPF
3.3. Risk Factors & Disease Causes
3.4. Symptoms
3.5. Pathogenesis
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7 MM Prevalent Population of IPF
4.3. Country Wise-Epidemiology of IPF
4.3.1. United States
4.3.2. Prevalent cases of IPF in the United States
4.3.3. Prevalent Population of IPF by severity
4.3.4. Gender-Specific IPF Prevalence
4.3.5. Age-Specific IPF Prevalence
4.3.6. EU5
4.3.7. Prevalent Population of IPF in EU5
4.3.8. France
4.3.9. Prevalent Population of IPF
4.3.10. Prevalent Population of IPF by severity
4.3.11. Gender-Specific IPF Prevalence
4.3.12. Age-Specific IPF Prevalence
4.3.13. Germany
4.3.14. Prevalent Population of IPF
4.3.15. Prevalent Population of IPF by severity
4.3.16. Gender-Specific IPF Prevalence
4.3.17. Age-Specific IPF Prevalence
4.3.18. Italy
4.3.19. Prevalent Population of IPF
4.3.20. Prevalent Population of IPF by severity
4.3.21. Gender-Specific IPF Prevalence
4.3.22. Age-Specific IPF Prevalence
4.3.23. Spain
4.3.24. Prevalent Population of IPF
4.3.25. Prevalent Population of IPF by severity
4.3.26. Gender-Specific IPF Prevalence
4.3.27. Age-Specific IPF Prevalence
4.3.28. United Kingdom
4.3.29. Prevalent Population of IPF
4.3.30. Prevalent Population of IPF by severity
4.3.31. Gender-Specific IPF Prevalence
4.3.32. Age-Specific IPF Prevalence
4.3.33. Japan
4.3.34. Prevalent Population of IPF
4.3.35. Prevalent Population of IPF by severity
4.3.36. Gender-SPECIFIC IPF Prevalence
4.3.37. Age-Specific IPF Prevalence
5. Current Treatment Practices
5.1. ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of IPF (An Update of 2011 Clinical Practice Guideline)
6. Unmet needs
7. Marketed Products
7.1. Esbriet (Pirfenidone): InterMune Inc.
7.1.1. Product Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Safety and Efficacy of Esbriet
7.1.5. Side effects of Esbriet
7.1.6. Product Profile
7.2. Ofev (Nintedanib): Boehringer Ingelheim Pharma GmbH & Co. KG
7.2.1. Product Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Safety and Efficacy of Ofev
7.2.5. Side effects of Ofev
7.2.6. Product Profile
8. Emerging Therapies
9. Key Cross Competition
10. Phase III Drugs
10.1. Thrombomodulin Alfa: Asahi Kasei Pharma Corporation
10.1.1. Drug Description
10.1.2. Product Profile
10.1.3. Clinical Development
10.1.4. Clinical Trials Information
10.1.5. Safety and Efficacy
11. Phase II Drugs
11.1. CC-90001: Celgene Corporation
11.1.1. Drug Description
11.1.2. Product Profile
11.1.3. Clinical Development
11.1.4. Clinical Trials Information
11.1.5. Safety and Efficacy
11.1.6. Drug Description
11.1.7. Product Profile
11.1.8. Other Development Activities
11.1.9. Clinical Development
11.1.10. Clinical Trials Information
11.1.11. Safety and Efficacy
11.2. Gefapixant: Merck & Co., Inc.
11.2.1. Drug Description
11.2.2. Product Profile
11.2.3. Other Development Activities
11.2.4. Clinical Development
11.2.5. Clinical Trials Information
11.2.6. Safety and Efficacy
11.3. GLPG1690: Galapagos NV
11.3.1. Drug Description
11.3.2. Product Profile
11.3.3. Regulatory Milestones
11.3.4. Other Development Activities
11.3.5. Clinical Development
11.3.6. Clinical Trials Information
11.3.7. Safety and Efficacy
11.4. LT-1001: LTT Bio-Pharma
11.4.1. Drug Description
11.4.2. Product Profile
11.4.3. Other Development Activities
11.4.4. Clinical Development
11.4.5. Clinical Trials Information
11.4.6. Safety and Efficacy
11.5. BG00011: Biogen Inc.
11.5.1. Drug Description
11.5.2. Product Profile
11.5.3. Regulatory Milestones
11.5.4. Other Development Activities
11.5.5. Clinical Development
11.5.6. Clinical Trials Information
11.5.7. Safety and Efficacy
11.6. BMS-986020: Bristol-Myers Squibb
11.6.1. Drug Description
11.6.2. Product Profile
11.6.3. Regulatory Milestones
11.6.4. Other Development Activities
11.6.5. Clinical Development
11.6.6. Clinical Trials Information
11.6.7. Safety and Efficacy
11.7. LT-1002: Chong Kun Dang Pharmaceutical
11.7.1. Drug Description
11.7.2. Product Profile
11.7.3. Other Development Activities
11.8. Pamrevlumab: FibroGen
11.8.1. Drug Description
11.8.2. Product Profile
11.8.3. Regulatory Milestones
11.8.4. Other Development Activities
11.8.5. Clinical Development
11.8.6. Clinical Trials Information
11.8.7. Safety and Efficacy
11.9. PBI4050: ProMetic Life Sciences
11.9.1. Drug Description
11.9.2. Product Profile
11.9.3. Regulatory Milestones
11.9.4. Other Development Activities
11.9.5. Clinical Development
11.9.6. Clinical Trials Information
11.9.7. Safety and Efficacy
11.10. PRM 151: Promedior, Inc.
11.10.1. Drug Description
11.10.2. Product Profile
11.10.3. Regulatory Milestones
11.10.4. Other Development Activities
11.10.5. Clinical Development
11.10.6. Clinical Trials Information
11.10.7. Safety and Efficacy
11.11. Tipelukast: MediciNova
11.11.1. Drug Description
11.11.2. Product Profile
11.11.3. Regulatory Milestones
11.11.4. Other Development Activities
11.11.5. Clinical Development
11.11.6. Clinical Trials Information
11.11.7. Safety and Efficacy
11.12. TD139: Bristol-Myers Squibb
11.12.1. Drug Description
11.12.2. Product Profile
11.12.3. Other Development Activities
11.12.4. Clinical Development
11.12.5. Clinical Trials Information
11.12.6. Safety and Efficacy
11.13. VAY736: Novartis
11.13.1. Drug Description
11.13.2. Product Profile
11.13.3. Other Development Activities
11.13.4. Clinical Development
11.13.5. Clinical Trials Information
11.14. TAS-115: Taiho Pharmaceutical
11.14.1. Drug Description
11.14.2. Product Profile
11.14.3. Clinical Development
11.14.4. Clinical Trials Information
12. IPF: Market Analysis
12.1. Key Findings
12.2. Total Market Size of IPF in 7 MM
12.3. Therapy Based Market Size of IPF in 7 MM
13. Market Size of IPF by Country
13.1. United States Market Analysis
13.1.1. Market Size of IPF in the US
13.1.2. Therapy Based Market Size of IPF in the US
13.2. EU5 Market Outlook
13.3. Germany
13.3.1. Market Size of IPF in Germany
13.3.2. Therapy Based Market Size of IPF in Germany
13.4. France
13.4.1. Market Size of IPF in France
13.4.2. Therapy Based Market Size of IPF in France
13.5. Italy
13.5.1. Market Size of IPF in Italy
13.5.2. Therapy Based Market Size of IPF in Italy
13.6. United Kingdom
13.6.1. Market Size of IPF in the UK
13.6.2. Therapy Based Market Size of IPF in the UK
13.7. Spain
13.7.1. Market Size of IPF in Spain
13.7.2. Therapy Based Market Size of IPF in Spain
13.8. Japan: Market Analysis
13.8.1. Market Size of IPF in Japan
13.8.2. Therapy Based Market Size of IPF in Japan
14. Market Drivers of IPF
15. Market Barriers of IPF
16. Appendix
16.1. Report Methodology
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

 

1. Key Insights
2. IPF Market Overview at a Glance
2.1. Market Share (%) Distribution of IPF in 2017
2.2. Market Share (%) Distribution of IPF in 2027
3. Disease Background and Overview: Idiopathic Pulmonary Fibrosis (IPF)
3.1. Introduction
3.2. Staging of IPF
3.3. Risk Factors & Disease Causes
3.4. Symptoms
3.5. Pathogenesis
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7 MM Prevalent Population of IPF
4.3. Country Wise-Epidemiology of IPF
4.3.1. United States
4.3.2. Prevalent cases of IPF in the United States
4.3.3. Prevalent Population of IPF by severity
4.3.4. Gender-Specific IPF Prevalence
4.3.5. Age-Specific IPF Prevalence
4.3.6. EU5
4.3.7. Prevalent Population of IPF in EU5
4.3.8. France
4.3.9. Prevalent Population of IPF
4.3.10. Prevalent Population of IPF by severity
4.3.11. Gender-Specific IPF Prevalence
4.3.12. Age-Specific IPF Prevalence
4.3.13. Germany
4.3.14. Prevalent Population of IPF
4.3.15. Prevalent Population of IPF by severity
4.3.16. Gender-Specific IPF Prevalence
4.3.17. Age-Specific IPF Prevalence
4.3.18. Italy
4.3.19. Prevalent Population of IPF
4.3.20. Prevalent Population of IPF by severity
4.3.21. Gender-Specific IPF Prevalence
4.3.22. Age-Specific IPF Prevalence
4.3.23. Spain
4.3.24. Prevalent Population of IPF
4.3.25. Prevalent Population of IPF by severity
4.3.26. Gender-Specific IPF Prevalence
4.3.27. Age-Specific IPF Prevalence
4.3.28. United Kingdom
4.3.29. Prevalent Population of IPF
4.3.30. Prevalent Population of IPF by severity
4.3.31. Gender-Specific IPF Prevalence
4.3.32. Age-Specific IPF Prevalence
4.3.33. Japan
4.3.34. Prevalent Population of IPF
4.3.35. Prevalent Population of IPF by severity
4.3.36. Gender-SPECIFIC IPF Prevalence
4.3.37. Age-Specific IPF Prevalence
5. Current Treatment Practices
5.1. ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of IPF (An Update of 2011 Clinical Practice Guideline)
6. Unmet needs
7. Marketed Products
7.1. Esbriet (Pirfenidone): InterMune Inc.
7.1.1. Product Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Safety and Efficacy of Esbriet
7.1.5. Side effects of Esbriet
7.1.6. Product Profile
7.2. Ofev (Nintedanib): Boehringer Ingelheim Pharma GmbH & Co. KG
7.2.1. Product Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Safety and Efficacy of Ofev
7.2.5. Side effects of Ofev
7.2.6. Product Profile
8. Emerging Therapies
9. Key Cross Competition
10. Phase III Drugs
10.1. Thrombomodulin Alfa: Asahi Kasei Pharma Corporation
10.1.1. Drug Description
10.1.2. Product Profile
10.1.3. Clinical Development
10.1.4. Clinical Trials Information
10.1.5. Safety and Efficacy
11. Phase II Drugs
11.1. CC-90001: Celgene Corporation
11.1.1. Drug Description
11.1.2. Product Profile
11.1.3. Clinical Development
11.1.4. Clinical Trials Information
11.1.5. Safety and Efficacy
11.1.6. Drug Description
11.1.7. Product Profile
11.1.8. Other Development Activities
11.1.9. Clinical Development
11.1.10. Clinical Trials Information
11.1.11. Safety and Efficacy
11.2. Gefapixant: Merck & Co., Inc.
11.2.1. Drug Description
11.2.2. Product Profile
11.2.3. Other Development Activities
11.2.4. Clinical Development
11.2.5. Clinical Trials Information
11.2.6. Safety and Efficacy
11.3. GLPG1690: Galapagos NV
11.3.1. Drug Description
11.3.2. Product Profile
11.3.3. Regulatory Milestones
11.3.4. Other Development Activities
11.3.5. Clinical Development
11.3.6. Clinical Trials Information
11.3.7. Safety and Efficacy
11.4. LT-1001: LTT Bio-Pharma
11.4.1. Drug Description
11.4.2. Product Profile
11.4.3. Other Development Activities
11.4.4. Clinical Development
11.4.5. Clinical Trials Information
11.4.6. Safety and Efficacy
11.5. BG00011: Biogen Inc.
11.5.1. Drug Description
11.5.2. Product Profile
11.5.3. Regulatory Milestones
11.5.4. Other Development Activities
11.5.5. Clinical Development
11.5.6. Clinical Trials Information
11.5.7. Safety and Efficacy
11.6. BMS-986020: Bristol-Myers Squibb
11.6.1. Drug Description
11.6.2. Product Profile
11.6.3. Regulatory Milestones
11.6.4. Other Development Activities
11.6.5. Clinical Development
11.6.6. Clinical Trials Information
11.6.7. Safety and Efficacy
11.7. LT-1002: Chong Kun Dang Pharmaceutical
11.7.1. Drug Description
11.7.2. Product Profile
11.7.3. Other Development Activities
11.8. Pamrevlumab: FibroGen
11.8.1. Drug Description
11.8.2. Product Profile
11.8.3. Regulatory Milestones
11.8.4. Other Development Activities
11.8.5. Clinical Development
11.8.6. Clinical Trials Information
11.8.7. Safety and Efficacy
11.9. PBI4050: ProMetic Life Sciences
11.9.1. Drug Description
11.9.2. Product Profile
11.9.3. Regulatory Milestones
11.9.4. Other Development Activities
11.9.5. Clinical Development
11.9.6. Clinical Trials Information
11.9.7. Safety and Efficacy
11.10. PRM 151: Promedior, Inc.
11.10.1. Drug Description
11.10.2. Product Profile
11.10.3. Regulatory Milestones
11.10.4. Other Development Activities
11.10.5. Clinical Development
11.10.6. Clinical Trials Information
11.10.7. Safety and Efficacy
11.11. Tipelukast: MediciNova
11.11.1. Drug Description
11.11.2. Product Profile
11.11.3. Regulatory Milestones
11.11.4. Other Development Activities
11.11.5. Clinical Development
11.11.6. Clinical Trials Information
11.11.7. Safety and Efficacy
11.12. TD139: Bristol-Myers Squibb
11.12.1. Drug Description
11.12.2. Product Profile
11.12.3. Other Development Activities
11.12.4. Clinical Development
11.12.5. Clinical Trials Information
11.12.6. Safety and Efficacy
11.13. VAY736: Novartis
11.13.1. Drug Description
11.13.2. Product Profile
11.13.3. Other Development Activities
11.13.4. Clinical Development
11.13.5. Clinical Trials Information
11.14. TAS-115: Taiho Pharmaceutical
11.14.1. Drug Description
11.14.2. Product Profile
11.14.3. Clinical Development
11.14.4. Clinical Trials Information
12. IPF: Market Analysis
12.1. Key Findings
12.2. Total Market Size of IPF in 7 MM
12.3. Therapy Based Market Size of IPF in 7 MM
13. Market Size of IPF by Country
13.1. United States Market Analysis
13.1.1. Market Size of IPF in the US
13.1.2. Therapy Based Market Size of IPF in the US
13.2. EU5 Market Outlook
13.3. Germany
13.3.1. Market Size of IPF in Germany
13.3.2. Therapy Based Market Size of IPF in Germany
13.4. France
13.4.1. Market Size of IPF in France
13.4.2. Therapy Based Market Size of IPF in France
13.5. Italy
13.5.1. Market Size of IPF in Italy
13.5.2. Therapy Based Market Size of IPF in Italy
13.6. United Kingdom
13.6.1. Market Size of IPF in the UK
13.6.2. Therapy Based Market Size of IPF in the UK
13.7. Spain
13.7.1. Market Size of IPF in Spain
13.7.2. Therapy Based Market Size of IPF in Spain
13.8. Japan: Market Analysis
13.8.1. Market Size of IPF in Japan
13.8.2. Therapy Based Market Size of IPF in Japan
14. Market Drivers of IPF
15. Market Barriers of IPF
16. Appendix
16.1. Report Methodology
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

 

1. Key Insights
2. IPF Market Overview at a Glance
2.1. Market Share (%) Distribution of IPF in 2017
2.2. Market Share (%) Distribution of IPF in 2027
3. Disease Background and Overview: Idiopathic Pulmonary Fibrosis (IPF)
3.1. Introduction
3.2. Staging of IPF
3.3. Risk Factors & Disease Causes
3.4. Symptoms
3.5. Pathogenesis
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7 MM Prevalent Population of IPF
4.3. Country Wise-Epidemiology of IPF
4.3.1. United States
4.3.2. Prevalent cases of IPF in the United States
4.3.3. Prevalent Population of IPF by severity
4.3.4. Gender-Specific IPF Prevalence
4.3.5. Age-Specific IPF Prevalence
4.3.6. EU5
4.3.7. Prevalent Population of IPF in EU5
4.3.8. France
4.3.9. Prevalent Population of IPF
4.3.10. Prevalent Population of IPF by severity
4.3.11. Gender-Specific IPF Prevalence
4.3.12. Age-Specific IPF Prevalence
4.3.13. Germany
4.3.14. Prevalent Population of IPF
4.3.15. Prevalent Population of IPF by severity
4.3.16. Gender-Specific IPF Prevalence
4.3.17. Age-Specific IPF Prevalence
4.3.18. Italy
4.3.19. Prevalent Population of IPF
4.3.20. Prevalent Population of IPF by severity
4.3.21. Gender-Specific IPF Prevalence
4.3.22. Age-Specific IPF Prevalence
4.3.23. Spain
4.3.24. Prevalent Population of IPF
4.3.25. Prevalent Population of IPF by severity
4.3.26. Gender-Specific IPF Prevalence
4.3.27. Age-Specific IPF Prevalence
4.3.28. United Kingdom
4.3.29. Prevalent Population of IPF
4.3.30. Prevalent Population of IPF by severity
4.3.31. Gender-Specific IPF Prevalence
4.3.32. Age-Specific IPF Prevalence
4.3.33. Japan
4.3.34. Prevalent Population of IPF
4.3.35. Prevalent Population of IPF by severity
4.3.36. Gender-SPECIFIC IPF Prevalence
4.3.37. Age-Specific IPF Prevalence
5. Current Treatment Practices
5.1. ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of IPF (An Update of 2011 Clinical Practice Guideline)
6. Unmet needs
7. Marketed Products
7.1. Esbriet (Pirfenidone): InterMune Inc.
7.1.1. Product Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Safety and Efficacy of Esbriet
7.1.5. Side effects of Esbriet
7.1.6. Product Profile
7.2. Ofev (Nintedanib): Boehringer Ingelheim Pharma GmbH & Co. KG
7.2.1. Product Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Safety and Efficacy of Ofev
7.2.5. Side effects of Ofev
7.2.6. Product Profile
8. Emerging Therapies
9. Key Cross Competition
10. Phase III Drugs
10.1. Thrombomodulin Alfa: Asahi Kasei Pharma Corporation
10.1.1. Drug Description
10.1.2. Product Profile
10.1.3. Clinical Development
10.1.4. Clinical Trials Information
10.1.5. Safety and Efficacy
11. Phase II Drugs
11.1. CC-90001: Celgene Corporation
11.1.1. Drug Description
11.1.2. Product Profile
11.1.3. Clinical Development
11.1.4. Clinical Trials Information
11.1.5. Safety and Efficacy
11.1.6. Drug Description
11.1.7. Product Profile
11.1.8. Other Development Activities
11.1.9. Clinical Development
11.1.10. Clinical Trials Information
11.1.11. Safety and Efficacy
11.2. Gefapixant: Merck & Co., Inc.
11.2.1. Drug Description
11.2.2. Product Profile
11.2.3. Other Development Activities
11.2.4. Clinical Development
11.2.5. Clinical Trials Information
11.2.6. Safety and Efficacy
11.3. GLPG1690: Galapagos NV
11.3.1. Drug Description
11.3.2. Product Profile
11.3.3. Regulatory Milestones
11.3.4. Other Development Activities
11.3.5. Clinical Development
11.3.6. Clinical Trials Information
11.3.7. Safety and Efficacy
11.4. LT-1001: LTT Bio-Pharma
11.4.1. Drug Description
11.4.2. Product Profile
11.4.3. Other Development Activities
11.4.4. Clinical Development
11.4.5. Clinical Trials Information
11.4.6. Safety and Efficacy
11.5. BG00011: Biogen Inc.
11.5.1. Drug Description
11.5.2. Product Profile
11.5.3. Regulatory Milestones
11.5.4. Other Development Activities
11.5.5. Clinical Development
11.5.6. Clinical Trials Information
11.5.7. Safety and Efficacy
11.6. BMS-986020: Bristol-Myers Squibb
11.6.1. Drug Description
11.6.2. Product Profile
11.6.3. Regulatory Milestones
11.6.4. Other Development Activities
11.6.5. Clinical Development
11.6.6. Clinical Trials Information
11.6.7. Safety and Efficacy
11.7. LT-1002: Chong Kun Dang Pharmaceutical
11.7.1. Drug Description
11.7.2. Product Profile
11.7.3. Other Development Activities
11.8. Pamrevlumab: FibroGen
11.8.1. Drug Description
11.8.2. Product Profile
11.8.3. Regulatory Milestones
11.8.4. Other Development Activities
11.8.5. Clinical Development
11.8.6. Clinical Trials Information
11.8.7. Safety and Efficacy
11.9. PBI4050: ProMetic Life Sciences
11.9.1. Drug Description
11.9.2. Product Profile
11.9.3. Regulatory Milestones
11.9.4. Other Development Activities
11.9.5. Clinical Development
11.9.6. Clinical Trials Information
11.9.7. Safety and Efficacy
11.10. PRM 151: Promedior, Inc.
11.10.1. Drug Description
11.10.2. Product Profile
11.10.3. Regulatory Milestones
11.10.4. Other Development Activities
11.10.5. Clinical Development
11.10.6. Clinical Trials Information
11.10.7. Safety and Efficacy
11.11. Tipelukast: MediciNova
11.11.1. Drug Description
11.11.2. Product Profile
11.11.3. Regulatory Milestones
11.11.4. Other Development Activities
11.11.5. Clinical Development
11.11.6. Clinical Trials Information
11.11.7. Safety and Efficacy
11.12. TD139: Bristol-Myers Squibb
11.12.1. Drug Description
11.12.2. Product Profile
11.12.3. Other Development Activities
11.12.4. Clinical Development
11.12.5. Clinical Trials Information
11.12.6. Safety and Efficacy
11.13. VAY736: Novartis
11.13.1. Drug Description
11.13.2. Product Profile
11.13.3. Other Development Activities
11.13.4. Clinical Development
11.13.5. Clinical Trials Information
11.14. TAS-115: Taiho Pharmaceutical
11.14.1. Drug Description
11.14.2. Product Profile
11.14.3. Clinical Development
11.14.4. Clinical Trials Information
12. IPF: Market Analysis
12.1. Key Findings
12.2. Total Market Size of IPF in 7 MM
12.3. Therapy Based Market Size of IPF in 7 MM
13. Market Size of IPF by Country
13.1. United States Market Analysis
13.1.1. Market Size of IPF in the US
13.1.2. Therapy Based Market Size of IPF in the US
13.2. EU5 Market Outlook
13.3. Germany
13.3.1. Market Size of IPF in Germany
13.3.2. Therapy Based Market Size of IPF in Germany
13.4. France
13.4.1. Market Size of IPF in France
13.4.2. Therapy Based Market Size of IPF in France
13.5. Italy
13.5.1. Market Size of IPF in Italy
13.5.2. Therapy Based Market Size of IPF in Italy
13.6. United Kingdom
13.6.1. Market Size of IPF in the UK
13.6.2. Therapy Based Market Size of IPF in the UK
13.7. Spain
13.7.1. Market Size of IPF in Spain
13.7.2. Therapy Based Market Size of IPF in Spain
13.8. Japan: Market Analysis
13.8.1. Market Size of IPF in Japan
13.8.2. Therapy Based Market Size of IPF in Japan
14. Market Drivers of IPF
15. Market Barriers of IPF
16. Appendix
16.1. Report Methodology
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

 

1. Key Insights
2. IPF Market Overview at a Glance
2.1. Market Share (%) Distribution of IPF in 2017
2.2. Market Share (%) Distribution of IPF in 2027
3. Disease Background and Overview: Idiopathic Pulmonary Fibrosis (IPF)
3.1. Introduction
3.2. Staging of IPF
3.3. Risk Factors & Disease Causes
3.4. Symptoms
3.5. Pathogenesis
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7 MM Prevalent Population of IPF
4.3. Country Wise-Epidemiology of IPF
4.3.1. United States
4.3.2. Prevalent cases of IPF in the United States
4.3.3. Prevalent Population of IPF by severity
4.3.4. Gender-Specific IPF Prevalence
4.3.5. Age-Specific IPF Prevalence
4.3.6. EU5
4.3.7. Prevalent Population of IPF in EU5
4.3.8. France
4.3.9. Prevalent Population of IPF
4.3.10. Prevalent Population of IPF by severity
4.3.11. Gender-Specific IPF Prevalence
4.3.12. Age-Specific IPF Prevalence
4.3.13. Germany
4.3.14. Prevalent Population of IPF
4.3.15. Prevalent Population of IPF by severity
4.3.16. Gender-Specific IPF Prevalence
4.3.17. Age-Specific IPF Prevalence
4.3.18. Italy
4.3.19. Prevalent Population of IPF
4.3.20. Prevalent Population of IPF by severity
4.3.21. Gender-Specific IPF Prevalence
4.3.22. Age-Specific IPF Prevalence
4.3.23. Spain
4.3.24. Prevalent Population of IPF
4.3.25. Prevalent Population of IPF by severity
4.3.26. Gender-Specific IPF Prevalence
4.3.27. Age-Specific IPF Prevalence
4.3.28. United Kingdom
4.3.29. Prevalent Population of IPF
4.3.30. Prevalent Population of IPF by severity
4.3.31. Gender-Specific IPF Prevalence
4.3.32. Age-Specific IPF Prevalence
4.3.33. Japan
4.3.34. Prevalent Population of IPF
4.3.35. Prevalent Population of IPF by severity
4.3.36. Gender-SPECIFIC IPF Prevalence
4.3.37. Age-Specific IPF Prevalence
5. Current Treatment Practices
5.1. ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of IPF (An Update of 2011 Clinical Practice Guideline)
6. Unmet needs
7. Marketed Products
7.1. Esbriet (Pirfenidone): InterMune Inc.
7.1.1. Product Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Safety and Efficacy of Esbriet
7.1.5. Side effects of Esbriet
7.1.6. Product Profile
7.2. Ofev (Nintedanib): Boehringer Ingelheim Pharma GmbH & Co. KG
7.2.1. Product Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Safety and Efficacy of Ofev
7.2.5. Side effects of Ofev
7.2.6. Product Profile
8. Emerging Therapies
9. Key Cross Competition
10. Phase III Drugs
10.1. Thrombomodulin Alfa: Asahi Kasei Pharma Corporation
10.1.1. Drug Description
10.1.2. Product Profile
10.1.3. Clinical Development
10.1.4. Clinical Trials Information
10.1.5. Safety and Efficacy
11. Phase II Drugs
11.1. CC-90001: Celgene Corporation
11.1.1. Drug Description
11.1.2. Product Profile
11.1.3. Clinical Development
11.1.4. Clinical Trials Information
11.1.5. Safety and Efficacy
11.1.6. Drug Description
11.1.7. Product Profile
11.1.8. Other Development Activities
11.1.9. Clinical Development
11.1.10. Clinical Trials Information
11.1.11. Safety and Efficacy
11.2. Gefapixant: Merck & Co., Inc.
11.2.1. Drug Description
11.2.2. Product Profile
11.2.3. Other Development Activities
11.2.4. Clinical Development
11.2.5. Clinical Trials Information
11.2.6. Safety and Efficacy
11.3. GLPG1690: Galapagos NV
11.3.1. Drug Description
11.3.2. Product Profile
11.3.3. Regulatory Milestones
11.3.4. Other Development Activities
11.3.5. Clinical Development
11.3.6. Clinical Trials Information
11.3.7. Safety and Efficacy
11.4. LT-1001: LTT Bio-Pharma
11.4.1. Drug Description
11.4.2. Product Profile
11.4.3. Other Development Activities
11.4.4. Clinical Development
11.4.5. Clinical Trials Information
11.4.6. Safety and Efficacy
11.5. BG00011: Biogen Inc.
11.5.1. Drug Description
11.5.2. Product Profile
11.5.3. Regulatory Milestones
11.5.4. Other Development Activities
11.5.5. Clinical Development
11.5.6. Clinical Trials Information
11.5.7. Safety and Efficacy
11.6. BMS-986020: Bristol-Myers Squibb
11.6.1. Drug Description
11.6.2. Product Profile
11.6.3. Regulatory Milestones
11.6.4. Other Development Activities
11.6.5. Clinical Development
11.6.6. Clinical Trials Information
11.6.7. Safety and Efficacy
11.7. LT-1002: Chong Kun Dang Pharmaceutical
11.7.1. Drug Description
11.7.2. Product Profile
11.7.3. Other Development Activities
11.8. Pamrevlumab: FibroGen
11.8.1. Drug Description
11.8.2. Product Profile
11.8.3. Regulatory Milestones
11.8.4. Other Development Activities
11.8.5. Clinical Development
11.8.6. Clinical Trials Information
11.8.7. Safety and Efficacy
11.9. PBI4050: ProMetic Life Sciences
11.9.1. Drug Description
11.9.2. Product Profile
11.9.3. Regulatory Milestones
11.9.4. Other Development Activities
11.9.5. Clinical Development
11.9.6. Clinical Trials Information
11.9.7. Safety and Efficacy
11.10. PRM 151: Promedior, Inc.
11.10.1. Drug Description
11.10.2. Product Profile
11.10.3. Regulatory Milestones
11.10.4. Other Development Activities
11.10.5. Clinical Development
11.10.6. Clinical Trials Information
11.10.7. Safety and Efficacy
11.11. Tipelukast: MediciNova
11.11.1. Drug Description
11.11.2. Product Profile
11.11.3. Regulatory Milestones
11.11.4. Other Development Activities
11.11.5. Clinical Development
11.11.6. Clinical Trials Information
11.11.7. Safety and Efficacy
11.12. TD139: Bristol-Myers Squibb
11.12.1. Drug Description
11.12.2. Product Profile
11.12.3. Other Development Activities
11.12.4. Clinical Development
11.12.5. Clinical Trials Information
11.12.6. Safety and Efficacy
11.13. VAY736: Novartis
11.13.1. Drug Description
11.13.2. Product Profile
11.13.3. Other Development Activities
11.13.4. Clinical Development
11.13.5. Clinical Trials Information
11.14. TAS-115: Taiho Pharmaceutical
11.14.1. Drug Description
11.14.2. Product Profile
11.14.3. Clinical Development
11.14.4. Clinical Trials Information
12. IPF: Market Analysis
12.1. Key Findings
12.2. Total Market Size of IPF in 7 MM
12.3. Therapy Based Market Size of IPF in 7 MM
13. Market Size of IPF by Country
13.1. United States Market Analysis
13.1.1. Market Size of IPF in the US
13.1.2. Therapy Based Market Size of IPF in the US
13.2. EU5 Market Outlook
13.3. Germany
13.3.1. Market Size of IPF in Germany
13.3.2. Therapy Based Market Size of IPF in Germany
13.4. France
13.4.1. Market Size of IPF in France
13.4.2. Therapy Based Market Size of IPF in France
13.5. Italy
13.5.1. Market Size of IPF in Italy
13.5.2. Therapy Based Market Size of IPF in Italy
13.6. United Kingdom
13.6.1. Market Size of IPF in the UK
13.6.2. Therapy Based Market Size of IPF in the UK
13.7. Spain
13.7.1. Market Size of IPF in Spain
13.7.2. Therapy Based Market Size of IPF in Spain
13.8. Japan: Market Analysis
13.8.1. Market Size of IPF in Japan
13.8.2. Therapy Based Market Size of IPF in Japan
14. Market Drivers of IPF
15. Market Barriers of IPF
16. Appendix
16.1. Report Methodology
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

 

1. Key Insights
2. IPF Market Overview at a Glance
2.1. Market Share (%) Distribution of IPF in 2017
2.2. Market Share (%) Distribution of IPF in 2027
3. Disease Background and Overview: Idiopathic Pulmonary Fibrosis (IPF)
3.1. Introduction
3.2. Staging of IPF
3.3. Risk Factors & Disease Causes
3.4. Symptoms
3.5. Pathogenesis
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7 MM Prevalent Population of IPF
4.3. Country Wise-Epidemiology of IPF
4.3.1. United States
4.3.2. Prevalent cases of IPF in the United States
4.3.3. Prevalent Population of IPF by severity
4.3.4. Gender-Specific IPF Prevalence
4.3.5. Age-Specific IPF Prevalence
4.3.6. EU5
4.3.7. Prevalent Population of IPF in EU5
4.3.8. France
4.3.9. Prevalent Population of IPF
4.3.10. Prevalent Population of IPF by severity
4.3.11. Gender-Specific IPF Prevalence
4.3.12. Age-Specific IPF Prevalence
4.3.13. Germany
4.3.14. Prevalent Population of IPF
4.3.15. Prevalent Population of IPF by severity
4.3.16. Gender-Specific IPF Prevalence
4.3.17. Age-Specific IPF Prevalence
4.3.18. Italy
4.3.19. Prevalent Population of IPF
4.3.20. Prevalent Population of IPF by severity
4.3.21. Gender-Specific IPF Prevalence
4.3.22. Age-Specific IPF Prevalence
4.3.23. Spain
4.3.24. Prevalent Population of IPF
4.3.25. Prevalent Population of IPF by severity
4.3.26. Gender-Specific IPF Prevalence
4.3.27. Age-Specific IPF Prevalence
4.3.28. United Kingdom
4.3.29. Prevalent Population of IPF
4.3.30. Prevalent Population of IPF by severity
4.3.31. Gender-Specific IPF Prevalence
4.3.32. Age-Specific IPF Prevalence
4.3.33. Japan
4.3.34. Prevalent Population of IPF
4.3.35. Prevalent Population of IPF by severity
4.3.36. Gender-SPECIFIC IPF Prevalence
4.3.37. Age-Specific IPF Prevalence
5. Current Treatment Practices
5.1. ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of IPF (An Update of 2011 Clinical Practice Guideline)
6. Unmet needs
7. Marketed Products
7.1. Esbriet (Pirfenidone): InterMune Inc.
7.1.1. Product Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Safety and Efficacy of Esbriet
7.1.5. Side effects of Esbriet
7.1.6. Product Profile
7.2. Ofev (Nintedanib): Boehringer Ingelheim Pharma GmbH & Co. KG
7.2.1. Product Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Safety and Efficacy of Ofev
7.2.5. Side effects of Ofev
7.2.6. Product Profile
8. Emerging Therapies
9. Key Cross Competition
10. Phase III Drugs
10.1. Thrombomodulin Alfa: Asahi Kasei Pharma Corporation
10.1.1. Drug Description
10.1.2. Product Profile
10.1.3. Clinical Development
10.1.4. Clinical Trials Information
10.1.5. Safety and Efficacy
11. Phase II Drugs
11.1. CC-90001: Celgene Corporation
11.1.1. Drug Description
11.1.2. Product Profile
11.1.3. Clinical Development
11.1.4. Clinical Trials Information
11.1.5. Safety and Efficacy
11.1.6. Drug Description
11.1.7. Product Profile
11.1.8. Other Development Activities
11.1.9. Clinical Development
11.1.10. Clinical Trials Information
11.1.11. Safety and Efficacy
11.2. Gefapixant: Merck & Co., Inc.
11.2.1. Drug Description
11.2.2. Product Profile
11.2.3. Other Development Activities
11.2.4. Clinical Development
11.2.5. Clinical Trials Information
11.2.6. Safety and Efficacy
11.3. GLPG1690: Galapagos NV
11.3.1. Drug Description
11.3.2. Product Profile
11.3.3. Regulatory Milestones
11.3.4. Other Development Activities
11.3.5. Clinical Development
11.3.6. Clinical Trials Information
11.3.7. Safety and Efficacy
11.4. LT-1001: LTT Bio-Pharma
11.4.1. Drug Description
11.4.2. Product Profile
11.4.3. Other Development Activities
11.4.4. Clinical Development
11.4.5. Clinical Trials Information
11.4.6. Safety and Efficacy
11.5. BG00011: Biogen Inc.
11.5.1. Drug Description
11.5.2. Product Profile
11.5.3. Regulatory Milestones
11.5.4. Other Development Activities
11.5.5. Clinical Development
11.5.6. Clinical Trials Information
11.5.7. Safety and Efficacy
11.6. BMS-986020: Bristol-Myers Squibb
11.6.1. Drug Description
11.6.2. Product Profile
11.6.3. Regulatory Milestones
11.6.4. Other Development Activities
11.6.5. Clinical Development
11.6.6. Clinical Trials Information
11.6.7. Safety and Efficacy
11.7. LT-1002: Chong Kun Dang Pharmaceutical
11.7.1. Drug Description
11.7.2. Product Profile
11.7.3. Other Development Activities
11.8. Pamrevlumab: FibroGen
11.8.1. Drug Description
11.8.2. Product Profile
11.8.3. Regulatory Milestones
11.8.4. Other Development Activities
11.8.5. Clinical Development
11.8.6. Clinical Trials Information
11.8.7. Safety and Efficacy
11.9. PBI4050: ProMetic Life Sciences
11.9.1. Drug Description
11.9.2. Product Profile
11.9.3. Regulatory Milestones
11.9.4. Other Development Activities
11.9.5. Clinical Development
11.9.6. Clinical Trials Information
11.9.7. Safety and Efficacy
11.10. PRM 151: Promedior, Inc.
11.10.1. Drug Description
11.10.2. Product Profile
11.10.3. Regulatory Milestones
11.10.4. Other Development Activities
11.10.5. Clinical Development
11.10.6. Clinical Trials Information
11.10.7. Safety and Efficacy
11.11. Tipelukast: MediciNova
11.11.1. Drug Description
11.11.2. Product Profile
11.11.3. Regulatory Milestones
11.11.4. Other Development Activities
11.11.5. Clinical Development
11.11.6. Clinical Trials Information
11.11.7. Safety and Efficacy
11.12. TD139: Bristol-Myers Squibb
11.12.1. Drug Description
11.12.2. Product Profile
11.12.3. Other Development Activities
11.12.4. Clinical Development
11.12.5. Clinical Trials Information
11.12.6. Safety and Efficacy
11.13. VAY736: Novartis
11.13.1. Drug Description
11.13.2. Product Profile
11.13.3. Other Development Activities
11.13.4. Clinical Development
11.13.5. Clinical Trials Information
11.14. TAS-115: Taiho Pharmaceutical
11.14.1. Drug Description
11.14.2. Product Profile
11.14.3. Clinical Development
11.14.4. Clinical Trials Information
12. IPF: Market Analysis
12.1. Key Findings
12.2. Total Market Size of IPF in 7 MM
12.3. Therapy Based Market Size of IPF in 7 MM
13. Market Size of IPF by Country
13.1. United States Market Analysis
13.1.1. Market Size of IPF in the US
13.1.2. Therapy Based Market Size of IPF in the US
13.2. EU5 Market Outlook
13.3. Germany
13.3.1. Market Size of IPF in Germany
13.3.2. Therapy Based Market Size of IPF in Germany
13.4. France
13.4.1. Market Size of IPF in France
13.4.2. Therapy Based Market Size of IPF in France
13.5. Italy
13.5.1. Market Size of IPF in Italy
13.5.2. Therapy Based Market Size of IPF in Italy
13.6. United Kingdom
13.6.1. Market Size of IPF in the UK
13.6.2. Therapy Based Market Size of IPF in the UK
13.7. Spain
13.7.1. Market Size of IPF in Spain
13.7.2. Therapy Based Market Size of IPF in Spain
13.8. Japan: Market Analysis
13.8.1. Market Size of IPF in Japan
13.8.2. Therapy Based Market Size of IPF in Japan
14. Market Drivers of IPF
15. Market Barriers of IPF
16. Appendix
16.1. Report Methodology
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

 

1. Key Insights
2. IPF Market Overview at a Glance
2.1. Market Share (%) Distribution of IPF in 2017
2.2. Market Share (%) Distribution of IPF in 2027
3. Disease Background and Overview: Idiopathic Pulmonary Fibrosis (IPF)
3.1. Introduction
3.2. Staging of IPF
3.3. Risk Factors & Disease Causes
3.4. Symptoms
3.5. Pathogenesis
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7 MM Prevalent Population of IPF
4.3. Country Wise-Epidemiology of IPF
4.3.1. United States
4.3.2. Prevalent cases of IPF in the United States
4.3.3. Prevalent Population of IPF by severity
4.3.4. Gender-Specific IPF Prevalence
4.3.5. Age-Specific IPF Prevalence
4.3.6. EU5
4.3.7. Prevalent Population of IPF in EU5
4.3.8. France
4.3.9. Prevalent Population of IPF
4.3.10. Prevalent Population of IPF by severity
4.3.11. Gender-Specific IPF Prevalence
4.3.12. Age-Specific IPF Prevalence
4.3.13. Germany
4.3.14. Prevalent Population of IPF
4.3.15. Prevalent Population of IPF by severity
4.3.16. Gender-Specific IPF Prevalence
4.3.17. Age-Specific IPF Prevalence
4.3.18. Italy
4.3.19. Prevalent Population of IPF
4.3.20. Prevalent Population of IPF by severity
4.3.21. Gender-Specific IPF Prevalence
4.3.22. Age-Specific IPF Prevalence
4.3.23. Spain
4.3.24. Prevalent Population of IPF
4.3.25. Prevalent Population of IPF by severity
4.3.26. Gender-Specific IPF Prevalence
4.3.27. Age-Specific IPF Prevalence
4.3.28. United Kingdom
4.3.29. Prevalent Population of IPF
4.3.30. Prevalent Population of IPF by severity
4.3.31. Gender-Specific IPF Prevalence
4.3.32. Age-Specific IPF Prevalence
4.3.33. Japan
4.3.34. Prevalent Population of IPF
4.3.35. Prevalent Population of IPF by severity
4.3.36. Gender-SPECIFIC IPF Prevalence
4.3.37. Age-Specific IPF Prevalence
5. Current Treatment Practices
5.1. ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of IPF (An Update of 2011 Clinical Practice Guideline)
6. Unmet needs
7. Marketed Products
7.1. Esbriet (Pirfenidone): InterMune Inc.
7.1.1. Product Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Safety and Efficacy of Esbriet
7.1.5. Side effects of Esbriet
7.1.6. Product Profile
7.2. Ofev (Nintedanib): Boehringer Ingelheim Pharma GmbH & Co. KG
7.2.1. Product Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Safety and Efficacy of Ofev
7.2.5. Side effects of Ofev
7.2.6. Product Profile
8. Emerging Therapies
9. Key Cross Competition
10. Phase III Drugs
10.1. Thrombomodulin Alfa: Asahi Kasei Pharma Corporation
10.1.1. Drug Description
10.1.2. Product Profile
10.1.3. Clinical Development
10.1.4. Clinical Trials Information
10.1.5. Safety and Efficacy
11. Phase II Drugs
11.1. CC-90001: Celgene Corporation
11.1.1. Drug Description
11.1.2. Product Profile
11.1.3. Clinical Development
11.1.4. Clinical Trials Information
11.1.5. Safety and Efficacy
11.1.6. Drug Description
11.1.7. Product Profile
11.1.8. Other Development Activities
11.1.9. Clinical Development
11.1.10. Clinical Trials Information
11.1.11. Safety and Efficacy
11.2. Gefapixant: Merck & Co., Inc.
11.2.1. Drug Description
11.2.2. Product Profile
11.2.3. Other Development Activities
11.2.4. Clinical Development
11.2.5. Clinical Trials Information
11.2.6. Safety and Efficacy
11.3. GLPG1690: Galapagos NV
11.3.1. Drug Description
11.3.2. Product Profile
11.3.3. Regulatory Milestones
11.3.4. Other Development Activities
11.3.5. Clinical Development
11.3.6. Clinical Trials Information
11.3.7. Safety and Efficacy
11.4. LT-1001: LTT Bio-Pharma
11.4.1. Drug Description
11.4.2. Product Profile
11.4.3. Other Development Activities
11.4.4. Clinical Development
11.4.5. Clinical Trials Information
11.4.6. Safety and Efficacy
11.5. BG00011: Biogen Inc.
11.5.1. Drug Description
11.5.2. Product Profile
11.5.3. Regulatory Milestones
11.5.4. Other Development Activities
11.5.5. Clinical Development
11.5.6. Clinical Trials Information
11.5.7. Safety and Efficacy
11.6. BMS-986020: Bristol-Myers Squibb
11.6.1. Drug Description
11.6.2. Product Profile
11.6.3. Regulatory Milestones
11.6.4. Other Development Activities
11.6.5. Clinical Development
11.6.6. Clinical Trials Information
11.6.7. Safety and Efficacy
11.7. LT-1002: Chong Kun Dang Pharmaceutical
11.7.1. Drug Description
11.7.2. Product Profile
11.7.3. Other Development Activities
11.8. Pamrevlumab: FibroGen
11.8.1. Drug Description
11.8.2. Product Profile
11.8.3. Regulatory Milestones
11.8.4. Other Development Activities
11.8.5. Clinical Development
11.8.6. Clinical Trials Information
11.8.7. Safety and Efficacy
11.9. PBI4050: ProMetic Life Sciences
11.9.1. Drug Description
11.9.2. Product Profile
11.9.3. Regulatory Milestones
11.9.4. Other Development Activities
11.9.5. Clinical Development
11.9.6. Clinical Trials Information
11.9.7. Safety and Efficacy
11.10. PRM 151: Promedior, Inc.
11.10.1. Drug Description
11.10.2. Product Profile
11.10.3. Regulatory Milestones
11.10.4. Other Development Activities
11.10.5. Clinical Development
11.10.6. Clinical Trials Information
11.10.7. Safety and Efficacy
11.11. Tipelukast: MediciNova
11.11.1. Drug Description
11.11.2. Product Profile
11.11.3. Regulatory Milestones
11.11.4. Other Development Activities
11.11.5. Clinical Development
11.11.6. Clinical Trials Information
11.11.7. Safety and Efficacy
11.12. TD139: Bristol-Myers Squibb
11.12.1. Drug Description
11.12.2. Product Profile
11.12.3. Other Development Activities
11.12.4. Clinical Development
11.12.5. Clinical Trials Information
11.12.6. Safety and Efficacy
11.13. VAY736: Novartis
11.13.1. Drug Description
11.13.2. Product Profile
11.13.3. Other Development Activities
11.13.4. Clinical Development
11.13.5. Clinical Trials Information
11.14. TAS-115: Taiho Pharmaceutical
11.14.1. Drug Description
11.14.2. Product Profile
11.14.3. Clinical Development
11.14.4. Clinical Trials Information
12. IPF: Market Analysis
12.1. Key Findings
12.2. Total Market Size of IPF in 7 MM
12.3. Therapy Based Market Size of IPF in 7 MM
13. Market Size of IPF by Country
13.1. United States Market Analysis
13.1.1. Market Size of IPF in the US
13.1.2. Therapy Based Market Size of IPF in the US
13.2. EU5 Market Outlook
13.3. Germany
13.3.1. Market Size of IPF in Germany
13.3.2. Therapy Based Market Size of IPF in Germany
13.4. France
13.4.1. Market Size of IPF in France
13.4.2. Therapy Based Market Size of IPF in France
13.5. Italy
13.5.1. Market Size of IPF in Italy
13.5.2. Therapy Based Market Size of IPF in Italy
13.6. United Kingdom
13.6.1. Market Size of IPF in the UK
13.6.2. Therapy Based Market Size of IPF in the UK
13.7. Spain
13.7.1. Market Size of IPF in Spain
13.7.2. Therapy Based Market Size of IPF in Spain
13.8. Japan: Market Analysis
13.8.1. Market Size of IPF in Japan
13.8.2. Therapy Based Market Size of IPF in Japan
14. Market Drivers of IPF
15. Market Barriers of IPF
16. Appendix
16.1. Report Methodology
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

 

1. Key Insights
2. IPF Market Overview at a Glance
2.1. Market Share (%) Distribution of IPF in 2017
2.2. Market Share (%) Distribution of IPF in 2027
3. Disease Background and Overview: Idiopathic Pulmonary Fibrosis (IPF)
3.1. Introduction
3.2. Staging of IPF
3.3. Risk Factors & Disease Causes
3.4. Symptoms
3.5. Pathogenesis
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7 MM Prevalent Population of IPF
4.3. Country Wise-Epidemiology of IPF
4.3.1. United States
4.3.2. Prevalent cases of IPF in the United States
4.3.3. Prevalent Population of IPF by severity
4.3.4. Gender-Specific IPF Prevalence
4.3.5. Age-Specific IPF Prevalence
4.3.6. EU5
4.3.7. Prevalent Population of IPF in EU5
4.3.8. France
4.3.9. Prevalent Population of IPF
4.3.10. Prevalent Population of IPF by severity
4.3.11. Gender-Specific IPF Prevalence
4.3.12. Age-Specific IPF Prevalence
4.3.13. Germany
4.3.14. Prevalent Population of IPF
4.3.15. Prevalent Population of IPF by severity
4.3.16. Gender-Specific IPF Prevalence
4.3.17. Age-Specific IPF Prevalence
4.3.18. Italy
4.3.19. Prevalent Population of IPF
4.3.20. Prevalent Population of IPF by severity
4.3.21. Gender-Specific IPF Prevalence
4.3.22. Age-Specific IPF Prevalence
4.3.23. Spain
4.3.24. Prevalent Population of IPF
4.3.25. Prevalent Population of IPF by severity
4.3.26. Gender-Specific IPF Prevalence
4.3.27. Age-Specific IPF Prevalence
4.3.28. United Kingdom
4.3.29. Prevalent Population of IPF
4.3.30. Prevalent Population of IPF by severity
4.3.31. Gender-Specific IPF Prevalence
4.3.32. Age-Specific IPF Prevalence
4.3.33. Japan
4.3.34. Prevalent Population of IPF
4.3.35. Prevalent Population of IPF by severity
4.3.36. Gender-SPECIFIC IPF Prevalence
4.3.37. Age-Specific IPF Prevalence
5. Current Treatment Practices
5.1. ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of IPF (An Update of 2011 Clinical Practice Guideline)
6. Unmet needs
7. Marketed Products
7.1. Esbriet (Pirfenidone): InterMune Inc.
7.1.1. Product Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Safety and Efficacy of Esbriet
7.1.5. Side effects of Esbriet
7.1.6. Product Profile
7.2. Ofev (Nintedanib): Boehringer Ingelheim Pharma GmbH & Co. KG
7.2.1. Product Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Safety and Efficacy of Ofev
7.2.5. Side effects of Ofev
7.2.6. Product Profile
8. Emerging Therapies
9. Key Cross Competition
10. Phase III Drugs
10.1. Thrombomodulin Alfa: Asahi Kasei Pharma Corporation
10.1.1. Drug Description
10.1.2. Product Profile
10.1.3. Clinical Development
10.1.4. Clinical Trials Information
10.1.5. Safety and Efficacy
11. Phase II Drugs
11.1. CC-90001: Celgene Corporation
11.1.1. Drug Description
11.1.2. Product Profile
11.1.3. Clinical Development
11.1.4. Clinical Trials Information
11.1.5. Safety and Efficacy
11.1.6. Drug Description
11.1.7. Product Profile
11.1.8. Other Development Activities
11.1.9. Clinical Development
11.1.10. Clinical Trials Information
11.1.11. Safety and Efficacy
11.2. Gefapixant: Merck & Co., Inc.
11.2.1. Drug Description
11.2.2. Product Profile
11.2.3. Other Development Activities
11.2.4. Clinical Development
11.2.5. Clinical Trials Information
11.2.6. Safety and Efficacy
11.3. GLPG1690: Galapagos NV
11.3.1. Drug Description
11.3.2. Product Profile
11.3.3. Regulatory Milestones
11.3.4. Other Development Activities
11.3.5. Clinical Development
11.3.6. Clinical Trials Information
11.3.7. Safety and Efficacy
11.4. LT-1001: LTT Bio-Pharma
11.4.1. Drug Description
11.4.2. Product Profile
11.4.3. Other Development Activities
11.4.4. Clinical Development
11.4.5. Clinical Trials Information
11.4.6. Safety and Efficacy
11.5. BG00011: Biogen Inc.
11.5.1. Drug Description
11.5.2. Product Profile
11.5.3. Regulatory Milestones
11.5.4. Other Development Activities
11.5.5. Clinical Development
11.5.6. Clinical Trials Information
11.5.7. Safety and Efficacy
11.6. BMS-986020: Bristol-Myers Squibb
11.6.1. Drug Description
11.6.2. Product Profile
11.6.3. Regulatory Milestones
11.6.4. Other Development Activities
11.6.5. Clinical Development
11.6.6. Clinical Trials Information
11.6.7. Safety and Efficacy
11.7. LT-1002: Chong Kun Dang Pharmaceutical
11.7.1. Drug Description
11.7.2. Product Profile
11.7.3. Other Development Activities
11.8. Pamrevlumab: FibroGen
11.8.1. Drug Description
11.8.2. Product Profile
11.8.3. Regulatory Milestones
11.8.4. Other Development Activities
11.8.5. Clinical Development
11.8.6. Clinical Trials Information
11.8.7. Safety and Efficacy
11.9. PBI4050: ProMetic Life Sciences
11.9.1. Drug Description
11.9.2. Product Profile
11.9.3. Regulatory Milestones
11.9.4. Other Development Activities
11.9.5. Clinical Development
11.9.6. Clinical Trials Information
11.9.7. Safety and Efficacy
11.10. PRM 151: Promedior, Inc.
11.10.1. Drug Description
11.10.2. Product Profile
11.10.3. Regulatory Milestones
11.10.4. Other Development Activities
11.10.5. Clinical Development
11.10.6. Clinical Trials Information
11.10.7. Safety and Efficacy
11.11. Tipelukast: MediciNova
11.11.1. Drug Description
11.11.2. Product Profile
11.11.3. Regulatory Milestones
11.11.4. Other Development Activities
11.11.5. Clinical Development
11.11.6. Clinical Trials Information
11.11.7. Safety and Efficacy
11.12. TD139: Bristol-Myers Squibb
11.12.1. Drug Description
11.12.2. Product Profile
11.12.3. Other Development Activities
11.12.4. Clinical Development
11.12.5. Clinical Trials Information
11.12.6. Safety and Efficacy
11.13. VAY736: Novartis
11.13.1. Drug Description
11.13.2. Product Profile
11.13.3. Other Development Activities
11.13.4. Clinical Development
11.13.5. Clinical Trials Information
11.14. TAS-115: Taiho Pharmaceutical
11.14.1. Drug Description
11.14.2. Product Profile
11.14.3. Clinical Development
11.14.4. Clinical Trials Information
12. IPF: Market Analysis
12.1. Key Findings
12.2. Total Market Size of IPF in 7 MM
12.3. Therapy Based Market Size of IPF in 7 MM
13. Market Size of IPF by Country
13.1. United States Market Analysis
13.1.1. Market Size of IPF in the US
13.1.2. Therapy Based Market Size of IPF in the US
13.2. EU5 Market Outlook
13.3. Germany
13.3.1. Market Size of IPF in Germany
13.3.2. Therapy Based Market Size of IPF in Germany
13.4. France
13.4.1. Market Size of IPF in France
13.4.2. Therapy Based Market Size of IPF in France
13.5. Italy
13.5.1. Market Size of IPF in Italy
13.5.2. Therapy Based Market Size of IPF in Italy
13.6. United Kingdom
13.6.1. Market Size of IPF in the UK
13.6.2. Therapy Based Market Size of IPF in the UK
13.7. Spain
13.7.1. Market Size of IPF in Spain
13.7.2. Therapy Based Market Size of IPF in Spain
13.8. Japan: Market Analysis
13.8.1. Market Size of IPF in Japan
13.8.2. Therapy Based Market Size of IPF in Japan
14. Market Drivers of IPF
15. Market Barriers of IPF
16. Appendix
16.1. Report Methodology
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

 

1. Key Insights
2. IPF Market Overview at a Glance
2.1. Market Share (%) Distribution of IPF in 2017
2.2. Market Share (%) Distribution of IPF in 2027
3. Disease Background and Overview: Idiopathic Pulmonary Fibrosis (IPF)
3.1. Introduction
3.2. Staging of IPF
3.3. Risk Factors & Disease Causes
3.4. Symptoms
3.5. Pathogenesis
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7 MM Prevalent Population of IPF
4.3. Country Wise-Epidemiology of IPF
4.3.1. United States
4.3.2. Prevalent cases of IPF in the United States
4.3.3. Prevalent Population of IPF by severity
4.3.4. Gender-Specific IPF Prevalence
4.3.5. Age-Specific IPF Prevalence
4.3.6. EU5
4.3.7. Prevalent Population of IPF in EU5
4.3.8. France
4.3.9. Prevalent Population of IPF
4.3.10. Prevalent Population of IPF by severity
4.3.11. Gender-Specific IPF Prevalence
4.3.12. Age-Specific IPF Prevalence
4.3.13. Germany
4.3.14. Prevalent Population of IPF
4.3.15. Prevalent Population of IPF by severity
4.3.16. Gender-Specific IPF Prevalence
4.3.17. Age-Specific IPF Prevalence
4.3.18. Italy
4.3.19. Prevalent Population of IPF
4.3.20. Prevalent Population of IPF by severity
4.3.21. Gender-Specific IPF Prevalence
4.3.22. Age-Specific IPF Prevalence
4.3.23. Spain
4.3.24. Prevalent Population of IPF
4.3.25. Prevalent Population of IPF by severity
4.3.26. Gender-Specific IPF Prevalence
4.3.27. Age-Specific IPF Prevalence
4.3.28. United Kingdom
4.3.29. Prevalent Population of IPF
4.3.30. Prevalent Population of IPF by severity
4.3.31. Gender-Specific IPF Prevalence
4.3.32. Age-Specific IPF Prevalence
4.3.33. Japan
4.3.34. Prevalent Population of IPF
4.3.35. Prevalent Population of IPF by severity
4.3.36. Gender-SPECIFIC IPF Prevalence
4.3.37. Age-Specific IPF Prevalence
5. Current Treatment Practices
5.1. ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of IPF (An Update of 2011 Clinical Practice Guideline)
6. Unmet needs
7. Marketed Products
7.1. Esbriet (Pirfenidone): InterMune Inc.
7.1.1. Product Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Safety and Efficacy of Esbriet
7.1.5. Side effects of Esbriet
7.1.6. Product Profile
7.2. Ofev (Nintedanib): Boehringer Ingelheim Pharma GmbH & Co. KG
7.2.1. Product Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Safety and Efficacy of Ofev
7.2.5. Side effects of Ofev
7.2.6. Product Profile
8. Emerging Therapies
9. Key Cross Competition
10. Phase III Drugs
10.1. Thrombomodulin Alfa: Asahi Kasei Pharma Corporation
10.1.1. Drug Description
10.1.2. Product Profile
10.1.3. Clinical Development
10.1.4. Clinical Trials Information
10.1.5. Safety and Efficacy
11. Phase II Drugs
11.1. CC-90001: Celgene Corporation
11.1.1. Drug Description
11.1.2. Product Profile
11.1.3. Clinical Development
11.1.4. Clinical Trials Information
11.1.5. Safety and Efficacy
11.1.6. Drug Description
11.1.7. Product Profile
11.1.8. Other Development Activities
11.1.9. Clinical Development
11.1.10. Clinical Trials Information
11.1.11. Safety and Efficacy
11.2. Gefapixant: Merck & Co., Inc.
11.2.1. Drug Description
11.2.2. Product Profile
11.2.3. Other Development Activities
11.2.4. Clinical Development
11.2.5. Clinical Trials Information
11.2.6. Safety and Efficacy
11.3. GLPG1690: Galapagos NV
11.3.1. Drug Description
11.3.2. Product Profile
11.3.3. Regulatory Milestones
11.3.4. Other Development Activities
11.3.5. Clinical Development
11.3.6. Clinical Trials Information
11.3.7. Safety and Efficacy
11.4. LT-1001: LTT Bio-Pharma
11.4.1. Drug Description
11.4.2. Product Profile
11.4.3. Other Development Activities
11.4.4. Clinical Development
11.4.5. Clinical Trials Information
11.4.6. Safety and Efficacy
11.5. BG00011: Biogen Inc.
11.5.1. Drug Description
11.5.2. Product Profile
11.5.3. Regulatory Milestones
11.5.4. Other Development Activities
11.5.5. Clinical Development
11.5.6. Clinical Trials Information
11.5.7. Safety and Efficacy
11.6. BMS-986020: Bristol-Myers Squibb
11.6.1. Drug Description
11.6.2. Product Profile
11.6.3. Regulatory Milestones
11.6.4. Other Development Activities
11.6.5. Clinical Development
11.6.6. Clinical Trials Information
11.6.7. Safety and Efficacy
11.7. LT-1002: Chong Kun Dang Pharmaceutical
11.7.1. Drug Description
11.7.2. Product Profile
11.7.3. Other Development Activities
11.8. Pamrevlumab: FibroGen
11.8.1. Drug Description
11.8.2. Product Profile
11.8.3. Regulatory Milestones
11.8.4. Other Development Activities
11.8.5. Clinical Development
11.8.6. Clinical Trials Information
11.8.7. Safety and Efficacy
11.9. PBI4050: ProMetic Life Sciences
11.9.1. Drug Description
11.9.2. Product Profile
11.9.3. Regulatory Milestones
11.9.4. Other Development Activities
11.9.5. Clinical Development
11.9.6. Clinical Trials Information
11.9.7. Safety and Efficacy
11.10. PRM 151: Promedior, Inc.
11.10.1. Drug Description
11.10.2. Product Profile
11.10.3. Regulatory Milestones
11.10.4. Other Development Activities
11.10.5. Clinical Development
11.10.6. Clinical Trials Information
11.10.7. Safety and Efficacy
11.11. Tipelukast: MediciNova
11.11.1. Drug Description
11.11.2. Product Profile
11.11.3. Regulatory Milestones
11.11.4. Other Development Activities
11.11.5. Clinical Development
11.11.6. Clinical Trials Information
11.11.7. Safety and Efficacy
11.12. TD139: Bristol-Myers Squibb
11.12.1. Drug Description
11.12.2. Product Profile
11.12.3. Other Development Activities
11.12.4. Clinical Development
11.12.5. Clinical Trials Information
11.12.6. Safety and Efficacy
11.13. VAY736: Novartis
11.13.1. Drug Description
11.13.2. Product Profile
11.13.3. Other Development Activities
11.13.4. Clinical Development
11.13.5. Clinical Trials Information
11.14. TAS-115: Taiho Pharmaceutical
11.14.1. Drug Description
11.14.2. Product Profile
11.14.3. Clinical Development
11.14.4. Clinical Trials Information
12. IPF: Market Analysis
12.1. Key Findings
12.2. Total Market Size of IPF in 7 MM
12.3. Therapy Based Market Size of IPF in 7 MM
13. Market Size of IPF by Country
13.1. United States Market Analysis
13.1.1. Market Size of IPF in the US
13.1.2. Therapy Based Market Size of IPF in the US
13.2. EU5 Market Outlook
13.3. Germany
13.3.1. Market Size of IPF in Germany
13.3.2. Therapy Based Market Size of IPF in Germany
13.4. France
13.4.1. Market Size of IPF in France
13.4.2. Therapy Based Market Size of IPF in France
13.5. Italy
13.5.1. Market Size of IPF in Italy
13.5.2. Therapy Based Market Size of IPF in Italy
13.6. United Kingdom
13.6.1. Market Size of IPF in the UK
13.6.2. Therapy Based Market Size of IPF in the UK
13.7. Spain
13.7.1. Market Size of IPF in Spain
13.7.2. Therapy Based Market Size of IPF in Spain
13.8. Japan: Market Analysis
13.8.1. Market Size of IPF in Japan
13.8.2. Therapy Based Market Size of IPF in Japan
14. Market Drivers of IPF
15. Market Barriers of IPF
16. Appendix
16.1. Report Methodology
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

 

1. Key Insights
2. IPF Market Overview at a Glance
2.1. Market Share (%) Distribution of IPF in 2017
2.2. Market Share (%) Distribution of IPF in 2027
3. Disease Background and Overview: Idiopathic Pulmonary Fibrosis (IPF)
3.1. Introduction
3.2. Staging of IPF
3.3. Risk Factors & Disease Causes
3.4. Symptoms
3.5. Pathogenesis
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7 MM Prevalent Population of IPF
4.3. Country Wise-Epidemiology of IPF
4.3.1. United States
4.3.2. Prevalent cases of IPF in the United States
4.3.3. Prevalent Population of IPF by severity
4.3.4. Gender-Specific IPF Prevalence
4.3.5. Age-Specific IPF Prevalence
4.3.6. EU5
4.3.7. Prevalent Population of IPF in EU5
4.3.8. France
4.3.9. Prevalent Population of IPF
4.3.10. Prevalent Population of IPF by severity
4.3.11. Gender-Specific IPF Prevalence
4.3.12. Age-Specific IPF Prevalence
4.3.13. Germany
4.3.14. Prevalent Population of IPF
4.3.15. Prevalent Population of IPF by severity
4.3.16. Gender-Specific IPF Prevalence
4.3.17. Age-Specific IPF Prevalence
4.3.18. Italy
4.3.19. Prevalent Population of IPF
4.3.20. Prevalent Population of IPF by severity
4.3.21. Gender-Specific IPF Prevalence
4.3.22. Age-Specific IPF Prevalence
4.3.23. Spain
4.3.24. Prevalent Population of IPF
4.3.25. Prevalent Population of IPF by severity
4.3.26. Gender-Specific IPF Prevalence
4.3.27. Age-Specific IPF Prevalence
4.3.28. United Kingdom
4.3.29. Prevalent Population of IPF
4.3.30. Prevalent Population of IPF by severity
4.3.31. Gender-Specific IPF Prevalence
4.3.32. Age-Specific IPF Prevalence
4.3.33. Japan
4.3.34. Prevalent Population of IPF
4.3.35. Prevalent Population of IPF by severity
4.3.36. Gender-SPECIFIC IPF Prevalence
4.3.37. Age-Specific IPF Prevalence
5. Current Treatment Practices
5.1. ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of IPF (An Update of 2011 Clinical Practice Guideline)
6. Unmet needs
7. Marketed Products
7.1. Esbriet (Pirfenidone): InterMune Inc.
7.1.1. Product Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Safety and Efficacy of Esbriet
7.1.5. Side effects of Esbriet
7.1.6. Product Profile
7.2. Ofev (Nintedanib): Boehringer Ingelheim Pharma GmbH & Co. KG
7.2.1. Product Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Safety and Efficacy of Ofev
7.2.5. Side effects of Ofev
7.2.6. Product Profile
8. Emerging Therapies
9. Key Cross Competition
10. Phase III Drugs
10.1. Thrombomodulin Alfa: Asahi Kasei Pharma Corporation
10.1.1. Drug Description
10.1.2. Product Profile
10.1.3. Clinical Development
10.1.4. Clinical Trials Information
10.1.5. Safety and Efficacy
11. Phase II Drugs
11.1. CC-90001: Celgene Corporation
11.1.1. Drug Description
11.1.2. Product Profile
11.1.3. Clinical Development
11.1.4. Clinical Trials Information
11.1.5. Safety and Efficacy
11.1.6. Drug Description
11.1.7. Product Profile
11.1.8. Other Development Activities
11.1.9. Clinical Development
11.1.10. Clinical Trials Information
11.1.11. Safety and Efficacy
11.2. Gefapixant: Merck & Co., Inc.
11.2.1. Drug Description
11.2.2. Product Profile
11.2.3. Other Development Activities
11.2.4. Clinical Development
11.2.5. Clinical Trials Information
11.2.6. Safety and Efficacy
11.3. GLPG1690: Galapagos NV
11.3.1. Drug Description
11.3.2. Product Profile
11.3.3. Regulatory Milestones
11.3.4. Other Development Activities
11.3.5. Clinical Development
11.3.6. Clinical Trials Information
11.3.7. Safety and Efficacy
11.4. LT-1001: LTT Bio-Pharma
11.4.1. Drug Description
11.4.2. Product Profile
11.4.3. Other Development Activities
11.4.4. Clinical Development
11.4.5. Clinical Trials Information
11.4.6. Safety and Efficacy
11.5. BG00011: Biogen Inc.
11.5.1. Drug Description
11.5.2. Product Profile
11.5.3. Regulatory Milestones
11.5.4. Other Development Activities
11.5.5. Clinical Development
11.5.6. Clinical Trials Information
11.5.7. Safety and Efficacy
11.6. BMS-986020: Bristol-Myers Squibb
11.6.1. Drug Description
11.6.2. Product Profile
11.6.3. Regulatory Milestones
11.6.4. Other Development Activities
11.6.5. Clinical Development
11.6.6. Clinical Trials Information
11.6.7. Safety and Efficacy
11.7. LT-1002: Chong Kun Dang Pharmaceutical
11.7.1. Drug Description
11.7.2. Product Profile
11.7.3. Other Development Activities
11.8. Pamrevlumab: FibroGen
11.8.1. Drug Description
11.8.2. Product Profile
11.8.3. Regulatory Milestones
11.8.4. Other Development Activities
11.8.5. Clinical Development
11.8.6. Clinical Trials Information
11.8.7. Safety and Efficacy
11.9. PBI4050: ProMetic Life Sciences
11.9.1. Drug Description
11.9.2. Product Profile
11.9.3. Regulatory Milestones
11.9.4. Other Development Activities
11.9.5. Clinical Development
11.9.6. Clinical Trials Information
11.9.7. Safety and Efficacy
11.10. PRM 151: Promedior, Inc.
11.10.1. Drug Description
11.10.2. Product Profile
11.10.3. Regulatory Milestones
11.10.4. Other Development Activities
11.10.5. Clinical Development
11.10.6. Clinical Trials Information
11.10.7. Safety and Efficacy
11.11. Tipelukast: MediciNova
11.11.1. Drug Description
11.11.2. Product Profile
11.11.3. Regulatory Milestones
11.11.4. Other Development Activities
11.11.5. Clinical Development
11.11.6. Clinical Trials Information
11.11.7. Safety and Efficacy
11.12. TD139: Bristol-Myers Squibb
11.12.1. Drug Description
11.12.2. Product Profile
11.12.3. Other Development Activities
11.12.4. Clinical Development
11.12.5. Clinical Trials Information
11.12.6. Safety and Efficacy
11.13. VAY736: Novartis
11.13.1. Drug Description
11.13.2. Product Profile
11.13.3. Other Development Activities
11.13.4. Clinical Development
11.13.5. Clinical Trials Information
11.14. TAS-115: Taiho Pharmaceutical
11.14.1. Drug Description
11.14.2. Product Profile
11.14.3. Clinical Development
11.14.4. Clinical Trials Information
12. IPF: Market Analysis
12.1. Key Findings
12.2. Total Market Size of IPF in 7 MM
12.3. Therapy Based Market Size of IPF in 7 MM
13. Market Size of IPF by Country
13.1. United States Market Analysis
13.1.1. Market Size of IPF in the US
13.1.2. Therapy Based Market Size of IPF in the US
13.2. EU5 Market Outlook
13.3. Germany
13.3.1. Market Size of IPF in Germany
13.3.2. Therapy Based Market Size of IPF in Germany
13.4. France
13.4.1. Market Size of IPF in France
13.4.2. Therapy Based Market Size of IPF in France
13.5. Italy
13.5.1. Market Size of IPF in Italy
13.5.2. Therapy Based Market Size of IPF in Italy
13.6. United Kingdom
13.6.1. Market Size of IPF in the UK
13.6.2. Therapy Based Market Size of IPF in the UK
13.7. Spain
13.7.1. Market Size of IPF in Spain
13.7.2. Therapy Based Market Size of IPF in Spain
13.8. Japan: Market Analysis
13.8.1. Market Size of IPF in Japan
13.8.2. Therapy Based Market Size of IPF in Japan
14. Market Drivers of IPF
15. Market Barriers of IPF
16. Appendix
16.1. Report Methodology
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

 

1. Key Insights
2. IPF Market Overview at a Glance
2.1. Market Share (%) Distribution of IPF in 2017
2.2. Market Share (%) Distribution of IPF in 2027
3. Disease Background and Overview: Idiopathic Pulmonary Fibrosis (IPF)
3.1. Introduction
3.2. Staging of IPF
3.3. Risk Factors & Disease Causes
3.4. Symptoms
3.5. Pathogenesis
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7 MM Prevalent Population of IPF
4.3. Country Wise-Epidemiology of IPF
4.3.1. United States
4.3.2. Prevalent cases of IPF in the United States
4.3.3. Prevalent Population of IPF by severity
4.3.4. Gender-Specific IPF Prevalence
4.3.5. Age-Specific IPF Prevalence
4.3.6. EU5
4.3.7. Prevalent Population of IPF in EU5
4.3.8. France
4.3.9. Prevalent Population of IPF
4.3.10. Prevalent Population of IPF by severity
4.3.11. Gender-Specific IPF Prevalence
4.3.12. Age-Specific IPF Prevalence
4.3.13. Germany
4.3.14. Prevalent Population of IPF
4.3.15. Prevalent Population of IPF by severity
4.3.16. Gender-Specific IPF Prevalence
4.3.17. Age-Specific IPF Prevalence
4.3.18. Italy
4.3.19. Prevalent Population of IPF
4.3.20. Prevalent Population of IPF by severity
4.3.21. Gender-Specific IPF Prevalence
4.3.22. Age-Specific IPF Prevalence
4.3.23. Spain
4.3.24. Prevalent Population of IPF
4.3.25. Prevalent Population of IPF by severity
4.3.26. Gender-Specific IPF Prevalence
4.3.27. Age-Specific IPF Prevalence
4.3.28. United Kingdom
4.3.29. Prevalent Population of IPF
4.3.30. Prevalent Population of IPF by severity
4.3.31. Gender-Specific IPF Prevalence
4.3.32. Age-Specific IPF Prevalence
4.3.33. Japan
4.3.34. Prevalent Population of IPF
4.3.35. Prevalent Population of IPF by severity
4.3.36. Gender-SPECIFIC IPF Prevalence
4.3.37. Age-Specific IPF Prevalence
5. Current Treatment Practices
5.1. ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of IPF (An Update of 2011 Clinical Practice Guideline)
6. Unmet needs
7. Marketed Products
7.1. Esbriet (Pirfenidone): InterMune Inc.
7.1.1. Product Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Safety and Efficacy of Esbriet
7.1.5. Side effects of Esbriet
7.1.6. Product Profile
7.2. Ofev (Nintedanib): Boehringer Ingelheim Pharma GmbH & Co. KG
7.2.1. Product Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Safety and Efficacy of Ofev
7.2.5. Side effects of Ofev
7.2.6. Product Profile
8. Emerging Therapies
9. Key Cross Competition
10. Phase III Drugs
10.1. Thrombomodulin Alfa: Asahi Kasei Pharma Corporation
10.1.1. Drug Description
10.1.2. Product Profile
10.1.3. Clinical Development
10.1.4. Clinical Trials Information
10.1.5. Safety and Efficacy
11. Phase II Drugs
11.1. CC-90001: Celgene Corporation
11.1.1. Drug Description
11.1.2. Product Profile
11.1.3. Clinical Development
11.1.4. Clinical Trials Information
11.1.5. Safety and Efficacy
11.1.6. Drug Description
11.1.7. Product Profile
11.1.8. Other Development Activities
11.1.9. Clinical Development
11.1.10. Clinical Trials Information
11.1.11. Safety and Efficacy
11.2. Gefapixant: Merck & Co., Inc.
11.2.1. Drug Description
11.2.2. Product Profile
11.2.3. Other Development Activities
11.2.4. Clinical Development
11.2.5. Clinical Trials Information
11.2.6. Safety and Efficacy
11.3. GLPG1690: Galapagos NV
11.3.1. Drug Description
11.3.2. Product Profile
11.3.3. Regulatory Milestones
11.3.4. Other Development Activities
11.3.5. Clinical Development
11.3.6. Clinical Trials Information
11.3.7. Safety and Efficacy
11.4. LT-1001: LTT Bio-Pharma
11.4.1. Drug Description
11.4.2. Product Profile
11.4.3. Other Development Activities
11.4.4. Clinical Development
11.4.5. Clinical Trials Information
11.4.6. Safety and Efficacy
11.5. BG00011: Biogen Inc.
11.5.1. Drug Description
11.5.2. Product Profile
11.5.3. Regulatory Milestones
11.5.4. Other Development Activities
11.5.5. Clinical Development
11.5.6. Clinical Trials Information
11.5.7. Safety and Efficacy
11.6. BMS-986020: Bristol-Myers Squibb
11.6.1. Drug Description
11.6.2. Product Profile
11.6.3. Regulatory Milestones
11.6.4. Other Development Activities
11.6.5. Clinical Development
11.6.6. Clinical Trials Information
11.6.7. Safety and Efficacy
11.7. LT-1002: Chong Kun Dang Pharmaceutical
11.7.1. Drug Description
11.7.2. Product Profile
11.7.3. Other Development Activities
11.8. Pamrevlumab: FibroGen
11.8.1. Drug Description
11.8.2. Product Profile
11.8.3. Regulatory Milestones
11.8.4. Other Development Activities
11.8.5. Clinical Development
11.8.6. Clinical Trials Information
11.8.7. Safety and Efficacy
11.9. PBI4050: ProMetic Life Sciences
11.9.1. Drug Description
11.9.2. Product Profile
11.9.3. Regulatory Milestones
11.9.4. Other Development Activities
11.9.5. Clinical Development
11.9.6. Clinical Trials Information
11.9.7. Safety and Efficacy
11.10. PRM 151: Promedior, Inc.
11.10.1. Drug Description
11.10.2. Product Profile
11.10.3. Regulatory Milestones
11.10.4. Other Development Activities
11.10.5. Clinical Development
11.10.6. Clinical Trials Information
11.10.7. Safety and Efficacy
11.11. Tipelukast: MediciNova
11.11.1. Drug Description
11.11.2. Product Profile
11.11.3. Regulatory Milestones
11.11.4. Other Development Activities
11.11.5. Clinical Development
11.11.6. Clinical Trials Information
11.11.7. Safety and Efficacy
11.12. TD139: Bristol-Myers Squibb
11.12.1. Drug Description
11.12.2. Product Profile
11.12.3. Other Development Activities
11.12.4. Clinical Development
11.12.5. Clinical Trials Information
11.12.6. Safety and Efficacy
11.13. VAY736: Novartis
11.13.1. Drug Description
11.13.2. Product Profile
11.13.3. Other Development Activities
11.13.4. Clinical Development
11.13.5. Clinical Trials Information
11.14. TAS-115: Taiho Pharmaceutical
11.14.1. Drug Description
11.14.2. Product Profile
11.14.3. Clinical Development
11.14.4. Clinical Trials Information
12. IPF: Market Analysis
12.1. Key Findings
12.2. Total Market Size of IPF in 7 MM
12.3. Therapy Based Market Size of IPF in 7 MM
13. Market Size of IPF by Country
13.1. United States Market Analysis
13.1.1. Market Size of IPF in the US
13.1.2. Therapy Based Market Size of IPF in the US
13.2. EU5 Market Outlook
13.3. Germany
13.3.1. Market Size of IPF in Germany
13.3.2. Therapy Based Market Size of IPF in Germany
13.4. France
13.4.1. Market Size of IPF in France
13.4.2. Therapy Based Market Size of IPF in France
13.5. Italy
13.5.1. Market Size of IPF in Italy
13.5.2. Therapy Based Market Size of IPF in Italy
13.6. United Kingdom
13.6.1. Market Size of IPF in the UK
13.6.2. Therapy Based Market Size of IPF in the UK
13.7. Spain
13.7.1. Market Size of IPF in Spain
13.7.2. Therapy Based Market Size of IPF in Spain
13.8. Japan: Market Analysis
13.8.1. Market Size of IPF in Japan
13.8.2. Therapy Based Market Size of IPF in Japan
14. Market Drivers of IPF
15. Market Barriers of IPF
16. Appendix
16.1. Report Methodology
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

 

1. Key Insights
2. IPF Market Overview at a Glance
2.1. Market Share (%) Distribution of IPF in 2017
2.2. Market Share (%) Distribution of IPF in 2027
3. Disease Background and Overview: Idiopathic Pulmonary Fibrosis (IPF)
3.1. Introduction
3.2. Staging of IPF
3.3. Risk Factors & Disease Causes
3.4. Symptoms
3.5. Pathogenesis
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7 MM Prevalent Population of IPF
4.3. Country Wise-Epidemiology of IPF
4.3.1. United States
4.3.2. Prevalent cases of IPF in the United States
4.3.3. Prevalent Population of IPF by severity
4.3.4. Gender-Specific IPF Prevalence
4.3.5. Age-Specific IPF Prevalence
4.3.6. EU5
4.3.7. Prevalent Population of IPF in EU5
4.3.8. France
4.3.9. Prevalent Population of IPF
4.3.10. Prevalent Population of IPF by severity
4.3.11. Gender-Specific IPF Prevalence
4.3.12. Age-Specific IPF Prevalence
4.3.13. Germany
4.3.14. Prevalent Population of IPF
4.3.15. Prevalent Population of IPF by severity
4.3.16. Gender-Specific IPF Prevalence
4.3.17. Age-Specific IPF Prevalence
4.3.18. Italy
4.3.19. Prevalent Population of IPF
4.3.20. Prevalent Population of IPF by severity
4.3.21. Gender-Specific IPF Prevalence
4.3.22. Age-Specific IPF Prevalence
4.3.23. Spain
4.3.24. Prevalent Population of IPF
4.3.25. Prevalent Population of IPF by severity
4.3.26. Gender-Specific IPF Prevalence
4.3.27. Age-Specific IPF Prevalence
4.3.28. United Kingdom
4.3.29. Prevalent Population of IPF
4.3.30. Prevalent Population of IPF by severity
4.3.31. Gender-Specific IPF Prevalence
4.3.32. Age-Specific IPF Prevalence
4.3.33. Japan
4.3.34. Prevalent Population of IPF
4.3.35. Prevalent Population of IPF by severity
4.3.36. Gender-SPECIFIC IPF Prevalence
4.3.37. Age-Specific IPF Prevalence
5. Current Treatment Practices
5.1. ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of IPF (An Update of 2011 Clinical Practice Guideline)
6. Unmet needs
7. Marketed Products
7.1. Esbriet (Pirfenidone): InterMune Inc.
7.1.1. Product Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Safety and Efficacy of Esbriet
7.1.5. Side effects of Esbriet
7.1.6. Product Profile
7.2. Ofev (Nintedanib): Boehringer Ingelheim Pharma GmbH & Co. KG
7.2.1. Product Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Safety and Efficacy of Ofev
7.2.5. Side effects of Ofev
7.2.6. Product Profile
8. Emerging Therapies
9. Key Cross Competition
10. Phase III Drugs
10.1. Thrombomodulin Alfa: Asahi Kasei Pharma Corporation
10.1.1. Drug Description
10.1.2. Product Profile
10.1.3. Clinical Development
10.1.4. Clinical Trials Information
10.1.5. Safety and Efficacy
11. Phase II Drugs
11.1. CC-90001: Celgene Corporation
11.1.1. Drug Description
11.1.2. Product Profile
11.1.3. Clinical Development
11.1.4. Clinical Trials Information
11.1.5. Safety and Efficacy
11.1.6. Drug Description
11.1.7. Product Profile
11.1.8. Other Development Activities
11.1.9. Clinical Development
11.1.10. Clinical Trials Information
11.1.11. Safety and Efficacy
11.2. Gefapixant: Merck & Co., Inc.
11.2.1. Drug Description
11.2.2. Product Profile
11.2.3. Other Development Activities
11.2.4. Clinical Development
11.2.5. Clinical Trials Information
11.2.6. Safety and Efficacy
11.3. GLPG1690: Galapagos NV
11.3.1. Drug Description
11.3.2. Product Profile
11.3.3. Regulatory Milestones
11.3.4. Other Development Activities
11.3.5. Clinical Development
11.3.6. Clinical Trials Information
11.3.7. Safety and Efficacy
11.4. LT-1001: LTT Bio-Pharma
11.4.1. Drug Description
11.4.2. Product Profile
11.4.3. Other Development Activities
11.4.4. Clinical Development
11.4.5. Clinical Trials Information
11.4.6. Safety and Efficacy
11.5. BG00011: Biogen Inc.
11.5.1. Drug Description
11.5.2. Product Profile
11.5.3. Regulatory Milestones
11.5.4. Other Development Activities
11.5.5. Clinical Development
11.5.6. Clinical Trials Information
11.5.7. Safety and Efficacy
11.6. BMS-986020: Bristol-Myers Squibb
11.6.1. Drug Description
11.6.2. Product Profile
11.6.3. Regulatory Milestones
11.6.4. Other Development Activities
11.6.5. Clinical Development
11.6.6. Clinical Trials Information
11.6.7. Safety and Efficacy
11.7. LT-1002: Chong Kun Dang Pharmaceutical
11.7.1. Drug Description
11.7.2. Product Profile
11.7.3. Other Development Activities
11.8. Pamrevlumab: FibroGen
11.8.1. Drug Description
11.8.2. Product Profile
11.8.3. Regulatory Milestones
11.8.4. Other Development Activities
11.8.5. Clinical Development
11.8.6. Clinical Trials Information
11.8.7. Safety and Efficacy
11.9. PBI4050: ProMetic Life Sciences
11.9.1. Drug Description
11.9.2. Product Profile
11.9.3. Regulatory Milestones
11.9.4. Other Development Activities
11.9.5. Clinical Development
11.9.6. Clinical Trials Information
11.9.7. Safety and Efficacy
11.10. PRM 151: Promedior, Inc.
11.10.1. Drug Description
11.10.2. Product Profile
11.10.3. Regulatory Milestones
11.10.4. Other Development Activities
11.10.5. Clinical Development
11.10.6. Clinical Trials Information
11.10.7. Safety and Efficacy
11.11. Tipelukast: MediciNova
11.11.1. Drug Description
11.11.2. Product Profile
11.11.3. Regulatory Milestones
11.11.4. Other Development Activities
11.11.5. Clinical Development
11.11.6. Clinical Trials Information
11.11.7. Safety and Efficacy
11.12. TD139: Bristol-Myers Squibb
11.12.1. Drug Description
11.12.2. Product Profile
11.12.3. Other Development Activities
11.12.4. Clinical Development
11.12.5. Clinical Trials Information
11.12.6. Safety and Efficacy
11.13. VAY736: Novartis
11.13.1. Drug Description
11.13.2. Product Profile
11.13.3. Other Development Activities
11.13.4. Clinical Development
11.13.5. Clinical Trials Information
11.14. TAS-115: Taiho Pharmaceutical
11.14.1. Drug Description
11.14.2. Product Profile
11.14.3. Clinical Development
11.14.4. Clinical Trials Information
12. IPF: Market Analysis
12.1. Key Findings
12.2. Total Market Size of IPF in 7 MM
12.3. Therapy Based Market Size of IPF in 7 MM
13. Market Size of IPF by Country
13.1. United States Market Analysis
13.1.1. Market Size of IPF in the US
13.1.2. Therapy Based Market Size of IPF in the US
13.2. EU5 Market Outlook
13.3. Germany
13.3.1. Market Size of IPF in Germany
13.3.2. Therapy Based Market Size of IPF in Germany
13.4. France
13.4.1. Market Size of IPF in France
13.4.2. Therapy Based Market Size of IPF in France
13.5. Italy
13.5.1. Market Size of IPF in Italy
13.5.2. Therapy Based Market Size of IPF in Italy
13.6. United Kingdom
13.6.1. Market Size of IPF in the UK
13.6.2. Therapy Based Market Size of IPF in the UK
13.7. Spain
13.7.1. Market Size of IPF in Spain
13.7.2. Therapy Based Market Size of IPF in Spain
13.8. Japan: Market Analysis
13.8.1. Market Size of IPF in Japan
13.8.2. Therapy Based Market Size of IPF in Japan
14. Market Drivers of IPF
15. Market Barriers of IPF
16. Appendix
16.1. Report Methodology
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

 

1. Key Insights
2. IPF Market Overview at a Glance
2.1. Market Share (%) Distribution of IPF in 2017
2.2. Market Share (%) Distribution of IPF in 2027
3. Disease Background and Overview: Idiopathic Pulmonary Fibrosis (IPF)
3.1. Introduction
3.2. Staging of IPF
3.3. Risk Factors & Disease Causes
3.4. Symptoms
3.5. Pathogenesis
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7 MM Prevalent Population of IPF
4.3. Country Wise-Epidemiology of IPF
4.3.1. United States
4.3.2. Prevalent cases of IPF in the United States
4.3.3. Prevalent Population of IPF by severity
4.3.4. Gender-Specific IPF Prevalence
4.3.5. Age-Specific IPF Prevalence
4.3.6. EU5
4.3.7. Prevalent Population of IPF in EU5
4.3.8. France
4.3.9. Prevalent Population of IPF
4.3.10. Prevalent Population of IPF by severity
4.3.11. Gender-Specific IPF Prevalence
4.3.12. Age-Specific IPF Prevalence
4.3.13. Germany
4.3.14. Prevalent Population of IPF
4.3.15. Prevalent Population of IPF by severity
4.3.16. Gender-Specific IPF Prevalence
4.3.17. Age-Specific IPF Prevalence
4.3.18. Italy
4.3.19. Prevalent Population of IPF
4.3.20. Prevalent Population of IPF by severity
4.3.21. Gender-Specific IPF Prevalence
4.3.22. Age-Specific IPF Prevalence
4.3.23. Spain
4.3.24. Prevalent Population of IPF
4.3.25. Prevalent Population of IPF by severity
4.3.26. Gender-Specific IPF Prevalence
4.3.27. Age-Specific IPF Prevalence
4.3.28. United Kingdom
4.3.29. Prevalent Population of IPF
4.3.30. Prevalent Population of IPF by severity
4.3.31. Gender-Specific IPF Prevalence
4.3.32. Age-Specific IPF Prevalence
4.3.33. Japan
4.3.34. Prevalent Population of IPF
4.3.35. Prevalent Population of IPF by severity
4.3.36. Gender-SPECIFIC IPF Prevalence
4.3.37. Age-Specific IPF Prevalence
5. Current Treatment Practices
5.1. ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of IPF (An Update of 2011 Clinical Practice Guideline)
6. Unmet needs
7. Marketed Products
7.1. Esbriet (Pirfenidone): InterMune Inc.
7.1.1. Product Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Safety and Efficacy of Esbriet
7.1.5. Side effects of Esbriet
7.1.6. Product Profile
7.2. Ofev (Nintedanib): Boehringer Ingelheim Pharma GmbH & Co. KG
7.2.1. Product Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Safety and Efficacy of Ofev
7.2.5. Side effects of Ofev
7.2.6. Product Profile
8. Emerging Therapies
9. Key Cross Competition
10. Phase III Drugs
10.1. Thrombomodulin Alfa: Asahi Kasei Pharma Corporation
10.1.1. Drug Description
10.1.2. Product Profile
10.1.3. Clinical Development
10.1.4. Clinical Trials Information
10.1.5. Safety and Efficacy
11. Phase II Drugs
11.1. CC-90001: Celgene Corporation
11.1.1. Drug Description
11.1.2. Product Profile
11.1.3. Clinical Development
11.1.4. Clinical Trials Information
11.1.5. Safety and Efficacy
11.1.6. Drug Description
11.1.7. Product Profile
11.1.8. Other Development Activities
11.1.9. Clinical Development
11.1.10. Clinical Trials Information
11.1.11. Safety and Efficacy
11.2. Gefapixant: Merck & Co., Inc.
11.2.1. Drug Description
11.2.2. Product Profile
11.2.3. Other Development Activities
11.2.4. Clinical Development
11.2.5. Clinical Trials Information
11.2.6. Safety and Efficacy
11.3. GLPG1690: Galapagos NV
11.3.1. Drug Description
11.3.2. Product Profile
11.3.3. Regulatory Milestones
11.3.4. Other Development Activities
11.3.5. Clinical Development
11.3.6. Clinical Trials Information
11.3.7. Safety and Efficacy
11.4. LT-1001: LTT Bio-Pharma
11.4.1. Drug Description
11.4.2. Product Profile
11.4.3. Other Development Activities
11.4.4. Clinical Development
11.4.5. Clinical Trials Information
11.4.6. Safety and Efficacy
11.5. BG00011: Biogen Inc.
11.5.1. Drug Description
11.5.2. Product Profile
11.5.3. Regulatory Milestones
11.5.4. Other Development Activities
11.5.5. Clinical Development
11.5.6. Clinical Trials Information
11.5.7. Safety and Efficacy
11.6. BMS-986020: Bristol-Myers Squibb
11.6.1. Drug Description
11.6.2. Product Profile
11.6.3. Regulatory Milestones
11.6.4. Other Development Activities
11.6.5. Clinical Development
11.6.6. Clinical Trials Information
11.6.7. Safety and Efficacy
11.7. LT-1002: Chong Kun Dang Pharmaceutical
11.7.1. Drug Description
11.7.2. Product Profile
11.7.3. Other Development Activities
11.8. Pamrevlumab: FibroGen
11.8.1. Drug Description
11.8.2. Product Profile
11.8.3. Regulatory Milestones
11.8.4. Other Development Activities
11.8.5. Clinical Development
11.8.6. Clinical Trials Information
11.8.7. Safety and Efficacy
11.9. PBI4050: ProMetic Life Sciences
11.9.1. Drug Description
11.9.2. Product Profile
11.9.3. Regulatory Milestones
11.9.4. Other Development Activities
11.9.5. Clinical Development
11.9.6. Clinical Trials Information
11.9.7. Safety and Efficacy
11.10. PRM 151: Promedior, Inc.
11.10.1. Drug Description
11.10.2. Product Profile
11.10.3. Regulatory Milestones
11.10.4. Other Development Activities
11.10.5. Clinical Development
11.10.6. Clinical Trials Information
11.10.7. Safety and Efficacy
11.11. Tipelukast: MediciNova
11.11.1. Drug Description
11.11.2. Product Profile
11.11.3. Regulatory Milestones
11.11.4. Other Development Activities
11.11.5. Clinical Development
11.11.6. Clinical Trials Information
11.11.7. Safety and Efficacy
11.12. TD139: Bristol-Myers Squibb
11.12.1. Drug Description
11.12.2. Product Profile
11.12.3. Other Development Activities
11.12.4. Clinical Development
11.12.5. Clinical Trials Information
11.12.6. Safety and Efficacy
11.13. VAY736: Novartis
11.13.1. Drug Description
11.13.2. Product Profile
11.13.3. Other Development Activities
11.13.4. Clinical Development
11.13.5. Clinical Trials Information
11.14. TAS-115: Taiho Pharmaceutical
11.14.1. Drug Description
11.14.2. Product Profile
11.14.3. Clinical Development
11.14.4. Clinical Trials Information
12. IPF: Market Analysis
12.1. Key Findings
12.2. Total Market Size of IPF in 7 MM
12.3. Therapy Based Market Size of IPF in 7 MM
13. Market Size of IPF by Country
13.1. United States Market Analysis
13.1.1. Market Size of IPF in the US
13.1.2. Therapy Based Market Size of IPF in the US
13.2. EU5 Market Outlook
13.3. Germany
13.3.1. Market Size of IPF in Germany
13.3.2. Therapy Based Market Size of IPF in Germany
13.4. France
13.4.1. Market Size of IPF in France
13.4.2. Therapy Based Market Size of IPF in France
13.5. Italy
13.5.1. Market Size of IPF in Italy
13.5.2. Therapy Based Market Size of IPF in Italy
13.6. United Kingdom
13.6.1. Market Size of IPF in the UK
13.6.2. Therapy Based Market Size of IPF in the UK
13.7. Spain
13.7.1. Market Size of IPF in Spain
13.7.2. Therapy Based Market Size of IPF in Spain
13.8. Japan: Market Analysis
13.8.1. Market Size of IPF in Japan
13.8.2. Therapy Based Market Size of IPF in Japan
14. Market Drivers of IPF
15. Market Barriers of IPF
16. Appendix
16.1. Report Methodology
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

 

1. Key Insights
2. IPF Market Overview at a Glance
2.1. Market Share (%) Distribution of IPF in 2017
2.2. Market Share (%) Distribution of IPF in 2027
3. Disease Background and Overview: Idiopathic Pulmonary Fibrosis (IPF)
3.1. Introduction
3.2. Staging of IPF
3.3. Risk Factors & Disease Causes
3.4. Symptoms
3.5. Pathogenesis
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7 MM Prevalent Population of IPF
4.3. Country Wise-Epidemiology of IPF
4.3.1. United States
4.3.2. Prevalent cases of IPF in the United States
4.3.3. Prevalent Population of IPF by severity
4.3.4. Gender-Specific IPF Prevalence
4.3.5. Age-Specific IPF Prevalence
4.3.6. EU5
4.3.7. Prevalent Population of IPF in EU5
4.3.8. France
4.3.9. Prevalent Population of IPF
4.3.10. Prevalent Population of IPF by severity
4.3.11. Gender-Specific IPF Prevalence
4.3.12. Age-Specific IPF Prevalence
4.3.13. Germany
4.3.14. Prevalent Population of IPF
4.3.15. Prevalent Population of IPF by severity
4.3.16. Gender-Specific IPF Prevalence
4.3.17. Age-Specific IPF Prevalence
4.3.18. Italy
4.3.19. Prevalent Population of IPF
4.3.20. Prevalent Population of IPF by severity
4.3.21. Gender-Specific IPF Prevalence
4.3.22. Age-Specific IPF Prevalence
4.3.23. Spain
4.3.24. Prevalent Population of IPF
4.3.25. Prevalent Population of IPF by severity
4.3.26. Gender-Specific IPF Prevalence
4.3.27. Age-Specific IPF Prevalence
4.3.28. United Kingdom
4.3.29. Prevalent Population of IPF
4.3.30. Prevalent Population of IPF by severity
4.3.31. Gender-Specific IPF Prevalence
4.3.32. Age-Specific IPF Prevalence
4.3.33. Japan
4.3.34. Prevalent Population of IPF
4.3.35. Prevalent Population of IPF by severity
4.3.36. Gender-SPECIFIC IPF Prevalence
4.3.37. Age-Specific IPF Prevalence
5. Current Treatment Practices
5.1. ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of IPF (An Update of 2011 Clinical Practice Guideline)
6. Unmet needs
7. Marketed Products
7.1. Esbriet (Pirfenidone): InterMune Inc.
7.1.1. Product Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Safety and Efficacy of Esbriet
7.1.5. Side effects of Esbriet
7.1.6. Product Profile
7.2. Ofev (Nintedanib): Boehringer Ingelheim Pharma GmbH & Co. KG
7.2.1. Product Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Safety and Efficacy of Ofev
7.2.5. Side effects of Ofev
7.2.6. Product Profile
8. Emerging Therapies
9. Key Cross Competition
10. Phase III Drugs
10.1. Thrombomodulin Alfa: Asahi Kasei Pharma Corporation
10.1.1. Drug Description
10.1.2. Product Profile
10.1.3. Clinical Development
10.1.4. Clinical Trials Information
10.1.5. Safety and Efficacy
11. Phase II Drugs
11.1. CC-90001: Celgene Corporation
11.1.1. Drug Description
11.1.2. Product Profile
11.1.3. Clinical Development
11.1.4. Clinical Trials Information
11.1.5. Safety and Efficacy
11.1.6. Drug Description
11.1.7. Product Profile
11.1.8. Other Development Activities
11.1.9. Clinical Development
11.1.10. Clinical Trials Information
11.1.11. Safety and Efficacy
11.2. Gefapixant: Merck & Co., Inc.
11.2.1. Drug Description
11.2.2. Product Profile
11.2.3. Other Development Activities
11.2.4. Clinical Development
11.2.5. Clinical Trials Information
11.2.6. Safety and Efficacy
11.3. GLPG1690: Galapagos NV
11.3.1. Drug Description
11.3.2. Product Profile
11.3.3. Regulatory Milestones
11.3.4. Other Development Activities
11.3.5. Clinical Development
11.3.6. Clinical Trials Information
11.3.7. Safety and Efficacy
11.4. LT-1001: LTT Bio-Pharma
11.4.1. Drug Description
11.4.2. Product Profile
11.4.3. Other Development Activities
11.4.4. Clinical Development
11.4.5. Clinical Trials Information
11.4.6. Safety and Efficacy
11.5. BG00011: Biogen Inc.
11.5.1. Drug Description
11.5.2. Product Profile
11.5.3. Regulatory Milestones
11.5.4. Other Development Activities
11.5.5. Clinical Development
11.5.6. Clinical Trials Information
11.5.7. Safety and Efficacy
11.6. BMS-986020: Bristol-Myers Squibb
11.6.1. Drug Description
11.6.2. Product Profile
11.6.3. Regulatory Milestones
11.6.4. Other Development Activities
11.6.5. Clinical Development
11.6.6. Clinical Trials Information
11.6.7. Safety and Efficacy
11.7. LT-1002: Chong Kun Dang Pharmaceutical
11.7.1. Drug Description
11.7.2. Product Profile
11.7.3. Other Development Activities
11.8. Pamrevlumab: FibroGen
11.8.1. Drug Description
11.8.2. Product Profile
11.8.3. Regulatory Milestones
11.8.4. Other Development Activities
11.8.5. Clinical Development
11.8.6. Clinical Trials Information
11.8.7. Safety and Efficacy
11.9. PBI4050: ProMetic Life Sciences
11.9.1. Drug Description
11.9.2. Product Profile
11.9.3. Regulatory Milestones
11.9.4. Other Development Activities
11.9.5. Clinical Development
11.9.6. Clinical Trials Information
11.9.7. Safety and Efficacy
11.10. PRM 151: Promedior, Inc.
11.10.1. Drug Description
11.10.2. Product Profile
11.10.3. Regulatory Milestones
11.10.4. Other Development Activities
11.10.5. Clinical Development
11.10.6. Clinical Trials Information
11.10.7. Safety and Efficacy
11.11. Tipelukast: MediciNova
11.11.1. Drug Description
11.11.2. Product Profile
11.11.3. Regulatory Milestones
11.11.4. Other Development Activities
11.11.5. Clinical Development
11.11.6. Clinical Trials Information
11.11.7. Safety and Efficacy
11.12. TD139: Bristol-Myers Squibb
11.12.1. Drug Description
11.12.2. Product Profile
11.12.3. Other Development Activities
11.12.4. Clinical Development
11.12.5. Clinical Trials Information
11.12.6. Safety and Efficacy
11.13. VAY736: Novartis
11.13.1. Drug Description
11.13.2. Product Profile
11.13.3. Other Development Activities
11.13.4. Clinical Development
11.13.5. Clinical Trials Information
11.14. TAS-115: Taiho Pharmaceutical
11.14.1. Drug Description
11.14.2. Product Profile
11.14.3. Clinical Development
11.14.4. Clinical Trials Information
12. IPF: Market Analysis
12.1. Key Findings
12.2. Total Market Size of IPF in 7 MM
12.3. Therapy Based Market Size of IPF in 7 MM
13. Market Size of IPF by Country
13.1. United States Market Analysis
13.1.1. Market Size of IPF in the US
13.1.2. Therapy Based Market Size of IPF in the US
13.2. EU5 Market Outlook
13.3. Germany
13.3.1. Market Size of IPF in Germany
13.3.2. Therapy Based Market Size of IPF in Germany
13.4. France
13.4.1. Market Size of IPF in France
13.4.2. Therapy Based Market Size of IPF in France
13.5. Italy
13.5.1. Market Size of IPF in Italy
13.5.2. Therapy Based Market Size of IPF in Italy
13.6. United Kingdom
13.6.1. Market Size of IPF in the UK
13.6.2. Therapy Based Market Size of IPF in the UK
13.7. Spain
13.7.1. Market Size of IPF in Spain
13.7.2. Therapy Based Market Size of IPF in Spain
13.8. Japan: Market Analysis
13.8.1. Market Size of IPF in Japan
13.8.2. Therapy Based Market Size of IPF in Japan
14. Market Drivers of IPF
15. Market Barriers of IPF
16. Appendix
16.1. Report Methodology
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

 

1. Key Insights
2. IPF Market Overview at a Glance
2.1. Market Share (%) Distribution of IPF in 2017
2.2. Market Share (%) Distribution of IPF in 2027
3. Disease Background and Overview: Idiopathic Pulmonary Fibrosis (IPF)
3.1. Introduction
3.2. Staging of IPF
3.3. Risk Factors & Disease Causes
3.4. Symptoms
3.5. Pathogenesis
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7 MM Prevalent Population of IPF
4.3. Country Wise-Epidemiology of IPF
4.3.1. United States
4.3.2. Prevalent cases of IPF in the United States
4.3.3. Prevalent Population of IPF by severity
4.3.4. Gender-Specific IPF Prevalence
4.3.5. Age-Specific IPF Prevalence
4.3.6. EU5
4.3.7. Prevalent Population of IPF in EU5
4.3.8. France
4.3.9. Prevalent Population of IPF
4.3.10. Prevalent Population of IPF by severity
4.3.11. Gender-Specific IPF Prevalence
4.3.12. Age-Specific IPF Prevalence
4.3.13. Germany
4.3.14. Prevalent Population of IPF
4.3.15. Prevalent Population of IPF by severity
4.3.16. Gender-Specific IPF Prevalence
4.3.17. Age-Specific IPF Prevalence
4.3.18. Italy
4.3.19. Prevalent Population of IPF
4.3.20. Prevalent Population of IPF by severity
4.3.21. Gender-Specific IPF Prevalence
4.3.22. Age-Specific IPF Prevalence
4.3.23. Spain
4.3.24. Prevalent Population of IPF
4.3.25. Prevalent Population of IPF by severity
4.3.26. Gender-Specific IPF Prevalence
4.3.27. Age-Specific IPF Prevalence
4.3.28. United Kingdom
4.3.29. Prevalent Population of IPF
4.3.30. Prevalent Population of IPF by severity
4.3.31. Gender-Specific IPF Prevalence
4.3.32. Age-Specific IPF Prevalence
4.3.33. Japan
4.3.34. Prevalent Population of IPF
4.3.35. Prevalent Population of IPF by severity
4.3.36. Gender-SPECIFIC IPF Prevalence
4.3.37. Age-Specific IPF Prevalence
5. Current Treatment Practices
5.1. ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of IPF (An Update of 2011 Clinical Practice Guideline)
6. Unmet needs
7. Marketed Products
7.1. Esbriet (Pirfenidone): InterMune Inc.
7.1.1. Product Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Safety and Efficacy of Esbriet
7.1.5. Side effects of Esbriet
7.1.6. Product Profile
7.2. Ofev (Nintedanib): Boehringer Ingelheim Pharma GmbH & Co. KG
7.2.1. Product Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Safety and Efficacy of Ofev
7.2.5. Side effects of Ofev
7.2.6. Product Profile
8. Emerging Therapies
9. Key Cross Competition
10. Phase III Drugs
10.1. Thrombomodulin Alfa: Asahi Kasei Pharma Corporation
10.1.1. Drug Description
10.1.2. Product Profile
10.1.3. Clinical Development
10.1.4. Clinical Trials Information
10.1.5. Safety and Efficacy
11. Phase II Drugs
11.1. CC-90001: Celgene Corporation
11.1.1. Drug Description
11.1.2. Product Profile
11.1.3. Clinical Development
11.1.4. Clinical Trials Information
11.1.5. Safety and Efficacy
11.1.6. Drug Description
11.1.7. Product Profile
11.1.8. Other Development Activities
11.1.9. Clinical Development
11.1.10. Clinical Trials Information
11.1.11. Safety and Efficacy
11.2. Gefapixant: Merck & Co., Inc.
11.2.1. Drug Description
11.2.2. Product Profile
11.2.3. Other Development Activities
11.2.4. Clinical Development
11.2.5. Clinical Trials Information
11.2.6. Safety and Efficacy
11.3. GLPG1690: Galapagos NV
11.3.1. Drug Description
11.3.2. Product Profile
11.3.3. Regulatory Milestones
11.3.4. Other Development Activities
11.3.5. Clinical Development
11.3.6. Clinical Trials Information
11.3.7. Safety and Efficacy
11.4. LT-1001: LTT Bio-Pharma
11.4.1. Drug Description
11.4.2. Product Profile
11.4.3. Other Development Activities
11.4.4. Clinical Development
11.4.5. Clinical Trials Information
11.4.6. Safety and Efficacy
11.5. BG00011: Biogen Inc.
11.5.1. Drug Description
11.5.2. Product Profile
11.5.3. Regulatory Milestones
11.5.4. Other Development Activities
11.5.5. Clinical Development
11.5.6. Clinical Trials Information
11.5.7. Safety and Efficacy
11.6. BMS-986020: Bristol-Myers Squibb
11.6.1. Drug Description
11.6.2. Product Profile
11.6.3. Regulatory Milestones
11.6.4. Other Development Activities
11.6.5. Clinical Development
11.6.6. Clinical Trials Information
11.6.7. Safety and Efficacy
11.7. LT-1002: Chong Kun Dang Pharmaceutical
11.7.1. Drug Description
11.7.2. Product Profile
11.7.3. Other Development Activities
11.8. Pamrevlumab: FibroGen
11.8.1. Drug Description
11.8.2. Product Profile
11.8.3. Regulatory Milestones
11.8.4. Other Development Activities
11.8.5. Clinical Development
11.8.6. Clinical Trials Information
11.8.7. Safety and Efficacy
11.9. PBI4050: ProMetic Life Sciences
11.9.1. Drug Description
11.9.2. Product Profile
11.9.3. Regulatory Milestones
11.9.4. Other Development Activities
11.9.5. Clinical Development
11.9.6. Clinical Trials Information
11.9.7. Safety and Efficacy
11.10. PRM 151: Promedior, Inc.
11.10.1. Drug Description
11.10.2. Product Profile
11.10.3. Regulatory Milestones
11.10.4. Other Development Activities
11.10.5. Clinical Development
11.10.6. Clinical Trials Information
11.10.7. Safety and Efficacy
11.11. Tipelukast: MediciNova
11.11.1. Drug Description
11.11.2. Product Profile
11.11.3. Regulatory Milestones
11.11.4. Other Development Activities
11.11.5. Clinical Development
11.11.6. Clinical Trials Information
11.11.7. Safety and Efficacy
11.12. TD139: Bristol-Myers Squibb
11.12.1. Drug Description
11.12.2. Product Profile
11.12.3. Other Development Activities
11.12.4. Clinical Development
11.12.5. Clinical Trials Information
11.12.6. Safety and Efficacy
11.13. VAY736: Novartis
11.13.1. Drug Description
11.13.2. Product Profile
11.13.3. Other Development Activities
11.13.4. Clinical Development
11.13.5. Clinical Trials Information
11.14. TAS-115: Taiho Pharmaceutical
11.14.1. Drug Description
11.14.2. Product Profile
11.14.3. Clinical Development
11.14.4. Clinical Trials Information
12. IPF: Market Analysis
12.1. Key Findings
12.2. Total Market Size of IPF in 7 MM
12.3. Therapy Based Market Size of IPF in 7 MM
13. Market Size of IPF by Country
13.1. United States Market Analysis
13.1.1. Market Size of IPF in the US
13.1.2. Therapy Based Market Size of IPF in the US
13.2. EU5 Market Outlook
13.3. Germany
13.3.1. Market Size of IPF in Germany
13.3.2. Therapy Based Market Size of IPF in Germany
13.4. France
13.4.1. Market Size of IPF in France
13.4.2. Therapy Based Market Size of IPF in France
13.5. Italy
13.5.1. Market Size of IPF in Italy
13.5.2. Therapy Based Market Size of IPF in Italy
13.6. United Kingdom
13.6.1. Market Size of IPF in the UK
13.6.2. Therapy Based Market Size of IPF in the UK
13.7. Spain
13.7.1. Market Size of IPF in Spain
13.7.2. Therapy Based Market Size of IPF in Spain
13.8. Japan: Market Analysis
13.8.1. Market Size of IPF in Japan
13.8.2. Therapy Based Market Size of IPF in Japan
14. Market Drivers of IPF
15. Market Barriers of IPF
16. Appendix
16.1. Report Methodology
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

 

1. Key Insights
2. IPF Market Overview at a Glance
2.1. Market Share (%) Distribution of IPF in 2017
2.2. Market Share (%) Distribution of IPF in 2027
3. Disease Background and Overview: Idiopathic Pulmonary Fibrosis (IPF)
3.1. Introduction
3.2. Staging of IPF
3.3. Risk Factors & Disease Causes
3.4. Symptoms
3.5. Pathogenesis
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7 MM Prevalent Population of IPF
4.3. Country Wise-Epidemiology of IPF
4.3.1. United States
4.3.2. Prevalent cases of IPF in the United States
4.3.3. Prevalent Population of IPF by severity
4.3.4. Gender-Specific IPF Prevalence
4.3.5. Age-Specific IPF Prevalence
4.3.6. EU5
4.3.7. Prevalent Population of IPF in EU5
4.3.8. France
4.3.9. Prevalent Population of IPF
4.3.10. Prevalent Population of IPF by severity
4.3.11. Gender-Specific IPF Prevalence
4.3.12. Age-Specific IPF Prevalence
4.3.13. Germany
4.3.14. Prevalent Population of IPF
4.3.15. Prevalent Population of IPF by severity
4.3.16. Gender-Specific IPF Prevalence
4.3.17. Age-Specific IPF Prevalence
4.3.18. Italy
4.3.19. Prevalent Population of IPF
4.3.20. Prevalent Population of IPF by severity
4.3.21. Gender-Specific IPF Prevalence
4.3.22. Age-Specific IPF Prevalence
4.3.23. Spain
4.3.24. Prevalent Population of IPF
4.3.25. Prevalent Population of IPF by severity
4.3.26. Gender-Specific IPF Prevalence
4.3.27. Age-Specific IPF Prevalence
4.3.28. United Kingdom
4.3.29. Prevalent Population of IPF
4.3.30. Prevalent Population of IPF by severity
4.3.31. Gender-Specific IPF Prevalence
4.3.32. Age-Specific IPF Prevalence
4.3.33. Japan
4.3.34. Prevalent Population of IPF
4.3.35. Prevalent Population of IPF by severity
4.3.36. Gender-SPECIFIC IPF Prevalence
4.3.37. Age-Specific IPF Prevalence
5. Current Treatment Practices
5.1. ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of IPF (An Update of 2011 Clinical Practice Guideline)
6. Unmet needs
7. Marketed Products
7.1. Esbriet (Pirfenidone): InterMune Inc.
7.1.1. Product Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Safety and Efficacy of Esbriet
7.1.5. Side effects of Esbriet
7.1.6. Product Profile
7.2. Ofev (Nintedanib): Boehringer Ingelheim Pharma GmbH & Co. KG
7.2.1. Product Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Safety and Efficacy of Ofev
7.2.5. Side effects of Ofev
7.2.6. Product Profile
8. Emerging Therapies
9. Key Cross Competition
10. Phase III Drugs
10.1. Thrombomodulin Alfa: Asahi Kasei Pharma Corporation
10.1.1. Drug Description
10.1.2. Product Profile
10.1.3. Clinical Development
10.1.4. Clinical Trials Information
10.1.5. Safety and Efficacy
11. Phase II Drugs
11.1. CC-90001: Celgene Corporation
11.1.1. Drug Description
11.1.2. Product Profile
11.1.3. Clinical Development
11.1.4. Clinical Trials Information
11.1.5. Safety and Efficacy
11.1.6. Drug Description
11.1.7. Product Profile
11.1.8. Other Development Activities
11.1.9. Clinical Development
11.1.10. Clinical Trials Information
11.1.11. Safety and Efficacy
11.2. Gefapixant: Merck & Co., Inc.
11.2.1. Drug Description
11.2.2. Product Profile
11.2.3. Other Development Activities
11.2.4. Clinical Development
11.2.5. Clinical Trials Information
11.2.6. Safety and Efficacy
11.3. GLPG1690: Galapagos NV
11.3.1. Drug Description
11.3.2. Product Profile
11.3.3. Regulatory Milestones
11.3.4. Other Development Activities
11.3.5. Clinical Development
11.3.6. Clinical Trials Information
11.3.7. Safety and Efficacy
11.4. LT-1001: LTT Bio-Pharma
11.4.1. Drug Description
11.4.2. Product Profile
11.4.3. Other Development Activities
11.4.4. Clinical Development
11.4.5. Clinical Trials Information
11.4.6. Safety and Efficacy
11.5. BG00011: Biogen Inc.
11.5.1. Drug Description
11.5.2. Product Profile
11.5.3. Regulatory Milestones
11.5.4. Other Development Activities
11.5.5. Clinical Development
11.5.6. Clinical Trials Information
11.5.7. Safety and Efficacy
11.6. BMS-986020: Bristol-Myers Squibb
11.6.1. Drug Description
11.6.2. Product Profile
11.6.3. Regulatory Milestones
11.6.4. Other Development Activities
11.6.5. Clinical Development
11.6.6. Clinical Trials Information
11.6.7. Safety and Efficacy
11.7. LT-1002: Chong Kun Dang Pharmaceutical
11.7.1. Drug Description
11.7.2. Product Profile
11.7.3. Other Development Activities
11.8. Pamrevlumab: FibroGen
11.8.1. Drug Description
11.8.2. Product Profile
11.8.3. Regulatory Milestones
11.8.4. Other Development Activities
11.8.5. Clinical Development
11.8.6. Clinical Trials Information
11.8.7. Safety and Efficacy
11.9. PBI4050: ProMetic Life Sciences
11.9.1. Drug Description
11.9.2. Product Profile
11.9.3. Regulatory Milestones
11.9.4. Other Development Activities
11.9.5. Clinical Development
11.9.6. Clinical Trials Information
11.9.7. Safety and Efficacy
11.10. PRM 151: Promedior, Inc.
11.10.1. Drug Description
11.10.2. Product Profile
11.10.3. Regulatory Milestones
11.10.4. Other Development Activities
11.10.5. Clinical Development
11.10.6. Clinical Trials Information
11.10.7. Safety and Efficacy
11.11. Tipelukast: MediciNova
11.11.1. Drug Description
11.11.2. Product Profile
11.11.3. Regulatory Milestones
11.11.4. Other Development Activities
11.11.5. Clinical Development
11.11.6. Clinical Trials Information
11.11.7. Safety and Efficacy
11.12. TD139: Bristol-Myers Squibb
11.12.1. Drug Description
11.12.2. Product Profile
11.12.3. Other Development Activities
11.12.4. Clinical Development
11.12.5. Clinical Trials Information
11.12.6. Safety and Efficacy
11.13. VAY736: Novartis
11.13.1. Drug Description
11.13.2. Product Profile
11.13.3. Other Development Activities
11.13.4. Clinical Development
11.13.5. Clinical Trials Information
11.14. TAS-115: Taiho Pharmaceutical
11.14.1. Drug Description
11.14.2. Product Profile
11.14.3. Clinical Development
11.14.4. Clinical Trials Information
12. IPF: Market Analysis
12.1. Key Findings
12.2. Total Market Size of IPF in 7 MM
12.3. Therapy Based Market Size of IPF in 7 MM
13. Market Size of IPF by Country
13.1. United States Market Analysis
13.1.1. Market Size of IPF in the US
13.1.2. Therapy Based Market Size of IPF in the US
13.2. EU5 Market Outlook
13.3. Germany
13.3.1. Market Size of IPF in Germany
13.3.2. Therapy Based Market Size of IPF in Germany
13.4. France
13.4.1. Market Size of IPF in France
13.4.2. Therapy Based Market Size of IPF in France
13.5. Italy
13.5.1. Market Size of IPF in Italy
13.5.2. Therapy Based Market Size of IPF in Italy
13.6. United Kingdom
13.6.1. Market Size of IPF in the UK
13.6.2. Therapy Based Market Size of IPF in the UK
13.7. Spain
13.7.1. Market Size of IPF in Spain
13.7.2. Therapy Based Market Size of IPF in Spain
13.8. Japan: Market Analysis
13.8.1. Market Size of IPF in Japan
13.8.2. Therapy Based Market Size of IPF in Japan
14. Market Drivers of IPF
15. Market Barriers of IPF
16. Appendix
16.1. Report Methodology
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

 

1. Key Insights
2. IPF Market Overview at a Glance
2.1. Market Share (%) Distribution of IPF in 2017
2.2. Market Share (%) Distribution of IPF in 2027
3. Disease Background and Overview: Idiopathic Pulmonary Fibrosis (IPF)
3.1. Introduction
3.2. Staging of IPF
3.3. Risk Factors & Disease Causes
3.4. Symptoms
3.5. Pathogenesis
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7 MM Prevalent Population of IPF
4.3. Country Wise-Epidemiology of IPF
4.3.1. United States
4.3.2. Prevalent cases of IPF in the United States
4.3.3. Prevalent Population of IPF by severity
4.3.4. Gender-Specific IPF Prevalence
4.3.5. Age-Specific IPF Prevalence
4.3.6. EU5
4.3.7. Prevalent Population of IPF in EU5
4.3.8. France
4.3.9. Prevalent Population of IPF
4.3.10. Prevalent Population of IPF by severity
4.3.11. Gender-Specific IPF Prevalence
4.3.12. Age-Specific IPF Prevalence
4.3.13. Germany
4.3.14. Prevalent Population of IPF
4.3.15. Prevalent Population of IPF by severity
4.3.16. Gender-Specific IPF Prevalence
4.3.17. Age-Specific IPF Prevalence
4.3.18. Italy
4.3.19. Prevalent Population of IPF
4.3.20. Prevalent Population of IPF by severity
4.3.21. Gender-Specific IPF Prevalence
4.3.22. Age-Specific IPF Prevalence
4.3.23. Spain
4.3.24. Prevalent Population of IPF
4.3.25. Prevalent Population of IPF by severity
4.3.26. Gender-Specific IPF Prevalence
4.3.27. Age-Specific IPF Prevalence
4.3.28. United Kingdom
4.3.29. Prevalent Population of IPF
4.3.30. Prevalent Population of IPF by severity
4.3.31. Gender-Specific IPF Prevalence
4.3.32. Age-Specific IPF Prevalence
4.3.33. Japan
4.3.34. Prevalent Population of IPF
4.3.35. Prevalent Population of IPF by severity
4.3.36. Gender-SPECIFIC IPF Prevalence
4.3.37. Age-Specific IPF Prevalence
5. Current Treatment Practices
5.1. ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of IPF (An Update of 2011 Clinical Practice Guideline)
6. Unmet needs
7. Marketed Products
7.1. Esbriet (Pirfenidone): InterMune Inc.
7.1.1. Product Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Safety and Efficacy of Esbriet
7.1.5. Side effects of Esbriet
7.1.6. Product Profile
7.2. Ofev (Nintedanib): Boehringer Ingelheim Pharma GmbH & Co. KG
7.2.1. Product Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Safety and Efficacy of Ofev
7.2.5. Side effects of Ofev
7.2.6. Product Profile
8. Emerging Therapies
9. Key Cross Competition
10. Phase III Drugs
10.1. Thrombomodulin Alfa: Asahi Kasei Pharma Corporation
10.1.1. Drug Description
10.1.2. Product Profile
10.1.3. Clinical Development
10.1.4. Clinical Trials Information
10.1.5. Safety and Efficacy
11. Phase II Drugs
11.1. CC-90001: Celgene Corporation
11.1.1. Drug Description
11.1.2. Product Profile
11.1.3. Clinical Development
11.1.4. Clinical Trials Information
11.1.5. Safety and Efficacy
11.1.6. Drug Description
11.1.7. Product Profile
11.1.8. Other Development Activities
11.1.9. Clinical Development
11.1.10. Clinical Trials Information
11.1.11. Safety and Efficacy
11.2. Gefapixant: Merck & Co., Inc.
11.2.1. Drug Description
11.2.2. Product Profile
11.2.3. Other Development Activities
11.2.4. Clinical Development
11.2.5. Clinical Trials Information
11.2.6. Safety and Efficacy
11.3. GLPG1690: Galapagos NV
11.3.1. Drug Description
11.3.2. Product Profile
11.3.3. Regulatory Milestones
11.3.4. Other Development Activities
11.3.5. Clinical Development
11.3.6. Clinical Trials Information
11.3.7. Safety and Efficacy
11.4. LT-1001: LTT Bio-Pharma
11.4.1. Drug Description
11.4.2. Product Profile
11.4.3. Other Development Activities
11.4.4. Clinical Development
11.4.5. Clinical Trials Information
11.4.6. Safety and Efficacy
11.5. BG00011: Biogen Inc.
11.5.1. Drug Description
11.5.2. Product Profile
11.5.3. Regulatory Milestones
11.5.4. Other Development Activities
11.5.5. Clinical Development
11.5.6. Clinical Trials Information
11.5.7. Safety and Efficacy
11.6. BMS-986020: Bristol-Myers Squibb
11.6.1. Drug Description
11.6.2. Product Profile
11.6.3. Regulatory Milestones
11.6.4. Other Development Activities
11.6.5. Clinical Development
11.6.6. Clinical Trials Information
11.6.7. Safety and Efficacy
11.7. LT-1002: Chong Kun Dang Pharmaceutical
11.7.1. Drug Description
11.7.2. Product Profile
11.7.3. Other Development Activities
11.8. Pamrevlumab: FibroGen
11.8.1. Drug Description
11.8.2. Product Profile
11.8.3. Regulatory Milestones
11.8.4. Other Development Activities
11.8.5. Clinical Development
11.8.6. Clinical Trials Information
11.8.7. Safety and Efficacy
11.9. PBI4050: ProMetic Life Sciences
11.9.1. Drug Description
11.9.2. Product Profile
11.9.3. Regulatory Milestones
11.9.4. Other Development Activities
11.9.5. Clinical Development
11.9.6. Clinical Trials Information
11.9.7. Safety and Efficacy
11.10. PRM 151: Promedior, Inc.
11.10.1. Drug Description
11.10.2. Product Profile
11.10.3. Regulatory Milestones
11.10.4. Other Development Activities
11.10.5. Clinical Development
11.10.6. Clinical Trials Information
11.10.7. Safety and Efficacy
11.11. Tipelukast: MediciNova
11.11.1. Drug Description
11.11.2. Product Profile
11.11.3. Regulatory Milestones
11.11.4. Other Development Activities
11.11.5. Clinical Development
11.11.6. Clinical Trials Information
11.11.7. Safety and Efficacy
11.12. TD139: Bristol-Myers Squibb
11.12.1. Drug Description
11.12.2. Product Profile
11.12.3. Other Development Activities
11.12.4. Clinical Development
11.12.5. Clinical Trials Information
11.12.6. Safety and Efficacy
11.13. VAY736: Novartis
11.13.1. Drug Description
11.13.2. Product Profile
11.13.3. Other Development Activities
11.13.4. Clinical Development
11.13.5. Clinical Trials Information
11.14. TAS-115: Taiho Pharmaceutical
11.14.1. Drug Description
11.14.2. Product Profile
11.14.3. Clinical Development
11.14.4. Clinical Trials Information
12. IPF: Market Analysis
12.1. Key Findings
12.2. Total Market Size of IPF in 7 MM
12.3. Therapy Based Market Size of IPF in 7 MM
13. Market Size of IPF by Country
13.1. United States Market Analysis
13.1.1. Market Size of IPF in the US
13.1.2. Therapy Based Market Size of IPF in the US
13.2. EU5 Market Outlook
13.3. Germany
13.3.1. Market Size of IPF in Germany
13.3.2. Therapy Based Market Size of IPF in Germany
13.4. France
13.4.1. Market Size of IPF in France
13.4.2. Therapy Based Market Size of IPF in France
13.5. Italy
13.5.1. Market Size of IPF in Italy
13.5.2. Therapy Based Market Size of IPF in Italy
13.6. United Kingdom
13.6.1. Market Size of IPF in the UK
13.6.2. Therapy Based Market Size of IPF in the UK
13.7. Spain
13.7.1. Market Size of IPF in Spain
13.7.2. Therapy Based Market Size of IPF in Spain
13.8. Japan: Market Analysis
13.8.1. Market Size of IPF in Japan
13.8.2. Therapy Based Market Size of IPF in Japan
14. Market Drivers of IPF
15. Market Barriers of IPF
16. Appendix
16.1. Report Methodology
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

 

1. Key Insights
2. IPF Market Overview at a Glance
2.1. Market Share (%) Distribution of IPF in 2017
2.2. Market Share (%) Distribution of IPF in 2027
3. Disease Background and Overview: Idiopathic Pulmonary Fibrosis (IPF)
3.1. Introduction
3.2. Staging of IPF
3.3. Risk Factors & Disease Causes
3.4. Symptoms
3.5. Pathogenesis
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7 MM Prevalent Population of IPF
4.3. Country Wise-Epidemiology of IPF
4.3.1. United States
4.3.2. Prevalent cases of IPF in the United States
4.3.3. Prevalent Population of IPF by severity
4.3.4. Gender-Specific IPF Prevalence
4.3.5. Age-Specific IPF Prevalence
4.3.6. EU5
4.3.7. Prevalent Population of IPF in EU5
4.3.8. France
4.3.9. Prevalent Population of IPF
4.3.10. Prevalent Population of IPF by severity
4.3.11. Gender-Specific IPF Prevalence
4.3.12. Age-Specific IPF Prevalence
4.3.13. Germany
4.3.14. Prevalent Population of IPF
4.3.15. Prevalent Population of IPF by severity
4.3.16. Gender-Specific IPF Prevalence
4.3.17. Age-Specific IPF Prevalence
4.3.18. Italy
4.3.19. Prevalent Population of IPF
4.3.20. Prevalent Population of IPF by severity
4.3.21. Gender-Specific IPF Prevalence
4.3.22. Age-Specific IPF Prevalence
4.3.23. Spain
4.3.24. Prevalent Population of IPF
4.3.25. Prevalent Population of IPF by severity
4.3.26. Gender-Specific IPF Prevalence
4.3.27. Age-Specific IPF Prevalence
4.3.28. United Kingdom
4.3.29. Prevalent Population of IPF
4.3.30. Prevalent Population of IPF by severity
4.3.31. Gender-Specific IPF Prevalence
4.3.32. Age-Specific IPF Prevalence
4.3.33. Japan
4.3.34. Prevalent Population of IPF
4.3.35. Prevalent Population of IPF by severity
4.3.36. Gender-SPECIFIC IPF Prevalence
4.3.37. Age-Specific IPF Prevalence
5. Current Treatment Practices
5.1. ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of IPF (An Update of 2011 Clinical Practice Guideline)
6. Unmet needs
7. Marketed Products
7.1. Esbriet (Pirfenidone): InterMune Inc.
7.1.1. Product Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Safety and Efficacy of Esbriet
7.1.5. Side effects of Esbriet
7.1.6. Product Profile
7.2. Ofev (Nintedanib): Boehringer Ingelheim Pharma GmbH & Co. KG
7.2.1. Product Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Safety and Efficacy of Ofev
7.2.5. Side effects of Ofev
7.2.6. Product Profile
8. Emerging Therapies
9. Key Cross Competition
10. Phase III Drugs
10.1. Thrombomodulin Alfa: Asahi Kasei Pharma Corporation
10.1.1. Drug Description
10.1.2. Product Profile
10.1.3. Clinical Development
10.1.4. Clinical Trials Information
10.1.5. Safety and Efficacy
11. Phase II Drugs
11.1. CC-90001: Celgene Corporation
11.1.1. Drug Description
11.1.2. Product Profile
11.1.3. Clinical Development
11.1.4. Clinical Trials Information
11.1.5. Safety and Efficacy
11.1.6. Drug Description
11.1.7. Product Profile
11.1.8. Other Development Activities
11.1.9. Clinical Development
11.1.10. Clinical Trials Information
11.1.11. Safety and Efficacy
11.2. Gefapixant: Merck & Co., Inc.
11.2.1. Drug Description
11.2.2. Product Profile
11.2.3. Other Development Activities
11.2.4. Clinical Development
11.2.5. Clinical Trials Information
11.2.6. Safety and Efficacy
11.3. GLPG1690: Galapagos NV
11.3.1. Drug Description
11.3.2. Product Profile
11.3.3. Regulatory Milestones
11.3.4. Other Development Activities
11.3.5. Clinical Development
11.3.6. Clinical Trials Information
11.3.7. Safety and Efficacy
11.4. LT-1001: LTT Bio-Pharma
11.4.1. Drug Description
11.4.2. Product Profile
11.4.3. Other Development Activities
11.4.4. Clinical Development
11.4.5. Clinical Trials Information
11.4.6. Safety and Efficacy
11.5. BG00011: Biogen Inc.
11.5.1. Drug Description
11.5.2. Product Profile
11.5.3. Regulatory Milestones
11.5.4. Other Development Activities
11.5.5. Clinical Development
11.5.6. Clinical Trials Information
11.5.7. Safety and Efficacy
11.6. BMS-986020: Bristol-Myers Squibb
11.6.1. Drug Description
11.6.2. Product Profile
11.6.3. Regulatory Milestones
11.6.4. Other Development Activities
11.6.5. Clinical Development
11.6.6. Clinical Trials Information
11.6.7. Safety and Efficacy
11.7. LT-1002: Chong Kun Dang Pharmaceutical
11.7.1. Drug Description
11.7.2. Product Profile
11.7.3. Other Development Activities
11.8. Pamrevlumab: FibroGen
11.8.1. Drug Description
11.8.2. Product Profile
11.8.3. Regulatory Milestones
11.8.4. Other Development Activities
11.8.5. Clinical Development
11.8.6. Clinical Trials Information
11.8.7. Safety and Efficacy
11.9. PBI4050: ProMetic Life Sciences
11.9.1. Drug Description
11.9.2. Product Profile
11.9.3. Regulatory Milestones
11.9.4. Other Development Activities
11.9.5. Clinical Development
11.9.6. Clinical Trials Information
11.9.7. Safety and Efficacy
11.10. PRM 151: Promedior, Inc.
11.10.1. Drug Description
11.10.2. Product Profile
11.10.3. Regulatory Milestones
11.10.4. Other Development Activities
11.10.5. Clinical Development
11.10.6. Clinical Trials Information
11.10.7. Safety and Efficacy
11.11. Tipelukast: MediciNova
11.11.1. Drug Description
11.11.2. Product Profile
11.11.3. Regulatory Milestones
11.11.4. Other Development Activities
11.11.5. Clinical Development
11.11.6. Clinical Trials Information
11.11.7. Safety and Efficacy
11.12. TD139: Bristol-Myers Squibb
11.12.1. Drug Description
11.12.2. Product Profile
11.12.3. Other Development Activities
11.12.4. Clinical Development
11.12.5. Clinical Trials Information
11.12.6. Safety and Efficacy
11.13. VAY736: Novartis
11.13.1. Drug Description
11.13.2. Product Profile
11.13.3. Other Development Activities
11.13.4. Clinical Development
11.13.5. Clinical Trials Information
11.14. TAS-115: Taiho Pharmaceutical
11.14.1. Drug Description
11.14.2. Product Profile
11.14.3. Clinical Development
11.14.4. Clinical Trials Information
12. IPF: Market Analysis
12.1. Key Findings
12.2. Total Market Size of IPF in 7 MM
12.3. Therapy Based Market Size of IPF in 7 MM
13. Market Size of IPF by Country
13.1. United States Market Analysis
13.1.1. Market Size of IPF in the US
13.1.2. Therapy Based Market Size of IPF in the US
13.2. EU5 Market Outlook
13.3. Germany
13.3.1. Market Size of IPF in Germany
13.3.2. Therapy Based Market Size of IPF in Germany
13.4. France
13.4.1. Market Size of IPF in France
13.4.2. Therapy Based Market Size of IPF in France
13.5. Italy
13.5.1. Market Size of IPF in Italy
13.5.2. Therapy Based Market Size of IPF in Italy
13.6. United Kingdom
13.6.1. Market Size of IPF in the UK
13.6.2. Therapy Based Market Size of IPF in the UK
13.7. Spain
13.7.1. Market Size of IPF in Spain
13.7.2. Therapy Based Market Size of IPF in Spain
13.8. Japan: Market Analysis
13.8.1. Market Size of IPF in Japan
13.8.2. Therapy Based Market Size of IPF in Japan
14. Market Drivers of IPF
15. Market Barriers of IPF
16. Appendix
16.1. Report Methodology
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

 

1. Key Insights
2. IPF Market Overview at a Glance
2.1. Market Share (%) Distribution of IPF in 2017
2.2. Market Share (%) Distribution of IPF in 2027
3. Disease Background and Overview: Idiopathic Pulmonary Fibrosis (IPF)
3.1. Introduction
3.2. Staging of IPF
3.3. Risk Factors & Disease Causes
3.4. Symptoms
3.5. Pathogenesis
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7 MM Prevalent Population of IPF
4.3. Country Wise-Epidemiology of IPF
4.3.1. United States
4.3.2. Prevalent cases of IPF in the United States
4.3.3. Prevalent Population of IPF by severity
4.3.4. Gender-Specific IPF Prevalence
4.3.5. Age-Specific IPF Prevalence
4.3.6. EU5
4.3.7. Prevalent Population of IPF in EU5
4.3.8. France
4.3.9. Prevalent Population of IPF
4.3.10. Prevalent Population of IPF by severity
4.3.11. Gender-Specific IPF Prevalence
4.3.12. Age-Specific IPF Prevalence
4.3.13. Germany
4.3.14. Prevalent Population of IPF
4.3.15. Prevalent Population of IPF by severity
4.3.16. Gender-Specific IPF Prevalence
4.3.17. Age-Specific IPF Prevalence
4.3.18. Italy
4.3.19. Prevalent Population of IPF
4.3.20. Prevalent Population of IPF by severity
4.3.21. Gender-Specific IPF Prevalence
4.3.22. Age-Specific IPF Prevalence
4.3.23. Spain
4.3.24. Prevalent Population of IPF
4.3.25. Prevalent Population of IPF by severity
4.3.26. Gender-Specific IPF Prevalence
4.3.27. Age-Specific IPF Prevalence
4.3.28. United Kingdom
4.3.29. Prevalent Population of IPF
4.3.30. Prevalent Population of IPF by severity
4.3.31. Gender-Specific IPF Prevalence
4.3.32. Age-Specific IPF Prevalence
4.3.33. Japan
4.3.34. Prevalent Population of IPF
4.3.35. Prevalent Population of IPF by severity
4.3.36. Gender-SPECIFIC IPF Prevalence
4.3.37. Age-Specific IPF Prevalence
5. Current Treatment Practices
5.1. ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of IPF (An Update of 2011 Clinical Practice Guideline)
6. Unmet needs
7. Marketed Products
7.1. Esbriet (Pirfenidone): InterMune Inc.
7.1.1. Product Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Safety and Efficacy of Esbriet
7.1.5. Side effects of Esbriet
7.1.6. Product Profile
7.2. Ofev (Nintedanib): Boehringer Ingelheim Pharma GmbH & Co. KG
7.2.1. Product Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Safety and Efficacy of Ofev
7.2.5. Side effects of Ofev
7.2.6. Product Profile
8. Emerging Therapies
9. Key Cross Competition
10. Phase III Drugs
10.1. Thrombomodulin Alfa: Asahi Kasei Pharma Corporation
10.1.1. Drug Description
10.1.2. Product Profile
10.1.3. Clinical Development
10.1.4. Clinical Trials Information
10.1.5. Safety and Efficacy
11. Phase II Drugs
11.1. CC-90001: Celgene Corporation
11.1.1. Drug Description
11.1.2. Product Profile
11.1.3. Clinical Development
11.1.4. Clinical Trials Information
11.1.5. Safety and Efficacy
11.1.6. Drug Description
11.1.7. Product Profile
11.1.8. Other Development Activities
11.1.9. Clinical Development
11.1.10. Clinical Trials Information
11.1.11. Safety and Efficacy
11.2. Gefapixant: Merck & Co., Inc.
11.2.1. Drug Description
11.2.2. Product Profile
11.2.3. Other Development Activities
11.2.4. Clinical Development
11.2.5. Clinical Trials Information
11.2.6. Safety and Efficacy
11.3. GLPG1690: Galapagos NV
11.3.1. Drug Description
11.3.2. Product Profile
11.3.3. Regulatory Milestones
11.3.4. Other Development Activities
11.3.5. Clinical Development
11.3.6. Clinical Trials Information
11.3.7. Safety and Efficacy
11.4. LT-1001: LTT Bio-Pharma
11.4.1. Drug Description
11.4.2. Product Profile
11.4.3. Other Development Activities
11.4.4. Clinical Development
11.4.5. Clinical Trials Information
11.4.6. Safety and Efficacy
11.5. BG00011: Biogen Inc.
11.5.1. Drug Description
11.5.2. Product Profile
11.5.3. Regulatory Milestones
11.5.4. Other Development Activities
11.5.5. Clinical Development
11.5.6. Clinical Trials Information
11.5.7. Safety and Efficacy
11.6. BMS-986020: Bristol-Myers Squibb
11.6.1. Drug Description
11.6.2. Product Profile
11.6.3. Regulatory Milestones
11.6.4. Other Development Activities
11.6.5. Clinical Development
11.6.6. Clinical Trials Information
11.6.7. Safety and Efficacy
11.7. LT-1002: Chong Kun Dang Pharmaceutical
11.7.1. Drug Description
11.7.2. Product Profile
11.7.3. Other Development Activities
11.8. Pamrevlumab: FibroGen
11.8.1. Drug Description
11.8.2. Product Profile
11.8.3. Regulatory Milestones
11.8.4. Other Development Activities
11.8.5. Clinical Development
11.8.6. Clinical Trials Information
11.8.7. Safety and Efficacy
11.9. PBI4050: ProMetic Life Sciences
11.9.1. Drug Description
11.9.2. Product Profile
11.9.3. Regulatory Milestones
11.9.4. Other Development Activities
11.9.5. Clinical Development
11.9.6. Clinical Trials Information
11.9.7. Safety and Efficacy
11.10. PRM 151: Promedior, Inc.
11.10.1. Drug Description
11.10.2. Product Profile
11.10.3. Regulatory Milestones
11.10.4. Other Development Activities
11.10.5. Clinical Development
11.10.6. Clinical Trials Information
11.10.7. Safety and Efficacy
11.11. Tipelukast: MediciNova
11.11.1. Drug Description
11.11.2. Product Profile
11.11.3. Regulatory Milestones
11.11.4. Other Development Activities
11.11.5. Clinical Development
11.11.6. Clinical Trials Information
11.11.7. Safety and Efficacy
11.12. TD139: Bristol-Myers Squibb
11.12.1. Drug Description
11.12.2. Product Profile
11.12.3. Other Development Activities
11.12.4. Clinical Development
11.12.5. Clinical Trials Information
11.12.6. Safety and Efficacy
11.13. VAY736: Novartis
11.13.1. Drug Description
11.13.2. Product Profile
11.13.3. Other Development Activities
11.13.4. Clinical Development
11.13.5. Clinical Trials Information
11.14. TAS-115: Taiho Pharmaceutical
11.14.1. Drug Description
11.14.2. Product Profile
11.14.3. Clinical Development
11.14.4. Clinical Trials Information
12. IPF: Market Analysis
12.1. Key Findings
12.2. Total Market Size of IPF in 7 MM
12.3. Therapy Based Market Size of IPF in 7 MM
13. Market Size of IPF by Country
13.1. United States Market Analysis
13.1.1. Market Size of IPF in the US
13.1.2. Therapy Based Market Size of IPF in the US
13.2. EU5 Market Outlook
13.3. Germany
13.3.1. Market Size of IPF in Germany
13.3.2. Therapy Based Market Size of IPF in Germany
13.4. France
13.4.1. Market Size of IPF in France
13.4.2. Therapy Based Market Size of IPF in France
13.5. Italy
13.5.1. Market Size of IPF in Italy
13.5.2. Therapy Based Market Size of IPF in Italy
13.6. United Kingdom
13.6.1. Market Size of IPF in the UK
13.6.2. Therapy Based Market Size of IPF in the UK
13.7. Spain
13.7.1. Market Size of IPF in Spain
13.7.2. Therapy Based Market Size of IPF in Spain
13.8. Japan: Market Analysis
13.8.1. Market Size of IPF in Japan
13.8.2. Therapy Based Market Size of IPF in Japan
14. Market Drivers of IPF
15. Market Barriers of IPF
16. Appendix
16.1. Report Methodology
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

 

1. Key Insights
2. IPF Market Overview at a Glance
2.1. Market Share (%) Distribution of IPF in 2017
2.2. Market Share (%) Distribution of IPF in 2027
3. Disease Background and Overview: Idiopathic Pulmonary Fibrosis (IPF)
3.1. Introduction
3.2. Staging of IPF
3.3. Risk Factors & Disease Causes
3.4. Symptoms
3.5. Pathogenesis
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7 MM Prevalent Population of IPF
4.3. Country Wise-Epidemiology of IPF
4.3.1. United States
4.3.2. Prevalent cases of IPF in the United States
4.3.3. Prevalent Population of IPF by severity
4.3.4. Gender-Specific IPF Prevalence
4.3.5. Age-Specific IPF Prevalence
4.3.6. EU5
4.3.7. Prevalent Population of IPF in EU5
4.3.8. France
4.3.9. Prevalent Population of IPF
4.3.10. Prevalent Population of IPF by severity
4.3.11. Gender-Specific IPF Prevalence
4.3.12. Age-Specific IPF Prevalence
4.3.13. Germany
4.3.14. Prevalent Population of IPF
4.3.15. Prevalent Population of IPF by severity
4.3.16. Gender-Specific IPF Prevalence
4.3.17. Age-Specific IPF Prevalence
4.3.18. Italy
4.3.19. Prevalent Population of IPF
4.3.20. Prevalent Population of IPF by severity
4.3.21. Gender-Specific IPF Prevalence
4.3.22. Age-Specific IPF Prevalence
4.3.23. Spain
4.3.24. Prevalent Population of IPF
4.3.25. Prevalent Population of IPF by severity
4.3.26. Gender-Specific IPF Prevalence
4.3.27. Age-Specific IPF Prevalence
4.3.28. United Kingdom
4.3.29. Prevalent Population of IPF
4.3.30. Prevalent Population of IPF by severity
4.3.31. Gender-Specific IPF Prevalence
4.3.32. Age-Specific IPF Prevalence
4.3.33. Japan
4.3.34. Prevalent Population of IPF
4.3.35. Prevalent Population of IPF by severity
4.3.36. Gender-SPECIFIC IPF Prevalence
4.3.37. Age-Specific IPF Prevalence
5. Current Treatment Practices
5.1. ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of IPF (An Update of 2011 Clinical Practice Guideline)
6. Unmet needs
7. Marketed Products
7.1. Esbriet (Pirfenidone): InterMune Inc.
7.1.1. Product Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Safety and Efficacy of Esbriet
7.1.5. Side effects of Esbriet
7.1.6. Product Profile
7.2. Ofev (Nintedanib): Boehringer Ingelheim Pharma GmbH & Co. KG
7.2.1. Product Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Safety and Efficacy of Ofev
7.2.5. Side effects of Ofev
7.2.6. Product Profile
8. Emerging Therapies
9. Key Cross Competition
10. Phase III Drugs
10.1. Thrombomodulin Alfa: Asahi Kasei Pharma Corporation
10.1.1. Drug Description
10.1.2. Product Profile
10.1.3. Clinical Development
10.1.4. Clinical Trials Information
10.1.5. Safety and Efficacy
11. Phase II Drugs
11.1. CC-90001: Celgene Corporation
11.1.1. Drug Description
11.1.2. Product Profile
11.1.3. Clinical Development
11.1.4. Clinical Trials Information
11.1.5. Safety and Efficacy
11.1.6. Drug Description
11.1.7. Product Profile
11.1.8. Other Development Activities
11.1.9. Clinical Development
11.1.10. Clinical Trials Information
11.1.11. Safety and Efficacy
11.2. Gefapixant: Merck & Co., Inc.
11.2.1. Drug Description
11.2.2. Product Profile
11.2.3. Other Development Activities
11.2.4. Clinical Development
11.2.5. Clinical Trials Information
11.2.6. Safety and Efficacy
11.3. GLPG1690: Galapagos NV
11.3.1. Drug Description
11.3.2. Product Profile
11.3.3. Regulatory Milestones
11.3.4. Other Development Activities
11.3.5. Clinical Development
11.3.6. Clinical Trials Information
11.3.7. Safety and Efficacy
11.4. LT-1001: LTT Bio-Pharma
11.4.1. Drug Description
11.4.2. Product Profile
11.4.3. Other Development Activities
11.4.4. Clinical Development
11.4.5. Clinical Trials Information
11.4.6. Safety and Efficacy
11.5. BG00011: Biogen Inc.
11.5.1. Drug Description
11.5.2. Product Profile
11.5.3. Regulatory Milestones
11.5.4. Other Development Activities
11.5.5. Clinical Development
11.5.6. Clinical Trials Information
11.5.7. Safety and Efficacy
11.6. BMS-986020: Bristol-Myers Squibb
11.6.1. Drug Description
11.6.2. Product Profile
11.6.3. Regulatory Milestones
11.6.4. Other Development Activities
11.6.5. Clinical Development
11.6.6. Clinical Trials Information
11.6.7. Safety and Efficacy
11.7. LT-1002: Chong Kun Dang Pharmaceutical
11.7.1. Drug Description
11.7.2. Product Profile
11.7.3. Other Development Activities
11.8. Pamrevlumab: FibroGen
11.8.1. Drug Description
11.8.2. Product Profile
11.8.3. Regulatory Milestones
11.8.4. Other Development Activities
11.8.5. Clinical Development
11.8.6. Clinical Trials Information
11.8.7. Safety and Efficacy
11.9. PBI4050: ProMetic Life Sciences
11.9.1. Drug Description
11.9.2. Product Profile
11.9.3. Regulatory Milestones
11.9.4. Other Development Activities
11.9.5. Clinical Development
11.9.6. Clinical Trials Information
11.9.7. Safety and Efficacy
11.10. PRM 151: Promedior, Inc.
11.10.1. Drug Description
11.10.2. Product Profile
11.10.3. Regulatory Milestones
11.10.4. Other Development Activities
11.10.5. Clinical Development
11.10.6. Clinical Trials Information
11.10.7. Safety and Efficacy
11.11. Tipelukast: MediciNova
11.11.1. Drug Description
11.11.2. Product Profile
11.11.3. Regulatory Milestones
11.11.4. Other Development Activities
11.11.5. Clinical Development
11.11.6. Clinical Trials Information
11.11.7. Safety and Efficacy
11.12. TD139: Bristol-Myers Squibb
11.12.1. Drug Description
11.12.2. Product Profile
11.12.3. Other Development Activities
11.12.4. Clinical Development
11.12.5. Clinical Trials Information
11.12.6. Safety and Efficacy
11.13. VAY736: Novartis
11.13.1. Drug Description
11.13.2. Product Profile
11.13.3. Other Development Activities
11.13.4. Clinical Development
11.13.5. Clinical Trials Information
11.14. TAS-115: Taiho Pharmaceutical
11.14.1. Drug Description
11.14.2. Product Profile
11.14.3. Clinical Development
11.14.4. Clinical Trials Information
12. IPF: Market Analysis
12.1. Key Findings
12.2. Total Market Size of IPF in 7 MM
12.3. Therapy Based Market Size of IPF in 7 MM
13. Market Size of IPF by Country
13.1. United States Market Analysis
13.1.1. Market Size of IPF in the US
13.1.2. Therapy Based Market Size of IPF in the US
13.2. EU5 Market Outlook
13.3. Germany
13.3.1. Market Size of IPF in Germany
13.3.2. Therapy Based Market Size of IPF in Germany
13.4. France
13.4.1. Market Size of IPF in France
13.4.2. Therapy Based Market Size of IPF in France
13.5. Italy
13.5.1. Market Size of IPF in Italy
13.5.2. Therapy Based Market Size of IPF in Italy
13.6. United Kingdom
13.6.1. Market Size of IPF in the UK
13.6.2. Therapy Based Market Size of IPF in the UK
13.7. Spain
13.7.1. Market Size of IPF in Spain
13.7.2. Therapy Based Market Size of IPF in Spain
13.8. Japan: Market Analysis
13.8.1. Market Size of IPF in Japan
13.8.2. Therapy Based Market Size of IPF in Japan
14. Market Drivers of IPF
15. Market Barriers of IPF
16. Appendix
16.1. Report Methodology
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

 

1. Key Insights
2. IPF Market Overview at a Glance
2.1. Market Share (%) Distribution of IPF in 2017
2.2. Market Share (%) Distribution of IPF in 2027
3. Disease Background and Overview: Idiopathic Pulmonary Fibrosis (IPF)
3.1. Introduction
3.2. Staging of IPF
3.3. Risk Factors & Disease Causes
3.4. Symptoms
3.5. Pathogenesis
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7 MM Prevalent Population of IPF
4.3. Country Wise-Epidemiology of IPF
4.3.1. United States
4.3.2. Prevalent cases of IPF in the United States
4.3.3. Prevalent Population of IPF by severity
4.3.4. Gender-Specific IPF Prevalence
4.3.5. Age-Specific IPF Prevalence
4.3.6. EU5
4.3.7. Prevalent Population of IPF in EU5
4.3.8. France
4.3.9. Prevalent Population of IPF
4.3.10. Prevalent Population of IPF by severity
4.3.11. Gender-Specific IPF Prevalence
4.3.12. Age-Specific IPF Prevalence
4.3.13. Germany
4.3.14. Prevalent Population of IPF
4.3.15. Prevalent Population of IPF by severity
4.3.16. Gender-Specific IPF Prevalence
4.3.17. Age-Specific IPF Prevalence
4.3.18. Italy
4.3.19. Prevalent Population of IPF
4.3.20. Prevalent Population of IPF by severity
4.3.21. Gender-Specific IPF Prevalence
4.3.22. Age-Specific IPF Prevalence
4.3.23. Spain
4.3.24. Prevalent Population of IPF
4.3.25. Prevalent Population of IPF by severity
4.3.26. Gender-Specific IPF Prevalence
4.3.27. Age-Specific IPF Prevalence
4.3.28. United Kingdom
4.3.29. Prevalent Population of IPF
4.3.30. Prevalent Population of IPF by severity
4.3.31. Gender-Specific IPF Prevalence
4.3.32. Age-Specific IPF Prevalence
4.3.33. Japan
4.3.34. Prevalent Population of IPF
4.3.35. Prevalent Population of IPF by severity
4.3.36. Gender-SPECIFIC IPF Prevalence
4.3.37. Age-Specific IPF Prevalence
5. Current Treatment Practices
5.1. ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of IPF (An Update of 2011 Clinical Practice Guideline)
6. Unmet needs
7. Marketed Products
7.1. Esbriet (Pirfenidone): InterMune Inc.
7.1.1. Product Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Safety and Efficacy of Esbriet
7.1.5. Side effects of Esbriet
7.1.6. Product Profile
7.2. Ofev (Nintedanib): Boehringer Ingelheim Pharma GmbH & Co. KG
7.2.1. Product Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Safety and Efficacy of Ofev
7.2.5. Side effects of Ofev
7.2.6. Product Profile
8. Emerging Therapies
9. Key Cross Competition
10. Phase III Drugs
10.1. Thrombomodulin Alfa: Asahi Kasei Pharma Corporation
10.1.1. Drug Description
10.1.2. Product Profile
10.1.3. Clinical Development
10.1.4. Clinical Trials Information
10.1.5. Safety and Efficacy
11. Phase II Drugs
11.1. CC-90001: Celgene Corporation
11.1.1. Drug Description
11.1.2. Product Profile
11.1.3. Clinical Development
11.1.4. Clinical Trials Information
11.1.5. Safety and Efficacy
11.1.6. Drug Description
11.1.7. Product Profile
11.1.8. Other Development Activities
11.1.9. Clinical Development
11.1.10. Clinical Trials Information
11.1.11. Safety and Efficacy
11.2. Gefapixant: Merck & Co., Inc.
11.2.1. Drug Description
11.2.2. Product Profile
11.2.3. Other Development Activities
11.2.4. Clinical Development
11.2.5. Clinical Trials Information
11.2.6. Safety and Efficacy
11.3. GLPG1690: Galapagos NV
11.3.1. Drug Description
11.3.2. Product Profile
11.3.3. Regulatory Milestones
11.3.4. Other Development Activities
11.3.5. Clinical Development
11.3.6. Clinical Trials Information
11.3.7. Safety and Efficacy
11.4. LT-1001: LTT Bio-Pharma
11.4.1. Drug Description
11.4.2. Product Profile
11.4.3. Other Development Activities
11.4.4. Clinical Development
11.4.5. Clinical Trials Information
11.4.6. Safety and Efficacy
11.5. BG00011: Biogen Inc.
11.5.1. Drug Description
11.5.2. Product Profile
11.5.3. Regulatory Milestones
11.5.4. Other Development Activities
11.5.5. Clinical Development
11.5.6. Clinical Trials Information
11.5.7. Safety and Efficacy
11.6. BMS-986020: Bristol-Myers Squibb
11.6.1. Drug Description
11.6.2. Product Profile
11.6.3. Regulatory Milestones
11.6.4. Other Development Activities
11.6.5. Clinical Development
11.6.6. Clinical Trials Information
11.6.7. Safety and Efficacy
11.7. LT-1002: Chong Kun Dang Pharmaceutical
11.7.1. Drug Description
11.7.2. Product Profile
11.7.3. Other Development Activities
11.8. Pamrevlumab: FibroGen
11.8.1. Drug Description
11.8.2. Product Profile
11.8.3. Regulatory Milestones
11.8.4. Other Development Activities
11.8.5. Clinical Development
11.8.6. Clinical Trials Information
11.8.7. Safety and Efficacy
11.9. PBI4050: ProMetic Life Sciences
11.9.1. Drug Description
11.9.2. Product Profile
11.9.3. Regulatory Milestones
11.9.4. Other Development Activities
11.9.5. Clinical Development
11.9.6. Clinical Trials Information
11.9.7. Safety and Efficacy
11.10. PRM 151: Promedior, Inc.
11.10.1. Drug Description
11.10.2. Product Profile
11.10.3. Regulatory Milestones
11.10.4. Other Development Activities
11.10.5. Clinical Development
11.10.6. Clinical Trials Information
11.10.7. Safety and Efficacy
11.11. Tipelukast: MediciNova
11.11.1. Drug Description
11.11.2. Product Profile
11.11.3. Regulatory Milestones
11.11.4. Other Development Activities
11.11.5. Clinical Development
11.11.6. Clinical Trials Information
11.11.7. Safety and Efficacy
11.12. TD139: Bristol-Myers Squibb
11.12.1. Drug Description
11.12.2. Product Profile
11.12.3. Other Development Activities
11.12.4. Clinical Development
11.12.5. Clinical Trials Information
11.12.6. Safety and Efficacy
11.13. VAY736: Novartis
11.13.1. Drug Description
11.13.2. Product Profile
11.13.3. Other Development Activities
11.13.4. Clinical Development
11.13.5. Clinical Trials Information
11.14. TAS-115: Taiho Pharmaceutical
11.14.1. Drug Description
11.14.2. Product Profile
11.14.3. Clinical Development
11.14.4. Clinical Trials Information
12. IPF: Market Analysis
12.1. Key Findings
12.2. Total Market Size of IPF in 7 MM
12.3. Therapy Based Market Size of IPF in 7 MM
13. Market Size of IPF by Country
13.1. United States Market Analysis
13.1.1. Market Size of IPF in the US
13.1.2. Therapy Based Market Size of IPF in the US
13.2. EU5 Market Outlook
13.3. Germany
13.3.1. Market Size of IPF in Germany
13.3.2. Therapy Based Market Size of IPF in Germany
13.4. France
13.4.1. Market Size of IPF in France
13.4.2. Therapy Based Market Size of IPF in France
13.5. Italy
13.5.1. Market Size of IPF in Italy
13.5.2. Therapy Based Market Size of IPF in Italy
13.6. United Kingdom
13.6.1. Market Size of IPF in the UK
13.6.2. Therapy Based Market Size of IPF in the UK
13.7. Spain
13.7.1. Market Size of IPF in Spain
13.7.2. Therapy Based Market Size of IPF in Spain
13.8. Japan: Market Analysis
13.8.1. Market Size of IPF in Japan
13.8.2. Therapy Based Market Size of IPF in Japan
14. Market Drivers of IPF
15. Market Barriers of IPF
16. Appendix
16.1. Report Methodology
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

 

1. Key Insights
2. IPF Market Overview at a Glance
2.1. Market Share (%) Distribution of IPF in 2017
2.2. Market Share (%) Distribution of IPF in 2027
3. Disease Background and Overview: Idiopathic Pulmonary Fibrosis (IPF)
3.1. Introduction
3.2. Staging of IPF
3.3. Risk Factors & Disease Causes
3.4. Symptoms
3.5. Pathogenesis
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7 MM Prevalent Population of IPF
4.3. Country Wise-Epidemiology of IPF
4.3.1. United States
4.3.2. Prevalent cases of IPF in the United States
4.3.3. Prevalent Population of IPF by severity
4.3.4. Gender-Specific IPF Prevalence
4.3.5. Age-Specific IPF Prevalence
4.3.6. EU5
4.3.7. Prevalent Population of IPF in EU5
4.3.8. France
4.3.9. Prevalent Population of IPF
4.3.10. Prevalent Population of IPF by severity
4.3.11. Gender-Specific IPF Prevalence
4.3.12. Age-Specific IPF Prevalence
4.3.13. Germany
4.3.14. Prevalent Population of IPF
4.3.15. Prevalent Population of IPF by severity
4.3.16. Gender-Specific IPF Prevalence
4.3.17. Age-Specific IPF Prevalence
4.3.18. Italy
4.3.19. Prevalent Population of IPF
4.3.20. Prevalent Population of IPF by severity
4.3.21. Gender-Specific IPF Prevalence
4.3.22. Age-Specific IPF Prevalence
4.3.23. Spain
4.3.24. Prevalent Population of IPF
4.3.25. Prevalent Population of IPF by severity
4.3.26. Gender-Specific IPF Prevalence
4.3.27. Age-Specific IPF Prevalence
4.3.28. United Kingdom
4.3.29. Prevalent Population of IPF
4.3.30. Prevalent Population of IPF by severity
4.3.31. Gender-Specific IPF Prevalence
4.3.32. Age-Specific IPF Prevalence
4.3.33. Japan
4.3.34. Prevalent Population of IPF
4.3.35. Prevalent Population of IPF by severity
4.3.36. Gender-SPECIFIC IPF Prevalence
4.3.37. Age-Specific IPF Prevalence
5. Current Treatment Practices
5.1. ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of IPF (An Update of 2011 Clinical Practice Guideline)
6. Unmet needs
7. Marketed Products
7.1. Esbriet (Pirfenidone): InterMune Inc.
7.1.1. Product Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Safety and Efficacy of Esbriet
7.1.5. Side effects of Esbriet
7.1.6. Product Profile
7.2. Ofev (Nintedanib): Boehringer Ingelheim Pharma GmbH & Co. KG
7.2.1. Product Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Safety and Efficacy of Ofev
7.2.5. Side effects of Ofev
7.2.6. Product Profile
8. Emerging Therapies
9. Key Cross Competition
10. Phase III Drugs
10.1. Thrombomodulin Alfa: Asahi Kasei Pharma Corporation
10.1.1. Drug Description
10.1.2. Product Profile
10.1.3. Clinical Development
10.1.4. Clinical Trials Information
10.1.5. Safety and Efficacy
11. Phase II Drugs
11.1. CC-90001: Celgene Corporation
11.1.1. Drug Description
11.1.2. Product Profile
11.1.3. Clinical Development
11.1.4. Clinical Trials Information
11.1.5. Safety and Efficacy
11.1.6. Drug Description
11.1.7. Product Profile
11.1.8. Other Development Activities
11.1.9. Clinical Development
11.1.10. Clinical Trials Information
11.1.11. Safety and Efficacy
11.2. Gefapixant: Merck & Co., Inc.
11.2.1. Drug Description
11.2.2. Product Profile
11.2.3. Other Development Activities
11.2.4. Clinical Development
11.2.5. Clinical Trials Information
11.2.6. Safety and Efficacy
11.3. GLPG1690: Galapagos NV
11.3.1. Drug Description
11.3.2. Product Profile
11.3.3. Regulatory Milestones
11.3.4. Other Development Activities
11.3.5. Clinical Development
11.3.6. Clinical Trials Information
11.3.7. Safety and Efficacy
11.4. LT-1001: LTT Bio-Pharma
11.4.1. Drug Description
11.4.2. Product Profile
11.4.3. Other Development Activities
11.4.4. Clinical Development
11.4.5. Clinical Trials Information
11.4.6. Safety and Efficacy
11.5. BG00011: Biogen Inc.
11.5.1. Drug Description
11.5.2. Product Profile
11.5.3. Regulatory Milestones
11.5.4. Other Development Activities
11.5.5. Clinical Development
11.5.6. Clinical Trials Information
11.5.7. Safety and Efficacy
11.6. BMS-986020: Bristol-Myers Squibb
11.6.1. Drug Description
11.6.2. Product Profile
11.6.3. Regulatory Milestones
11.6.4. Other Development Activities
11.6.5. Clinical Development
11.6.6. Clinical Trials Information
11.6.7. Safety and Efficacy
11.7. LT-1002: Chong Kun Dang Pharmaceutical
11.7.1. Drug Description
11.7.2. Product Profile
11.7.3. Other Development Activities
11.8. Pamrevlumab: FibroGen
11.8.1. Drug Description
11.8.2. Product Profile
11.8.3. Regulatory Milestones
11.8.4. Other Development Activities
11.8.5. Clinical Development
11.8.6. Clinical Trials Information
11.8.7. Safety and Efficacy
11.9. PBI4050: ProMetic Life Sciences
11.9.1. Drug Description
11.9.2. Product Profile
11.9.3. Regulatory Milestones
11.9.4. Other Development Activities
11.9.5. Clinical Development
11.9.6. Clinical Trials Information
11.9.7. Safety and Efficacy
11.10. PRM 151: Promedior, Inc.
11.10.1. Drug Description
11.10.2. Product Profile
11.10.3. Regulatory Milestones
11.10.4. Other Development Activities
11.10.5. Clinical Development
11.10.6. Clinical Trials Information
11.10.7. Safety and Efficacy
11.11. Tipelukast: MediciNova
11.11.1. Drug Description
11.11.2. Product Profile
11.11.3. Regulatory Milestones
11.11.4. Other Development Activities
11.11.5. Clinical Development
11.11.6. Clinical Trials Information
11.11.7. Safety and Efficacy
11.12. TD139: Bristol-Myers Squibb
11.12.1. Drug Description
11.12.2. Product Profile
11.12.3. Other Development Activities
11.12.4. Clinical Development
11.12.5. Clinical Trials Information
11.12.6. Safety and Efficacy
11.13. VAY736: Novartis
11.13.1. Drug Description
11.13.2. Product Profile
11.13.3. Other Development Activities
11.13.4. Clinical Development
11.13.5. Clinical Trials Information
11.14. TAS-115: Taiho Pharmaceutical
11.14.1. Drug Description
11.14.2. Product Profile
11.14.3. Clinical Development
11.14.4. Clinical Trials Information
12. IPF: Market Analysis
12.1. Key Findings
12.2. Total Market Size of IPF in 7 MM
12.3. Therapy Based Market Size of IPF in 7 MM
13. Market Size of IPF by Country
13.1. United States Market Analysis
13.1.1. Market Size of IPF in the US
13.1.2. Therapy Based Market Size of IPF in the US
13.2. EU5 Market Outlook
13.3. Germany
13.3.1. Market Size of IPF in Germany
13.3.2. Therapy Based Market Size of IPF in Germany
13.4. France
13.4.1. Market Size of IPF in France
13.4.2. Therapy Based Market Size of IPF in France
13.5. Italy
13.5.1. Market Size of IPF in Italy
13.5.2. Therapy Based Market Size of IPF in Italy
13.6. United Kingdom
13.6.1. Market Size of IPF in the UK
13.6.2. Therapy Based Market Size of IPF in the UK
13.7. Spain
13.7.1. Market Size of IPF in Spain
13.7.2. Therapy Based Market Size of IPF in Spain
13.8. Japan: Market Analysis
13.8.1. Market Size of IPF in Japan
13.8.2. Therapy Based Market Size of IPF in Japan
14. Market Drivers of IPF
15. Market Barriers of IPF
16. Appendix
16.1. Report Methodology
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

 

1. Key Insights
2. IPF Market Overview at a Glance
2.1. Market Share (%) Distribution of IPF in 2017
2.2. Market Share (%) Distribution of IPF in 2027
3. Disease Background and Overview: Idiopathic Pulmonary Fibrosis (IPF)
3.1. Introduction
3.2. Staging of IPF
3.3. Risk Factors & Disease Causes
3.4. Symptoms
3.5. Pathogenesis
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7 MM Prevalent Population of IPF
4.3. Country Wise-Epidemiology of IPF
4.3.1. United States
4.3.2. Prevalent cases of IPF in the United States
4.3.3. Prevalent Population of IPF by severity
4.3.4. Gender-Specific IPF Prevalence
4.3.5. Age-Specific IPF Prevalence
4.3.6. EU5
4.3.7. Prevalent Population of IPF in EU5
4.3.8. France
4.3.9. Prevalent Population of IPF
4.3.10. Prevalent Population of IPF by severity
4.3.11. Gender-Specific IPF Prevalence
4.3.12. Age-Specific IPF Prevalence
4.3.13. Germany
4.3.14. Prevalent Population of IPF
4.3.15. Prevalent Population of IPF by severity
4.3.16. Gender-Specific IPF Prevalence
4.3.17. Age-Specific IPF Prevalence
4.3.18. Italy
4.3.19. Prevalent Population of IPF
4.3.20. Prevalent Population of IPF by severity
4.3.21. Gender-Specific IPF Prevalence
4.3.22. Age-Specific IPF Prevalence
4.3.23. Spain
4.3.24. Prevalent Population of IPF
4.3.25. Prevalent Population of IPF by severity
4.3.26. Gender-Specific IPF Prevalence
4.3.27. Age-Specific IPF Prevalence
4.3.28. United Kingdom
4.3.29. Prevalent Population of IPF
4.3.30. Prevalent Population of IPF by severity
4.3.31. Gender-Specific IPF Prevalence
4.3.32. Age-Specific IPF Prevalence
4.3.33. Japan
4.3.34. Prevalent Population of IPF
4.3.35. Prevalent Population of IPF by severity
4.3.36. Gender-SPECIFIC IPF Prevalence
4.3.37. Age-Specific IPF Prevalence
5. Current Treatment Practices
5.1. ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of IPF (An Update of 2011 Clinical Practice Guideline)
6. Unmet needs
7. Marketed Products
7.1. Esbriet (Pirfenidone): InterMune Inc.
7.1.1. Product Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Safety and Efficacy of Esbriet
7.1.5. Side effects of Esbriet
7.1.6. Product Profile
7.2. Ofev (Nintedanib): Boehringer Ingelheim Pharma GmbH & Co. KG
7.2.1. Product Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Safety and Efficacy of Ofev
7.2.5. Side effects of Ofev
7.2.6. Product Profile
8. Emerging Therapies
9. Key Cross Competition
10. Phase III Drugs
10.1. Thrombomodulin Alfa: Asahi Kasei Pharma Corporation
10.1.1. Drug Description
10.1.2. Product Profile
10.1.3. Clinical Development
10.1.4. Clinical Trials Information
10.1.5. Safety and Efficacy
11. Phase II Drugs
11.1. CC-90001: Celgene Corporation
11.1.1. Drug Description
11.1.2. Product Profile
11.1.3. Clinical Development
11.1.4. Clinical Trials Information
11.1.5. Safety and Efficacy
11.1.6. Drug Description
11.1.7. Product Profile
11.1.8. Other Development Activities
11.1.9. Clinical Development
11.1.10. Clinical Trials Information
11.1.11. Safety and Efficacy
11.2. Gefapixant: Merck & Co., Inc.
11.2.1. Drug Description
11.2.2. Product Profile
11.2.3. Other Development Activities
11.2.4. Clinical Development
11.2.5. Clinical Trials Information
11.2.6. Safety and Efficacy
11.3. GLPG1690: Galapagos NV
11.3.1. Drug Description
11.3.2. Product Profile
11.3.3. Regulatory Milestones
11.3.4. Other Development Activities
11.3.5. Clinical Development
11.3.6. Clinical Trials Information
11.3.7. Safety and Efficacy
11.4. LT-1001: LTT Bio-Pharma
11.4.1. Drug Description
11.4.2. Product Profile
11.4.3. Other Development Activities
11.4.4. Clinical Development
11.4.5. Clinical Trials Information
11.4.6. Safety and Efficacy
11.5. BG00011: Biogen Inc.
11.5.1. Drug Description
11.5.2. Product Profile
11.5.3. Regulatory Milestones
11.5.4. Other Development Activities
11.5.5. Clinical Development
11.5.6. Clinical Trials Information
11.5.7. Safety and Efficacy
11.6. BMS-986020: Bristol-Myers Squibb
11.6.1. Drug Description
11.6.2. Product Profile
11.6.3. Regulatory Milestones
11.6.4. Other Development Activities
11.6.5. Clinical Development
11.6.6. Clinical Trials Information
11.6.7. Safety and Efficacy
11.7. LT-1002: Chong Kun Dang Pharmaceutical
11.7.1. Drug Description
11.7.2. Product Profile
11.7.3. Other Development Activities
11.8. Pamrevlumab: FibroGen
11.8.1. Drug Description
11.8.2. Product Profile
11.8.3. Regulatory Milestones
11.8.4. Other Development Activities
11.8.5. Clinical Development
11.8.6. Clinical Trials Information
11.8.7. Safety and Efficacy
11.9. PBI4050: ProMetic Life Sciences
11.9.1. Drug Description
11.9.2. Product Profile
11.9.3. Regulatory Milestones
11.9.4. Other Development Activities
11.9.5. Clinical Development
11.9.6. Clinical Trials Information
11.9.7. Safety and Efficacy
11.10. PRM 151: Promedior, Inc.
11.10.1. Drug Description
11.10.2. Product Profile
11.10.3. Regulatory Milestones
11.10.4. Other Development Activities
11.10.5. Clinical Development
11.10.6. Clinical Trials Information
11.10.7. Safety and Efficacy
11.11. Tipelukast: MediciNova
11.11.1. Drug Description
11.11.2. Product Profile
11.11.3. Regulatory Milestones
11.11.4. Other Development Activities
11.11.5. Clinical Development
11.11.6. Clinical Trials Information
11.11.7. Safety and Efficacy
11.12. TD139: Bristol-Myers Squibb
11.12.1. Drug Description
11.12.2. Product Profile
11.12.3. Other Development Activities
11.12.4. Clinical Development
11.12.5. Clinical Trials Information
11.12.6. Safety and Efficacy
11.13. VAY736: Novartis
11.13.1. Drug Description
11.13.2. Product Profile
11.13.3. Other Development Activities
11.13.4. Clinical Development
11.13.5. Clinical Trials Information
11.14. TAS-115: Taiho Pharmaceutical
11.14.1. Drug Description
11.14.2. Product Profile
11.14.3. Clinical Development
11.14.4. Clinical Trials Information
12. IPF: Market Analysis
12.1. Key Findings
12.2. Total Market Size of IPF in 7 MM
12.3. Therapy Based Market Size of IPF in 7 MM
13. Market Size of IPF by Country
13.1. United States Market Analysis
13.1.1. Market Size of IPF in the US
13.1.2. Therapy Based Market Size of IPF in the US
13.2. EU5 Market Outlook
13.3. Germany
13.3.1. Market Size of IPF in Germany
13.3.2. Therapy Based Market Size of IPF in Germany
13.4. France
13.4.1. Market Size of IPF in France
13.4.2. Therapy Based Market Size of IPF in France
13.5. Italy
13.5.1. Market Size of IPF in Italy
13.5.2. Therapy Based Market Size of IPF in Italy
13.6. United Kingdom
13.6.1. Market Size of IPF in the UK
13.6.2. Therapy Based Market Size of IPF in the UK
13.7. Spain
13.7.1. Market Size of IPF in Spain
13.7.2. Therapy Based Market Size of IPF in Spain
13.8. Japan: Market Analysis
13.8.1. Market Size of IPF in Japan
13.8.2. Therapy Based Market Size of IPF in Japan
14. Market Drivers of IPF
15. Market Barriers of IPF
16. Appendix
16.1. Report Methodology
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

 

1. Key Insights
2. IPF Market Overview at a Glance
2.1. Market Share (%) Distribution of IPF in 2017
2.2. Market Share (%) Distribution of IPF in 2027
3. Disease Background and Overview: Idiopathic Pulmonary Fibrosis (IPF)
3.1. Introduction
3.2. Staging of IPF
3.3. Risk Factors & Disease Causes
3.4. Symptoms
3.5. Pathogenesis
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7 MM Prevalent Population of IPF
4.3. Country Wise-Epidemiology of IPF
4.3.1. United States
4.3.2. Prevalent cases of IPF in the United States
4.3.3. Prevalent Population of IPF by severity
4.3.4. Gender-Specific IPF Prevalence
4.3.5. Age-Specific IPF Prevalence
4.3.6. EU5
4.3.7. Prevalent Population of IPF in EU5
4.3.8. France
4.3.9. Prevalent Population of IPF
4.3.10. Prevalent Population of IPF by severity
4.3.11. Gender-Specific IPF Prevalence
4.3.12. Age-Specific IPF Prevalence
4.3.13. Germany
4.3.14. Prevalent Population of IPF
4.3.15. Prevalent Population of IPF by severity
4.3.16. Gender-Specific IPF Prevalence
4.3.17. Age-Specific IPF Prevalence
4.3.18. Italy
4.3.19. Prevalent Population of IPF
4.3.20. Prevalent Population of IPF by severity
4.3.21. Gender-Specific IPF Prevalence
4.3.22. Age-Specific IPF Prevalence
4.3.23. Spain
4.3.24. Prevalent Population of IPF
4.3.25. Prevalent Population of IPF by severity
4.3.26. Gender-Specific IPF Prevalence
4.3.27. Age-Specific IPF Prevalence
4.3.28. United Kingdom
4.3.29. Prevalent Population of IPF
4.3.30. Prevalent Population of IPF by severity
4.3.31. Gender-Specific IPF Prevalence
4.3.32. Age-Specific IPF Prevalence
4.3.33. Japan
4.3.34. Prevalent Population of IPF
4.3.35. Prevalent Population of IPF by severity
4.3.36. Gender-SPECIFIC IPF Prevalence
4.3.37. Age-Specific IPF Prevalence
5. Current Treatment Practices
5.1. ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of IPF (An Update of 2011 Clinical Practice Guideline)
6. Unmet needs
7. Marketed Products
7.1. Esbriet (Pirfenidone): InterMune Inc.
7.1.1. Product Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Safety and Efficacy of Esbriet
7.1.5. Side effects of Esbriet
7.1.6. Product Profile
7.2. Ofev (Nintedanib): Boehringer Ingelheim Pharma GmbH & Co. KG
7.2.1. Product Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Safety and Efficacy of Ofev
7.2.5. Side effects of Ofev
7.2.6. Product Profile
8. Emerging Therapies
9. Key Cross Competition
10. Phase III Drugs
10.1. Thrombomodulin Alfa: Asahi Kasei Pharma Corporation
10.1.1. Drug Description
10.1.2. Product Profile
10.1.3. Clinical Development
10.1.4. Clinical Trials Information
10.1.5. Safety and Efficacy
11. Phase II Drugs
11.1. CC-90001: Celgene Corporation
11.1.1. Drug Description
11.1.2. Product Profile
11.1.3. Clinical Development
11.1.4. Clinical Trials Information
11.1.5. Safety and Efficacy
11.1.6. Drug Description
11.1.7. Product Profile
11.1.8. Other Development Activities
11.1.9. Clinical Development
11.1.10. Clinical Trials Information
11.1.11. Safety and Efficacy
11.2. Gefapixant: Merck & Co., Inc.
11.2.1. Drug Description
11.2.2. Product Profile
11.2.3. Other Development Activities
11.2.4. Clinical Development
11.2.5. Clinical Trials Information
11.2.6. Safety and Efficacy
11.3. GLPG1690: Galapagos NV
11.3.1. Drug Description
11.3.2. Product Profile
11.3.3. Regulatory Milestones
11.3.4. Other Development Activities
11.3.5. Clinical Development
11.3.6. Clinical Trials Information
11.3.7. Safety and Efficacy
11.4. LT-1001: LTT Bio-Pharma
11.4.1. Drug Description
11.4.2. Product Profile
11.4.3. Other Development Activities
11.4.4. Clinical Development
11.4.5. Clinical Trials Information
11.4.6. Safety and Efficacy
11.5. BG00011: Biogen Inc.
11.5.1. Drug Description
11.5.2. Product Profile
11.5.3. Regulatory Milestones
11.5.4. Other Development Activities
11.5.5. Clinical Development
11.5.6. Clinical Trials Information
11.5.7. Safety and Efficacy
11.6. BMS-986020: Bristol-Myers Squibb
11.6.1. Drug Description
11.6.2. Product Profile
11.6.3. Regulatory Milestones
11.6.4. Other Development Activities
11.6.5. Clinical Development
11.6.6. Clinical Trials Information
11.6.7. Safety and Efficacy
11.7. LT-1002: Chong Kun Dang Pharmaceutical
11.7.1. Drug Description
11.7.2. Product Profile
11.7.3. Other Development Activities
11.8. Pamrevlumab: FibroGen
11.8.1. Drug Description
11.8.2. Product Profile
11.8.3. Regulatory Milestones
11.8.4. Other Development Activities
11.8.5. Clinical Development
11.8.6. Clinical Trials Information
11.8.7. Safety and Efficacy
11.9. PBI4050: ProMetic Life Sciences
11.9.1. Drug Description
11.9.2. Product Profile
11.9.3. Regulatory Milestones
11.9.4. Other Development Activities
11.9.5. Clinical Development
11.9.6. Clinical Trials Information
11.9.7. Safety and Efficacy
11.10. PRM 151: Promedior, Inc.
11.10.1. Drug Description
11.10.2. Product Profile
11.10.3. Regulatory Milestones
11.10.4. Other Development Activities
11.10.5. Clinical Development
11.10.6. Clinical Trials Information
11.10.7. Safety and Efficacy
11.11. Tipelukast: MediciNova
11.11.1. Drug Description
11.11.2. Product Profile
11.11.3. Regulatory Milestones
11.11.4. Other Development Activities
11.11.5. Clinical Development
11.11.6. Clinical Trials Information
11.11.7. Safety and Efficacy
11.12. TD139: Bristol-Myers Squibb
11.12.1. Drug Description
11.12.2. Product Profile
11.12.3. Other Development Activities
11.12.4. Clinical Development
11.12.5. Clinical Trials Information
11.12.6. Safety and Efficacy
11.13. VAY736: Novartis
11.13.1. Drug Description
11.13.2. Product Profile
11.13.3. Other Development Activities
11.13.4. Clinical Development
11.13.5. Clinical Trials Information
11.14. TAS-115: Taiho Pharmaceutical
11.14.1. Drug Description
11.14.2. Product Profile
11.14.3. Clinical Development
11.14.4. Clinical Trials Information
12. IPF: Market Analysis
12.1. Key Findings
12.2. Total Market Size of IPF in 7 MM
12.3. Therapy Based Market Size of IPF in 7 MM
13. Market Size of IPF by Country
13.1. United States Market Analysis
13.1.1. Market Size of IPF in the US
13.1.2. Therapy Based Market Size of IPF in the US
13.2. EU5 Market Outlook
13.3. Germany
13.3.1. Market Size of IPF in Germany
13.3.2. Therapy Based Market Size of IPF in Germany
13.4. France
13.4.1. Market Size of IPF in France
13.4.2. Therapy Based Market Size of IPF in France
13.5. Italy
13.5.1. Market Size of IPF in Italy
13.5.2. Therapy Based Market Size of IPF in Italy
13.6. United Kingdom
13.6.1. Market Size of IPF in the UK
13.6.2. Therapy Based Market Size of IPF in the UK
13.7. Spain
13.7.1. Market Size of IPF in Spain
13.7.2. Therapy Based Market Size of IPF in Spain
13.8. Japan: Market Analysis
13.8.1. Market Size of IPF in Japan
13.8.2. Therapy Based Market Size of IPF in Japan
14. Market Drivers of IPF
15. Market Barriers of IPF
16. Appendix
16.1. Report Methodology
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

 

1. Key Insights
2. IPF Market Overview at a Glance
2.1. Market Share (%) Distribution of IPF in 2017
2.2. Market Share (%) Distribution of IPF in 2027
3. Disease Background and Overview: Idiopathic Pulmonary Fibrosis (IPF)
3.1. Introduction
3.2. Staging of IPF
3.3. Risk Factors & Disease Causes
3.4. Symptoms
3.5. Pathogenesis
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7 MM Prevalent Population of IPF
4.3. Country Wise-Epidemiology of IPF
4.3.1. United States
4.3.2. Prevalent cases of IPF in the United States
4.3.3. Prevalent Population of IPF by severity
4.3.4. Gender-Specific IPF Prevalence
4.3.5. Age-Specific IPF Prevalence
4.3.6. EU5
4.3.7. Prevalent Population of IPF in EU5
4.3.8. France
4.3.9. Prevalent Population of IPF
4.3.10. Prevalent Population of IPF by severity
4.3.11. Gender-Specific IPF Prevalence
4.3.12. Age-Specific IPF Prevalence
4.3.13. Germany
4.3.14. Prevalent Population of IPF
4.3.15. Prevalent Population of IPF by severity
4.3.16. Gender-Specific IPF Prevalence
4.3.17. Age-Specific IPF Prevalence
4.3.18. Italy
4.3.19. Prevalent Population of IPF
4.3.20. Prevalent Population of IPF by severity
4.3.21. Gender-Specific IPF Prevalence
4.3.22. Age-Specific IPF Prevalence
4.3.23. Spain
4.3.24. Prevalent Population of IPF
4.3.25. Prevalent Population of IPF by severity
4.3.26. Gender-Specific IPF Prevalence
4.3.27. Age-Specific IPF Prevalence
4.3.28. United Kingdom
4.3.29. Prevalent Population of IPF
4.3.30. Prevalent Population of IPF by severity
4.3.31. Gender-Specific IPF Prevalence
4.3.32. Age-Specific IPF Prevalence
4.3.33. Japan
4.3.34. Prevalent Population of IPF
4.3.35. Prevalent Population of IPF by severity
4.3.36. Gender-SPECIFIC IPF Prevalence
4.3.37. Age-Specific IPF Prevalence
5. Current Treatment Practices
5.1. ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of IPF (An Update of 2011 Clinical Practice Guideline)
6. Unmet needs
7. Marketed Products
7.1. Esbriet (Pirfenidone): InterMune Inc.
7.1.1. Product Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Safety and Efficacy of Esbriet
7.1.5. Side effects of Esbriet
7.1.6. Product Profile
7.2. Ofev (Nintedanib): Boehringer Ingelheim Pharma GmbH & Co. KG
7.2.1. Product Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Safety and Efficacy of Ofev
7.2.5. Side effects of Ofev
7.2.6. Product Profile
8. Emerging Therapies
9. Key Cross Competition
10. Phase III Drugs
10.1. Thrombomodulin Alfa: Asahi Kasei Pharma Corporation
10.1.1. Drug Description
10.1.2. Product Profile
10.1.3. Clinical Development
10.1.4. Clinical Trials Information
10.1.5. Safety and Efficacy
11. Phase II Drugs
11.1. CC-90001: Celgene Corporation
11.1.1. Drug Description
11.1.2. Product Profile
11.1.3. Clinical Development
11.1.4. Clinical Trials Information
11.1.5. Safety and Efficacy
11.1.6. Drug Description
11.1.7. Product Profile
11.1.8. Other Development Activities
11.1.9. Clinical Development
11.1.10. Clinical Trials Information
11.1.11. Safety and Efficacy
11.2. Gefapixant: Merck & Co., Inc.
11.2.1. Drug Description
11.2.2. Product Profile
11.2.3. Other Development Activities
11.2.4. Clinical Development
11.2.5. Clinical Trials Information
11.2.6. Safety and Efficacy
11.3. GLPG1690: Galapagos NV
11.3.1. Drug Description
11.3.2. Product Profile
11.3.3. Regulatory Milestones
11.3.4. Other Development Activities
11.3.5. Clinical Development
11.3.6. Clinical Trials Information
11.3.7. Safety and Efficacy
11.4. LT-1001: LTT Bio-Pharma
11.4.1. Drug Description
11.4.2. Product Profile
11.4.3. Other Development Activities
11.4.4. Clinical Development
11.4.5. Clinical Trials Information
11.4.6. Safety and Efficacy
11.5. BG00011: Biogen Inc.
11.5.1. Drug Description
11.5.2. Product Profile
11.5.3. Regulatory Milestones
11.5.4. Other Development Activities
11.5.5. Clinical Development
11.5.6. Clinical Trials Information
11.5.7. Safety and Efficacy
11.6. BMS-986020: Bristol-Myers Squibb
11.6.1. Drug Description
11.6.2. Product Profile
11.6.3. Regulatory Milestones
11.6.4. Other Development Activities
11.6.5. Clinical Development
11.6.6. Clinical Trials Information
11.6.7. Safety and Efficacy
11.7. LT-1002: Chong Kun Dang Pharmaceutical
11.7.1. Drug Description
11.7.2. Product Profile
11.7.3. Other Development Activities
11.8. Pamrevlumab: FibroGen
11.8.1. Drug Description
11.8.2. Product Profile
11.8.3. Regulatory Milestones
11.8.4. Other Development Activities
11.8.5. Clinical Development
11.8.6. Clinical Trials Information
11.8.7. Safety and Efficacy
11.9. PBI4050: ProMetic Life Sciences
11.9.1. Drug Description
11.9.2. Product Profile
11.9.3. Regulatory Milestones
11.9.4. Other Development Activities
11.9.5. Clinical Development
11.9.6. Clinical Trials Information
11.9.7. Safety and Efficacy
11.10. PRM 151: Promedior, Inc.
11.10.1. Drug Description
11.10.2. Product Profile
11.10.3. Regulatory Milestones
11.10.4. Other Development Activities
11.10.5. Clinical Development
11.10.6. Clinical Trials Information
11.10.7. Safety and Efficacy
11.11. Tipelukast: MediciNova
11.11.1. Drug Description
11.11.2. Product Profile
11.11.3. Regulatory Milestones
11.11.4. Other Development Activities
11.11.5. Clinical Development
11.11.6. Clinical Trials Information
11.11.7. Safety and Efficacy
11.12. TD139: Bristol-Myers Squibb
11.12.1. Drug Description
11.12.2. Product Profile
11.12.3. Other Development Activities
11.12.4. Clinical Development
11.12.5. Clinical Trials Information
11.12.6. Safety and Efficacy
11.13. VAY736: Novartis
11.13.1. Drug Description
11.13.2. Product Profile
11.13.3. Other Development Activities
11.13.4. Clinical Development
11.13.5. Clinical Trials Information
11.14. TAS-115: Taiho Pharmaceutical
11.14.1. Drug Description
11.14.2. Product Profile
11.14.3. Clinical Development
11.14.4. Clinical Trials Information
12. IPF: Market Analysis
12.1. Key Findings
12.2. Total Market Size of IPF in 7 MM
12.3. Therapy Based Market Size of IPF in 7 MM
13. Market Size of IPF by Country
13.1. United States Market Analysis
13.1.1. Market Size of IPF in the US
13.1.2. Therapy Based Market Size of IPF in the US
13.2. EU5 Market Outlook
13.3. Germany
13.3.1. Market Size of IPF in Germany
13.3.2. Therapy Based Market Size of IPF in Germany
13.4. France
13.4.1. Market Size of IPF in France
13.4.2. Therapy Based Market Size of IPF in France
13.5. Italy
13.5.1. Market Size of IPF in Italy
13.5.2. Therapy Based Market Size of IPF in Italy
13.6. United Kingdom
13.6.1. Market Size of IPF in the UK
13.6.2. Therapy Based Market Size of IPF in the UK
13.7. Spain
13.7.1. Market Size of IPF in Spain
13.7.2. Therapy Based Market Size of IPF in Spain
13.8. Japan: Market Analysis
13.8.1. Market Size of IPF in Japan
13.8.2. Therapy Based Market Size of IPF in Japan
14. Market Drivers of IPF
15. Market Barriers of IPF
16. Appendix
16.1. Report Methodology
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

 

1. Key Insights
2. IPF Market Overview at a Glance
2.1. Market Share (%) Distribution of IPF in 2017
2.2. Market Share (%) Distribution of IPF in 2027
3. Disease Background and Overview: Idiopathic Pulmonary Fibrosis (IPF)
3.1. Introduction
3.2. Staging of IPF
3.3. Risk Factors & Disease Causes
3.4. Symptoms
3.5. Pathogenesis
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7 MM Prevalent Population of IPF
4.3. Country Wise-Epidemiology of IPF
4.3.1. United States
4.3.2. Prevalent cases of IPF in the United States
4.3.3. Prevalent Population of IPF by severity
4.3.4. Gender-Specific IPF Prevalence
4.3.5. Age-Specific IPF Prevalence
4.3.6. EU5
4.3.7. Prevalent Population of IPF in EU5
4.3.8. France
4.3.9. Prevalent Population of IPF
4.3.10. Prevalent Population of IPF by severity
4.3.11. Gender-Specific IPF Prevalence
4.3.12. Age-Specific IPF Prevalence
4.3.13. Germany
4.3.14. Prevalent Population of IPF
4.3.15. Prevalent Population of IPF by severity
4.3.16. Gender-Specific IPF Prevalence
4.3.17. Age-Specific IPF Prevalence
4.3.18. Italy
4.3.19. Prevalent Population of IPF
4.3.20. Prevalent Population of IPF by severity
4.3.21. Gender-Specific IPF Prevalence
4.3.22. Age-Specific IPF Prevalence
4.3.23. Spain
4.3.24. Prevalent Population of IPF
4.3.25. Prevalent Population of IPF by severity
4.3.26. Gender-Specific IPF Prevalence
4.3.27. Age-Specific IPF Prevalence
4.3.28. United Kingdom
4.3.29. Prevalent Population of IPF
4.3.30. Prevalent Population of IPF by severity
4.3.31. Gender-Specific IPF Prevalence
4.3.32. Age-Specific IPF Prevalence
4.3.33. Japan
4.3.34. Prevalent Population of IPF
4.3.35. Prevalent Population of IPF by severity
4.3.36. Gender-SPECIFIC IPF Prevalence
4.3.37. Age-Specific IPF Prevalence
5. Current Treatment Practices
5.1. ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of IPF (An Update of 2011 Clinical Practice Guideline)
6. Unmet needs
7. Marketed Products
7.1. Esbriet (Pirfenidone): InterMune Inc.
7.1.1. Product Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Safety and Efficacy of Esbriet
7.1.5. Side effects of Esbriet
7.1.6. Product Profile
7.2. Ofev (Nintedanib): Boehringer Ingelheim Pharma GmbH & Co. KG
7.2.1. Product Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Safety and Efficacy of Ofev
7.2.5. Side effects of Ofev
7.2.6. Product Profile
8. Emerging Therapies
9. Key Cross Competition
10. Phase III Drugs
10.1. Thrombomodulin Alfa: Asahi Kasei Pharma Corporation
10.1.1. Drug Description
10.1.2. Product Profile
10.1.3. Clinical Development
10.1.4. Clinical Trials Information
10.1.5. Safety and Efficacy
11. Phase II Drugs
11.1. CC-90001: Celgene Corporation
11.1.1. Drug Description
11.1.2. Product Profile
11.1.3. Clinical Development
11.1.4. Clinical Trials Information
11.1.5. Safety and Efficacy
11.1.6. Drug Description
11.1.7. Product Profile
11.1.8. Other Development Activities
11.1.9. Clinical Development
11.1.10. Clinical Trials Information
11.1.11. Safety and Efficacy
11.2. Gefapixant: Merck & Co., Inc.
11.2.1. Drug Description
11.2.2. Product Profile
11.2.3. Other Development Activities
11.2.4. Clinical Development
11.2.5. Clinical Trials Information
11.2.6. Safety and Efficacy
11.3. GLPG1690: Galapagos NV
11.3.1. Drug Description
11.3.2. Product Profile
11.3.3. Regulatory Milestones
11.3.4. Other Development Activities
11.3.5. Clinical Development
11.3.6. Clinical Trials Information
11.3.7. Safety and Efficacy
11.4. LT-1001: LTT Bio-Pharma
11.4.1. Drug Description
11.4.2. Product Profile
11.4.3. Other Development Activities
11.4.4. Clinical Development
11.4.5. Clinical Trials Information
11.4.6. Safety and Efficacy
11.5. BG00011: Biogen Inc.
11.5.1. Drug Description
11.5.2. Product Profile
11.5.3. Regulatory Milestones
11.5.4. Other Development Activities
11.5.5. Clinical Development
11.5.6. Clinical Trials Information
11.5.7. Safety and Efficacy
11.6. BMS-986020: Bristol-Myers Squibb
11.6.1. Drug Description
11.6.2. Product Profile
11.6.3. Regulatory Milestones
11.6.4. Other Development Activities
11.6.5. Clinical Development
11.6.6. Clinical Trials Information
11.6.7. Safety and Efficacy
11.7. LT-1002: Chong Kun Dang Pharmaceutical
11.7.1. Drug Description
11.7.2. Product Profile
11.7.3. Other Development Activities
11.8. Pamrevlumab: FibroGen
11.8.1. Drug Description
11.8.2. Product Profile
11.8.3. Regulatory Milestones
11.8.4. Other Development Activities
11.8.5. Clinical Development
11.8.6. Clinical Trials Information
11.8.7. Safety and Efficacy
11.9. PBI4050: ProMetic Life Sciences
11.9.1. Drug Description
11.9.2. Product Profile
11.9.3. Regulatory Milestones
11.9.4. Other Development Activities
11.9.5. Clinical Development
11.9.6. Clinical Trials Information
11.9.7. Safety and Efficacy
11.10. PRM 151: Promedior, Inc.
11.10.1. Drug Description
11.10.2. Product Profile
11.10.3. Regulatory Milestones
11.10.4. Other Development Activities
11.10.5. Clinical Development
11.10.6. Clinical Trials Information
11.10.7. Safety and Efficacy
11.11. Tipelukast: MediciNova
11.11.1. Drug Description
11.11.2. Product Profile
11.11.3. Regulatory Milestones
11.11.4. Other Development Activities
11.11.5. Clinical Development
11.11.6. Clinical Trials Information
11.11.7. Safety and Efficacy
11.12. TD139: Bristol-Myers Squibb
11.12.1. Drug Description
11.12.2. Product Profile
11.12.3. Other Development Activities
11.12.4. Clinical Development
11.12.5. Clinical Trials Information
11.12.6. Safety and Efficacy
11.13. VAY736: Novartis
11.13.1. Drug Description
11.13.2. Product Profile
11.13.3. Other Development Activities
11.13.4. Clinical Development
11.13.5. Clinical Trials Information
11.14. TAS-115: Taiho Pharmaceutical
11.14.1. Drug Description
11.14.2. Product Profile
11.14.3. Clinical Development
11.14.4. Clinical Trials Information
12. IPF: Market Analysis
12.1. Key Findings
12.2. Total Market Size of IPF in 7 MM
12.3. Therapy Based Market Size of IPF in 7 MM
13. Market Size of IPF by Country
13.1. United States Market Analysis
13.1.1. Market Size of IPF in the US
13.1.2. Therapy Based Market Size of IPF in the US
13.2. EU5 Market Outlook
13.3. Germany
13.3.1. Market Size of IPF in Germany
13.3.2. Therapy Based Market Size of IPF in Germany
13.4. France
13.4.1. Market Size of IPF in France
13.4.2. Therapy Based Market Size of IPF in France
13.5. Italy
13.5.1. Market Size of IPF in Italy
13.5.2. Therapy Based Market Size of IPF in Italy
13.6. United Kingdom
13.6.1. Market Size of IPF in the UK
13.6.2. Therapy Based Market Size of IPF in the UK
13.7. Spain
13.7.1. Market Size of IPF in Spain
13.7.2. Therapy Based Market Size of IPF in Spain
13.8. Japan: Market Analysis
13.8.1. Market Size of IPF in Japan
13.8.2. Therapy Based Market Size of IPF in Japan
14. Market Drivers of IPF
15. Market Barriers of IPF
16. Appendix
16.1. Report Methodology
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

 

1. Key Insights
2. IPF Market Overview at a Glance
2.1. Market Share (%) Distribution of IPF in 2017
2.2. Market Share (%) Distribution of IPF in 2027
3. Disease Background and Overview: Idiopathic Pulmonary Fibrosis (IPF)
3.1. Introduction
3.2. Staging of IPF
3.3. Risk Factors & Disease Causes
3.4. Symptoms
3.5. Pathogenesis
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7 MM Prevalent Population of IPF
4.3. Country Wise-Epidemiology of IPF
4.3.1. United States
4.3.2. Prevalent cases of IPF in the United States
4.3.3. Prevalent Population of IPF by severity
4.3.4. Gender-Specific IPF Prevalence
4.3.5. Age-Specific IPF Prevalence
4.3.6. EU5
4.3.7. Prevalent Population of IPF in EU5
4.3.8. France
4.3.9. Prevalent Population of IPF
4.3.10. Prevalent Population of IPF by severity
4.3.11. Gender-Specific IPF Prevalence
4.3.12. Age-Specific IPF Prevalence
4.3.13. Germany
4.3.14. Prevalent Population of IPF
4.3.15. Prevalent Population of IPF by severity
4.3.16. Gender-Specific IPF Prevalence
4.3.17. Age-Specific IPF Prevalence
4.3.18. Italy
4.3.19. Prevalent Population of IPF
4.3.20. Prevalent Population of IPF by severity
4.3.21. Gender-Specific IPF Prevalence
4.3.22. Age-Specific IPF Prevalence
4.3.23. Spain
4.3.24. Prevalent Population of IPF
4.3.25. Prevalent Population of IPF by severity
4.3.26. Gender-Specific IPF Prevalence
4.3.27. Age-Specific IPF Prevalence
4.3.28. United Kingdom
4.3.29. Prevalent Population of IPF
4.3.30. Prevalent Population of IPF by severity
4.3.31. Gender-Specific IPF Prevalence
4.3.32. Age-Specific IPF Prevalence
4.3.33. Japan
4.3.34. Prevalent Population of IPF
4.3.35. Prevalent Population of IPF by severity
4.3.36. Gender-SPECIFIC IPF Prevalence
4.3.37. Age-Specific IPF Prevalence
5. Current Treatment Practices
5.1. ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of IPF (An Update of 2011 Clinical Practice Guideline)
6. Unmet needs
7. Marketed Products
7.1. Esbriet (Pirfenidone): InterMune Inc.
7.1.1. Product Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Safety and Efficacy of Esbriet
7.1.5. Side effects of Esbriet
7.1.6. Product Profile
7.2. Ofev (Nintedanib): Boehringer Ingelheim Pharma GmbH & Co. KG
7.2.1. Product Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Safety and Efficacy of Ofev
7.2.5. Side effects of Ofev
7.2.6. Product Profile
8. Emerging Therapies
9. Key Cross Competition
10. Phase III Drugs
10.1. Thrombomodulin Alfa: Asahi Kasei Pharma Corporation
10.1.1. Drug Description
10.1.2. Product Profile
10.1.3. Clinical Development
10.1.4. Clinical Trials Information
10.1.5. Safety and Efficacy
11. Phase II Drugs
11.1. CC-90001: Celgene Corporation
11.1.1. Drug Description
11.1.2. Product Profile
11.1.3. Clinical Development
11.1.4. Clinical Trials Information
11.1.5. Safety and Efficacy
11.1.6. Drug Description
11.1.7. Product Profile
11.1.8. Other Development Activities
11.1.9. Clinical Development
11.1.10. Clinical Trials Information
11.1.11. Safety and Efficacy
11.2. Gefapixant: Merck & Co., Inc.
11.2.1. Drug Description
11.2.2. Product Profile
11.2.3. Other Development Activities
11.2.4. Clinical Development
11.2.5. Clinical Trials Information
11.2.6. Safety and Efficacy
11.3. GLPG1690: Galapagos NV
11.3.1. Drug Description
11.3.2. Product Profile
11.3.3. Regulatory Milestones
11.3.4. Other Development Activities
11.3.5. Clinical Development
11.3.6. Clinical Trials Information
11.3.7. Safety and Efficacy
11.4. LT-1001: LTT Bio-Pharma
11.4.1. Drug Description
11.4.2. Product Profile
11.4.3. Other Development Activities
11.4.4. Clinical Development
11.4.5. Clinical Trials Information
11.4.6. Safety and Efficacy
11.5. BG00011: Biogen Inc.
11.5.1. Drug Description
11.5.2. Product Profile
11.5.3. Regulatory Milestones
11.5.4. Other Development Activities
11.5.5. Clinical Development
11.5.6. Clinical Trials Information
11.5.7. Safety and Efficacy
11.6. BMS-986020: Bristol-Myers Squibb
11.6.1. Drug Description
11.6.2. Product Profile
11.6.3. Regulatory Milestones
11.6.4. Other Development Activities
11.6.5. Clinical Development
11.6.6. Clinical Trials Information
11.6.7. Safety and Efficacy
11.7. LT-1002: Chong Kun Dang Pharmaceutical
11.7.1. Drug Description
11.7.2. Product Profile
11.7.3. Other Development Activities
11.8. Pamrevlumab: FibroGen
11.8.1. Drug Description
11.8.2. Product Profile
11.8.3. Regulatory Milestones
11.8.4. Other Development Activities
11.8.5. Clinical Development
11.8.6. Clinical Trials Information
11.8.7. Safety and Efficacy
11.9. PBI4050: ProMetic Life Sciences
11.9.1. Drug Description
11.9.2. Product Profile
11.9.3. Regulatory Milestones
11.9.4. Other Development Activities
11.9.5. Clinical Development
11.9.6. Clinical Trials Information
11.9.7. Safety and Efficacy
11.10. PRM 151: Promedior, Inc.
11.10.1. Drug Description
11.10.2. Product Profile
11.10.3. Regulatory Milestones
11.10.4. Other Development Activities
11.10.5. Clinical Development
11.10.6. Clinical Trials Information
11.10.7. Safety and Efficacy
11.11. Tipelukast: MediciNova
11.11.1. Drug Description
11.11.2. Product Profile
11.11.3. Regulatory Milestones
11.11.4. Other Development Activities
11.11.5. Clinical Development
11.11.6. Clinical Trials Information
11.11.7. Safety and Efficacy
11.12. TD139: Bristol-Myers Squibb
11.12.1. Drug Description
11.12.2. Product Profile
11.12.3. Other Development Activities
11.12.4. Clinical Development
11.12.5. Clinical Trials Information
11.12.6. Safety and Efficacy
11.13. VAY736: Novartis
11.13.1. Drug Description
11.13.2. Product Profile
11.13.3. Other Development Activities
11.13.4. Clinical Development
11.13.5. Clinical Trials Information
11.14. TAS-115: Taiho Pharmaceutical
11.14.1. Drug Description
11.14.2. Product Profile
11.14.3. Clinical Development
11.14.4. Clinical Trials Information
12. IPF: Market Analysis
12.1. Key Findings
12.2. Total Market Size of IPF in 7 MM
12.3. Therapy Based Market Size of IPF in 7 MM
13. Market Size of IPF by Country
13.1. United States Market Analysis
13.1.1. Market Size of IPF in the US
13.1.2. Therapy Based Market Size of IPF in the US
13.2. EU5 Market Outlook
13.3. Germany
13.3.1. Market Size of IPF in Germany
13.3.2. Therapy Based Market Size of IPF in Germany
13.4. France
13.4.1. Market Size of IPF in France
13.4.2. Therapy Based Market Size of IPF in France
13.5. Italy
13.5.1. Market Size of IPF in Italy
13.5.2. Therapy Based Market Size of IPF in Italy
13.6. United Kingdom
13.6.1. Market Size of IPF in the UK
13.6.2. Therapy Based Market Size of IPF in the UK
13.7. Spain
13.7.1. Market Size of IPF in Spain
13.7.2. Therapy Based Market Size of IPF in Spain
13.8. Japan: Market Analysis
13.8.1. Market Size of IPF in Japan
13.8.2. Therapy Based Market Size of IPF in Japan
14. Market Drivers of IPF
15. Market Barriers of IPF
16. Appendix
16.1. Report Methodology
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

 

1. Key Insights
2. IPF Market Overview at a Glance
2.1. Market Share (%) Distribution of IPF in 2017
2.2. Market Share (%) Distribution of IPF in 2027
3. Disease Background and Overview: Idiopathic Pulmonary Fibrosis (IPF)
3.1. Introduction
3.2. Staging of IPF
3.3. Risk Factors & Disease Causes
3.4. Symptoms
3.5. Pathogenesis
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7 MM Prevalent Population of IPF
4.3. Country Wise-Epidemiology of IPF
4.3.1. United States
4.3.2. Prevalent cases of IPF in the United States
4.3.3. Prevalent Population of IPF by severity
4.3.4. Gender-Specific IPF Prevalence
4.3.5. Age-Specific IPF Prevalence
4.3.6. EU5
4.3.7. Prevalent Population of IPF in EU5
4.3.8. France
4.3.9. Prevalent Population of IPF
4.3.10. Prevalent Population of IPF by severity
4.3.11. Gender-Specific IPF Prevalence
4.3.12. Age-Specific IPF Prevalence
4.3.13. Germany
4.3.14. Prevalent Population of IPF
4.3.15. Prevalent Population of IPF by severity
4.3.16. Gender-Specific IPF Prevalence
4.3.17. Age-Specific IPF Prevalence
4.3.18. Italy
4.3.19. Prevalent Population of IPF
4.3.20. Prevalent Population of IPF by severity
4.3.21. Gender-Specific IPF Prevalence
4.3.22. Age-Specific IPF Prevalence
4.3.23. Spain
4.3.24. Prevalent Population of IPF
4.3.25. Prevalent Population of IPF by severity
4.3.26. Gender-Specific IPF Prevalence
4.3.27. Age-Specific IPF Prevalence
4.3.28. United Kingdom
4.3.29. Prevalent Population of IPF
4.3.30. Prevalent Population of IPF by severity
4.3.31. Gender-Specific IPF Prevalence
4.3.32. Age-Specific IPF Prevalence
4.3.33. Japan
4.3.34. Prevalent Population of IPF
4.3.35. Prevalent Population of IPF by severity
4.3.36. Gender-SPECIFIC IPF Prevalence
4.3.37. Age-Specific IPF Prevalence
5. Current Treatment Practices
5.1. ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of IPF (An Update of 2011 Clinical Practice Guideline)
6. Unmet needs
7. Marketed Products
7.1. Esbriet (Pirfenidone): InterMune Inc.
7.1.1. Product Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Safety and Efficacy of Esbriet
7.1.5. Side effects of Esbriet
7.1.6. Product Profile
7.2. Ofev (Nintedanib): Boehringer Ingelheim Pharma GmbH & Co. KG
7.2.1. Product Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Safety and Efficacy of Ofev
7.2.5. Side effects of Ofev
7.2.6. Product Profile
8. Emerging Therapies
9. Key Cross Competition
10. Phase III Drugs
10.1. Thrombomodulin Alfa: Asahi Kasei Pharma Corporation
10.1.1. Drug Description
10.1.2. Product Profile
10.1.3. Clinical Development
10.1.4. Clinical Trials Information
10.1.5. Safety and Efficacy
11. Phase II Drugs
11.1. CC-90001: Celgene Corporation
11.1.1. Drug Description
11.1.2. Product Profile
11.1.3. Clinical Development
11.1.4. Clinical Trials Information
11.1.5. Safety and Efficacy
11.1.6. Drug Description
11.1.7. Product Profile
11.1.8. Other Development Activities
11.1.9. Clinical Development
11.1.10. Clinical Trials Information
11.1.11. Safety and Efficacy
11.2. Gefapixant: Merck & Co., Inc.
11.2.1. Drug Description
11.2.2. Product Profile
11.2.3. Other Development Activities
11.2.4. Clinical Development
11.2.5. Clinical Trials Information
11.2.6. Safety and Efficacy
11.3. GLPG1690: Galapagos NV
11.3.1. Drug Description
11.3.2. Product Profile
11.3.3. Regulatory Milestones
11.3.4. Other Development Activities
11.3.5. Clinical Development
11.3.6. Clinical Trials Information
11.3.7. Safety and Efficacy
11.4. LT-1001: LTT Bio-Pharma
11.4.1. Drug Description
11.4.2. Product Profile
11.4.3. Other Development Activities
11.4.4. Clinical Development
11.4.5. Clinical Trials Information
11.4.6. Safety and Efficacy
11.5. BG00011: Biogen Inc.
11.5.1. Drug Description
11.5.2. Product Profile
11.5.3. Regulatory Milestones
11.5.4. Other Development Activities
11.5.5. Clinical Development
11.5.6. Clinical Trials Information
11.5.7. Safety and Efficacy
11.6. BMS-986020: Bristol-Myers Squibb
11.6.1. Drug Description
11.6.2. Product Profile
11.6.3. Regulatory Milestones
11.6.4. Other Development Activities
11.6.5. Clinical Development
11.6.6. Clinical Trials Information
11.6.7. Safety and Efficacy
11.7. LT-1002: Chong Kun Dang Pharmaceutical
11.7.1. Drug Description
11.7.2. Product Profile
11.7.3. Other Development Activities
11.8. Pamrevlumab: FibroGen
11.8.1. Drug Description
11.8.2. Product Profile
11.8.3. Regulatory Milestones
11.8.4. Other Development Activities
11.8.5. Clinical Development
11.8.6. Clinical Trials Information
11.8.7. Safety and Efficacy
11.9. PBI4050: ProMetic Life Sciences
11.9.1. Drug Description
11.9.2. Product Profile
11.9.3. Regulatory Milestones
11.9.4. Other Development Activities
11.9.5. Clinical Development
11.9.6. Clinical Trials Information
11.9.7. Safety and Efficacy
11.10. PRM 151: Promedior, Inc.
11.10.1. Drug Description
11.10.2. Product Profile
11.10.3. Regulatory Milestones
11.10.4. Other Development Activities
11.10.5. Clinical Development
11.10.6. Clinical Trials Information
11.10.7. Safety and Efficacy
11.11. Tipelukast: MediciNova
11.11.1. Drug Description
11.11.2. Product Profile
11.11.3. Regulatory Milestones
11.11.4. Other Development Activities
11.11.5. Clinical Development
11.11.6. Clinical Trials Information
11.11.7. Safety and Efficacy
11.12. TD139: Bristol-Myers Squibb
11.12.1. Drug Description
11.12.2. Product Profile
11.12.3. Other Development Activities
11.12.4. Clinical Development
11.12.5. Clinical Trials Information
11.12.6. Safety and Efficacy
11.13. VAY736: Novartis
11.13.1. Drug Description
11.13.2. Product Profile
11.13.3. Other Development Activities
11.13.4. Clinical Development
11.13.5. Clinical Trials Information
11.14. TAS-115: Taiho Pharmaceutical
11.14.1. Drug Description
11.14.2. Product Profile
11.14.3. Clinical Development
11.14.4. Clinical Trials Information
12. IPF: Market Analysis
12.1. Key Findings
12.2. Total Market Size of IPF in 7 MM
12.3. Therapy Based Market Size of IPF in 7 MM
13. Market Size of IPF by Country
13.1. United States Market Analysis
13.1.1. Market Size of IPF in the US
13.1.2. Therapy Based Market Size of IPF in the US
13.2. EU5 Market Outlook
13.3. Germany
13.3.1. Market Size of IPF in Germany
13.3.2. Therapy Based Market Size of IPF in Germany
13.4. France
13.4.1. Market Size of IPF in France
13.4.2. Therapy Based Market Size of IPF in France
13.5. Italy
13.5.1. Market Size of IPF in Italy
13.5.2. Therapy Based Market Size of IPF in Italy
13.6. United Kingdom
13.6.1. Market Size of IPF in the UK
13.6.2. Therapy Based Market Size of IPF in the UK
13.7. Spain
13.7.1. Market Size of IPF in Spain
13.7.2. Therapy Based Market Size of IPF in Spain
13.8. Japan: Market Analysis
13.8.1. Market Size of IPF in Japan
13.8.2. Therapy Based Market Size of IPF in Japan
14. Market Drivers of IPF
15. Market Barriers of IPF
16. Appendix
16.1. Report Methodology
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

 

1. Key Insights
2. IPF Market Overview at a Glance
2.1. Market Share (%) Distribution of IPF in 2017
2.2. Market Share (%) Distribution of IPF in 2027
3. Disease Background and Overview: Idiopathic Pulmonary Fibrosis (IPF)
3.1. Introduction
3.2. Staging of IPF
3.3. Risk Factors & Disease Causes
3.4. Symptoms
3.5. Pathogenesis
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7 MM Prevalent Population of IPF
4.3. Country Wise-Epidemiology of IPF
4.3.1. United States
4.3.2. Prevalent cases of IPF in the United States
4.3.3. Prevalent Population of IPF by severity
4.3.4. Gender-Specific IPF Prevalence
4.3.5. Age-Specific IPF Prevalence
4.3.6. EU5
4.3.7. Prevalent Population of IPF in EU5
4.3.8. France
4.3.9. Prevalent Population of IPF
4.3.10. Prevalent Population of IPF by severity
4.3.11. Gender-Specific IPF Prevalence
4.3.12. Age-Specific IPF Prevalence
4.3.13. Germany
4.3.14. Prevalent Population of IPF
4.3.15. Prevalent Population of IPF by severity
4.3.16. Gender-Specific IPF Prevalence
4.3.17. Age-Specific IPF Prevalence
4.3.18. Italy
4.3.19. Prevalent Population of IPF
4.3.20. Prevalent Population of IPF by severity
4.3.21. Gender-Specific IPF Prevalence
4.3.22. Age-Specific IPF Prevalence
4.3.23. Spain
4.3.24. Prevalent Population of IPF
4.3.25. Prevalent Population of IPF by severity
4.3.26. Gender-Specific IPF Prevalence
4.3.27. Age-Specific IPF Prevalence
4.3.28. United Kingdom
4.3.29. Prevalent Population of IPF
4.3.30. Prevalent Population of IPF by severity
4.3.31. Gender-Specific IPF Prevalence
4.3.32. Age-Specific IPF Prevalence
4.3.33. Japan
4.3.34. Prevalent Population of IPF
4.3.35. Prevalent Population of IPF by severity
4.3.36. Gender-SPECIFIC IPF Prevalence
4.3.37. Age-Specific IPF Prevalence
5. Current Treatment Practices
5.1. ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of IPF (An Update of 2011 Clinical Practice Guideline)
6. Unmet needs
7. Marketed Products
7.1. Esbriet (Pirfenidone): InterMune Inc.
7.1.1. Product Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Safety and Efficacy of Esbriet
7.1.5. Side effects of Esbriet
7.1.6. Product Profile
7.2. Ofev (Nintedanib): Boehringer Ingelheim Pharma GmbH & Co. KG
7.2.1. Product Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Safety and Efficacy of Ofev
7.2.5. Side effects of Ofev
7.2.6. Product Profile
8. Emerging Therapies
9. Key Cross Competition
10. Phase III Drugs
10.1. Thrombomodulin Alfa: Asahi Kasei Pharma Corporation
10.1.1. Drug Description
10.1.2. Product Profile
10.1.3. Clinical Development
10.1.4. Clinical Trials Information
10.1.5. Safety and Efficacy
11. Phase II Drugs
11.1. CC-90001: Celgene Corporation
11.1.1. Drug Description
11.1.2. Product Profile
11.1.3. Clinical Development
11.1.4. Clinical Trials Information
11.1.5. Safety and Efficacy
11.1.6. Drug Description
11.1.7. Product Profile
11.1.8. Other Development Activities
11.1.9. Clinical Development
11.1.10. Clinical Trials Information
11.1.11. Safety and Efficacy
11.2. Gefapixant: Merck & Co., Inc.
11.2.1. Drug Description
11.2.2. Product Profile
11.2.3. Other Development Activities
11.2.4. Clinical Development
11.2.5. Clinical Trials Information
11.2.6. Safety and Efficacy
11.3. GLPG1690: Galapagos NV
11.3.1. Drug Description
11.3.2. Product Profile
11.3.3. Regulatory Milestones
11.3.4. Other Development Activities
11.3.5. Clinical Development
11.3.6. Clinical Trials Information
11.3.7. Safety and Efficacy
11.4. LT-1001: LTT Bio-Pharma
11.4.1. Drug Description
11.4.2. Product Profile
11.4.3. Other Development Activities
11.4.4. Clinical Development
11.4.5. Clinical Trials Information
11.4.6. Safety and Efficacy
11.5. BG00011: Biogen Inc.
11.5.1. Drug Description
11.5.2. Product Profile
11.5.3. Regulatory Milestones
11.5.4. Other Development Activities
11.5.5. Clinical Development
11.5.6. Clinical Trials Information
11.5.7. Safety and Efficacy
11.6. BMS-986020: Bristol-Myers Squibb
11.6.1. Drug Description
11.6.2. Product Profile
11.6.3. Regulatory Milestones
11.6.4. Other Development Activities
11.6.5. Clinical Development
11.6.6. Clinical Trials Information
11.6.7. Safety and Efficacy
11.7. LT-1002: Chong Kun Dang Pharmaceutical
11.7.1. Drug Description
11.7.2. Product Profile
11.7.3. Other Development Activities
11.8. Pamrevlumab: FibroGen
11.8.1. Drug Description
11.8.2. Product Profile
11.8.3. Regulatory Milestones
11.8.4. Other Development Activities
11.8.5. Clinical Development
11.8.6. Clinical Trials Information
11.8.7. Safety and Efficacy
11.9. PBI4050: ProMetic Life Sciences
11.9.1. Drug Description
11.9.2. Product Profile
11.9.3. Regulatory Milestones
11.9.4. Other Development Activities
11.9.5. Clinical Development
11.9.6. Clinical Trials Information
11.9.7. Safety and Efficacy
11.10. PRM 151: Promedior, Inc.
11.10.1. Drug Description
11.10.2. Product Profile
11.10.3. Regulatory Milestones
11.10.4. Other Development Activities
11.10.5. Clinical Development
11.10.6. Clinical Trials Information
11.10.7. Safety and Efficacy
11.11. Tipelukast: MediciNova
11.11.1. Drug Description
11.11.2. Product Profile
11.11.3. Regulatory Milestones
11.11.4. Other Development Activities
11.11.5. Clinical Development
11.11.6. Clinical Trials Information
11.11.7. Safety and Efficacy
11.12. TD139: Bristol-Myers Squibb
11.12.1. Drug Description
11.12.2. Product Profile
11.12.3. Other Development Activities
11.12.4. Clinical Development
11.12.5. Clinical Trials Information
11.12.6. Safety and Efficacy
11.13. VAY736: Novartis
11.13.1. Drug Description
11.13.2. Product Profile
11.13.3. Other Development Activities
11.13.4. Clinical Development
11.13.5. Clinical Trials Information
11.14. TAS-115: Taiho Pharmaceutical
11.14.1. Drug Description
11.14.2. Product Profile
11.14.3. Clinical Development
11.14.4. Clinical Trials Information
12. IPF: Market Analysis
12.1. Key Findings
12.2. Total Market Size of IPF in 7 MM
12.3. Therapy Based Market Size of IPF in 7 MM
13. Market Size of IPF by Country
13.1. United States Market Analysis
13.1.1. Market Size of IPF in the US
13.1.2. Therapy Based Market Size of IPF in the US
13.2. EU5 Market Outlook
13.3. Germany
13.3.1. Market Size of IPF in Germany
13.3.2. Therapy Based Market Size of IPF in Germany
13.4. France
13.4.1. Market Size of IPF in France
13.4.2. Therapy Based Market Size of IPF in France
13.5. Italy
13.5.1. Market Size of IPF in Italy
13.5.2. Therapy Based Market Size of IPF in Italy
13.6. United Kingdom
13.6.1. Market Size of IPF in the UK
13.6.2. Therapy Based Market Size of IPF in the UK
13.7. Spain
13.7.1. Market Size of IPF in Spain
13.7.2. Therapy Based Market Size of IPF in Spain
13.8. Japan: Market Analysis
13.8.1. Market Size of IPF in Japan
13.8.2. Therapy Based Market Size of IPF in Japan
14. Market Drivers of IPF
15. Market Barriers of IPF
16. Appendix
16.1. Report Methodology
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

 

1. Key Insights
2. IPF Market Overview at a Glance
2.1. Market Share (%) Distribution of IPF in 2017
2.2. Market Share (%) Distribution of IPF in 2027
3. Disease Background and Overview: Idiopathic Pulmonary Fibrosis (IPF)
3.1. Introduction
3.2. Staging of IPF
3.3. Risk Factors & Disease Causes
3.4. Symptoms
3.5. Pathogenesis
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7 MM Prevalent Population of IPF
4.3. Country Wise-Epidemiology of IPF
4.3.1. United States
4.3.2. Prevalent cases of IPF in the United States
4.3.3. Prevalent Population of IPF by severity
4.3.4. Gender-Specific IPF Prevalence
4.3.5. Age-Specific IPF Prevalence
4.3.6. EU5
4.3.7. Prevalent Population of IPF in EU5
4.3.8. France
4.3.9. Prevalent Population of IPF
4.3.10. Prevalent Population of IPF by severity
4.3.11. Gender-Specific IPF Prevalence
4.3.12. Age-Specific IPF Prevalence
4.3.13. Germany
4.3.14. Prevalent Population of IPF
4.3.15. Prevalent Population of IPF by severity
4.3.16. Gender-Specific IPF Prevalence
4.3.17. Age-Specific IPF Prevalence
4.3.18. Italy
4.3.19. Prevalent Population of IPF
4.3.20. Prevalent Population of IPF by severity
4.3.21. Gender-Specific IPF Prevalence
4.3.22. Age-Specific IPF Prevalence
4.3.23. Spain
4.3.24. Prevalent Population of IPF
4.3.25. Prevalent Population of IPF by severity
4.3.26. Gender-Specific IPF Prevalence
4.3.27. Age-Specific IPF Prevalence
4.3.28. United Kingdom
4.3.29. Prevalent Population of IPF
4.3.30. Prevalent Population of IPF by severity
4.3.31. Gender-Specific IPF Prevalence
4.3.32. Age-Specific IPF Prevalence
4.3.33. Japan
4.3.34. Prevalent Population of IPF
4.3.35. Prevalent Population of IPF by severity
4.3.36. Gender-SPECIFIC IPF Prevalence
4.3.37. Age-Specific IPF Prevalence
5. Current Treatment Practices
5.1. ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of IPF (An Update of 2011 Clinical Practice Guideline)
6. Unmet needs
7. Marketed Products
7.1. Esbriet (Pirfenidone): InterMune Inc.
7.1.1. Product Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Safety and Efficacy of Esbriet
7.1.5. Side effects of Esbriet
7.1.6. Product Profile
7.2. Ofev (Nintedanib): Boehringer Ingelheim Pharma GmbH & Co. KG
7.2.1. Product Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Safety and Efficacy of Ofev
7.2.5. Side effects of Ofev
7.2.6. Product Profile
8. Emerging Therapies
9. Key Cross Competition
10. Phase III Drugs
10.1. Thrombomodulin Alfa: Asahi Kasei Pharma Corporation
10.1.1. Drug Description
10.1.2. Product Profile
10.1.3. Clinical Development
10.1.4. Clinical Trials Information
10.1.5. Safety and Efficacy
11. Phase II Drugs
11.1. CC-90001: Celgene Corporation
11.1.1. Drug Description
11.1.2. Product Profile
11.1.3. Clinical Development
11.1.4. Clinical Trials Information
11.1.5. Safety and Efficacy
11.1.6. Drug Description
11.1.7. Product Profile
11.1.8. Other Development Activities
11.1.9. Clinical Development
11.1.10. Clinical Trials Information
11.1.11. Safety and Efficacy
11.2. Gefapixant: Merck & Co., Inc.
11.2.1. Drug Description
11.2.2. Product Profile
11.2.3. Other Development Activities
11.2.4. Clinical Development
11.2.5. Clinical Trials Information
11.2.6. Safety and Efficacy
11.3. GLPG1690: Galapagos NV
11.3.1. Drug Description
11.3.2. Product Profile
11.3.3. Regulatory Milestones
11.3.4. Other Development Activities
11.3.5. Clinical Development
11.3.6. Clinical Trials Information
11.3.7. Safety and Efficacy
11.4. LT-1001: LTT Bio-Pharma
11.4.1. Drug Description
11.4.2. Product Profile
11.4.3. Other Development Activities
11.4.4. Clinical Development
11.4.5. Clinical Trials Information
11.4.6. Safety and Efficacy
11.5. BG00011: Biogen Inc.
11.5.1. Drug Description
11.5.2. Product Profile
11.5.3. Regulatory Milestones
11.5.4. Other Development Activities
11.5.5. Clinical Development
11.5.6. Clinical Trials Information
11.5.7. Safety and Efficacy
11.6. BMS-986020: Bristol-Myers Squibb
11.6.1. Drug Description
11.6.2. Product Profile
11.6.3. Regulatory Milestones
11.6.4. Other Development Activities
11.6.5. Clinical Development
11.6.6. Clinical Trials Information
11.6.7. Safety and Efficacy
11.7. LT-1002: Chong Kun Dang Pharmaceutical
11.7.1. Drug Description
11.7.2. Product Profile
11.7.3. Other Development Activities
11.8. Pamrevlumab: FibroGen
11.8.1. Drug Description
11.8.2. Product Profile
11.8.3. Regulatory Milestones
11.8.4. Other Development Activities
11.8.5. Clinical Development
11.8.6. Clinical Trials Information
11.8.7. Safety and Efficacy
11.9. PBI4050: ProMetic Life Sciences
11.9.1. Drug Description
11.9.2. Product Profile
11.9.3. Regulatory Milestones
11.9.4. Other Development Activities
11.9.5. Clinical Development
11.9.6. Clinical Trials Information
11.9.7. Safety and Efficacy
11.10. PRM 151: Promedior, Inc.
11.10.1. Drug Description
11.10.2. Product Profile
11.10.3. Regulatory Milestones
11.10.4. Other Development Activities
11.10.5. Clinical Development
11.10.6. Clinical Trials Information
11.10.7. Safety and Efficacy
11.11. Tipelukast: MediciNova
11.11.1. Drug Description
11.11.2. Product Profile
11.11.3. Regulatory Milestones
11.11.4. Other Development Activities
11.11.5. Clinical Development
11.11.6. Clinical Trials Information
11.11.7. Safety and Efficacy
11.12. TD139: Bristol-Myers Squibb
11.12.1. Drug Description
11.12.2. Product Profile
11.12.3. Other Development Activities
11.12.4. Clinical Development
11.12.5. Clinical Trials Information
11.12.6. Safety and Efficacy
11.13. VAY736: Novartis
11.13.1. Drug Description
11.13.2. Product Profile
11.13.3. Other Development Activities
11.13.4. Clinical Development
11.13.5. Clinical Trials Information
11.14. TAS-115: Taiho Pharmaceutical
11.14.1. Drug Description
11.14.2. Product Profile
11.14.3. Clinical Development
11.14.4. Clinical Trials Information
12. IPF: Market Analysis
12.1. Key Findings
12.2. Total Market Size of IPF in 7 MM
12.3. Therapy Based Market Size of IPF in 7 MM
13. Market Size of IPF by Country
13.1. United States Market Analysis
13.1.1. Market Size of IPF in the US
13.1.2. Therapy Based Market Size of IPF in the US
13.2. EU5 Market Outlook
13.3. Germany
13.3.1. Market Size of IPF in Germany
13.3.2. Therapy Based Market Size of IPF in Germany
13.4. France
13.4.1. Market Size of IPF in France
13.4.2. Therapy Based Market Size of IPF in France
13.5. Italy
13.5.1. Market Size of IPF in Italy
13.5.2. Therapy Based Market Size of IPF in Italy
13.6. United Kingdom
13.6.1. Market Size of IPF in the UK
13.6.2. Therapy Based Market Size of IPF in the UK
13.7. Spain
13.7.1. Market Size of IPF in Spain
13.7.2. Therapy Based Market Size of IPF in Spain
13.8. Japan: Market Analysis
13.8.1. Market Size of IPF in Japan
13.8.2. Therapy Based Market Size of IPF in Japan
14. Market Drivers of IPF
15. Market Barriers of IPF
16. Appendix
16.1. Report Methodology
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

 

1. Key Insights
2. IPF Market Overview at a Glance
2.1. Market Share (%) Distribution of IPF in 2017
2.2. Market Share (%) Distribution of IPF in 2027
3. Disease Background and Overview: Idiopathic Pulmonary Fibrosis (IPF)
3.1. Introduction
3.2. Staging of IPF
3.3. Risk Factors & Disease Causes
3.4. Symptoms
3.5. Pathogenesis
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7 MM Prevalent Population of IPF
4.3. Country Wise-Epidemiology of IPF
4.3.1. United States
4.3.2. Prevalent cases of IPF in the United States
4.3.3. Prevalent Population of IPF by severity
4.3.4. Gender-Specific IPF Prevalence
4.3.5. Age-Specific IPF Prevalence
4.3.6. EU5
4.3.7. Prevalent Population of IPF in EU5
4.3.8. France
4.3.9. Prevalent Population of IPF
4.3.10. Prevalent Population of IPF by severity
4.3.11. Gender-Specific IPF Prevalence
4.3.12. Age-Specific IPF Prevalence
4.3.13. Germany
4.3.14. Prevalent Population of IPF
4.3.15. Prevalent Population of IPF by severity
4.3.16. Gender-Specific IPF Prevalence
4.3.17. Age-Specific IPF Prevalence
4.3.18. Italy
4.3.19. Prevalent Population of IPF
4.3.20. Prevalent Population of IPF by severity
4.3.21. Gender-Specific IPF Prevalence
4.3.22. Age-Specific IPF Prevalence
4.3.23. Spain
4.3.24. Prevalent Population of IPF
4.3.25. Prevalent Population of IPF by severity
4.3.26. Gender-Specific IPF Prevalence
4.3.27. Age-Specific IPF Prevalence
4.3.28. United Kingdom
4.3.29. Prevalent Population of IPF
4.3.30. Prevalent Population of IPF by severity
4.3.31. Gender-Specific IPF Prevalence
4.3.32. Age-Specific IPF Prevalence
4.3.33. Japan
4.3.34. Prevalent Population of IPF
4.3.35. Prevalent Population of IPF by severity
4.3.36. Gender-SPECIFIC IPF Prevalence
4.3.37. Age-Specific IPF Prevalence
5. Current Treatment Practices
5.1. ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of IPF (An Update of 2011 Clinical Practice Guideline)
6. Unmet needs
7. Marketed Products
7.1. Esbriet (Pirfenidone): InterMune Inc.
7.1.1. Product Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Safety and Efficacy of Esbriet
7.1.5. Side effects of Esbriet
7.1.6. Product Profile
7.2. Ofev (Nintedanib): Boehringer Ingelheim Pharma GmbH & Co. KG
7.2.1. Product Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Safety and Efficacy of Ofev
7.2.5. Side effects of Ofev
7.2.6. Product Profile
8. Emerging Therapies
9. Key Cross Competition
10. Phase III Drugs
10.1. Thrombomodulin Alfa: Asahi Kasei Pharma Corporation
10.1.1. Drug Description
10.1.2. Product Profile
10.1.3. Clinical Development
10.1.4. Clinical Trials Information
10.1.5. Safety and Efficacy
11. Phase II Drugs
11.1. CC-90001: Celgene Corporation
11.1.1. Drug Description
11.1.2. Product Profile
11.1.3. Clinical Development
11.1.4. Clinical Trials Information
11.1.5. Safety and Efficacy
11.1.6. Drug Description
11.1.7. Product Profile
11.1.8. Other Development Activities
11.1.9. Clinical Development
11.1.10. Clinical Trials Information
11.1.11. Safety and Efficacy
11.2. Gefapixant: Merck & Co., Inc.
11.2.1. Drug Description
11.2.2. Product Profile
11.2.3. Other Development Activities
11.2.4. Clinical Development
11.2.5. Clinical Trials Information
11.2.6. Safety and Efficacy
11.3. GLPG1690: Galapagos NV
11.3.1. Drug Description
11.3.2. Product Profile
11.3.3. Regulatory Milestones
11.3.4. Other Development Activities
11.3.5. Clinical Development
11.3.6. Clinical Trials Information
11.3.7. Safety and Efficacy
11.4. LT-1001: LTT Bio-Pharma
11.4.1. Drug Description
11.4.2. Product Profile
11.4.3. Other Development Activities
11.4.4. Clinical Development
11.4.5. Clinical Trials Information
11.4.6. Safety and Efficacy
11.5. BG00011: Biogen Inc.
11.5.1. Drug Description
11.5.2. Product Profile
11.5.3. Regulatory Milestones
11.5.4. Other Development Activities
11.5.5. Clinical Development
11.5.6. Clinical Trials Information
11.5.7. Safety and Efficacy
11.6. BMS-986020: Bristol-Myers Squibb
11.6.1. Drug Description
11.6.2. Product Profile
11.6.3. Regulatory Milestones
11.6.4. Other Development Activities
11.6.5. Clinical Development
11.6.6. Clinical Trials Information
11.6.7. Safety and Efficacy
11.7. LT-1002: Chong Kun Dang Pharmaceutical
11.7.1. Drug Description
11.7.2. Product Profile
11.7.3. Other Development Activities
11.8. Pamrevlumab: FibroGen
11.8.1. Drug Description
11.8.2. Product Profile
11.8.3. Regulatory Milestones
11.8.4. Other Development Activities
11.8.5. Clinical Development
11.8.6. Clinical Trials Information
11.8.7. Safety and Efficacy
11.9. PBI4050: ProMetic Life Sciences
11.9.1. Drug Description
11.9.2. Product Profile
11.9.3. Regulatory Milestones
11.9.4. Other Development Activities
11.9.5. Clinical Development
11.9.6. Clinical Trials Information
11.9.7. Safety and Efficacy
11.10. PRM 151: Promedior, Inc.
11.10.1. Drug Description
11.10.2. Product Profile
11.10.3. Regulatory Milestones
11.10.4. Other Development Activities
11.10.5. Clinical Development
11.10.6. Clinical Trials Information
11.10.7. Safety and Efficacy
11.11. Tipelukast: MediciNova
11.11.1. Drug Description
11.11.2. Product Profile
11.11.3. Regulatory Milestones
11.11.4. Other Development Activities
11.11.5. Clinical Development
11.11.6. Clinical Trials Information
11.11.7. Safety and Efficacy
11.12. TD139: Bristol-Myers Squibb
11.12.1. Drug Description
11.12.2. Product Profile
11.12.3. Other Development Activities
11.12.4. Clinical Development
11.12.5. Clinical Trials Information
11.12.6. Safety and Efficacy
11.13. VAY736: Novartis
11.13.1. Drug Description
11.13.2. Product Profile
11.13.3. Other Development Activities
11.13.4. Clinical Development
11.13.5. Clinical Trials Information
11.14. TAS-115: Taiho Pharmaceutical
11.14.1. Drug Description
11.14.2. Product Profile
11.14.3. Clinical Development
11.14.4. Clinical Trials Information
12. IPF: Market Analysis
12.1. Key Findings
12.2. Total Market Size of IPF in 7 MM
12.3. Therapy Based Market Size of IPF in 7 MM
13. Market Size of IPF by Country
13.1. United States Market Analysis
13.1.1. Market Size of IPF in the US
13.1.2. Therapy Based Market Size of IPF in the US
13.2. EU5 Market Outlook
13.3. Germany
13.3.1. Market Size of IPF in Germany
13.3.2. Therapy Based Market Size of IPF in Germany
13.4. France
13.4.1. Market Size of IPF in France
13.4.2. Therapy Based Market Size of IPF in France
13.5. Italy
13.5.1. Market Size of IPF in Italy
13.5.2. Therapy Based Market Size of IPF in Italy
13.6. United Kingdom
13.6.1. Market Size of IPF in the UK
13.6.2. Therapy Based Market Size of IPF in the UK
13.7. Spain
13.7.1. Market Size of IPF in Spain
13.7.2. Therapy Based Market Size of IPF in Spain
13.8. Japan: Market Analysis
13.8.1. Market Size of IPF in Japan
13.8.2. Therapy Based Market Size of IPF in Japan
14. Market Drivers of IPF
15. Market Barriers of IPF
16. Appendix
16.1. Report Methodology
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

 

1. Key Insights
2. IPF Market Overview at a Glance
2.1. Market Share (%) Distribution of IPF in 2017
2.2. Market Share (%) Distribution of IPF in 2027
3. Disease Background and Overview: Idiopathic Pulmonary Fibrosis (IPF)
3.1. Introduction
3.2. Staging of IPF
3.3. Risk Factors & Disease Causes
3.4. Symptoms
3.5. Pathogenesis
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7 MM Prevalent Population of IPF
4.3. Country Wise-Epidemiology of IPF
4.3.1. United States
4.3.2. Prevalent cases of IPF in the United States
4.3.3. Prevalent Population of IPF by severity
4.3.4. Gender-Specific IPF Prevalence
4.3.5. Age-Specific IPF Prevalence
4.3.6. EU5
4.3.7. Prevalent Population of IPF in EU5
4.3.8. France
4.3.9. Prevalent Population of IPF
4.3.10. Prevalent Population of IPF by severity
4.3.11. Gender-Specific IPF Prevalence
4.3.12. Age-Specific IPF Prevalence
4.3.13. Germany
4.3.14. Prevalent Population of IPF
4.3.15. Prevalent Population of IPF by severity
4.3.16. Gender-Specific IPF Prevalence
4.3.17. Age-Specific IPF Prevalence
4.3.18. Italy
4.3.19. Prevalent Population of IPF
4.3.20. Prevalent Population of IPF by severity
4.3.21. Gender-Specific IPF Prevalence
4.3.22. Age-Specific IPF Prevalence
4.3.23. Spain
4.3.24. Prevalent Population of IPF
4.3.25. Prevalent Population of IPF by severity
4.3.26. Gender-Specific IPF Prevalence
4.3.27. Age-Specific IPF Prevalence
4.3.28. United Kingdom
4.3.29. Prevalent Population of IPF
4.3.30. Prevalent Population of IPF by severity
4.3.31. Gender-Specific IPF Prevalence
4.3.32. Age-Specific IPF Prevalence
4.3.33. Japan
4.3.34. Prevalent Population of IPF
4.3.35. Prevalent Population of IPF by severity
4.3.36. Gender-SPECIFIC IPF Prevalence
4.3.37. Age-Specific IPF Prevalence
5. Current Treatment Practices
5.1. ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of IPF (An Update of 2011 Clinical Practice Guideline)
6. Unmet needs
7. Marketed Products
7.1. Esbriet (Pirfenidone): InterMune Inc.
7.1.1. Product Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Safety and Efficacy of Esbriet
7.1.5. Side effects of Esbriet
7.1.6. Product Profile
7.2. Ofev (Nintedanib): Boehringer Ingelheim Pharma GmbH & Co. KG
7.2.1. Product Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Safety and Efficacy of Ofev
7.2.5. Side effects of Ofev
7.2.6. Product Profile
8. Emerging Therapies
9. Key Cross Competition
10. Phase III Drugs
10.1. Thrombomodulin Alfa: Asahi Kasei Pharma Corporation
10.1.1. Drug Description
10.1.2. Product Profile
10.1.3. Clinical Development
10.1.4. Clinical Trials Information
10.1.5. Safety and Efficacy
11. Phase II Drugs
11.1. CC-90001: Celgene Corporation
11.1.1. Drug Description
11.1.2. Product Profile
11.1.3. Clinical Development
11.1.4. Clinical Trials Information
11.1.5. Safety and Efficacy
11.1.6. Drug Description
11.1.7. Product Profile
11.1.8. Other Development Activities
11.1.9. Clinical Development
11.1.10. Clinical Trials Information
11.1.11. Safety and Efficacy
11.2. Gefapixant: Merck & Co., Inc.
11.2.1. Drug Description
11.2.2. Product Profile
11.2.3. Other Development Activities
11.2.4. Clinical Development
11.2.5. Clinical Trials Information
11.2.6. Safety and Efficacy
11.3. GLPG1690: Galapagos NV
11.3.1. Drug Description
11.3.2. Product Profile
11.3.3. Regulatory Milestones
11.3.4. Other Development Activities
11.3.5. Clinical Development
11.3.6. Clinical Trials Information
11.3.7. Safety and Efficacy
11.4. LT-1001: LTT Bio-Pharma
11.4.1. Drug Description
11.4.2. Product Profile
11.4.3. Other Development Activities
11.4.4. Clinical Development
11.4.5. Clinical Trials Information
11.4.6. Safety and Efficacy
11.5. BG00011: Biogen Inc.
11.5.1. Drug Description
11.5.2. Product Profile
11.5.3. Regulatory Milestones
11.5.4. Other Development Activities
11.5.5. Clinical Development
11.5.6. Clinical Trials Information
11.5.7. Safety and Efficacy
11.6. BMS-986020: Bristol-Myers Squibb
11.6.1. Drug Description
11.6.2. Product Profile
11.6.3. Regulatory Milestones
11.6.4. Other Development Activities
11.6.5. Clinical Development
11.6.6. Clinical Trials Information
11.6.7. Safety and Efficacy
11.7. LT-1002: Chong Kun Dang Pharmaceutical
11.7.1. Drug Description
11.7.2. Product Profile
11.7.3. Other Development Activities
11.8. Pamrevlumab: FibroGen
11.8.1. Drug Description
11.8.2. Product Profile
11.8.3. Regulatory Milestones
11.8.4. Other Development Activities
11.8.5. Clinical Development
11.8.6. Clinical Trials Information
11.8.7. Safety and Efficacy
11.9. PBI4050: ProMetic Life Sciences
11.9.1. Drug Description
11.9.2. Product Profile
11.9.3. Regulatory Milestones
11.9.4. Other Development Activities
11.9.5. Clinical Development
11.9.6. Clinical Trials Information
11.9.7. Safety and Efficacy
11.10. PRM 151: Promedior, Inc.
11.10.1. Drug Description
11.10.2. Product Profile
11.10.3. Regulatory Milestones
11.10.4. Other Development Activities
11.10.5. Clinical Development
11.10.6. Clinical Trials Information
11.10.7. Safety and Efficacy
11.11. Tipelukast: MediciNova
11.11.1. Drug Description
11.11.2. Product Profile
11.11.3. Regulatory Milestones
11.11.4. Other Development Activities
11.11.5. Clinical Development
11.11.6. Clinical Trials Information
11.11.7. Safety and Efficacy
11.12. TD139: Bristol-Myers Squibb
11.12.1. Drug Description
11.12.2. Product Profile
11.12.3. Other Development Activities
11.12.4. Clinical Development
11.12.5. Clinical Trials Information
11.12.6. Safety and Efficacy
11.13. VAY736: Novartis
11.13.1. Drug Description
11.13.2. Product Profile
11.13.3. Other Development Activities
11.13.4. Clinical Development
11.13.5. Clinical Trials Information
11.14. TAS-115: Taiho Pharmaceutical
11.14.1. Drug Description
11.14.2. Product Profile
11.14.3. Clinical Development
11.14.4. Clinical Trials Information
12. IPF: Market Analysis
12.1. Key Findings
12.2. Total Market Size of IPF in 7 MM
12.3. Therapy Based Market Size of IPF in 7 MM
13. Market Size of IPF by Country
13.1. United States Market Analysis
13.1.1. Market Size of IPF in the US
13.1.2. Therapy Based Market Size of IPF in the US
13.2. EU5 Market Outlook
13.3. Germany
13.3.1. Market Size of IPF in Germany
13.3.2. Therapy Based Market Size of IPF in Germany
13.4. France
13.4.1. Market Size of IPF in France
13.4.2. Therapy Based Market Size of IPF in France
13.5. Italy
13.5.1. Market Size of IPF in Italy
13.5.2. Therapy Based Market Size of IPF in Italy
13.6. United Kingdom
13.6.1. Market Size of IPF in the UK
13.6.2. Therapy Based Market Size of IPF in the UK
13.7. Spain
13.7.1. Market Size of IPF in Spain
13.7.2. Therapy Based Market Size of IPF in Spain
13.8. Japan: Market Analysis
13.8.1. Market Size of IPF in Japan
13.8.2. Therapy Based Market Size of IPF in Japan
14. Market Drivers of IPF
15. Market Barriers of IPF
16. Appendix
16.1. Report Methodology
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

 

1. Key Insights
2. IPF Market Overview at a Glance
2.1. Market Share (%) Distribution of IPF in 2017
2.2. Market Share (%) Distribution of IPF in 2027
3. Disease Background and Overview: Idiopathic Pulmonary Fibrosis (IPF)
3.1. Introduction
3.2. Staging of IPF
3.3. Risk Factors & Disease Causes
3.4. Symptoms
3.5. Pathogenesis
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7 MM Prevalent Population of IPF
4.3. Country Wise-Epidemiology of IPF
4.3.1. United States
4.3.2. Prevalent cases of IPF in the United States
4.3.3. Prevalent Population of IPF by severity
4.3.4. Gender-Specific IPF Prevalence
4.3.5. Age-Specific IPF Prevalence
4.3.6. EU5
4.3.7. Prevalent Population of IPF in EU5
4.3.8. France
4.3.9. Prevalent Population of IPF
4.3.10. Prevalent Population of IPF by severity
4.3.11. Gender-Specific IPF Prevalence
4.3.12. Age-Specific IPF Prevalence
4.3.13. Germany
4.3.14. Prevalent Population of IPF
4.3.15. Prevalent Population of IPF by severity
4.3.16. Gender-Specific IPF Prevalence
4.3.17. Age-Specific IPF Prevalence
4.3.18. Italy
4.3.19. Prevalent Population of IPF
4.3.20. Prevalent Population of IPF by severity
4.3.21. Gender-Specific IPF Prevalence
4.3.22. Age-Specific IPF Prevalence
4.3.23. Spain
4.3.24. Prevalent Population of IPF
4.3.25. Prevalent Population of IPF by severity
4.3.26. Gender-Specific IPF Prevalence
4.3.27. Age-Specific IPF Prevalence
4.3.28. United Kingdom
4.3.29. Prevalent Population of IPF
4.3.30. Prevalent Population of IPF by severity
4.3.31. Gender-Specific IPF Prevalence
4.3.32. Age-Specific IPF Prevalence
4.3.33. Japan
4.3.34. Prevalent Population of IPF
4.3.35. Prevalent Population of IPF by severity
4.3.36. Gender-SPECIFIC IPF Prevalence
4.3.37. Age-Specific IPF Prevalence
5. Current Treatment Practices
5.1. ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of IPF (An Update of 2011 Clinical Practice Guideline)
6. Unmet needs
7. Marketed Products
7.1. Esbriet (Pirfenidone): InterMune Inc.
7.1.1. Product Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Safety and Efficacy of Esbriet
7.1.5. Side effects of Esbriet
7.1.6. Product Profile
7.2. Ofev (Nintedanib): Boehringer Ingelheim Pharma GmbH & Co. KG
7.2.1. Product Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Safety and Efficacy of Ofev
7.2.5. Side effects of Ofev
7.2.6. Product Profile
8. Emerging Therapies
9. Key Cross Competition
10. Phase III Drugs
10.1. Thrombomodulin Alfa: Asahi Kasei Pharma Corporation
10.1.1. Drug Description
10.1.2. Product Profile
10.1.3. Clinical Development
10.1.4. Clinical Trials Information
10.1.5. Safety and Efficacy
11. Phase II Drugs
11.1. CC-90001: Celgene Corporation
11.1.1. Drug Description
11.1.2. Product Profile
11.1.3. Clinical Development
11.1.4. Clinical Trials Information
11.1.5. Safety and Efficacy
11.1.6. Drug Description
11.1.7. Product Profile
11.1.8. Other Development Activities
11.1.9. Clinical Development
11.1.10. Clinical Trials Information
11.1.11. Safety and Efficacy
11.2. Gefapixant: Merck & Co., Inc.
11.2.1. Drug Description
11.2.2. Product Profile
11.2.3. Other Development Activities
11.2.4. Clinical Development
11.2.5. Clinical Trials Information
11.2.6. Safety and Efficacy
11.3. GLPG1690: Galapagos NV
11.3.1. Drug Description
11.3.2. Product Profile
11.3.3. Regulatory Milestones
11.3.4. Other Development Activities
11.3.5. Clinical Development
11.3.6. Clinical Trials Information
11.3.7. Safety and Efficacy
11.4. LT-1001: LTT Bio-Pharma
11.4.1. Drug Description
11.4.2. Product Profile
11.4.3. Other Development Activities
11.4.4. Clinical Development
11.4.5. Clinical Trials Information
11.4.6. Safety and Efficacy
11.5. BG00011: Biogen Inc.
11.5.1. Drug Description
11.5.2. Product Profile
11.5.3. Regulatory Milestones
11.5.4. Other Development Activities
11.5.5. Clinical Development
11.5.6. Clinical Trials Information
11.5.7. Safety and Efficacy
11.6. BMS-986020: Bristol-Myers Squibb
11.6.1. Drug Description
11.6.2. Product Profile
11.6.3. Regulatory Milestones
11.6.4. Other Development Activities
11.6.5. Clinical Development
11.6.6. Clinical Trials Information
11.6.7. Safety and Efficacy
11.7. LT-1002: Chong Kun Dang Pharmaceutical
11.7.1. Drug Description
11.7.2. Product Profile
11.7.3. Other Development Activities
11.8. Pamrevlumab: FibroGen
11.8.1. Drug Description
11.8.2. Product Profile
11.8.3. Regulatory Milestones
11.8.4. Other Development Activities
11.8.5. Clinical Development
11.8.6. Clinical Trials Information
11.8.7. Safety and Efficacy
11.9. PBI4050: ProMetic Life Sciences
11.9.1. Drug Description
11.9.2. Product Profile
11.9.3. Regulatory Milestones
11.9.4. Other Development Activities
11.9.5. Clinical Development
11.9.6. Clinical Trials Information
11.9.7. Safety and Efficacy
11.10. PRM 151: Promedior, Inc.
11.10.1. Drug Description
11.10.2. Product Profile
11.10.3. Regulatory Milestones
11.10.4. Other Development Activities
11.10.5. Clinical Development
11.10.6. Clinical Trials Information
11.10.7. Safety and Efficacy
11.11. Tipelukast: MediciNova
11.11.1. Drug Description
11.11.2. Product Profile
11.11.3. Regulatory Milestones
11.11.4. Other Development Activities
11.11.5. Clinical Development
11.11.6. Clinical Trials Information
11.11.7. Safety and Efficacy
11.12. TD139: Bristol-Myers Squibb
11.12.1. Drug Description
11.12.2. Product Profile
11.12.3. Other Development Activities
11.12.4. Clinical Development
11.12.5. Clinical Trials Information
11.12.6. Safety and Efficacy
11.13. VAY736: Novartis
11.13.1. Drug Description
11.13.2. Product Profile
11.13.3. Other Development Activities
11.13.4. Clinical Development
11.13.5. Clinical Trials Information
11.14. TAS-115: Taiho Pharmaceutical
11.14.1. Drug Description
11.14.2. Product Profile
11.14.3. Clinical Development
11.14.4. Clinical Trials Information
12. IPF: Market Analysis
12.1. Key Findings
12.2. Total Market Size of IPF in 7 MM
12.3. Therapy Based Market Size of IPF in 7 MM
13. Market Size of IPF by Country
13.1. United States Market Analysis
13.1.1. Market Size of IPF in the US
13.1.2. Therapy Based Market Size of IPF in the US
13.2. EU5 Market Outlook
13.3. Germany
13.3.1. Market Size of IPF in Germany
13.3.2. Therapy Based Market Size of IPF in Germany
13.4. France
13.4.1. Market Size of IPF in France
13.4.2. Therapy Based Market Size of IPF in France
13.5. Italy
13.5.1. Market Size of IPF in Italy
13.5.2. Therapy Based Market Size of IPF in Italy
13.6. United Kingdom
13.6.1. Market Size of IPF in the UK
13.6.2. Therapy Based Market Size of IPF in the UK
13.7. Spain
13.7.1. Market Size of IPF in Spain
13.7.2. Therapy Based Market Size of IPF in Spain
13.8. Japan: Market Analysis
13.8.1. Market Size of IPF in Japan
13.8.2. Therapy Based Market Size of IPF in Japan
14. Market Drivers of IPF
15. Market Barriers of IPF
16. Appendix
16.1. Report Methodology
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

 

1. Key Insights
2. IPF Market Overview at a Glance
2.1. Market Share (%) Distribution of IPF in 2017
2.2. Market Share (%) Distribution of IPF in 2027
3. Disease Background and Overview: Idiopathic Pulmonary Fibrosis (IPF)
3.1. Introduction
3.2. Staging of IPF
3.3. Risk Factors & Disease Causes
3.4. Symptoms
3.5. Pathogenesis
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7 MM Prevalent Population of IPF
4.3. Country Wise-Epidemiology of IPF
4.3.1. United States
4.3.2. Prevalent cases of IPF in the United States
4.3.3. Prevalent Population of IPF by severity
4.3.4. Gender-Specific IPF Prevalence
4.3.5. Age-Specific IPF Prevalence
4.3.6. EU5
4.3.7. Prevalent Population of IPF in EU5
4.3.8. France
4.3.9. Prevalent Population of IPF
4.3.10. Prevalent Population of IPF by severity
4.3.11. Gender-Specific IPF Prevalence
4.3.12. Age-Specific IPF Prevalence
4.3.13. Germany
4.3.14. Prevalent Population of IPF
4.3.15. Prevalent Population of IPF by severity
4.3.16. Gender-Specific IPF Prevalence
4.3.17. Age-Specific IPF Prevalence
4.3.18. Italy
4.3.19. Prevalent Population of IPF
4.3.20. Prevalent Population of IPF by severity
4.3.21. Gender-Specific IPF Prevalence
4.3.22. Age-Specific IPF Prevalence
4.3.23. Spain
4.3.24. Prevalent Population of IPF
4.3.25. Prevalent Population of IPF by severity
4.3.26. Gender-Specific IPF Prevalence
4.3.27. Age-Specific IPF Prevalence
4.3.28. United Kingdom
4.3.29. Prevalent Population of IPF
4.3.30. Prevalent Population of IPF by severity
4.3.31. Gender-Specific IPF Prevalence
4.3.32. Age-Specific IPF Prevalence
4.3.33. Japan
4.3.34. Prevalent Population of IPF
4.3.35. Prevalent Population of IPF by severity
4.3.36. Gender-SPECIFIC IPF Prevalence
4.3.37. Age-Specific IPF Prevalence
5. Current Treatment Practices
5.1. ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of IPF (An Update of 2011 Clinical Practice Guideline)
6. Unmet needs
7. Marketed Products
7.1. Esbriet (Pirfenidone): InterMune Inc.
7.1.1. Product Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Safety and Efficacy of Esbriet
7.1.5. Side effects of Esbriet
7.1.6. Product Profile
7.2. Ofev (Nintedanib): Boehringer Ingelheim Pharma GmbH & Co. KG
7.2.1. Product Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Safety and Efficacy of Ofev
7.2.5. Side effects of Ofev
7.2.6. Product Profile
8. Emerging Therapies
9. Key Cross Competition
10. Phase III Drugs
10.1. Thrombomodulin Alfa: Asahi Kasei Pharma Corporation
10.1.1. Drug Description
10.1.2. Product Profile
10.1.3. Clinical Development
10.1.4. Clinical Trials Information
10.1.5. Safety and Efficacy
11. Phase II Drugs
11.1. CC-90001: Celgene Corporation
11.1.1. Drug Description
11.1.2. Product Profile
11.1.3. Clinical Development
11.1.4. Clinical Trials Information
11.1.5. Safety and Efficacy
11.1.6. Drug Description
11.1.7. Product Profile
11.1.8. Other Development Activities
11.1.9. Clinical Development
11.1.10. Clinical Trials Information
11.1.11. Safety and Efficacy
11.2. Gefapixant: Merck & Co., Inc.
11.2.1. Drug Description
11.2.2. Product Profile
11.2.3. Other Development Activities
11.2.4. Clinical Development
11.2.5. Clinical Trials Information
11.2.6. Safety and Efficacy
11.3. GLPG1690: Galapagos NV
11.3.1. Drug Description
11.3.2. Product Profile
11.3.3. Regulatory Milestones
11.3.4. Other Development Activities
11.3.5. Clinical Development
11.3.6. Clinical Trials Information
11.3.7. Safety and Efficacy
11.4. LT-1001: LTT Bio-Pharma
11.4.1. Drug Description
11.4.2. Product Profile
11.4.3. Other Development Activities
11.4.4. Clinical Development
11.4.5. Clinical Trials Information
11.4.6. Safety and Efficacy
11.5. BG00011: Biogen Inc.
11.5.1. Drug Description
11.5.2. Product Profile
11.5.3. Regulatory Milestones
11.5.4. Other Development Activities
11.5.5. Clinical Development
11.5.6. Clinical Trials Information
11.5.7. Safety and Efficacy
11.6. BMS-986020: Bristol-Myers Squibb
11.6.1. Drug Description
11.6.2. Product Profile
11.6.3. Regulatory Milestones
11.6.4. Other Development Activities
11.6.5. Clinical Development
11.6.6. Clinical Trials Information
11.6.7. Safety and Efficacy
11.7. LT-1002: Chong Kun Dang Pharmaceutical
11.7.1. Drug Description
11.7.2. Product Profile
11.7.3. Other Development Activities
11.8. Pamrevlumab: FibroGen
11.8.1. Drug Description
11.8.2. Product Profile
11.8.3. Regulatory Milestones
11.8.4. Other Development Activities
11.8.5. Clinical Development
11.8.6. Clinical Trials Information
11.8.7. Safety and Efficacy
11.9. PBI4050: ProMetic Life Sciences
11.9.1. Drug Description
11.9.2. Product Profile
11.9.3. Regulatory Milestones
11.9.4. Other Development Activities
11.9.5. Clinical Development
11.9.6. Clinical Trials Information
11.9.7. Safety and Efficacy
11.10. PRM 151: Promedior, Inc.
11.10.1. Drug Description
11.10.2. Product Profile
11.10.3. Regulatory Milestones
11.10.4. Other Development Activities
11.10.5. Clinical Development
11.10.6. Clinical Trials Information
11.10.7. Safety and Efficacy
11.11. Tipelukast: MediciNova
11.11.1. Drug Description
11.11.2. Product Profile
11.11.3. Regulatory Milestones
11.11.4. Other Development Activities
11.11.5. Clinical Development
11.11.6. Clinical Trials Information
11.11.7. Safety and Efficacy
11.12. TD139: Bristol-Myers Squibb
11.12.1. Drug Description
11.12.2. Product Profile
11.12.3. Other Development Activities
11.12.4. Clinical Development
11.12.5. Clinical Trials Information
11.12.6. Safety and Efficacy
11.13. VAY736: Novartis
11.13.1. Drug Description
11.13.2. Product Profile
11.13.3. Other Development Activities
11.13.4. Clinical Development
11.13.5. Clinical Trials Information
11.14. TAS-115: Taiho Pharmaceutical
11.14.1. Drug Description
11.14.2. Product Profile
11.14.3. Clinical Development
11.14.4. Clinical Trials Information
12. IPF: Market Analysis
12.1. Key Findings
12.2. Total Market Size of IPF in 7 MM
12.3. Therapy Based Market Size of IPF in 7 MM
13. Market Size of IPF by Country
13.1. United States Market Analysis
13.1.1. Market Size of IPF in the US
13.1.2. Therapy Based Market Size of IPF in the US
13.2. EU5 Market Outlook
13.3. Germany
13.3.1. Market Size of IPF in Germany
13.3.2. Therapy Based Market Size of IPF in Germany
13.4. France
13.4.1. Market Size of IPF in France
13.4.2. Therapy Based Market Size of IPF in France
13.5. Italy
13.5.1. Market Size of IPF in Italy
13.5.2. Therapy Based Market Size of IPF in Italy
13.6. United Kingdom
13.6.1. Market Size of IPF in the UK
13.6.2. Therapy Based Market Size of IPF in the UK
13.7. Spain
13.7.1. Market Size of IPF in Spain
13.7.2. Therapy Based Market Size of IPF in Spain
13.8. Japan: Market Analysis
13.8.1. Market Size of IPF in Japan
13.8.2. Therapy Based Market Size of IPF in Japan
14. Market Drivers of IPF
15. Market Barriers of IPF
16. Appendix
16.1. Report Methodology
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

 

1. Key Insights
2. IPF Market Overview at a Glance
2.1. Market Share (%) Distribution of IPF in 2017
2.2. Market Share (%) Distribution of IPF in 2027
3. Disease Background and Overview: Idiopathic Pulmonary Fibrosis (IPF)
3.1. Introduction
3.2. Staging of IPF
3.3. Risk Factors & Disease Causes
3.4. Symptoms
3.5. Pathogenesis
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7 MM Prevalent Population of IPF
4.3. Country Wise-Epidemiology of IPF
4.3.1. United States
4.3.2. Prevalent cases of IPF in the United States
4.3.3. Prevalent Population of IPF by severity
4.3.4. Gender-Specific IPF Prevalence
4.3.5. Age-Specific IPF Prevalence
4.3.6. EU5
4.3.7. Prevalent Population of IPF in EU5
4.3.8. France
4.3.9. Prevalent Population of IPF
4.3.10. Prevalent Population of IPF by severity
4.3.11. Gender-Specific IPF Prevalence
4.3.12. Age-Specific IPF Prevalence
4.3.13. Germany
4.3.14. Prevalent Population of IPF
4.3.15. Prevalent Population of IPF by severity
4.3.16. Gender-Specific IPF Prevalence
4.3.17. Age-Specific IPF Prevalence
4.3.18. Italy
4.3.19. Prevalent Population of IPF
4.3.20. Prevalent Population of IPF by severity
4.3.21. Gender-Specific IPF Prevalence
4.3.22. Age-Specific IPF Prevalence
4.3.23. Spain
4.3.24. Prevalent Population of IPF
4.3.25. Prevalent Population of IPF by severity
4.3.26. Gender-Specific IPF Prevalence
4.3.27. Age-Specific IPF Prevalence
4.3.28. United Kingdom
4.3.29. Prevalent Population of IPF
4.3.30. Prevalent Population of IPF by severity
4.3.31. Gender-Specific IPF Prevalence
4.3.32. Age-Specific IPF Prevalence
4.3.33. Japan
4.3.34. Prevalent Population of IPF
4.3.35. Prevalent Population of IPF by severity
4.3.36. Gender-SPECIFIC IPF Prevalence
4.3.37. Age-Specific IPF Prevalence
5. Current Treatment Practices
5.1. ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of IPF (An Update of 2011 Clinical Practice Guideline)
6. Unmet needs
7. Marketed Products
7.1. Esbriet (Pirfenidone): InterMune Inc.
7.1.1. Product Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Safety and Efficacy of Esbriet
7.1.5. Side effects of Esbriet
7.1.6. Product Profile
7.2. Ofev (Nintedanib): Boehringer Ingelheim Pharma GmbH & Co. KG
7.2.1. Product Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Safety and Efficacy of Ofev
7.2.5. Side effects of Ofev
7.2.6. Product Profile
8. Emerging Therapies
9. Key Cross Competition
10. Phase III Drugs
10.1. Thrombomodulin Alfa: Asahi Kasei Pharma Corporation
10.1.1. Drug Description
10.1.2. Product Profile
10.1.3. Clinical Development
10.1.4. Clinical Trials Information
10.1.5. Safety and Efficacy
11. Phase II Drugs
11.1. CC-90001: Celgene Corporation
11.1.1. Drug Description
11.1.2. Product Profile
11.1.3. Clinical Development
11.1.4. Clinical Trials Information
11.1.5. Safety and Efficacy
11.1.6. Drug Description
11.1.7. Product Profile
11.1.8. Other Development Activities
11.1.9. Clinical Development
11.1.10. Clinical Trials Information
11.1.11. Safety and Efficacy
11.2. Gefapixant: Merck & Co., Inc.
11.2.1. Drug Description
11.2.2. Product Profile
11.2.3. Other Development Activities
11.2.4. Clinical Development
11.2.5. Clinical Trials Information
11.2.6. Safety and Efficacy
11.3. GLPG1690: Galapagos NV
11.3.1. Drug Description
11.3.2. Product Profile
11.3.3. Regulatory Milestones
11.3.4. Other Development Activities
11.3.5. Clinical Development
11.3.6. Clinical Trials Information
11.3.7. Safety and Efficacy
11.4. LT-1001: LTT Bio-Pharma
11.4.1. Drug Description
11.4.2. Product Profile
11.4.3. Other Development Activities
11.4.4. Clinical Development
11.4.5. Clinical Trials Information
11.4.6. Safety and Efficacy
11.5. BG00011: Biogen Inc.
11.5.1. Drug Description
11.5.2. Product Profile
11.5.3. Regulatory Milestones
11.5.4. Other Development Activities
11.5.5. Clinical Development
11.5.6. Clinical Trials Information
11.5.7. Safety and Efficacy
11.6. BMS-986020: Bristol-Myers Squibb
11.6.1. Drug Description
11.6.2. Product Profile
11.6.3. Regulatory Milestones
11.6.4. Other Development Activities
11.6.5. Clinical Development
11.6.6. Clinical Trials Information
11.6.7. Safety and Efficacy
11.7. LT-1002: Chong Kun Dang Pharmaceutical
11.7.1. Drug Description
11.7.2. Product Profile
11.7.3. Other Development Activities
11.8. Pamrevlumab: FibroGen
11.8.1. Drug Description
11.8.2. Product Profile
11.8.3. Regulatory Milestones
11.8.4. Other Development Activities
11.8.5. Clinical Development
11.8.6. Clinical Trials Information
11.8.7. Safety and Efficacy
11.9. PBI4050: ProMetic Life Sciences
11.9.1. Drug Description
11.9.2. Product Profile
11.9.3. Regulatory Milestones
11.9.4. Other Development Activities
11.9.5. Clinical Development
11.9.6. Clinical Trials Information
11.9.7. Safety and Efficacy
11.10. PRM 151: Promedior, Inc.
11.10.1. Drug Description
11.10.2. Product Profile
11.10.3. Regulatory Milestones
11.10.4. Other Development Activities
11.10.5. Clinical Development
11.10.6. Clinical Trials Information
11.10.7. Safety and Efficacy
11.11. Tipelukast: MediciNova
11.11.1. Drug Description
11.11.2. Product Profile
11.11.3. Regulatory Milestones
11.11.4. Other Development Activities
11.11.5. Clinical Development
11.11.6. Clinical Trials Information
11.11.7. Safety and Efficacy
11.12. TD139: Bristol-Myers Squibb
11.12.1. Drug Description
11.12.2. Product Profile
11.12.3. Other Development Activities
11.12.4. Clinical Development
11.12.5. Clinical Trials Information
11.12.6. Safety and Efficacy
11.13. VAY736: Novartis
11.13.1. Drug Description
11.13.2. Product Profile
11.13.3. Other Development Activities
11.13.4. Clinical Development
11.13.5. Clinical Trials Information
11.14. TAS-115: Taiho Pharmaceutical
11.14.1. Drug Description
11.14.2. Product Profile
11.14.3. Clinical Development
11.14.4. Clinical Trials Information
12. IPF: Market Analysis
12.1. Key Findings
12.2. Total Market Size of IPF in 7 MM
12.3. Therapy Based Market Size of IPF in 7 MM
13. Market Size of IPF by Country
13.1. United States Market Analysis
13.1.1. Market Size of IPF in the US
13.1.2. Therapy Based Market Size of IPF in the US
13.2. EU5 Market Outlook
13.3. Germany
13.3.1. Market Size of IPF in Germany
13.3.2. Therapy Based Market Size of IPF in Germany
13.4. France
13.4.1. Market Size of IPF in France
13.4.2. Therapy Based Market Size of IPF in France
13.5. Italy
13.5.1. Market Size of IPF in Italy
13.5.2. Therapy Based Market Size of IPF in Italy
13.6. United Kingdom
13.6.1. Market Size of IPF in the UK
13.6.2. Therapy Based Market Size of IPF in the UK
13.7. Spain
13.7.1. Market Size of IPF in Spain
13.7.2. Therapy Based Market Size of IPF in Spain
13.8. Japan: Market Analysis
13.8.1. Market Size of IPF in Japan
13.8.2. Therapy Based Market Size of IPF in Japan
14. Market Drivers of IPF
15. Market Barriers of IPF
16. Appendix
16.1. Report Methodology
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

 

1. Key Insights
2. IPF Market Overview at a Glance
2.1. Market Share (%) Distribution of IPF in 2017
2.2. Market Share (%) Distribution of IPF in 2027
3. Disease Background and Overview: Idiopathic Pulmonary Fibrosis (IPF)
3.1. Introduction
3.2. Staging of IPF
3.3. Risk Factors & Disease Causes
3.4. Symptoms
3.5. Pathogenesis
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7 MM Prevalent Population of IPF
4.3. Country Wise-Epidemiology of IPF
4.3.1. United States
4.3.2. Prevalent cases of IPF in the United States
4.3.3. Prevalent Population of IPF by severity
4.3.4. Gender-Specific IPF Prevalence
4.3.5. Age-Specific IPF Prevalence
4.3.6. EU5
4.3.7. Prevalent Population of IPF in EU5
4.3.8. France
4.3.9. Prevalent Population of IPF
4.3.10. Prevalent Population of IPF by severity
4.3.11. Gender-Specific IPF Prevalence
4.3.12. Age-Specific IPF Prevalence
4.3.13. Germany
4.3.14. Prevalent Population of IPF
4.3.15. Prevalent Population of IPF by severity
4.3.16. Gender-Specific IPF Prevalence
4.3.17. Age-Specific IPF Prevalence
4.3.18. Italy
4.3.19. Prevalent Population of IPF
4.3.20. Prevalent Population of IPF by severity
4.3.21. Gender-Specific IPF Prevalence
4.3.22. Age-Specific IPF Prevalence
4.3.23. Spain
4.3.24. Prevalent Population of IPF
4.3.25. Prevalent Population of IPF by severity
4.3.26. Gender-Specific IPF Prevalence
4.3.27. Age-Specific IPF Prevalence
4.3.28. United Kingdom
4.3.29. Prevalent Population of IPF
4.3.30. Prevalent Population of IPF by severity
4.3.31. Gender-Specific IPF Prevalence
4.3.32. Age-Specific IPF Prevalence
4.3.33. Japan
4.3.34. Prevalent Population of IPF
4.3.35. Prevalent Population of IPF by severity
4.3.36. Gender-SPECIFIC IPF Prevalence
4.3.37. Age-Specific IPF Prevalence
5. Current Treatment Practices
5.1. ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of IPF (An Update of 2011 Clinical Practice Guideline)
6. Unmet needs
7. Marketed Products
7.1. Esbriet (Pirfenidone): InterMune Inc.
7.1.1. Product Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Safety and Efficacy of Esbriet
7.1.5. Side effects of Esbriet
7.1.6. Product Profile
7.2. Ofev (Nintedanib): Boehringer Ingelheim Pharma GmbH & Co. KG
7.2.1. Product Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Safety and Efficacy of Ofev
7.2.5. Side effects of Ofev
7.2.6. Product Profile
8. Emerging Therapies
9. Key Cross Competition
10. Phase III Drugs
10.1. Thrombomodulin Alfa: Asahi Kasei Pharma Corporation
10.1.1. Drug Description
10.1.2. Product Profile
10.1.3. Clinical Development
10.1.4. Clinical Trials Information
10.1.5. Safety and Efficacy
11. Phase II Drugs
11.1. CC-90001: Celgene Corporation
11.1.1. Drug Description
11.1.2. Product Profile
11.1.3. Clinical Development
11.1.4. Clinical Trials Information
11.1.5. Safety and Efficacy
11.1.6. Drug Description
11.1.7. Product Profile
11.1.8. Other Development Activities
11.1.9. Clinical Development
11.1.10. Clinical Trials Information
11.1.11. Safety and Efficacy
11.2. Gefapixant: Merck & Co., Inc.
11.2.1. Drug Description
11.2.2. Product Profile
11.2.3. Other Development Activities
11.2.4. Clinical Development
11.2.5. Clinical Trials Information
11.2.6. Safety and Efficacy
11.3. GLPG1690: Galapagos NV
11.3.1. Drug Description
11.3.2. Product Profile
11.3.3. Regulatory Milestones
11.3.4. Other Development Activities
11.3.5. Clinical Development
11.3.6. Clinical Trials Information
11.3.7. Safety and Efficacy
11.4. LT-1001: LTT Bio-Pharma
11.4.1. Drug Description
11.4.2. Product Profile
11.4.3. Other Development Activities
11.4.4. Clinical Development
11.4.5. Clinical Trials Information
11.4.6. Safety and Efficacy
11.5. BG00011: Biogen Inc.
11.5.1. Drug Description
11.5.2. Product Profile
11.5.3. Regulatory Milestones
11.5.4. Other Development Activities
11.5.5. Clinical Development
11.5.6. Clinical Trials Information
11.5.7. Safety and Efficacy
11.6. BMS-986020: Bristol-Myers Squibb
11.6.1. Drug Description
11.6.2. Product Profile
11.6.3. Regulatory Milestones
11.6.4. Other Development Activities
11.6.5. Clinical Development
11.6.6. Clinical Trials Information
11.6.7. Safety and Efficacy
11.7. LT-1002: Chong Kun Dang Pharmaceutical
11.7.1. Drug Description
11.7.2. Product Profile
11.7.3. Other Development Activities
11.8. Pamrevlumab: FibroGen
11.8.1. Drug Description
11.8.2. Product Profile
11.8.3. Regulatory Milestones
11.8.4. Other Development Activities
11.8.5. Clinical Development
11.8.6. Clinical Trials Information
11.8.7. Safety and Efficacy
11.9. PBI4050: ProMetic Life Sciences
11.9.1. Drug Description
11.9.2. Product Profile
11.9.3. Regulatory Milestones
11.9.4. Other Development Activities
11.9.5. Clinical Development
11.9.6. Clinical Trials Information
11.9.7. Safety and Efficacy
11.10. PRM 151: Promedior, Inc.
11.10.1. Drug Description
11.10.2. Product Profile
11.10.3. Regulatory Milestones
11.10.4. Other Development Activities
11.10.5. Clinical Development
11.10.6. Clinical Trials Information
11.10.7. Safety and Efficacy
11.11. Tipelukast: MediciNova
11.11.1. Drug Description
11.11.2. Product Profile
11.11.3. Regulatory Milestones
11.11.4. Other Development Activities
11.11.5. Clinical Development
11.11.6. Clinical Trials Information
11.11.7. Safety and Efficacy
11.12. TD139: Bristol-Myers Squibb
11.12.1. Drug Description
11.12.2. Product Profile
11.12.3. Other Development Activities
11.12.4. Clinical Development
11.12.5. Clinical Trials Information
11.12.6. Safety and Efficacy
11.13. VAY736: Novartis
11.13.1. Drug Description
11.13.2. Product Profile
11.13.3. Other Development Activities
11.13.4. Clinical Development
11.13.5. Clinical Trials Information
11.14. TAS-115: Taiho Pharmaceutical
11.14.1. Drug Description
11.14.2. Product Profile
11.14.3. Clinical Development
11.14.4. Clinical Trials Information
12. IPF: Market Analysis
12.1. Key Findings
12.2. Total Market Size of IPF in 7 MM
12.3. Therapy Based Market Size of IPF in 7 MM
13. Market Size of IPF by Country
13.1. United States Market Analysis
13.1.1. Market Size of IPF in the US
13.1.2. Therapy Based Market Size of IPF in the US
13.2. EU5 Market Outlook
13.3. Germany
13.3.1. Market Size of IPF in Germany
13.3.2. Therapy Based Market Size of IPF in Germany
13.4. France
13.4.1. Market Size of IPF in France
13.4.2. Therapy Based Market Size of IPF in France
13.5. Italy
13.5.1. Market Size of IPF in Italy
13.5.2. Therapy Based Market Size of IPF in Italy
13.6. United Kingdom
13.6.1. Market Size of IPF in the UK
13.6.2. Therapy Based Market Size of IPF in the UK
13.7. Spain
13.7.1. Market Size of IPF in Spain
13.7.2. Therapy Based Market Size of IPF in Spain
13.8. Japan: Market Analysis
13.8.1. Market Size of IPF in Japan
13.8.2. Therapy Based Market Size of IPF in Japan
14. Market Drivers of IPF
15. Market Barriers of IPF
16. Appendix
16.1. Report Methodology
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

 

1. Key Insights
2. IPF Market Overview at a Glance
2.1. Market Share (%) Distribution of IPF in 2017
2.2. Market Share (%) Distribution of IPF in 2027
3. Disease Background and Overview: Idiopathic Pulmonary Fibrosis (IPF)
3.1. Introduction
3.2. Staging of IPF
3.3. Risk Factors & Disease Causes
3.4. Symptoms
3.5. Pathogenesis
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7 MM Prevalent Population of IPF
4.3. Country Wise-Epidemiology of IPF
4.3.1. United States
4.3.2. Prevalent cases of IPF in the United States
4.3.3. Prevalent Population of IPF by severity
4.3.4. Gender-Specific IPF Prevalence
4.3.5. Age-Specific IPF Prevalence
4.3.6. EU5
4.3.7. Prevalent Population of IPF in EU5
4.3.8. France
4.3.9. Prevalent Population of IPF
4.3.10. Prevalent Population of IPF by severity
4.3.11. Gender-Specific IPF Prevalence
4.3.12. Age-Specific IPF Prevalence
4.3.13. Germany
4.3.14. Prevalent Population of IPF
4.3.15. Prevalent Population of IPF by severity
4.3.16. Gender-Specific IPF Prevalence
4.3.17. Age-Specific IPF Prevalence
4.3.18. Italy
4.3.19. Prevalent Population of IPF
4.3.20. Prevalent Population of IPF by severity
4.3.21. Gender-Specific IPF Prevalence
4.3.22. Age-Specific IPF Prevalence
4.3.23. Spain
4.3.24. Prevalent Population of IPF
4.3.25. Prevalent Population of IPF by severity
4.3.26. Gender-Specific IPF Prevalence
4.3.27. Age-Specific IPF Prevalence
4.3.28. United Kingdom
4.3.29. Prevalent Population of IPF
4.3.30. Prevalent Population of IPF by severity
4.3.31. Gender-Specific IPF Prevalence
4.3.32. Age-Specific IPF Prevalence
4.3.33. Japan
4.3.34. Prevalent Population of IPF
4.3.35. Prevalent Population of IPF by severity
4.3.36. Gender-SPECIFIC IPF Prevalence
4.3.37. Age-Specific IPF Prevalence
5. Current Treatment Practices
5.1. ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of IPF (An Update of 2011 Clinical Practice Guideline)
6. Unmet needs
7. Marketed Products
7.1. Esbriet (Pirfenidone): InterMune Inc.
7.1.1. Product Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Safety and Efficacy of Esbriet
7.1.5. Side effects of Esbriet
7.1.6. Product Profile
7.2. Ofev (Nintedanib): Boehringer Ingelheim Pharma GmbH & Co. KG
7.2.1. Product Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Safety and Efficacy of Ofev
7.2.5. Side effects of Ofev
7.2.6. Product Profile
8. Emerging Therapies
9. Key Cross Competition
10. Phase III Drugs
10.1. Thrombomodulin Alfa: Asahi Kasei Pharma Corporation
10.1.1. Drug Description
10.1.2. Product Profile
10.1.3. Clinical Development
10.1.4. Clinical Trials Information
10.1.5. Safety and Efficacy
11. Phase II Drugs
11.1. CC-90001: Celgene Corporation
11.1.1. Drug Description
11.1.2. Product Profile
11.1.3. Clinical Development
11.1.4. Clinical Trials Information
11.1.5. Safety and Efficacy
11.1.6. Drug Description
11.1.7. Product Profile
11.1.8. Other Development Activities
11.1.9. Clinical Development
11.1.10. Clinical Trials Information
11.1.11. Safety and Efficacy
11.2. Gefapixant: Merck & Co., Inc.
11.2.1. Drug Description
11.2.2. Product Profile
11.2.3. Other Development Activities
11.2.4. Clinical Development
11.2.5. Clinical Trials Information
11.2.6. Safety and Efficacy
11.3. GLPG1690: Galapagos NV
11.3.1. Drug Description
11.3.2. Product Profile
11.3.3. Regulatory Milestones
11.3.4. Other Development Activities
11.3.5. Clinical Development
11.3.6. Clinical Trials Information
11.3.7. Safety and Efficacy
11.4. LT-1001: LTT Bio-Pharma
11.4.1. Drug Description
11.4.2. Product Profile
11.4.3. Other Development Activities
11.4.4. Clinical Development
11.4.5. Clinical Trials Information
11.4.6. Safety and Efficacy
11.5. BG00011: Biogen Inc.
11.5.1. Drug Description
11.5.2. Product Profile
11.5.3. Regulatory Milestones
11.5.4. Other Development Activities
11.5.5. Clinical Development
11.5.6. Clinical Trials Information
11.5.7. Safety and Efficacy
11.6. BMS-986020: Bristol-Myers Squibb
11.6.1. Drug Description
11.6.2. Product Profile
11.6.3. Regulatory Milestones
11.6.4. Other Development Activities
11.6.5. Clinical Development
11.6.6. Clinical Trials Information
11.6.7. Safety and Efficacy
11.7. LT-1002: Chong Kun Dang Pharmaceutical
11.7.1. Drug Description
11.7.2. Product Profile
11.7.3. Other Development Activities
11.8. Pamrevlumab: FibroGen
11.8.1. Drug Description
11.8.2. Product Profile
11.8.3. Regulatory Milestones
11.8.4. Other Development Activities
11.8.5. Clinical Development
11.8.6. Clinical Trials Information
11.8.7. Safety and Efficacy
11.9. PBI4050: ProMetic Life Sciences
11.9.1. Drug Description
11.9.2. Product Profile
11.9.3. Regulatory Milestones
11.9.4. Other Development Activities
11.9.5. Clinical Development
11.9.6. Clinical Trials Information
11.9.7. Safety and Efficacy
11.10. PRM 151: Promedior, Inc.
11.10.1. Drug Description
11.10.2. Product Profile
11.10.3. Regulatory Milestones
11.10.4. Other Development Activities
11.10.5. Clinical Development
11.10.6. Clinical Trials Information
11.10.7. Safety and Efficacy
11.11. Tipelukast: MediciNova
11.11.1. Drug Description
11.11.2. Product Profile
11.11.3. Regulatory Milestones
11.11.4. Other Development Activities
11.11.5. Clinical Development
11.11.6. Clinical Trials Information
11.11.7. Safety and Efficacy
11.12. TD139: Bristol-Myers Squibb
11.12.1. Drug Description
11.12.2. Product Profile
11.12.3. Other Development Activities
11.12.4. Clinical Development
11.12.5. Clinical Trials Information
11.12.6. Safety and Efficacy
11.13. VAY736: Novartis
11.13.1. Drug Description
11.13.2. Product Profile
11.13.3. Other Development Activities
11.13.4. Clinical Development
11.13.5. Clinical Trials Information
11.14. TAS-115: Taiho Pharmaceutical
11.14.1. Drug Description
11.14.2. Product Profile
11.14.3. Clinical Development
11.14.4. Clinical Trials Information
12. IPF: Market Analysis
12.1. Key Findings
12.2. Total Market Size of IPF in 7 MM
12.3. Therapy Based Market Size of IPF in 7 MM
13. Market Size of IPF by Country
13.1. United States Market Analysis
13.1.1. Market Size of IPF in the US
13.1.2. Therapy Based Market Size of IPF in the US
13.2. EU5 Market Outlook
13.3. Germany
13.3.1. Market Size of IPF in Germany
13.3.2. Therapy Based Market Size of IPF in Germany
13.4. France
13.4.1. Market Size of IPF in France
13.4.2. Therapy Based Market Size of IPF in France
13.5. Italy
13.5.1. Market Size of IPF in Italy
13.5.2. Therapy Based Market Size of IPF in Italy
13.6. United Kingdom
13.6.1. Market Size of IPF in the UK
13.6.2. Therapy Based Market Size of IPF in the UK
13.7. Spain
13.7.1. Market Size of IPF in Spain
13.7.2. Therapy Based Market Size of IPF in Spain
13.8. Japan: Market Analysis
13.8.1. Market Size of IPF in Japan
13.8.2. Therapy Based Market Size of IPF in Japan
14. Market Drivers of IPF
15. Market Barriers of IPF
16. Appendix
16.1. Report Methodology
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

 

1. Key Insights
2. IPF Market Overview at a Glance
2.1. Market Share (%) Distribution of IPF in 2017
2.2. Market Share (%) Distribution of IPF in 2027
3. Disease Background and Overview: Idiopathic Pulmonary Fibrosis (IPF)
3.1. Introduction
3.2. Staging of IPF
3.3. Risk Factors & Disease Causes
3.4. Symptoms
3.5. Pathogenesis
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7 MM Prevalent Population of IPF
4.3. Country Wise-Epidemiology of IPF
4.3.1. United States
4.3.2. Prevalent cases of IPF in the United States
4.3.3. Prevalent Population of IPF by severity
4.3.4. Gender-Specific IPF Prevalence
4.3.5. Age-Specific IPF Prevalence
4.3.6. EU5
4.3.7. Prevalent Population of IPF in EU5
4.3.8. France
4.3.9. Prevalent Population of IPF
4.3.10. Prevalent Population of IPF by severity
4.3.11. Gender-Specific IPF Prevalence
4.3.12. Age-Specific IPF Prevalence
4.3.13. Germany
4.3.14. Prevalent Population of IPF
4.3.15. Prevalent Population of IPF by severity
4.3.16. Gender-Specific IPF Prevalence
4.3.17. Age-Specific IPF Prevalence
4.3.18. Italy
4.3.19. Prevalent Population of IPF
4.3.20. Prevalent Population of IPF by severity
4.3.21. Gender-Specific IPF Prevalence
4.3.22. Age-Specific IPF Prevalence
4.3.23. Spain
4.3.24. Prevalent Population of IPF
4.3.25. Prevalent Population of IPF by severity
4.3.26. Gender-Specific IPF Prevalence
4.3.27. Age-Specific IPF Prevalence
4.3.28. United Kingdom
4.3.29. Prevalent Population of IPF
4.3.30. Prevalent Population of IPF by severity
4.3.31. Gender-Specific IPF Prevalence
4.3.32. Age-Specific IPF Prevalence
4.3.33. Japan
4.3.34. Prevalent Population of IPF
4.3.35. Prevalent Population of IPF by severity
4.3.36. Gender-SPECIFIC IPF Prevalence
4.3.37. Age-Specific IPF Prevalence
5. Current Treatment Practices
5.1. ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of IPF (An Update of 2011 Clinical Practice Guideline)
6. Unmet needs
7. Marketed Products
7.1. Esbriet (Pirfenidone): InterMune Inc.
7.1.1. Product Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Safety and Efficacy of Esbriet
7.1.5. Side effects of Esbriet
7.1.6. Product Profile
7.2. Ofev (Nintedanib): Boehringer Ingelheim Pharma GmbH & Co. KG
7.2.1. Product Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Safety and Efficacy of Ofev
7.2.5. Side effects of Ofev
7.2.6. Product Profile
8. Emerging Therapies
9. Key Cross Competition
10. Phase III Drugs
10.1. Thrombomodulin Alfa: Asahi Kasei Pharma Corporation
10.1.1. Drug Description
10.1.2. Product Profile
10.1.3. Clinical Development
10.1.4. Clinical Trials Information
10.1.5. Safety and Efficacy
11. Phase II Drugs
11.1. CC-90001: Celgene Corporation
11.1.1. Drug Description
11.1.2. Product Profile
11.1.3. Clinical Development
11.1.4. Clinical Trials Information
11.1.5. Safety and Efficacy
11.1.6. Drug Description
11.1.7. Product Profile
11.1.8. Other Development Activities
11.1.9. Clinical Development
11.1.10. Clinical Trials Information
11.1.11. Safety and Efficacy
11.2. Gefapixant: Merck & Co., Inc.
11.2.1. Drug Description
11.2.2. Product Profile
11.2.3. Other Development Activities
11.2.4. Clinical Development
11.2.5. Clinical Trials Information
11.2.6. Safety and Efficacy
11.3. GLPG1690: Galapagos NV
11.3.1. Drug Description
11.3.2. Product Profile
11.3.3. Regulatory Milestones
11.3.4. Other Development Activities
11.3.5. Clinical Development
11.3.6. Clinical Trials Information
11.3.7. Safety and Efficacy
11.4. LT-1001: LTT Bio-Pharma
11.4.1. Drug Description
11.4.2. Product Profile
11.4.3. Other Development Activities
11.4.4. Clinical Development
11.4.5. Clinical Trials Information
11.4.6. Safety and Efficacy
11.5. BG00011: Biogen Inc.
11.5.1. Drug Description
11.5.2. Product Profile
11.5.3. Regulatory Milestones
11.5.4. Other Development Activities
11.5.5. Clinical Development
11.5.6. Clinical Trials Information
11.5.7. Safety and Efficacy
11.6. BMS-986020: Bristol-Myers Squibb
11.6.1. Drug Description
11.6.2. Product Profile
11.6.3. Regulatory Milestones
11.6.4. Other Development Activities
11.6.5. Clinical Development
11.6.6. Clinical Trials Information
11.6.7. Safety and Efficacy
11.7. LT-1002: Chong Kun Dang Pharmaceutical
11.7.1. Drug Description
11.7.2. Product Profile
11.7.3. Other Development Activities
11.8. Pamrevlumab: FibroGen
11.8.1. Drug Description
11.8.2. Product Profile
11.8.3. Regulatory Milestones
11.8.4. Other Development Activities
11.8.5. Clinical Development
11.8.6. Clinical Trials Information
11.8.7. Safety and Efficacy
11.9. PBI4050: ProMetic Life Sciences
11.9.1. Drug Description
11.9.2. Product Profile
11.9.3. Regulatory Milestones
11.9.4. Other Development Activities
11.9.5. Clinical Development
11.9.6. Clinical Trials Information
11.9.7. Safety and Efficacy
11.10. PRM 151: Promedior, Inc.
11.10.1. Drug Description
11.10.2. Product Profile
11.10.3. Regulatory Milestones
11.10.4. Other Development Activities
11.10.5. Clinical Development
11.10.6. Clinical Trials Information
11.10.7. Safety and Efficacy
11.11. Tipelukast: MediciNova
11.11.1. Drug Description
11.11.2. Product Profile
11.11.3. Regulatory Milestones
11.11.4. Other Development Activities
11.11.5. Clinical Development
11.11.6. Clinical Trials Information
11.11.7. Safety and Efficacy
11.12. TD139: Bristol-Myers Squibb
11.12.1. Drug Description
11.12.2. Product Profile
11.12.3. Other Development Activities
11.12.4. Clinical Development
11.12.5. Clinical Trials Information
11.12.6. Safety and Efficacy
11.13. VAY736: Novartis
11.13.1. Drug Description
11.13.2. Product Profile
11.13.3. Other Development Activities
11.13.4. Clinical Development
11.13.5. Clinical Trials Information
11.14. TAS-115: Taiho Pharmaceutical
11.14.1. Drug Description
11.14.2. Product Profile
11.14.3. Clinical Development
11.14.4. Clinical Trials Information
12. IPF: Market Analysis
12.1. Key Findings
12.2. Total Market Size of IPF in 7 MM
12.3. Therapy Based Market Size of IPF in 7 MM
13. Market Size of IPF by Country
13.1. United States Market Analysis
13.1.1. Market Size of IPF in the US
13.1.2. Therapy Based Market Size of IPF in the US
13.2. EU5 Market Outlook
13.3. Germany
13.3.1. Market Size of IPF in Germany
13.3.2. Therapy Based Market Size of IPF in Germany
13.4. France
13.4.1. Market Size of IPF in France
13.4.2. Therapy Based Market Size of IPF in France
13.5. Italy
13.5.1. Market Size of IPF in Italy
13.5.2. Therapy Based Market Size of IPF in Italy
13.6. United Kingdom
13.6.1. Market Size of IPF in the UK
13.6.2. Therapy Based Market Size of IPF in the UK
13.7. Spain
13.7.1. Market Size of IPF in Spain
13.7.2. Therapy Based Market Size of IPF in Spain
13.8. Japan: Market Analysis
13.8.1. Market Size of IPF in Japan
13.8.2. Therapy Based Market Size of IPF in Japan
14. Market Drivers of IPF
15. Market Barriers of IPF
16. Appendix
16.1. Report Methodology
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

 

1. Key Insights
2. IPF Market Overview at a Glance
2.1. Market Share (%) Distribution of IPF in 2017
2.2. Market Share (%) Distribution of IPF in 2027
3. Disease Background and Overview: Idiopathic Pulmonary Fibrosis (IPF)
3.1. Introduction
3.2. Staging of IPF
3.3. Risk Factors & Disease Causes
3.4. Symptoms
3.5. Pathogenesis
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7 MM Prevalent Population of IPF
4.3. Country Wise-Epidemiology of IPF
4.3.1. United States
4.3.2. Prevalent cases of IPF in the United States
4.3.3. Prevalent Population of IPF by severity
4.3.4. Gender-Specific IPF Prevalence
4.3.5. Age-Specific IPF Prevalence
4.3.6. EU5
4.3.7. Prevalent Population of IPF in EU5
4.3.8. France
4.3.9. Prevalent Population of IPF
4.3.10. Prevalent Population of IPF by severity
4.3.11. Gender-Specific IPF Prevalence
4.3.12. Age-Specific IPF Prevalence
4.3.13. Germany
4.3.14. Prevalent Population of IPF
4.3.15. Prevalent Population of IPF by severity
4.3.16. Gender-Specific IPF Prevalence
4.3.17. Age-Specific IPF Prevalence
4.3.18. Italy
4.3.19. Prevalent Population of IPF
4.3.20. Prevalent Population of IPF by severity
4.3.21. Gender-Specific IPF Prevalence
4.3.22. Age-Specific IPF Prevalence
4.3.23. Spain
4.3.24. Prevalent Population of IPF
4.3.25. Prevalent Population of IPF by severity
4.3.26. Gender-Specific IPF Prevalence
4.3.27. Age-Specific IPF Prevalence
4.3.28. United Kingdom
4.3.29. Prevalent Population of IPF
4.3.30. Prevalent Population of IPF by severity
4.3.31. Gender-Specific IPF Prevalence
4.3.32. Age-Specific IPF Prevalence
4.3.33. Japan
4.3.34. Prevalent Population of IPF
4.3.35. Prevalent Population of IPF by severity
4.3.36. Gender-SPECIFIC IPF Prevalence
4.3.37. Age-Specific IPF Prevalence
5. Current Treatment Practices
5.1. ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of IPF (An Update of 2011 Clinical Practice Guideline)
6. Unmet needs
7. Marketed Products
7.1. Esbriet (Pirfenidone): InterMune Inc.
7.1.1. Product Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Safety and Efficacy of Esbriet
7.1.5. Side effects of Esbriet
7.1.6. Product Profile
7.2. Ofev (Nintedanib): Boehringer Ingelheim Pharma GmbH & Co. KG
7.2.1. Product Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Safety and Efficacy of Ofev
7.2.5. Side effects of Ofev
7.2.6. Product Profile
8. Emerging Therapies
9. Key Cross Competition
10. Phase III Drugs
10.1. Thrombomodulin Alfa: Asahi Kasei Pharma Corporation
10.1.1. Drug Description
10.1.2. Product Profile
10.1.3. Clinical Development
10.1.4. Clinical Trials Information
10.1.5. Safety and Efficacy
11. Phase II Drugs
11.1. CC-90001: Celgene Corporation
11.1.1. Drug Description
11.1.2. Product Profile
11.1.3. Clinical Development
11.1.4. Clinical Trials Information
11.1.5. Safety and Efficacy
11.1.6. Drug Description
11.1.7. Product Profile
11.1.8. Other Development Activities
11.1.9. Clinical Development
11.1.10. Clinical Trials Information
11.1.11. Safety and Efficacy
11.2. Gefapixant: Merck & Co., Inc.
11.2.1. Drug Description
11.2.2. Product Profile
11.2.3. Other Development Activities
11.2.4. Clinical Development
11.2.5. Clinical Trials Information
11.2.6. Safety and Efficacy
11.3. GLPG1690: Galapagos NV
11.3.1. Drug Description
11.3.2. Product Profile
11.3.3. Regulatory Milestones
11.3.4. Other Development Activities
11.3.5. Clinical Development
11.3.6. Clinical Trials Information
11.3.7. Safety and Efficacy
11.4. LT-1001: LTT Bio-Pharma
11.4.1. Drug Description
11.4.2. Product Profile
11.4.3. Other Development Activities
11.4.4. Clinical Development
11.4.5. Clinical Trials Information
11.4.6. Safety and Efficacy
11.5. BG00011: Biogen Inc.
11.5.1. Drug Description
11.5.2. Product Profile
11.5.3. Regulatory Milestones
11.5.4. Other Development Activities
11.5.5. Clinical Development
11.5.6. Clinical Trials Information
11.5.7. Safety and Efficacy
11.6. BMS-986020: Bristol-Myers Squibb
11.6.1. Drug Description
11.6.2. Product Profile
11.6.3. Regulatory Milestones
11.6.4. Other Development Activities
11.6.5. Clinical Development
11.6.6. Clinical Trials Information
11.6.7. Safety and Efficacy
11.7. LT-1002: Chong Kun Dang Pharmaceutical
11.7.1. Drug Description
11.7.2. Product Profile
11.7.3. Other Development Activities
11.8. Pamrevlumab: FibroGen
11.8.1. Drug Description
11.8.2. Product Profile
11.8.3. Regulatory Milestones
11.8.4. Other Development Activities
11.8.5. Clinical Development
11.8.6. Clinical Trials Information
11.8.7. Safety and Efficacy
11.9. PBI4050: ProMetic Life Sciences
11.9.1. Drug Description
11.9.2. Product Profile
11.9.3. Regulatory Milestones
11.9.4. Other Development Activities
11.9.5. Clinical Development
11.9.6. Clinical Trials Information
11.9.7. Safety and Efficacy
11.10. PRM 151: Promedior, Inc.
11.10.1. Drug Description
11.10.2. Product Profile
11.10.3. Regulatory Milestones
11.10.4. Other Development Activities
11.10.5. Clinical Development
11.10.6. Clinical Trials Information
11.10.7. Safety and Efficacy
11.11. Tipelukast: MediciNova
11.11.1. Drug Description
11.11.2. Product Profile
11.11.3. Regulatory Milestones
11.11.4. Other Development Activities
11.11.5. Clinical Development
11.11.6. Clinical Trials Information
11.11.7. Safety and Efficacy
11.12. TD139: Bristol-Myers Squibb
11.12.1. Drug Description
11.12.2. Product Profile
11.12.3. Other Development Activities
11.12.4. Clinical Development
11.12.5. Clinical Trials Information
11.12.6. Safety and Efficacy
11.13. VAY736: Novartis
11.13.1. Drug Description
11.13.2. Product Profile
11.13.3. Other Development Activities
11.13.4. Clinical Development
11.13.5. Clinical Trials Information
11.14. TAS-115: Taiho Pharmaceutical
11.14.1. Drug Description
11.14.2. Product Profile
11.14.3. Clinical Development
11.14.4. Clinical Trials Information
12. IPF: Market Analysis
12.1. Key Findings
12.2. Total Market Size of IPF in 7 MM
12.3. Therapy Based Market Size of IPF in 7 MM
13. Market Size of IPF by Country
13.1. United States Market Analysis
13.1.1. Market Size of IPF in the US
13.1.2. Therapy Based Market Size of IPF in the US
13.2. EU5 Market Outlook
13.3. Germany
13.3.1. Market Size of IPF in Germany
13.3.2. Therapy Based Market Size of IPF in Germany
13.4. France
13.4.1. Market Size of IPF in France
13.4.2. Therapy Based Market Size of IPF in France
13.5. Italy
13.5.1. Market Size of IPF in Italy
13.5.2. Therapy Based Market Size of IPF in Italy
13.6. United Kingdom
13.6.1. Market Size of IPF in the UK
13.6.2. Therapy Based Market Size of IPF in the UK
13.7. Spain
13.7.1. Market Size of IPF in Spain
13.7.2. Therapy Based Market Size of IPF in Spain
13.8. Japan: Market Analysis
13.8.1. Market Size of IPF in Japan
13.8.2. Therapy Based Market Size of IPF in Japan
14. Market Drivers of IPF
15. Market Barriers of IPF
16. Appendix
16.1. Report Methodology
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

 

1. Key Insights
2. IPF Market Overview at a Glance
2.1. Market Share (%) Distribution of IPF in 2017
2.2. Market Share (%) Distribution of IPF in 2027
3. Disease Background and Overview: Idiopathic Pulmonary Fibrosis (IPF)
3.1. Introduction
3.2. Staging of IPF
3.3. Risk Factors & Disease Causes
3.4. Symptoms
3.5. Pathogenesis
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7 MM Prevalent Population of IPF
4.3. Country Wise-Epidemiology of IPF
4.3.1. United States
4.3.2. Prevalent cases of IPF in the United States
4.3.3. Prevalent Population of IPF by severity
4.3.4. Gender-Specific IPF Prevalence
4.3.5. Age-Specific IPF Prevalence
4.3.6. EU5
4.3.7. Prevalent Population of IPF in EU5
4.3.8. France
4.3.9. Prevalent Population of IPF
4.3.10. Prevalent Population of IPF by severity
4.3.11. Gender-Specific IPF Prevalence
4.3.12. Age-Specific IPF Prevalence
4.3.13. Germany
4.3.14. Prevalent Population of IPF
4.3.15. Prevalent Population of IPF by severity
4.3.16. Gender-Specific IPF Prevalence
4.3.17. Age-Specific IPF Prevalence
4.3.18. Italy
4.3.19. Prevalent Population of IPF
4.3.20. Prevalent Population of IPF by severity
4.3.21. Gender-Specific IPF Prevalence
4.3.22. Age-Specific IPF Prevalence
4.3.23. Spain
4.3.24. Prevalent Population of IPF
4.3.25. Prevalent Population of IPF by severity
4.3.26. Gender-Specific IPF Prevalence
4.3.27. Age-Specific IPF Prevalence
4.3.28. United Kingdom
4.3.29. Prevalent Population of IPF
4.3.30. Prevalent Population of IPF by severity
4.3.31. Gender-Specific IPF Prevalence
4.3.32. Age-Specific IPF Prevalence
4.3.33. Japan
4.3.34. Prevalent Population of IPF
4.3.35. Prevalent Population of IPF by severity
4.3.36. Gender-SPECIFIC IPF Prevalence
4.3.37. Age-Specific IPF Prevalence
5. Current Treatment Practices
5.1. ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of IPF (An Update of 2011 Clinical Practice Guideline)
6. Unmet needs
7. Marketed Products
7.1. Esbriet (Pirfenidone): InterMune Inc.
7.1.1. Product Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Safety and Efficacy of Esbriet
7.1.5. Side effects of Esbriet
7.1.6. Product Profile
7.2. Ofev (Nintedanib): Boehringer Ingelheim Pharma GmbH & Co. KG
7.2.1. Product Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Safety and Efficacy of Ofev
7.2.5. Side effects of Ofev
7.2.6. Product Profile
8. Emerging Therapies
9. Key Cross Competition
10. Phase III Drugs
10.1. Thrombomodulin Alfa: Asahi Kasei Pharma Corporation
10.1.1. Drug Description
10.1.2. Product Profile
10.1.3. Clinical Development
10.1.4. Clinical Trials Information
10.1.5. Safety and Efficacy
11. Phase II Drugs
11.1. CC-90001: Celgene Corporation
11.1.1. Drug Description
11.1.2. Product Profile
11.1.3. Clinical Development
11.1.4. Clinical Trials Information
11.1.5. Safety and Efficacy
11.1.6. Drug Description
11.1.7. Product Profile
11.1.8. Other Development Activities
11.1.9. Clinical Development
11.1.10. Clinical Trials Information
11.1.11. Safety and Efficacy
11.2. Gefapixant: Merck & Co., Inc.
11.2.1. Drug Description
11.2.2. Product Profile
11.2.3. Other Development Activities
11.2.4. Clinical Development
11.2.5. Clinical Trials Information
11.2.6. Safety and Efficacy
11.3. GLPG1690: Galapagos NV
11.3.1. Drug Description
11.3.2. Product Profile
11.3.3. Regulatory Milestones
11.3.4. Other Development Activities
11.3.5. Clinical Development
11.3.6. Clinical Trials Information
11.3.7. Safety and Efficacy
11.4. LT-1001: LTT Bio-Pharma
11.4.1. Drug Description
11.4.2. Product Profile
11.4.3. Other Development Activities
11.4.4. Clinical Development
11.4.5. Clinical Trials Information
11.4.6. Safety and Efficacy
11.5. BG00011: Biogen Inc.
11.5.1. Drug Description
11.5.2. Product Profile
11.5.3. Regulatory Milestones
11.5.4. Other Development Activities
11.5.5. Clinical Development
11.5.6. Clinical Trials Information
11.5.7. Safety and Efficacy
11.6. BMS-986020: Bristol-Myers Squibb
11.6.1. Drug Description
11.6.2. Product Profile
11.6.3. Regulatory Milestones
11.6.4. Other Development Activities
11.6.5. Clinical Development
11.6.6. Clinical Trials Information
11.6.7. Safety and Efficacy
11.7. LT-1002: Chong Kun Dang Pharmaceutical
11.7.1. Drug Description
11.7.2. Product Profile
11.7.3. Other Development Activities
11.8. Pamrevlumab: FibroGen
11.8.1. Drug Description
11.8.2. Product Profile
11.8.3. Regulatory Milestones
11.8.4. Other Development Activities
11.8.5. Clinical Development
11.8.6. Clinical Trials Information
11.8.7. Safety and Efficacy
11.9. PBI4050: ProMetic Life Sciences
11.9.1. Drug Description
11.9.2. Product Profile
11.9.3. Regulatory Milestones
11.9.4. Other Development Activities
11.9.5. Clinical Development
11.9.6. Clinical Trials Information
11.9.7. Safety and Efficacy
11.10. PRM 151: Promedior, Inc.
11.10.1. Drug Description
11.10.2. Product Profile
11.10.3. Regulatory Milestones
11.10.4. Other Development Activities
11.10.5. Clinical Development
11.10.6. Clinical Trials Information
11.10.7. Safety and Efficacy
11.11. Tipelukast: MediciNova
11.11.1. Drug Description
11.11.2. Product Profile
11.11.3. Regulatory Milestones
11.11.4. Other Development Activities
11.11.5. Clinical Development
11.11.6. Clinical Trials Information
11.11.7. Safety and Efficacy
11.12. TD139: Bristol-Myers Squibb
11.12.1. Drug Description
11.12.2. Product Profile
11.12.3. Other Development Activities
11.12.4. Clinical Development
11.12.5. Clinical Trials Information
11.12.6. Safety and Efficacy
11.13. VAY736: Novartis
11.13.1. Drug Description
11.13.2. Product Profile
11.13.3. Other Development Activities
11.13.4. Clinical Development
11.13.5. Clinical Trials Information
11.14. TAS-115: Taiho Pharmaceutical
11.14.1. Drug Description
11.14.2. Product Profile
11.14.3. Clinical Development
11.14.4. Clinical Trials Information
12. IPF: Market Analysis
12.1. Key Findings
12.2. Total Market Size of IPF in 7 MM
12.3. Therapy Based Market Size of IPF in 7 MM
13. Market Size of IPF by Country
13.1. United States Market Analysis
13.1.1. Market Size of IPF in the US
13.1.2. Therapy Based Market Size of IPF in the US
13.2. EU5 Market Outlook
13.3. Germany
13.3.1. Market Size of IPF in Germany
13.3.2. Therapy Based Market Size of IPF in Germany
13.4. France
13.4.1. Market Size of IPF in France
13.4.2. Therapy Based Market Size of IPF in France
13.5. Italy
13.5.1. Market Size of IPF in Italy
13.5.2. Therapy Based Market Size of IPF in Italy
13.6. United Kingdom
13.6.1. Market Size of IPF in the UK
13.6.2. Therapy Based Market Size of IPF in the UK
13.7. Spain
13.7.1. Market Size of IPF in Spain
13.7.2. Therapy Based Market Size of IPF in Spain
13.8. Japan: Market Analysis
13.8.1. Market Size of IPF in Japan
13.8.2. Therapy Based Market Size of IPF in Japan
14. Market Drivers of IPF
15. Market Barriers of IPF
16. Appendix
16.1. Report Methodology
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

 

1. Key Insights
2. IPF Market Overview at a Glance
2.1. Market Share (%) Distribution of IPF in 2017
2.2. Market Share (%) Distribution of IPF in 2027
3. Disease Background and Overview: Idiopathic Pulmonary Fibrosis (IPF)
3.1. Introduction
3.2. Staging of IPF
3.3. Risk Factors & Disease Causes
3.4. Symptoms
3.5. Pathogenesis
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7 MM Prevalent Population of IPF
4.3. Country Wise-Epidemiology of IPF
4.3.1. United States
4.3.2. Prevalent cases of IPF in the United States
4.3.3. Prevalent Population of IPF by severity
4.3.4. Gender-Specific IPF Prevalence
4.3.5. Age-Specific IPF Prevalence
4.3.6. EU5
4.3.7. Prevalent Population of IPF in EU5
4.3.8. France
4.3.9. Prevalent Population of IPF
4.3.10. Prevalent Population of IPF by severity
4.3.11. Gender-Specific IPF Prevalence
4.3.12. Age-Specific IPF Prevalence
4.3.13. Germany
4.3.14. Prevalent Population of IPF
4.3.15. Prevalent Population of IPF by severity
4.3.16. Gender-Specific IPF Prevalence
4.3.17. Age-Specific IPF Prevalence
4.3.18. Italy
4.3.19. Prevalent Population of IPF
4.3.20. Prevalent Population of IPF by severity
4.3.21. Gender-Specific IPF Prevalence
4.3.22. Age-Specific IPF Prevalence
4.3.23. Spain
4.3.24. Prevalent Population of IPF
4.3.25. Prevalent Population of IPF by severity
4.3.26. Gender-Specific IPF Prevalence
4.3.27. Age-Specific IPF Prevalence
4.3.28. United Kingdom
4.3.29. Prevalent Population of IPF
4.3.30. Prevalent Population of IPF by severity
4.3.31. Gender-Specific IPF Prevalence
4.3.32. Age-Specific IPF Prevalence
4.3.33. Japan
4.3.34. Prevalent Population of IPF
4.3.35. Prevalent Population of IPF by severity
4.3.36. Gender-SPECIFIC IPF Prevalence
4.3.37. Age-Specific IPF Prevalence
5. Current Treatment Practices
5.1. ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of IPF (An Update of 2011 Clinical Practice Guideline)
6. Unmet needs
7. Marketed Products
7.1. Esbriet (Pirfenidone): InterMune Inc.
7.1.1. Product Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Safety and Efficacy of Esbriet
7.1.5. Side effects of Esbriet
7.1.6. Product Profile
7.2. Ofev (Nintedanib): Boehringer Ingelheim Pharma GmbH & Co. KG
7.2.1. Product Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Safety and Efficacy of Ofev
7.2.5. Side effects of Ofev
7.2.6. Product Profile
8. Emerging Therapies
9. Key Cross Competition
10. Phase III Drugs
10.1. Thrombomodulin Alfa: Asahi Kasei Pharma Corporation
10.1.1. Drug Description
10.1.2. Product Profile
10.1.3. Clinical Development
10.1.4. Clinical Trials Information
10.1.5. Safety and Efficacy
11. Phase II Drugs
11.1. CC-90001: Celgene Corporation
11.1.1. Drug Description
11.1.2. Product Profile
11.1.3. Clinical Development
11.1.4. Clinical Trials Information
11.1.5. Safety and Efficacy
11.1.6. Drug Description
11.1.7. Product Profile
11.1.8. Other Development Activities
11.1.9. Clinical Development
11.1.10. Clinical Trials Information
11.1.11. Safety and Efficacy
11.2. Gefapixant: Merck & Co., Inc.
11.2.1. Drug Description
11.2.2. Product Profile
11.2.3. Other Development Activities
11.2.4. Clinical Development
11.2.5. Clinical Trials Information
11.2.6. Safety and Efficacy
11.3. GLPG1690: Galapagos NV
11.3.1. Drug Description
11.3.2. Product Profile
11.3.3. Regulatory Milestones
11.3.4. Other Development Activities
11.3.5. Clinical Development
11.3.6. Clinical Trials Information
11.3.7. Safety and Efficacy
11.4. LT-1001: LTT Bio-Pharma
11.4.1. Drug Description
11.4.2. Product Profile
11.4.3. Other Development Activities
11.4.4. Clinical Development
11.4.5. Clinical Trials Information
11.4.6. Safety and Efficacy
11.5. BG00011: Biogen Inc.
11.5.1. Drug Description
11.5.2. Product Profile
11.5.3. Regulatory Milestones
11.5.4. Other Development Activities
11.5.5. Clinical Development
11.5.6. Clinical Trials Information
11.5.7. Safety and Efficacy
11.6. BMS-986020: Bristol-Myers Squibb
11.6.1. Drug Description
11.6.2. Product Profile
11.6.3. Regulatory Milestones
11.6.4. Other Development Activities
11.6.5. Clinical Development
11.6.6. Clinical Trials Information
11.6.7. Safety and Efficacy
11.7. LT-1002: Chong Kun Dang Pharmaceutical
11.7.1. Drug Description
11.7.2. Product Profile
11.7.3. Other Development Activities
11.8. Pamrevlumab: FibroGen
11.8.1. Drug Description
11.8.2. Product Profile
11.8.3. Regulatory Milestones
11.8.4. Other Development Activities
11.8.5. Clinical Development
11.8.6. Clinical Trials Information
11.8.7. Safety and Efficacy
11.9. PBI4050: ProMetic Life Sciences
11.9.1. Drug Description
11.9.2. Product Profile
11.9.3. Regulatory Milestones
11.9.4. Other Development Activities
11.9.5. Clinical Development
11.9.6. Clinical Trials Information
11.9.7. Safety and Efficacy
11.10. PRM 151: Promedior, Inc.
11.10.1. Drug Description
11.10.2. Product Profile
11.10.3. Regulatory Milestones
11.10.4. Other Development Activities
11.10.5. Clinical Development
11.10.6. Clinical Trials Information
11.10.7. Safety and Efficacy
11.11. Tipelukast: MediciNova
11.11.1. Drug Description
11.11.2. Product Profile
11.11.3. Regulatory Milestones
11.11.4. Other Development Activities
11.11.5. Clinical Development
11.11.6. Clinical Trials Information
11.11.7. Safety and Efficacy
11.12. TD139: Bristol-Myers Squibb
11.12.1. Drug Description
11.12.2. Product Profile
11.12.3. Other Development Activities
11.12.4. Clinical Development
11.12.5. Clinical Trials Information
11.12.6. Safety and Efficacy
11.13. VAY736: Novartis
11.13.1. Drug Description
11.13.2. Product Profile
11.13.3. Other Development Activities
11.13.4. Clinical Development
11.13.5. Clinical Trials Information
11.14. TAS-115: Taiho Pharmaceutical
11.14.1. Drug Description
11.14.2. Product Profile
11.14.3. Clinical Development
11.14.4. Clinical Trials Information
12. IPF: Market Analysis
12.1. Key Findings
12.2. Total Market Size of IPF in 7 MM
12.3. Therapy Based Market Size of IPF in 7 MM
13. Market Size of IPF by Country
13.1. United States Market Analysis
13.1.1. Market Size of IPF in the US
13.1.2. Therapy Based Market Size of IPF in the US
13.2. EU5 Market Outlook
13.3. Germany
13.3.1. Market Size of IPF in Germany
13.3.2. Therapy Based Market Size of IPF in Germany
13.4. France
13.4.1. Market Size of IPF in France
13.4.2. Therapy Based Market Size of IPF in France
13.5. Italy
13.5.1. Market Size of IPF in Italy
13.5.2. Therapy Based Market Size of IPF in Italy
13.6. United Kingdom
13.6.1. Market Size of IPF in the UK
13.6.2. Therapy Based Market Size of IPF in the UK
13.7. Spain
13.7.1. Market Size of IPF in Spain
13.7.2. Therapy Based Market Size of IPF in Spain
13.8. Japan: Market Analysis
13.8.1. Market Size of IPF in Japan
13.8.2. Therapy Based Market Size of IPF in Japan
14. Market Drivers of IPF
15. Market Barriers of IPF
16. Appendix
16.1. Report Methodology
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

 

1. Key Insights
2. IPF Market Overview at a Glance
2.1. Market Share (%) Distribution of IPF in 2017
2.2. Market Share (%) Distribution of IPF in 2027
3. Disease Background and Overview: Idiopathic Pulmonary Fibrosis (IPF)
3.1. Introduction
3.2. Staging of IPF
3.3. Risk Factors & Disease Causes
3.4. Symptoms
3.5. Pathogenesis
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7 MM Prevalent Population of IPF
4.3. Country Wise-Epidemiology of IPF
4.3.1. United States
4.3.2. Prevalent cases of IPF in the United States
4.3.3. Prevalent Population of IPF by severity
4.3.4. Gender-Specific IPF Prevalence
4.3.5. Age-Specific IPF Prevalence
4.3.6. EU5
4.3.7. Prevalent Population of IPF in EU5
4.3.8. France
4.3.9. Prevalent Population of IPF
4.3.10. Prevalent Population of IPF by severity
4.3.11. Gender-Specific IPF Prevalence
4.3.12. Age-Specific IPF Prevalence
4.3.13. Germany
4.3.14. Prevalent Population of IPF
4.3.15. Prevalent Population of IPF by severity
4.3.16. Gender-Specific IPF Prevalence
4.3.17. Age-Specific IPF Prevalence
4.3.18. Italy
4.3.19. Prevalent Population of IPF
4.3.20. Prevalent Population of IPF by severity
4.3.21. Gender-Specific IPF Prevalence
4.3.22. Age-Specific IPF Prevalence
4.3.23. Spain
4.3.24. Prevalent Population of IPF
4.3.25. Prevalent Population of IPF by severity
4.3.26. Gender-Specific IPF Prevalence
4.3.27. Age-Specific IPF Prevalence
4.3.28. United Kingdom
4.3.29. Prevalent Population of IPF
4.3.30. Prevalent Population of IPF by severity
4.3.31. Gender-Specific IPF Prevalence
4.3.32. Age-Specific IPF Prevalence
4.3.33. Japan
4.3.34. Prevalent Population of IPF
4.3.35. Prevalent Population of IPF by severity
4.3.36. Gender-SPECIFIC IPF Prevalence
4.3.37. Age-Specific IPF Prevalence
5. Current Treatment Practices
5.1. ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of IPF (An Update of 2011 Clinical Practice Guideline)
6. Unmet needs
7. Marketed Products
7.1. Esbriet (Pirfenidone): InterMune Inc.
7.1.1. Product Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Safety and Efficacy of Esbriet
7.1.5. Side effects of Esbriet
7.1.6. Product Profile
7.2. Ofev (Nintedanib): Boehringer Ingelheim Pharma GmbH & Co. KG
7.2.1. Product Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Safety and Efficacy of Ofev
7.2.5. Side effects of Ofev
7.2.6. Product Profile
8. Emerging Therapies
9. Key Cross Competition
10. Phase III Drugs
10.1. Thrombomodulin Alfa: Asahi Kasei Pharma Corporation
10.1.1. Drug Description
10.1.2. Product Profile
10.1.3. Clinical Development
10.1.4. Clinical Trials Information
10.1.5. Safety and Efficacy
11. Phase II Drugs
11.1. CC-90001: Celgene Corporation
11.1.1. Drug Description
11.1.2. Product Profile
11.1.3. Clinical Development
11.1.4. Clinical Trials Information
11.1.5. Safety and Efficacy
11.1.6. Drug Description
11.1.7. Product Profile
11.1.8. Other Development Activities
11.1.9. Clinical Development
11.1.10. Clinical Trials Information
11.1.11. Safety and Efficacy
11.2. Gefapixant: Merck & Co., Inc.
11.2.1. Drug Description
11.2.2. Product Profile
11.2.3. Other Development Activities
11.2.4. Clinical Development
11.2.5. Clinical Trials Information
11.2.6. Safety and Efficacy
11.3. GLPG1690: Galapagos NV
11.3.1. Drug Description
11.3.2. Product Profile
11.3.3. Regulatory Milestones
11.3.4. Other Development Activities
11.3.5. Clinical Development
11.3.6. Clinical Trials Information
11.3.7. Safety and Efficacy
11.4. LT-1001: LTT Bio-Pharma
11.4.1. Drug Description
11.4.2. Product Profile
11.4.3. Other Development Activities
11.4.4. Clinical Development
11.4.5. Clinical Trials Information
11.4.6. Safety and Efficacy
11.5. BG00011: Biogen Inc.
11.5.1. Drug Description
11.5.2. Product Profile
11.5.3. Regulatory Milestones
11.5.4. Other Development Activities
11.5.5. Clinical Development
11.5.6. Clinical Trials Information
11.5.7. Safety and Efficacy
11.6. BMS-986020: Bristol-Myers Squibb
11.6.1. Drug Description
11.6.2. Product Profile
11.6.3. Regulatory Milestones
11.6.4. Other Development Activities
11.6.5. Clinical Development
11.6.6. Clinical Trials Information
11.6.7. Safety and Efficacy
11.7. LT-1002: Chong Kun Dang Pharmaceutical
11.7.1. Drug Description
11.7.2. Product Profile
11.7.3. Other Development Activities
11.8. Pamrevlumab: FibroGen
11.8.1. Drug Description
11.8.2. Product Profile
11.8.3. Regulatory Milestones
11.8.4. Other Development Activities
11.8.5. Clinical Development
11.8.6. Clinical Trials Information
11.8.7. Safety and Efficacy
11.9. PBI4050: ProMetic Life Sciences
11.9.1. Drug Description
11.9.2. Product Profile
11.9.3. Regulatory Milestones
11.9.4. Other Development Activities
11.9.5. Clinical Development
11.9.6. Clinical Trials Information
11.9.7. Safety and Efficacy
11.10. PRM 151: Promedior, Inc.
11.10.1. Drug Description
11.10.2. Product Profile
11.10.3. Regulatory Milestones
11.10.4. Other Development Activities
11.10.5. Clinical Development
11.10.6. Clinical Trials Information
11.10.7. Safety and Efficacy
11.11. Tipelukast: MediciNova
11.11.1. Drug Description
11.11.2. Product Profile
11.11.3. Regulatory Milestones
11.11.4. Other Development Activities
11.11.5. Clinical Development
11.11.6. Clinical Trials Information
11.11.7. Safety and Efficacy
11.12. TD139: Bristol-Myers Squibb
11.12.1. Drug Description
11.12.2. Product Profile
11.12.3. Other Development Activities
11.12.4. Clinical Development
11.12.5. Clinical Trials Information
11.12.6. Safety and Efficacy
11.13. VAY736: Novartis
11.13.1. Drug Description
11.13.2. Product Profile
11.13.3. Other Development Activities
11.13.4. Clinical Development
11.13.5. Clinical Trials Information
11.14. TAS-115: Taiho Pharmaceutical
11.14.1. Drug Description
11.14.2. Product Profile
11.14.3. Clinical Development
11.14.4. Clinical Trials Information
12. IPF: Market Analysis
12.1. Key Findings
12.2. Total Market Size of IPF in 7 MM
12.3. Therapy Based Market Size of IPF in 7 MM
13. Market Size of IPF by Country
13.1. United States Market Analysis
13.1.1. Market Size of IPF in the US
13.1.2. Therapy Based Market Size of IPF in the US
13.2. EU5 Market Outlook
13.3. Germany
13.3.1. Market Size of IPF in Germany
13.3.2. Therapy Based Market Size of IPF in Germany
13.4. France
13.4.1. Market Size of IPF in France
13.4.2. Therapy Based Market Size of IPF in France
13.5. Italy
13.5.1. Market Size of IPF in Italy
13.5.2. Therapy Based Market Size of IPF in Italy
13.6. United Kingdom
13.6.1. Market Size of IPF in the UK
13.6.2. Therapy Based Market Size of IPF in the UK
13.7. Spain
13.7.1. Market Size of IPF in Spain
13.7.2. Therapy Based Market Size of IPF in Spain
13.8. Japan: Market Analysis
13.8.1. Market Size of IPF in Japan
13.8.2. Therapy Based Market Size of IPF in Japan
14. Market Drivers of IPF
15. Market Barriers of IPF
16. Appendix
16.1. Report Methodology
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

 

1. Key Insights
2. IPF Market Overview at a Glance
2.1. Market Share (%) Distribution of IPF in 2017
2.2. Market Share (%) Distribution of IPF in 2027
3. Disease Background and Overview: Idiopathic Pulmonary Fibrosis (IPF)
3.1. Introduction
3.2. Staging of IPF
3.3. Risk Factors & Disease Causes
3.4. Symptoms
3.5. Pathogenesis
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7 MM Prevalent Population of IPF
4.3. Country Wise-Epidemiology of IPF
4.3.1. United States
4.3.2. Prevalent cases of IPF in the United States
4.3.3. Prevalent Population of IPF by severity
4.3.4. Gender-Specific IPF Prevalence
4.3.5. Age-Specific IPF Prevalence
4.3.6. EU5
4.3.7. Prevalent Population of IPF in EU5
4.3.8. France
4.3.9. Prevalent Population of IPF
4.3.10. Prevalent Population of IPF by severity
4.3.11. Gender-Specific IPF Prevalence
4.3.12. Age-Specific IPF Prevalence
4.3.13. Germany
4.3.14. Prevalent Population of IPF
4.3.15. Prevalent Population of IPF by severity
4.3.16. Gender-Specific IPF Prevalence
4.3.17. Age-Specific IPF Prevalence
4.3.18. Italy
4.3.19. Prevalent Population of IPF
4.3.20. Prevalent Population of IPF by severity
4.3.21. Gender-Specific IPF Prevalence
4.3.22. Age-Specific IPF Prevalence
4.3.23. Spain
4.3.24. Prevalent Population of IPF
4.3.25. Prevalent Population of IPF by severity
4.3.26. Gender-Specific IPF Prevalence
4.3.27. Age-Specific IPF Prevalence
4.3.28. United Kingdom
4.3.29. Prevalent Population of IPF
4.3.30. Prevalent Population of IPF by severity
4.3.31. Gender-Specific IPF Prevalence
4.3.32. Age-Specific IPF Prevalence
4.3.33. Japan
4.3.34. Prevalent Population of IPF
4.3.35. Prevalent Population of IPF by severity
4.3.36. Gender-SPECIFIC IPF Prevalence
4.3.37. Age-Specific IPF Prevalence
5. Current Treatment Practices
5.1. ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of IPF (An Update of 2011 Clinical Practice Guideline)
6. Unmet needs
7. Marketed Products
7.1. Esbriet (Pirfenidone): InterMune Inc.
7.1.1. Product Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Safety and Efficacy of Esbriet
7.1.5. Side effects of Esbriet
7.1.6. Product Profile
7.2. Ofev (Nintedanib): Boehringer Ingelheim Pharma GmbH & Co. KG
7.2.1. Product Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Safety and Efficacy of Ofev
7.2.5. Side effects of Ofev
7.2.6. Product Profile
8. Emerging Therapies
9. Key Cross Competition
10. Phase III Drugs
10.1. Thrombomodulin Alfa: Asahi Kasei Pharma Corporation
10.1.1. Drug Description
10.1.2. Product Profile
10.1.3. Clinical Development
10.1.4. Clinical Trials Information
10.1.5. Safety and Efficacy
11. Phase II Drugs
11.1. CC-90001: Celgene Corporation
11.1.1. Drug Description
11.1.2. Product Profile
11.1.3. Clinical Development
11.1.4. Clinical Trials Information
11.1.5. Safety and Efficacy
11.1.6. Drug Description
11.1.7. Product Profile
11.1.8. Other Development Activities
11.1.9. Clinical Development
11.1.10. Clinical Trials Information
11.1.11. Safety and Efficacy
11.2. Gefapixant: Merck & Co., Inc.
11.2.1. Drug Description
11.2.2. Product Profile
11.2.3. Other Development Activities
11.2.4. Clinical Development
11.2.5. Clinical Trials Information
11.2.6. Safety and Efficacy
11.3. GLPG1690: Galapagos NV
11.3.1. Drug Description
11.3.2. Product Profile
11.3.3. Regulatory Milestones
11.3.4. Other Development Activities
11.3.5. Clinical Development
11.3.6. Clinical Trials Information
11.3.7. Safety and Efficacy
11.4. LT-1001: LTT Bio-Pharma
11.4.1. Drug Description
11.4.2. Product Profile
11.4.3. Other Development Activities
11.4.4. Clinical Development
11.4.5. Clinical Trials Information
11.4.6. Safety and Efficacy
11.5. BG00011: Biogen Inc.
11.5.1. Drug Description
11.5.2. Product Profile
11.5.3. Regulatory Milestones
11.5.4. Other Development Activities
11.5.5. Clinical Development
11.5.6. Clinical Trials Information
11.5.7. Safety and Efficacy
11.6. BMS-986020: Bristol-Myers Squibb
11.6.1. Drug Description
11.6.2. Product Profile
11.6.3. Regulatory Milestones
11.6.4. Other Development Activities
11.6.5. Clinical Development
11.6.6. Clinical Trials Information
11.6.7. Safety and Efficacy
11.7. LT-1002: Chong Kun Dang Pharmaceutical
11.7.1. Drug Description
11.7.2. Product Profile
11.7.3. Other Development Activities
11.8. Pamrevlumab: FibroGen
11.8.1. Drug Description
11.8.2. Product Profile
11.8.3. Regulatory Milestones
11.8.4. Other Development Activities
11.8.5. Clinical Development
11.8.6. Clinical Trials Information
11.8.7. Safety and Efficacy
11.9. PBI4050: ProMetic Life Sciences
11.9.1. Drug Description
11.9.2. Product Profile
11.9.3. Regulatory Milestones
11.9.4. Other Development Activities
11.9.5. Clinical Development
11.9.6. Clinical Trials Information
11.9.7. Safety and Efficacy
11.10. PRM 151: Promedior, Inc.
11.10.1. Drug Description
11.10.2. Product Profile
11.10.3. Regulatory Milestones
11.10.4. Other Development Activities
11.10.5. Clinical Development
11.10.6. Clinical Trials Information
11.10.7. Safety and Efficacy
11.11. Tipelukast: MediciNova
11.11.1. Drug Description
11.11.2. Product Profile
11.11.3. Regulatory Milestones
11.11.4. Other Development Activities
11.11.5. Clinical Development
11.11.6. Clinical Trials Information
11.11.7. Safety and Efficacy
11.12. TD139: Bristol-Myers Squibb
11.12.1. Drug Description
11.12.2. Product Profile
11.12.3. Other Development Activities
11.12.4. Clinical Development
11.12.5. Clinical Trials Information
11.12.6. Safety and Efficacy
11.13. VAY736: Novartis
11.13.1. Drug Description
11.13.2. Product Profile
11.13.3. Other Development Activities
11.13.4. Clinical Development
11.13.5. Clinical Trials Information
11.14. TAS-115: Taiho Pharmaceutical
11.14.1. Drug Description
11.14.2. Product Profile
11.14.3. Clinical Development
11.14.4. Clinical Trials Information
12. IPF: Market Analysis
12.1. Key Findings
12.2. Total Market Size of IPF in 7 MM
12.3. Therapy Based Market Size of IPF in 7 MM
13. Market Size of IPF by Country
13.1. United States Market Analysis
13.1.1. Market Size of IPF in the US
13.1.2. Therapy Based Market Size of IPF in the US
13.2. EU5 Market Outlook
13.3. Germany
13.3.1. Market Size of IPF in Germany
13.3.2. Therapy Based Market Size of IPF in Germany
13.4. France
13.4.1. Market Size of IPF in France
13.4.2. Therapy Based Market Size of IPF in France
13.5. Italy
13.5.1. Market Size of IPF in Italy
13.5.2. Therapy Based Market Size of IPF in Italy
13.6. United Kingdom
13.6.1. Market Size of IPF in the UK
13.6.2. Therapy Based Market Size of IPF in the UK
13.7. Spain
13.7.1. Market Size of IPF in Spain
13.7.2. Therapy Based Market Size of IPF in Spain
13.8. Japan: Market Analysis
13.8.1. Market Size of IPF in Japan
13.8.2. Therapy Based Market Size of IPF in Japan
14. Market Drivers of IPF
15. Market Barriers of IPF
16. Appendix
16.1. Report Methodology
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

 

1. Key Insights
2. IPF Market Overview at a Glance
2.1. Market Share (%) Distribution of IPF in 2017
2.2. Market Share (%) Distribution of IPF in 2027
3. Disease Background and Overview: Idiopathic Pulmonary Fibrosis (IPF)
3.1. Introduction
3.2. Staging of IPF
3.3. Risk Factors & Disease Causes
3.4. Symptoms
3.5. Pathogenesis
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7 MM Prevalent Population of IPF
4.3. Country Wise-Epidemiology of IPF
4.3.1. United States
4.3.2. Prevalent cases of IPF in the United States
4.3.3. Prevalent Population of IPF by severity
4.3.4. Gender-Specific IPF Prevalence
4.3.5. Age-Specific IPF Prevalence
4.3.6. EU5
4.3.7. Prevalent Population of IPF in EU5
4.3.8. France
4.3.9. Prevalent Population of IPF
4.3.10. Prevalent Population of IPF by severity
4.3.11. Gender-Specific IPF Prevalence
4.3.12. Age-Specific IPF Prevalence
4.3.13. Germany
4.3.14. Prevalent Population of IPF
4.3.15. Prevalent Population of IPF by severity
4.3.16. Gender-Specific IPF Prevalence
4.3.17. Age-Specific IPF Prevalence
4.3.18. Italy
4.3.19. Prevalent Population of IPF
4.3.20. Prevalent Population of IPF by severity
4.3.21. Gender-Specific IPF Prevalence
4.3.22. Age-Specific IPF Prevalence
4.3.23. Spain
4.3.24. Prevalent Population of IPF
4.3.25. Prevalent Population of IPF by severity
4.3.26. Gender-Specific IPF Prevalence
4.3.27. Age-Specific IPF Prevalence
4.3.28. United Kingdom
4.3.29. Prevalent Population of IPF
4.3.30. Prevalent Population of IPF by severity
4.3.31. Gender-Specific IPF Prevalence
4.3.32. Age-Specific IPF Prevalence
4.3.33. Japan
4.3.34. Prevalent Population of IPF
4.3.35. Prevalent Population of IPF by severity
4.3.36. Gender-SPECIFIC IPF Prevalence
4.3.37. Age-Specific IPF Prevalence
5. Current Treatment Practices
5.1. ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of IPF (An Update of 2011 Clinical Practice Guideline)
6. Unmet needs
7. Marketed Products
7.1. Esbriet (Pirfenidone): InterMune Inc.
7.1.1. Product Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Safety and Efficacy of Esbriet
7.1.5. Side effects of Esbriet
7.1.6. Product Profile
7.2. Ofev (Nintedanib): Boehringer Ingelheim Pharma GmbH & Co. KG
7.2.1. Product Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Safety and Efficacy of Ofev
7.2.5. Side effects of Ofev
7.2.6. Product Profile
8. Emerging Therapies
9. Key Cross Competition
10. Phase III Drugs
10.1. Thrombomodulin Alfa: Asahi Kasei Pharma Corporation
10.1.1. Drug Description
10.1.2. Product Profile
10.1.3. Clinical Development
10.1.4. Clinical Trials Information
10.1.5. Safety and Efficacy
11. Phase II Drugs
11.1. CC-90001: Celgene Corporation
11.1.1. Drug Description
11.1.2. Product Profile
11.1.3. Clinical Development
11.1.4. Clinical Trials Information
11.1.5. Safety and Efficacy
11.1.6. Drug Description
11.1.7. Product Profile
11.1.8. Other Development Activities
11.1.9. Clinical Development
11.1.10. Clinical Trials Information
11.1.11. Safety and Efficacy
11.2. Gefapixant: Merck & Co., Inc.
11.2.1. Drug Description
11.2.2. Product Profile
11.2.3. Other Development Activities
11.2.4. Clinical Development
11.2.5. Clinical Trials Information
11.2.6. Safety and Efficacy
11.3. GLPG1690: Galapagos NV
11.3.1. Drug Description
11.3.2. Product Profile
11.3.3. Regulatory Milestones
11.3.4. Other Development Activities
11.3.5. Clinical Development
11.3.6. Clinical Trials Information
11.3.7. Safety and Efficacy
11.4. LT-1001: LTT Bio-Pharma
11.4.1. Drug Description
11.4.2. Product Profile
11.4.3. Other Development Activities
11.4.4. Clinical Development
11.4.5. Clinical Trials Information
11.4.6. Safety and Efficacy
11.5. BG00011: Biogen Inc.
11.5.1. Drug Description
11.5.2. Product Profile
11.5.3. Regulatory Milestones
11.5.4. Other Development Activities
11.5.5. Clinical Development
11.5.6. Clinical Trials Information
11.5.7. Safety and Efficacy
11.6. BMS-986020: Bristol-Myers Squibb
11.6.1. Drug Description
11.6.2. Product Profile
11.6.3. Regulatory Milestones
11.6.4. Other Development Activities
11.6.5. Clinical Development
11.6.6. Clinical Trials Information
11.6.7. Safety and Efficacy
11.7. LT-1002: Chong Kun Dang Pharmaceutical
11.7.1. Drug Description
11.7.2. Product Profile
11.7.3. Other Development Activities
11.8. Pamrevlumab: FibroGen
11.8.1. Drug Description
11.8.2. Product Profile
11.8.3. Regulatory Milestones
11.8.4. Other Development Activities
11.8.5. Clinical Development
11.8.6. Clinical Trials Information
11.8.7. Safety and Efficacy
11.9. PBI4050: ProMetic Life Sciences
11.9.1. Drug Description
11.9.2. Product Profile
11.9.3. Regulatory Milestones
11.9.4. Other Development Activities
11.9.5. Clinical Development
11.9.6. Clinical Trials Information
11.9.7. Safety and Efficacy
11.10. PRM 151: Promedior, Inc.
11.10.1. Drug Description
11.10.2. Product Profile
11.10.3. Regulatory Milestones
11.10.4. Other Development Activities
11.10.5. Clinical Development
11.10.6. Clinical Trials Information
11.10.7. Safety and Efficacy
11.11. Tipelukast: MediciNova
11.11.1. Drug Description
11.11.2. Product Profile
11.11.3. Regulatory Milestones
11.11.4. Other Development Activities
11.11.5. Clinical Development
11.11.6. Clinical Trials Information
11.11.7. Safety and Efficacy
11.12. TD139: Bristol-Myers Squibb
11.12.1. Drug Description
11.12.2. Product Profile
11.12.3. Other Development Activities
11.12.4. Clinical Development
11.12.5. Clinical Trials Information
11.12.6. Safety and Efficacy
11.13. VAY736: Novartis
11.13.1. Drug Description
11.13.2. Product Profile
11.13.3. Other Development Activities
11.13.4. Clinical Development
11.13.5. Clinical Trials Information
11.14. TAS-115: Taiho Pharmaceutical
11.14.1. Drug Description
11.14.2. Product Profile
11.14.3. Clinical Development
11.14.4. Clinical Trials Information
12. IPF: Market Analysis
12.1. Key Findings
12.2. Total Market Size of IPF in 7 MM
12.3. Therapy Based Market Size of IPF in 7 MM
13. Market Size of IPF by Country
13.1. United States Market Analysis
13.1.1. Market Size of IPF in the US
13.1.2. Therapy Based Market Size of IPF in the US
13.2. EU5 Market Outlook
13.3. Germany
13.3.1. Market Size of IPF in Germany
13.3.2. Therapy Based Market Size of IPF in Germany
13.4. France
13.4.1. Market Size of IPF in France
13.4.2. Therapy Based Market Size of IPF in France
13.5. Italy
13.5.1. Market Size of IPF in Italy
13.5.2. Therapy Based Market Size of IPF in Italy
13.6. United Kingdom
13.6.1. Market Size of IPF in the UK
13.6.2. Therapy Based Market Size of IPF in the UK
13.7. Spain
13.7.1. Market Size of IPF in Spain
13.7.2. Therapy Based Market Size of IPF in Spain
13.8. Japan: Market Analysis
13.8.1. Market Size of IPF in Japan
13.8.2. Therapy Based Market Size of IPF in Japan
14. Market Drivers of IPF
15. Market Barriers of IPF
16. Appendix
16.1. Report Methodology
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

 

1. Key Insights
2. IPF Market Overview at a Glance
2.1. Market Share (%) Distribution of IPF in 2017
2.2. Market Share (%) Distribution of IPF in 2027
3. Disease Background and Overview: Idiopathic Pulmonary Fibrosis (IPF)
3.1. Introduction
3.2. Staging of IPF
3.3. Risk Factors & Disease Causes
3.4. Symptoms
3.5. Pathogenesis
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7 MM Prevalent Population of IPF
4.3. Country Wise-Epidemiology of IPF
4.3.1. United States
4.3.2. Prevalent cases of IPF in the United States
4.3.3. Prevalent Population of IPF by severity
4.3.4. Gender-Specific IPF Prevalence
4.3.5. Age-Specific IPF Prevalence
4.3.6. EU5
4.3.7. Prevalent Population of IPF in EU5
4.3.8. France
4.3.9. Prevalent Population of IPF
4.3.10. Prevalent Population of IPF by severity
4.3.11. Gender-Specific IPF Prevalence
4.3.12. Age-Specific IPF Prevalence
4.3.13. Germany
4.3.14. Prevalent Population of IPF
4.3.15. Prevalent Population of IPF by severity
4.3.16. Gender-Specific IPF Prevalence
4.3.17. Age-Specific IPF Prevalence
4.3.18. Italy
4.3.19. Prevalent Population of IPF
4.3.20. Prevalent Population of IPF by severity
4.3.21. Gender-Specific IPF Prevalence
4.3.22. Age-Specific IPF Prevalence
4.3.23. Spain
4.3.24. Prevalent Population of IPF
4.3.25. Prevalent Population of IPF by severity
4.3.26. Gender-Specific IPF Prevalence
4.3.27. Age-Specific IPF Prevalence
4.3.28. United Kingdom
4.3.29. Prevalent Population of IPF
4.3.30. Prevalent Population of IPF by severity
4.3.31. Gender-Specific IPF Prevalence
4.3.32. Age-Specific IPF Prevalence
4.3.33. Japan
4.3.34. Prevalent Population of IPF
4.3.35. Prevalent Population of IPF by severity
4.3.36. Gender-SPECIFIC IPF Prevalence
4.3.37. Age-Specific IPF Prevalence
5. Current Treatment Practices
5.1. ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of IPF (An Update of 2011 Clinical Practice Guideline)
6. Unmet needs
7. Marketed Products
7.1. Esbriet (Pirfenidone): InterMune Inc.
7.1.1. Product Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Safety and Efficacy of Esbriet
7.1.5. Side effects of Esbriet
7.1.6. Product Profile
7.2. Ofev (Nintedanib): Boehringer Ingelheim Pharma GmbH & Co. KG
7.2.1. Product Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Safety and Efficacy of Ofev
7.2.5. Side effects of Ofev
7.2.6. Product Profile
8. Emerging Therapies
9. Key Cross Competition
10. Phase III Drugs
10.1. Thrombomodulin Alfa: Asahi Kasei Pharma Corporation
10.1.1. Drug Description
10.1.2. Product Profile
10.1.3. Clinical Development
10.1.4. Clinical Trials Information
10.1.5. Safety and Efficacy
11. Phase II Drugs
11.1. CC-90001: Celgene Corporation
11.1.1. Drug Description
11.1.2. Product Profile
11.1.3. Clinical Development
11.1.4. Clinical Trials Information
11.1.5. Safety and Efficacy
11.1.6. Drug Description
11.1.7. Product Profile
11.1.8. Other Development Activities
11.1.9. Clinical Development
11.1.10. Clinical Trials Information
11.1.11. Safety and Efficacy
11.2. Gefapixant: Merck & Co., Inc.
11.2.1. Drug Description
11.2.2. Product Profile
11.2.3. Other Development Activities
11.2.4. Clinical Development
11.2.5. Clinical Trials Information
11.2.6. Safety and Efficacy
11.3. GLPG1690: Galapagos NV
11.3.1. Drug Description
11.3.2. Product Profile
11.3.3. Regulatory Milestones
11.3.4. Other Development Activities
11.3.5. Clinical Development
11.3.6. Clinical Trials Information
11.3.7. Safety and Efficacy
11.4. LT-1001: LTT Bio-Pharma
11.4.1. Drug Description
11.4.2. Product Profile
11.4.3. Other Development Activities
11.4.4. Clinical Development
11.4.5. Clinical Trials Information
11.4.6. Safety and Efficacy
11.5. BG00011: Biogen Inc.
11.5.1. Drug Description
11.5.2. Product Profile
11.5.3. Regulatory Milestones
11.5.4. Other Development Activities
11.5.5. Clinical Development
11.5.6. Clinical Trials Information
11.5.7. Safety and Efficacy
11.6. BMS-986020: Bristol-Myers Squibb
11.6.1. Drug Description
11.6.2. Product Profile
11.6.3. Regulatory Milestones
11.6.4. Other Development Activities
11.6.5. Clinical Development
11.6.6. Clinical Trials Information
11.6.7. Safety and Efficacy
11.7. LT-1002: Chong Kun Dang Pharmaceutical
11.7.1. Drug Description
11.7.2. Product Profile
11.7.3. Other Development Activities
11.8. Pamrevlumab: FibroGen
11.8.1. Drug Description
11.8.2. Product Profile
11.8.3. Regulatory Milestones
11.8.4. Other Development Activities
11.8.5. Clinical Development
11.8.6. Clinical Trials Information
11.8.7. Safety and Efficacy
11.9. PBI4050: ProMetic Life Sciences
11.9.1. Drug Description
11.9.2. Product Profile
11.9.3. Regulatory Milestones
11.9.4. Other Development Activities
11.9.5. Clinical Development
11.9.6. Clinical Trials Information
11.9.7. Safety and Efficacy
11.10. PRM 151: Promedior, Inc.
11.10.1. Drug Description
11.10.2. Product Profile
11.10.3. Regulatory Milestones
11.10.4. Other Development Activities
11.10.5. Clinical Development
11.10.6. Clinical Trials Information
11.10.7. Safety and Efficacy
11.11. Tipelukast: MediciNova
11.11.1. Drug Description
11.11.2. Product Profile
11.11.3. Regulatory Milestones
11.11.4. Other Development Activities
11.11.5. Clinical Development
11.11.6. Clinical Trials Information
11.11.7. Safety and Efficacy
11.12. TD139: Bristol-Myers Squibb
11.12.1. Drug Description
11.12.2. Product Profile
11.12.3. Other Development Activities
11.12.4. Clinical Development
11.12.5. Clinical Trials Information
11.12.6. Safety and Efficacy
11.13. VAY736: Novartis
11.13.1. Drug Description
11.13.2. Product Profile
11.13.3. Other Development Activities
11.13.4. Clinical Development
11.13.5. Clinical Trials Information
11.14. TAS-115: Taiho Pharmaceutical
11.14.1. Drug Description
11.14.2. Product Profile
11.14.3. Clinical Development
11.14.4. Clinical Trials Information
12. IPF: Market Analysis
12.1. Key Findings
12.2. Total Market Size of IPF in 7 MM
12.3. Therapy Based Market Size of IPF in 7 MM
13. Market Size of IPF by Country
13.1. United States Market Analysis
13.1.1. Market Size of IPF in the US
13.1.2. Therapy Based Market Size of IPF in the US
13.2. EU5 Market Outlook
13.3. Germany
13.3.1. Market Size of IPF in Germany
13.3.2. Therapy Based Market Size of IPF in Germany
13.4. France
13.4.1. Market Size of IPF in France
13.4.2. Therapy Based Market Size of IPF in France
13.5. Italy
13.5.1. Market Size of IPF in Italy
13.5.2. Therapy Based Market Size of IPF in Italy
13.6. United Kingdom
13.6.1. Market Size of IPF in the UK
13.6.2. Therapy Based Market Size of IPF in the UK
13.7. Spain
13.7.1. Market Size of IPF in Spain
13.7.2. Therapy Based Market Size of IPF in Spain
13.8. Japan: Market Analysis
13.8.1. Market Size of IPF in Japan
13.8.2. Therapy Based Market Size of IPF in Japan
14. Market Drivers of IPF
15. Market Barriers of IPF
16. Appendix
16.1. Report Methodology
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

 

1. Key Insights
2. IPF Market Overview at a Glance
2.1. Market Share (%) Distribution of IPF in 2017
2.2. Market Share (%) Distribution of IPF in 2027
3. Disease Background and Overview: Idiopathic Pulmonary Fibrosis (IPF)
3.1. Introduction
3.2. Staging of IPF
3.3. Risk Factors & Disease Causes
3.4. Symptoms
3.5. Pathogenesis
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7 MM Prevalent Population of IPF
4.3. Country Wise-Epidemiology of IPF
4.3.1. United States
4.3.2. Prevalent cases of IPF in the United States
4.3.3. Prevalent Population of IPF by severity
4.3.4. Gender-Specific IPF Prevalence
4.3.5. Age-Specific IPF Prevalence
4.3.6. EU5
4.3.7. Prevalent Population of IPF in EU5
4.3.8. France
4.3.9. Prevalent Population of IPF
4.3.10. Prevalent Population of IPF by severity
4.3.11. Gender-Specific IPF Prevalence
4.3.12. Age-Specific IPF Prevalence
4.3.13. Germany
4.3.14. Prevalent Population of IPF
4.3.15. Prevalent Population of IPF by severity
4.3.16. Gender-Specific IPF Prevalence
4.3.17. Age-Specific IPF Prevalence
4.3.18. Italy
4.3.19. Prevalent Population of IPF
4.3.20. Prevalent Population of IPF by severity
4.3.21. Gender-Specific IPF Prevalence
4.3.22. Age-Specific IPF Prevalence
4.3.23. Spain
4.3.24. Prevalent Population of IPF
4.3.25. Prevalent Population of IPF by severity
4.3.26. Gender-Specific IPF Prevalence
4.3.27. Age-Specific IPF Prevalence
4.3.28. United Kingdom
4.3.29. Prevalent Population of IPF
4.3.30. Prevalent Population of IPF by severity
4.3.31. Gender-Specific IPF Prevalence
4.3.32. Age-Specific IPF Prevalence
4.3.33. Japan
4.3.34. Prevalent Population of IPF
4.3.35. Prevalent Population of IPF by severity
4.3.36. Gender-SPECIFIC IPF Prevalence
4.3.37. Age-Specific IPF Prevalence
5. Current Treatment Practices
5.1. ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of IPF (An Update of 2011 Clinical Practice Guideline)
6. Unmet needs
7. Marketed Products
7.1. Esbriet (Pirfenidone): InterMune Inc.
7.1.1. Product Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Safety and Efficacy of Esbriet
7.1.5. Side effects of Esbriet
7.1.6. Product Profile
7.2. Ofev (Nintedanib): Boehringer Ingelheim Pharma GmbH & Co. KG
7.2.1. Product Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Safety and Efficacy of Ofev
7.2.5. Side effects of Ofev
7.2.6. Product Profile
8. Emerging Therapies
9. Key Cross Competition
10. Phase III Drugs
10.1. Thrombomodulin Alfa: Asahi Kasei Pharma Corporation
10.1.1. Drug Description
10.1.2. Product Profile
10.1.3. Clinical Development
10.1.4. Clinical Trials Information
10.1.5. Safety and Efficacy
11. Phase II Drugs
11.1. CC-90001: Celgene Corporation
11.1.1. Drug Description
11.1.2. Product Profile
11.1.3. Clinical Development
11.1.4. Clinical Trials Information
11.1.5. Safety and Efficacy
11.1.6. Drug Description
11.1.7. Product Profile
11.1.8. Other Development Activities
11.1.9. Clinical Development
11.1.10. Clinical Trials Information
11.1.11. Safety and Efficacy
11.2. Gefapixant: Merck & Co., Inc.
11.2.1. Drug Description
11.2.2. Product Profile
11.2.3. Other Development Activities
11.2.4. Clinical Development
11.2.5. Clinical Trials Information
11.2.6. Safety and Efficacy
11.3. GLPG1690: Galapagos NV
11.3.1. Drug Description
11.3.2. Product Profile
11.3.3. Regulatory Milestones
11.3.4. Other Development Activities
11.3.5. Clinical Development
11.3.6. Clinical Trials Information
11.3.7. Safety and Efficacy
11.4. LT-1001: LTT Bio-Pharma
11.4.1. Drug Description
11.4.2. Product Profile
11.4.3. Other Development Activities
11.4.4. Clinical Development
11.4.5. Clinical Trials Information
11.4.6. Safety and Efficacy
11.5. BG00011: Biogen Inc.
11.5.1. Drug Description
11.5.2. Product Profile
11.5.3. Regulatory Milestones
11.5.4. Other Development Activities
11.5.5. Clinical Development
11.5.6. Clinical Trials Information
11.5.7. Safety and Efficacy
11.6. BMS-986020: Bristol-Myers Squibb
11.6.1. Drug Description
11.6.2. Product Profile
11.6.3. Regulatory Milestones
11.6.4. Other Development Activities
11.6.5. Clinical Development
11.6.6. Clinical Trials Information
11.6.7. Safety and Efficacy
11.7. LT-1002: Chong Kun Dang Pharmaceutical
11.7.1. Drug Description
11.7.2. Product Profile
11.7.3. Other Development Activities
11.8. Pamrevlumab: FibroGen
11.8.1. Drug Description
11.8.2. Product Profile
11.8.3. Regulatory Milestones
11.8.4. Other Development Activities
11.8.5. Clinical Development
11.8.6. Clinical Trials Information
11.8.7. Safety and Efficacy
11.9. PBI4050: ProMetic Life Sciences
11.9.1. Drug Description
11.9.2. Product Profile
11.9.3. Regulatory Milestones
11.9.4. Other Development Activities
11.9.5. Clinical Development
11.9.6. Clinical Trials Information
11.9.7. Safety and Efficacy
11.10. PRM 151: Promedior, Inc.
11.10.1. Drug Description
11.10.2. Product Profile
11.10.3. Regulatory Milestones
11.10.4. Other Development Activities
11.10.5. Clinical Development
11.10.6. Clinical Trials Information
11.10.7. Safety and Efficacy
11.11. Tipelukast: MediciNova
11.11.1. Drug Description
11.11.2. Product Profile
11.11.3. Regulatory Milestones
11.11.4. Other Development Activities
11.11.5. Clinical Development
11.11.6. Clinical Trials Information
11.11.7. Safety and Efficacy
11.12. TD139: Bristol-Myers Squibb
11.12.1. Drug Description
11.12.2. Product Profile
11.12.3. Other Development Activities
11.12.4. Clinical Development
11.12.5. Clinical Trials Information
11.12.6. Safety and Efficacy
11.13. VAY736: Novartis
11.13.1. Drug Description
11.13.2. Product Profile
11.13.3. Other Development Activities
11.13.4. Clinical Development
11.13.5. Clinical Trials Information
11.14. TAS-115: Taiho Pharmaceutical
11.14.1. Drug Description
11.14.2. Product Profile
11.14.3. Clinical Development
11.14.4. Clinical Trials Information
12. IPF: Market Analysis
12.1. Key Findings
12.2. Total Market Size of IPF in 7 MM
12.3. Therapy Based Market Size of IPF in 7 MM
13. Market Size of IPF by Country
13.1. United States Market Analysis
13.1.1. Market Size of IPF in the US
13.1.2. Therapy Based Market Size of IPF in the US
13.2. EU5 Market Outlook
13.3. Germany
13.3.1. Market Size of IPF in Germany
13.3.2. Therapy Based Market Size of IPF in Germany
13.4. France
13.4.1. Market Size of IPF in France
13.4.2. Therapy Based Market Size of IPF in France
13.5. Italy
13.5.1. Market Size of IPF in Italy
13.5.2. Therapy Based Market Size of IPF in Italy
13.6. United Kingdom
13.6.1. Market Size of IPF in the UK
13.6.2. Therapy Based Market Size of IPF in the UK
13.7. Spain
13.7.1. Market Size of IPF in Spain
13.7.2. Therapy Based Market Size of IPF in Spain
13.8. Japan: Market Analysis
13.8.1. Market Size of IPF in Japan
13.8.2. Therapy Based Market Size of IPF in Japan
14. Market Drivers of IPF
15. Market Barriers of IPF
16. Appendix
16.1. Report Methodology
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

 

1. Key Insights
2. IPF Market Overview at a Glance
2.1. Market Share (%) Distribution of IPF in 2017
2.2. Market Share (%) Distribution of IPF in 2027
3. Disease Background and Overview: Idiopathic Pulmonary Fibrosis (IPF)
3.1. Introduction
3.2. Staging of IPF
3.3. Risk Factors & Disease Causes
3.4. Symptoms
3.5. Pathogenesis
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7 MM Prevalent Population of IPF
4.3. Country Wise-Epidemiology of IPF
4.3.1. United States
4.3.2. Prevalent cases of IPF in the United States
4.3.3. Prevalent Population of IPF by severity
4.3.4. Gender-Specific IPF Prevalence
4.3.5. Age-Specific IPF Prevalence
4.3.6. EU5
4.3.7. Prevalent Population of IPF in EU5
4.3.8. France
4.3.9. Prevalent Population of IPF
4.3.10. Prevalent Population of IPF by severity
4.3.11. Gender-Specific IPF Prevalence
4.3.12. Age-Specific IPF Prevalence
4.3.13. Germany
4.3.14. Prevalent Population of IPF
4.3.15. Prevalent Population of IPF by severity
4.3.16. Gender-Specific IPF Prevalence
4.3.17. Age-Specific IPF Prevalence
4.3.18. Italy
4.3.19. Prevalent Population of IPF
4.3.20. Prevalent Population of IPF by severity
4.3.21. Gender-Specific IPF Prevalence
4.3.22. Age-Specific IPF Prevalence
4.3.23. Spain
4.3.24. Prevalent Population of IPF
4.3.25. Prevalent Population of IPF by severity
4.3.26. Gender-Specific IPF Prevalence
4.3.27. Age-Specific IPF Prevalence
4.3.28. United Kingdom
4.3.29. Prevalent Population of IPF
4.3.30. Prevalent Population of IPF by severity
4.3.31. Gender-Specific IPF Prevalence
4.3.32. Age-Specific IPF Prevalence
4.3.33. Japan
4.3.34. Prevalent Population of IPF
4.3.35. Prevalent Population of IPF by severity
4.3.36. Gender-SPECIFIC IPF Prevalence
4.3.37. Age-Specific IPF Prevalence
5. Current Treatment Practices
5.1. ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of IPF (An Update of 2011 Clinical Practice Guideline)
6. Unmet needs
7. Marketed Products
7.1. Esbriet (Pirfenidone): InterMune Inc.
7.1.1. Product Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Safety and Efficacy of Esbriet
7.1.5. Side effects of Esbriet
7.1.6. Product Profile
7.2. Ofev (Nintedanib): Boehringer Ingelheim Pharma GmbH & Co. KG
7.2.1. Product Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Safety and Efficacy of Ofev
7.2.5. Side effects of Ofev
7.2.6. Product Profile
8. Emerging Therapies
9. Key Cross Competition
10. Phase III Drugs
10.1. Thrombomodulin Alfa: Asahi Kasei Pharma Corporation
10.1.1. Drug Description
10.1.2. Product Profile
10.1.3. Clinical Development
10.1.4. Clinical Trials Information
10.1.5. Safety and Efficacy
11. Phase II Drugs
11.1. CC-90001: Celgene Corporation
11.1.1. Drug Description
11.1.2. Product Profile
11.1.3. Clinical Development
11.1.4. Clinical Trials Information
11.1.5. Safety and Efficacy
11.1.6. Drug Description
11.1.7. Product Profile
11.1.8. Other Development Activities
11.1.9. Clinical Development
11.1.10. Clinical Trials Information
11.1.11. Safety and Efficacy
11.2. Gefapixant: Merck & Co., Inc.
11.2.1. Drug Description
11.2.2. Product Profile
11.2.3. Other Development Activities
11.2.4. Clinical Development
11.2.5. Clinical Trials Information
11.2.6. Safety and Efficacy
11.3. GLPG1690: Galapagos NV
11.3.1. Drug Description
11.3.2. Product Profile
11.3.3. Regulatory Milestones
11.3.4. Other Development Activities
11.3.5. Clinical Development
11.3.6. Clinical Trials Information
11.3.7. Safety and Efficacy
11.4. LT-1001: LTT Bio-Pharma
11.4.1. Drug Description
11.4.2. Product Profile
11.4.3. Other Development Activities
11.4.4. Clinical Development
11.4.5. Clinical Trials Information
11.4.6. Safety and Efficacy
11.5. BG00011: Biogen Inc.
11.5.1. Drug Description
11.5.2. Product Profile
11.5.3. Regulatory Milestones
11.5.4. Other Development Activities
11.5.5. Clinical Development
11.5.6. Clinical Trials Information
11.5.7. Safety and Efficacy
11.6. BMS-986020: Bristol-Myers Squibb
11.6.1. Drug Description
11.6.2. Product Profile
11.6.3. Regulatory Milestones
11.6.4. Other Development Activities
11.6.5. Clinical Development
11.6.6. Clinical Trials Information
11.6.7. Safety and Efficacy
11.7. LT-1002: Chong Kun Dang Pharmaceutical
11.7.1. Drug Description
11.7.2. Product Profile
11.7.3. Other Development Activities
11.8. Pamrevlumab: FibroGen
11.8.1. Drug Description
11.8.2. Product Profile
11.8.3. Regulatory Milestones
11.8.4. Other Development Activities
11.8.5. Clinical Development
11.8.6. Clinical Trials Information
11.8.7. Safety and Efficacy
11.9. PBI4050: ProMetic Life Sciences
11.9.1. Drug Description
11.9.2. Product Profile
11.9.3. Regulatory Milestones
11.9.4. Other Development Activities
11.9.5. Clinical Development
11.9.6. Clinical Trials Information
11.9.7. Safety and Efficacy
11.10. PRM 151: Promedior, Inc.
11.10.1. Drug Description
11.10.2. Product Profile
11.10.3. Regulatory Milestones
11.10.4. Other Development Activities
11.10.5. Clinical Development
11.10.6. Clinical Trials Information
11.10.7. Safety and Efficacy
11.11. Tipelukast: MediciNova
11.11.1. Drug Description
11.11.2. Product Profile
11.11.3. Regulatory Milestones
11.11.4. Other Development Activities
11.11.5. Clinical Development
11.11.6. Clinical Trials Information
11.11.7. Safety and Efficacy
11.12. TD139: Bristol-Myers Squibb
11.12.1. Drug Description
11.12.2. Product Profile
11.12.3. Other Development Activities
11.12.4. Clinical Development
11.12.5. Clinical Trials Information
11.12.6. Safety and Efficacy
11.13. VAY736: Novartis
11.13.1. Drug Description
11.13.2. Product Profile
11.13.3. Other Development Activities
11.13.4. Clinical Development
11.13.5. Clinical Trials Information
11.14. TAS-115: Taiho Pharmaceutical
11.14.1. Drug Description
11.14.2. Product Profile
11.14.3. Clinical Development
11.14.4. Clinical Trials Information
12. IPF: Market Analysis
12.1. Key Findings
12.2. Total Market Size of IPF in 7 MM
12.3. Therapy Based Market Size of IPF in 7 MM
13. Market Size of IPF by Country
13.1. United States Market Analysis
13.1.1. Market Size of IPF in the US
13.1.2. Therapy Based Market Size of IPF in the US
13.2. EU5 Market Outlook
13.3. Germany
13.3.1. Market Size of IPF in Germany
13.3.2. Therapy Based Market Size of IPF in Germany
13.4. France
13.4.1. Market Size of IPF in France
13.4.2. Therapy Based Market Size of IPF in France
13.5. Italy
13.5.1. Market Size of IPF in Italy
13.5.2. Therapy Based Market Size of IPF in Italy
13.6. United Kingdom
13.6.1. Market Size of IPF in the UK
13.6.2. Therapy Based Market Size of IPF in the UK
13.7. Spain
13.7.1. Market Size of IPF in Spain
13.7.2. Therapy Based Market Size of IPF in Spain
13.8. Japan: Market Analysis
13.8.1. Market Size of IPF in Japan
13.8.2. Therapy Based Market Size of IPF in Japan
14. Market Drivers of IPF
15. Market Barriers of IPF
16. Appendix
16.1. Report Methodology
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

 

1. Key Insights
2. IPF Market Overview at a Glance
2.1. Market Share (%) Distribution of IPF in 2017
2.2. Market Share (%) Distribution of IPF in 2027
3. Disease Background and Overview: Idiopathic Pulmonary Fibrosis (IPF)
3.1. Introduction
3.2. Staging of IPF
3.3. Risk Factors & Disease Causes
3.4. Symptoms
3.5. Pathogenesis
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7 MM Prevalent Population of IPF
4.3. Country Wise-Epidemiology of IPF
4.3.1. United States
4.3.2. Prevalent cases of IPF in the United States
4.3.3. Prevalent Population of IPF by severity
4.3.4. Gender-Specific IPF Prevalence
4.3.5. Age-Specific IPF Prevalence
4.3.6. EU5
4.3.7. Prevalent Population of IPF in EU5
4.3.8. France
4.3.9. Prevalent Population of IPF
4.3.10. Prevalent Population of IPF by severity
4.3.11. Gender-Specific IPF Prevalence
4.3.12. Age-Specific IPF Prevalence
4.3.13. Germany
4.3.14. Prevalent Population of IPF
4.3.15. Prevalent Population of IPF by severity
4.3.16. Gender-Specific IPF Prevalence
4.3.17. Age-Specific IPF Prevalence
4.3.18. Italy
4.3.19. Prevalent Population of IPF
4.3.20. Prevalent Population of IPF by severity
4.3.21. Gender-Specific IPF Prevalence
4.3.22. Age-Specific IPF Prevalence
4.3.23. Spain
4.3.24. Prevalent Population of IPF
4.3.25. Prevalent Population of IPF by severity
4.3.26. Gender-Specific IPF Prevalence
4.3.27. Age-Specific IPF Prevalence
4.3.28. United Kingdom
4.3.29. Prevalent Population of IPF
4.3.30. Prevalent Population of IPF by severity
4.3.31. Gender-Specific IPF Prevalence
4.3.32. Age-Specific IPF Prevalence
4.3.33. Japan
4.3.34. Prevalent Population of IPF
4.3.35. Prevalent Population of IPF by severity
4.3.36. Gender-SPECIFIC IPF Prevalence
4.3.37. Age-Specific IPF Prevalence
5. Current Treatment Practices
5.1. ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of IPF (An Update of 2011 Clinical Practice Guideline)
6. Unmet needs
7. Marketed Products
7.1. Esbriet (Pirfenidone): InterMune Inc.
7.1.1. Product Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Safety and Efficacy of Esbriet
7.1.5. Side effects of Esbriet
7.1.6. Product Profile
7.2. Ofev (Nintedanib): Boehringer Ingelheim Pharma GmbH & Co. KG
7.2.1. Product Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Safety and Efficacy of Ofev
7.2.5. Side effects of Ofev
7.2.6. Product Profile
8. Emerging Therapies
9. Key Cross Competition
10. Phase III Drugs
10.1. Thrombomodulin Alfa: Asahi Kasei Pharma Corporation
10.1.1. Drug Description
10.1.2. Product Profile
10.1.3. Clinical Development
10.1.4. Clinical Trials Information
10.1.5. Safety and Efficacy
11. Phase II Drugs
11.1. CC-90001: Celgene Corporation
11.1.1. Drug Description
11.1.2. Product Profile
11.1.3. Clinical Development
11.1.4. Clinical Trials Information
11.1.5. Safety and Efficacy
11.1.6. Drug Description
11.1.7. Product Profile
11.1.8. Other Development Activities
11.1.9. Clinical Development
11.1.10. Clinical Trials Information
11.1.11. Safety and Efficacy
11.2. Gefapixant: Merck & Co., Inc.
11.2.1. Drug Description
11.2.2. Product Profile
11.2.3. Other Development Activities
11.2.4. Clinical Development
11.2.5. Clinical Trials Information
11.2.6. Safety and Efficacy
11.3. GLPG1690: Galapagos NV
11.3.1. Drug Description
11.3.2. Product Profile
11.3.3. Regulatory Milestones
11.3.4. Other Development Activities
11.3.5. Clinical Development
11.3.6. Clinical Trials Information
11.3.7. Safety and Efficacy
11.4. LT-1001: LTT Bio-Pharma
11.4.1. Drug Description
11.4.2. Product Profile
11.4.3. Other Development Activities
11.4.4. Clinical Development
11.4.5. Clinical Trials Information
11.4.6. Safety and Efficacy
11.5. BG00011: Biogen Inc.
11.5.1. Drug Description
11.5.2. Product Profile
11.5.3. Regulatory Milestones
11.5.4. Other Development Activities
11.5.5. Clinical Development
11.5.6. Clinical Trials Information
11.5.7. Safety and Efficacy
11.6. BMS-986020: Bristol-Myers Squibb
11.6.1. Drug Description
11.6.2. Product Profile
11.6.3. Regulatory Milestones
11.6.4. Other Development Activities
11.6.5. Clinical Development
11.6.6. Clinical Trials Information
11.6.7. Safety and Efficacy
11.7. LT-1002: Chong Kun Dang Pharmaceutical
11.7.1. Drug Description
11.7.2. Product Profile
11.7.3. Other Development Activities
11.8. Pamrevlumab: FibroGen
11.8.1. Drug Description
11.8.2. Product Profile
11.8.3. Regulatory Milestones
11.8.4. Other Development Activities
11.8.5. Clinical Development
11.8.6. Clinical Trials Information
11.8.7. Safety and Efficacy
11.9. PBI4050: ProMetic Life Sciences
11.9.1. Drug Description
11.9.2. Product Profile
11.9.3. Regulatory Milestones
11.9.4. Other Development Activities
11.9.5. Clinical Development
11.9.6. Clinical Trials Information
11.9.7. Safety and Efficacy
11.10. PRM 151: Promedior, Inc.
11.10.1. Drug Description
11.10.2. Product Profile
11.10.3. Regulatory Milestones
11.10.4. Other Development Activities
11.10.5. Clinical Development
11.10.6. Clinical Trials Information
11.10.7. Safety and Efficacy
11.11. Tipelukast: MediciNova
11.11.1. Drug Description
11.11.2. Product Profile
11.11.3. Regulatory Milestones
11.11.4. Other Development Activities
11.11.5. Clinical Development
11.11.6. Clinical Trials Information
11.11.7. Safety and Efficacy
11.12. TD139: Bristol-Myers Squibb
11.12.1. Drug Description
11.12.2. Product Profile
11.12.3. Other Development Activities
11.12.4. Clinical Development
11.12.5. Clinical Trials Information
11.12.6. Safety and Efficacy
11.13. VAY736: Novartis
11.13.1. Drug Description
11.13.2. Product Profile
11.13.3. Other Development Activities
11.13.4. Clinical Development
11.13.5. Clinical Trials Information
11.14. TAS-115: Taiho Pharmaceutical
11.14.1. Drug Description
11.14.2. Product Profile
11.14.3. Clinical Development
11.14.4. Clinical Trials Information
12. IPF: Market Analysis
12.1. Key Findings
12.2. Total Market Size of IPF in 7 MM
12.3. Therapy Based Market Size of IPF in 7 MM
13. Market Size of IPF by Country
13.1. United States Market Analysis
13.1.1. Market Size of IPF in the US
13.1.2. Therapy Based Market Size of IPF in the US
13.2. EU5 Market Outlook
13.3. Germany
13.3.1. Market Size of IPF in Germany
13.3.2. Therapy Based Market Size of IPF in Germany
13.4. France
13.4.1. Market Size of IPF in France
13.4.2. Therapy Based Market Size of IPF in France
13.5. Italy
13.5.1. Market Size of IPF in Italy
13.5.2. Therapy Based Market Size of IPF in Italy
13.6. United Kingdom
13.6.1. Market Size of IPF in the UK
13.6.2. Therapy Based Market Size of IPF in the UK
13.7. Spain
13.7.1. Market Size of IPF in Spain
13.7.2. Therapy Based Market Size of IPF in Spain
13.8. Japan: Market Analysis
13.8.1. Market Size of IPF in Japan
13.8.2. Therapy Based Market Size of IPF in Japan
14. Market Drivers of IPF
15. Market Barriers of IPF
16. Appendix
16.1. Report Methodology
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

 

1. Key Insights
2. IPF Market Overview at a Glance
2.1. Market Share (%) Distribution of IPF in 2017
2.2. Market Share (%) Distribution of IPF in 2027
3. Disease Background and Overview: Idiopathic Pulmonary Fibrosis (IPF)
3.1. Introduction
3.2. Staging of IPF
3.3. Risk Factors & Disease Causes
3.4. Symptoms
3.5. Pathogenesis
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7 MM Prevalent Population of IPF
4.3. Country Wise-Epidemiology of IPF
4.3.1. United States
4.3.2. Prevalent cases of IPF in the United States
4.3.3. Prevalent Population of IPF by severity
4.3.4. Gender-Specific IPF Prevalence
4.3.5. Age-Specific IPF Prevalence
4.3.6. EU5
4.3.7. Prevalent Population of IPF in EU5
4.3.8. France
4.3.9. Prevalent Population of IPF
4.3.10. Prevalent Population of IPF by severity
4.3.11. Gender-Specific IPF Prevalence
4.3.12. Age-Specific IPF Prevalence
4.3.13. Germany
4.3.14. Prevalent Population of IPF
4.3.15. Prevalent Population of IPF by severity
4.3.16. Gender-Specific IPF Prevalence
4.3.17. Age-Specific IPF Prevalence
4.3.18. Italy
4.3.19. Prevalent Population of IPF
4.3.20. Prevalent Population of IPF by severity
4.3.21. Gender-Specific IPF Prevalence
4.3.22. Age-Specific IPF Prevalence
4.3.23. Spain
4.3.24. Prevalent Population of IPF
4.3.25. Prevalent Population of IPF by severity
4.3.26. Gender-Specific IPF Prevalence
4.3.27. Age-Specific IPF Prevalence
4.3.28. United Kingdom
4.3.29. Prevalent Population of IPF
4.3.30. Prevalent Population of IPF by severity
4.3.31. Gender-Specific IPF Prevalence
4.3.32. Age-Specific IPF Prevalence
4.3.33. Japan
4.3.34. Prevalent Population of IPF
4.3.35. Prevalent Population of IPF by severity
4.3.36. Gender-SPECIFIC IPF Prevalence
4.3.37. Age-Specific IPF Prevalence
5. Current Treatment Practices
5.1. ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of IPF (An Update of 2011 Clinical Practice Guideline)
6. Unmet needs
7. Marketed Products
7.1. Esbriet (Pirfenidone): InterMune Inc.
7.1.1. Product Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Safety and Efficacy of Esbriet
7.1.5. Side effects of Esbriet
7.1.6. Product Profile
7.2. Ofev (Nintedanib): Boehringer Ingelheim Pharma GmbH & Co. KG
7.2.1. Product Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Safety and Efficacy of Ofev
7.2.5. Side effects of Ofev
7.2.6. Product Profile
8. Emerging Therapies
9. Key Cross Competition
10. Phase III Drugs
10.1. Thrombomodulin Alfa: Asahi Kasei Pharma Corporation
10.1.1. Drug Description
10.1.2. Product Profile
10.1.3. Clinical Development
10.1.4. Clinical Trials Information
10.1.5. Safety and Efficacy
11. Phase II Drugs
11.1. CC-90001: Celgene Corporation
11.1.1. Drug Description
11.1.2. Product Profile
11.1.3. Clinical Development
11.1.4. Clinical Trials Information
11.1.5. Safety and Efficacy
11.1.6. Drug Description
11.1.7. Product Profile
11.1.8. Other Development Activities
11.1.9. Clinical Development
11.1.10. Clinical Trials Information
11.1.11. Safety and Efficacy
11.2. Gefapixant: Merck & Co., Inc.
11.2.1. Drug Description
11.2.2. Product Profile
11.2.3. Other Development Activities
11.2.4. Clinical Development
11.2.5. Clinical Trials Information
11.2.6. Safety and Efficacy
11.3. GLPG1690: Galapagos NV
11.3.1. Drug Description
11.3.2. Product Profile
11.3.3. Regulatory Milestones
11.3.4. Other Development Activities
11.3.5. Clinical Development
11.3.6. Clinical Trials Information
11.3.7. Safety and Efficacy
11.4. LT-1001: LTT Bio-Pharma
11.4.1. Drug Description
11.4.2. Product Profile
11.4.3. Other Development Activities
11.4.4. Clinical Development
11.4.5. Clinical Trials Information
11.4.6. Safety and Efficacy
11.5. BG00011: Biogen Inc.
11.5.1. Drug Description
11.5.2. Product Profile
11.5.3. Regulatory Milestones
11.5.4. Other Development Activities
11.5.5. Clinical Development
11.5.6. Clinical Trials Information
11.5.7. Safety and Efficacy
11.6. BMS-986020: Bristol-Myers Squibb
11.6.1. Drug Description
11.6.2. Product Profile
11.6.3. Regulatory Milestones
11.6.4. Other Development Activities
11.6.5. Clinical Development
11.6.6. Clinical Trials Information
11.6.7. Safety and Efficacy
11.7. LT-1002: Chong Kun Dang Pharmaceutical
11.7.1. Drug Description
11.7.2. Product Profile
11.7.3. Other Development Activities
11.8. Pamrevlumab: FibroGen
11.8.1. Drug Description
11.8.2. Product Profile
11.8.3. Regulatory Milestones
11.8.4. Other Development Activities
11.8.5. Clinical Development
11.8.6. Clinical Trials Information
11.8.7. Safety and Efficacy
11.9. PBI4050: ProMetic Life Sciences
11.9.1. Drug Description
11.9.2. Product Profile
11.9.3. Regulatory Milestones
11.9.4. Other Development Activities
11.9.5. Clinical Development
11.9.6. Clinical Trials Information
11.9.7. Safety and Efficacy
11.10. PRM 151: Promedior, Inc.
11.10.1. Drug Description
11.10.2. Product Profile
11.10.3. Regulatory Milestones
11.10.4. Other Development Activities
11.10.5. Clinical Development
11.10.6. Clinical Trials Information
11.10.7. Safety and Efficacy
11.11. Tipelukast: MediciNova
11.11.1. Drug Description
11.11.2. Product Profile
11.11.3. Regulatory Milestones
11.11.4. Other Development Activities
11.11.5. Clinical Development
11.11.6. Clinical Trials Information
11.11.7. Safety and Efficacy
11.12. TD139: Bristol-Myers Squibb
11.12.1. Drug Description
11.12.2. Product Profile
11.12.3. Other Development Activities
11.12.4. Clinical Development
11.12.5. Clinical Trials Information
11.12.6. Safety and Efficacy
11.13. VAY736: Novartis
11.13.1. Drug Description
11.13.2. Product Profile
11.13.3. Other Development Activities
11.13.4. Clinical Development
11.13.5. Clinical Trials Information
11.14. TAS-115: Taiho Pharmaceutical
11.14.1. Drug Description
11.14.2. Product Profile
11.14.3. Clinical Development
11.14.4. Clinical Trials Information
12. IPF: Market Analysis
12.1. Key Findings
12.2. Total Market Size of IPF in 7 MM
12.3. Therapy Based Market Size of IPF in 7 MM
13. Market Size of IPF by Country
13.1. United States Market Analysis
13.1.1. Market Size of IPF in the US
13.1.2. Therapy Based Market Size of IPF in the US
13.2. EU5 Market Outlook
13.3. Germany
13.3.1. Market Size of IPF in Germany
13.3.2. Therapy Based Market Size of IPF in Germany
13.4. France
13.4.1. Market Size of IPF in France
13.4.2. Therapy Based Market Size of IPF in France
13.5. Italy
13.5.1. Market Size of IPF in Italy
13.5.2. Therapy Based Market Size of IPF in Italy
13.6. United Kingdom
13.6.1. Market Size of IPF in the UK
13.6.2. Therapy Based Market Size of IPF in the UK
13.7. Spain
13.7.1. Market Size of IPF in Spain
13.7.2. Therapy Based Market Size of IPF in Spain
13.8. Japan: Market Analysis
13.8.1. Market Size of IPF in Japan
13.8.2. Therapy Based Market Size of IPF in Japan
14. Market Drivers of IPF
15. Market Barriers of IPF
16. Appendix
16.1. Report Methodology
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

 

1. Key Insights
2. IPF Market Overview at a Glance
2.1. Market Share (%) Distribution of IPF in 2017
2.2. Market Share (%) Distribution of IPF in 2027
3. Disease Background and Overview: Idiopathic Pulmonary Fibrosis (IPF)
3.1. Introduction
3.2. Staging of IPF
3.3. Risk Factors & Disease Causes
3.4. Symptoms
3.5. Pathogenesis
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7 MM Prevalent Population of IPF
4.3. Country Wise-Epidemiology of IPF
4.3.1. United States
4.3.2. Prevalent cases of IPF in the United States
4.3.3. Prevalent Population of IPF by severity
4.3.4. Gender-Specific IPF Prevalence
4.3.5. Age-Specific IPF Prevalence
4.3.6. EU5
4.3.7. Prevalent Population of IPF in EU5
4.3.8. France
4.3.9. Prevalent Population of IPF
4.3.10. Prevalent Population of IPF by severity
4.3.11. Gender-Specific IPF Prevalence
4.3.12. Age-Specific IPF Prevalence
4.3.13. Germany
4.3.14. Prevalent Population of IPF
4.3.15. Prevalent Population of IPF by severity
4.3.16. Gender-Specific IPF Prevalence
4.3.17. Age-Specific IPF Prevalence
4.3.18. Italy
4.3.19. Prevalent Population of IPF
4.3.20. Prevalent Population of IPF by severity
4.3.21. Gender-Specific IPF Prevalence
4.3.22. Age-Specific IPF Prevalence
4.3.23. Spain
4.3.24. Prevalent Population of IPF
4.3.25. Prevalent Population of IPF by severity
4.3.26. Gender-Specific IPF Prevalence
4.3.27. Age-Specific IPF Prevalence
4.3.28. United Kingdom
4.3.29. Prevalent Population of IPF
4.3.30. Prevalent Population of IPF by severity
4.3.31. Gender-Specific IPF Prevalence
4.3.32. Age-Specific IPF Prevalence
4.3.33. Japan
4.3.34. Prevalent Population of IPF
4.3.35. Prevalent Population of IPF by severity
4.3.36. Gender-SPECIFIC IPF Prevalence
4.3.37. Age-Specific IPF Prevalence
5. Current Treatment Practices
5.1. ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of IPF (An Update of 2011 Clinical Practice Guideline)
6. Unmet needs
7. Marketed Products
7.1. Esbriet (Pirfenidone): InterMune Inc.
7.1.1. Product Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Safety and Efficacy of Esbriet
7.1.5. Side effects of Esbriet
7.1.6. Product Profile
7.2. Ofev (Nintedanib): Boehringer Ingelheim Pharma GmbH & Co. KG
7.2.1. Product Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Safety and Efficacy of Ofev
7.2.5. Side effects of Ofev
7.2.6. Product Profile
8. Emerging Therapies
9. Key Cross Competition
10. Phase III Drugs
10.1. Thrombomodulin Alfa: Asahi Kasei Pharma Corporation
10.1.1. Drug Description
10.1.2. Product Profile
10.1.3. Clinical Development
10.1.4. Clinical Trials Information
10.1.5. Safety and Efficacy
11. Phase II Drugs
11.1. CC-90001: Celgene Corporation
11.1.1. Drug Description
11.1.2. Product Profile
11.1.3. Clinical Development
11.1.4. Clinical Trials Information
11.1.5. Safety and Efficacy
11.1.6. Drug Description
11.1.7. Product Profile
11.1.8. Other Development Activities
11.1.9. Clinical Development
11.1.10. Clinical Trials Information
11.1.11. Safety and Efficacy
11.2. Gefapixant: Merck & Co., Inc.
11.2.1. Drug Description
11.2.2. Product Profile
11.2.3. Other Development Activities
11.2.4. Clinical Development
11.2.5. Clinical Trials Information
11.2.6. Safety and Efficacy
11.3. GLPG1690: Galapagos NV
11.3.1. Drug Description
11.3.2. Product Profile
11.3.3. Regulatory Milestones
11.3.4. Other Development Activities
11.3.5. Clinical Development
11.3.6. Clinical Trials Information
11.3.7. Safety and Efficacy
11.4. LT-1001: LTT Bio-Pharma
11.4.1. Drug Description
11.4.2. Product Profile
11.4.3. Other Development Activities
11.4.4. Clinical Development
11.4.5. Clinical Trials Information
11.4.6. Safety and Efficacy
11.5. BG00011: Biogen Inc.
11.5.1. Drug Description
11.5.2. Product Profile
11.5.3. Regulatory Milestones
11.5.4. Other Development Activities
11.5.5. Clinical Development
11.5.6. Clinical Trials Information
11.5.7. Safety and Efficacy
11.6. BMS-986020: Bristol-Myers Squibb
11.6.1. Drug Description
11.6.2. Product Profile
11.6.3. Regulatory Milestones
11.6.4. Other Development Activities
11.6.5. Clinical Development
11.6.6. Clinical Trials Information
11.6.7. Safety and Efficacy
11.7. LT-1002: Chong Kun Dang Pharmaceutical
11.7.1. Drug Description
11.7.2. Product Profile
11.7.3. Other Development Activities
11.8. Pamrevlumab: FibroGen
11.8.1. Drug Description
11.8.2. Product Profile
11.8.3. Regulatory Milestones
11.8.4. Other Development Activities
11.8.5. Clinical Development
11.8.6. Clinical Trials Information
11.8.7. Safety and Efficacy
11.9. PBI4050: ProMetic Life Sciences
11.9.1. Drug Description
11.9.2. Product Profile
11.9.3. Regulatory Milestones
11.9.4. Other Development Activities
11.9.5. Clinical Development
11.9.6. Clinical Trials Information
11.9.7. Safety and Efficacy
11.10. PRM 151: Promedior, Inc.
11.10.1. Drug Description
11.10.2. Product Profile
11.10.3. Regulatory Milestones
11.10.4. Other Development Activities
11.10.5. Clinical Development
11.10.6. Clinical Trials Information
11.10.7. Safety and Efficacy
11.11. Tipelukast: MediciNova
11.11.1. Drug Description
11.11.2. Product Profile
11.11.3. Regulatory Milestones
11.11.4. Other Development Activities
11.11.5. Clinical Development
11.11.6. Clinical Trials Information
11.11.7. Safety and Efficacy
11.12. TD139: Bristol-Myers Squibb
11.12.1. Drug Description
11.12.2. Product Profile
11.12.3. Other Development Activities
11.12.4. Clinical Development
11.12.5. Clinical Trials Information
11.12.6. Safety and Efficacy
11.13. VAY736: Novartis
11.13.1. Drug Description
11.13.2. Product Profile
11.13.3. Other Development Activities
11.13.4. Clinical Development
11.13.5. Clinical Trials Information
11.14. TAS-115: Taiho Pharmaceutical
11.14.1. Drug Description
11.14.2. Product Profile
11.14.3. Clinical Development
11.14.4. Clinical Trials Information
12. IPF: Market Analysis
12.1. Key Findings
12.2. Total Market Size of IPF in 7 MM
12.3. Therapy Based Market Size of IPF in 7 MM
13. Market Size of IPF by Country
13.1. United States Market Analysis
13.1.1. Market Size of IPF in the US
13.1.2. Therapy Based Market Size of IPF in the US
13.2. EU5 Market Outlook
13.3. Germany
13.3.1. Market Size of IPF in Germany
13.3.2. Therapy Based Market Size of IPF in Germany
13.4. France
13.4.1. Market Size of IPF in France
13.4.2. Therapy Based Market Size of IPF in France
13.5. Italy
13.5.1. Market Size of IPF in Italy
13.5.2. Therapy Based Market Size of IPF in Italy
13.6. United Kingdom
13.6.1. Market Size of IPF in the UK
13.6.2. Therapy Based Market Size of IPF in the UK
13.7. Spain
13.7.1. Market Size of IPF in Spain
13.7.2. Therapy Based Market Size of IPF in Spain
13.8. Japan: Market Analysis
13.8.1. Market Size of IPF in Japan
13.8.2. Therapy Based Market Size of IPF in Japan
14. Market Drivers of IPF
15. Market Barriers of IPF
16. Appendix
16.1. Report Methodology
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

 

1. Key Insights
2. IPF Market Overview at a Glance
2.1. Market Share (%) Distribution of IPF in 2017
2.2. Market Share (%) Distribution of IPF in 2027
3. Disease Background and Overview: Idiopathic Pulmonary Fibrosis (IPF)
3.1. Introduction
3.2. Staging of IPF
3.3. Risk Factors & Disease Causes
3.4. Symptoms
3.5. Pathogenesis
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7 MM Prevalent Population of IPF
4.3. Country Wise-Epidemiology of IPF
4.3.1. United States
4.3.2. Prevalent cases of IPF in the United States
4.3.3. Prevalent Population of IPF by severity
4.3.4. Gender-Specific IPF Prevalence
4.3.5. Age-Specific IPF Prevalence
4.3.6. EU5
4.3.7. Prevalent Population of IPF in EU5
4.3.8. France
4.3.9. Prevalent Population of IPF
4.3.10. Prevalent Population of IPF by severity
4.3.11. Gender-Specific IPF Prevalence
4.3.12. Age-Specific IPF Prevalence
4.3.13. Germany
4.3.14. Prevalent Population of IPF
4.3.15. Prevalent Population of IPF by severity
4.3.16. Gender-Specific IPF Prevalence
4.3.17. Age-Specific IPF Prevalence
4.3.18. Italy
4.3.19. Prevalent Population of IPF
4.3.20. Prevalent Population of IPF by severity
4.3.21. Gender-Specific IPF Prevalence
4.3.22. Age-Specific IPF Prevalence
4.3.23. Spain
4.3.24. Prevalent Population of IPF
4.3.25. Prevalent Population of IPF by severity
4.3.26. Gender-Specific IPF Prevalence
4.3.27. Age-Specific IPF Prevalence
4.3.28. United Kingdom
4.3.29. Prevalent Population of IPF
4.3.30. Prevalent Population of IPF by severity
4.3.31. Gender-Specific IPF Prevalence
4.3.32. Age-Specific IPF Prevalence
4.3.33. Japan
4.3.34. Prevalent Population of IPF
4.3.35. Prevalent Population of IPF by severity
4.3.36. Gender-SPECIFIC IPF Prevalence
4.3.37. Age-Specific IPF Prevalence
5. Current Treatment Practices
5.1. ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of IPF (An Update of 2011 Clinical Practice Guideline)
6. Unmet needs
7. Marketed Products
7.1. Esbriet (Pirfenidone): InterMune Inc.
7.1.1. Product Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Safety and Efficacy of Esbriet
7.1.5. Side effects of Esbriet
7.1.6. Product Profile
7.2. Ofev (Nintedanib): Boehringer Ingelheim Pharma GmbH & Co. KG
7.2.1. Product Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Safety and Efficacy of Ofev
7.2.5. Side effects of Ofev
7.2.6. Product Profile
8. Emerging Therapies
9. Key Cross Competition
10. Phase III Drugs
10.1. Thrombomodulin Alfa: Asahi Kasei Pharma Corporation
10.1.1. Drug Description
10.1.2. Product Profile
10.1.3. Clinical Development
10.1.4. Clinical Trials Information
10.1.5. Safety and Efficacy
11. Phase II Drugs
11.1. CC-90001: Celgene Corporation
11.1.1. Drug Description
11.1.2. Product Profile
11.1.3. Clinical Development
11.1.4. Clinical Trials Information
11.1.5. Safety and Efficacy
11.1.6. Drug Description
11.1.7. Product Profile
11.1.8. Other Development Activities
11.1.9. Clinical Development
11.1.10. Clinical Trials Information
11.1.11. Safety and Efficacy
11.2. Gefapixant: Merck & Co., Inc.
11.2.1. Drug Description
11.2.2. Product Profile
11.2.3. Other Development Activities
11.2.4. Clinical Development
11.2.5. Clinical Trials Information
11.2.6. Safety and Efficacy
11.3. GLPG1690: Galapagos NV
11.3.1. Drug Description
11.3.2. Product Profile
11.3.3. Regulatory Milestones
11.3.4. Other Development Activities
11.3.5. Clinical Development
11.3.6. Clinical Trials Information
11.3.7. Safety and Efficacy
11.4. LT-1001: LTT Bio-Pharma
11.4.1. Drug Description
11.4.2. Product Profile
11.4.3. Other Development Activities
11.4.4. Clinical Development
11.4.5. Clinical Trials Information
11.4.6. Safety and Efficacy
11.5. BG00011: Biogen Inc.
11.5.1. Drug Description
11.5.2. Product Profile
11.5.3. Regulatory Milestones
11.5.4. Other Development Activities
11.5.5. Clinical Development
11.5.6. Clinical Trials Information
11.5.7. Safety and Efficacy
11.6. BMS-986020: Bristol-Myers Squibb
11.6.1. Drug Description
11.6.2. Product Profile
11.6.3. Regulatory Milestones
11.6.4. Other Development Activities
11.6.5. Clinical Development
11.6.6. Clinical Trials Information
11.6.7. Safety and Efficacy
11.7. LT-1002: Chong Kun Dang Pharmaceutical
11.7.1. Drug Description
11.7.2. Product Profile
11.7.3. Other Development Activities
11.8. Pamrevlumab: FibroGen
11.8.1. Drug Description
11.8.2. Product Profile
11.8.3. Regulatory Milestones
11.8.4. Other Development Activities
11.8.5. Clinical Development
11.8.6. Clinical Trials Information
11.8.7. Safety and Efficacy
11.9. PBI4050: ProMetic Life Sciences
11.9.1. Drug Description
11.9.2. Product Profile
11.9.3. Regulatory Milestones
11.9.4. Other Development Activities
11.9.5. Clinical Development
11.9.6. Clinical Trials Information
11.9.7. Safety and Efficacy
11.10. PRM 151: Promedior, Inc.
11.10.1. Drug Description
11.10.2. Product Profile
11.10.3. Regulatory Milestones
11.10.4. Other Development Activities
11.10.5. Clinical Development
11.10.6. Clinical Trials Information
11.10.7. Safety and Efficacy
11.11. Tipelukast: MediciNova
11.11.1. Drug Description
11.11.2. Product Profile
11.11.3. Regulatory Milestones
11.11.4. Other Development Activities
11.11.5. Clinical Development
11.11.6. Clinical Trials Information
11.11.7. Safety and Efficacy
11.12. TD139: Bristol-Myers Squibb
11.12.1. Drug Description
11.12.2. Product Profile
11.12.3. Other Development Activities
11.12.4. Clinical Development
11.12.5. Clinical Trials Information
11.12.6. Safety and Efficacy
11.13. VAY736: Novartis
11.13.1. Drug Description
11.13.2. Product Profile
11.13.3. Other Development Activities
11.13.4. Clinical Development
11.13.5. Clinical Trials Information
11.14. TAS-115: Taiho Pharmaceutical
11.14.1. Drug Description
11.14.2. Product Profile
11.14.3. Clinical Development
11.14.4. Clinical Trials Information
12. IPF: Market Analysis
12.1. Key Findings
12.2. Total Market Size of IPF in 7 MM
12.3. Therapy Based Market Size of IPF in 7 MM
13. Market Size of IPF by Country
13.1. United States Market Analysis
13.1.1. Market Size of IPF in the US
13.1.2. Therapy Based Market Size of IPF in the US
13.2. EU5 Market Outlook
13.3. Germany
13.3.1. Market Size of IPF in Germany
13.3.2. Therapy Based Market Size of IPF in Germany
13.4. France
13.4.1. Market Size of IPF in France
13.4.2. Therapy Based Market Size of IPF in France
13.5. Italy
13.5.1. Market Size of IPF in Italy
13.5.2. Therapy Based Market Size of IPF in Italy
13.6. United Kingdom
13.6.1. Market Size of IPF in the UK
13.6.2. Therapy Based Market Size of IPF in the UK
13.7. Spain
13.7.1. Market Size of IPF in Spain
13.7.2. Therapy Based Market Size of IPF in Spain
13.8. Japan: Market Analysis
13.8.1. Market Size of IPF in Japan
13.8.2. Therapy Based Market Size of IPF in Japan
14. Market Drivers of IPF
15. Market Barriers of IPF
16. Appendix
16.1. Report Methodology
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

 

1. Key Insights
2. IPF Market Overview at a Glance
2.1. Market Share (%) Distribution of IPF in 2017
2.2. Market Share (%) Distribution of IPF in 2027
3. Disease Background and Overview: Idiopathic Pulmonary Fibrosis (IPF)
3.1. Introduction
3.2. Staging of IPF
3.3. Risk Factors & Disease Causes
3.4. Symptoms
3.5. Pathogenesis
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7 MM Prevalent Population of IPF
4.3. Country Wise-Epidemiology of IPF
4.3.1. United States
4.3.2. Prevalent cases of IPF in the United States
4.3.3. Prevalent Population of IPF by severity
4.3.4. Gender-Specific IPF Prevalence
4.3.5. Age-Specific IPF Prevalence
4.3.6. EU5
4.3.7. Prevalent Population of IPF in EU5
4.3.8. France
4.3.9. Prevalent Population of IPF
4.3.10. Prevalent Population of IPF by severity
4.3.11. Gender-Specific IPF Prevalence
4.3.12. Age-Specific IPF Prevalence
4.3.13. Germany
4.3.14. Prevalent Population of IPF
4.3.15. Prevalent Population of IPF by severity
4.3.16. Gender-Specific IPF Prevalence
4.3.17. Age-Specific IPF Prevalence
4.3.18. Italy
4.3.19. Prevalent Population of IPF
4.3.20. Prevalent Population of IPF by severity
4.3.21. Gender-Specific IPF Prevalence
4.3.22. Age-Specific IPF Prevalence
4.3.23. Spain
4.3.24. Prevalent Population of IPF
4.3.25. Prevalent Population of IPF by severity
4.3.26. Gender-Specific IPF Prevalence
4.3.27. Age-Specific IPF Prevalence
4.3.28. United Kingdom
4.3.29. Prevalent Population of IPF
4.3.30. Prevalent Population of IPF by severity
4.3.31. Gender-Specific IPF Prevalence
4.3.32. Age-Specific IPF Prevalence
4.3.33. Japan
4.3.34. Prevalent Population of IPF
4.3.35. Prevalent Population of IPF by severity
4.3.36. Gender-SPECIFIC IPF Prevalence
4.3.37. Age-Specific IPF Prevalence
5. Current Treatment Practices
5.1. ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of IPF (An Update of 2011 Clinical Practice Guideline)
6. Unmet needs
7. Marketed Products
7.1. Esbriet (Pirfenidone): InterMune Inc.
7.1.1. Product Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Safety and Efficacy of Esbriet
7.1.5. Side effects of Esbriet
7.1.6. Product Profile
7.2. Ofev (Nintedanib): Boehringer Ingelheim Pharma GmbH & Co. KG
7.2.1. Product Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Safety and Efficacy of Ofev
7.2.5. Side effects of Ofev
7.2.6. Product Profile
8. Emerging Therapies
9. Key Cross Competition
10. Phase III Drugs
10.1. Thrombomodulin Alfa: Asahi Kasei Pharma Corporation
10.1.1. Drug Description
10.1.2. Product Profile
10.1.3. Clinical Development
10.1.4. Clinical Trials Information
10.1.5. Safety and Efficacy
11. Phase II Drugs
11.1. CC-90001: Celgene Corporation
11.1.1. Drug Description
11.1.2. Product Profile
11.1.3. Clinical Development
11.1.4. Clinical Trials Information
11.1.5. Safety and Efficacy
11.1.6. Drug Description
11.1.7. Product Profile
11.1.8. Other Development Activities
11.1.9. Clinical Development
11.1.10. Clinical Trials Information
11.1.11. Safety and Efficacy
11.2. Gefapixant: Merck & Co., Inc.
11.2.1. Drug Description
11.2.2. Product Profile
11.2.3. Other Development Activities
11.2.4. Clinical Development
11.2.5. Clinical Trials Information
11.2.6. Safety and Efficacy
11.3. GLPG1690: Galapagos NV
11.3.1. Drug Description
11.3.2. Product Profile
11.3.3. Regulatory Milestones
11.3.4. Other Development Activities
11.3.5. Clinical Development
11.3.6. Clinical Trials Information
11.3.7. Safety and Efficacy
11.4. LT-1001: LTT Bio-Pharma
11.4.1. Drug Description
11.4.2. Product Profile
11.4.3. Other Development Activities
11.4.4. Clinical Development
11.4.5. Clinical Trials Information
11.4.6. Safety and Efficacy
11.5. BG00011: Biogen Inc.
11.5.1. Drug Description
11.5.2. Product Profile
11.5.3. Regulatory Milestones
11.5.4. Other Development Activities
11.5.5. Clinical Development
11.5.6. Clinical Trials Information
11.5.7. Safety and Efficacy
11.6. BMS-986020: Bristol-Myers Squibb
11.6.1. Drug Description
11.6.2. Product Profile
11.6.3. Regulatory Milestones
11.6.4. Other Development Activities
11.6.5. Clinical Development
11.6.6. Clinical Trials Information
11.6.7. Safety and Efficacy
11.7. LT-1002: Chong Kun Dang Pharmaceutical
11.7.1. Drug Description
11.7.2. Product Profile
11.7.3. Other Development Activities
11.8. Pamrevlumab: FibroGen
11.8.1. Drug Description
11.8.2. Product Profile
11.8.3. Regulatory Milestones
11.8.4. Other Development Activities
11.8.5. Clinical Development
11.8.6. Clinical Trials Information
11.8.7. Safety and Efficacy
11.9. PBI4050: ProMetic Life Sciences
11.9.1. Drug Description
11.9.2. Product Profile
11.9.3. Regulatory Milestones
11.9.4. Other Development Activities
11.9.5. Clinical Development
11.9.6. Clinical Trials Information
11.9.7. Safety and Efficacy
11.10. PRM 151: Promedior, Inc.
11.10.1. Drug Description
11.10.2. Product Profile
11.10.3. Regulatory Milestones
11.10.4. Other Development Activities
11.10.5. Clinical Development
11.10.6. Clinical Trials Information
11.10.7. Safety and Efficacy
11.11. Tipelukast: MediciNova
11.11.1. Drug Description
11.11.2. Product Profile
11.11.3. Regulatory Milestones
11.11.4. Other Development Activities
11.11.5. Clinical Development
11.11.6. Clinical Trials Information
11.11.7. Safety and Efficacy
11.12. TD139: Bristol-Myers Squibb
11.12.1. Drug Description
11.12.2. Product Profile
11.12.3. Other Development Activities
11.12.4. Clinical Development
11.12.5. Clinical Trials Information
11.12.6. Safety and Efficacy
11.13. VAY736: Novartis
11.13.1. Drug Description
11.13.2. Product Profile
11.13.3. Other Development Activities
11.13.4. Clinical Development
11.13.5. Clinical Trials Information
11.14. TAS-115: Taiho Pharmaceutical
11.14.1. Drug Description
11.14.2. Product Profile
11.14.3. Clinical Development
11.14.4. Clinical Trials Information
12. IPF: Market Analysis
12.1. Key Findings
12.2. Total Market Size of IPF in 7 MM
12.3. Therapy Based Market Size of IPF in 7 MM
13. Market Size of IPF by Country
13.1. United States Market Analysis
13.1.1. Market Size of IPF in the US
13.1.2. Therapy Based Market Size of IPF in the US
13.2. EU5 Market Outlook
13.3. Germany
13.3.1. Market Size of IPF in Germany
13.3.2. Therapy Based Market Size of IPF in Germany
13.4. France
13.4.1. Market Size of IPF in France
13.4.2. Therapy Based Market Size of IPF in France
13.5. Italy
13.5.1. Market Size of IPF in Italy
13.5.2. Therapy Based Market Size of IPF in Italy
13.6. United Kingdom
13.6.1. Market Size of IPF in the UK
13.6.2. Therapy Based Market Size of IPF in the UK
13.7. Spain
13.7.1. Market Size of IPF in Spain
13.7.2. Therapy Based Market Size of IPF in Spain
13.8. Japan: Market Analysis
13.8.1. Market Size of IPF in Japan
13.8.2. Therapy Based Market Size of IPF in Japan
14. Market Drivers of IPF
15. Market Barriers of IPF
16. Appendix
16.1. Report Methodology
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

 

1. Key Insights
2. IPF Market Overview at a Glance
2.1. Market Share (%) Distribution of IPF in 2017
2.2. Market Share (%) Distribution of IPF in 2027
3. Disease Background and Overview: Idiopathic Pulmonary Fibrosis (IPF)
3.1. Introduction
3.2. Staging of IPF
3.3. Risk Factors & Disease Causes
3.4. Symptoms
3.5. Pathogenesis
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7 MM Prevalent Population of IPF
4.3. Country Wise-Epidemiology of IPF
4.3.1. United States
4.3.2. Prevalent cases of IPF in the United States
4.3.3. Prevalent Population of IPF by severity
4.3.4. Gender-Specific IPF Prevalence
4.3.5. Age-Specific IPF Prevalence
4.3.6. EU5
4.3.7. Prevalent Population of IPF in EU5
4.3.8. France
4.3.9. Prevalent Population of IPF
4.3.10. Prevalent Population of IPF by severity
4.3.11. Gender-Specific IPF Prevalence
4.3.12. Age-Specific IPF Prevalence
4.3.13. Germany
4.3.14. Prevalent Population of IPF
4.3.15. Prevalent Population of IPF by severity
4.3.16. Gender-Specific IPF Prevalence
4.3.17. Age-Specific IPF Prevalence
4.3.18. Italy
4.3.19. Prevalent Population of IPF
4.3.20. Prevalent Population of IPF by severity
4.3.21. Gender-Specific IPF Prevalence
4.3.22. Age-Specific IPF Prevalence
4.3.23. Spain
4.3.24. Prevalent Population of IPF
4.3.25. Prevalent Population of IPF by severity
4.3.26. Gender-Specific IPF Prevalence
4.3.27. Age-Specific IPF Prevalence
4.3.28. United Kingdom
4.3.29. Prevalent Population of IPF
4.3.30. Prevalent Population of IPF by severity
4.3.31. Gender-Specific IPF Prevalence
4.3.32. Age-Specific IPF Prevalence
4.3.33. Japan
4.3.34. Prevalent Population of IPF
4.3.35. Prevalent Population of IPF by severity
4.3.36. Gender-SPECIFIC IPF Prevalence
4.3.37. Age-Specific IPF Prevalence
5. Current Treatment Practices
5.1. ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of IPF (An Update of 2011 Clinical Practice Guideline)
6. Unmet needs
7. Marketed Products
7.1. Esbriet (Pirfenidone): InterMune Inc.
7.1.1. Product Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Safety and Efficacy of Esbriet
7.1.5. Side effects of Esbriet
7.1.6. Product Profile
7.2. Ofev (Nintedanib): Boehringer Ingelheim Pharma GmbH & Co. KG
7.2.1. Product Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Safety and Efficacy of Ofev
7.2.5. Side effects of Ofev
7.2.6. Product Profile
8. Emerging Therapies
9. Key Cross Competition
10. Phase III Drugs
10.1. Thrombomodulin Alfa: Asahi Kasei Pharma Corporation
10.1.1. Drug Description
10.1.2. Product Profile
10.1.3. Clinical Development
10.1.4. Clinical Trials Information
10.1.5. Safety and Efficacy
11. Phase II Drugs
11.1. CC-90001: Celgene Corporation
11.1.1. Drug Description
11.1.2. Product Profile
11.1.3. Clinical Development
11.1.4. Clinical Trials Information
11.1.5. Safety and Efficacy
11.1.6. Drug Description
11.1.7. Product Profile
11.1.8. Other Development Activities
11.1.9. Clinical Development
11.1.10. Clinical Trials Information
11.1.11. Safety and Efficacy
11.2. Gefapixant: Merck & Co., Inc.
11.2.1. Drug Description
11.2.2. Product Profile
11.2.3. Other Development Activities
11.2.4. Clinical Development
11.2.5. Clinical Trials Information
11.2.6. Safety and Efficacy
11.3. GLPG1690: Galapagos NV
11.3.1. Drug Description
11.3.2. Product Profile
11.3.3. Regulatory Milestones
11.3.4. Other Development Activities
11.3.5. Clinical Development
11.3.6. Clinical Trials Information
11.3.7. Safety and Efficacy
11.4. LT-1001: LTT Bio-Pharma
11.4.1. Drug Description
11.4.2. Product Profile
11.4.3. Other Development Activities
11.4.4. Clinical Development
11.4.5. Clinical Trials Information
11.4.6. Safety and Efficacy
11.5. BG00011: Biogen Inc.
11.5.1. Drug Description
11.5.2. Product Profile
11.5.3. Regulatory Milestones
11.5.4. Other Development Activities
11.5.5. Clinical Development
11.5.6. Clinical Trials Information
11.5.7. Safety and Efficacy
11.6. BMS-986020: Bristol-Myers Squibb
11.6.1. Drug Description
11.6.2. Product Profile
11.6.3. Regulatory Milestones
11.6.4. Other Development Activities
11.6.5. Clinical Development
11.6.6. Clinical Trials Information
11.6.7. Safety and Efficacy
11.7. LT-1002: Chong Kun Dang Pharmaceutical
11.7.1. Drug Description
11.7.2. Product Profile
11.7.3. Other Development Activities
11.8. Pamrevlumab: FibroGen
11.8.1. Drug Description
11.8.2. Product Profile
11.8.3. Regulatory Milestones
11.8.4. Other Development Activities
11.8.5. Clinical Development
11.8.6. Clinical Trials Information
11.8.7. Safety and Efficacy
11.9. PBI4050: ProMetic Life Sciences
11.9.1. Drug Description
11.9.2. Product Profile
11.9.3. Regulatory Milestones
11.9.4. Other Development Activities
11.9.5. Clinical Development
11.9.6. Clinical Trials Information
11.9.7. Safety and Efficacy
11.10. PRM 151: Promedior, Inc.
11.10.1. Drug Description
11.10.2. Product Profile
11.10.3. Regulatory Milestones
11.10.4. Other Development Activities
11.10.5. Clinical Development
11.10.6. Clinical Trials Information
11.10.7. Safety and Efficacy
11.11. Tipelukast: MediciNova
11.11.1. Drug Description
11.11.2. Product Profile
11.11.3. Regulatory Milestones
11.11.4. Other Development Activities
11.11.5. Clinical Development
11.11.6. Clinical Trials Information
11.11.7. Safety and Efficacy
11.12. TD139: Bristol-Myers Squibb
11.12.1. Drug Description
11.12.2. Product Profile
11.12.3. Other Development Activities
11.12.4. Clinical Development
11.12.5. Clinical Trials Information
11.12.6. Safety and Efficacy
11.13. VAY736: Novartis
11.13.1. Drug Description
11.13.2. Product Profile
11.13.3. Other Development Activities
11.13.4. Clinical Development
11.13.5. Clinical Trials Information
11.14. TAS-115: Taiho Pharmaceutical
11.14.1. Drug Description
11.14.2. Product Profile
11.14.3. Clinical Development
11.14.4. Clinical Trials Information
12. IPF: Market Analysis
12.1. Key Findings
12.2. Total Market Size of IPF in 7 MM
12.3. Therapy Based Market Size of IPF in 7 MM
13. Market Size of IPF by Country
13.1. United States Market Analysis
13.1.1. Market Size of IPF in the US
13.1.2. Therapy Based Market Size of IPF in the US
13.2. EU5 Market Outlook
13.3. Germany
13.3.1. Market Size of IPF in Germany
13.3.2. Therapy Based Market Size of IPF in Germany
13.4. France
13.4.1. Market Size of IPF in France
13.4.2. Therapy Based Market Size of IPF in France
13.5. Italy
13.5.1. Market Size of IPF in Italy
13.5.2. Therapy Based Market Size of IPF in Italy
13.6. United Kingdom
13.6.1. Market Size of IPF in the UK
13.6.2. Therapy Based Market Size of IPF in the UK
13.7. Spain
13.7.1. Market Size of IPF in Spain
13.7.2. Therapy Based Market Size of IPF in Spain
13.8. Japan: Market Analysis
13.8.1. Market Size of IPF in Japan
13.8.2. Therapy Based Market Size of IPF in Japan
14. Market Drivers of IPF
15. Market Barriers of IPF
16. Appendix
16.1. Report Methodology
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

 

1. Key Insights
2. IPF Market Overview at a Glance
2.1. Market Share (%) Distribution of IPF in 2017
2.2. Market Share (%) Distribution of IPF in 2027
3. Disease Background and Overview: Idiopathic Pulmonary Fibrosis (IPF)
3.1. Introduction
3.2. Staging of IPF
3.3. Risk Factors & Disease Causes
3.4. Symptoms
3.5. Pathogenesis
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7 MM Prevalent Population of IPF
4.3. Country Wise-Epidemiology of IPF
4.3.1. United States
4.3.2. Prevalent cases of IPF in the United States
4.3.3. Prevalent Population of IPF by severity
4.3.4. Gender-Specific IPF Prevalence
4.3.5. Age-Specific IPF Prevalence
4.3.6. EU5
4.3.7. Prevalent Population of IPF in EU5
4.3.8. France
4.3.9. Prevalent Population of IPF
4.3.10. Prevalent Population of IPF by severity
4.3.11. Gender-Specific IPF Prevalence
4.3.12. Age-Specific IPF Prevalence
4.3.13. Germany
4.3.14. Prevalent Population of IPF
4.3.15. Prevalent Population of IPF by severity
4.3.16. Gender-Specific IPF Prevalence
4.3.17. Age-Specific IPF Prevalence
4.3.18. Italy
4.3.19. Prevalent Population of IPF
4.3.20. Prevalent Population of IPF by severity
4.3.21. Gender-Specific IPF Prevalence
4.3.22. Age-Specific IPF Prevalence
4.3.23. Spain
4.3.24. Prevalent Population of IPF
4.3.25. Prevalent Population of IPF by severity
4.3.26. Gender-Specific IPF Prevalence
4.3.27. Age-Specific IPF Prevalence
4.3.28. United Kingdom
4.3.29. Prevalent Population of IPF
4.3.30. Prevalent Population of IPF by severity
4.3.31. Gender-Specific IPF Prevalence
4.3.32. Age-Specific IPF Prevalence
4.3.33. Japan
4.3.34. Prevalent Population of IPF
4.3.35. Prevalent Population of IPF by severity
4.3.36. Gender-SPECIFIC IPF Prevalence
4.3.37. Age-Specific IPF Prevalence
5. Current Treatment Practices
5.1. ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of IPF (An Update of 2011 Clinical Practice Guideline)
6. Unmet needs
7. Marketed Products
7.1. Esbriet (Pirfenidone): InterMune Inc.
7.1.1. Product Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Safety and Efficacy of Esbriet
7.1.5. Side effects of Esbriet
7.1.6. Product Profile
7.2. Ofev (Nintedanib): Boehringer Ingelheim Pharma GmbH & Co. KG
7.2.1. Product Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Safety and Efficacy of Ofev
7.2.5. Side effects of Ofev
7.2.6. Product Profile
8. Emerging Therapies
9. Key Cross Competition
10. Phase III Drugs
10.1. Thrombomodulin Alfa: Asahi Kasei Pharma Corporation
10.1.1. Drug Description
10.1.2. Product Profile
10.1.3. Clinical Development
10.1.4. Clinical Trials Information
10.1.5. Safety and Efficacy
11. Phase II Drugs
11.1. CC-90001: Celgene Corporation
11.1.1. Drug Description
11.1.2. Product Profile
11.1.3. Clinical Development
11.1.4. Clinical Trials Information
11.1.5. Safety and Efficacy
11.1.6. Drug Description
11.1.7. Product Profile
11.1.8. Other Development Activities
11.1.9. Clinical Development
11.1.10. Clinical Trials Information
11.1.11. Safety and Efficacy
11.2. Gefapixant: Merck & Co., Inc.
11.2.1. Drug Description
11.2.2. Product Profile
11.2.3. Other Development Activities
11.2.4. Clinical Development
11.2.5. Clinical Trials Information
11.2.6. Safety and Efficacy
11.3. GLPG1690: Galapagos NV
11.3.1. Drug Description
11.3.2. Product Profile
11.3.3. Regulatory Milestones
11.3.4. Other Development Activities
11.3.5. Clinical Development
11.3.6. Clinical Trials Information
11.3.7. Safety and Efficacy
11.4. LT-1001: LTT Bio-Pharma
11.4.1. Drug Description
11.4.2. Product Profile
11.4.3. Other Development Activities
11.4.4. Clinical Development
11.4.5. Clinical Trials Information
11.4.6. Safety and Efficacy
11.5. BG00011: Biogen Inc.
11.5.1. Drug Description
11.5.2. Product Profile
11.5.3. Regulatory Milestones
11.5.4. Other Development Activities
11.5.5. Clinical Development
11.5.6. Clinical Trials Information
11.5.7. Safety and Efficacy
11.6. BMS-986020: Bristol-Myers Squibb
11.6.1. Drug Description
11.6.2. Product Profile
11.6.3. Regulatory Milestones
11.6.4. Other Development Activities
11.6.5. Clinical Development
11.6.6. Clinical Trials Information
11.6.7. Safety and Efficacy
11.7. LT-1002: Chong Kun Dang Pharmaceutical
11.7.1. Drug Description
11.7.2. Product Profile
11.7.3. Other Development Activities
11.8. Pamrevlumab: FibroGen
11.8.1. Drug Description
11.8.2. Product Profile
11.8.3. Regulatory Milestones
11.8.4. Other Development Activities
11.8.5. Clinical Development
11.8.6. Clinical Trials Information
11.8.7. Safety and Efficacy
11.9. PBI4050: ProMetic Life Sciences
11.9.1. Drug Description
11.9.2. Product Profile
11.9.3. Regulatory Milestones
11.9.4. Other Development Activities
11.9.5. Clinical Development
11.9.6. Clinical Trials Information
11.9.7. Safety and Efficacy
11.10. PRM 151: Promedior, Inc.
11.10.1. Drug Description
11.10.2. Product Profile
11.10.3. Regulatory Milestones
11.10.4. Other Development Activities
11.10.5. Clinical Development
11.10.6. Clinical Trials Information
11.10.7. Safety and Efficacy
11.11. Tipelukast: MediciNova
11.11.1. Drug Description
11.11.2. Product Profile
11.11.3. Regulatory Milestones
11.11.4. Other Development Activities
11.11.5. Clinical Development
11.11.6. Clinical Trials Information
11.11.7. Safety and Efficacy
11.12. TD139: Bristol-Myers Squibb
11.12.1. Drug Description
11.12.2. Product Profile
11.12.3. Other Development Activities
11.12.4. Clinical Development
11.12.5. Clinical Trials Information
11.12.6. Safety and Efficacy
11.13. VAY736: Novartis
11.13.1. Drug Description
11.13.2. Product Profile
11.13.3. Other Development Activities
11.13.4. Clinical Development
11.13.5. Clinical Trials Information
11.14. TAS-115: Taiho Pharmaceutical
11.14.1. Drug Description
11.14.2. Product Profile
11.14.3. Clinical Development
11.14.4. Clinical Trials Information
12. IPF: Market Analysis
12.1. Key Findings
12.2. Total Market Size of IPF in 7 MM
12.3. Therapy Based Market Size of IPF in 7 MM
13. Market Size of IPF by Country
13.1. United States Market Analysis
13.1.1. Market Size of IPF in the US
13.1.2. Therapy Based Market Size of IPF in the US
13.2. EU5 Market Outlook
13.3. Germany
13.3.1. Market Size of IPF in Germany
13.3.2. Therapy Based Market Size of IPF in Germany
13.4. France
13.4.1. Market Size of IPF in France
13.4.2. Therapy Based Market Size of IPF in France
13.5. Italy
13.5.1. Market Size of IPF in Italy
13.5.2. Therapy Based Market Size of IPF in Italy
13.6. United Kingdom
13.6.1. Market Size of IPF in the UK
13.6.2. Therapy Based Market Size of IPF in the UK
13.7. Spain
13.7.1. Market Size of IPF in Spain
13.7.2. Therapy Based Market Size of IPF in Spain
13.8. Japan: Market Analysis
13.8.1. Market Size of IPF in Japan
13.8.2. Therapy Based Market Size of IPF in Japan
14. Market Drivers of IPF
15. Market Barriers of IPF
16. Appendix
16.1. Report Methodology
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

 

1. Key Insights
2. IPF Market Overview at a Glance
2.1. Market Share (%) Distribution of IPF in 2017
2.2. Market Share (%) Distribution of IPF in 2027
3. Disease Background and Overview: Idiopathic Pulmonary Fibrosis (IPF)
3.1. Introduction
3.2. Staging of IPF
3.3. Risk Factors & Disease Causes
3.4. Symptoms
3.5. Pathogenesis
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7 MM Prevalent Population of IPF
4.3. Country Wise-Epidemiology of IPF
4.3.1. United States
4.3.2. Prevalent cases of IPF in the United States
4.3.3. Prevalent Population of IPF by severity
4.3.4. Gender-Specific IPF Prevalence
4.3.5. Age-Specific IPF Prevalence
4.3.6. EU5
4.3.7. Prevalent Population of IPF in EU5
4.3.8. France
4.3.9. Prevalent Population of IPF
4.3.10. Prevalent Population of IPF by severity
4.3.11. Gender-Specific IPF Prevalence
4.3.12. Age-Specific IPF Prevalence
4.3.13. Germany
4.3.14. Prevalent Population of IPF
4.3.15. Prevalent Population of IPF by severity
4.3.16. Gender-Specific IPF Prevalence
4.3.17. Age-Specific IPF Prevalence
4.3.18. Italy
4.3.19. Prevalent Population of IPF
4.3.20. Prevalent Population of IPF by severity
4.3.21. Gender-Specific IPF Prevalence
4.3.22. Age-Specific IPF Prevalence
4.3.23. Spain
4.3.24. Prevalent Population of IPF
4.3.25. Prevalent Population of IPF by severity
4.3.26. Gender-Specific IPF Prevalence
4.3.27. Age-Specific IPF Prevalence
4.3.28. United Kingdom
4.3.29. Prevalent Population of IPF
4.3.30. Prevalent Population of IPF by severity
4.3.31. Gender-Specific IPF Prevalence
4.3.32. Age-Specific IPF Prevalence
4.3.33. Japan
4.3.34. Prevalent Population of IPF
4.3.35. Prevalent Population of IPF by severity
4.3.36. Gender-SPECIFIC IPF Prevalence
4.3.37. Age-Specific IPF Prevalence
5. Current Treatment Practices
5.1. ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of IPF (An Update of 2011 Clinical Practice Guideline)
6. Unmet needs
7. Marketed Products
7.1. Esbriet (Pirfenidone): InterMune Inc.
7.1.1. Product Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Safety and Efficacy of Esbriet
7.1.5. Side effects of Esbriet
7.1.6. Product Profile
7.2. Ofev (Nintedanib): Boehringer Ingelheim Pharma GmbH & Co. KG
7.2.1. Product Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Safety and Efficacy of Ofev
7.2.5. Side effects of Ofev
7.2.6. Product Profile
8. Emerging Therapies
9. Key Cross Competition
10. Phase III Drugs
10.1. Thrombomodulin Alfa: Asahi Kasei Pharma Corporation
10.1.1. Drug Description
10.1.2. Product Profile
10.1.3. Clinical Development
10.1.4. Clinical Trials Information
10.1.5. Safety and Efficacy
11. Phase II Drugs
11.1. CC-90001: Celgene Corporation
11.1.1. Drug Description
11.1.2. Product Profile
11.1.3. Clinical Development
11.1.4. Clinical Trials Information
11.1.5. Safety and Efficacy
11.1.6. Drug Description
11.1.7. Product Profile
11.1.8. Other Development Activities
11.1.9. Clinical Development
11.1.10. Clinical Trials Information
11.1.11. Safety and Efficacy
11.2. Gefapixant: Merck & Co., Inc.
11.2.1. Drug Description
11.2.2. Product Profile
11.2.3. Other Development Activities
11.2.4. Clinical Development
11.2.5. Clinical Trials Information
11.2.6. Safety and Efficacy
11.3. GLPG1690: Galapagos NV
11.3.1. Drug Description
11.3.2. Product Profile
11.3.3. Regulatory Milestones
11.3.4. Other Development Activities
11.3.5. Clinical Development
11.3.6. Clinical Trials Information
11.3.7. Safety and Efficacy
11.4. LT-1001: LTT Bio-Pharma
11.4.1. Drug Description
11.4.2. Product Profile
11.4.3. Other Development Activities
11.4.4. Clinical Development
11.4.5. Clinical Trials Information
11.4.6. Safety and Efficacy
11.5. BG00011: Biogen Inc.
11.5.1. Drug Description
11.5.2. Product Profile
11.5.3. Regulatory Milestones
11.5.4. Other Development Activities
11.5.5. Clinical Development
11.5.6. Clinical Trials Information
11.5.7. Safety and Efficacy
11.6. BMS-986020: Bristol-Myers Squibb
11.6.1. Drug Description
11.6.2. Product Profile
11.6.3. Regulatory Milestones
11.6.4. Other Development Activities
11.6.5. Clinical Development
11.6.6. Clinical Trials Information
11.6.7. Safety and Efficacy
11.7. LT-1002: Chong Kun Dang Pharmaceutical
11.7.1. Drug Description
11.7.2. Product Profile
11.7.3. Other Development Activities
11.8. Pamrevlumab: FibroGen
11.8.1. Drug Description
11.8.2. Product Profile
11.8.3. Regulatory Milestones
11.8.4. Other Development Activities
11.8.5. Clinical Development
11.8.6. Clinical Trials Information
11.8.7. Safety and Efficacy
11.9. PBI4050: ProMetic Life Sciences
11.9.1. Drug Description
11.9.2. Product Profile
11.9.3. Regulatory Milestones
11.9.4. Other Development Activities
11.9.5. Clinical Development
11.9.6. Clinical Trials Information
11.9.7. Safety and Efficacy
11.10. PRM 151: Promedior, Inc.
11.10.1. Drug Description
11.10.2. Product Profile
11.10.3. Regulatory Milestones
11.10.4. Other Development Activities
11.10.5. Clinical Development
11.10.6. Clinical Trials Information
11.10.7. Safety and Efficacy
11.11. Tipelukast: MediciNova
11.11.1. Drug Description
11.11.2. Product Profile
11.11.3. Regulatory Milestones
11.11.4. Other Development Activities
11.11.5. Clinical Development
11.11.6. Clinical Trials Information
11.11.7. Safety and Efficacy
11.12. TD139: Bristol-Myers Squibb
11.12.1. Drug Description
11.12.2. Product Profile
11.12.3. Other Development Activities
11.12.4. Clinical Development
11.12.5. Clinical Trials Information
11.12.6. Safety and Efficacy
11.13. VAY736: Novartis
11.13.1. Drug Description
11.13.2. Product Profile
11.13.3. Other Development Activities
11.13.4. Clinical Development
11.13.5. Clinical Trials Information
11.14. TAS-115: Taiho Pharmaceutical
11.14.1. Drug Description
11.14.2. Product Profile
11.14.3. Clinical Development
11.14.4. Clinical Trials Information
12. IPF: Market Analysis
12.1. Key Findings
12.2. Total Market Size of IPF in 7 MM
12.3. Therapy Based Market Size of IPF in 7 MM
13. Market Size of IPF by Country
13.1. United States Market Analysis
13.1.1. Market Size of IPF in the US
13.1.2. Therapy Based Market Size of IPF in the US
13.2. EU5 Market Outlook
13.3. Germany
13.3.1. Market Size of IPF in Germany
13.3.2. Therapy Based Market Size of IPF in Germany
13.4. France
13.4.1. Market Size of IPF in France
13.4.2. Therapy Based Market Size of IPF in France
13.5. Italy
13.5.1. Market Size of IPF in Italy
13.5.2. Therapy Based Market Size of IPF in Italy
13.6. United Kingdom
13.6.1. Market Size of IPF in the UK
13.6.2. Therapy Based Market Size of IPF in the UK
13.7. Spain
13.7.1. Market Size of IPF in Spain
13.7.2. Therapy Based Market Size of IPF in Spain
13.8. Japan: Market Analysis
13.8.1. Market Size of IPF in Japan
13.8.2. Therapy Based Market Size of IPF in Japan
14. Market Drivers of IPF
15. Market Barriers of IPF
16. Appendix
16.1. Report Methodology
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

 

1. Key Insights
2. IPF Market Overview at a Glance
2.1. Market Share (%) Distribution of IPF in 2017
2.2. Market Share (%) Distribution of IPF in 2027
3. Disease Background and Overview: Idiopathic Pulmonary Fibrosis (IPF)
3.1. Introduction
3.2. Staging of IPF
3.3. Risk Factors & Disease Causes
3.4. Symptoms
3.5. Pathogenesis
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7 MM Prevalent Population of IPF
4.3. Country Wise-Epidemiology of IPF
4.3.1. United States
4.3.2. Prevalent cases of IPF in the United States
4.3.3. Prevalent Population of IPF by severity
4.3.4. Gender-Specific IPF Prevalence
4.3.5. Age-Specific IPF Prevalence
4.3.6. EU5
4.3.7. Prevalent Population of IPF in EU5
4.3.8. France
4.3.9. Prevalent Population of IPF
4.3.10. Prevalent Population of IPF by severity
4.3.11. Gender-Specific IPF Prevalence
4.3.12. Age-Specific IPF Prevalence
4.3.13. Germany
4.3.14. Prevalent Population of IPF
4.3.15. Prevalent Population of IPF by severity
4.3.16. Gender-Specific IPF Prevalence
4.3.17. Age-Specific IPF Prevalence
4.3.18. Italy
4.3.19. Prevalent Population of IPF
4.3.20. Prevalent Population of IPF by severity
4.3.21. Gender-Specific IPF Prevalence
4.3.22. Age-Specific IPF Prevalence
4.3.23. Spain
4.3.24. Prevalent Population of IPF
4.3.25. Prevalent Population of IPF by severity
4.3.26. Gender-Specific IPF Prevalence
4.3.27. Age-Specific IPF Prevalence
4.3.28. United Kingdom
4.3.29. Prevalent Population of IPF
4.3.30. Prevalent Population of IPF by severity
4.3.31. Gender-Specific IPF Prevalence
4.3.32. Age-Specific IPF Prevalence
4.3.33. Japan
4.3.34. Prevalent Population of IPF
4.3.35. Prevalent Population of IPF by severity
4.3.36. Gender-SPECIFIC IPF Prevalence
4.3.37. Age-Specific IPF Prevalence
5. Current Treatment Practices
5.1. ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of IPF (An Update of 2011 Clinical Practice Guideline)
6. Unmet needs
7. Marketed Products
7.1. Esbriet (Pirfenidone): InterMune Inc.
7.1.1. Product Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Safety and Efficacy of Esbriet
7.1.5. Side effects of Esbriet
7.1.6. Product Profile
7.2. Ofev (Nintedanib): Boehringer Ingelheim Pharma GmbH & Co. KG
7.2.1. Product Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Safety and Efficacy of Ofev
7.2.5. Side effects of Ofev
7.2.6. Product Profile
8. Emerging Therapies
9. Key Cross Competition
10. Phase III Drugs
10.1. Thrombomodulin Alfa: Asahi Kasei Pharma Corporation
10.1.1. Drug Description
10.1.2. Product Profile
10.1.3. Clinical Development
10.1.4. Clinical Trials Information
10.1.5. Safety and Efficacy
11. Phase II Drugs
11.1. CC-90001: Celgene Corporation
11.1.1. Drug Description
11.1.2. Product Profile
11.1.3. Clinical Development
11.1.4. Clinical Trials Information
11.1.5. Safety and Efficacy
11.1.6. Drug Description
11.1.7. Product Profile
11.1.8. Other Development Activities
11.1.9. Clinical Development
11.1.10. Clinical Trials Information
11.1.11. Safety and Efficacy
11.2. Gefapixant: Merck & Co., Inc.
11.2.1. Drug Description
11.2.2. Product Profile
11.2.3. Other Development Activities
11.2.4. Clinical Development
11.2.5. Clinical Trials Information
11.2.6. Safety and Efficacy
11.3. GLPG1690: Galapagos NV
11.3.1. Drug Description
11.3.2. Product Profile
11.3.3. Regulatory Milestones
11.3.4. Other Development Activities
11.3.5. Clinical Development
11.3.6. Clinical Trials Information
11.3.7. Safety and Efficacy
11.4. LT-1001: LTT Bio-Pharma
11.4.1. Drug Description
11.4.2. Product Profile
11.4.3. Other Development Activities
11.4.4. Clinical Development
11.4.5. Clinical Trials Information
11.4.6. Safety and Efficacy
11.5. BG00011: Biogen Inc.
11.5.1. Drug Description
11.5.2. Product Profile
11.5.3. Regulatory Milestones
11.5.4. Other Development Activities
11.5.5. Clinical Development
11.5.6. Clinical Trials Information
11.5.7. Safety and Efficacy
11.6. BMS-986020: Bristol-Myers Squibb
11.6.1. Drug Description
11.6.2. Product Profile
11.6.3. Regulatory Milestones
11.6.4. Other Development Activities
11.6.5. Clinical Development
11.6.6. Clinical Trials Information
11.6.7. Safety and Efficacy
11.7. LT-1002: Chong Kun Dang Pharmaceutical
11.7.1. Drug Description
11.7.2. Product Profile
11.7.3. Other Development Activities
11.8. Pamrevlumab: FibroGen
11.8.1. Drug Description
11.8.2. Product Profile
11.8.3. Regulatory Milestones
11.8.4. Other Development Activities
11.8.5. Clinical Development
11.8.6. Clinical Trials Information
11.8.7. Safety and Efficacy
11.9. PBI4050: ProMetic Life Sciences
11.9.1. Drug Description
11.9.2. Product Profile
11.9.3. Regulatory Milestones
11.9.4. Other Development Activities
11.9.5. Clinical Development
11.9.6. Clinical Trials Information
11.9.7. Safety and Efficacy
11.10. PRM 151: Promedior, Inc.
11.10.1. Drug Description
11.10.2. Product Profile
11.10.3. Regulatory Milestones
11.10.4. Other Development Activities
11.10.5. Clinical Development
11.10.6. Clinical Trials Information
11.10.7. Safety and Efficacy
11.11. Tipelukast: MediciNova
11.11.1. Drug Description
11.11.2. Product Profile
11.11.3. Regulatory Milestones
11.11.4. Other Development Activities
11.11.5. Clinical Development
11.11.6. Clinical Trials Information
11.11.7. Safety and Efficacy
11.12. TD139: Bristol-Myers Squibb
11.12.1. Drug Description
11.12.2. Product Profile
11.12.3. Other Development Activities
11.12.4. Clinical Development
11.12.5. Clinical Trials Information
11.12.6. Safety and Efficacy
11.13. VAY736: Novartis
11.13.1. Drug Description
11.13.2. Product Profile
11.13.3. Other Development Activities
11.13.4. Clinical Development
11.13.5. Clinical Trials Information
11.14. TAS-115: Taiho Pharmaceutical
11.14.1. Drug Description
11.14.2. Product Profile
11.14.3. Clinical Development
11.14.4. Clinical Trials Information
12. IPF: Market Analysis
12.1. Key Findings
12.2. Total Market Size of IPF in 7 MM
12.3. Therapy Based Market Size of IPF in 7 MM
13. Market Size of IPF by Country
13.1. United States Market Analysis
13.1.1. Market Size of IPF in the US
13.1.2. Therapy Based Market Size of IPF in the US
13.2. EU5 Market Outlook
13.3. Germany
13.3.1. Market Size of IPF in Germany
13.3.2. Therapy Based Market Size of IPF in Germany
13.4. France
13.4.1. Market Size of IPF in France
13.4.2. Therapy Based Market Size of IPF in France
13.5. Italy
13.5.1. Market Size of IPF in Italy
13.5.2. Therapy Based Market Size of IPF in Italy
13.6. United Kingdom
13.6.1. Market Size of IPF in the UK
13.6.2. Therapy Based Market Size of IPF in the UK
13.7. Spain
13.7.1. Market Size of IPF in Spain
13.7.2. Therapy Based Market Size of IPF in Spain
13.8. Japan: Market Analysis
13.8.1. Market Size of IPF in Japan
13.8.2. Therapy Based Market Size of IPF in Japan
14. Market Drivers of IPF
15. Market Barriers of IPF
16. Appendix
16.1. Report Methodology
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

 

1. Key Insights
2. IPF Market Overview at a Glance
2.1. Market Share (%) Distribution of IPF in 2017
2.2. Market Share (%) Distribution of IPF in 2027
3. Disease Background and Overview: Idiopathic Pulmonary Fibrosis (IPF)
3.1. Introduction
3.2. Staging of IPF
3.3. Risk Factors & Disease Causes
3.4. Symptoms
3.5. Pathogenesis
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7 MM Prevalent Population of IPF
4.3. Country Wise-Epidemiology of IPF
4.3.1. United States
4.3.2. Prevalent cases of IPF in the United States
4.3.3. Prevalent Population of IPF by severity
4.3.4. Gender-Specific IPF Prevalence
4.3.5. Age-Specific IPF Prevalence
4.3.6. EU5
4.3.7. Prevalent Population of IPF in EU5
4.3.8. France
4.3.9. Prevalent Population of IPF
4.3.10. Prevalent Population of IPF by severity
4.3.11. Gender-Specific IPF Prevalence
4.3.12. Age-Specific IPF Prevalence
4.3.13. Germany
4.3.14. Prevalent Population of IPF
4.3.15. Prevalent Population of IPF by severity
4.3.16. Gender-Specific IPF Prevalence
4.3.17. Age-Specific IPF Prevalence
4.3.18. Italy
4.3.19. Prevalent Population of IPF
4.3.20. Prevalent Population of IPF by severity
4.3.21. Gender-Specific IPF Prevalence
4.3.22. Age-Specific IPF Prevalence
4.3.23. Spain
4.3.24. Prevalent Population of IPF
4.3.25. Prevalent Population of IPF by severity
4.3.26. Gender-Specific IPF Prevalence
4.3.27. Age-Specific IPF Prevalence
4.3.28. United Kingdom
4.3.29. Prevalent Population of IPF
4.3.30. Prevalent Population of IPF by severity
4.3.31. Gender-Specific IPF Prevalence
4.3.32. Age-Specific IPF Prevalence
4.3.33. Japan
4.3.34. Prevalent Population of IPF
4.3.35. Prevalent Population of IPF by severity
4.3.36. Gender-SPECIFIC IPF Prevalence
4.3.37. Age-Specific IPF Prevalence
5. Current Treatment Practices
5.1. ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of IPF (An Update of 2011 Clinical Practice Guideline)
6. Unmet needs
7. Marketed Products
7.1. Esbriet (Pirfenidone): InterMune Inc.
7.1.1. Product Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Safety and Efficacy of Esbriet
7.1.5. Side effects of Esbriet
7.1.6. Product Profile
7.2. Ofev (Nintedanib): Boehringer Ingelheim Pharma GmbH & Co. KG
7.2.1. Product Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Safety and Efficacy of Ofev
7.2.5. Side effects of Ofev
7.2.6. Product Profile
8. Emerging Therapies
9. Key Cross Competition
10. Phase III Drugs
10.1. Thrombomodulin Alfa: Asahi Kasei Pharma Corporation
10.1.1. Drug Description
10.1.2. Product Profile
10.1.3. Clinical Development
10.1.4. Clinical Trials Information
10.1.5. Safety and Efficacy
11. Phase II Drugs
11.1. CC-90001: Celgene Corporation
11.1.1. Drug Description
11.1.2. Product Profile
11.1.3. Clinical Development
11.1.4. Clinical Trials Information
11.1.5. Safety and Efficacy
11.1.6. Drug Description
11.1.7. Product Profile
11.1.8. Other Development Activities
11.1.9. Clinical Development
11.1.10. Clinical Trials Information
11.1.11. Safety and Efficacy
11.2. Gefapixant: Merck & Co., Inc.
11.2.1. Drug Description
11.2.2. Product Profile
11.2.3. Other Development Activities
11.2.4. Clinical Development
11.2.5. Clinical Trials Information
11.2.6. Safety and Efficacy
11.3. GLPG1690: Galapagos NV
11.3.1. Drug Description
11.3.2. Product Profile
11.3.3. Regulatory Milestones
11.3.4. Other Development Activities
11.3.5. Clinical Development
11.3.6. Clinical Trials Information
11.3.7. Safety and Efficacy
11.4. LT-1001: LTT Bio-Pharma
11.4.1. Drug Description
11.4.2. Product Profile
11.4.3. Other Development Activities
11.4.4. Clinical Development
11.4.5. Clinical Trials Information
11.4.6. Safety and Efficacy
11.5. BG00011: Biogen Inc.
11.5.1. Drug Description
11.5.2. Product Profile
11.5.3. Regulatory Milestones
11.5.4. Other Development Activities
11.5.5. Clinical Development
11.5.6. Clinical Trials Information
11.5.7. Safety and Efficacy
11.6. BMS-986020: Bristol-Myers Squibb
11.6.1. Drug Description
11.6.2. Product Profile
11.6.3. Regulatory Milestones
11.6.4. Other Development Activities
11.6.5. Clinical Development
11.6.6. Clinical Trials Information
11.6.7. Safety and Efficacy
11.7. LT-1002: Chong Kun Dang Pharmaceutical
11.7.1. Drug Description
11.7.2. Product Profile
11.7.3. Other Development Activities
11.8. Pamrevlumab: FibroGen
11.8.1. Drug Description
11.8.2. Product Profile
11.8.3. Regulatory Milestones
11.8.4. Other Development Activities
11.8.5. Clinical Development
11.8.6. Clinical Trials Information
11.8.7. Safety and Efficacy
11.9. PBI4050: ProMetic Life Sciences
11.9.1. Drug Description
11.9.2. Product Profile
11.9.3. Regulatory Milestones
11.9.4. Other Development Activities
11.9.5. Clinical Development
11.9.6. Clinical Trials Information
11.9.7. Safety and Efficacy
11.10. PRM 151: Promedior, Inc.
11.10.1. Drug Description
11.10.2. Product Profile
11.10.3. Regulatory Milestones
11.10.4. Other Development Activities
11.10.5. Clinical Development
11.10.6. Clinical Trials Information
11.10.7. Safety and Efficacy
11.11. Tipelukast: MediciNova
11.11.1. Drug Description
11.11.2. Product Profile
11.11.3. Regulatory Milestones
11.11.4. Other Development Activities
11.11.5. Clinical Development
11.11.6. Clinical Trials Information
11.11.7. Safety and Efficacy
11.12. TD139: Bristol-Myers Squibb
11.12.1. Drug Description
11.12.2. Product Profile
11.12.3. Other Development Activities
11.12.4. Clinical Development
11.12.5. Clinical Trials Information
11.12.6. Safety and Efficacy
11.13. VAY736: Novartis
11.13.1. Drug Description
11.13.2. Product Profile
11.13.3. Other Development Activities
11.13.4. Clinical Development
11.13.5. Clinical Trials Information
11.14. TAS-115: Taiho Pharmaceutical
11.14.1. Drug Description
11.14.2. Product Profile
11.14.3. Clinical Development
11.14.4. Clinical Trials Information
12. IPF: Market Analysis
12.1. Key Findings
12.2. Total Market Size of IPF in 7 MM
12.3. Therapy Based Market Size of IPF in 7 MM
13. Market Size of IPF by Country
13.1. United States Market Analysis
13.1.1. Market Size of IPF in the US
13.1.2. Therapy Based Market Size of IPF in the US
13.2. EU5 Market Outlook
13.3. Germany
13.3.1. Market Size of IPF in Germany
13.3.2. Therapy Based Market Size of IPF in Germany
13.4. France
13.4.1. Market Size of IPF in France
13.4.2. Therapy Based Market Size of IPF in France
13.5. Italy
13.5.1. Market Size of IPF in Italy
13.5.2. Therapy Based Market Size of IPF in Italy
13.6. United Kingdom
13.6.1. Market Size of IPF in the UK
13.6.2. Therapy Based Market Size of IPF in the UK
13.7. Spain
13.7.1. Market Size of IPF in Spain
13.7.2. Therapy Based Market Size of IPF in Spain
13.8. Japan: Market Analysis
13.8.1. Market Size of IPF in Japan
13.8.2. Therapy Based Market Size of IPF in Japan
14. Market Drivers of IPF
15. Market Barriers of IPF
16. Appendix
16.1. Report Methodology
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

 

1. Key Insights
2. IPF Market Overview at a Glance
2.1. Market Share (%) Distribution of IPF in 2017
2.2. Market Share (%) Distribution of IPF in 2027
3. Disease Background and Overview: Idiopathic Pulmonary Fibrosis (IPF)
3.1. Introduction
3.2. Staging of IPF
3.3. Risk Factors & Disease Causes
3.4. Symptoms
3.5. Pathogenesis
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7 MM Prevalent Population of IPF
4.3. Country Wise-Epidemiology of IPF
4.3.1. United States
4.3.2. Prevalent cases of IPF in the United States
4.3.3. Prevalent Population of IPF by severity
4.3.4. Gender-Specific IPF Prevalence
4.3.5. Age-Specific IPF Prevalence
4.3.6. EU5
4.3.7. Prevalent Population of IPF in EU5
4.3.8. France
4.3.9. Prevalent Population of IPF
4.3.10. Prevalent Population of IPF by severity
4.3.11. Gender-Specific IPF Prevalence
4.3.12. Age-Specific IPF Prevalence
4.3.13. Germany
4.3.14. Prevalent Population of IPF
4.3.15. Prevalent Population of IPF by severity
4.3.16. Gender-Specific IPF Prevalence
4.3.17. Age-Specific IPF Prevalence
4.3.18. Italy
4.3.19. Prevalent Population of IPF
4.3.20. Prevalent Population of IPF by severity
4.3.21. Gender-Specific IPF Prevalence
4.3.22. Age-Specific IPF Prevalence
4.3.23. Spain
4.3.24. Prevalent Population of IPF
4.3.25. Prevalent Population of IPF by severity
4.3.26. Gender-Specific IPF Prevalence
4.3.27. Age-Specific IPF Prevalence
4.3.28. United Kingdom
4.3.29. Prevalent Population of IPF
4.3.30. Prevalent Population of IPF by severity
4.3.31. Gender-Specific IPF Prevalence
4.3.32. Age-Specific IPF Prevalence
4.3.33. Japan
4.3.34. Prevalent Population of IPF
4.3.35. Prevalent Population of IPF by severity
4.3.36. Gender-SPECIFIC IPF Prevalence
4.3.37. Age-Specific IPF Prevalence
5. Current Treatment Practices
5.1. ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of IPF (An Update of 2011 Clinical Practice Guideline)
6. Unmet needs
7. Marketed Products
7.1. Esbriet (Pirfenidone): InterMune Inc.
7.1.1. Product Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Safety and Efficacy of Esbriet
7.1.5. Side effects of Esbriet
7.1.6. Product Profile
7.2. Ofev (Nintedanib): Boehringer Ingelheim Pharma GmbH & Co. KG
7.2.1. Product Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Safety and Efficacy of Ofev
7.2.5. Side effects of Ofev
7.2.6. Product Profile
8. Emerging Therapies
9. Key Cross Competition
10. Phase III Drugs
10.1. Thrombomodulin Alfa: Asahi Kasei Pharma Corporation
10.1.1. Drug Description
10.1.2. Product Profile
10.1.3. Clinical Development
10.1.4. Clinical Trials Information
10.1.5. Safety and Efficacy
11. Phase II Drugs
11.1. CC-90001: Celgene Corporation
11.1.1. Drug Description
11.1.2. Product Profile
11.1.3. Clinical Development
11.1.4. Clinical Trials Information
11.1.5. Safety and Efficacy
11.1.6. Drug Description
11.1.7. Product Profile
11.1.8. Other Development Activities
11.1.9. Clinical Development
11.1.10. Clinical Trials Information
11.1.11. Safety and Efficacy
11.2. Gefapixant: Merck & Co., Inc.
11.2.1. Drug Description
11.2.2. Product Profile
11.2.3. Other Development Activities
11.2.4. Clinical Development
11.2.5. Clinical Trials Information
11.2.6. Safety and Efficacy
11.3. GLPG1690: Galapagos NV
11.3.1. Drug Description
11.3.2. Product Profile
11.3.3. Regulatory Milestones
11.3.4. Other Development Activities
11.3.5. Clinical Development
11.3.6. Clinical Trials Information
11.3.7. Safety and Efficacy
11.4. LT-1001: LTT Bio-Pharma
11.4.1. Drug Description
11.4.2. Product Profile
11.4.3. Other Development Activities
11.4.4. Clinical Development
11.4.5. Clinical Trials Information
11.4.6. Safety and Efficacy
11.5. BG00011: Biogen Inc.
11.5.1. Drug Description
11.5.2. Product Profile
11.5.3. Regulatory Milestones
11.5.4. Other Development Activities
11.5.5. Clinical Development
11.5.6. Clinical Trials Information
11.5.7. Safety and Efficacy
11.6. BMS-986020: Bristol-Myers Squibb
11.6.1. Drug Description
11.6.2. Product Profile
11.6.3. Regulatory Milestones
11.6.4. Other Development Activities
11.6.5. Clinical Development
11.6.6. Clinical Trials Information
11.6.7. Safety and Efficacy
11.7. LT-1002: Chong Kun Dang Pharmaceutical
11.7.1. Drug Description
11.7.2. Product Profile
11.7.3. Other Development Activities
11.8. Pamrevlumab: FibroGen
11.8.1. Drug Description
11.8.2. Product Profile
11.8.3. Regulatory Milestones
11.8.4. Other Development Activities
11.8.5. Clinical Development
11.8.6. Clinical Trials Information
11.8.7. Safety and Efficacy
11.9. PBI4050: ProMetic Life Sciences
11.9.1. Drug Description
11.9.2. Product Profile
11.9.3. Regulatory Milestones
11.9.4. Other Development Activities
11.9.5. Clinical Development
11.9.6. Clinical Trials Information
11.9.7. Safety and Efficacy
11.10. PRM 151: Promedior, Inc.
11.10.1. Drug Description
11.10.2. Product Profile
11.10.3. Regulatory Milestones
11.10.4. Other Development Activities
11.10.5. Clinical Development
11.10.6. Clinical Trials Information
11.10.7. Safety and Efficacy
11.11. Tipelukast: MediciNova
11.11.1. Drug Description
11.11.2. Product Profile
11.11.3. Regulatory Milestones
11.11.4. Other Development Activities
11.11.5. Clinical Development
11.11.6. Clinical Trials Information
11.11.7. Safety and Efficacy
11.12. TD139: Bristol-Myers Squibb
11.12.1. Drug Description
11.12.2. Product Profile
11.12.3. Other Development Activities
11.12.4. Clinical Development
11.12.5. Clinical Trials Information
11.12.6. Safety and Efficacy
11.13. VAY736: Novartis
11.13.1. Drug Description
11.13.2. Product Profile
11.13.3. Other Development Activities
11.13.4. Clinical Development
11.13.5. Clinical Trials Information
11.14. TAS-115: Taiho Pharmaceutical
11.14.1. Drug Description
11.14.2. Product Profile
11.14.3. Clinical Development
11.14.4. Clinical Trials Information
12. IPF: Market Analysis
12.1. Key Findings
12.2. Total Market Size of IPF in 7 MM
12.3. Therapy Based Market Size of IPF in 7 MM
13. Market Size of IPF by Country
13.1. United States Market Analysis
13.1.1. Market Size of IPF in the US
13.1.2. Therapy Based Market Size of IPF in the US
13.2. EU5 Market Outlook
13.3. Germany
13.3.1. Market Size of IPF in Germany
13.3.2. Therapy Based Market Size of IPF in Germany
13.4. France
13.4.1. Market Size of IPF in France
13.4.2. Therapy Based Market Size of IPF in France
13.5. Italy
13.5.1. Market Size of IPF in Italy
13.5.2. Therapy Based Market Size of IPF in Italy
13.6. United Kingdom
13.6.1. Market Size of IPF in the UK
13.6.2. Therapy Based Market Size of IPF in the UK
13.7. Spain
13.7.1. Market Size of IPF in Spain
13.7.2. Therapy Based Market Size of IPF in Spain
13.8. Japan: Market Analysis
13.8.1. Market Size of IPF in Japan
13.8.2. Therapy Based Market Size of IPF in Japan
14. Market Drivers of IPF
15. Market Barriers of IPF
16. Appendix
16.1. Report Methodology
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

 

1. Key Insights
2. IPF Market Overview at a Glance
2.1. Market Share (%) Distribution of IPF in 2017
2.2. Market Share (%) Distribution of IPF in 2027
3. Disease Background and Overview: Idiopathic Pulmonary Fibrosis (IPF)
3.1. Introduction
3.2. Staging of IPF
3.3. Risk Factors & Disease Causes
3.4. Symptoms
3.5. Pathogenesis
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7 MM Prevalent Population of IPF
4.3. Country Wise-Epidemiology of IPF
4.3.1. United States
4.3.2. Prevalent cases of IPF in the United States
4.3.3. Prevalent Population of IPF by severity
4.3.4. Gender-Specific IPF Prevalence
4.3.5. Age-Specific IPF Prevalence
4.3.6. EU5
4.3.7. Prevalent Population of IPF in EU5
4.3.8. France
4.3.9. Prevalent Population of IPF
4.3.10. Prevalent Population of IPF by severity
4.3.11. Gender-Specific IPF Prevalence
4.3.12. Age-Specific IPF Prevalence
4.3.13. Germany
4.3.14. Prevalent Population of IPF
4.3.15. Prevalent Population of IPF by severity
4.3.16. Gender-Specific IPF Prevalence
4.3.17. Age-Specific IPF Prevalence
4.3.18. Italy
4.3.19. Prevalent Population of IPF
4.3.20. Prevalent Population of IPF by severity
4.3.21. Gender-Specific IPF Prevalence
4.3.22. Age-Specific IPF Prevalence
4.3.23. Spain
4.3.24. Prevalent Population of IPF
4.3.25. Prevalent Population of IPF by severity
4.3.26. Gender-Specific IPF Prevalence
4.3.27. Age-Specific IPF Prevalence
4.3.28. United Kingdom
4.3.29. Prevalent Population of IPF
4.3.30. Prevalent Population of IPF by severity
4.3.31. Gender-Specific IPF Prevalence
4.3.32. Age-Specific IPF Prevalence
4.3.33. Japan
4.3.34. Prevalent Population of IPF
4.3.35. Prevalent Population of IPF by severity
4.3.36. Gender-SPECIFIC IPF Prevalence
4.3.37. Age-Specific IPF Prevalence
5. Current Treatment Practices
5.1. ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of IPF (An Update of 2011 Clinical Practice Guideline)
6. Unmet needs
7. Marketed Products
7.1. Esbriet (Pirfenidone): InterMune Inc.
7.1.1. Product Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Safety and Efficacy of Esbriet
7.1.5. Side effects of Esbriet
7.1.6. Product Profile
7.2. Ofev (Nintedanib): Boehringer Ingelheim Pharma GmbH & Co. KG
7.2.1. Product Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Safety and Efficacy of Ofev
7.2.5. Side effects of Ofev
7.2.6. Product Profile
8. Emerging Therapies
9. Key Cross Competition
10. Phase III Drugs
10.1. Thrombomodulin Alfa: Asahi Kasei Pharma Corporation
10.1.1. Drug Description
10.1.2. Product Profile
10.1.3. Clinical Development
10.1.4. Clinical Trials Information
10.1.5. Safety and Efficacy
11. Phase II Drugs
11.1. CC-90001: Celgene Corporation
11.1.1. Drug Description
11.1.2. Product Profile
11.1.3. Clinical Development
11.1.4. Clinical Trials Information
11.1.5. Safety and Efficacy
11.1.6. Drug Description
11.1.7. Product Profile
11.1.8. Other Development Activities
11.1.9. Clinical Development
11.1.10. Clinical Trials Information
11.1.11. Safety and Efficacy
11.2. Gefapixant: Merck & Co., Inc.
11.2.1. Drug Description
11.2.2. Product Profile
11.2.3. Other Development Activities
11.2.4. Clinical Development
11.2.5. Clinical Trials Information
11.2.6. Safety and Efficacy
11.3. GLPG1690: Galapagos NV
11.3.1. Drug Description
11.3.2. Product Profile
11.3.3. Regulatory Milestones
11.3.4. Other Development Activities
11.3.5. Clinical Development
11.3.6. Clinical Trials Information
11.3.7. Safety and Efficacy
11.4. LT-1001: LTT Bio-Pharma
11.4.1. Drug Description
11.4.2. Product Profile
11.4.3. Other Development Activities
11.4.4. Clinical Development
11.4.5. Clinical Trials Information
11.4.6. Safety and Efficacy
11.5. BG00011: Biogen Inc.
11.5.1. Drug Description
11.5.2. Product Profile
11.5.3. Regulatory Milestones
11.5.4. Other Development Activities
11.5.5. Clinical Development
11.5.6. Clinical Trials Information
11.5.7. Safety and Efficacy
11.6. BMS-986020: Bristol-Myers Squibb
11.6.1. Drug Description
11.6.2. Product Profile
11.6.3. Regulatory Milestones
11.6.4. Other Development Activities
11.6.5. Clinical Development
11.6.6. Clinical Trials Information
11.6.7. Safety and Efficacy
11.7. LT-1002: Chong Kun Dang Pharmaceutical
11.7.1. Drug Description
11.7.2. Product Profile
11.7.3. Other Development Activities
11.8. Pamrevlumab: FibroGen
11.8.1. Drug Description
11.8.2. Product Profile
11.8.3. Regulatory Milestones
11.8.4. Other Development Activities
11.8.5. Clinical Development
11.8.6. Clinical Trials Information
11.8.7. Safety and Efficacy
11.9. PBI4050: ProMetic Life Sciences
11.9.1. Drug Description
11.9.2. Product Profile
11.9.3. Regulatory Milestones
11.9.4. Other Development Activities
11.9.5. Clinical Development
11.9.6. Clinical Trials Information
11.9.7. Safety and Efficacy
11.10. PRM 151: Promedior, Inc.
11.10.1. Drug Description
11.10.2. Product Profile
11.10.3. Regulatory Milestones
11.10.4. Other Development Activities
11.10.5. Clinical Development
11.10.6. Clinical Trials Information
11.10.7. Safety and Efficacy
11.11. Tipelukast: MediciNova
11.11.1. Drug Description
11.11.2. Product Profile
11.11.3. Regulatory Milestones
11.11.4. Other Development Activities
11.11.5. Clinical Development
11.11.6. Clinical Trials Information
11.11.7. Safety and Efficacy
11.12. TD139: Bristol-Myers Squibb
11.12.1. Drug Description
11.12.2. Product Profile
11.12.3. Other Development Activities
11.12.4. Clinical Development
11.12.5. Clinical Trials Information
11.12.6. Safety and Efficacy
11.13. VAY736: Novartis
11.13.1. Drug Description
11.13.2. Product Profile
11.13.3. Other Development Activities
11.13.4. Clinical Development
11.13.5. Clinical Trials Information
11.14. TAS-115: Taiho Pharmaceutical
11.14.1. Drug Description
11.14.2. Product Profile
11.14.3. Clinical Development
11.14.4. Clinical Trials Information
12. IPF: Market Analysis
12.1. Key Findings
12.2. Total Market Size of IPF in 7 MM
12.3. Therapy Based Market Size of IPF in 7 MM
13. Market Size of IPF by Country
13.1. United States Market Analysis
13.1.1. Market Size of IPF in the US
13.1.2. Therapy Based Market Size of IPF in the US
13.2. EU5 Market Outlook
13.3. Germany
13.3.1. Market Size of IPF in Germany
13.3.2. Therapy Based Market Size of IPF in Germany
13.4. France
13.4.1. Market Size of IPF in France
13.4.2. Therapy Based Market Size of IPF in France
13.5. Italy
13.5.1. Market Size of IPF in Italy
13.5.2. Therapy Based Market Size of IPF in Italy
13.6. United Kingdom
13.6.1. Market Size of IPF in the UK
13.6.2. Therapy Based Market Size of IPF in the UK
13.7. Spain
13.7.1. Market Size of IPF in Spain
13.7.2. Therapy Based Market Size of IPF in Spain
13.8. Japan: Market Analysis
13.8.1. Market Size of IPF in Japan
13.8.2. Therapy Based Market Size of IPF in Japan
14. Market Drivers of IPF
15. Market Barriers of IPF
16. Appendix
16.1. Report Methodology
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

 

1. Key Insights
2. IPF Market Overview at a Glance
2.1. Market Share (%) Distribution of IPF in 2017
2.2. Market Share (%) Distribution of IPF in 2027
3. Disease Background and Overview: Idiopathic Pulmonary Fibrosis (IPF)
3.1. Introduction
3.2. Staging of IPF
3.3. Risk Factors & Disease Causes
3.4. Symptoms
3.5. Pathogenesis
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7 MM Prevalent Population of IPF
4.3. Country Wise-Epidemiology of IPF
4.3.1. United States
4.3.2. Prevalent cases of IPF in the United States
4.3.3. Prevalent Population of IPF by severity
4.3.4. Gender-Specific IPF Prevalence
4.3.5. Age-Specific IPF Prevalence
4.3.6. EU5
4.3.7. Prevalent Population of IPF in EU5
4.3.8. France
4.3.9. Prevalent Population of IPF
4.3.10. Prevalent Population of IPF by severity
4.3.11. Gender-Specific IPF Prevalence
4.3.12. Age-Specific IPF Prevalence
4.3.13. Germany
4.3.14. Prevalent Population of IPF
4.3.15. Prevalent Population of IPF by severity
4.3.16. Gender-Specific IPF Prevalence
4.3.17. Age-Specific IPF Prevalence
4.3.18. Italy
4.3.19. Prevalent Population of IPF
4.3.20. Prevalent Population of IPF by severity
4.3.21. Gender-Specific IPF Prevalence
4.3.22. Age-Specific IPF Prevalence
4.3.23. Spain
4.3.24. Prevalent Population of IPF
4.3.25. Prevalent Population of IPF by severity
4.3.26. Gender-Specific IPF Prevalence
4.3.27. Age-Specific IPF Prevalence
4.3.28. United Kingdom
4.3.29. Prevalent Population of IPF
4.3.30. Prevalent Population of IPF by severity
4.3.31. Gender-Specific IPF Prevalence
4.3.32. Age-Specific IPF Prevalence
4.3.33. Japan
4.3.34. Prevalent Population of IPF
4.3.35. Prevalent Population of IPF by severity
4.3.36. Gender-SPECIFIC IPF Prevalence
4.3.37. Age-Specific IPF Prevalence
5. Current Treatment Practices
5.1. ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of IPF (An Update of 2011 Clinical Practice Guideline)
6. Unmet needs
7. Marketed Products
7.1. Esbriet (Pirfenidone): InterMune Inc.
7.1.1. Product Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Safety and Efficacy of Esbriet
7.1.5. Side effects of Esbriet
7.1.6. Product Profile
7.2. Ofev (Nintedanib): Boehringer Ingelheim Pharma GmbH & Co. KG
7.2.1. Product Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Safety and Efficacy of Ofev
7.2.5. Side effects of Ofev
7.2.6. Product Profile
8. Emerging Therapies
9. Key Cross Competition
10. Phase III Drugs
10.1. Thrombomodulin Alfa: Asahi Kasei Pharma Corporation
10.1.1. Drug Description
10.1.2. Product Profile
10.1.3. Clinical Development
10.1.4. Clinical Trials Information
10.1.5. Safety and Efficacy
11. Phase II Drugs
11.1. CC-90001: Celgene Corporation
11.1.1. Drug Description
11.1.2. Product Profile
11.1.3. Clinical Development
11.1.4. Clinical Trials Information
11.1.5. Safety and Efficacy
11.1.6. Drug Description
11.1.7. Product Profile
11.1.8. Other Development Activities
11.1.9. Clinical Development
11.1.10. Clinical Trials Information
11.1.11. Safety and Efficacy
11.2. Gefapixant: Merck & Co., Inc.
11.2.1. Drug Description
11.2.2. Product Profile
11.2.3. Other Development Activities
11.2.4. Clinical Development
11.2.5. Clinical Trials Information
11.2.6. Safety and Efficacy
11.3. GLPG1690: Galapagos NV
11.3.1. Drug Description
11.3.2. Product Profile
11.3.3. Regulatory Milestones
11.3.4. Other Development Activities
11.3.5. Clinical Development
11.3.6. Clinical Trials Information
11.3.7. Safety and Efficacy
11.4. LT-1001: LTT Bio-Pharma
11.4.1. Drug Description
11.4.2. Product Profile
11.4.3. Other Development Activities
11.4.4. Clinical Development
11.4.5. Clinical Trials Information
11.4.6. Safety and Efficacy
11.5. BG00011: Biogen Inc.
11.5.1. Drug Description
11.5.2. Product Profile
11.5.3. Regulatory Milestones
11.5.4. Other Development Activities
11.5.5. Clinical Development
11.5.6. Clinical Trials Information
11.5.7. Safety and Efficacy
11.6. BMS-986020: Bristol-Myers Squibb
11.6.1. Drug Description
11.6.2. Product Profile
11.6.3. Regulatory Milestones
11.6.4. Other Development Activities
11.6.5. Clinical Development
11.6.6. Clinical Trials Information
11.6.7. Safety and Efficacy
11.7. LT-1002: Chong Kun Dang Pharmaceutical
11.7.1. Drug Description
11.7.2. Product Profile
11.7.3. Other Development Activities
11.8. Pamrevlumab: FibroGen
11.8.1. Drug Description
11.8.2. Product Profile
11.8.3. Regulatory Milestones
11.8.4. Other Development Activities
11.8.5. Clinical Development
11.8.6. Clinical Trials Information
11.8.7. Safety and Efficacy
11.9. PBI4050: ProMetic Life Sciences
11.9.1. Drug Description
11.9.2. Product Profile
11.9.3. Regulatory Milestones
11.9.4. Other Development Activities
11.9.5. Clinical Development
11.9.6. Clinical Trials Information
11.9.7. Safety and Efficacy
11.10. PRM 151: Promedior, Inc.
11.10.1. Drug Description
11.10.2. Product Profile
11.10.3. Regulatory Milestones
11.10.4. Other Development Activities
11.10.5. Clinical Development
11.10.6. Clinical Trials Information
11.10.7. Safety and Efficacy
11.11. Tipelukast: MediciNova
11.11.1. Drug Description
11.11.2. Product Profile
11.11.3. Regulatory Milestones
11.11.4. Other Development Activities
11.11.5. Clinical Development
11.11.6. Clinical Trials Information
11.11.7. Safety and Efficacy
11.12. TD139: Bristol-Myers Squibb
11.12.1. Drug Description
11.12.2. Product Profile
11.12.3. Other Development Activities
11.12.4. Clinical Development
11.12.5. Clinical Trials Information
11.12.6. Safety and Efficacy
11.13. VAY736: Novartis
11.13.1. Drug Description
11.13.2. Product Profile
11.13.3. Other Development Activities
11.13.4. Clinical Development
11.13.5. Clinical Trials Information
11.14. TAS-115: Taiho Pharmaceutical
11.14.1. Drug Description
11.14.2. Product Profile
11.14.3. Clinical Development
11.14.4. Clinical Trials Information
12. IPF: Market Analysis
12.1. Key Findings
12.2. Total Market Size of IPF in 7 MM
12.3. Therapy Based Market Size of IPF in 7 MM
13. Market Size of IPF by Country
13.1. United States Market Analysis
13.1.1. Market Size of IPF in the US
13.1.2. Therapy Based Market Size of IPF in the US
13.2. EU5 Market Outlook
13.3. Germany
13.3.1. Market Size of IPF in Germany
13.3.2. Therapy Based Market Size of IPF in Germany
13.4. France
13.4.1. Market Size of IPF in France
13.4.2. Therapy Based Market Size of IPF in France
13.5. Italy
13.5.1. Market Size of IPF in Italy
13.5.2. Therapy Based Market Size of IPF in Italy
13.6. United Kingdom
13.6.1. Market Size of IPF in the UK
13.6.2. Therapy Based Market Size of IPF in the UK
13.7. Spain
13.7.1. Market Size of IPF in Spain
13.7.2. Therapy Based Market Size of IPF in Spain
13.8. Japan: Market Analysis
13.8.1. Market Size of IPF in Japan
13.8.2. Therapy Based Market Size of IPF in Japan
14. Market Drivers of IPF
15. Market Barriers of IPF
16. Appendix
16.1. Report Methodology
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

 

1. Key Insights
2. IPF Market Overview at a Glance
2.1. Market Share (%) Distribution of IPF in 2017
2.2. Market Share (%) Distribution of IPF in 2027
3. Disease Background and Overview: Idiopathic Pulmonary Fibrosis (IPF)
3.1. Introduction
3.2. Staging of IPF
3.3. Risk Factors & Disease Causes
3.4. Symptoms
3.5. Pathogenesis
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7 MM Prevalent Population of IPF
4.3. Country Wise-Epidemiology of IPF
4.3.1. United States
4.3.2. Prevalent cases of IPF in the United States
4.3.3. Prevalent Population of IPF by severity
4.3.4. Gender-Specific IPF Prevalence
4.3.5. Age-Specific IPF Prevalence
4.3.6. EU5
4.3.7. Prevalent Population of IPF in EU5
4.3.8. France
4.3.9. Prevalent Population of IPF
4.3.10. Prevalent Population of IPF by severity
4.3.11. Gender-Specific IPF Prevalence
4.3.12. Age-Specific IPF Prevalence
4.3.13. Germany
4.3.14. Prevalent Population of IPF
4.3.15. Prevalent Population of IPF by severity
4.3.16. Gender-Specific IPF Prevalence
4.3.17. Age-Specific IPF Prevalence
4.3.18. Italy
4.3.19. Prevalent Population of IPF
4.3.20. Prevalent Population of IPF by severity
4.3.21. Gender-Specific IPF Prevalence
4.3.22. Age-Specific IPF Prevalence
4.3.23. Spain
4.3.24. Prevalent Population of IPF
4.3.25. Prevalent Population of IPF by severity
4.3.26. Gender-Specific IPF Prevalence
4.3.27. Age-Specific IPF Prevalence
4.3.28. United Kingdom
4.3.29. Prevalent Population of IPF
4.3.30. Prevalent Population of IPF by severity
4.3.31. Gender-Specific IPF Prevalence
4.3.32. Age-Specific IPF Prevalence
4.3.33. Japan
4.3.34. Prevalent Population of IPF
4.3.35. Prevalent Population of IPF by severity
4.3.36. Gender-SPECIFIC IPF Prevalence
4.3.37. Age-Specific IPF Prevalence
5. Current Treatment Practices
5.1. ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of IPF (An Update of 2011 Clinical Practice Guideline)
6. Unmet needs
7. Marketed Products
7.1. Esbriet (Pirfenidone): InterMune Inc.
7.1.1. Product Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Safety and Efficacy of Esbriet
7.1.5. Side effects of Esbriet
7.1.6. Product Profile
7.2. Ofev (Nintedanib): Boehringer Ingelheim Pharma GmbH & Co. KG
7.2.1. Product Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Safety and Efficacy of Ofev
7.2.5. Side effects of Ofev
7.2.6. Product Profile
8. Emerging Therapies
9. Key Cross Competition
10. Phase III Drugs
10.1. Thrombomodulin Alfa: Asahi Kasei Pharma Corporation
10.1.1. Drug Description
10.1.2. Product Profile
10.1.3. Clinical Development
10.1.4. Clinical Trials Information
10.1.5. Safety and Efficacy
11. Phase II Drugs
11.1. CC-90001: Celgene Corporation
11.1.1. Drug Description
11.1.2. Product Profile
11.1.3. Clinical Development
11.1.4. Clinical Trials Information
11.1.5. Safety and Efficacy
11.1.6. Drug Description
11.1.7. Product Profile
11.1.8. Other Development Activities
11.1.9. Clinical Development
11.1.10. Clinical Trials Information
11.1.11. Safety and Efficacy
11.2. Gefapixant: Merck & Co., Inc.
11.2.1. Drug Description
11.2.2. Product Profile
11.2.3. Other Development Activities
11.2.4. Clinical Development
11.2.5. Clinical Trials Information
11.2.6. Safety and Efficacy
11.3. GLPG1690: Galapagos NV
11.3.1. Drug Description
11.3.2. Product Profile
11.3.3. Regulatory Milestones
11.3.4. Other Development Activities
11.3.5. Clinical Development
11.3.6. Clinical Trials Information
11.3.7. Safety and Efficacy
11.4. LT-1001: LTT Bio-Pharma
11.4.1. Drug Description
11.4.2. Product Profile
11.4.3. Other Development Activities
11.4.4. Clinical Development
11.4.5. Clinical Trials Information
11.4.6. Safety and Efficacy
11.5. BG00011: Biogen Inc.
11.5.1. Drug Description
11.5.2. Product Profile
11.5.3. Regulatory Milestones
11.5.4. Other Development Activities
11.5.5. Clinical Development
11.5.6. Clinical Trials Information
11.5.7. Safety and Efficacy
11.6. BMS-986020: Bristol-Myers Squibb
11.6.1. Drug Description
11.6.2. Product Profile
11.6.3. Regulatory Milestones
11.6.4. Other Development Activities
11.6.5. Clinical Development
11.6.6. Clinical Trials Information
11.6.7. Safety and Efficacy
11.7. LT-1002: Chong Kun Dang Pharmaceutical
11.7.1. Drug Description
11.7.2. Product Profile
11.7.3. Other Development Activities
11.8. Pamrevlumab: FibroGen
11.8.1. Drug Description
11.8.2. Product Profile
11.8.3. Regulatory Milestones
11.8.4. Other Development Activities
11.8.5. Clinical Development
11.8.6. Clinical Trials Information
11.8.7. Safety and Efficacy
11.9. PBI4050: ProMetic Life Sciences
11.9.1. Drug Description
11.9.2. Product Profile
11.9.3. Regulatory Milestones
11.9.4. Other Development Activities
11.9.5. Clinical Development
11.9.6. Clinical Trials Information
11.9.7. Safety and Efficacy
11.10. PRM 151: Promedior, Inc.
11.10.1. Drug Description
11.10.2. Product Profile
11.10.3. Regulatory Milestones
11.10.4. Other Development Activities
11.10.5. Clinical Development
11.10.6. Clinical Trials Information
11.10.7. Safety and Efficacy
11.11. Tipelukast: MediciNova
11.11.1. Drug Description
11.11.2. Product Profile
11.11.3. Regulatory Milestones
11.11.4. Other Development Activities
11.11.5. Clinical Development
11.11.6. Clinical Trials Information
11.11.7. Safety and Efficacy
11.12. TD139: Bristol-Myers Squibb
11.12.1. Drug Description
11.12.2. Product Profile
11.12.3. Other Development Activities
11.12.4. Clinical Development
11.12.5. Clinical Trials Information
11.12.6. Safety and Efficacy
11.13. VAY736: Novartis
11.13.1. Drug Description
11.13.2. Product Profile
11.13.3. Other Development Activities
11.13.4. Clinical Development
11.13.5. Clinical Trials Information
11.14. TAS-115: Taiho Pharmaceutical
11.14.1. Drug Description
11.14.2. Product Profile
11.14.3. Clinical Development
11.14.4. Clinical Trials Information
12. IPF: Market Analysis
12.1. Key Findings
12.2. Total Market Size of IPF in 7 MM
12.3. Therapy Based Market Size of IPF in 7 MM
13. Market Size of IPF by Country
13.1. United States Market Analysis
13.1.1. Market Size of IPF in the US
13.1.2. Therapy Based Market Size of IPF in the US
13.2. EU5 Market Outlook
13.3. Germany
13.3.1. Market Size of IPF in Germany
13.3.2. Therapy Based Market Size of IPF in Germany
13.4. France
13.4.1. Market Size of IPF in France
13.4.2. Therapy Based Market Size of IPF in France
13.5. Italy
13.5.1. Market Size of IPF in Italy
13.5.2. Therapy Based Market Size of IPF in Italy
13.6. United Kingdom
13.6.1. Market Size of IPF in the UK
13.6.2. Therapy Based Market Size of IPF in the UK
13.7. Spain
13.7.1. Market Size of IPF in Spain
13.7.2. Therapy Based Market Size of IPF in Spain
13.8. Japan: Market Analysis
13.8.1. Market Size of IPF in Japan
13.8.2. Therapy Based Market Size of IPF in Japan
14. Market Drivers of IPF
15. Market Barriers of IPF
16. Appendix
16.1. Report Methodology
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

 

1. Key Insights
2. IPF Market Overview at a Glance
2.1. Market Share (%) Distribution of IPF in 2017
2.2. Market Share (%) Distribution of IPF in 2027
3. Disease Background and Overview: Idiopathic Pulmonary Fibrosis (IPF)
3.1. Introduction
3.2. Staging of IPF
3.3. Risk Factors & Disease Causes
3.4. Symptoms
3.5. Pathogenesis
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7 MM Prevalent Population of IPF
4.3. Country Wise-Epidemiology of IPF
4.3.1. United States
4.3.2. Prevalent cases of IPF in the United States
4.3.3. Prevalent Population of IPF by severity
4.3.4. Gender-Specific IPF Prevalence
4.3.5. Age-Specific IPF Prevalence
4.3.6. EU5
4.3.7. Prevalent Population of IPF in EU5
4.3.8. France
4.3.9. Prevalent Population of IPF
4.3.10. Prevalent Population of IPF by severity
4.3.11. Gender-Specific IPF Prevalence
4.3.12. Age-Specific IPF Prevalence
4.3.13. Germany
4.3.14. Prevalent Population of IPF
4.3.15. Prevalent Population of IPF by severity
4.3.16. Gender-Specific IPF Prevalence
4.3.17. Age-Specific IPF Prevalence
4.3.18. Italy
4.3.19. Prevalent Population of IPF
4.3.20. Prevalent Population of IPF by severity
4.3.21. Gender-Specific IPF Prevalence
4.3.22. Age-Specific IPF Prevalence
4.3.23. Spain
4.3.24. Prevalent Population of IPF
4.3.25. Prevalent Population of IPF by severity
4.3.26. Gender-Specific IPF Prevalence
4.3.27. Age-Specific IPF Prevalence
4.3.28. United Kingdom
4.3.29. Prevalent Population of IPF
4.3.30. Prevalent Population of IPF by severity
4.3.31. Gender-Specific IPF Prevalence
4.3.32. Age-Specific IPF Prevalence
4.3.33. Japan
4.3.34. Prevalent Population of IPF
4.3.35. Prevalent Population of IPF by severity
4.3.36. Gender-SPECIFIC IPF Prevalence
4.3.37. Age-Specific IPF Prevalence
5. Current Treatment Practices
5.1. ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of IPF (An Update of 2011 Clinical Practice Guideline)
6. Unmet needs
7. Marketed Products
7.1. Esbriet (Pirfenidone): InterMune Inc.
7.1.1. Product Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Safety and Efficacy of Esbriet
7.1.5. Side effects of Esbriet
7.1.6. Product Profile
7.2. Ofev (Nintedanib): Boehringer Ingelheim Pharma GmbH & Co. KG
7.2.1. Product Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Safety and Efficacy of Ofev
7.2.5. Side effects of Ofev
7.2.6. Product Profile
8. Emerging Therapies
9. Key Cross Competition
10. Phase III Drugs
10.1. Thrombomodulin Alfa: Asahi Kasei Pharma Corporation
10.1.1. Drug Description
10.1.2. Product Profile
10.1.3. Clinical Development
10.1.4. Clinical Trials Information
10.1.5. Safety and Efficacy
11. Phase II Drugs
11.1. CC-90001: Celgene Corporation
11.1.1. Drug Description
11.1.2. Product Profile
11.1.3. Clinical Development
11.1.4. Clinical Trials Information
11.1.5. Safety and Efficacy
11.1.6. Drug Description
11.1.7. Product Profile
11.1.8. Other Development Activities
11.1.9. Clinical Development
11.1.10. Clinical Trials Information
11.1.11. Safety and Efficacy
11.2. Gefapixant: Merck & Co., Inc.
11.2.1. Drug Description
11.2.2. Product Profile
11.2.3. Other Development Activities
11.2.4. Clinical Development
11.2.5. Clinical Trials Information
11.2.6. Safety and Efficacy
11.3. GLPG1690: Galapagos NV
11.3.1. Drug Description
11.3.2. Product Profile
11.3.3. Regulatory Milestones
11.3.4. Other Development Activities
11.3.5. Clinical Development
11.3.6. Clinical Trials Information
11.3.7. Safety and Efficacy
11.4. LT-1001: LTT Bio-Pharma
11.4.1. Drug Description
11.4.2. Product Profile
11.4.3. Other Development Activities
11.4.4. Clinical Development
11.4.5. Clinical Trials Information
11.4.6. Safety and Efficacy
11.5. BG00011: Biogen Inc.
11.5.1. Drug Description
11.5.2. Product Profile
11.5.3. Regulatory Milestones
11.5.4. Other Development Activities
11.5.5. Clinical Development
11.5.6. Clinical Trials Information
11.5.7. Safety and Efficacy
11.6. BMS-986020: Bristol-Myers Squibb
11.6.1. Drug Description
11.6.2. Product Profile
11.6.3. Regulatory Milestones
11.6.4. Other Development Activities
11.6.5. Clinical Development
11.6.6. Clinical Trials Information
11.6.7. Safety and Efficacy
11.7. LT-1002: Chong Kun Dang Pharmaceutical
11.7.1. Drug Description
11.7.2. Product Profile
11.7.3. Other Development Activities
11.8. Pamrevlumab: FibroGen
11.8.1. Drug Description
11.8.2. Product Profile
11.8.3. Regulatory Milestones
11.8.4. Other Development Activities
11.8.5. Clinical Development
11.8.6. Clinical Trials Information
11.8.7. Safety and Efficacy
11.9. PBI4050: ProMetic Life Sciences
11.9.1. Drug Description
11.9.2. Product Profile
11.9.3. Regulatory Milestones
11.9.4. Other Development Activities
11.9.5. Clinical Development
11.9.6. Clinical Trials Information
11.9.7. Safety and Efficacy
11.10. PRM 151: Promedior, Inc.
11.10.1. Drug Description
11.10.2. Product Profile
11.10.3. Regulatory Milestones
11.10.4. Other Development Activities
11.10.5. Clinical Development
11.10.6. Clinical Trials Information
11.10.7. Safety and Efficacy
11.11. Tipelukast: MediciNova
11.11.1. Drug Description
11.11.2. Product Profile
11.11.3. Regulatory Milestones
11.11.4. Other Development Activities
11.11.5. Clinical Development
11.11.6. Clinical Trials Information
11.11.7. Safety and Efficacy
11.12. TD139: Bristol-Myers Squibb
11.12.1. Drug Description
11.12.2. Product Profile
11.12.3. Other Development Activities
11.12.4. Clinical Development
11.12.5. Clinical Trials Information
11.12.6. Safety and Efficacy
11.13. VAY736: Novartis
11.13.1. Drug Description
11.13.2. Product Profile
11.13.3. Other Development Activities
11.13.4. Clinical Development
11.13.5. Clinical Trials Information
11.14. TAS-115: Taiho Pharmaceutical
11.14.1. Drug Description
11.14.2. Product Profile
11.14.3. Clinical Development
11.14.4. Clinical Trials Information
12. IPF: Market Analysis
12.1. Key Findings
12.2. Total Market Size of IPF in 7 MM
12.3. Therapy Based Market Size of IPF in 7 MM
13. Market Size of IPF by Country
13.1. United States Market Analysis
13.1.1. Market Size of IPF in the US
13.1.2. Therapy Based Market Size of IPF in the US
13.2. EU5 Market Outlook
13.3. Germany
13.3.1. Market Size of IPF in Germany
13.3.2. Therapy Based Market Size of IPF in Germany
13.4. France
13.4.1. Market Size of IPF in France
13.4.2. Therapy Based Market Size of IPF in France
13.5. Italy
13.5.1. Market Size of IPF in Italy
13.5.2. Therapy Based Market Size of IPF in Italy
13.6. United Kingdom
13.6.1. Market Size of IPF in the UK
13.6.2. Therapy Based Market Size of IPF in the UK
13.7. Spain
13.7.1. Market Size of IPF in Spain
13.7.2. Therapy Based Market Size of IPF in Spain
13.8. Japan: Market Analysis
13.8.1. Market Size of IPF in Japan
13.8.2. Therapy Based Market Size of IPF in Japan
14. Market Drivers of IPF
15. Market Barriers of IPF
16. Appendix
16.1. Report Methodology
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

 

1. Key Insights
2. IPF Market Overview at a Glance
2.1. Market Share (%) Distribution of IPF in 2017
2.2. Market Share (%) Distribution of IPF in 2027
3. Disease Background and Overview: Idiopathic Pulmonary Fibrosis (IPF)
3.1. Introduction
3.2. Staging of IPF
3.3. Risk Factors & Disease Causes
3.4. Symptoms
3.5. Pathogenesis
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7 MM Prevalent Population of IPF
4.3. Country Wise-Epidemiology of IPF
4.3.1. United States
4.3.2. Prevalent cases of IPF in the United States
4.3.3. Prevalent Population of IPF by severity
4.3.4. Gender-Specific IPF Prevalence
4.3.5. Age-Specific IPF Prevalence
4.3.6. EU5
4.3.7. Prevalent Population of IPF in EU5
4.3.8. France
4.3.9. Prevalent Population of IPF
4.3.10. Prevalent Population of IPF by severity
4.3.11. Gender-Specific IPF Prevalence
4.3.12. Age-Specific IPF Prevalence
4.3.13. Germany
4.3.14. Prevalent Population of IPF
4.3.15. Prevalent Population of IPF by severity
4.3.16. Gender-Specific IPF Prevalence
4.3.17. Age-Specific IPF Prevalence
4.3.18. Italy
4.3.19. Prevalent Population of IPF
4.3.20. Prevalent Population of IPF by severity
4.3.21. Gender-Specific IPF Prevalence
4.3.22. Age-Specific IPF Prevalence
4.3.23. Spain
4.3.24. Prevalent Population of IPF
4.3.25. Prevalent Population of IPF by severity
4.3.26. Gender-Specific IPF Prevalence
4.3.27. Age-Specific IPF Prevalence
4.3.28. United Kingdom
4.3.29. Prevalent Population of IPF
4.3.30. Prevalent Population of IPF by severity
4.3.31. Gender-Specific IPF Prevalence
4.3.32. Age-Specific IPF Prevalence
4.3.33. Japan
4.3.34. Prevalent Population of IPF
4.3.35. Prevalent Population of IPF by severity
4.3.36. Gender-SPECIFIC IPF Prevalence
4.3.37. Age-Specific IPF Prevalence
5. Current Treatment Practices
5.1. ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of IPF (An Update of 2011 Clinical Practice Guideline)
6. Unmet needs
7. Marketed Products
7.1. Esbriet (Pirfenidone): InterMune Inc.
7.1.1. Product Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Safety and Efficacy of Esbriet
7.1.5. Side effects of Esbriet
7.1.6. Product Profile
7.2. Ofev (Nintedanib): Boehringer Ingelheim Pharma GmbH & Co. KG
7.2.1. Product Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Safety and Efficacy of Ofev
7.2.5. Side effects of Ofev
7.2.6. Product Profile
8. Emerging Therapies
9. Key Cross Competition
10. Phase III Drugs
10.1. Thrombomodulin Alfa: Asahi Kasei Pharma Corporation
10.1.1. Drug Description
10.1.2. Product Profile
10.1.3. Clinical Development
10.1.4. Clinical Trials Information
10.1.5. Safety and Efficacy
11. Phase II Drugs
11.1. CC-90001: Celgene Corporation
11.1.1. Drug Description
11.1.2. Product Profile
11.1.3. Clinical Development
11.1.4. Clinical Trials Information
11.1.5. Safety and Efficacy
11.1.6. Drug Description
11.1.7. Product Profile
11.1.8. Other Development Activities
11.1.9. Clinical Development
11.1.10. Clinical Trials Information
11.1.11. Safety and Efficacy
11.2. Gefapixant: Merck & Co., Inc.
11.2.1. Drug Description
11.2.2. Product Profile
11.2.3. Other Development Activities
11.2.4. Clinical Development
11.2.5. Clinical Trials Information
11.2.6. Safety and Efficacy
11.3. GLPG1690: Galapagos NV
11.3.1. Drug Description
11.3.2. Product Profile
11.3.3. Regulatory Milestones
11.3.4. Other Development Activities
11.3.5. Clinical Development
11.3.6. Clinical Trials Information
11.3.7. Safety and Efficacy
11.4. LT-1001: LTT Bio-Pharma
11.4.1. Drug Description
11.4.2. Product Profile
11.4.3. Other Development Activities
11.4.4. Clinical Development
11.4.5. Clinical Trials Information
11.4.6. Safety and Efficacy
11.5. BG00011: Biogen Inc.
11.5.1. Drug Description
11.5.2. Product Profile
11.5.3. Regulatory Milestones
11.5.4. Other Development Activities
11.5.5. Clinical Development
11.5.6. Clinical Trials Information
11.5.7. Safety and Efficacy
11.6. BMS-986020: Bristol-Myers Squibb
11.6.1. Drug Description
11.6.2. Product Profile
11.6.3. Regulatory Milestones
11.6.4. Other Development Activities
11.6.5. Clinical Development
11.6.6. Clinical Trials Information
11.6.7. Safety and Efficacy
11.7. LT-1002: Chong Kun Dang Pharmaceutical
11.7.1. Drug Description
11.7.2. Product Profile
11.7.3. Other Development Activities
11.8. Pamrevlumab: FibroGen
11.8.1. Drug Description
11.8.2. Product Profile
11.8.3. Regulatory Milestones
11.8.4. Other Development Activities
11.8.5. Clinical Development
11.8.6. Clinical Trials Information
11.8.7. Safety and Efficacy
11.9. PBI4050: ProMetic Life Sciences
11.9.1. Drug Description
11.9.2. Product Profile
11.9.3. Regulatory Milestones
11.9.4. Other Development Activities
11.9.5. Clinical Development
11.9.6. Clinical Trials Information
11.9.7. Safety and Efficacy
11.10. PRM 151: Promedior, Inc.
11.10.1. Drug Description
11.10.2. Product Profile
11.10.3. Regulatory Milestones
11.10.4. Other Development Activities
11.10.5. Clinical Development
11.10.6. Clinical Trials Information
11.10.7. Safety and Efficacy
11.11. Tipelukast: MediciNova
11.11.1. Drug Description
11.11.2. Product Profile
11.11.3. Regulatory Milestones
11.11.4. Other Development Activities
11.11.5. Clinical Development
11.11.6. Clinical Trials Information
11.11.7. Safety and Efficacy
11.12. TD139: Bristol-Myers Squibb
11.12.1. Drug Description
11.12.2. Product Profile
11.12.3. Other Development Activities
11.12.4. Clinical Development
11.12.5. Clinical Trials Information
11.12.6. Safety and Efficacy
11.13. VAY736: Novartis
11.13.1. Drug Description
11.13.2. Product Profile
11.13.3. Other Development Activities
11.13.4. Clinical Development
11.13.5. Clinical Trials Information
11.14. TAS-115: Taiho Pharmaceutical
11.14.1. Drug Description
11.14.2. Product Profile
11.14.3. Clinical Development
11.14.4. Clinical Trials Information
12. IPF: Market Analysis
12.1. Key Findings
12.2. Total Market Size of IPF in 7 MM
12.3. Therapy Based Market Size of IPF in 7 MM
13. Market Size of IPF by Country
13.1. United States Market Analysis
13.1.1. Market Size of IPF in the US
13.1.2. Therapy Based Market Size of IPF in the US
13.2. EU5 Market Outlook
13.3. Germany
13.3.1. Market Size of IPF in Germany
13.3.2. Therapy Based Market Size of IPF in Germany
13.4. France
13.4.1. Market Size of IPF in France
13.4.2. Therapy Based Market Size of IPF in France
13.5. Italy
13.5.1. Market Size of IPF in Italy
13.5.2. Therapy Based Market Size of IPF in Italy
13.6. United Kingdom
13.6.1. Market Size of IPF in the UK
13.6.2. Therapy Based Market Size of IPF in the UK
13.7. Spain
13.7.1. Market Size of IPF in Spain
13.7.2. Therapy Based Market Size of IPF in Spain
13.8. Japan: Market Analysis
13.8.1. Market Size of IPF in Japan
13.8.2. Therapy Based Market Size of IPF in Japan
14. Market Drivers of IPF
15. Market Barriers of IPF
16. Appendix
16.1. Report Methodology
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

 

1. Key Insights
2. IPF Market Overview at a Glance
2.1. Market Share (%) Distribution of IPF in 2017
2.2. Market Share (%) Distribution of IPF in 2027
3. Disease Background and Overview: Idiopathic Pulmonary Fibrosis (IPF)
3.1. Introduction
3.2. Staging of IPF
3.3. Risk Factors & Disease Causes
3.4. Symptoms
3.5. Pathogenesis
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7 MM Prevalent Population of IPF
4.3. Country Wise-Epidemiology of IPF
4.3.1. United States
4.3.2. Prevalent cases of IPF in the United States
4.3.3. Prevalent Population of IPF by severity
4.3.4. Gender-Specific IPF Prevalence
4.3.5. Age-Specific IPF Prevalence
4.3.6. EU5
4.3.7. Prevalent Population of IPF in EU5
4.3.8. France
4.3.9. Prevalent Population of IPF
4.3.10. Prevalent Population of IPF by severity
4.3.11. Gender-Specific IPF Prevalence
4.3.12. Age-Specific IPF Prevalence
4.3.13. Germany
4.3.14. Prevalent Population of IPF
4.3.15. Prevalent Population of IPF by severity
4.3.16. Gender-Specific IPF Prevalence
4.3.17. Age-Specific IPF Prevalence
4.3.18. Italy
4.3.19. Prevalent Population of IPF
4.3.20. Prevalent Population of IPF by severity
4.3.21. Gender-Specific IPF Prevalence
4.3.22. Age-Specific IPF Prevalence
4.3.23. Spain
4.3.24. Prevalent Population of IPF
4.3.25. Prevalent Population of IPF by severity
4.3.26. Gender-Specific IPF Prevalence
4.3.27. Age-Specific IPF Prevalence
4.3.28. United Kingdom
4.3.29. Prevalent Population of IPF
4.3.30. Prevalent Population of IPF by severity
4.3.31. Gender-Specific IPF Prevalence
4.3.32. Age-Specific IPF Prevalence
4.3.33. Japan
4.3.34. Prevalent Population of IPF
4.3.35. Prevalent Population of IPF by severity
4.3.36. Gender-SPECIFIC IPF Prevalence
4.3.37. Age-Specific IPF Prevalence
5. Current Treatment Practices
5.1. ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of IPF (An Update of 2011 Clinical Practice Guideline)
6. Unmet needs
7. Marketed Products
7.1. Esbriet (Pirfenidone): InterMune Inc.
7.1.1. Product Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Safety and Efficacy of Esbriet
7.1.5. Side effects of Esbriet
7.1.6. Product Profile
7.2. Ofev (Nintedanib): Boehringer Ingelheim Pharma GmbH & Co. KG
7.2.1. Product Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Safety and Efficacy of Ofev
7.2.5. Side effects of Ofev
7.2.6. Product Profile
8. Emerging Therapies
9. Key Cross Competition
10. Phase III Drugs
10.1. Thrombomodulin Alfa: Asahi Kasei Pharma Corporation
10.1.1. Drug Description
10.1.2. Product Profile
10.1.3. Clinical Development
10.1.4. Clinical Trials Information
10.1.5. Safety and Efficacy
11. Phase II Drugs
11.1. CC-90001: Celgene Corporation
11.1.1. Drug Description
11.1.2. Product Profile
11.1.3. Clinical Development
11.1.4. Clinical Trials Information
11.1.5. Safety and Efficacy
11.1.6. Drug Description
11.1.7. Product Profile
11.1.8. Other Development Activities
11.1.9. Clinical Development
11.1.10. Clinical Trials Information
11.1.11. Safety and Efficacy
11.2. Gefapixant: Merck & Co., Inc.
11.2.1. Drug Description
11.2.2. Product Profile
11.2.3. Other Development Activities
11.2.4. Clinical Development
11.2.5. Clinical Trials Information
11.2.6. Safety and Efficacy
11.3. GLPG1690: Galapagos NV
11.3.1. Drug Description
11.3.2. Product Profile
11.3.3. Regulatory Milestones
11.3.4. Other Development Activities
11.3.5. Clinical Development
11.3.6. Clinical Trials Information
11.3.7. Safety and Efficacy
11.4. LT-1001: LTT Bio-Pharma
11.4.1. Drug Description
11.4.2. Product Profile
11.4.3. Other Development Activities
11.4.4. Clinical Development
11.4.5. Clinical Trials Information
11.4.6. Safety and Efficacy
11.5. BG00011: Biogen Inc.
11.5.1. Drug Description
11.5.2. Product Profile
11.5.3. Regulatory Milestones
11.5.4. Other Development Activities
11.5.5. Clinical Development
11.5.6. Clinical Trials Information
11.5.7. Safety and Efficacy
11.6. BMS-986020: Bristol-Myers Squibb
11.6.1. Drug Description
11.6.2. Product Profile
11.6.3. Regulatory Milestones
11.6.4. Other Development Activities
11.6.5. Clinical Development
11.6.6. Clinical Trials Information
11.6.7. Safety and Efficacy
11.7. LT-1002: Chong Kun Dang Pharmaceutical
11.7.1. Drug Description
11.7.2. Product Profile
11.7.3. Other Development Activities
11.8. Pamrevlumab: FibroGen
11.8.1. Drug Description
11.8.2. Product Profile
11.8.3. Regulatory Milestones
11.8.4. Other Development Activities
11.8.5. Clinical Development
11.8.6. Clinical Trials Information
11.8.7. Safety and Efficacy
11.9. PBI4050: ProMetic Life Sciences
11.9.1. Drug Description
11.9.2. Product Profile
11.9.3. Regulatory Milestones
11.9.4. Other Development Activities
11.9.5. Clinical Development
11.9.6. Clinical Trials Information
11.9.7. Safety and Efficacy
11.10. PRM 151: Promedior, Inc.
11.10.1. Drug Description
11.10.2. Product Profile
11.10.3. Regulatory Milestones
11.10.4. Other Development Activities
11.10.5. Clinical Development
11.10.6. Clinical Trials Information
11.10.7. Safety and Efficacy
11.11. Tipelukast: MediciNova
11.11.1. Drug Description
11.11.2. Product Profile
11.11.3. Regulatory Milestones
11.11.4. Other Development Activities
11.11.5. Clinical Development
11.11.6. Clinical Trials Information
11.11.7. Safety and Efficacy
11.12. TD139: Bristol-Myers Squibb
11.12.1. Drug Description
11.12.2. Product Profile
11.12.3. Other Development Activities
11.12.4. Clinical Development
11.12.5. Clinical Trials Information
11.12.6. Safety and Efficacy
11.13. VAY736: Novartis
11.13.1. Drug Description
11.13.2. Product Profile
11.13.3. Other Development Activities
11.13.4. Clinical Development
11.13.5. Clinical Trials Information
11.14. TAS-115: Taiho Pharmaceutical
11.14.1. Drug Description
11.14.2. Product Profile
11.14.3. Clinical Development
11.14.4. Clinical Trials Information
12. IPF: Market Analysis
12.1. Key Findings
12.2. Total Market Size of IPF in 7 MM
12.3. Therapy Based Market Size of IPF in 7 MM
13. Market Size of IPF by Country
13.1. United States Market Analysis
13.1.1. Market Size of IPF in the US
13.1.2. Therapy Based Market Size of IPF in the US
13.2. EU5 Market Outlook
13.3. Germany
13.3.1. Market Size of IPF in Germany
13.3.2. Therapy Based Market Size of IPF in Germany
13.4. France
13.4.1. Market Size of IPF in France
13.4.2. Therapy Based Market Size of IPF in France
13.5. Italy
13.5.1. Market Size of IPF in Italy
13.5.2. Therapy Based Market Size of IPF in Italy
13.6. United Kingdom
13.6.1. Market Size of IPF in the UK
13.6.2. Therapy Based Market Size of IPF in the UK
13.7. Spain
13.7.1. Market Size of IPF in Spain
13.7.2. Therapy Based Market Size of IPF in Spain
13.8. Japan: Market Analysis
13.8.1. Market Size of IPF in Japan
13.8.2. Therapy Based Market Size of IPF in Japan
14. Market Drivers of IPF
15. Market Barriers of IPF
16. Appendix
16.1. Report Methodology
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

 

1. Key Insights
2. IPF Market Overview at a Glance
2.1. Market Share (%) Distribution of IPF in 2017
2.2. Market Share (%) Distribution of IPF in 2027
3. Disease Background and Overview: Idiopathic Pulmonary Fibrosis (IPF)
3.1. Introduction
3.2. Staging of IPF
3.3. Risk Factors & Disease Causes
3.4. Symptoms
3.5. Pathogenesis
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7 MM Prevalent Population of IPF
4.3. Country Wise-Epidemiology of IPF
4.3.1. United States
4.3.2. Prevalent cases of IPF in the United States
4.3.3. Prevalent Population of IPF by severity
4.3.4. Gender-Specific IPF Prevalence
4.3.5. Age-Specific IPF Prevalence
4.3.6. EU5
4.3.7. Prevalent Population of IPF in EU5
4.3.8. France
4.3.9. Prevalent Population of IPF
4.3.10. Prevalent Population of IPF by severity
4.3.11. Gender-Specific IPF Prevalence
4.3.12. Age-Specific IPF Prevalence
4.3.13. Germany
4.3.14. Prevalent Population of IPF
4.3.15. Prevalent Population of IPF by severity
4.3.16. Gender-Specific IPF Prevalence
4.3.17. Age-Specific IPF Prevalence
4.3.18. Italy
4.3.19. Prevalent Population of IPF
4.3.20. Prevalent Population of IPF by severity
4.3.21. Gender-Specific IPF Prevalence
4.3.22. Age-Specific IPF Prevalence
4.3.23. Spain
4.3.24. Prevalent Population of IPF
4.3.25. Prevalent Population of IPF by severity
4.3.26. Gender-Specific IPF Prevalence
4.3.27. Age-Specific IPF Prevalence
4.3.28. United Kingdom
4.3.29. Prevalent Population of IPF
4.3.30. Prevalent Population of IPF by severity
4.3.31. Gender-Specific IPF Prevalence
4.3.32. Age-Specific IPF Prevalence
4.3.33. Japan
4.3.34. Prevalent Population of IPF
4.3.35. Prevalent Population of IPF by severity
4.3.36. Gender-SPECIFIC IPF Prevalence
4.3.37. Age-Specific IPF Prevalence
5. Current Treatment Practices
5.1. ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of IPF (An Update of 2011 Clinical Practice Guideline)
6. Unmet needs
7. Marketed Products
7.1. Esbriet (Pirfenidone): InterMune Inc.
7.1.1. Product Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Safety and Efficacy of Esbriet
7.1.5. Side effects of Esbriet
7.1.6. Product Profile
7.2. Ofev (Nintedanib): Boehringer Ingelheim Pharma GmbH & Co. KG
7.2.1. Product Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Safety and Efficacy of Ofev
7.2.5. Side effects of Ofev
7.2.6. Product Profile
8. Emerging Therapies
9. Key Cross Competition
10. Phase III Drugs
10.1. Thrombomodulin Alfa: Asahi Kasei Pharma Corporation
10.1.1. Drug Description
10.1.2. Product Profile
10.1.3. Clinical Development
10.1.4. Clinical Trials Information
10.1.5. Safety and Efficacy
11. Phase II Drugs
11.1. CC-90001: Celgene Corporation
11.1.1. Drug Description
11.1.2. Product Profile
11.1.3. Clinical Development
11.1.4. Clinical Trials Information
11.1.5. Safety and Efficacy
11.1.6. Drug Description
11.1.7. Product Profile
11.1.8. Other Development Activities
11.1.9. Clinical Development
11.1.10. Clinical Trials Information
11.1.11. Safety and Efficacy
11.2. Gefapixant: Merck & Co., Inc.
11.2.1. Drug Description
11.2.2. Product Profile
11.2.3. Other Development Activities
11.2.4. Clinical Development
11.2.5. Clinical Trials Information
11.2.6. Safety and Efficacy
11.3. GLPG1690: Galapagos NV
11.3.1. Drug Description
11.3.2. Product Profile
11.3.3. Regulatory Milestones
11.3.4. Other Development Activities
11.3.5. Clinical Development
11.3.6. Clinical Trials Information
11.3.7. Safety and Efficacy
11.4. LT-1001: LTT Bio-Pharma
11.4.1. Drug Description
11.4.2. Product Profile
11.4.3. Other Development Activities
11.4.4. Clinical Development
11.4.5. Clinical Trials Information
11.4.6. Safety and Efficacy
11.5. BG00011: Biogen Inc.
11.5.1. Drug Description
11.5.2. Product Profile
11.5.3. Regulatory Milestones
11.5.4. Other Development Activities
11.5.5. Clinical Development
11.5.6. Clinical Trials Information
11.5.7. Safety and Efficacy
11.6. BMS-986020: Bristol-Myers Squibb
11.6.1. Drug Description
11.6.2. Product Profile
11.6.3. Regulatory Milestones
11.6.4. Other Development Activities
11.6.5. Clinical Development
11.6.6. Clinical Trials Information
11.6.7. Safety and Efficacy
11.7. LT-1002: Chong Kun Dang Pharmaceutical
11.7.1. Drug Description
11.7.2. Product Profile
11.7.3. Other Development Activities
11.8. Pamrevlumab: FibroGen
11.8.1. Drug Description
11.8.2. Product Profile
11.8.3. Regulatory Milestones
11.8.4. Other Development Activities
11.8.5. Clinical Development
11.8.6. Clinical Trials Information
11.8.7. Safety and Efficacy
11.9. PBI4050: ProMetic Life Sciences
11.9.1. Drug Description
11.9.2. Product Profile
11.9.3. Regulatory Milestones
11.9.4. Other Development Activities
11.9.5. Clinical Development
11.9.6. Clinical Trials Information
11.9.7. Safety and Efficacy
11.10. PRM 151: Promedior, Inc.
11.10.1. Drug Description
11.10.2. Product Profile
11.10.3. Regulatory Milestones
11.10.4. Other Development Activities
11.10.5. Clinical Development
11.10.6. Clinical Trials Information
11.10.7. Safety and Efficacy
11.11. Tipelukast: MediciNova
11.11.1. Drug Description
11.11.2. Product Profile
11.11.3. Regulatory Milestones
11.11.4. Other Development Activities
11.11.5. Clinical Development
11.11.6. Clinical Trials Information
11.11.7. Safety and Efficacy
11.12. TD139: Bristol-Myers Squibb
11.12.1. Drug Description
11.12.2. Product Profile
11.12.3. Other Development Activities
11.12.4. Clinical Development
11.12.5. Clinical Trials Information
11.12.6. Safety and Efficacy
11.13. VAY736: Novartis
11.13.1. Drug Description
11.13.2. Product Profile
11.13.3. Other Development Activities
11.13.4. Clinical Development
11.13.5. Clinical Trials Information
11.14. TAS-115: Taiho Pharmaceutical
11.14.1. Drug Description
11.14.2. Product Profile
11.14.3. Clinical Development
11.14.4. Clinical Trials Information
12. IPF: Market Analysis
12.1. Key Findings
12.2. Total Market Size of IPF in 7 MM
12.3. Therapy Based Market Size of IPF in 7 MM
13. Market Size of IPF by Country
13.1. United States Market Analysis
13.1.1. Market Size of IPF in the US
13.1.2. Therapy Based Market Size of IPF in the US
13.2. EU5 Market Outlook
13.3. Germany
13.3.1. Market Size of IPF in Germany
13.3.2. Therapy Based Market Size of IPF in Germany
13.4. France
13.4.1. Market Size of IPF in France
13.4.2. Therapy Based Market Size of IPF in France
13.5. Italy
13.5.1. Market Size of IPF in Italy
13.5.2. Therapy Based Market Size of IPF in Italy
13.6. United Kingdom
13.6.1. Market Size of IPF in the UK
13.6.2. Therapy Based Market Size of IPF in the UK
13.7. Spain
13.7.1. Market Size of IPF in Spain
13.7.2. Therapy Based Market Size of IPF in Spain
13.8. Japan: Market Analysis
13.8.1. Market Size of IPF in Japan
13.8.2. Therapy Based Market Size of IPF in Japan
14. Market Drivers of IPF
15. Market Barriers of IPF
16. Appendix
16.1. Report Methodology
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

 

1. Key Insights
2. IPF Market Overview at a Glance
2.1. Market Share (%) Distribution of IPF in 2017
2.2. Market Share (%) Distribution of IPF in 2027
3. Disease Background and Overview: Idiopathic Pulmonary Fibrosis (IPF)
3.1. Introduction
3.2. Staging of IPF
3.3. Risk Factors & Disease Causes
3.4. Symptoms
3.5. Pathogenesis
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7 MM Prevalent Population of IPF
4.3. Country Wise-Epidemiology of IPF
4.3.1. United States
4.3.2. Prevalent cases of IPF in the United States
4.3.3. Prevalent Population of IPF by severity
4.3.4. Gender-Specific IPF Prevalence
4.3.5. Age-Specific IPF Prevalence
4.3.6. EU5
4.3.7. Prevalent Population of IPF in EU5
4.3.8. France
4.3.9. Prevalent Population of IPF
4.3.10. Prevalent Population of IPF by severity
4.3.11. Gender-Specific IPF Prevalence
4.3.12. Age-Specific IPF Prevalence
4.3.13. Germany
4.3.14. Prevalent Population of IPF
4.3.15. Prevalent Population of IPF by severity
4.3.16. Gender-Specific IPF Prevalence
4.3.17. Age-Specific IPF Prevalence
4.3.18. Italy
4.3.19. Prevalent Population of IPF
4.3.20. Prevalent Population of IPF by severity
4.3.21. Gender-Specific IPF Prevalence
4.3.22. Age-Specific IPF Prevalence
4.3.23. Spain
4.3.24. Prevalent Population of IPF
4.3.25. Prevalent Population of IPF by severity
4.3.26. Gender-Specific IPF Prevalence
4.3.27. Age-Specific IPF Prevalence
4.3.28. United Kingdom
4.3.29. Prevalent Population of IPF
4.3.30. Prevalent Population of IPF by severity
4.3.31. Gender-Specific IPF Prevalence
4.3.32. Age-Specific IPF Prevalence
4.3.33. Japan
4.3.34. Prevalent Population of IPF
4.3.35. Prevalent Population of IPF by severity
4.3.36. Gender-SPECIFIC IPF Prevalence
4.3.37. Age-Specific IPF Prevalence
5. Current Treatment Practices
5.1. ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of IPF (An Update of 2011 Clinical Practice Guideline)
6. Unmet needs
7. Marketed Products
7.1. Esbriet (Pirfenidone): InterMune Inc.
7.1.1. Product Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Safety and Efficacy of Esbriet
7.1.5. Side effects of Esbriet
7.1.6. Product Profile
7.2. Ofev (Nintedanib): Boehringer Ingelheim Pharma GmbH & Co. KG
7.2.1. Product Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Safety and Efficacy of Ofev
7.2.5. Side effects of Ofev
7.2.6. Product Profile
8. Emerging Therapies
9. Key Cross Competition
10. Phase III Drugs
10.1. Thrombomodulin Alfa: Asahi Kasei Pharma Corporation
10.1.1. Drug Description
10.1.2. Product Profile
10.1.3. Clinical Development
10.1.4. Clinical Trials Information
10.1.5. Safety and Efficacy
11. Phase II Drugs
11.1. CC-90001: Celgene Corporation
11.1.1. Drug Description
11.1.2. Product Profile
11.1.3. Clinical Development
11.1.4. Clinical Trials Information
11.1.5. Safety and Efficacy
11.1.6. Drug Description
11.1.7. Product Profile
11.1.8. Other Development Activities
11.1.9. Clinical Development
11.1.10. Clinical Trials Information
11.1.11. Safety and Efficacy
11.2. Gefapixant: Merck & Co., Inc.
11.2.1. Drug Description
11.2.2. Product Profile
11.2.3. Other Development Activities
11.2.4. Clinical Development
11.2.5. Clinical Trials Information
11.2.6. Safety and Efficacy
11.3. GLPG1690: Galapagos NV
11.3.1. Drug Description
11.3.2. Product Profile
11.3.3. Regulatory Milestones
11.3.4. Other Development Activities
11.3.5. Clinical Development
11.3.6. Clinical Trials Information
11.3.7. Safety and Efficacy
11.4. LT-1001: LTT Bio-Pharma
11.4.1. Drug Description
11.4.2. Product Profile
11.4.3. Other Development Activities
11.4.4. Clinical Development
11.4.5. Clinical Trials Information
11.4.6. Safety and Efficacy
11.5. BG00011: Biogen Inc.
11.5.1. Drug Description
11.5.2. Product Profile
11.5.3. Regulatory Milestones
11.5.4. Other Development Activities
11.5.5. Clinical Development
11.5.6. Clinical Trials Information
11.5.7. Safety and Efficacy
11.6. BMS-986020: Bristol-Myers Squibb
11.6.1. Drug Description
11.6.2. Product Profile
11.6.3. Regulatory Milestones
11.6.4. Other Development Activities
11.6.5. Clinical Development
11.6.6. Clinical Trials Information
11.6.7. Safety and Efficacy
11.7. LT-1002: Chong Kun Dang Pharmaceutical
11.7.1. Drug Description
11.7.2. Product Profile
11.7.3. Other Development Activities
11.8. Pamrevlumab: FibroGen
11.8.1. Drug Description
11.8.2. Product Profile
11.8.3. Regulatory Milestones
11.8.4. Other Development Activities
11.8.5. Clinical Development
11.8.6. Clinical Trials Information
11.8.7. Safety and Efficacy
11.9. PBI4050: ProMetic Life Sciences
11.9.1. Drug Description
11.9.2. Product Profile
11.9.3. Regulatory Milestones
11.9.4. Other Development Activities
11.9.5. Clinical Development
11.9.6. Clinical Trials Information
11.9.7. Safety and Efficacy
11.10. PRM 151: Promedior, Inc.
11.10.1. Drug Description
11.10.2. Product Profile
11.10.3. Regulatory Milestones
11.10.4. Other Development Activities
11.10.5. Clinical Development
11.10.6. Clinical Trials Information
11.10.7. Safety and Efficacy
11.11. Tipelukast: MediciNova
11.11.1. Drug Description
11.11.2. Product Profile
11.11.3. Regulatory Milestones
11.11.4. Other Development Activities
11.11.5. Clinical Development
11.11.6. Clinical Trials Information
11.11.7. Safety and Efficacy
11.12. TD139: Bristol-Myers Squibb
11.12.1. Drug Description
11.12.2. Product Profile
11.12.3. Other Development Activities
11.12.4. Clinical Development
11.12.5. Clinical Trials Information
11.12.6. Safety and Efficacy
11.13. VAY736: Novartis
11.13.1. Drug Description
11.13.2. Product Profile
11.13.3. Other Development Activities
11.13.4. Clinical Development
11.13.5. Clinical Trials Information
11.14. TAS-115: Taiho Pharmaceutical
11.14.1. Drug Description
11.14.2. Product Profile
11.14.3. Clinical Development
11.14.4. Clinical Trials Information
12. IPF: Market Analysis
12.1. Key Findings
12.2. Total Market Size of IPF in 7 MM
12.3. Therapy Based Market Size of IPF in 7 MM
13. Market Size of IPF by Country
13.1. United States Market Analysis
13.1.1. Market Size of IPF in the US
13.1.2. Therapy Based Market Size of IPF in the US
13.2. EU5 Market Outlook
13.3. Germany
13.3.1. Market Size of IPF in Germany
13.3.2. Therapy Based Market Size of IPF in Germany
13.4. France
13.4.1. Market Size of IPF in France
13.4.2. Therapy Based Market Size of IPF in France
13.5. Italy
13.5.1. Market Size of IPF in Italy
13.5.2. Therapy Based Market Size of IPF in Italy
13.6. United Kingdom
13.6.1. Market Size of IPF in the UK
13.6.2. Therapy Based Market Size of IPF in the UK
13.7. Spain
13.7.1. Market Size of IPF in Spain
13.7.2. Therapy Based Market Size of IPF in Spain
13.8. Japan: Market Analysis
13.8.1. Market Size of IPF in Japan
13.8.2. Therapy Based Market Size of IPF in Japan
14. Market Drivers of IPF
15. Market Barriers of IPF
16. Appendix
16.1. Report Methodology
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

 

1. Key Insights
2. IPF Market Overview at a Glance
2.1. Market Share (%) Distribution of IPF in 2017
2.2. Market Share (%) Distribution of IPF in 2027
3. Disease Background and Overview: Idiopathic Pulmonary Fibrosis (IPF)
3.1. Introduction
3.2. Staging of IPF
3.3. Risk Factors & Disease Causes
3.4. Symptoms
3.5. Pathogenesis
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7 MM Prevalent Population of IPF
4.3. Country Wise-Epidemiology of IPF
4.3.1. United States
4.3.2. Prevalent cases of IPF in the United States
4.3.3. Prevalent Population of IPF by severity
4.3.4. Gender-Specific IPF Prevalence
4.3.5. Age-Specific IPF Prevalence
4.3.6. EU5
4.3.7. Prevalent Population of IPF in EU5
4.3.8. France
4.3.9. Prevalent Population of IPF
4.3.10. Prevalent Population of IPF by severity
4.3.11. Gender-Specific IPF Prevalence
4.3.12. Age-Specific IPF Prevalence
4.3.13. Germany
4.3.14. Prevalent Population of IPF
4.3.15. Prevalent Population of IPF by severity
4.3.16. Gender-Specific IPF Prevalence
4.3.17. Age-Specific IPF Prevalence
4.3.18. Italy
4.3.19. Prevalent Population of IPF
4.3.20. Prevalent Population of IPF by severity
4.3.21. Gender-Specific IPF Prevalence
4.3.22. Age-Specific IPF Prevalence
4.3.23. Spain
4.3.24. Prevalent Population of IPF
4.3.25. Prevalent Population of IPF by severity
4.3.26. Gender-Specific IPF Prevalence
4.3.27